

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

Jointly Administered

DECLARATION OF MAUREEN M. CHAKRABORTY


AUGUST 4, 2021

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Under 28 U.S.C. § 1746, I, Maureen Chakraborty, declare:

1. I submitted an expert report in this matter on June 15, 2021. Attached to this declaration is the corrected version of that report, which I submitted on July 26, 2021.
2. The corrected report constitutes my direct testimony in this matter. I declare under penalty of perjury that it is true and correct.
3. I declare under penalty of perjury that the foregoing is true and correct.

Executed on August 4, 2021

A handwritten signature in cursive script, reading "Maureen M. Chakraborty", is written over a horizontal line.

Maureen Chakraborty, Ph.D.

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

PUBLIC REDACTED VERSION

EXPERT REPORT OF MAUREEN M. CHAKRABORTY, PH.D.

JUNE 15, 2021

CORRECTED AS OF JULY 26, 2021

TABLE OF CONTENTS

I.	Introduction.....	1
A.	Qualifications.....	1
B.	Assignment	1
C.	Summary of Opinions	5
II.	Background.....	8
A.	PPLP’s Business	8
B.	PPLP’s At-Issue Distributions	9
C.	Opioid Litigation and Settlements	12
III.	Market Value of Purdue’s Assets	14
A.	Approach for Valuing Purdue’s Assets.....	16
B.	Factors Affecting the Fair Market Value of Purdue’s Operating Assets	18
	1. Loss of Exclusivity	20
	2. Purdue’s Drug Pipeline and Expected Approval of New Drugs.....	21
C.	Purdue’s Financial Forecasts	23
D.	Purdue’s Historical and Projected Financial Position During the 2008- 16 Period	26
E.	DCF Valuation of Purdue’s Operating Assets During the 2008-16 Period	27
	1. Terminal Value	30
	2. Discount Rate.....	31
	3. Asset Valuation.....	33
F.	Guideline Public Company Valuation of Purdue.....	35
IV.	Value of Purdue’s Liabilities	37
A.	Purdue’s Balance Sheet Liabilities	38
	1. Current Liabilities	38
	2. Long-Term Liabilities.....	39
B.	Purdue’s Additional Opioid Litigation Liabilities	40
	1. Overview.....	40
	2. Purdue’s Opioid Litigation Trends Prior to, During, and Following the 2008-16 Period	42
	3. Review of Purdue’s Audited Financial Statements	48
	4. Third Party Valuations and Credit Assessments of Purdue Did Not Anticipate a Significant Increase in the Pending	

Actions or Include Additional Opioid Litigation Liabilities in Their Analyses	52
5. Disclosure of Opioid Litigation Risk in the Litigation Comparables' Financial Statements.....	54
6. Market Valuations of the Litigation Comparables' Financial Securities Do Not Anticipate Pending Actions Liability Prior to 2017.....	60
7. The Economic Foreseeability of the Increase in Pending Actions Based on the Foregoing Information.....	69
C. Analysis of Market Reaction to Disclosures of Investigations.....	69
1. The Purdue 2020 Guilty Plea.....	73
D. The Aggregate Value of Purdue's Liabilities During the 2008-16 Period	74
V. The Balance Sheet Test.....	75
VI. The Cash Flow Test	79
VII. The Capital Adequacy Test.....	85
A. Stress-test Scenario related to Purdue's Pipeline.....	87
B. Ratio Analysis of Purdue's Financial Health.....	89
C. Purdue's Access to Capital	90

I. INTRODUCTION

A. Qualifications

1. I am a Managing Principal at Analysis Group, Inc., and I earned my Ph.D. in Economics from the University of Notre Dame and my B.A. in Economics from Colby College. Analysis Group provides economic, financial, and business strategy consulting to its clients and specializes in the interpretation of economic and financial data and the development of economic and financial models. I have an extensive background in economics, finance, accounting, and valuation. I have served both as an expert witness and as a consultant in a number of matters involving valuation, solvency, fraudulent conveyance, securities, and economic damages. I work on matters involving companies in many industries, including pharmaceuticals.

2. My *curriculum vitae*, which includes a list of all publications I have authored, is attached as **Appendix A** to this report, and a list of cases in which I have provided expert testimony in the last four years is attached as **Appendix B**.

B. Assignment

3. I have been retained by Milbank LLP and Joseph Hage Aaronson LLC, counsel for the Raymond Sackler Family (“Counsel”) in this matter. Counsel informed me that this proceeding stems from the bankruptcy of Purdue Pharma L.P. (“PPLP”), Purdue Pharma Inc. (“PPI”), the general partner of PPLP, and other debtors (collectively “Debtors”) in *In re Purdue Pharma L.P.*, Case No. 19-23646 (RDD). The Debtors filed for Chapter 11 protection in September 2019. I understand from Counsel that the Debtors’ bankruptcy was triggered by the filing of more than 2,700 opioid actions in the United States, nearly all of which were filed between 2017 and 2019 (the “Pending Actions”). I understand that most of these lawsuits were brought by governmental entities seeking to hold PPLP and other entities, including other opioid manufacturers, broadly responsible for the costs of the opioid epidemic.¹ I also understand that on October 20, 2020,

¹ See *In re Purdue Pharma L.P., et al.*, Case No. 19-23649-rdd (U.S. Bankruptcy Court Southern District of New York), ECF No. 17, Debtors’ Informational Brief, September 15, 2019 (“Debtors’ Informational Brief”), p. 1. The Pending Actions are listed in **Appendix G**, which was supplied to me by Counsel. I understand from Counsel that the list of Pending Actions is based on the state, federal and tribal proceedings listed in Exhibits A,

PPLP agreed to plead guilty to three felony charges (the “Purdue 2020 Guilty Plea”) and to settle certain claims brought by the federal government (the “Purdue 2020 Civil Settlement”).

4. I understand that PPLP made cash distributions in each year during the period from 2008 to 2017, totaling approximately \$10.3 billion (a figure that includes approximately \$4.6 billion in tax distributions). I understand that of that total, \$10.1 billion in distributions were made between 2008 and 2016 and the remaining \$187 million in distributions were made in 2017 for the purpose of paying taxes (with the exception of one non-tax distribution of \$198,544).² I also understand that between 2008 and 2019, PPLP made certain non-cash transfers to other entities beneficially owned by the Sackler Families, and that it has been alleged that the value of the non-cash transfers was at least \$1 billion.³ I further understand that it has been alleged that PPLP was insolvent, or was rendered insolvent, at the time of each such distribution.

5. Counsel has asked me to conduct a solvency analysis of PPLP. At the request of Counsel, I have conducted such an analysis for the period from 2008 through 2016 (“the 2008-16 Period”). Specifically, I have been asked to opine on:

- Whether PPLP was insolvent during the 2008-16 Period; and

B and C to the Complaint for Injunctive Relief, *PPLP v. Commonwealth of Massachusetts*, Adv. Pro. No. 19-8289-rdd [Dkt. Nos. 1-1 and 1-2] and the exhibits to the preliminary injunction order now in effect [Dkt. No. 264 (18th Amended Order)], that were pending as of September 15, 2019, when Purdue filed for bankruptcy.

² See **Exhibits 3a** and **3b** and **Appendix H**, discussed *infra* at footnote 26 and ¶ 37; *In re Purdue Pharma L.P. et al.*, Case No. 19-23649-rdd (U.S. Bankruptcy Court Southern District of New York), Notice of Filing of Report of the Special Committee, December 16, 2019, Exhibit A (“AlixPartners Report”), p. 25; Summary of PPLP Distributions prepared by Purdue, PPLPUCC9011830859 (the “PPLP Distributions Summary”). The PPLP Distributions Summary details cash distributions made by PPLP during the 1995-2017 period. The AlixPartners Report details cash distributions from PPLP and identifies net cash distributions of \$28.5 million from Rhodes Pharmaceutical L.P. (“Rhodes Pharma”) and affiliated entities (together, the “Rhodes Entities”) to Sackler-affiliated entities over the 2008-2017 period. See AlixPartners Report, p. 25. Rhodes Pharma is a Purdue subsidiary created in 2007 that operates Purdue’s generic prescription pharmaceutical business. See Debtors’ Informational Brief, p. 9. Until May 2019, the Rhodes Entities were managed separately from PPLP by different boards of directors from that of PPLP. See *id.* at pp. 10-11. I have not been asked by Counsel to address the solvency of the Rhodes Entities during the 2008-16 Period.

³ *In re Purdue Pharma L.P. et al.*, Case No. 19-23649-rdd (U.S. Bankruptcy Court Southern District of New York), Official Committee of Unsecured Creditors’ Motion to Compel Production of Purportedly Privileged Documents or For In Camera Review, Based on Good Cause, Crime Fraud, and At Issue Exceptions to Claims of Privilege, September 29, 2020 (“Unsecured Creditors’ Motion to Compel Production”), at ¶¶ 44 and 45.

- Whether any of the distributions made by PPLP to entities beneficially owned by the Sackler Families during the 2008-16 Period either occurred at a time when PPLP was insolvent or rendered PPLP insolvent.

6. Economists typically assess a company's solvency using three generally accepted analyses or tests. From an economic perspective, a company is deemed solvent if it passes all three of these solvency tests. Conversely, a company is not deemed solvent if it does not pass any one of these tests.

- Balance Sheet Test. This test determines whether the fair market value of the subject company's assets exceeds the value of its aggregate liabilities.⁴ If so, the company has positive equity value and is deemed solvent under the Balance Sheet Test.
- Cash Flow Test. This test determines whether the subject company's reasonably expected cash flows are sufficient to meet its liabilities as and when they come due, typically over a finite projection period.⁵ If so, the company is deemed solvent under the Cash Flow Test.
- Capital Adequacy Test. This test determines whether the subject company has an adequate amount of capital to sustain operations under a possible, reasonably adverse set of operating conditions, including reasonable stress-test scenarios.⁶ If so, the company is deemed solvent under the Capital Adequacy Test.

7. To assess the solvency of PPLP as of the distribution dates within the 2008-16 Period, my analysis relies on management forecasts of financial performance prepared in the ordinary course of business and on publicly available data. I understand that because PPI is the

⁴ For purposes of a solvency analysis, aggregate liabilities include off-balance sheet liabilities and contingent liabilities. For any liabilities that can be appropriately considered as contingent liabilities, such as environmental cleanup costs at work sites that have been contaminated, they are discounted to account for the fact that the requirement to pay or the amount of the payment is uncertain. *See* Heaton, J.B., "Solvency Tests," *The Business Lawyer*, Vol 62, May 2007, pp. 983-1006 ("Heaton (2007)"), at p. 991; Stearn, Robert J., Jr., "Proving Solvency: Defending Preference and Fraudulent Transfer Litigation," *The Business Lawyer*, Vol. 62, February 2007, pp. 359-395 ("Stearn (2007)") at p. 361, footnote 8.

⁵ Heaton (2007) at 983, 988-990.

⁶ Heaton (2007) at 983, 995-996.

general partner of PPLP, PPI's net assets should be factored into an analysis of PPLP's solvency.⁷ I also understand from Counsel that the financial forecasts on which my solvency analysis is based include both PPLP and PPI.⁸ In the remainder of this report, I refer to PPLP and PPI collectively as "Purdue" unless otherwise noted.

8. The at-issue cash distributions were made on 425 unique days over the 2008-16 Period.⁹ Non-cash transfers also were made during the 2008-16 Period.¹⁰ As discussed below, I assess the value of Purdue's assets and expected cash flows on dates when management forecasts satisfy certain criteria, which I explain in **Section III.C**. In order to have at least one valuation per calendar year, in years where none of the management forecasts satisfy all of the criteria, I chose the forecast that is closest to meeting the criteria and made any necessary adjustments, as described in **Appendix D** of my report. As a result, my analyses of Purdue's assets and cash flows for purposes of my solvency tests do not correspond to every date that the at-issue distributions were made. However, I determined that my assessments of Purdue's value, cash flows, and liabilities can be reasonably extrapolated to the interim periods between my valuation dates and that the solvency conclusions that I have reached as of the valuation dates can be applied to the date of any at-issue distribution made during the 2008-16 Period. I explain my basis for this conclusion in **Section III.A**.

9. To conduct my assignment, I reviewed certain submitted legal filings, certain materials that have been produced in this matter, and certain publicly available information. A complete list of the documents that I considered in forming my opinions is attached as **Appendix C** to this report. I, and others working under my direction, have had access to a database that I understand contains all documents produced by or to the Raymond Sackler Family in these

⁷ Counsel has informed me that when assessing PPLP's solvency, it is appropriate to include PPI's net assets, because PPI is PPLP's general partner. *See also* Bankruptcy Code 11 U.S.C 101(32)(B) (defining "insolvent" for a partnership as the "financial condition such that the sum of such partnership's debts is greater than the aggregate of, at a fair valuation (i) all of such partnership's property ... and (ii) the sum of the excess of the value of each general partner's nonpartnership property ...").

⁸ For purposes of my analysis, I rely on management forecasts for Purdue's business in the United States, which I understand from Counsel includes PPLP and PPI.

⁹ The 425 unique days do not account for certain distributions for which only the year of distribution but not the exact date of distribution is known. *See Exhibits 3a and 3b and Appendix H*, discussed *infra* at ¶ 37.

¹⁰ *See* discussion of these non-cash transfers in **Section II.B** below.

proceedings, but I do not claim to be familiar with the entire universe of information disclosed, which I understand to be in excess of 100 million pages.

10. For my work on this matter, Analysis Group is compensated at a rate of \$915 per hour. Analysis Group invoices the work of personnel working under my direction and supervision at standard hourly rates. Neither my compensation nor that of Analysis Group is contingent upon my findings, the testimony I may give, or the outcome of this matter.

C. Summary of Opinions

11. Unlike in many bankruptcy cases where a debtor files for bankruptcy protection because it is unable to meet payment obligations on its debt, Purdue's bankruptcy was not caused by any default on debt, as Purdue did not have any funded debt, material past due trade obligations, or judgment creditors. Rather, I understand that Purdue's bankruptcy was triggered because the "sheer number and scale of the Pending Actions [was] simply unmanageable."¹¹ Therefore, a key element of Purdue's solvency during the 2008-16 Period is the extent to which the number and scale of the Pending Actions, and the associated potential liabilities (including those associated with the Purdue 2020 Guilty Plea and the Purdue 2020 Civil Settlement), were reasonably foreseeable and quantifiable from an economic perspective.¹²

12. I rely on contemporaneous management projections and utilize the Discounted Cash Flow method to estimate the value of Purdue's operating assets during the 2008-16 Period. I also conduct sensitivity analyses using differing valuation assumptions. It is my opinion that the combined value of Purdue's operating assets and excess cash was not less than \$1.9 billion and was as high as \$9.5 billion during the 2008-16 Period. As discussed below, the value of Purdue's operating assets declined over the period due to, among other factors, the proximity of the expected loss of exclusivity for OxyContin to the valuation date and resulting expectation of declining sales and margins. My conclusions regarding the value of Purdue's operating assets and excess cash during the 2008-16 Period are summarized in **Section III.E.3**.

¹¹ Debtors' Informational Brief, p. 37.

¹² As I discuss in **Section IV**, I analyze the reasonable foreseeability of the number and scale of the Pending Actions, and the associated potential liabilities, based on Purdue's financial projections and reports as well as market information.

13. I assess Purdue's balance sheet liabilities, as well as any additional liabilities that were not required to be reported on the balance sheet that may have been reasonably expected, as of the 2008-16 Period. This includes obligations that may arise from future opioid actions, including the Pending Actions. From an economic perspective, I conclude that the ultimate number and scale of the Pending Actions, and any potential liabilities associated with those actions, were not reasonably foreseeable during the 2008-16 Period. My conclusion is based on, among other things, an analysis of the following information:

- My review of relevant data shows that there was a sharp increase in the number of Pending Actions filed against Purdue only starting in 2017.
- Assessments of Purdue made by investment banks and credit rating agencies that I reviewed are consistent with my finding that market participants did not anticipate the sharp increase in Pending Actions in 2017 during the 2008-16 Period.
- Other opioid manufacturers also faced opioid litigation, including the sharp increase in Pending Actions filed starting in 2017. Unlike Purdue, some of these other opioid manufacturers were publicly traded. I therefore analyze movements in the prices and trading patterns of their equity securities and credit ratings to assess market expectations and the foreseeability of future opioid litigation, including the Pending Actions. Based on my analyses of these data, I conclude that market valuations of the publicly-traded equity securities and credit ratings of other opioid manufacturers indicate that during the 2008-16 Period, the market did not anticipate that a significant number of opioid actions would be commenced against these companies, nor that there were any significant current or future associated liabilities.

14. During the 2008-16 Period, Purdue's "Other Liabilities," which generally were comprised of employee benefits and the non-current portion of accrued settlement expenses,¹³ ranged between \$128 million to \$226 million.¹⁴ In addition, Purdue faced pending product liability

¹³ The audited combined financial statements for Purdue and its associated companies break out both accrued expenses and other liabilities into their subcomponents. *See, e.g.*, Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended December 31, 2007 and 2008, PPLPC012000221168-206 at 185, 186.

¹⁴ *See Exhibit 25*, discussed *infra* at ¶ 157.

lawsuits and certain state attorney general cases, and received subpoenas from certain government entities during the 2008-16 Period. Although no liability associated with these pending lawsuits and government investigations was required to be recorded on Purdue's balance sheet, I nevertheless estimated, and included in my solvency analysis, additional liabilities associated with these pending lawsuits and government investigations. I discuss the bases for these estimates in **Section IV.B.2**. Based on my analyses, I estimate the following additional liabilities for purposes of my solvency analysis during the 2008-16 Period:

- From 2008 through 2011, \$200 million;
- In 2012, \$19 million;
- In 2013 through 2015, \$19 million to \$491 million; and
- In 2016, zero to \$472 million.

15. My Balance Sheet Test indicates that, using the highest estimate of liabilities, the difference between Purdue's assets and liabilities was never less than \$1.3 billion, and as high as \$9.2 billion, during the 2008-16 Period. As such, the value of Purdue's operating assets and excess cash exceeded the value of its liabilities as of each date at which I assessed Purdue's solvency. I conclude that Purdue was solvent under the Balance Sheet Test during the 2008-16 Period.

16. My Cash Flow Test, using the highest estimate of liabilities, indicates that during the 2008-16 Period, as of each date at which I assessed Purdue's solvency, Purdue's reasonably expected cash flows were sufficient to meet its reasonably expected liabilities as and when they would come due over a multi-year future period. I conclude that Purdue was solvent under the Cash Flow Test during the 2008-16 Period.

17. My Capital Adequacy Test, using the highest estimate of liabilities, indicates that during the 2008-16 Period, as of each date at which I assessed Purdue's solvency, Purdue had an adequate amount of capital to sustain its operations under a stress-test scenario. I conclude that Purdue was solvent under the Capital Adequacy Test during the 2008-16 Period.

18. Accordingly, I conclude that Purdue was solvent during the 2008-16 Period.

II. BACKGROUND

A. PPLP's Business

19. PPLP is a pharmaceutical manufacturer. Its primary business during the 2008-16 Period was the manufacturing and selling of FDA-approved opioid-based pain medications.¹⁵ PPLP's three primary products over the 2008-16 Period were the extended-release opioid-based pain medications OxyContin, Hysingla, and Butrans:

- **OxyContin** is an extended-release, long-acting opioid pain medication with an active ingredient of oxycodone. OxyContin was approved by the FDA in 1995 and launched in 1996.¹⁶ Between 2008 and 2013, OxyContin contributed more than 90 percent of PPLP's annual revenue, but that contribution fell to 79 percent by 2016.¹⁷ In 2010, a reformulated version of OxyContin was approved by the FDA that made OxyContin more difficult to crush and dissolve.¹⁸ As of June 2021, OxyContin had 19 active associated patents that were anticipated to expire between 2023 and 2030.¹⁹
- **Hysingla** is an extended-release, long-acting opioid pain medication with an active ingredient of hydrocodone. It was approved by the FDA in 2014 in a tamper resistant

¹⁵ See *In re Purdue Pharma L.P., et al.*, Debtors, Case No. 19-23649, Disclosure Statement for Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors, June 2, 2021, pp. 47-49.

¹⁶ See "OxyContin Abuse Deterrent Formulation (ADF)," FDA Briefing Document, Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC), FDA, September 10-11, 2020, pp. 7, 347.

¹⁷ See *State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon vs. Richard S. Sackler, et al.*, Case No. 19CV22185, Complaint, May 16, 2019, ¶ 40; Executive Committee Meeting Materials, PPLP, August 10, 2017, PPLPC053000122044-169 at 087.

¹⁸ See "OxyContin Abuse Deterrent Formulation (ADF)," FDA Briefing Document, Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC), FDA, September 10-11, 2020, p. 7. The 2010 version of OxyContin's tamper resistant formulation breaks into large pieces and when exposed to solvents generally becomes a gelatinous mass, making it difficult to achieve full immediate release of the oxycodone dosage. See Goldman Sachs Confidential Information Memorandum prepared for PPLP, 2008, PPLPC039000358902-9028 at 8935-8937.

¹⁹ Active patents for OxyContin were obtained through the FDA's Online Orange Book Drug Database, which identifies drug products approved by the FDA and contains related patent and exclusivity information. OxyContin patents were found within the database by searching for the patent application number N022272. The FDA Orange Book database is available at <https://www.accessdata.fda.gov/scripts/cder/ob/>.

formulation.²⁰ As of June 2021, Hysingla had 26 active patents associated with it that were anticipated to expire between 2021 and 2031.²¹

- **Butrans** is a transdermal patch that provides pain relief for seven days with an active ingredient of buprenorphine. It was approved by the FDA in 2010.²² In 2010, Purdue received patent approval, and that patent expired in 2017.²³ As of June 2021, Butrans did not have any active patents associated with it.²⁴

20. Within the prescription market for opioids, there are both branded opioids such as OxyContin and generic variants. Based on a measure called morphine milligram equivalent (“MME”), generics rose to account for around 90 percent of prescribed opioids by 2016.²⁵

B. PPLP’s At-Issue Distributions

21. I understand that during the 2008-16 Period, PPLP made cash distributions to its limited partner, and certain of those distributions were received by entities beneficially owned by

²⁰ See “Information Page: FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties,” FDA, available at <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-page-fda-approves-extended-release-single-entity-hydrocodone-product-abuse-deterrent>, accessed May 28, 2021.

²¹ Active patents for Hysingla were obtained through the FDA’s Online Orange Book Drug Database, which identifies drug products approved by the FDA and contains related patent and exclusivity information. Hysingla patents were found within the database by searching for the patent application number 206627. The FDA Orange Book database is available at <https://www.accessdata.fda.gov/scripts/cder/ob/>.

²² See FDA Drug Approval Package for Butrans (buprenorphine) Transdermal System for transdermal administration (5 mcg/hour, 10 mcg/hour, and 20 mcg/hour), FDA, available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021306_butrans_toc.cfm, accessed May 28, 2021; “What is Butrans,” Butrans, available at <https://butrans.com/patient/what-is-butrans.html>, accessed June 4, 2021.

²³ See United States Patent No. US-RE41571-E, August 24, 2010; “Top Drug Patent Losses in 2017,” *PBA Health*, January 13, 2017, available at https://www.pbahealth.com/portal_news/top-drug-patent-losses-in-2017/, accessed June 4, 2021.

²⁴ Active patents for Butrans were searched for through the FDA’s Online Orange Book Drug Database, which identifies drug products approved by the FDA and contains related patent and exclusivity information. Butrans patents were searched for within the database by searching for the patent application number 021306. The FDA Orange Book database is available at <https://www.accessdata.fda.gov/scripts/cder/ob/>.

²⁵ See “FDA Analysis of Long-Term Trends in Prescription Opioid Analgesic Products: Quantity, Sales, and Price Trends,” FDA, March 1, 2018, available at <https://www.fda.gov/media/111695/download>.

the Sackler Families. **Exhibit 1** and **Figure 1** summarize these cash distributions by year and show that the total amount distributed from 2008 to 2017 was approximately \$10.3 billion.²⁶

Figure 1. PPLP's Cash Distributions from the AlixPartners Report (\$ millions)

Distribution Year	Partner Cash Distributions	Ex-U.S. Cash Distributions	Investment in Associated Companies	Tax Distributions	Total Distributions
2008	752	0	76	540	1,368
2009	899	0	112	711	1,721
2010	860	112	0	654	1,626
2011	554	113	0	556	1,223
2012	439	122	0	460	1,021
2013	298	234	0	401	934
2014	128	232	0	436	795
2015	129	297	0	366	792
2016	154	247	0	249	651
2017	0	0	0	187	187
Total	4,213	1,359	188	4,559	10,318

22. Of this \$10.3 billion in cash distributions, approximately \$4.6 billion were distributions made to PPLP's partners in amounts reflective of their estimated tax liability as a result of PPLP's income, and approximately \$1.5 billion were distributions to Pharmaceutical Research Associates L.P. ("PRA"), PPLP's limited partner, which ultimately reinvested in non-U.S. pharmaceutical affiliates.²⁷

23. Of the \$10.3 billion in total cash distributions, \$10.1 billion (98.2 percent) were made prior to 2017 (*i.e.*, during the 2008-16 Period), and \$187 million (1.8 percent) were made in 2017. In addition, all of the 2017 cash distributions were tax distributions, with the exception of one U.S. Partner distribution of \$198,544 that I understand was made in June 2017 but had been approved by the PPI Board in August 2016.²⁸ I understand that, aside from that one exception, PPLP stopped making non-tax distributions in 2016 and it stopped making tax distributions in 2017.

²⁶ **Exhibit 1** is based on **Appendix H**, which was prepared by Analysis Group personnel working at my direction and under my supervision. **Appendix H** sets forth all individual cash distributions made by PPLP from 2008 to 2017, by date in reverse chronological order, and by distribution type (U.S. Partner Distribution, Ex-U.S. Distribution, and Tax Distribution). I understand that **Appendix H** is sourced from the PPLP Distributions Summary (PPLPUCC9011830859). Analysis Group personnel working under my supervision performed a full reconciliation of the PPLP Distributions Summary with the AlixPartners Report (**Appendix H**, Tab 2).

²⁷ AlixPartners Report, p. 25.

²⁸ PPLP Distributions Summary; "Decision," PPLP, August 23, 2016, PPLP004417632-633 at 633.

24. PPLP also made certain non-cash transfers to entities beneficially owned by the Sackler Families during the 2008-16 Period. The approved Disclosure Statement states that the non-cash transfers “may total in excess of an additional \$1.4 billion in value to or for the benefit of the Sackler Families or Sackler Entities from 2008-2019.”²⁹ I understand that certain claimants in the Purdue bankruptcy have called four such transfers with an alleged total value of at least \$1 billion “problematic.”³⁰ These four transactions related to: (1) royalties from international sales of OxyContin paid to PPLP each year during the 2008-16 Period, (2) the transfer of PPLP’s intellectual property rights for a certain OxyContin formulation in 2017, (3) the transfer of PPLP’s equity interest in Infinity Pharmaceuticals in 2008, 2009 and 2013, and (4) the transfer of PPLP’s equity interest in Lucien Holdings in 2010.³¹ Although I do not express an opinion on the value of these transfers and whether PPLP received fair consideration for them, I consider three of these transfers in reaching my solvency opinion. The other transfer (the second in the above list) occurred in January 2017, when PPLP transferred the intellectual property rights to the non-abuse deterrent formulation of OxyContin to its parent company Pharmaceutical Research Associates (“PRA”) for no consideration.³² This transaction occurred after the 2008-16 Period and I am not offering a solvency opinion as of the date of this transfer. As I describe in my assessment of solvency, the other three transfers that took place during the 2008-2016 Period do not impact my conclusion regarding the solvency of Purdue during that time.

25. The solvency tests that I conduct for 2008 assess the effect on Purdue’s solvency of the cash and non-cash transfers made from January 1, 2008 through the valuation date in 2008. For each subsequent year, the solvency tests that I conduct for a given year assess the cumulative effect on Purdue’s solvency of the cash and non-cash transfers made through the valuation date in that particular year. As discussed further below, the solvency tests that I conduct for 2016 assess the cumulative effect of the cash and non-cash transfers made through December 31, 2016 on Purdue’s solvency.

²⁹ *In re Purdue Pharma L.P., et al.*, Debtors, Case No. 19-23649, Disclosure Statement for Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors, June 2, 2021, p. 165.

³⁰ Unsecured Creditors’ Motion to Compel Production, ¶¶ 44-45.

³¹ Unsecured Creditors’ Motion to Compel Production, ¶¶ 44-45. I discuss each of these transactions in more detail in **Section V** below.

³² Unsecured Creditors’ Motion to Compel Production, ¶ 44b.

C. Opioid Litigation and Settlements

26. For purposes of my solvency analysis, I reviewed Purdue's opioid litigations and major settlements through the end of the 2008-16 Period, which I outline below.

27. In 2007, the year preceding the start of the 2008-16 Period, Purdue reached several OxyContin-related settlement agreements with both individual plaintiffs and government entities. In January 2007, Purdue settled over 1,100 lawsuits — “nearly all existing products-liability litigation against the company” — for \$75 million.³³ Purdue entered into a Plea Agreement with the U.S. Department of Justice in May 2007 and a settlement of certain Medicaid claims with 48 states and the District of Columbia shortly thereafter, and, in connection with those settlements, paid over \$600 million in criminal and civil penalties to resolve allegations of OxyContin misbranding based on conduct in 2001 or before.³⁴ I understand that two states did not join this settlement: West Virginia, which had entered into a separate settlement with Purdue in 2004,³⁵ and Kentucky, which was the only state to file a separate action against Purdue.³⁶ In May 2007, Purdue also entered into a Consent Judgment and an additional \$19.5 million settlement with 26 states and the District of Columbia.³⁷

³³ Email from Howard Udell, Subject: “RE: Settlement,” January 27, 2007, PPLPC044000010048-054 at 051, 052.

³⁴ See *United States of America v. The Purdue Frederick Company, Inc.*, Case No. 1:07CR29, Plea Agreement, May 10, 2007 (“Purdue 2007 Guilty Plea”), pp. 3-6; *U.S. v. Purdue Frederick Co.*, Case No. 1:08CR00029, Settlement Agreement, May 10, 2007, pp. 2-3; “Pharmaceutical & Medical Device Manufacturers: Recent Settlements and Investigations Related to Marketing, Pricing and Associated Activities, Public Settlements & Investigations,” *Epstein Becker & Green*, October 16, 2009, p. 24.

³⁵ *State of West Virginia v. Purdue Pharma, L.P.*, Case No. 01-CV-137, Settlement Agreement and Release, December 15, 2004.

³⁶ See First Amended Complaint, *Commonwealth of Kentucky v. Purdue Pharma L.P.*, Civ. A. No. 07-CI-01303 (Pike Cir. Ct. Div. No. II) (filed October 10, 2007). I understand from Counsel that nearly all of the claims alleged by Kentucky in its 2007 suit pertained to alleged misconduct that preceded 2001 and that corresponded almost identically to conduct admitted in connection with the Purdue 2007 Guilty Plea and previously settled by 49 other states. See First Amended Complaint, *Commonwealth of Kentucky v. Purdue Pharma L.P.*, Civ. A. No. 07-CI-01303 (Pike Cir. Ct. Div. No. II) (filed October 10, 2007); Information and Attachment B thereto, *United States v. The Purdue Frederick Co.*, 1:07-cr-0029 (W.D. Va. May 10, 2007), ECF No. 5-2 (2007 Agreed Statement of Facts).

³⁷ “Pharmaceutical & Medical Device Manufacturers: Recent Settlements and Investigations Related to Marketing, Pricing and Associated Activities, Public Settlements & Investigations,” *Epstein Becker & Green*, October 16, 2009, p. 24.

28. In January 2008, at the start of the 2008-16 Period, Purdue management advised the Board that a possible reserve for closing out all OxyContin litigation would be \$200 million.³⁸ As I discuss in **Section IV.B.2**, the number of outstanding product liability lawsuits against Purdue decreased starting in 2009,³⁹ and by April 5, 2012, there were 24 pending product liability lawsuits against Purdue, of which only three were actively litigated.⁴⁰ By March 31, 2016, there were 18 pending product liability lawsuits against Purdue, none of which were active.⁴¹

29. Certain outstanding lawsuits and investigations were resolved during the 2008-16 Period. In August 2015, Purdue settled a business practices investigation by the New York Attorney General by entering into an Assurance of Discontinuance under which it agreed to a payment of \$75,000.⁴² In December 2015, Purdue agreed to pay \$24 million over eight years to settle the lawsuit brought by Kentucky when it opted out of the May 2007 settlement between Purdue, the U.S. Department of Justice, and the other 48 states and D.C.⁴³ In total, Purdue paid \$342 million in opioid-related and all other non-IP-related settlements between 2008 and 2019.⁴⁴ To put this into context, during the 2008-16 Period, Purdue and its associated companies earned net profits of \$10.6 billion.⁴⁵

³⁸ Board of Directors Meeting Agenda, PPLP, January 11, 2008, PPLP004400663-719 at 677. It is my understanding that Purdue was not required to record a reserve on its balance sheet.

³⁹ See also “OxyContin Market Events,” Purdue, April 12, 2012, PPLPC012000372436-437, slide 4.

⁴⁰ Purdue Pharma L.P., Audited Combined Financial Statements for the Years Ended December 31, 2011 and 2010, PPLPMDL0040000537-583 at 574.

⁴¹ Purdue Pharma L.P., Audited Combined Financial Statements for the Years Ended December 31, 2015 and 2014, PPLPC011000090527-581 at 570.

⁴² *In the Matter of Purdue Pharma L.P. et al.*, Assurance No. 15-151 (N.Y. Aug. 19, 2015), Assurance of Discontinuance.

⁴³ *In re Commonwealth of Kentucky v. Purdue Pharma L.P. et al.*, Settlement Agreement and General Release, December 18, 2015, PPLPUCC000701839-859; Lowrey, Brandon, “Kentucky AG Settles OxyContin, Risperdal Suits For \$39.5M,” *Law360*, December 23, 2015. I understand from Counsel that nearly all of the claims alleged by Kentucky in its 2007 suit pertained to alleged misconduct that preceded 2001 and that corresponded almost verbatim to conduct admitted in connection with the Purdue 2007 Guilty Plea and settled by 48 other states and D.C. In addition, as discussed in footnote 118, *infra*, I also understand that the amount of this settlement was inflated because Purdue had been judicially determined to have admitted liability by failing to respond to requests for admission.

⁴⁴ *In re Purdue Pharma L.P., et al.*, Debtors, Case No. 19-23649, Disclosure Statement for Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors, June 2, 2021, p. 166.

⁴⁵ See **Exhibit 7**, discussed in **Section III.D** below.

30. As discussed above, I understand that Purdue's bankruptcy was ultimately caused by the "sheer number and scale of the Pending Actions."⁴⁶ Only five of the Pending Actions were filed during the 2008-16 Period. *See Exhibit 2*. In contrast, more than 2,700 Pending Actions were brought by a wide array of plaintiffs in the 2017 to 2019 period.⁴⁷

III. MARKET VALUE OF PURDUE'S ASSETS

31. A solvency analysis is conducted on an *ex ante* basis, meaning that a valuation of the assets and assessment of liabilities should be based on information that is known or reasonably knowable as of the valuation date.⁴⁸ In other words, it is not appropriate to consider factors or events that could only be known with the benefit of hindsight. Furthermore, every firm faces risk, and while it is appropriate to take into account known risks when conducting a solvency analysis, there is a distinction between the risk that an event could occur in the future, and an actual materialization of that risk.⁴⁹ For purposes of my solvency analysis, I assess whether the materialization of potential risks is reasonably foreseeable, reasonably measurable, and sufficiently likely to occur such that, from an economic perspective, an adjustment to the asset value or liabilities is warranted.

⁴⁶ Debtors' Informational Brief, p. 37.

⁴⁷ *See* Debtors' Informational Brief, p. 38. **Exhibit 2** is based on the list of Pending Actions supplied to me by Counsel and provided in **Appendix G**.

⁴⁸ *See, e.g.*, Stearn (2007) at p. 373 ("As in a business valuation, in a solvency analysis an expert only should consider information that was known or reasonably available on the valuation/ solvency date: 'The valuation date is the date to which the analyst's opinion of value applies. ... The analyst should consider only the information that was known or 'knowable' as of that time and nothing else. This is true even if the analyst knows that events that transpired since then would have a material impact on the value.") *See also* Reilly, Robert F., and Robert P. Schweihs, *Handbook of Advanced Business Valuation*, McGraw-Hill, 2000 ("Reilly and Schweihs (2000)"), p. 340 ("[A] solvency analysis determines if at the time of the transactions (giving effect to the transaction) ... [certain] conditions exist"); *In re Commercial Financial Services, Inc.*, Case No. 03-0008-R (Bankr. N.D. Okla. 2005), Order Denying Defendants' Motions in Limine to Exclude Testimony of Plaintiffs' Expert Carmen R. Eggleston, September 14, 2005, at 30 ("For the purpose of a solvency analysis ... assets and liabilities must be valued based upon information *known or knowable* as of the date of the challenged transfer."); *In re WRT Energy Corp.*, Case No. 282 B.R. 343, Decision, August 24, 2001, at 407 ("Solvency valuations, including those undertaken by experts, generally must be based on conditions and standards as they existed at the time of the transaction at issue, not on hindsight.").

⁴⁹ *See, e.g.*, Koller, Tim, Marc Goedhart, and David Wessels, *Valuation: Measuring and Managing the Value of Companies*, McKinsey & Company, John Wiley & Sons, Inc., Fifth Edition, 2010 ("McKinsey (2010)"), pp. 285-286.

32. In this section, I begin by establishing the fair market value of Purdue’s operating assets during the 2008-16 Period. In this context, the fair market value refers to the price that Purdue’s operating assets would sell for in a transaction between a willing buyer and a willing seller, neither under compulsion to transact.⁵⁰ I then add Purdue’s excess cash to the value of Purdue’s operating assets.⁵¹ I value Purdue’s assets before giving consideration to the company’s non-operating liabilities, which I establish in **Section IV** of this report. I then show in **Section V** through **Section VII** that, during the 2008-16 Period, the total value of Purdue’s assets was sufficient to satisfy the company’s aggregate liabilities, that Purdue’s cash flow was sufficient to pay its reasonably expected obligations in full and on time, and that Purdue had adequate capital to satisfy its obligations under reasonable downside scenarios. I also show that none of the cash distributions or non-cash transfers rendered Purdue insolvent at any point during the 2008-16 Period.

33. In the paragraphs that follow, I describe the methodologies I use to value Purdue’s assets over the 2008-16 Period. As summarized in **Figure 2** and detailed in **Section III.E.3** below, I conclude that during the 2008-16 Period, the value of Purdue’s assets, including excess cash, was never less than \$1.9 billion and was as high as \$9.5 billion based on the Discounted Cash Flow (“DCF”) Method.

Figure 2. Valuation of Purdue’s Assets Using the DCF Method, 2008-2016

Operating Assets	\$1.4 - \$9.2 billion
Excess Cash	\$232 - \$750 million
Total Assets	\$1.9 - \$9.5 billion

⁵⁰ “Fair market value is defined by the [American Society of Appraisers] as ‘the amount at which ‘property would change hands between a willing seller and a willing buyer when neither is acting under compulsion and when both have reasonable knowledge of the relevant facts.’” (emphasis in original). See Pratt, Shannon, *Valuing a Business: The Analysis and Appraisal of Closely Held Companies*, McGraw Hill, Fifth Edition, 2008 (“Pratt (2008)”), pp. 41-42. See also *In re WRT Energy Corp.*, Case No. 282 B.R. 343, Decision, August 24, 2001, at 369 (“For purposes of a ‘fair valuation,’ the fair market value of the property must be measured by what the property would bring if actually sold on the market at the time of the transfer, assuming an informed, hypothetical willing seller and an informed, hypothetical willing buyer not under compulsion to buy or sell, and having a reasonable amount of time to sell the property.”).

⁵¹ As I discuss below, “excess cash” is cash that is in excess of the amount needed to operate a company as a going concern. See McKinsey (2010), p. 145. I estimate excess cash as cash in excess of current liabilities and restricted cash.

A. Approach for Valuing Purdue's Assets

34. To estimate the fair market value of Purdue's operating assets, I use the Income Approach. Under the Income Approach, often referred to as the DCF Method, the value of a business is measured based on the present value of the business' expected future cash.⁵² I detail my methodology for this valuation approach below and in **Appendix D**. The DCF models as of each date I value Purdue's operating assets during the 2008-16 Period are presented in **Exhibits D-1 to D-9**.

35. Other commonly used valuation approaches include the Guideline Public Company Method ("GPCM"), the Guideline Transactions Method ("GTM"), and the Cost Approach. The Cost Approach values an asset based on the cost required to replace the asset. This approach is more commonly used for valuing a fixed asset such as a building rather than an ongoing business operation with intangibles, as the approach does not take into account the value that an asset can create.⁵³ The GPCM indicates the value of a business based on the implied price multiples of comparable public companies using relevant financial indicators such as earnings, earnings before interest, taxes, depreciation and amortization ("EBITDA"), or sales.⁵⁴ The multiples are adjusted to account for differences between the subject company and the comparable public companies. The GTM indicates the value of a business based on pricing multiples derived from the sale of comparable companies, after adjustments. This is also referred to as the "Guideline Merged and Acquired Company" Method.⁵⁵ Both the GPCM and GTM methods are "market approaches" as they rely on market transactions to establish values, either in the form of the stock prices of publicly-traded companies or the transaction prices for the sale of a company or line of business. While I considered GPCM, I rely mainly on the Income Approach because it better allows for the

⁵² Stearn (2007) at p. 378. *See also* Damodaran, Aswath, *Investment Valuation*, John Wiley & Sons, Inc., Third Edition, 2012 ("Damodaran (2012)"), pp. 11-12.

⁵³ *See* Pratt (2008), p. 358.

⁵⁴ Pratt (2008), pp. 265-266; Damodaran (2012), p. 19.

⁵⁵ *See* Pratt (2008), pp. 310-311.

ability to assess certain key issues facing a company, such as those associated with a loss of exclusivity for a key product, than the other approaches.⁵⁶

36. In the remainder of this section, I present Purdue's actual financial position as well as Purdue management's financial projections of Purdue's future financial position during the 2008-16 Period. Using management's financial projections, I use the DCF approach to value Purdue's operating assets on the following dates, presented in **Figure 3** below.⁵⁷ I discuss the criteria for selecting these dates in **Section III.C**.

Figure 3. Summary of as-of Dates for Management Projections used in the DCF Valuation, 2008-2016

2008	April 18, 2008	2013	May 3, 2013
2009	July 15, 2009	2014	May 2, 2014
2010	June 1, 2010	2015	June 9, 2015
2011	June 21, 2011	2016	June 8, 2016
2012	February 15, 2012		

37. As shown in **Appendix H** and **Exhibits 3a** and **3b**, Purdue's distributions occurred over a wide range of dates during the 2008-16 Period. Because financial projections are not

⁵⁶ The reliability of GTM is dependent on identification of transactions involving comparable companies as well as disentangling the stand-alone value of operating assets from a transaction price. This can be difficult, particularly where synergies or pre-existing commercial relationships may exist between the parties. As a result, I have not considered the GTM in this report.

⁵⁷ The following is a list of the documents with management projections on which I rely for the DCF valuation of Purdue's operating assets: Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687; Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065; Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662; Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453; Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012.; Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668; Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592; 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543; Finance Update, June 9, 2015, PPLPC054000123288; Purdue Mid-Year Update, June 8, 2016, RSF00017771-921. As explained in **Appendix D** and **Exhibit D-2**, I also rely on a second document in my 2009 DCF valuation, the December 31, 2009 projections, to make cash adjustments to the model, as this document is the only projection prepared in 2009 with a cash flow statement. See Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662. Finally, I also review a June 2017 management projection for purposes of evaluating the remaining at-issue transfers after June 2016. This document also included projections as of January 2017. See Mid Year Financial Update to the Board, Purdue, June 2017, PPLPUCC9003546781.

available as of each transfer date, I establish a value of Purdue's operating assets as of the dates listed in **Figure 3**, which have the most complete financial forecast information. For the interim periods between these dates, I compare the trends of financial forecasts prepared by Purdue's management over the 2008-16 Period and observe a relatively steady, although declining, trend in forecasted sales of OxyContin. I am not aware of any evidence that would suggest the financial condition and projections for Purdue varied materially in the interim periods between valuation dates. I also have evaluated management projections as of June 2017, which include a reference to their January 2017 projections, to determine whether there was a significant change in management's expectations for Purdue's performance following the June 2016 valuation date and the 2016 distributions made following that date.⁵⁸

B. Factors Affecting the Fair Market Value of Purdue's Operating Assets

38. When assessing the fair market value of a company, it is appropriate to take into account risks, or other factors, that can have a material impact on the business. These factors will vary across industries and companies and are not easily quantifiable.⁵⁹ In the case of Purdue, I determined that the following risks would be considered by a willing buyer and therefore I consider the impact they may have on the value of Purdue's operating assets (and solvency).

39. First, a significant portion of Purdue's sales prior to and during the 2008-16 Period is from one product: OxyContin. As shown in **Exhibit 4**, based on actual gross sales reported in Purdue management's projections, OxyContin accounted for a major portion of Purdue's gross sales during the 2008-16 Period, constituting up to approximately 96 percent of overall sales (in 2009 and 2010). Thereafter, OxyContin's contribution to gross sales decreased somewhat as new

⁵⁸ Mid Year Financial Update to the Board, Purdue, June 2017, PPLPUCC9003546781.

⁵⁹ See Pratt (2008), p. 68; McKinsey (2010), pp. 35-36. See also Oppenheimer & Co. Inc., "Examining the Impact of ENDP's Additional Mesh Liability," July 23, 2017, pp. 4-5. Regarding thousands of product liability claims relating to Endo's surgical mesh product, an Oppenheimer analyst noted that, "[w]hile we understand management's strategy of keeping quiet, we believe investors want to be able to quantify the potential liability associated with these unfunded claims as they remain an overhang for the stock as they could impair the company's ability to de-lever its balance sheet in the near to medium term. Though we recognize it is difficult to fully quantify the potential liability for the remaining claims, for the sake of this analysis we attempt to do so."

products such as Butrans and Hysingla were introduced.⁶⁰ By the end of the 2008-16 Period, OxyContin Net Sales still accounted for 79 percent of the company's overall gross sales.⁶¹ The financial projections I have relied upon demonstrate that after 2016, OxyContin was expected to account for at least 69 percent of Purdue's future sales up until its loss of exclusivity.⁶² The value of Purdue's operating assets is therefore affected by the expected remaining period of sales exclusivity for OxyContin and Purdue's other approved medications. I discuss the impact of the expected loss of exclusivity on the value of Purdue's operating assets in **Section III.B.1** below.

40. Similarly, Purdue's financial statements discuss patent litigation that Purdue had brought against other opioid manufacturers alleging that they had violated OxyContin's exclusivity. Prior to the 2008-16 Period, this litigation and the corresponding impact on the enforceability of Purdue's intellectual property impacted its financial forecasts.⁶³ As I discuss in my report, the loss of exclusivity on Purdue's patents is an important part of my solvency analysis.

41. Second, a key driver of the value of pharmaceutical companies in both the short and long run is the development of their drug pipelines and success in receiving regulatory

⁶⁰ See, e.g., 2017 Budget, Purdue Pharma, November 30, 2016, PPLPUCC001746935-7012 at 6986 and 6992-6994. OxyContin accounted for 84 percent of overall Net Sales in 2015, the year in which Hysingla was launched.

⁶¹ Mid-Year Financial Update to the Board, Purdue Pharma, June 2017, PPLPUCC9003546781-836 at 824 and 829. Per the latest estimated P&L as of June 2017, management expected OxyContin to constitute 78 percent of the overall sales.

⁶² Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 892. In management projections from 2012, the proportion of Purdue's risk-adjusted gross sales attributed to OxyContin declined from 56 percent in the last year of exclusivity (2017) to less than 10 percent by 2020, three years after the loss of exclusivity. At the same time, the proportion of Purdue's risk-adjusted gross sales attributed to pipeline products increased from 27 percent in the last year of exclusivity (2017) to 71 percent three years after loss of exclusivity (2020). See Purdue 2012 10-Year Plan, February 15, 2012, PPLPC053000063393-668 at 506.

⁶³ Starting in 1999, Purdue was involved in a series of patent infringement lawsuits against competitors such as Endo and Teva, who had filed for FDA approvals to sell generic controlled-release oxycodone products. In one such lawsuit involving Endo in 2004, the Federal District Court in Manhattan ruled that the OxyContin patent was unenforceable, which led to Purdue losing exclusivity over OxyContin. See "Judge Says Maker Of OxyContin Misled Officials To Win Patents," *The New York Times*, January 6, 2004. Further, in 2005, United States Court of Appeals for the Federal Circuit in Washington upheld this judgment. See "Court Says OxyContin Patent Is Invalid," *The New York Times*, June 8, 2005. Subsequently, between 2006 and 2008, Purdue entered into settlements with many of its competitors, which affirmed the validity and enforceability of the OxyContin patents. Further, in January 2008, in a patent infringement litigation involving KV Pharmaceuticals, Actavis and Apotex, the U.S. District Court for the Southern District of New York upheld the validity and enforceability of the OxyContin patents, finding that Purdue had not engaged in conduct that invalidated these patents. See Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended December 31, 2008 and 2007, PPLPC012000221168-1206 at 1201, 1202.

approval to market and to sell new drugs.⁶⁴ I discuss the impact of Purdue's drug pipeline and expected approval of new drugs on the value of Purdue's operating assets in **Section III.B.2** below.

42. Third, given that the value of Purdue's operating assets is largely predicated on sales of opioid drugs, a willing buyer would assess the risk of current and future opioid litigation and the impact of that risk on Purdue's value and solvency. I address Purdue's potential future litigation risk and liabilities in **Section IV** below.

1. Loss of Exclusivity

43. When a pharmaceutical company's drug is approved for use in the United States, the FDA grants the company a period of "exclusivity" in which it has exclusive rights to market and sell the drug.⁶⁵ While the typical period of exclusivity is three to seven years, this can vary depending on a number of factors.⁶⁶ After the expiration or loss of exclusivity, other companies may obtain FDA approval to market and sell generic versions of the drug, resulting in substantially fewer sales of the branded drug. In addition, generic manufacturers sell the products at a much lower price, thus eroding the profit margins of the branded drug. The dramatic decline in revenue and profit of a drug following generic entry is sometimes referred to as a "patent cliff." Patent cliffs can have a dramatic impact on the cash flows of a pharmaceutical company, depending on the company's other sources of revenue.⁶⁷ Thus, exclusivity (and the subsequent loss thereof) is an important factor that should be taken into account in the valuation of pharmaceutical companies.

⁶⁴ See, e.g., Bennett, Johanna, "3 Small Biotech Stocks with Cash, Hot Pipelines," *Barron's*, June 3, 2015; "Diamonds in the Rough," Morgan Stanley, November 29, 2017, p. 23.

⁶⁵ A drug must meet certain statutory requirements to receive exclusivity. Exclusivity differs from patents granted by the U.S. Patent and Trademark Office, which can be received by a drug at any point in the drug's lifecycle, and typically last for 20 years in length from the point they are granted. While patent protection and exclusivity may run concurrently, that is not necessarily the case. "Frequently Asked Questions on Patents and Exclusivity," U.S. Food and Drug Administration, available at https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity#What_is_the_difference_between_patents_a, accessed May 27, 2021.

⁶⁶ "Frequently Asked Questions on Patents and Exclusivity," U.S. Food and Drug Administration, available at <https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity#howlongexclusivity>, accessed May 27, 2021.

⁶⁷ See DeRuiter, Jack, and Pamela L. Holston, "Drug Patent Expirations and the 'Patent Cliff,'" *U.S. Pharmacist*, June 20, 2012; Doughman, Elizabeth, "Impending Patent Cliff Threatens Billions of Global Prescription Drug Sales," *Pharmaceutical Processing World*, June 6, 2019; "Plunging off the Patent Cliff," *Healthcare Global*, May 17, 2020.

44. Management updated expectations of OxyContin's loss of exclusivity and timing of expected generic competition several times during the 2008-16 Period. These changes were driven by several factors, [REDACTED].⁶⁸ In 2008, Purdue expected that OxyContin would face generic competition in 2016 (*i.e.*, sales and margins of OxyContin would drop in 2016),⁶⁹ and in 2009, the company revised its expectation of generic entry to 2018 (*i.e.*, sales of OxyContin would drop in 2018).⁷⁰ In 2013, [REDACTED] Purdue updated its expectation of generic entry to 2021. [REDACTED] the FDA recognized OxyContin's 2010 re-formulation as an abuse-deterrent version.⁷¹ Management, in 2015, ultimately extended their expectation of OxyContin's exclusivity to 2022.⁷²

2. *Purdue's Drug Pipeline and Expected Approval of New Drugs*

45. Another key factor driving the cash flows of pharmaceutical companies is the development of their drug pipeline, and the expected success in gaining regulatory approval for new drugs.⁷³ Drugs must pass through a rigorous drug development process to establish both the

⁶⁸ See, e.g., Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453 at 332 and 334.

⁶⁹ Purdue Pharma Boards of Directors Meetings (U.S. Companies), April 18, 2008, PPLPC012000179049-100 at 085.

⁷⁰ See Purdue Pharma 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 033.

⁷¹ Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 492; Meier, Barry, "F.D.A. Bars Generic OxyContin," *The New York Times*, April 16, 2013.

⁷² See Purdue Pharma Finance Update, June 9, 2015, PPLPC054000123288 at p. 60. The FDA granted approval of extended release oxycodone for pediatric use in August 2015. Yang, Y. Tony, Brian Chen, and Charles L. Bennett, "FDA Approval of Extended Release Oxycodone for Children with Severe Pain," *Pediatrics*, April 2016, available at <https://pediatrics.aappublications.org/content/early/2016/04/16/peds.2016-0205#:~:text=In%20a%20highly%20controversial%20decision,alternative%20treatment%20options%20are%20inadequate.%E2%80%9D> In a Mid-Year Strategic Review, management indicated that this anticipated decision would extend OxyContin's exclusivity by six months. Purdue, Mid-Year Strategy Review, PPLPC011000036000.pptx, pp. 4, 10.

⁷³ See, e.g., Bennett, Johanna, "3 Small Biotech Stocks with Cash, Hot Pipelines," *Barron's*, June 3, 2015; "Diamonds in the Rough," Morgan Stanley, November 29, 2017, p. 23.

efficacy and safety of the drug before seeking regulatory approvals to sell the drug.⁷⁴ This process is uncertain and many drugs in a pipeline fail to obtain regulatory approval. While the success rate varies by therapeutic area, a recent study found that only 13.8 percent of all drug candidates successfully passed through clinical trials and received FDA approval.⁷⁵ For the valuation of pharmaceutical companies with a pipeline of drugs in development, the uncertainty associated with the approval process and commercial success is measured probabilistically, reflecting factors such as the stage of development, clinical trial success, and anticipated efficacy and ultimate adoption of the drug in the market.⁷⁶

46. To reflect the uncertainty associated with the success of a pipeline drug, financial forecasts are typically “risk-adjusted,” in that they reflect management’s expectations of a pipeline drug’s “probability of regulatory and technical success” (“PTRS”).⁷⁷ These expectations can vary markedly both over time and across pipeline products. For example, Purdue management’s estimate of PTRS for pipeline drugs in its 2015 projections ranged from 4.1 percent for its [REDACTED] to 28.2 percent for [REDACTED] (also referred to as [REDACTED]).⁷⁸ By June 2016, management’s estimate of BOX’s PTRS had increased to 34 percent, while the drug with the lowest PTRS was [REDACTED], another chronic pain medication, with a PTRS of 16 percent.⁷⁹

47. Taking into account the risks associated with drug development has a major impact on Purdue’s expected sales and value. As of June 2015, management-projected sales of pipeline products were projected to grow from \$13.9 million in 2019 to \$1.98 billion by 2025 prior to taking into account risk. However, once the PTRS is taken into account, the risk-adjusted net revenues in 2025 were projected to be \$331 million.⁸⁰ Failure to take into account the probability that

⁷⁴ “Development & Approval Process | Drugs,” FDA, available at <https://www.fda.gov/drugs/development-approval-process-drugs#:~:text=Developed%20and%20Approved.-,FDA%20Approval%3A%20What%20it%20means,risks%20for%20the%20intended%20population.,> accessed May 27, 2021.

⁷⁵ Berezow, Alex, “Clinical Trial Success Rates By Phase and Therapeutic Area,” *American Council on Science and Health*, June 11, 2020.

⁷⁶ See, e.g., “Our ECTRIMS Slide Deck Thoughts, Detailed Conf Planner and CONFIRM Expectations,” *RBC Capital Markets*, October 12, 2011, pp. 1-93 at p. 71.

⁷⁷ See, e.g., Finance Update, June 9, 2015, PPLPC054000123288 at p. 18.

⁷⁸ Finance Update, June 9, 2015, PPLPC054000123288 at p. 18.

⁷⁹ Purdue Mid-year Update, June 8, 2016, RSF00017771-921 at 916.

⁸⁰ Finance Update, June 9, 2015, PPLPC054000123288 at p. 18.

pipeline drugs may not succeed would result in significant overstatement of Purdue's expected sales and asset value. At the same time, using non-risk-adjusted expenses will tend to understate the value of Purdue's pipeline products. This is because Purdue would not incur further expenses on a product (*e.g.*, sales and promotion expenses or R&D costs) if the drug fails in a clinical trial or does not receive regulatory approval. Given the uncertainty of approval and commercial success of a drug in development, pipeline drugs at an early stage of their development are expected to have a relatively small impact on the value of Purdue relative to the value associated with OxyContin, other existing products, or products closer to final regulatory approval.

48. In the next section of my report, I discuss how I incorporate these factors that affect the fair market value of Purdue's operating assets into my valuation. I also outline the criteria for selecting the Purdue management projections that I base my DCF valuation on.

C. Purdue's Financial Forecasts

49. A valuation of a company or its assets is inherently forward looking. The value of an asset at a particular point in time is based on the future benefits that the owner of the asset expects to enjoy in the form of cash flows, rather than past performance:

The truth is that, when earnings have once been "realized," so that they can be expressed with some approach to accuracy in the company's accounts, they are already water under the mill and have no direct bearing on what the property in question is now worth. Value, under any plausible theory of capitalized earning power, is necessarily forward looking. It is an expression of the advantage that an owner of the property may expect to secure from the ownership in the future. The past earnings are therefore beside the point, save as a possible index of future earnings.⁸¹

50. In order to implement the Income Approach to value Purdue's operating assets, I have utilized projections of financial performance that Purdue's management produced in the ordinary course of business. Based on my experience, reliance on management projections of this type is a customary starting point to value a business both in business contexts and in the litigation context. I received a total of 46 sets of financial projections that I understand were prepared by

⁸¹ Bonbright, James C., *Valuation of Property*, 1937, as quoted in Pratt (2008), p. 59 (emphasis in original).

management over the 2008-16 Period.⁸² (See **Exhibit 5**). I reviewed the projections for completeness and reasonableness. I selected the projections that I mainly use for the DCF analysis based on the following criteria:⁸³

- Draft versus final documents. I gave less weight to projections that were labeled or appeared as drafts—except in the limited instances for which no final projections were available in a given year—because documents that do not appear to be finalized may not fully represent management’s contemporaneous views.⁸⁴
- Availability of financial statement information. I selected sources that provide projections for the Income Statement and Cash Flow Statement. These statements together provide the necessary inputs into the DCF analysis.
- Projection period includes loss of exclusivity. Where available, I selected sources which explicitly model the loss of exclusivity of OxyContin, and the impact of that loss on financial performance. As I discussed above and in more detail below, loss of exclusivity has a significant impact on projected revenues and profit margins and thus on estimates of the value of the company. The specific year at which management expected Purdue to lose exclusivity of OxyContin changed over the 2008-16 Period and, for my analysis, I use the expected date of loss of exclusivity at the time each forecast was prepared.
- Risk-adjusted projections for pipeline products. When valuing the expected value of pipeline pharmaceuticals, it is appropriate to discount the expected value of a pharmaceutical pipeline for the probabilities of achieving regulatory approval and

⁸² See **Appendix D** and **Exhibit 5**. Many of these projections did not meet the full set of selection criteria because of missing financial statements, projection periods that did not include loss of exclusivity, or did not provide risk-adjusted forecasts of the development pipeline. In cases where multiple projections in a single year met the criteria (e.g., in 2014, 2015, and 2016), the projections were identical to one another. If none of the projections for a single year met the criteria, I chose the projection that was closest to meeting the criteria and adjusted it as appropriate.

⁸³ See **Appendix D** for a more in-depth discussion of the projections used in my valuations.

⁸⁴ In some years, only a draft version of a particular financial statement was available. For example, of the projections available in 2009, only one document, an internal Excel workbook, contained a forecasted 10-year Cash Flow Statement. For my 2009 DCF model, I therefore relied on this Cash Flow Statement, which appears to have been a draft document. See Purdue Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662.

commercial success. Therefore, I utilize “risk-adjusted” projections that reflect management’s expectations of the probability of success of drugs in Purdue’s development pipeline. For years where risk-adjusted projections were not available, I risk-adjusted the sales forecasts based on the most contemporaneous success probabilities available. In these instances, I use non-risk-adjusted projections of expenses. As noted above, using non-risk-adjusted expenses will undervalue Purdue’s drug pipeline because it does not adjust for expenses that Purdue would not incur if a pipeline drug fails to achieve regulatory approval.

- Separate projections for existing products. As I discuss in **Section VII** below, to conduct the Capital Adequacy Test, I consider a scenario which only ascribes value to Purdue’s existing products. In other words, I assume that a willing buyer would assign no value to Purdue’s drug pipeline. Thus, I identify management projections that provide management sales projections for just existing products.

51. These criteria are designed so that the projections used in each valuation of Purdue’s operating assets capture as much as possible Purdue management’s expectations of the key long-term drivers of the firm’s value. This is reasonable given that the value of Purdue fluctuates with respect to the expected remaining time before Purdue loses its exclusive right to sell OxyContin, based on changes in the expected success of its pipeline products, and based on changing trends in sales of its products. Basing the valuation only on projections that do not extend beyond OxyContin’s loss of exclusivity or which do not adjust pipeline products for the risk that they will not succeed would result in an over-estimate of the value of Purdue’s operating assets. I also note that the projections typically do not vary greatly within a particular year and generally are produced at regular points in time in each calendar year.⁸⁵ Where there are significant changes in management’s expectations, the projections generally discuss the reasons for those changes.⁸⁶

⁸⁵ Many of the available financial projections date from May, June, or November of a year, as these appear to be times in which Purdue management regularly updated their forecasts of business performance. See **Exhibit 5** and **Appendix D**.

⁸⁶ See, e.g., Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 8. In these 10-year financial projections dated June 2015, management notes a change in the 2016 Net Sales projection for Butrans from the prior 10-year plan. Management cites an anticipated settlement and higher rebates, partially offset by stronger demand, as the reasons for this change.

D. Purdue's Historical and Projected Financial Position During the 2008-16 Period

52. In this section, I provide background and context for the consistency and reasonableness of the forecasts used for my valuation analysis. First, I present a series of exhibits based on the historical, consolidated, audited financials of Purdue and its “associated companies”⁸⁷ for the years 2008 through 2016. I do not have historical audited financial information specifically for PPLP and PPI (the entities included in management’s forecasts and used for my valuation of Purdue’s operating assets), but I have reviewed the audited financials for Purdue and its associated companies. I am not aware of any documents or other evidence indicating that those audited financials are not reliable. Second, based on my review of Purdue’s actual financial results and the trends and issues facing the company during the 2008-16 Period, I am not aware of any reason why the management projections should be set aside as unreasonable.

53. **Exhibit 6** compares the historical sales of Purdue to Purdue management’s Net Sales forecasts as of each year from 2008 through 2016. As shown in **Exhibit 6**, Purdue’s forecasted sales during the 2008-16 Period generally followed the trend in the actual sales of Purdue. The forecasts also reflect a substantial decline in forecasted Net Sales following the loss of exclusivity of OxyContin, which shows the substantial impact that the patent cliff has on Purdue’s forecasted Net Sales.⁸⁸

54. **Exhibit 7** shows a summary of components of the consolidated income statements of Purdue and its associated companies from 2008 to 2016. Net sales increased from \$2,098 million in 2008 to \$2,450 million in 2009, before decreasing to \$1,599 million in 2016. Similarly, net income increased from \$1,352 million in 2008 to \$1,605 million in 2010, before decreasing to

⁸⁷ The consolidated audited financial statements prepared by Ernst & Young LLP cover a set of companies that are broader than PPLP, including but not limited to PRA and its subsidiaries, Pharma Associates Inc., and companies classified as “associated companies,” among others. These small number of non-debtor entities likely do not have a substantial impact on the consolidated financial statements relative to PPLP, and it is reasonable to compare the historical sales of Purdue’s consolidated entities to the forecasted sales of PPLP to assess the reasonableness of management’s forecasts.

⁸⁸ As discussed in more depth in **Appendix D**, management projections for 2008, 2009, and 2016 did not extend far enough into the future to capture the expected impact of patent cliffs. It was therefore necessary to extend management’s projections using other years’ projections in order to reflect this impact on Purdue’s value.

\$576 million in 2016. Research and development expenses ranged from \$182 million to \$327 million annually during this period.

55. **Exhibit 8** shows the consolidated cash and cash equivalents of Purdue and its associated companies from 2008 to 2016, along with free cash flows from operations calculated from its historical income statement.⁸⁹ Purdue's cash ranged from \$339 million in 2009 to \$1,217 million in 2015, and decreased to \$1,153 million in 2016.⁹⁰ Purdue's free cash flows from operations ranged from \$615 million in 2016 to \$1,715 million in 2010, decreasing steadily during that time.

E. DCF Valuation of Purdue's Operating Assets During the 2008-16 Period

56. To assess the value of Purdue's operating assets, I use the DCF model to estimate the present value of Purdue's expected future income. As I discuss above, the remaining time of exclusivity for OxyContin is highly relevant to the value of Purdue's operating assets, especially given the limited expected contribution of Purdue's drug pipeline during the 2008-16 Period. For these reasons, it is my opinion that a DCF analysis is the most appropriate method for the valuation of Purdue's operating assets as it allows the most flexibility for accounting for the expected cash flow from Purdue's specific drug portfolio.

57. My approach is consistent with both the theory and practice of valuation. In particular, the DCF is used extensively by both practitioners and academics to value companies and is widely accepted in courts.⁹¹ Unlike valuation approaches that rely on historical data, the

⁸⁹ Free Cash Flows are calculated as (Income Before Taxes) - (the sum of all interest accounts) - (Income Tax Provisions) + (Depreciation and Amortization) - (increases in Working Capital) - (Capital Expenditures).

⁹⁰ Purdue's cash does not include restricted cash amounts listed on the balance sheet. Restricted cash is included on Purdue's balance sheet in 2010 through 2014, and ranges from \$8 million to \$53 million. See **Exhibit 8**.

⁹¹ See, e.g., Pratt (2008), p. 57 ("it is noteworthy that in recent years courts have become much more accepting of the application of the discounted cash flow method as a valuation methodology"); Stearn (2007), p. 379 ("...at least some courts have expressed a preference for the income approach), citing the following three cases: (1) *In re Med Diversified, Inc.*, 334 B.R. at *9-*10 ("the leading authorities on business valuation . . . 'recognize that the most reliable method for determining the value of a business is the Discounted Cash Flow ('DCF') method.'"); (2) *In re Longview Aluminum, L.L.C.*, 2005 Bankr. LEXIS 1312, at *11 ("The preferred method of valuing a business as a going concern is by performing a discounted cash flow analysis."); (3) *Lippe v. Bairnco Corp.*, 288 B.R. 678, 689 (S.D.N.Y. 2003) ("Many authorities recognize that the most reliable method for determining the value of a business is the discounted cash flow ('DCF') method.").

DCF allows for the flexibility to directly model key value drivers of a business that are expected to change in the future (e.g., loss of exclusivity).⁹² As Pratt (2008) discusses:

*In the simplest sense, the theory surrounding the value of an interest in a business depends on the future benefits that will accrue to its owner. The value of the business interest, then, depends upon an estimate of the future benefits and the required rate of return at which those future benefits are discounted back to present value as of the valuation date. Thus, the theoretically correct approach is to project some category or categories of the future benefits of ownership (usually some measure of economic income, such as cash flow, earnings, or dividends) and estimate the present value of those future benefits by discounting them based upon the time value of money and the risks associated with ownership.*⁹³

58. In my DCF analysis, I use management's financial forecasts of sales, expenses, and income discussed above, in combination with estimates of expected tax obligations on that income, changes in working capital, and expected long-term growth rate to estimate the expected future free cash flows of the firm. I then express the free cash flows in present value terms as of the valuation date, using a discount rate that is equal to Purdue's cost of equity (which I discuss below in **Section III.E.2** and **Appendix E**).

59. Free cash flow represents the net cash a company generates from its operations and which is available to stakeholders. In deriving the free cash flows, I consider both the sources and uses of cash. I convert the projected EBIT to free cash flows by:

- Subtracting the income tax obligations;⁹⁴

⁹² See, e.g., Stearn (2007), p. 379 ("The income approach may be particularly useful when the debtor was engaged in an expansion plan on the transfer date, as the value of the plan may be reflected in the debtor's projections."), citing Del. Open MRI Radiology Assocs., P.A. v. Kessler, 898 A.2d 290, 315 n.51 (Del. Ch. 2006) ("When the court determines that the company's business plan as of the [valuation date] included specific expansion plans or changes in strategy, those are corporate opportunities that must be considered part of the firm's value.").

⁹³ Pratt (2008), p. 56.

⁹⁴ I understand that, pursuant to its limited partner structure, PPLP did not pay taxes directly, and instead made a tax distribution that the limited partners would use to pay taxes. See *In re Purdue Pharma L.P., et al.*, Debtors, Case No. 19-23649, Disclosure Statement for Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors, June 2, 2021, p. 168. However, in assessing the value that a willing buyer would pay, it is reasonable to assume that such a buyer would account for the buyer's anticipated tax obligation in determining the value of the assets because the buyer would assume the tax obligation upon acquiring the entity.

- Adding back depreciation and amortization as they do not represent actual use of cash;
- Adjusting for non-cash gains or losses on Purdue's investments as such gains/losses do not represent an actual source or use of cash;
- Adjusting for changes in net working capital; and
- Subtracting capital expenditures.

60. In the case of net working capital (which is the difference between a company's current assets and its current liabilities, and is an indicator of the short-term cash sources/needs to support the operation), a negative change (*i.e.*, a decrease) in net working capital implies a delay in the use of cash, which would increase the cash balance. Conversely, a positive change (*i.e.*, an increase) in net working capital requires the use of cash, which would decrease the cash balance.

61. The period over which free cash flows are projected should ideally be long enough to capture expected changes in the performance of the business (in particular the loss of exclusivity for OxyContin), while at the same time recognizing that uncertainty about business prospects increases the farther one goes into the future. Therefore, I calculate Purdue's annual expected free cash flows over a set period of time, typically ten years from the valuation date.⁹⁵

62. Because projections are only for a set period of time, it is necessary to estimate the value of the firm beyond the explicit annual projection period. This is typically done by estimating the "terminal value" of the firm, which is the discounted value of the future free cash flows beyond the projection period in perpetuity. The terminal free cash flows are estimated based on an expectation about the long term growth of free cash flows (*i.e.*, the terminal growth rate).

63. Since the purpose of the DCF valuation is to estimate an asset value as of a specific date, the free cash flows in both the projection period and in the terminal period are expressed in terms of their present value as of the valuation date. The discount rate used to calculate the present value is typically the firm's weighted average cost of capital ("WACC"), which represents the rate

⁹⁵ For 2009, I extend the projection period of the DCF model by one additional year beyond management projections, to 11 years, to include the second year after OxyContin loss of exclusivity. For 2012, the projection period of the DCF model is nine years, based on the projections provided by management. For 2015, the projection period of the DCF model is 11 years, based on the projections provided by management. *See Exhibit D-2, Exhibit D-5, and Exhibit D-8.*

a company expects to pay, on average, to finance its assets.⁹⁶ The sum of the present value of all future free cash flows, including the terminal value, represents the value of the company as a whole, or what is often referred to as the “enterprise value.” In the rest of this section I discuss the inputs into the DCF and my calculations in more detail.

1. Terminal Value

64. As discussed above, “terminal value” refers to the portion of a firm’s value after the forecast period. Terminal value is typically computed using what is referred to as the “Gordon Growth Model,” which assumes that cash flows will grow at the same rate (g) in perpetuity.⁹⁷ This model is based on the assumption that, as of the terminal value date, the firm has reached a steady state in which cash flows will grow at a constant rate and factors such as profit margins and tax rates will remain stable. Terminal value is calculated using the following formula:

$$\text{Terminal Value} = FCF_n * (1 + g)/(r - g)$$

where FCF_n is the free cash flow in the final year of the forecast period, g is the terminal growth rate, and r is the WACC. Other things being equal, the terminal value will be higher when free cash flows in year n are higher, the WACC is lower, and the terminal growth rate is higher.

65. The terminal growth rate is the long-term growth rate of revenues, earnings, and cash flows for the firm. Because a company cannot grow faster than the economy as a whole in the long run, the nominal rate of growth in gross domestic product (GDP) is generally viewed as the upper bound on a terminal growth rate. During the relevant time period, estimates of long-term nominal GDP growth rates for the United States typically were four percent or less.⁹⁸

66. In the case of Purdue, however, lower estimates of the firm’s long-term growth rate are justified. The company’s projections generally indicate that the company’s revenues and cash flows were not expected to maintain its historical levels of growth after it lost exclusivity for

⁹⁶ McKinsey (2010), p. 108 (“...the WACC represents rates of return required by the company’s debt and equity holders blended together, and as such is the company’s opportunity cost of funds.”).

⁹⁷ Pratt (2008), p. 242; Damodaran (2012), p. 324.

⁹⁸ OECD data shows that median nominal GDP growth in the 2008-16 Period was 3.7 percent (range: -1.79 percent to 4.42 percent). See “Economic Outlook No. 109 - May 2021,” OECD, available at <https://stats.oecd.org/Index.aspx?DataSetCode=EO#>, accessed June 4, 2021.

OxyContin, and expectations varied over time depending on management's forecasts for the firm's drug pipeline. Maintaining a long-term positive growth rate for the firm would require Purdue to consistently develop and gain approval for new products that would more than replace the loss of existing products' declining revenues and margins over time. Although Purdue's historical financial statements show Purdue's sustained investment in its pipeline, Purdue's lack of a diversified product mix and track record in gaining approval for new products does not provide sufficient support for such an assumption.⁹⁹ As I discuss below, I utilize terminal growth rates of zero percent and negative four percent across the valuation scenarios that I estimate to reflect the long-term growth expectations for Purdue under each scenario.¹⁰⁰

2. *Discount Rate*

67. In order to value a company as of a specific point in time (*i.e.*, on the valuation date), it is necessary that all future cash flows be discounted back to that valuation date. To do this, a discount rate that is commensurate with the risk of these cash flows is needed. The discount rate reflects an investor's opportunity cost of their investment and is the rate of return that they would earn on an investment with comparable risk. Discount rates typically reflect a firm's WACC, which represents the cost of different components of a firm's capital, such as debt and equity. The weights used in the WACC reflect the capital structure of the firm.

68. To estimate a discount rate for Purdue, I considered the following. First, Purdue does not have appreciable long term debt. As a result, I assume that the relevant discount rate is the rate of return that equity investors would expect to receive for a company without debt. This cost of equity capital is more precisely referred to as an unlevered equity discount rate. Second, because Purdue is a privately-held company and, as such, does not have its own publicly-traded stock from which to estimate a discount rate, I estimate its discount rate from data for a set of

⁹⁹ Research and development expenses ranged from \$182 million to \$327 million annually during the 2008-16 Period. See **Exhibit 7**.

¹⁰⁰ The long-term growth rates I utilize are consistent with those assumed for Purdue by JPMorgan and Goldman Sachs. JPMorgan valued PPLP in 2014 and assumed a terminal growth rate in the range of negative two percent to zero percent. See "Discussion Materials," J.P. Morgan, August 13, 2014, PPLPC022000838293-373 at 308. Goldman Sachs valued PPLP in 2009 and assumed a terminal growth rate in the range of negative four percent to zero percent. See "Discussion Materials for Purdue," Goldman, Sachs & Co., July 14, 2009, PPLPC042000017723-775 at 742.

public companies which are comparable to Purdue. I discuss my methodology for identifying comparable companies and calculating the discount rate in more depth in **Appendix E**.

69. To estimate the cost of equity capital for the comparable firms, I use the Capital Asset Pricing Model (“CAPM”). The CAPM is a simple and widely used model for deriving the cost of equity capital for firms that is based on the following formula:¹⁰¹

$$\text{Cost of Equity} = \underbrace{r_f}_{\text{Risk-free Return}} + \underbrace{\beta * (\text{Expected Return}_{\text{Market}} - r_f)}_{\text{Non-diversifiable Risk Premium}}$$

70. In the CAPM, a firm’s cost of equity capital is the sum of the expected return on a risk-free investment and a risk premium for non-diversifiable risk (systematic risk) that the holder of the stock bears.¹⁰² The risk premium for the cost of equity capital is calculated as the product of the risk premium of the broad market and a firm’s beta, which represents how sensitive a stock is to the returns of the broader market. As I am measuring an unlevered equity discount rate, I use an unlevered beta, which assumes a firm finances itself exclusively with equity.

71. The CAPM requires three inputs: the risk-free rate, beta (in this case, estimated based on the comparable companies), and the U.S. market risk premium. I estimate Purdue’s discount rate as of each year’s valuation date for each year between 2008 and 2016. Discount rates can vary over time to reflect changes in the risk of cash flows as of the point in time of each valuation date. The details of the estimation for each of these inputs is described in **Appendix E**.

72. **Exhibit 9** present the results of my estimate of a reasonable discount rate to calculate the present value of Purdue’s expected future cash flows for each year between 2008 and 2016. While all of the comparable firms selected operate in the pharmaceutical industry, most of these firms’ sales are more diversified than those of Purdue. Given the concentrated nature of Purdue’s product portfolio, the expected decline in Purdue’s sales after the loss of exclusivity without replacement, and the greater risk that this presents, it is my opinion that it is appropriate to consider a premium to the median discount rate implied by the comparable companies. I therefore benchmark Purdue’s discount rate to the rates implied by the upper quartile of discount rates implied by the comparable companies. Therefore, based on the range of discount rates

¹⁰¹ See, e.g., Brealey, Richard, et al., *Principles of Corporate Finance*, McGraw-Hill Irwin, Tenth Edition, 2011, (“Brealey 2011”), pp. 192-193.

¹⁰² See Brealey 2011, pp. 192-193; Pratt (2008), p. 201.

implied by the comparable firms and the characteristics of those firms relative to Purdue, I estimate that Purdue's discount rate ranged between nine percent to twelve percent over the 2008-16 Period.

3. *Asset Valuation*

73. To estimate the value of Purdue's operating assets for purposes of my solvency analysis, I consider all future expected cash flows of Purdue, including the expected risk-adjusted cash flows from its drug pipeline. In other words, I include the expected risk-adjusted sales from Purdue management's forecasts, taking into account the expenses associated with developing the drugs and the cost of seeking FDA approval, which are also included in management's forecasts. I calculate a terminal value with a long-term growth rate assumption of zero percent after the loss of OxyContin exclusivity.¹⁰³ For each year of the 2008-16 Period, I also run sensitivities on the valuation by 1) varying the discount rate by plus and minus two percent, and 2) varying the terminal growth rate by minus four percent. These sensitivities are designed to assess the extent to which my valuations of Purdue's operating assets are affected by my modeling assumptions, as well as the robustness of my opinion regarding the Balance Sheet Test of solvency.¹⁰⁴ The results of the sensitivity analyses are shown in **Exhibit 10**. Based on these results, I conclude that the value of Purdue's operating assets (before taking into consideration Purdue's excess cash) was not less than \$1.4 billion, and was as high as \$9.2 billion during the 2008-16 Period, with sensitivities not less than \$1.3 billion, and as high as \$10.6 billion during the 2008-16 Period. The declining trend in value over the 2008-16 Period reflects expectations about the loss of exclusivity related to OxyContin, as well as the decreasing optimism of Purdue's management regarding the company's pipeline products.

¹⁰³ See, e.g., Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453 at 376.

¹⁰⁴ I do not incorporate a terminal value in my valuation of Purdue's operating assets for 2009, 2011, and 2014. As discussed in **Appendix D**, both 2009 and 2011 utilize non-risk-adjusted expenses which result in an understatement of the value of Purdue's pipeline and thus its expected long-term growth and terminal value. Management projections for 2014 did not incorporate projections for Purdue's pipeline, which was considered "fairly weak" at that point in time. See, e.g., Email from David Sackler to Paulo Costa *et al.*, Subject: "RE: (BN) S&P 500 Companies Spend Almost All Profits on Buybacks, Payouts," October 27, 2014, RSF00735509-516 at 509.

74. My valuation of Purdue's assets also takes into account the excess cash that Purdue held on each of the valuation dates that is not captured in the value of the operating assets.¹⁰⁵ It is appropriate to consider excess cash when assessing the solvency of a company using the balance sheet test, because excess cash represents cash available to the company in excess of that needed to operate the business and that is not restricted. My calculation of excess cash is net of all distributions that had been made by PPLP up to the valuation date. I calculate excess cash as follows:

$$\begin{aligned} \text{Excess Cash} &= \text{Cash and Cash Equivalents} \\ &\quad - \text{Max [Total Current Liabilities} \\ &\quad - (\text{Total Current Assets} - \text{Cash and Cash Equivalents}), 0] \\ &\quad - \text{Restricted Cash} \end{aligned}$$

I determine that during the 2008-16 Period, Purdue held excess cash ranging from \$232 to \$750 million. See **Exhibit 11**.

75. I summarize my calculations of the value of Purdue's assets for the 2008-16 Period in **Exhibit 12** and in **Figure 4** below. Based on my analyses, I conclude that the combined value of Purdue's operating assets and excess cash was not less than \$1.9 billion and was as high as \$9.5 billion during the 2008-16 Period.

¹⁰⁵ "Excess cash" is cash that is in excess of the amount needed to operate a company as a going concern and is not restricted for other uses. If the operating assets of a company are to be sold, then the owner would typically distribute the excess cash to shareholders before the sale. See McKinsey (2010), p. 145.

Figure 4. Summary of DCF Valuation of Purdue's Assets, 2008-2016¹⁰⁶

Year	Valuation (\$ millions)		
	Value of Operating Assets	Excess Cash	Total
2008	9,157	386	9,543
2009	5,724	282	6,006
2010	7,457	232	7,689
2011	4,693	264	4,958
2012	4,590	349	4,939
2013	2,967	562	3,530
2014	1,377	568	1,945
2015	2,103	750	2,853
2016	1,625	693	2,318

F. Guideline Public Company Valuation of Purdue

76. I also consider the valuation multiples implied by the GPCM valuation approach for the purposes of my solvency opinion. As previously mentioned, GPCM is a market-based approach that indicates the value of a business based on the implied price multiples of comparable public companies using relevant financial indicators such as earnings, earnings before interest, taxes, depreciation and amortization (“EBITDA”), or sales.

77. Market-based approaches can provide valuable information regarding how investors evaluate the financial prospects and condition of companies, as well as how news or changing information can affect those assessments. To be a reliable valuation method, however, this approach requires a set of comparable companies that are as similar to the subject firm as possible. The comparable companies should be similar with respect to the general business model and industry in which the companies operate. They should also have similar key value drivers, such as growth, profitability, geographic coverage, and size. In addition, comparable companies

¹⁰⁶ The DCF valuation for 2014 is lower than that of 2013 or 2015 because management did not project a significant contribution to future performance from its pipeline drugs. See **Exhibit 12, Appendix D**, and **Exhibit D-7**.

will ideally be in a steady state of their life cycle, rather than an early stage, late stage, or period of transition.

78. While the comparable companies I identified to estimate Purdue's discount rate face similar risks as Purdue, Purdue has unique characteristics that reduce the reliability of the GPCM approach for valuing the firm's assets. In particular, Purdue's heavy reliance on OxyContin sales means that expectations of its future growth and profitability are tied to the expected timing of OxyContin's patent cliff, trends in opioid prescriptions generally, and Purdue's success in developing its pipeline drugs. As discussed previously, Purdue's sales and profits were expected to decline considerably in the years following the patent cliff, before eventually stabilizing at a lower sales level in the long term. These factors are difficult to control for in the context of the GPCM, particularly given expected changes in Purdue's value as the patent cliff approaches and the prospects for some pipeline drugs dimmed over time.

79. I nonetheless have implemented the GPCM approach for valuing Purdue's operating assets utilizing the set of comparable companies I previously identified.¹⁰⁷ I obtained Enterprise Value ("EV") to Revenue, EV to earnings before interest and taxes ("EBIT"), and EV to EBITDA multiples of the comparable companies based on expected performance over the next twelve months from CapIQ. **Exhibits 13a to 13c** report the multiples for each comparable company over time, as well as the median and interquartile range of multiples. The exhibits also show the implied value of Purdue's operating assets based on these trading multiples and projections of its next twelve month financial performance as of each valuation date.¹⁰⁸ As can be seen by comparison to the valuation of Purdue's operating assets in **Exhibits 13a to 13c**, both the 25th percentile and median value estimates based on the comparable company trading multiples are generally higher than those I estimate based on the DCF Method.

80. Based on my review of Purdue's financial results and projections and comparable companies, it is my opinion that the DCF valuation is more appropriate given the facts of this case. Given the company-specific valuation drivers for Purdue, I do not believe the valuations that I obtain through the GPCM approach are as reliable in this case as the values derived from the DCF

¹⁰⁷ I also analyzed the trading multiples for a set of publicly traded opioid manufacturers that I describe in my report. The trading multiples of these entities do not change the conclusions that I draw from the trading multiples of the broader set of comparable entities.

¹⁰⁸ For purposes of this analysis, I did not adjust the implied value of Purdue to reflect a control premium.

approach presented above. As I discuss in **Section IV**, however, I do find that market information about other companies currently with significant opioid-related litigation can provide insight regarding investors' perceptions of the specific risks associated with manufacturing and marketing opioid products. Although the primary drivers of Purdue's asset value differ considerably from those of other pharmaceutical companies, both Purdue and other companies that have been involved in opioid litigation have faced similar opioid related litigation risk.

IV. VALUE OF PURDUE'S LIABILITIES

81. In **Section III** above, I described my methods for assessing the value of Purdue's assets. Specifically, I calculate a value of the assets based on my analysis of Purdue's expected free cash flows as of each valuation date in the 2008-16 Period. To conduct a solvency analysis, one must compare the value of the subject company's assets to its total liabilities, and compare its expected cash flow in each period contemporaneously to payments that the subject company is expected to make to satisfy its liabilities in full, and on time, in each period. In this section of my report, I discuss the liability obligations that Purdue faced as of each valuation date over the 2008-16 Period.¹⁰⁹

82. To assess the liabilities of Purdue, I analyze the company's balance sheet from the consolidated, audited financials of Purdue and its associated companies and financial forecasts from Purdue's management. A company's balance sheet contains a snapshot of both the current and future liabilities of the firm as of a point in time. However, as I discuss below, because the balance sheet is prepared according to generally accepted accounting principles ("GAAP"), it may not reflect all of the company's future liabilities. Therefore, it is necessary to look beyond just the reported liabilities on the balance sheet to obtain an understanding of a firm's total liability and potential liability obligations at any point in time. In this case, I analyze Purdue's balance sheet liabilities as of the date of each valuation as well as any future opioid litigation liabilities that may

¹⁰⁹ I understand Purdue had in excess of \$3 billion in insurance coverage for some liabilities, but my analysis does not consider such insurance coverage or how it might reduce Purdue's estimated liabilities. See *Purdue Pharma L.P., et al. v. AIG Specialty Insurance Company (F/K/A/ American International Specialty Lines Insurance Company), et al.*, Adv. Pro. No. 21-7005, Complaint, p. 5. My analysis is thus conservative to the extent insurance coverage can be used to offset any of the potential liabilities described in this section.

have reasonably been expected over the 2008-16 Period but were not required to be reported on Purdue's balance sheet.

83. I describe my analyses of Purdue's liabilities below, starting with Purdue's balance sheet liabilities, followed by my analysis of whether there was a reasonable expectation of the 2017 increase in Pending Actions over the 2008-16 Period and my estimate of Purdue's potential future opioid litigation liabilities at various points in time over the 2008-16 Period. As discussed below, I conclude that Purdue's aggregate liabilities did not reasonably exceed \$694 million at any point during the 2008-16 Period and that the 2017 increase in Pending Actions was reasonably not anticipated.

A. Purdue's Balance Sheet Liabilities

84. **Exhibit 14** shows the current and long-term liabilities of Purdue and its affiliated companies as reported on its audited balance sheet as of each valuation date during the 2008-16 Period. Current and long-term liabilities ranged from a minimum of \$529 million in 2008 to a maximum of \$922 million in 2014. I explain each of these liabilities and how I incorporate them in my solvency analysis below.

1. Current Liabilities

85. Current liabilities represent the majority of Purdue's balance sheet liabilities during the 2008-16 Period, ranging from a minimum of \$307 million in 2008 to a maximum of \$636 million in 2014. Current liabilities include accrued expenses (such as accrued rebates, accrued bonuses and salaries, and the current portion of accrued settlement expenses), which are explained in more detail below:

- Accrued rebates: The largest portion of accrued expenses on Purdue's balance sheet are rebates offered by Purdue to payers. A rebate is the return of part of the purchase price of a prescription drug by the manufacturer to the payer, and is most commonly used for brand-name prescription drugs to incentivize payers to include the

manufacturer's drugs on their formularies.¹¹⁰ Rebates are recorded as accrued expenses at the time of the sale. At the time the rebate is made (which is usually after the sale), Purdue records a reduction in its accrued expenses.

- Accrued settlement expenses: This item represents Purdue's liability associated with the various lawsuits that Purdue settled. While these amounts include settlement expenses related to legal proceedings involving Purdue's opioid products, they also include settlements related to other types of lawsuits such as patent infringement, and antitrust proceedings, among others. During the 2008-16 Period, the highest accrued settlement expense recorded for a given year during the 2008-16 Period was \$65.4 million in 2014 for various lawsuits, claims and proceedings.¹¹¹

86. The accrued settlement expenses are incorporated in my DCF as an annual expense line item. Similarly, the accrued rebate expenses are reflected in the DCF in the change in net working capital line item. Accordingly, and as explained in more detail in **Section IV.D** below, I do not include Purdue's current liabilities in my calculation of the liabilities to offset against Purdue's asset value and cash flows for the purpose of my solvency analysis, so as not to double count the liability.

2. *Long-Term Liabilities*

87. During the 2008-16 Period, Purdue had virtually no long-term debt, with \$770,000 reported in 2014 only. Purdue's long-term liabilities during this time pertained almost exclusively to "Other Liabilities," generally comprised of employee benefits and the non-current portion of accrued settlement expenses.¹¹² As shown on **Exhibit 14**, these "Other Liabilities" ranged from a minimum of \$128 million in 2009 to a maximum of \$226 million in 2012. As explained in more detail in **Section IV.D** below, I incorporate these "Other Liabilities" in my solvency analysis.

¹¹⁰ See "A primer on prescription drug rebates: Insights into why rebates are a target for reducing prices," *Milliman*, May 21, 2018, available at <https://www.milliman.com/en/insight/a-primer-on-prescription-drug-rebates-insights-into-why-rebates-are-a-target-for-reducing>, accessed June 12, 2021.

¹¹¹ Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2014 and 2013, POK003285615-664 at 635, 654-662.

¹¹² The financial statements break out both accrued expenses and other liabilities into their subcomponents. See, e.g., Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended December 31, 2007 and 2008, PPLPC012000221168-206 at 185, 186.

B. Purdue's Additional Opioid Litigation Liabilities

1. Overview

88. Unlike many bankruptcies, where a debtor files for bankruptcy because it is unable to meet payment obligations on its debt, Purdue's bankruptcy was not caused by any default on debt, as Purdue did not have any substantial debt during the 2008-16 Period. Rather, as discussed previously, I understand that Purdue's bankruptcy was triggered by more than 2,700 opioid actions filed against it in the Pending Actions. Nearly all of these Pending Actions were filed in or after 2017, and thus after the 2008-16 Period. *See Exhibit 2.* A key element in assessing Purdue's liabilities is therefore the extent to which the increase in Pending Actions and any future associated liabilities from those actions were anticipated. I assess the reasonable foreseeability of the sharp increase in Pending Actions from an economic perspective, and the extent to which associated future litigation expenses and liabilities could be reasonably anticipated over the 2008-16 Period by evaluating market-based evidence.

89. I first review trends of pending litigations involving Purdue prior to, during, and after each valuation date as well as Purdue's history of settling and resolving opioid related claims.¹¹³ I also evaluate contemporaneous public information regarding opioid related litigation, investigations, and settlements by certain other manufacturers of opioid drugs. These trends inform how a contemporaneous market participant may have evaluated the risk that significant future litigation would materialize against Purdue, and the extent of any associated liabilities.

90. Next, I review contemporaneous disclosures made by Purdue in its audited financial statements regarding its litigation risk and liabilities associated with its opioid drugs. Purdue and its auditors did not disclose significant litigation liabilities associated with product liability and personal injury claims, nor did the audited financial statements during the 2008-16 Period disclose any risk or liabilities associated with the eventual increase in Pending Actions. As I discuss in **Section IV.B.3**, the fact that there were no disclosures anticipating the substantial increase in the Pending Actions until 2017 is consistent with the conclusion that Purdue's management considered the prospect of a substantial increase in litigations to be at most a remote risk and not quantifiable.

¹¹³ *See, e.g.*, Email from Howard Udell, Subject: "RE: Settlement," January 27, 2007, PPLPC044000010048-054.

91. I also evaluate contemporaneous analyses by investment banks and credit rating agencies that assessed the value and creditworthiness of Purdue during the 2008-16 Period. A review of those analyses indicate that sophisticated third parties did not anticipate a significant increase in litigation risk, the Pending Actions or associated liabilities, during the 2008-16 Period.

92. In addition to information specific to Purdue, I analyze contemporaneous market information to infer how the broader market viewed the exposure of other entities involved with the manufacturing of prescription opioids to litigation risk, the Pending Actions, and associated liabilities. Many of the other pharmaceutical firms that were also defendants in the Pending Actions had publicly-traded stocks and credit ratings during the 2008-16 Period. Contemporaneous analysis of how the market valued these stocks and assessed the companies' creditworthiness is useful because one can infer from such information how the market has collectively "priced" the opioid litigation risk that is at issue at various points in time. The securities I have analyzed trade in equity markets that are widely accepted as liquid and quickly incorporate information into the price of the securities. Thus, I analyze the price movements of these securities over the 2008-16 Period to assess the extent to which market valuations of the equity of public companies that were also subject to the Pending Actions reflect an anticipation of significant future liabilities associated with the increase in opioid litigation beginning in 2017. From these analyses, I conclude that the market did not anticipate the increase in Pending Actions, or related liabilities associated with the large increase in Pending Actions in 2017, during the 2008-16 Period.¹¹⁴

93. Based on the totality of the evidence described above (and explained in detail below), I conclude that during the 2008-16 Period, the risk of a substantial increase in the number of Pending Actions was not reasonably foreseeable. However, as described in **Section IV.B.2** below, I estimate and include for purposes of my solvency analysis additional opioid-related liabilities beyond the amounts recorded on Purdue's balance sheet during the 2008-16 Period.

¹¹⁴ As described later in my report, I do note that, at least in one instance, the market price of one company, Insys, declined in December 2013 following news of a subpoena. I incorporate this reaction into my analysis of Purdue's potential future opioid related liabilities.

2. *Purdue's Opioid Litigation Trends Prior to, During, and Following the 2008-16 Period*

94. As I discuss in **Section II.C**, Purdue was facing certain pending lawsuits and investigations related to their opioid products during the 2008-16 Period. To summarize, I include the following additional liabilities that were not required to be reported on Purdue's balance sheet in my solvency analysis:

- I understand that in January 2008, management advised Purdue's board of directors that all outstanding OxyContin lawsuits could be settled for approximately \$200 million.¹¹⁵ By the end of 2011, the majority of these lawsuits had been dismissed or settled. *See Section IV.B.2.a*. Thus, for the purposes of conducting the solvency tests, between 2008 and 2011, I add an additional \$200 million liability to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation.¹¹⁶
- Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses.¹¹⁷ Thus, of the \$200 million in potential future liabilities, \$19 million remained after 2011, when the majority of the product liability cases were settled. Therefore, between 2012 and 2015, I add an additional \$19 million liability to the liabilities reported on Purdue's balance sheet to account for the remaining portion of management's expectation of future settlements of pending opioid litigation (the difference between Purdue management's 2008 estimate of \$200 million to settle pending lawsuits and \$181 million of settlement expenses already accrued). In 2015, Purdue settled a litigation with the state of Kentucky for \$24 million.¹¹⁸ I am aware

¹¹⁵ Board of Directors Meeting Agenda, PPLP, January 11, 2008, PPLP004400663-719 at 677.

¹¹⁶ Board of Directors Meeting Agenda, PPLP, January 11, 2008, PPLP004400663-719 at 677.

¹¹⁷ Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2009 and 2008, PPLPC012000270659-697 at 677, 678; Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2010 and 2009, PPLPC012000323951-991 at 970; Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2011 and 2010, PPLPMDL0040000537-583 at 558.

¹¹⁸ *In re Commonwealth of Kentucky v. Purdue Pharma L.P. et al.*, Settlement Agreement and General Release, December 18, 2015, PPLPUCC000701839-859; Lowrey, Brandon, "Kentucky AG Settles OxyContin, Risperdal Suits For \$39.5M," *Law360*, December 23, 2015. I also understand from Counsel that the \$24 million settlement with Kentucky was inflated by a procedural error that put Purdue at risk of admitting liability, and a

that this settlement resolved a longstanding case brought by the state of Kentucky, even after the other product liability cases had been settled. Rather than foreshadowing future litigation and settlements with other states, this 2015 settlement resolved the known claims of a holdout from litigation filed in 2007.¹¹⁹ In 2015, Purdue also settled an investigation by the New York Attorney General for a payment of \$75,000.¹²⁰

- Finally, as described in greater detail below, beginning at the end of 2013 when Purdue received a subpoena from the New York Attorney General followed by a few other investigations as described below, I estimate and add, in my conservative case, an additional \$472 million in liabilities to the liabilities reported on Purdue's balance sheet for 2013 to 2016 to account for potential liabilities associated with government investigations into Purdue's marketing practices. This figure is based on my event study of Litigation Comparables which finds that the announcement of such investigations could result in between zero and \$472 million in liabilities.

95. To sum up, my estimates of future liabilities associated with the pending suits and government investigations faced by Purdue during the 2008-16 Period are as follows:

- From 2008 through 2011, \$200 million;
- In 2012, \$19 million;
- In 2013 through 2015, \$19 million to \$491 million (which is the sum of \$19 million and \$472 million); and
- In 2016, zero to \$472 million.

Purdue executive submitted an affidavit to address the potential adverse consequences of that procedural error. *See Purdue Pharma L.P. v. Commonwealth of Kentucky ex rel. Conway*, Case No. 2013-CA-001941, Affidavit of Edward B. Mahony, February 4, 2014; *Purdue Pharma L.P. v. Commonwealth of Kentucky ex rel. Conway*, Case No. 2013-CA-001941, Opinion and Order Denying Petition for Writ of Prohibition, February 28, 2014.

¹¹⁹ Lowrey, Brandon, "Kentucky AG Settles OxyContin, Risperdal Suits For \$39.5M," *Law360*, December 23, 2015. As noted in footnote 43, *supra*, I understand from Counsel that nearly all of the claims alleged by Kentucky in its 2007 suit pertained to alleged misconduct that preceded 2001 and that corresponded almost verbatim to conduct admitted in connection with the Purdue 2007 Guilty Plea and settled by D.C. and the other 49 states.

¹²⁰ *See In the Matter of Purdue Pharma L.P. et al.*, Assurance No. 15-151 (N.Y. Aug. 19, 2015), Assurance of Discontinuance.

96. The types of opioid litigation that gave rise to potential liabilities during or prior to the 2008-16 Period can be grouped into two categories: 1) litigation from individual opioid users who claim to have been injured by Purdue's products and 2) litigation brought by non-individual plaintiffs, including government entities, against Purdue and other entities that manufactured and distributed prescription opioids. In the next section, I discuss trends in these categories.

a. Litigation Trends from Individual Opioid Users


97. Prior to the 2008-16 Period, Purdue faced litigation from individual opioid users who claimed to have been injured by Purdue's products. While many of those individual cases were either dismissed or settled prior to the 2008-16 Period,¹²¹ Purdue still faced a number of outstanding product liability claims during the 2008-16 Period.

98. **Figure 5** and **Exhibit 15** show the number of pending domestic OxyContin product liability litigations against Purdue during the 2008-16 Period on an annual basis.¹²² By the end of 2011, the majority of the pending lawsuits during the period from 2008 to 2010 were either dismissed or settled. Between April 2012 and March 2017, Purdue faced between 18 and 24 domestic product liability cases with, at most, only three of those cases being actively litigated in any year. By March 2016, there were no domestic product liability cases being actively litigated against Purdue.

¹²¹ See, e.g., Email from Howard Udell, Subject: "RE: Settlement," January 27, 2007, PPLPC044000010048-054 at 051, 052.

¹²² Exhibit C to the Complaint for Injunctive Relief, *PPLP v. Commonwealth of Massachusetts*, Adv. Pro. No. 19-8289-rdd [Dkt. Nos. 1-3] identifies 13 Canadian proceedings that were pending against Purdue when the bankruptcy commenced. I understand from counsel that 11 of those proceedings were filed during the 2008-16 Period, 10 of which were putative class actions disclosed in Purdue's financial statements and that are the subject of a \$20 million settlement pending court approval since February 2017. See Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2016 and 2015, PPLPC021000890262-316 at 304 (noting the settlement as of February 2017). I understand from counsel that the one remaining Canadian action pending during the 2008-16 Period was an individual personal injury action.

Figure 5. Purdue Financial Statement Disclosures of OxyContin Civil Product Liability Litigation: Number of Pending and Actively Litigated Product Liability Lawsuits



99. As described in **Section II.C** above, Purdue’s management advised the board of directors that all of the pending opioid litigation could be settled for \$200 million.¹²³ As shown in **Figure 5**, the vast majority of these lawsuits were subsequently dismissed or settled by April 2012. Therefore, for the purposes of my solvency analysis, I add an additional \$200 million liability to the liabilities reported on Purdue’s balance sheet in 2008 through 2011 to account for management’s expectation of future settlements of pending opioid litigation. Of management’s estimate of \$200 million to settle future liabilities, \$19 million remained after 2011 when the majority of the product liability cases were settled. I therefore add an additional \$19 million liability to Purdue’s balance sheet liabilities for potential future settlements from 2012 to 2015, when the Kentucky litigation was settled.

¹²³ Board of Directors Meeting Agenda, PPLP, January 11, 2008, PPLP004400663-719 at 677.

b. Litigation and Investigation Trends by Non-Individual Plaintiffs

100. I also consider the trend of opioid litigation brought by non-individual plaintiffs, including government entities, against Purdue and other entities that manufactured and distributed prescription opioids during the 2008-16 Period. This category—which post-dates the 2007 settlement with the U.S. Department of Justice, the 2007 settlement of certain Medicaid claims with 48 states and the District of Columbia, and the 2007 Consent Judgments with 26 states—includes two matters with New York and Kentucky that resulted in settlements during the 2008-16 Period.¹²⁴ It also includes the few Pending Actions that commenced during the 2008-16 Period. *See Exhibit 2*. I do not offer an opinion as to the merits of any of the Pending Actions, which I understand were disputed by the Debtors prior to bankruptcy.¹²⁵

101. The number of newly filed opioid litigations against Purdue brought by non-individuals during the 2008-16 Period was small in number and is in direct contrast to the sharp uptick in the Pending Actions that began in 2017. As shown in *Exhibit 2*, in each of the years from 2014 to 2016, only one or two of the Pending Actions were filed against Purdue.¹²⁶ In 2017, however, there were 344 new opioid cases filed against Purdue, and by 2018, 1,486 new cases had been filed. I also understand that by 2019, the vast majority of these lawsuits were still outstanding and additional lawsuits were continuing to be filed, which triggered Purdue's bankruptcy.¹²⁷ Thus,

¹²⁴ See “Justice Department Recovers \$2 Billion for Fraud Against the Government in FY 2007; More Than \$20 Billion Since 1986,” U.S. Department of Justice, November 1, 2007, available at https://www.justice.gov/archive/opa/pr/2007/November/07_civ_873.html, accessed June 3, 2021; Silverman, Ed, “J&J and Purdue Pharma settle with Kentucky for \$40M over marketing claims,” *Stat*, December 23, 2015, available at <https://www.statnews.com/pharmalot/2015/12/23/20818/>, accessed June 9, 2021; *In the Matter of Purdue Pharma L.P. et al.*, Assurance No. 15-151 (N.Y. Aug. 19, 2015), Assurance of Discontinuance..

¹²⁵ Debtors' Informational Brief, p. 1 (“... Debtors have contested—and continue to contest—their liability in the Pending Actions ...”).

¹²⁶ As explained in footnote 1 above, the Pending Actions are listed in **Appendix G**, supplied by Counsel, which I understand from Counsel is based on the state, federal and tribal proceedings listed in Exhibits A, B and C to the Complaint for Injunctive Relief, *PPLP v. Commonwealth of Massachusetts*, Adv. Pro. No. 19-8289-rdd [Dkt. Nos. 1-1 and 1-2] and the exhibits to the preliminary injunction order now in effect [Dkt. No. 264 (18th Amended Order)]. Five Pending Actions filed before 2017 were referenced in Purdue's financial statements. *See, e.g.*, Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2014 and 2013, POK003285615-664 at 661-662.

¹²⁷ Debtors' Informational Brief, pp. 1-3.

the litigation that ultimately caused Purdue to file for bankruptcy was the large uptick in new opioid litigation from 2017 onwards, the majority involving claims brought by non-individuals.¹²⁸

102. Although the number of Pending Actions did not increase meaningfully until 2017 and 2018, I have seen references in Purdue's documents that certain governmental entities sent subpoenas and began investigations prior to 2017. Specifically, apart from the 2013 investigation by New York that resulted in a \$75,000 settlement in 2015, Purdue's financial statements describe a request for information from the Attorney Generals ("AGs") in Tennessee and California in 2014,¹²⁹ subpoenas or similar requests from the Massachusetts, New Hampshire and Oregon AGs in 2015,¹³⁰ and the formation of a multi-state AG investigation in December 2016.¹³¹ As I describe later in my report, other firms were also defendants in the Pending Actions, and made public disclosures that they also received subpoenas or similar requests from Attorneys General. Despite the disclosures made by those public companies, before 2017, analysts did not foresee, and market prices did not reflect, the exponential number of Pending Actions that also affected these firms beginning in 2017, nor an expectation of large future opioid related litigation liabilities. However, as I describe below, in at least one instance, there was a negative impact to the equity value of one company that also marketed and sold opioid products when it announced it had received a subpoena from the Office of Inspector General of the Department of Health and Human Services ("HHS") in connection with an investigation of potential violations involving HHS programs.¹³² I discuss this in more detail in **Section IV.B.5**, **Section IV.B.6**, and **Section IV.C** below.

¹²⁸ Debtors' Informational Brief, p. 38 ("the vast majority of plaintiffs in the Pending Actions – approximately 2,250, or more than 85% – are governmental entities").

¹²⁹ See Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2014 and 2013, POK003285615-664, at 661.

¹³⁰ See Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2015 and 2014, PPLPCO11000090527, p. 50.

¹³¹ See Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2016 and 2015, PPLPC021000890262-316 at 310. As discussed below in **Section IV.C.1**, Purdue also received subpoenas from the U.S. Attorney for the District of Connecticut "related to OxyContin and Q12 dosing" in June and September 2016.

¹³² "Insys Therapeutics Receives Subpoena From Office of Inspector General," *Bloomberg*, December 12, 2013.

3. *Review of Purdue's Audited Financial Statements*

103. To inform my analysis of Purdue's potential liabilities for purposes of my solvency analysis, I reviewed Purdue's Audited Combined Financial Statements for the years 2008 through 2017. The objective of this research was twofold. First, I reviewed the audited financial statements for disclosures about opioid litigation generally, and the Pending Actions specifically. Under GAAP, companies must include on the balance sheet any "existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an entity that will ultimately be resolved when one or more future events occur or fail to occur."¹³³ A loss contingency is recorded as a liability on the balance sheet only when (i) it is "probable" that a liability had been incurred, and (ii) the amount of the loss can be reasonably estimated.¹³⁴ The term "probable" in this instance is used when "[t]he future event or events are likely to occur."¹³⁵ For companies facing potential litigation that has not yet been asserted (an "Unasserted Claim"), the company must first assess whether it is probable that litigation claims may be filed, and, if so, then assess the probability of an unfavorable outcome.¹³⁶

104. If an estimated liability from a loss contingency is not required to be accrued on the company's balance sheet, GAAP may require that the company disclose the risk associated with the loss contingency if there is at least a reasonable possibility that a liability may be incurred at a future date, but does not require the disclosure of an associated liability amount.¹³⁷ GAAP defines the term "reasonably possible" as "[t]he chance of the future event or events occurring is more than remote but less than likely."¹³⁸ No accrual or disclosure is required for events for which the likelihood of loss is remote. In the specific instance of Unasserted Claims, no accrual or disclosure

¹³³ Accounting Standards Codification ("ASC") 450-20-20 (Glossary).

¹³⁴ ASC 450-20-25-2.

¹³⁵ ASC 450-20-20 (Glossary).

¹³⁶ ASC 450-20-55-14 and 15. GAAP requires the best estimate of a loss contingency to be accrued, but also recognizes that there are situations in which a company can only reasonably estimate a range of amounts. When no single amount within a range is determined to be a better estimate than any other, a company is only required to recognize the minimum amount within the range. See ASC 450-20-25-5 and ASC 450-20-30-1.

¹³⁷ ASC 450-20-50-3 and 450-20-50-4. The disclosure shall include the "nature of the contingency" and "[a]n estimate of the possible loss or range of loss or a statement that such an estimate cannot be made."

¹³⁸ ASC 450-20-20 (Glossary). GAAP also defines "remote" as "[t]he chance of the future event or events occurring is slight."

is required “if there has been no manifestation by a potential claimant of an awareness of a possible claim,” unless the company determines that it is probable a claim will be asserted and it is reasonably possible that the outcome will be unfavorable.¹³⁹

105. I reviewed the audited financials of Purdue and its associated companies, Purdue’s financial results that were included in its management projections, as well as the audited financials of certain publicly-traded companies that also marketed and sold opioid products during the 2008-16 Period. **Appendix F** lists the litigation disclosures made by Purdue and the other manufacturers of opioid medications during the 2008-16 Period that I evaluated, and **Section IV.B.5** describes the litigation disclosures of these other manufacturers of opioid medications during the 2008-16 Period. None of the companies’ audited financial statements I reviewed made disclosures about the risk, or potential liabilities, associated with the 2017 uptick in Pending Actions during the 2008-16 Period. In other words, while there were disclosures about a small number of investigations, neither Purdue nor other manufacturers of opioid drugs, nor their auditors, considered a growing volume of Pending Actions to be “probable” or even “reasonably likely.” The fact that there were no disclosures over the 2008-16 Period anticipating an uptick in the Pending Actions that were filed in 2017 corroborates that such an uptick in litigation was remote at most.


106. The accounting standards reflect the fact that all businesses face remote events that may give rise to loss contingencies that are not reasonably predictable *ex ante* — including, for example, potential criminal misconduct by employees, natural disasters and health epidemics. These are risks that, if materialized, could have an impact on the company’s business. Such remote events are not required to be recorded or expected to be disclosed under the accounting standards. It is assumed that all businesses face such events that might give rise to loss contingencies.

107. The second reason for reviewing the audited financial statements is to assess the amount of legal fees and settlement expenses disclosed by Purdue to establish a benchmark from which to evaluate potential liabilities related to the claims that had been filed against Purdue during the 2008-16 Period. Furthermore, a meaningful increase in litigation or settlement expenses may suggest a heightened exposure to litigation risk.

¹³⁹ ASC 450-20-50-6.

108. Data from the audited financials of Purdue and its associated companies, as well as Purdue's historical financials (as aggregated from Purdue management's projections), demonstrate the limited financial impact of actual opioid litigation costs and settlements on its financial position during the 2008-16 Period. **Figure 6** and **Exhibit 16** show the accrued settlement expenses and legal expenses reported in Purdue's financial statements from 2006 through 2016. I note that the legal expenses include expenses for litigation and services not related to opioid litigation and therefore overstate the historical costs of these litigations. For example, the legal expenses also include the cost incurred in connection with patent litigation.¹⁴⁰

Figure 6. Purdue's Accrued Settlement Expenses and Legal Expenses, 2006-2016¹⁴¹



109. As **Figure 6** shows, during the 2008-16 Period, Purdue incurred total legal expenses of \$527 million from 2008 through 2016, for an average of \$59 million per year and a maximum

¹⁴⁰ See, e.g., "Finance Update," June 9, 2015, PPLPC054000123288, at p. 60.

¹⁴¹ The sharp increase in Accrued Settlement Expenses in 2006 represents the \$579 million accrual pertaining largely to Purdue's settlement with the U.S. Attorney's Office for the Western District of Virginia in July 2007. See Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended December 31, 2008 and 2007, PPLPC012000221168-206 at 199, 200; Purdue, "2008-2009 Budget Submission," November 2008, PPLPC051000064746 at p. 418.

of \$78 million in 2008 and minimum of \$47 million in 2014. Overall, while legal expenses were relatively higher in the years preceding the 2008-16 Period, they generally stabilized over the duration of the 2008-16 Period. Purdue's legal expenses increased thereafter, rising to \$67 million in 2017 and \$128 million in 2018.¹⁴²


110. **Figure 6** also shows, in 2006, Purdue incurred a large accrued settlement expense of \$529 million associated with the more than \$600 million settlement with the U.S. Department of Justice and 49 states, and the majority of its then-outstanding individual personal injury and product liability cases. Of the \$529 million in accrued settlement expenses, \$490 million was reported as a current liability, whereas \$39 million was reported as a non-current liability.¹⁴³ By 2007, following the aforementioned settlement with the U.S. Department of Justice and 49 states, Purdue's current accrued settlement expense dropped to \$45 million, and at the start of the 2008-16 Period, Purdue had only \$19 million in current accrued settlement liabilities. Current accrued settlement expenses declined to as low as \$16.5 million by the end of 2016.

111. **Figure 7** and **Exhibit 17** show Purdue management's forecasts of legal expenses over the 2008 to 2025 period, as of each of the valuation dates. Within the 2008-16 Period, the forecasts for legal expenses began trending downward starting with the 2012 forecast, thereby indicating that management was not anticipating a significant increase in legal expenses during or after the 2008-16 Period.

¹⁴² See Purdue Pharma Inc., "Board of Directors Meeting Finance Update," March 7, 2019, PPLPUCC9002365418-440 at 421; Purdue, "Board of Directors Meeting: Finance Update and 2019 Budget Proposal," December 7, 2018, PPLPUCC9002364573-680 at 581.

¹⁴³ Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended December 31, 2006 and 2005, PPLPC012000144598-636 at 614.

Figure 7. Management Projections for Purdue's Legal Expenses, 2008-2016



112. These financial metrics show that, after the 2007 settlements and during the 2008-16 Period, Purdue did not incur or expect to incur other large settlements or legal fees, and it did not accrue or have the reasonable expectation of any additional substantial settlement liabilities.

113. The financial metrics and disclosures discussed above were reported in Purdue's audited financial statements during the 2008-2016 Period, when a small number of Pending Actions were first launched, and when Purdue settled with the New York Attorney General and with Kentucky in 2015. These audited financial statements are consistent with the conclusion that the company and its auditors-untainted by hindsight-did not expect that substantial additional Pending Actions would be filed and that significant additional liabilities would be incurred.

4. *Third Party Valuations and Credit Assessments of Purdue Did Not Anticipate a Significant Increase in the Pending Actions or Include Additional Opioid Litigation Liabilities in Their Analyses*

114. Sophisticated third parties, such as Goldman Sachs, J.P. Morgan, and credit rating agencies Moody's and Standard & Poor's, evaluated Purdue's (and specifically PPLP's) financial projections and business risks at various points in time over the 2008-16 Period. This information

is informative for assessing the economic foreseeability of the substantial increase in Pending Actions and any potential future liabilities associated with opioid litigation and investigations not already accounted for on Purdue's balance sheet. Goldman Sachs prepared an assessment of Purdue's business in July 2009.¹⁴⁴ JPMorgan likewise prepared a valuation and assessment in August 2014.¹⁴⁵ Around April 2016, Moody's and Standard & Poor's provided indicative credit ratings for PPLP as part of an evaluation of the firm's ability to access debt markets to raise capital.¹⁴⁶

115. These assessments of Purdue's financial prospects and risks provide a contemporaneous evaluation of Purdue by sophisticated third-party market professionals. This section of the report comments on the extent to which these contemporaneous assessments indicate that significant future liabilities associated with opioid litigation were anticipated. As discussed below, these reports did not incorporate an anticipation of significant future risk of opioid litigation, including the large increase in Pending Actions that ultimately led to PPLP's filing for bankruptcy, nor did these reports anticipate future litigation liabilities that would render Purdue insolvent.

116. The 2009 Goldman Sachs presentation did not identify a risk that Purdue could be subject to new opioid litigations. Rather, the litigation-related risk that Goldman Sachs identified was patent litigation between Purdue and other opioid manufacturers, Endo and Teva.¹⁴⁷ These firms were attempting to manufacture drugs similar to OxyContin, which could significantly impact Purdue's sales and profit margins.¹⁴⁸ JPMorgan also did not indicate the potential for an uptick in opioid litigation as a risk to Purdue as of 2014. Instead, JPMorgan discussed Purdue's litigation risk related to ongoing patent litigation with other opioid manufacturers that could impact the exclusivity of OxyContin.¹⁴⁹

¹⁴⁴ See "Discussion Materials for Purdue," Goldman, Sachs & Co., July 14, 2009, PPLPC042000017723-775.

¹⁴⁵ See "Discussion Materials," J.P. Morgan, August 13, 2014, PPLPC022000838293-373.

¹⁴⁶ Indicative Ratings Letter, Moody's Investors Service, March 30, 2016, PPLPUCC003938943-946; Indicative Ratings Letter, Standard & Poor's, April 7, 2016, PPLPUCC000360920-926.

¹⁴⁷ "Discussion Materials for Purdue," Goldman, Sachs & Co., July 14, 2009, PPLPC042000017723-775 at 733.

¹⁴⁸ "Discussion Materials for Purdue," Goldman, Sachs & Co., July 14, 2009, PPLPC042000017723-775 at 733.

¹⁴⁹ "Discussion Materials," J.P. Morgan, August 13, 2014, PPLPC022000838293-373 at 336.

117. Similarly, Moody's and Standard & Poor's rated a potential PPLP issuance of \$400 million of senior secured loan debt at Ba3/BBB, and a \$100 million senior secured revolver at Ba3/BBB-, and provided a corporate credit rating of BB/Ba3 with a Stable outlook.¹⁵⁰ Moody's commented that the notes had "minimal risk of debt impairment," while Standard & Poor's commented that lenders could expect a "very high" recovery in the event of default.¹⁵¹ The only litigation risk that the two rating agencies identified as a risk to its ability to repay debt was that associated with Purdue's settlements with generics manufacturers. Specifically, Moody's March 30, 2016 report anticipated a "steady erosion" of PPLP's OxyContin sales "[a]s a result of declining market demand, increased competition from new branded abuse-deterrent medications and authorized generic sales of OxyContin (as per Purdue's settlement agreement with generic drug companies)."¹⁵² Shortly after, Standard & Poor's April 7, 2016 report modeled base case cash flows for PPLP with the expectation that "EBITDA will decline following the [authorized generic] settlements."¹⁵³ The ratings agencies notably did not discuss the risk of current or future Pending Actions or investigations as a risk to Purdue's ability to repay debt, which is consistent with a finding that Purdue was solvent as of 2016.

118. These analyses by sophisticated third-party market professionals did not identify an expectation of a substantial increase in Pending Actions, or additional opioid litigation liabilities, as a potential risk to Purdue in general or to PPLP in particular. Furthermore, the analyses undertaken in these reports do not suggest that Purdue was insolvent, or was in jeopardy of becoming insolvent.

5. *Disclosure of Opioid Litigation Risk in the Litigation Comparables' Financial Statements*

119. The Pending Actions were filed against many other opioid manufacturers in addition to Purdue. A review of the opioid litigation-related risk disclosures, including provision

¹⁵⁰ Indicative Ratings Letter, Moody's Investors Service, March 30, 2016, PPLPUCC003938943-946 at 943; Indicative Ratings Letter, Standard & Poor's, April 7, 2016, PPLPUCC000360920-926 at 920.

¹⁵¹ Indicative Ratings Letter, Moody's Investors Service, March 30, 2016, PPLPUCC003938943-946 at 943; Indicative Ratings Letter, Standard & Poor's, April 7, 2016, PPLPUCC000360920-926 at 921.

¹⁵² Indicative Ratings Letter, Moody's Investors Service, March 30, 2016, PPLPUCC003938943-946 at 944.

¹⁵³ Indicative Ratings Letter, Standard & Poor's, April 7, 2016, PPLPUCC000360920-926 at 924.

of any anticipated or realized accruals for these risks in the SEC filings by companies facing similar opioid litigation risk as Purdue provides useful information about the extent to which other market participants foresaw a significant increase in Pending Actions in the 2008-16 Period.

120. To determine an appropriate list of companies exposed to similar opioid litigation risk as Purdue, I identified the companies most often named as co-defendants in lawsuits brought against Purdue in the Pending Actions. Across all of these lawsuits, the top 20 most-named co-defendants are listed in **Figure 8** and **Exhibit 18**. These companies are all named co-defendants with Purdue in more than 750 opioid litigations.¹⁵⁴ This list includes opioid manufacturers, distributors, and pharmacies. A brief business description for each company is also included in **Exhibit 19**.

121. **Figure 8** and **Exhibit 18** show, by year, the number of lawsuits filed against each of these codefendants in the Pending Actions. This summary does not include any additional opioid lawsuits brought against these companies in which Purdue was not named as a co-defendant.

¹⁵⁴ See also **Appendix G**.

Figure 8. New Case Filings Related to Pending Actions Over Time Where Purdue is Also a Named Defendant (Top 20 Co-Defendants), 2014-2019

	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>Total</u>
Purdue	2	1	2	344	1,486	884	2,719
Endo	2	1	1	339	1,475	837	2,655
Janssen	2	1	1	332	1,429	844	2,609
Teva	1	1	1	328	1,408	841	2,580
Cephalon	1	1	1	331	1,406	796	2,536
AmerisourceBergen	-	-	2	309	1,373	835	2,519
Johnson & Johnson	2	1	1	320	1,367	797	2,488
Cardinal Health	-	-	2	310	1,350	810	2,472
Actavis	2	1	-	313	1,313	763	2,392
Allergan	2	1	-	311	1,303	775	2,392
Watson	2	1	-	306	1,306	723	2,338
Mallinckrodt	-	-	1	249	1,238	812	2,300
McKesson	-	-	2	299	1,197	784	2,282
Noramco	-	-	-	202	838	459	1,499
Walmart	-	-	2	151	654	486	1,293
Insys	-	-	1	155	567	545	1,268
Walgreens	-	-	1	118	491	504	1,114
CVS Health	-	-	1	123	509	480	1,113
Par	-	-	1	109	378	391	879
Rite Aid	-	-	1	109	403	303	816
SpecGx	-	-	-	95	274	423	792

122. Of the top 20 most-named co-defendants, six are prescription opioid manufacturers. Two of these six manufacturers are Johnson & Johnson and Allergan, which are large diversified pharmaceutical companies. Given that opioid medications represent a relatively small portion of the overall portfolios of Johnson & Johnson and Allergan, opioid litigation risk may affect their businesses differently than it would impact a company such as Purdue, which has a product portfolio concentrated on opioid products. Thus, I consider the litigation risk of the remaining four defendant manufacturers, Endo, Insys, Mallinckrodt, and Teva, to be most comparable to Purdue (hereafter, the “Litigation Comparables”). Two of these four companies, Insys and Mallinckrodt, filed for Chapter 11 protection in June 2019 and October 2020, respectively. In **Exhibit 20**, I provide a brief description of the opioid business of each Litigation Comparable relative to the overall businesses of each firm as a whole.

123. I reviewed each of the four Litigation Comparables' SEC Forms 10-K (and Forms 20-F and 10-K for Teva¹⁵⁵) for opioid litigation-related risk disclosures, including provision of any anticipated or realized accruals for these risks. Excerpts from those public filings that reference opioid litigation-related risk and provisions are set forth in **Appendix F**. As discussed below, like Purdue, while these other companies did disclose a small number of investigations and subpoenas during the 2008-16 Period, these companies did not disclose a risk of a substantial increase in Pending Actions until after the 2008-16 Period.

124. Prior to the end of 2013, the Litigation Comparables did not make any disclosures related to the Pending Actions to which they are now a party. During this period, the audited financials of these companies contained general discussions of risks related to product liability and government oversight of opioid drugs. Around 2014, the SEC filings of these companies began to disclose the receipt of subpoenas and commencement of investigations. In **Section IV.C** below, I analyze each company's stock price reaction to these disclosures. As discussed below, general price movements of the publicly traded securities of these companies suggest that even after these disclosures were made, the market did not reflect an anticipation of a significant uptick in opioid lawsuits that would later result in a few of them filing for bankruptcy.

125. Prior to its fiscal year 2017 10-K filing, Mallinckrodt did not include in its SEC filings any direct mention of the risk or foreseeability of a significant increase in Pending Actions. Mallinckrodt filed 10-Ks for the fiscal years ended September 2013 (filed December 2013) through December 2017 (filed February 2018). In its December 2013 filing, Mallinckrodt stated, "the DEA continues to increase its efforts to hold manufacturers, distributors and pharmacies accountable through various enforcement actions as well as the implementation of compliance practices for controlled substances, including [suspicious ordering monitoring] activities for Schedule II opioids."¹⁵⁶ In its 10-K for the fiscal year ended September 2015 (filed November 2015), Mallinckrodt disclosed it "may be involved in various legal proceedings and certain government inquiries and investigations."¹⁵⁷ The February 2018 filing was the first filing where Mallinckrodt

¹⁵⁵ Teva Pharmaceuticals is an Israeli company and trades on both the Tel Aviv Stock Exchange and certain U.S. stock exchanges. See Teva Pharmaceuticals Industries Limited, SEC Form 20-F, for the fiscal year ended December 31, 2014, p. 2.

¹⁵⁶ Mallinckrodt plc, SEC Form 10-K, for the fiscal year ended September 27, 2013, p. 30.

¹⁵⁷ Mallinckrodt plc, SEC Form 10-K, for the fiscal year ended September 25, 2015, p. 30.

discussed the multidistrict opioid litigation. It stated, “[t]he Company has been named in lawsuits court brought by various counties, cities, Native American tribes, hospitals, third-party payers and others against opioid manufacturers and, often, distributors.”¹⁵⁸

126. A review of 10-Ks filed by Endo shows that between 2007 and 2012, Endo’s 10-Ks contained disclosure language that acknowledged a risk of potential litigation, but did not specifically discuss an expectation of the high volume of litigations that were ultimately filed. For example, Endo stated, “[w]e may be subject to litigation similar to the OxyContin suits related to any narcotic-containing product that we market.”¹⁵⁹ Beginning with its 10-K for the fiscal year ended December 2013 (filed March 2014), Endo disclosed that it received subpoenas from the City of Chicago and State of New York Office of Attorney General related to its sales and marketing of Opana.¹⁶⁰ In its 10-K for the fiscal year ended December 2014, Endo disclosed that the City of Chicago and Orange County, California had filed lawsuits against multiple defendants, including Endo.¹⁶¹ However, Endo did not make any disclosures about widespread litigation targeting the company until 2018. In that year, it acknowledged that “any significant product liability or mass tort litigation in which we are a defendant could have a larger number of plaintiffs than such actions have seen historically and we could also see an increase in number of cases filed against us because of the increasing use of widespread and media-varied advertising.”¹⁶² Endo also stated that it was “unable to predict the outcomes of these matters or to estimate the possible range of any losses that could be incurred.”¹⁶³

127. Insys filed its first 10-K for the fiscal year ended December 2013. In that 10-K filing, Insys disclosed that it had “received a subpoena dated December 9, 2013 from the U.S. Department of Health and Human Services, Office of Inspector General.”¹⁶⁴ Insys further

¹⁵⁸ Mallinckrodt plc, SEC Form 10-K, for the fiscal year ended December 29, 2017, p. 124.

¹⁵⁹ *See* Endo Pharmaceuticals Holdings, SEC Form 10-K, for the fiscal year ended December 31, 2011, p. 44. *See also* Endo Pharmaceuticals Holdings, SEC Form 10-K/A, for the fiscal year ended December 31, 2007, p. 9.

¹⁶⁰ Endo Health Solutions Inc., SEC Form 10-K, for the fiscal year ended December 31, 2013, p. F-56.

¹⁶¹ Endo International plc, SEC Form 10-K, for the fiscal year ended December 31, 2014, pp. F-58-F-59.

¹⁶² Endo International plc, SEC Form 10-K, for the fiscal year ended December 31, 2017, p. 20.

¹⁶³ Endo International plc, SEC Form 10-K, for the fiscal year ended December 31, 2017, pp. F-50-F-51.

¹⁶⁴ Insys Therapeutics, Inc., SEC Form 10-K, for the fiscal year ended December 31, 2013, p. 47.

disclosed that the subpoena “primarily requests documents relating to the marketing of Subsys.”¹⁶⁵ In its 2014 10-K filing, Insys disclosed that it had also received a subpoena dated September 8, 2014 from the U.S. District Attorney’s Office for the District of Massachusetts.¹⁶⁶ Notably, Insys’ fiscal year 2017 10-K was the first one to disclose widespread litigation filed against it: “Multi-District Prescription Opioid Litigation. We have been named along with various other opioid manufacturers, opioid distributors, prescribers and others in complaints focused on the national opioid epidemic filed by various cities, counties, states, and third-party payers in many state and federal courts...[w]e are involved in more than 100 of these cases, over 70 of which have been consolidated into multi-district litigation...”¹⁶⁷

128. Teva filed 20-Fs for the fiscal years ending December 2006 through 2016, and a 10-K for the fiscal year ending December 2017. In Teva’s 2014 20-F filing, it disclosed that on May 21, 2014, “counsel for Santa Clara County and Orange County...filed a complaint in the Superior Court for Orange County, California against Teva and Cephalon...contending that defendants allegedly engaged in off-label promotion in the sale of opioids.”¹⁶⁸ As with the previously discussed companies, Teva’s 2017 10-K was the first of its annual filings to disclose widespread litigation filed against it with respect to opioid sales and distribution. In Teva’s 2017 10-K, it disclosed that the federal cases against Teva had been consolidated into a multi-district litigation in the Northern District of Ohio and that a “number of State Attorneys General, including a coordinated multistate effort, have initiated investigations into sales and marketing practices of Teva and its affiliates with respect to opioids.”¹⁶⁹

129. Prior to 2017, like Purdue, these firms had a few Pending Actions filed against them, but the companies, and their auditors, did not deem the likelihood of a large increase in such actions reasonably likely such that, under GAAP accounting, they would have to disclose the risk or an associated liability. This is additional corroborative support that market participants did not foresee the post-2017 proliferation of the Pending Actions during the 2008-16 Period.

¹⁶⁵ Insys Therapeutics, Inc., SEC Form 10-K, for the fiscal year ended December 31, 2013, p. 47.

¹⁶⁶ Insys Therapeutics, Inc., SEC Form 10-K, for the fiscal year ended December 31, 2014, p. 45

¹⁶⁷ Insys Therapeutics, Inc., SEC Form 10-K, for the fiscal year ended December 31, 2017, p. 105.

¹⁶⁸ Teva Pharmaceuticals Industries Limited, Form 20-F, for the fiscal year ended December 31, 2014, p. F-37.

¹⁶⁹ Teva Pharmaceuticals Industries Limited, SEC Form 10-K, for the fiscal year ended December 31, 2017, p. 163.

6. *Market Valuations of the Litigation Comparables' Financial Securities Do Not Anticipate Pending Actions Liability Prior to 2017*

130. In this section, I analyze the publicly traded securities prices of Purdue's Litigation Comparables. I use public market data to assess how market participants "priced" the risk of opioid litigation, and the incremental risk of the Pending Actions over the 2008-16 Period. The use of market data to infer the importance of an event, or expected event, on a company's value is common in economics.¹⁷⁰ Public markets value financial securities by aggregating and factoring in information from various sources that may be important to a company's value. One category of information that is relevant to the value of a company is risk, including the litigation risk a company and/or its industry may face. Moreover, the price of an efficiently traded public security reflects the market consensus at the time, which is untainted by information that only becomes known at a later time. If there is new information or an event that meaningfully changes market participants' expectations about future opioid litigation risk, one would expect to observe corresponding changes in the market's valuation or assessment of the company's publicly traded securities. Thus, by analyzing the market prices of the Litigation Comparables' securities, I am able to infer whether market valuations of the Litigation Comparables' stock reflect an anticipation of significant future opioid litigation and associated liabilities during the 2008-16 Period. In this section, I discuss the information I review, and the analyses I undertake, to assess whether the market prices of the Litigation Comparables' stock over the 2008-16 Period reflect an expectation that there would be a significant increase in the number of Pending Actions and related liabilities. Specifically, I analyze the Litigation Comparables' stock prices, equity analyst commentaries, credit ratings and report commentaries and the companies' abilities to raise capital.

a. *Stock Prices and Equity Analyst Commentaries*

131. A company's stock price represents the market's consensus estimate of the current value of the company based on its expected future cash flows, incorporating various sources of information about the company. One type of information relevant for the stock valuation is the

¹⁷⁰ See, e.g., Brav, Alon and J.B. Heaton, "Event Studies in Securities Litigation: Low Power, Confounding Effects, and Bias," *Washington University Law Review*, Vol. 93, No. 2, 2015, pp. 583-614, at p. 583; MacKinlay, Craig A., "Event Studies in Economics and Finance," *Journal of Economic Literature*, Vol. 35, 2007, pp. 13-39, at p. 13.

risks facing the company, including litigation risk. All else being equal, a heightened level of litigation risk increases the firm's expected future liabilities and reduces expected future cash flows available for equity holders, which in turn causes the stock price to decline. In addition, as the perceived increase in litigation risk creates meaningful downward movements in the stock price, one would expect to see more commentaries about the risk and its impact on the value of the stock in equity analyst reports.

132. In **Exhibits 21a to 21d**, I show the stock price of each of the Litigation Comparables from 2008 to 2020. The years after the 2008-16 Period, 2017 to 2020, are shaded in gray. I include years prior to the 2008-16 Period to analyze the possibility that the market had foreseen the Pending Actions and the associated liabilities in the years leading up to the start of the 2008-16 Period. On each exhibit, I benchmark the stock price to the S&P Pharmaceuticals Select Industry Index as of the first year of the stock price series.¹⁷¹ The stock prices of Endo, Insys, and Mallinckrodt all increased through early to mid-2015, and then drifted downwardly afterwards. Teva's stock price fluctuated between approximately \$30 and \$60 through 2015 and then declined persistently starting in 2016.

133. To determine whether the Litigation Comparables' stock prices trended downwardly starting in 2015 or 2016 because the market foresaw a large amount of opioid litigations to come in 2017, I reviewed a wide array of reports covering each of the Litigation Comparables authored by equity research analysts at either investment banks or equity research firms.¹⁷² I carried out two exercises. First, I looked for analyst commentary that discusses the reasons for the downward stock price movements starting in 2015 or 2016. Second, I conducted three separate keyword searches for "opioid," "litigation," and "settlement," respectively in the equity analyst reports issued during the 2008-16 Period. I then reviewed the results from the

¹⁷¹ The S&P 500 Pharmaceuticals Index (ticker: S5PHAR) is comprised of a subset of companies in the S&P 500 index that are classified in the pharmaceuticals sub-industry. For example, as of June 2021, the index constituents include, among others, Johnson & Johnson, Merck & Co, and Pfizer.

¹⁷² The equity analyst reports that I reviewed are those available on S&P Capital IQ. The publishers of the reports include: Barclays, Buckingham Research, Canaccord Genuity, Cantor Fitzgerald, CIBC Capital Markets, Credit Suisse, CRT Capital Group, Deutsche Bank, Duncan-Williams, FTN Midwest, G. Research, Gleacher & Co., Guggenheim Securities, J.P. Morgan, Janney Montgomery Scott, Jeffries, JPM Securities, Morningstar, Natixis Bleichroeder, Needham & Co., Northland Capital Markets, Oppenheimer, Piper Sandler, Raymond James, RBC, Roth Capital Partners, Sterne Agee & Leach, Susquehanna Financial Group, ThinkEquity, UBS, Wedbush Securities, and W.R. Hambrecht.

searches to determine whether the commentary discussed the risk of widespread future opioid litigation, the anticipation of significant new opioid lawsuits, or any expectation or estimation of settlements or liabilities related to new or existing opioid litigation.

134. In my first exercise, I found that overall, during the 2008-16 Period, equity analysts attributed the decline in the Litigation Comparables' stock prices to factors unrelated to the risk of opioid litigations. Specifically,

- In 2015 through early 2016, Endo's stock price fell sharply from the peak of nearly \$100 per share to under \$20, due to both a large litigation accrual relating to estimated claims against its surgical mesh product and increased competitive pressures in its generics business.¹⁷³ By 2017, Endo's stock price declined beneath \$10 a share, caused by additional accruals from the mesh litigation and settlements as well as the withdrawal of Opana ER from the market in June 2017.¹⁷⁴ This event occurred after the end of the time period for which I assess Purdue's solvency.
- From Insys's IPO in May 2013 through mid-2015, its stock price increased significantly from an opening price of around \$5 per share to a peak of nearly \$45 per share, with a brief but relatively sharp decline in early 2014. Equity analysts attributed the decline to allegations that a Michigan neurologist engaged in Medicare fraud pertaining to improper prescribing of Subsys, Insys's fentanyl-based opioid product.¹⁷⁵ From 2014 onward, equity analysts noted government investigations into the off-label promotion and marketing practices of Subsys as an overhang on Insys.¹⁷⁶ Despite this issue, analysts modified revenue forecasts only slightly and remained positive on the stock.¹⁷⁷ After reaching a peak in mid-2015, Insys's stock price began an initially sharp but increasingly gradual decline through the end of 2016,

¹⁷³ See "4Q15 Results: Mesh Liability and Generic Weakness Lead to Share Declines," *Oppenheimer*, March 1, 2016, p. 1.

¹⁷⁴ See "2Q Takeaways: Despite Strategic Actions, 2017/2018 Setup Remains Challenging," *J.P. Morgan*, August 7, 2017, p. 1.

¹⁷⁵ See "INSY: Lowering Estimates And Valuation Range But Remaining Positive On The Stock," *Wells Fargo Securities*, May 14, 2014, p. 1.

¹⁷⁶ See, e.g., "1Q14 Results: Revenue Misses, But Rx's Still Strong," *Oppenheimer*, May 14, 2014, p. 1.

¹⁷⁷ See "INSY: Michigan Neurologist Investigation Poses Risks But Sales Contribution Appears Modest," *Wells Fargo Securities*, May 12, 2014, p. 1.

attributable to the following factors: (1) a reduction in prescriptions for Subsys, as a result of competitive pressures from other generics manufacturers as well as physicians' cutting back on fentanyl-based pain medications,¹⁷⁸ (2) the delay in the FDA approval of one of Insys's non-opioid drugs, Syndros,¹⁷⁹ and (3) a DOJ investigation that ultimately resulted in the indictment of several former executives in late 2016 for bribery and a large expected settlement with the company.¹⁸⁰ Although negative news was released that related to investigations centered around Insys's opioid products, which is discussed further in the paragraphs that follow, there was no discussion of an expectation of the future increase in Pending Actions.

- Mallinckrodt's stock price generally increased between 2013 and 2014, and then declined starting in 2015. The stock price was relatively stable between late 2015 and mid-2016, with a short-term increase in price followed again by a downward trajectory into the end of 2016. Equity analysts' commentary attributed the price declines to issues related to the company's non-opioid product, Acthar.¹⁸¹ Sell-off of the stock also occurred following a patent litigation in September 2017 related to another of the company's non-opioid products, Inomax.¹⁸²
- Teva's stock price declined in 2010 due to the deterioration of sales of its leading non-opioid product, Copaxone, and challenges associated with integrating a company that it acquired in 2008.¹⁸³ Teva's stock price declined again in 2016 as a result of disappointing financial results attributable to the negative effect of the approval and launch of Mylan's generic competitor to Teva's Copaxone.¹⁸⁴

¹⁷⁸ See "2Q15 Results: Subsys Beat Not Enough," *Oppenheimer*, August 7, 2015, p. 1.

¹⁷⁹ See "Subsys Continues to Face Challenges," *Oppenheimer*, April 11, 2016, p. 1.

¹⁸⁰ See "Staying on the Sidelines for Now, But Pipeline Remains Potential Source of LT Upside," *Oppenheimer*, January 17, 2017, pp. 1, 3-4.

¹⁸¹ See, e.g., "Ghost from the past haunting MNK?" *Barclays*, September 21, 2015, p. 1; "Recent insider share purchases are encouraging; have we hit a valuation floor?" *Canaccord Genuity*, November 13, 2017, p. 1; "Quick thoughts on Generic sale speculation," *Deutsche Bank*, May 30, 2017, p. 1.

¹⁸² See "Inomax reaction overblown; legal fight not over," *Canaccord Genuity*, September 5, 2017, p. 1.

¹⁸³ See "Laquinimod Not Looking So Good" *UBS*, August 1, 2011, p. 2.

¹⁸⁴ See "Estimates, price target down again," *Barclays*, November 3, 2017, p. 1.

135. As to my second exercise, from my review, I did not find any analyst commentary consistent with an expectation of a large increase in opioid litigation risk and related liabilities during the 2008-16 Period. Instead, my review shows that during this period, equity analysts frequently commented on other non-opioid litigation matters, such as patent litigation and non-opioid product liability lawsuits, suggesting that litigation risk was a focus of the equity analysts covering these companies. However, many of the lawsuits discussed in those commentaries during the 2008-2016 Period, including product liability lawsuits, were not related to opioids. For example, Endo was a defendant in thousands of product liability lawsuits related to its surgical mesh product, which was a frequent topic of discussion in analyst reports in 2015 and 2016.

136. Equity analysts did discuss the regulatory risk associated with opioids, including commentary on actions of the Centers for Disease Control and Prevention (CDC), Drug Enforcement Administration (DEA), and Food and Drug Administration (FDA) with respect to opioids. While these commentaries during the 2008-16 Period demonstrate that prescription opioids are highly regulated and their manufacturers and distributors are subject to regulatory risk, equity analysts making these commentaries did not indicate that they were anticipating an eventual uptick in opioid lawsuits and liabilities like the uptick in Pending Actions observed starting in 2017.¹⁸⁵

137. My review of the analyst reports also suggests that in 2018 and 2019, equity analysts covering the Litigation Comparables started to consistently discuss the opioid litigation risk as a reason for the poor stock performances of these companies. These discussions contrasted considerably with the absence of commentary on the risk of increased litigation and associated liabilities during the 2008-16 Period. For example, a Deutsche Bank analyst report covering Endo in July 2018 referred to the opioid litigation as “a significant overhang.”¹⁸⁶ Similarly, a Barclays analyst report in September 2019 stated that “opioid lawsuits ... have been a significant overhang

¹⁸⁵ For example, on May 12, 2014, a Jefferies analyst wrote: “With opioid abuse being highly scrutinized in the US by the Drug Enforcement Agency (DEA) and more recently by FDA, we asked respondents if they are starting [to] notice external pressures to begin writing more scripts for abuse deterrent opioids and if so where these pressures are coming from. Nearly 20% confirmed this trend with one-third citing the need for FDA REMS compliance and half citing internal and third-party payer pressures.” See “Pain Survey Points to Strong Demand for Xartemis XR,” *Jefferies*, May 12, 2014, pp. 10, 12.

¹⁸⁶ See “What Could Make ENDP Work,” *Deutsche Bank*, June 1, 2018, p. 1.

on [Mallinckrodt's] shares.”¹⁸⁷ In May 2019, a Piper Jaffray analyst covering Insys commented that “given the recent conviction of [former CEO] John Kapoor, and the intense public pressure to punish not just individuals but companies that have played a role in one way or another in the opioid crisis, perhaps the end game of the federal government is INSY no longer being a going concern.”¹⁸⁸

138. To sum up, my review of the stock prices of the Litigation Comparables and equity analyst reports covering these companies did not find any information suggesting that prior to 2017, equity market participants anticipated the large uptick in Pending Actions against opioid manufacturers and distributors.

b. Credit Ratings

139. If an anticipation of an increase in opioid litigation and associated liabilities negatively affected the market's valuation and assessment of the Litigation Comparables' stocks, it may also have negatively impacted their debt securities, which are typically senior to equity. Opioid lawsuits ultimately led two of the four Litigation Comparables (as well as Purdue) to file for bankruptcy. Had the market begun to foresee the extent of the Pending Actions (or even a significant portion of them) during the 2008-16 Period, credit rating agencies the evaluated the debt of the Litigation Comparables would likely have commented on such risk.

140. A credit rating is a quantified assessment of the creditworthiness of a borrower. The two leading credit rating agencies for corporations are Moody's and Standard and Poor's ("S&P"). In their credit assessments, they consider various risk factors (including litigation risk) that could hinder a borrower's ability to repay its debt. I analyzed the changes in the Litigation Comparables' Moody's and S&P credit ratings during the 2008-16 Period and investigated whether in their credit ratings reports, the rating agencies commented on an expectation of increased opioid litigation risk, related liabilities that could impact the borrower's ability to pay.

¹⁸⁷ See “MNK: Is divestiture a prelude to a settlement?” *Barclays*, September 10, 2019, p. 1.

¹⁸⁸ See “The Writing Is On The Wall For Insys; Reiterating Underweight,” *Piper Jaffray*, May 12, 2019, p. 1.

141. Of the four Litigation Comparables, credit ratings were issued by Moody's or S&P for Endo, Mallinckrodt, and Teva.¹⁸⁹ **Exhibits 22a to 22c** show the credit ratings for these three companies. Similar to my analysis of the stock prices, here again, I review the time period from 2008 to 2020, with the years from 2017 to 2020 shaded in gray. My review shows that for each of the three Litigation Comparables with credit rating reports, the credit rating agencies' earliest reference to the increase in Pending Actions happened after the 2008-16 Period. **Exhibits 23a to 23c** provide all excerpts discussing opioid litigation risk. I also review the credit rating agencies' explanations for downward changes in credit ratings and provide the excerpts for such explanations in **Exhibits 23a to 23c**. Specifically,

- Endo: from 2011 to 2016, Moody's and S&P downgraded Endo several times, citing reasons including higher leverage, generic competition, and litigations and settlements relating to Endo's mesh product. The first time Endo's opioid litigation risk was mentioned in a Moody's report was on November 29, 2017. In that report, Moody's affirmed Endo's rating, but revised the outlook down from "stable" to "negative," stating that "[t]he negative outlook also reflects rising exposure to opioid-related litigation and declining opioid prescriptions volume trends."¹⁹⁰ The first time the opioid litigation was cited as one of the reasons for a credit downgrade was in July 2019, when Moody's downgraded Endo from "B2" to "B3."¹⁹¹ S&P did not mention the opioid litigations in its reports on Endo until September 2019.¹⁹²
- Mallinckrodt: during the 2008-16 Period, Moody's and S&P downgraded Mallinckrodt once, in 2014, citing higher leverage arising from an acquisition as a

¹⁸⁹ I did not find credit ratings for Insys by either Moody's or S&P.

¹⁹⁰ "Moody's revises Endo's outlook to negative from stable; affirms ratings," *Moody's Investors Service*, November 29, 2017, available at https://www.moody's.com/research/Moodys-revises-Endos-outlook-to-negative-from-stable-affirms-ratings--PR_376112, accessed June 2, 2021.

¹⁹¹ "Moody's downgrades Endo's CFR to B3; outlook revised to stable," *Moody's Investors Service*, July 01, 2019, available at https://www.moody's.com/research/Moodys-downgrades-Endos-CFR-to-B3-outlook-revised-to-stable--PR_404097, accessed June 2, 2021.

¹⁹² See "Endo International PLC Outlook Revised to Negative From Stable On Potential Costs Of Opioid Settlement; Ratings Affirmed," *S&P Global Ratings*, September 23, 2019.

reason.¹⁹³ The first time a credit rating report on Mallinckrodt mentioned opioid litigation risk was in a Moody's January 2018 report and in a May 2018 S&P report.¹⁹⁴ From 2018 to 2020, Mallinckrodt was downgraded several times by Moody's and S&P, with opioid litigation risk often cited as one of the reasons for the downgrade.¹⁹⁵

- Teva: in 2015 and 2016, Moody's and S&P downgraded Teva several times, citing reasons including higher leverage and the expected loss of exclusivity for key products.¹⁹⁶ The first time a credit rating report on Teva mentioned opioid litigation risk was in a Moody's August 2019 report and in an S&P September 2019 report.¹⁹⁷

142. My review of the changes in the credit ratings of the Litigation Comparables and the accompanying rating agency reports did not find any information suggesting that prior to 2017, debt market participants anticipated an increase in liabilities associated with a greater number of opioid lawsuits or liabilities.

¹⁹³ See "Moody's downgrades Mallinckrodt's CFR to Ba3; stable outlook," *Moody's Investors Service*, February 20, 2014. See also "Mallinckrodt plc Downgraded To 'BB-' From 'BBB-,' Off Watch On Acquisition Of Cadence; Outlook Stable; New Debt Rated," *S&P Global Ratings*, February 20, 2014.

¹⁹⁴ See "Moody's confirms Mallinckrodt Ba3 CFR; outlook changed to negative," *Moody's Investors Service*, January 29, 2018, available at https://www.moodys.com/research/Moodys-confirms-Mallinckrodt-Ba3-CFR-outlook-changed-to-negative--PR_378601, accessed June 2, 2021. See also S&P Global Ratings, (14 May 2018), "Mallinckrodt PLC Downgraded To 'B+' From 'BB-,' Outlook Stable," S&P Global Ratings, May 14, 2018.

¹⁹⁵ See, e.g., "Moody's downgrades Mallinckrodt's CFR to B1; outlook negative," *Moody's Investors Service*, April 24, 2019; "Mallinckrodt PLC Downgraded To 'CCC' On Increased Distressed Exchange Risk; Outlook Negative," *S&P Global Ratings*, September 11, 2019; Moody's Investors Services, "Moody's downgrades Mallinckrodt's CFR to Caa2; considers transaction a distressed exchange," December 09, 2019; and "Mallinckrodt PLC Downgraded To 'CCC-,' On CreditWatch Negative On Possible Restructuring," *S&P Global Ratings*, August 06, 2020.

¹⁹⁶ See, e.g., "Moody's Downgrades Teva's Rating to Baa1; Ratings on Review for Downgrade," July 27, 2015, *Moody's Investors Service*, available at https://www.moodys.com/research/Moodys-Downgrades-Texas-Rating-to-Baa1-Ratings-on-Review-for--PR_331025, accessed June 2, 2021. See also "Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BBB' From 'BBB+'; Outlook Stable," *S&P Global Ratings*, July 13, 2016.

¹⁹⁷ "Moody's affirms Teva's Ba2 CFR; outlook revised to negative," *Moody's Investors Service*, August 14, 2019, https://www.moodys.com/research/Moodys-affirms-Texas-Ba2-CFR-outlook-revised-to-negative--PR_406868, accessed June 2, 2021. See also "Teva Pharmaceutical Industries Ltd. 'BB' Rating Affirmed; Litigation Capacity Updated; Outlook Negative," *S&P Global Ratings*, September 23, 2019.

c. New Equity or Debt Offerings

143. In addition to information relating to the stock prices and credit ratings, I also examine the Litigation Comparables' ability to raise capital. If the market had expected a significant increase in opioid litigations and associated liabilities, such expectation could hinder a company's ability to raise new equity or debt capital. At least two of the Litigation Comparables raised additional equity capital during the 2008-16 Period. First, in connection with its acquisition of Par Pharmaceuticals, Endo made a \$2 billion stock offering in June 2015.¹⁹⁸ Second, in connection with acquiring Actavis from Allegan, Teva raised \$3.38 billion in an equity offering in December 2015.¹⁹⁹

144. Furthermore, in 2015, Endo, Teva, and Mallinckrodt each was able to borrow more than \$2 billion in corporate debt.²⁰⁰ In addition, to fund the Actavis acquisition mentioned above, Teva raised \$20 billion in debt in 2016, which Teva described as highly successful with the yield on the issuance below its expectations and investor demand greater than the offering size.²⁰¹

145. These capital raisings provide additional confirmation that as late as 2015 to 2016, the market did not anticipate a significant increase in opioid litigations and associated liabilities for at least three of Purdue's Litigation Comparables.

¹⁹⁸ See Endo International plc, SEC Form 424(b)(5), June 08, 2015 p. 2. ("We are offering 24,024,025 ordinary shares (the 'Ordinary Shares') of Endo International plc (the 'Company'). We intend to use a portion of the net proceeds of this offering, together with the net proceeds of the Debt Financings (as defined herein), to finance the Acquisition [of Par Pharmaceuticals] (as defined herein), refinance certain outstanding debt and to pay related fees and expenses").

¹⁹⁹ See Teva Pharmaceutical Industries Limited, SEC Form 424(b)(5), December 03, 2015 p. 2 ("We are offering 54,000,000 of our American Depositary Shares ('ADSs'), each representing one of our ordinary shares, nominal (par) value NIS 0.10 per share ('ordinary shares'). [...] We intend to use the net proceeds of this offering, together with the net proceeds of the concurrent Mandatory Convertible Preferred Shares offering and the proposed debt financings (each as described herein), to finance our pending acquisition of Allergan plc's worldwide generic pharmaceuticals business, and related fees and expenses, to finance our pending Rimsa acquisition (as described below) and/or otherwise for general corporate purposes").

²⁰⁰ See, e.g., Endo International plc, SEC Form 10-K, for the fiscal year ended December 31, 2015, pp. F-51 and F-53; Mallinckrodt plc, SEC Form 10-K, for the fiscal year ended September 25, 2015, pp. 102-103; Teva Pharmaceutical Industries Limited, Form 20-F, for the fiscal year ended December 31, 2015, p. 75.

²⁰¹ See Teva Pharmaceutical Industries Ltd, SEC Form 6-K, July 21, 2016.

7. *The Economic Foreseeability of the Increase in Pending Actions Based on the Foregoing Information*

146. Viewed in totality, the information presented above supports a finding that during the 2008-16 Period, the large number of Pending Actions that eventually led Purdue to commence bankruptcy proceedings were not foreseen by market participants and observers from an economic perspective. As I noted above, a solvency analysis is conducted on an *ex ante* basis using information reasonably known or knowable as of the time at which solvency is evaluated. The materials I have analyzed show that during the 2008-16 Period, Purdue faced very few Pending Actions and that neither Purdue nor its auditors quantified probable future liabilities either from the Pending Actions or from other unasserted litigation. My analysis of market information of other companies corroborates the finding that market participants similarly did not anticipate or expect opioid-related litigation or liabilities on the scale of the Pending Actions. I am aware of no information which would show that, from an *ex ante* basis (*i.e.*, without relying on improper inferences from hindsight), either Purdue's management or market participants foresaw the number of Pending Actions later filed against Purdue or the liabilities associated with the Purdue 2020 Guilty Plea or the Purdue 2020 Civil Settlement. While, as described above, there were disclosures of a small number of investigations starting around 2014, the market evidence suggests that these investigations did not lead market participants to anticipate the large number of Pending Actions that began to be filed in 2017. To the contrary, the market data confirms that market participants—including those evaluating Purdue and other comparable companies—did not foresee the significant uptick in Pending Actions that occurred in 2017 during the 2008-16 Period.

C. Analysis of Market Reaction to Disclosures of Investigations

147. As part of my evaluation of Purdue's solvency, I consider whether investigations into Purdue's sales and marketing practices may have impacted the equity value of Purdue over the 2008-16 Period. As previously mentioned, Purdue received subpoenas from municipal entities as early as December 2013.²⁰² I understand that the investigation started by the New York

²⁰² "In December 2013, PPLP received a subpoena from the New York Attorney General's office that requested a broad array of documents and items related to the marketing of OxyContin and certain other Purdue programs and websites." Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended December 31, 2013 and 2012, PPLPC029000589136-174, at 172.

Attorney General in 2013 later settled for \$75,000 in 2015. After 2013, Purdue's financial statements describe a request for information from the AGs in Tennessee and California in 2014,²⁰³ subpoenas or similar requests from the Massachusetts, New Hampshire and Oregon AGs in 2015,²⁰⁴ and the formation of a multi-state AG investigation in December 2016.²⁰⁵ In 2014, Purdue, along with other opioid manufacturers, was named in complaints filed by two counties in California and the City of Chicago.²⁰⁶ Purdue also received subpoenas from the United States District Attorney for the District of Connecticut in June and September 2016.²⁰⁷

148. The equity value of Purdue is equivalent to the remaining value of the firm after all debts are paid. Therefore, an estimation of the price impact of the investigations on Purdue's equity value provides an approximate measure of the expected liability risk associated with the investigations. It is difficult to precisely quantify the impact that any particular subpoena or investigation may have on a firm, as there are many different factors, including product- and firm-specific factors as well as the exact nature and scope of the subpoena or investigation, that can affect the size of the impact. For example, a federal investigation into the sales and marketing practices across an entire firm and over a long period of time may have a much larger impact than a narrow State issued subpoena focusing on a small product over a short period of time. In order to provide a conservative estimate of any expected liabilities that the subpoenas created in the 2013 to 2016 time period for Purdue, I conduct the analysis described in this section.

149. To approximate the impact of the disclosed investigations on Purdue's liabilities for purposes of my solvency analysis, I evaluate the stock price changes associated with disclosures of investigations into the sales and marketing practices of the Litigation Comparables during the 2008-16 Period. First, I identified the dates on which the Litigation Comparables disclosed that they had received subpoenas regarding their sales and marketing practices or dates

²⁰³ See Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2014 and 2013, POK003285615-664, at 661.

²⁰⁴ See Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2015 and 2014, PPLPC011000090527, p. 50.

²⁰⁵ See Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2016 and 2015, PPLPC021000890262-316 at 310. As discussed below in **Section IV.C.1**.

²⁰⁶ See Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended 2014 and 2013, POK003285615-664, at 662.

²⁰⁷ Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2017 and 2016, PPLPC029000692681-739 at 737.

on which Litigation Comparables disclosed the commencement of opioid-related investigations. I also identified any other company-specific, value-relevant disclosures on the same day. Next, I measured the abnormal return associated with each such disclosure using an event study methodology, which is a widely used statistical method that measures the movements of stock prices on dates when new information is disclosed.²⁰⁸ The abnormal return measures the unexpected return (positive or negative) after controlling for market and industry factors, and is a measurement of the price movement caused by a firm-specific event such as the disclosure of unexpected news.²⁰⁹ In this case, the abnormal return can be interpreted as a proxy for the impact that disclosures of subpoenas and investigations into the sales and marketing practices of the Litigation Comparables had on the stock prices of these firms. I then use the abnormal returns to estimate the impact that disclosures of state investigations might have on the value of Purdue's equity over the 2008-16 Period. As I discuss below, I conclude that the impact is between zero and \$472 million. To be conservative, for purposes of my solvency analysis, I add an additional \$472 million of liability starting in 2013 to reflect the value of expected liability risk from disclosed investigations into the sales and marketing practices of Purdue.

150. During the 2008-16 Period, I identified four dates when the market learned that the Litigation Comparables were the subject of such investigations and lawsuits: (1) On November 15, 2013, Endo announced it received a subpoena from the City of Chicago;²¹⁰ (2) After market close on December 12, 2013, Insys announced it received a subpoena from the Office of Inspector General of the Department of Health and Human Services;²¹¹ (3) On September 12, 2014, after

²⁰⁸ MacKinlay, A. Craig, "Event Studies in Economics and Finance," *Journal of Economic Literature*, Vol. 35, March 1997.

²⁰⁹ MacKinlay, A. Craig, "Event Studies in Economics and Finance," *Journal of Economic Literature*, Vol. 35, March 1997, pp. 14-15.

²¹⁰ "Lawyers for the city of Chicago are investigating marketing claims by producers of narcotic painkillers as a prelude to a possible lawsuit against them, according to interviews and a court filing...A spokesman for another opioid producer, Endo Pharmaceuticals, said that company had received a subpoena from the city of Chicago and was cooperating with it." "Chicago Said to Weigh Suit Over Marketing of Painkillers," *The New York Times*, November 15, 2013.

²¹¹ "Insys Therapeutics, Inc. (NASDAQ: INSY) announced today that it has received a subpoena from the Office of Inspector General of the Department of Health and Human Services ('HHS') in connection with an investigation of potential violations involving HHS programs. The subpoena requests documents regarding Subsys®, including Insys' sales and marketing practices relating to this product. Insys intends to cooperate with the investigation." "Insys Therapeutics Receives Subpoena From Office of Inspector General," *Bloomberg*, December 12, 2013.

market close, Insys announced it received a subpoena from the U.S. Attorney's Office for Massachusetts;²¹² and (4) On May 21, 2014, it was reported after market close, that Teva was named in a lawsuit filed by two municipalities in California, which it later disclosed in its SEC filings.²¹³ I am not aware of any confounding news made public on these dates.

151. I then conducted an event study to determine whether, on these announcement dates, the stock prices of the Litigation Comparables changed in a manner that was statistically different from how the stock price moved on the non-events days during the period. Based on my event study, I found that the abnormal returns following three of the four announcements were not statistically significant. (See **Exhibit 24**). Following the disclosures of city and state investigations by Endo and Teva, I found no statistically significant change in their stock prices after controlling for market and industry factors. The information released on these dates regarding the Chicago investigation and the California lawsuits, as described above, also involved Purdue. This implies that the information in these disclosures was not economically material enough to change the equity value of these companies in a meaningful way. From this, I conclude that the market did not attach a meaningful liability to the news. However, I found that Insys's after-market December 12, 2013 federal subpoena disclosure from the Office of Inspector General was associated with a 15.9 percent statistically significant negative abnormal return on Insys stock, which translated to a loss of \$153.6 million of equity value. While I am not aware of a similar, contemporaneous investigation by this entity into Purdue, I nonetheless consider this abnormal return for a conservative estimate of an expected liability arising from investigations of Purdue between 2013 and 2016. I also note, as shown in **Exhibit 24**, that the subsequent federal

²¹² "On September 8, 2014, Insys Therapeutics, Inc. received a subpoena issued pursuant to the Health Insurance Portability and Accountability Act of 1996, as amended, from the U.S. Attorney's Office for the District of Massachusetts. The subpoena requests documents regarding Subsyst, including Insys' sales and marketing practices related to this product." "Insys Therapeutics Gets Sept. 8 Subpoena on Main Product Subsyst," *Bloomberg*, September 12, 2014.

²¹³ "Two California counties sued five of the world's largest narcotics manufacturers on Wednesday, accusing the companies of causing the nation's prescription drug epidemic by waging a 'campaign of deception' aimed at boosting sales of potent painkillers such as OxyContin." "Counties Sue Narcotics Makers, Alleging 'Campaign of Deception'" *Los Angeles Times*, May 21, 2014, available at <https://www.latimes.com/local/la-me-rx-big-pharma-suit-20140522-story.html>, accessed on June 13, 2021; Teva Pharmaceutical Industries Limited, Form 20-F, for the fiscal year ended December 31, 2014, p. F-37.

investigation of Insys by the U.S. Attorney's Office for Massachusetts announced in September 2014 was not statistically significant and Insys did not file for bankruptcy for another 5 years.²¹⁴

152. Based on the price reactions of the Litigation Comparables stock prices to disclosures of investigations, I conclude that the subpoena received by Purdue in 2013 would likely not create an expected liability for Purdue. However, over the 2013 to 2016 period, I assess the expected aggregate liability related to the investigations to be between zero and \$472 million, which is equal to 15.9 percent of my calculation of the value of Purdue's operating assets in 2013.

*1. The Purdue 2020 Guilty Plea*²¹⁵

153. In my evaluation of Purdue's estimated liabilities during the 2014-2016 period, I have considered whether the fact that PPLP entered into the 2020 Guilty Plea in which it admitted to criminal conduct during the 2008-16 Period affects my analysis. I conclude that it does not based on the following.

154. I understand from counsel that Counts I and II of the Purdue 2020 Guilty Plea related to problems with Purdue's anti-diversion and speaker programs starting in 2007 and throughout the 2008-16 Period²¹⁶ and that Count III related to a "one year 'Statement of Work' contract with Practice Fusion, effective as of March 1, 2016."²¹⁷ I also understand from counsel that various compliance mechanisms were in place at Purdue to monitor sales and marketing practices during the same period, including: (1) from 2007 through 2012, Purdue was under a Corporate Integrity Agreement ("CIA") and federal monitorship;²¹⁸ (2) after the CIA and federal monitorship ended in 2012, Purdue maintained responsibility for the compliance functions that had been required under the CIA and engaged outside compliance counsel to provide compliance

²¹⁴ "Insys Files For Chapter 11, Days After Landmark Opioid Settlement of \$225 Million," *NPR*, June 10, 2019, available at <https://www.npr.org/2019/06/10/731363225/insys-files-for-chapter-11-days-after-landmark-opioid-settlement-of-225-million>, accessed June 14, 2021.

²¹⁵ According to Purdue's financial statements, Purdue received subpoenas from the United States District Attorney for the District of Connecticut in June 2016, September 2016 and August 2017 and from the Department of Justice in December 2017. *See* Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2017 and 2016, PPLPC029000692681-739 at 737.

²¹⁶ Purdue 2020 Guilty Plea at 15-17.

²¹⁷ Purdue 2020 Guilty Plea at 15-18.

²¹⁸ *See* Information, Attachment E, *United States v. The Purdue Frederick Co.*, 1:07-cr-0029 (W.D. Va. May 10, 2007), ECF No. 5-5.

reviews;²¹⁹ and (3) as part of the 2015 AOD, a New York AG appointed auditor reviewed some of Purdue's compliance functions starting in 2016 (the same year Purdue received two subpoenas from the U.S. Attorney for the District of Connecticut, both "related to OxyContin and Q12 dosing"²²⁰), with no negative findings.²²¹ I understand from counsel that during the 2008-16 Period none of the monitoring mechanisms in place detected the conduct that ultimately led to the 2020 Guilty Plea.

D. The Aggregate Value of Purdue's Liabilities During the 2008-16 Period

155. As discussed in **Section IV.A**, based on my review of the balance sheet from the consolidated, audited financials of Purdue and its associated companies, only Purdue's long-term liabilities, which consist of "Other Liabilities" that amounted to \$128 million to \$226 million during the 2008-16 Period, should be included in Purdue's aggregate liabilities for the purpose of my solvency analysis.

156. In addition, as discussed in **Section IV.B**, I include \$200 million in future liabilities between 2008 and 2011 to the liabilities reported on Purdue's balance sheet. This is to reflect Purdue's management expectation that all of the pending opioid litigation could be settled with \$200 million, and that most of these cases were dismissed or settled by the end of 2011.²²² Between 2012 and 2015, I include \$19 million in litigation liabilities related to the Kentucky matter that, though filed in 2007, was not resolved until 2015. Finally, as discussed above, I include between zero and \$472 million in liabilities associated with the subpoenas filed beginning in 2013. Because I conclude that the risk of future litigation arising from the increase in Pending Actions starting in 2017 was not reasonably foreseeable during the 2008-16 Period, I conclude that no additional

²¹⁹ See Nov. 5, 2019 Declaration of Patrick Fitzgerald, Esq. (Dkt. 438-2), at ¶4; 2Q 2012 Quarterly Compliance Report (PPLPUCC9002892662) at slide 3; 4Q 2015 Quarterly Compliance Report (PPLPC063000018836) at slides 2-3; 3Q 2016 Quarterly Compliance Report (PPLPUCC9002790025) at slide 3 (notes).

²²⁰ Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2016, PPLPC021000890262-316 at 311.

²²¹ AOD at ¶41(b); Oct. 7, 2016 Auditor's First Report on Purdue's ADD Program (PPLP004473667-708); Oct. 20, 2017 Auditor's Second Report on Purdue's ADD Program (PPLP004473709-737); Oct. 19, 2018 Auditor's Third Report on Purdue's ADD Program (PPLP004473738-756).

²²² Board of Directors Meeting Agenda, PPLP, January 11, 2008, PPLP004400663-719 at 677.

future litigation liabilities should be considered in a solvency analysis of Purdue above those I have included.

157. Combining Purdue’s “Other Liabilities” with my conclusion described above on the estimated future liabilities associated with opioid litigation and investigations during the 2008-16 Period, I derive the amounts of Purdue’s liabilities as follows for the purposes of the solvency analysis, as shown in **Figure 9** and **Exhibit 25**.

Figure 9. Summary of Purdue’s Liabilities, 2008-2016

	Long-Term Debt	Other Liabilities	Estimated Opioid Litigation Liabilities - Low	Estimated Opioid Litigation Liabilities - High	Total Liabilities - Low	Total Liabilities - High
2008	0	142	200	200	342	342
2009	0	128	200	200	328	328
2010	0	131	200	200	331	331
2011	0	219	200	200	419	419
2012	0	226	19	19	245	245
2013	0	163	19	491	182	654
2014	1	202	19	491	222	694
2015	0	194	19	491	213	685
2016	0	169	0	472	169	641

V. THE BALANCE SHEET TEST

158. Application of the balance sheet test for solvency is straightforward: the fair market value of a firm’s assets is compared to its liabilities, and if the value of assets is greater than liabilities, then the firm is considered solvent for the purposes of the test.²²³ For purposes of implementing the test, I conservatively use the high end of the estimated opioid litigation liability for 2013 through 2016.

²²³ Stearn (2007), p. 384, citing 11 U.S.C. § 101(32)(A) (West 2004 & Supp. 2006) (“The term ‘insolvent’ means ... financial condition such that the sum of such entity’s debts is greater than all of such entity’s property...”). See also *In re Trans World Airlines, Inc.*, 134 F.3d at 198 (TWA was insolvent on transfer date because liabilities exceeded valuation of assets). See also Reilly and Schweih (2000), p. 340.

159. I estimated the value of Purdue's operating assets for each year in the 2008-16 Period in **Section III**; this is the amount a willing buyer would pay to a willing seller, with neither under compulsion to transact. Based on my analysis, during the 2008-16 Period, Purdue's operating assets to satisfy the balance sheet test were not less than \$1.4 billion, and were as high as \$9.2 billion. In addition, during the 2008-16 Period, Purdue held excess cash of \$232 to \$750 million. *See Figure 4 and Exhibit 12.* The excess cash held by Purdue as of each valuation date is net of the at-issue distributions made through that valuation date. For example, the excess cash I calculate as of June 1, 2010 reflects all cash distributions made between July 15, 2009 (the prior valuation date) and June 1, 2010. Taking into account the excess cash held by Purdue over the 2008-16 Period, the combined value of Purdue's operating assets and excess cash was not less than \$1.9 billion (\$1.38 billion in operating assets and \$568 million in excess cash), and was as high as \$9.5 billion (\$9.16 billion in operating assets and \$386 million in excess cash) during the 2008-16 Period.

160. As discussed in **Section IV.D**, Purdue did not have long-term debt outstanding in the 2008-16 Period. Instead, the majority of Purdue's liabilities come from the "Accrued Expenses" under the current liabilities and "Other Liabilities" included in the long-term liabilities on the balance sheet. Because accrued expenses are already accounted for in my DCF analysis of Purdue's operating assets, I do not include them again when quantifying Purdue's liabilities for purposes of the solvency analysis so as not to double count the liability. Purdue's "Other Liabilities" are comprised primarily of Purdue's liability relating to its pension and post-retirement benefits plan during the 2008-16 Period.

161. In addition, as discussed in **Section IV.B**, Purdue was facing pending product liability lawsuits, certain state attorney general cases, and pending investigations during certain years of the 2008-16 Period. Therefore, for the purpose of my solvency analysis, I quantified the impact of the overhang of the pending litigations and investigations and included those additional potential liabilities that Purdue might face that were not required to be reflected on Purdue's balance sheet in my solvency analysis. When combined with Purdue's "Other Liabilities," I conclude that Purdue's liabilities did not exceed \$694 million at any point during the 2008-16 Period.

162. **Exhibit 26** and **Figure 10** below compare my valuations of Purdue’s operating assets plus excess cash to Purdue’s liabilities as of each valuation date. On each of the valuation dates, the value of Purdue’s assets exceed its aggregate liabilities. In particular, the difference between Purdue’s assets and liabilities was never less than \$1.3 billion, and was as high as \$9.2 billion during the 2008-16 Period. As discussed in **Section III.A**, my assessments of Purdue’s value, cash flows, and liabilities can be reasonably extrapolated to the interim periods between my valuation dates such that the solvency conclusions that I have reached as of the dates when management forecasts were made can be applied to the date of any at-issue distribution made in the interim periods between my valuation dates during the 2008-16 Period. The value of Purdue’s operating assets and liabilities thus would not fluctuate to such an extreme degree that Purdue would be considered solvent on two valuation dates but would temporarily become insolvent at some point between those two dates. Therefore, I conclude that Purdue was solvent based on the balance sheet test and that the at-issue distributions did not render Purdue insolvent at any point during the 2008-16 Period.²²⁴

Figure 10. Summary of Purdue’s Balance Sheet Test for Solvency

Year	Assets			Liabilities				Solvency Cushion
	Operating Assets	Excess Cash	Total Assets	Long-Term Debt	Other Liabilities	Estimated Opioid Litigation		
						Liabilities	Total Liabilities	
[i]	[ii]	[iii] = [i] + [ii]	[iv]	[v]	[vi]	[vii] = [iv] + [v] + [vi]	[iii] - [vii]	
2008	9,157	386	9,543	0	142	200	342	9,201
2009	5,724	282	6,006	0	128	200	328	5,678
2010	7,457	232	7,689	0	131	200	331	7,359
2011	4,693	264	4,958	0	219	200	419	4,538
2012	4,590	349	4,939	0	226	19	245	4,694
2013	2,967	562	3,530	0	163	491	654	2,876
2014	1,377	568	1,945	1	202	491	694	1,251
2015	2,103	750	2,853	0	194	491	685	2,168
2016	1,625	693	2,318	0	169	472	641	1,677

²²⁴ I note that, although I did not value the operating assets as of January 2017, the excess cash would have been enough to satisfy total liabilities. I also reviewed the draft forecasts prepared as of January 2017 (see PPLPUCC9003546803), and although forecasted cash flows from operations were 13 percent lower than those forecasted as of June 2016, that does not change my conclusion since cash flows were still projected to be positive.

163. As previously mentioned, there were three non-cash transfers that took place between 2008 and 2016. These non-cash transfers do not impact my conclusion regarding the solvency of Purdue during the 2008-16 Period for the following reasons:

- *Royalties from international sales of OxyContin by associated companies.* It has been alleged that the OxyContin royalties received by Purdue from independent associated companies were “far below market.”²²⁵ The net royalties received by Purdue totaled approximately \$622 million between 2008 and 2019.²²⁶ Although I do not express an opinion regarding the reasonableness of the royalty payments, I conclude that the lower royalties did not render Purdue insolvent.
- *Transfer of PPLP’s equity interest in Infinity Pharmaceuticals, a publicly-traded company.* In 2008, 2009, and 2013, PPLP transferred Infinity Pharmaceuticals shares, which had a total market value of \$263 million to its parent PRA for no consideration.²²⁷ These shares were reported on the combined companies' balance sheet before the transfer.²²⁸ My solvency analysis does not include the value of the shares on the balance sheet before they were transferred, and therefore I conclude that the transfer does not change my solvency opinion.
- *Transfer of PPLP’s equity interest in Lucien Holdings, an independent affiliated company.* In 2010, Lucien Holdings was transferred from PPLP to PRA at a book value of negative \$0.5 million.²²⁹ Since I find that PPLP was solvent in 2010 and at all times during the 2008-16 Period, I conclude that the transfer did not occur at a time when Purdue was insolvent, nor did the transfer render the company insolvent.

²²⁵ Unsecured Creditors’ Motion to Compel Production, ¶ 44a.

²²⁶ AlixPartners, “Intercompany and Non-Cash Transfers Analysis,” May 28, 2020, p. 39.

²²⁷ Unsecured Creditors’ Motion to Compel Production, ¶ 44c.

²²⁸ See, e.g., Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697 at 673; Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174 at 148-149.

²²⁹ Unsecured Creditors’ Motion to Compel Production, ¶ 44d.

VI. THE CASH FLOW TEST

164. As described above, a Cash Flow Test evaluates whether a company can meet its payment obligations in full and on time over a projected period. For a company to be solvent on a cash flow basis, it must have sufficient resources to (1) cover its operating expenses, (2) make capital reinvestment as needed, and (3) meet its liability obligations (including both debt and non-debt liabilities) in full and on time. Typically, resources are not limited to the company's readily available cash balance at the start of the test period, but also include the additional income expected to be generated during the test period, as well as other sources of cash such as monetization through asset sales or borrowing capacity, if and when needed.

165. My Cash Flow Test is carried out as of the same dates at which I assess the Balance Sheet Test. As with the Balance Sheet Test, I conservatively use the high end of the estimated opioid litigation liability for 2013 through 2016. As previously described, while it is typically the case that, in a solvency analysis, one would conduct a solvency test as of the date of each at-issue distribution, given the large number of distributions, I conduct the solvency tests as of several valuation dates over the 2008-16 Period. In doing so, my Cash Flow Test assesses whether the at-issue distributions through each valuation date left Purdue with insufficient cash flow to meet its obligations. For example, for 2008, my Cash Flow Test is assessed as of April 18, 2008. It therefore evaluates whether the cumulative at-issue distributions made from January 1, 2008 through April 18, 2008 rendered Purdue cash flow insolvent. For 2009, I conduct the Cash Flow Test as of July 15, 2009, and thus analyze whether the cumulative at-issue distributions made in the period from April 19, 2008 (*i.e.*, the prior valuation date) through July 15, 2009 (*i.e.*, the current valuation date) rendered Purdue cash flow insolvent. This treatment applies to each subsequent year, except for 2016. I assess the Cash Flow Test for 2016 differently given that the last asset valuation is assessed as of June 8, 2016. I explain in more detail below how I evaluate the remainder of 2016. I start with Purdue's cash balance as of June 8, 2016, which reflects the effect of the cumulative at-issue distributions made through June 8, 2016. I then subtract from that cash balance the total amount of the at-issue distributions made from June 9, 2016 to December 31,

2016. By doing so, my Cash Flow Test for 2016 is capable of assessing whether the at-issue distributions made in 2016 rendered Purdue cash flow insolvent.²³⁰

166. For each Cash Flow Test, I examine Purdue's ability to meet its payment obligations for a multi-year period starting from the valuation date. I am not aware of any explicit rule for the length of a Cash Flow Test in the context of assessing solvency, but I observe that in practice, a period of up to five years is often used for a Cash Flow Test. From a valuation perspective, however, the proper length of a Cash Flow Test should be one that is sufficiently long to provide enough visibility into a company's expected cash flow requirements and changes in operations. For instance, if a company has a loan of a significant size that is not due until seven years from the valuation date, then it would be reasonable to extend the Cash Flow Test beyond five years to capture the period of the loan repayment. Purdue had no material debt during the 2008-16 Period. However, there are two factors that I took into consideration when determining the proper length of time for the Cash Flow Test.

167. First, as discussed above, Purdue's cash flows from operations are affected by the loss of exclusivity of OxyContin. As I discuss in **Section III.B.1** and show in **Exhibit D-1** to **Exhibit D-9**, after the loss of exclusivity, Purdue's projected free cash flows from operations could become negative for a short time, as the declining revenues from OxyContin become insufficient to satisfy the operating expenses accrued from prior periods (such as rebate expenses, which typically lag behind the revenue recognition for some time). To ensure that the Cash Flow Test fully incorporates the negative cash impact of the loss of exclusivity, I perform the Cash Flow Test through the year in which the projected free cash flows from operations become temporarily negative. In cases where the loss of exclusivity is not expected to result in negative free cash flows, I assess the Cash Flow Test through the year with the most significant decrease in projected free cash flows from the prior year.

168. Second, I offset the cash flows by the potential liabilities associated with pending opioid litigations and investigations beyond the accrued settlement expenses already recorded on

²³⁰ As noted above, although I did not value the operating assets as of January 2017, the excess cash would have been enough to satisfy total liabilities. I also reviewed the draft forecasts prepared as of January 2017 (see PPLPUCC9003546803), and although forecasted cash flows from operations were 13 percent lower than those forecasted as of June 2016, that does not change my conclusion since cash flows were still projected to be positive.

Purdue's balance sheet. As I discussed in **Section IV**, I conclude that the large number of Pending Actions that eventually led Purdue to commence bankruptcy proceedings were not foreseen by market participants and observers. Therefore, from an economic perspective, I conclude that during the 2008-16 Period, there were no incremental liabilities associated with Pending Actions beyond those that I discussed above and quantified.

169. Specifically, I conduct the following steps to evaluate the solvency of Purdue using the Cash Flow Test during the 2008-16 Period. **Exhibits 27a to 27i** provide the details of my Cash Flow Test analysis and I refer to the line numbers on those exhibits when describing the steps below.

- First, as shown on line 1, I start with Purdue's unrestricted cash balance as of the valuation date. I approximate the starting cash balance using the unrestricted cash balance as of or close to the valuation date when it is included within the management financial projection materials.²³¹ In years when the starting cash balance was not reported in the management projection materials, I use the reported cash balance from Purdue's interim financial statements, Flash Reports, or Weekly Cash Reports that are closest to the valuation date.²³² In a given year, the time gap between the date of the nearest cash balance and the valuation date is never more than one and a half months. When the "as-of date" of the cash balance is earlier than the valuation date, I subtract from the cash balance the total amount of the at-issue distributions made from the cash balance as-of date to the valuation date.²³³ The result represents a "pro-forma" cash balance that is net of the at-issue cash distributions paid through the valuation date. For 2016, as discussed above, I subtract from the starting cash balance the total amount of all at-issue distributions made in 2016, regardless of whether it

²³¹ Management projection materials are used in years 2012 and 2016. For 2012, the cash balance is from the management projection materials but as of the end of 2011. See Purdue Mid-Year Update, June 8, 2016, RSF00017771-921; Purdue 2012 10-Year Plan, February 15, 2012, PPLPC053000063393-668.

²³² Interim financial statements, Flash Reports or Weekly Cash Reports are used in years 2008, 2009, 2010, 2011, 2013, 2014, and 2015. See Purdue Finance Flash Report, May 2015, RSF00016745; Purdue Weekly Cash Forecast, May 13, 2014, PPLPUCC9003551645; Purdue Weekly Cash Forecast, May 10, 2013, PPLPUCC000638139; Purdue Weekly Cash Forecast, June 17, 2011, PPLPUCC000638863; Purdue Financial Statement, June 2010, PPLPC054000051935; Purdue Financial Statements, June 2009, PPLPC042000017701; Purdue Weekly Cash Forecast, March 14, 2008, PPLPUCC001552391.

²³³ I do not make this adjustment when the cash balance as-of date is later than the valuation date.

was paid before or after the valuation date. The description above pertains to how the starting cash balance in the first year of a Cash Flow Test is calculated. For all future years in a given Cash Flow Test, the cash balance reflects the projected balance as of January 1 of a year, which is set to be equal to the projected cash balance as of December 31 of the preceding year.

- On lines 2 to 9, I incorporate the cash inflows and outflows from Purdue's operations. The addition and subtraction of these items results in the free cash flow from operations that is calculated in line 9. In estimating these free cash flows from operations, I account for both the sources of cash (such as after-tax income) and the uses of cash (such as capital expenditures and increases in net working capital) within the period. Line items 2, and 4 to 8 are sourced from my DCF analysis as discussed in **Section III**.²³⁴ Line 3, Taxes, differs from that in my DCF analysis. In the DCF valuation, the tax line item reflects the estimated corporate income tax obligations associated with the forecasts of EBIT. Using corporate income taxes in the context of my DCF valuation is reasonable, because a hypothetical willing buyer of Purdue is likely to assess the standalone value of Purdue independent of its specific business structure and associated tax implications. However, in the Cash Flow Test, the focus is to assess Purdue's ability to meet its payment obligations given its operative reality (including the fact that Purdue is structured as a partnership, not subject to corporate income taxes). Even though I understand that a partnership such as Purdue is exempt from corporate income taxes, its income is allocated, for tax purposes, to its ultimate members, who are, in turn, subject to income taxes on the allocated income.²³⁵ I understand that it is a general practice for a partnership to make cash distributions to its members based on a single standardized tax rate, so that members have sufficient

²³⁴ As discussed in **Section III**, I deduct capital expenditures when calculating free cash flows, as these expenditures are considered necessary for a firm to continue to operate. However, I do not take into account other investing activities from the Cash Flow Statement (e.g., Investments in JV and associates), as these are discretionary investments. The amounts of these investments are not projected to be sufficiently large that they would affect my solvency opinion.

²³⁵ Benjamin Page, Jeffrey Rohaly, Thornton Matheson, and Aravind Boddupalli, "Tax Incentives for Pass-Through Income," Tax Policy Center, July 15, 2020, available at <https://www.taxpolicycenter.org/sites/default/files/publication/159744/tax-incentives-for-pass-through-income.pdf>, p. 1.

liquidity to pay the income tax obligations arising from the allocated partnership income.²³⁶ Further, I understand that Purdue distributed cash for tax purposes “throughout [its] history going back well before 2008.”²³⁷ Thus, in my Cash Flow Test, line 3, Taxes, effectively represents the future tax cash distributions expected to be made by Purdue to its members which were generally forecasted by management as of each valuation date.²³⁸ I therefore use management forecasts for the tax distributions whenever available. When management forecasts for the tax distributions are not available, I estimate the tax distributions by applying to the projected EBIT the implied tax rate from the last year that management forecasted tax distributions. For example, the 2008 management forecasts only projected the tax distributions through 2013. For years after 2013 in my 2008 Cash Flow Test, I estimate the tax distributions by using the 40 percent tax rate implied by the 2008 management forecasts for the tax distributions for 2013. The 2009 management forecasts do not report the tax and non-tax distributions separately. Thus, in my 2009 Cash Flow Test, I estimate the tax distributions for each year by using a 40 percent tax rate, which is the average implied tax rate across the forecasted years in the 2008 management forecasts for the tax distributions. I subtract from the available cash the expected tax distributions in the future years, but do not consider any future non-tax cash distributions in my Cash Flow Test, because such non-tax cash distributions are discretionary and therefore do not constitute Purdue’s payment obligations. On line 9, I calculate Purdue’s projected free cash flows. A positive amount represents net cash inflows that would increase Purdue’s cash balance, whereas a negative amount represents net cash outflow that would decrease Purdue’s cash balance.

²³⁶ Bahar A. Schippel, “Boilerplate Tax Distribution Provisions Can Get You Into Hot Water,” *Tax Management Real Estate Journal*, Vol. 32, 2, February 3, 2016, pp. 1, 6.

²³⁷ *In re Purdue Pharma L.P. et al*, Debtors, Case No. 19-23649, Disclosure Statement for Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and its Affiliated Debtors, June 2, 2021, p. 169.

²³⁸ The only exception is year 2016 in the Cash Flow Test for 2016. For that year, because I subtract from the starting cash balance the total amount of the at-issue cash distributions made in 2016 (including both the non-tax distributions and the tax distributions actually made), there is no need to further deduct taxes associated with the projected EBIT for the remaining year of 2016 from the valuation date to the year-end.

- Next, on line 10, I include Purdue's expected payment obligations in connection with its remaining balance sheet liabilities that have not already been accounted for in the calculation of Purdue's free cash flows from operations. As discussed, Purdue had no material debts during the 2008-16 Period. Thus, I assess Purdue's non-debt long term liabilities reported on its projected balance sheet, which consist primarily of obligations relating to pension and post-retirement benefits.²³⁹ Unlike debt, these liabilities do not have a specific payment schedule, and as a result, I estimate the amounts and timing of the payments of these liabilities. When the projected balance of the long-term liabilities at the end of a year is lower than that at the end of the prior year, the decrease reflects a cash outflow in the management cash flow forecasts (and accordingly is included in my calculation of free cash flows from operations as a cash outflow on line 8, "Other Items"). In other words, management forecasts that in each year, a small payment of the associated liability is made to reduce the balance of the projected long-term liabilities. The remaining balance outstanding at the end of the forecast period is not expected to be paid off during the forecast period. However, to be conservative, I assume an acceleration of the entire outstanding balance of the long-term liabilities would become payable in the first year of the test period.
- Line 11 reflects the amount of cash available after satisfying the expected payment obligations in connection with Purdue reported balance sheet liabilities.
- Then, on line 12, I incorporate my estimates of the potential future liabilities, as discussed above, associated with the pending opioid-related lawsuits and government investigations that were not required to be reflected on Purdue's balance sheet. It is not possible to know when these potential payments would reasonably be expected to be made. However, as **Exhibits 27a to 27i** show, Purdue had enough cash to satisfy the estimated liabilities in full within the first year of the test period.
- Adjusting the starting cash balance by the free cash flows from operations and subtracting Purdue's obligations, I project Purdue's cash balance as of the end of the first partial calendar year on line 13. A positive balance means that as of the valuation

²³⁹ See **Exhibit D-1 to Exhibit D-9**. See also Audited Combined Financial Statements for Purdue Pharma L.P. and Associated Companies 2008-2017.

date, Purdue would be expected to meet its payment obligations in full and on time in that year.

- The ending cash balance from the first year then becomes the initial cash balance in the second year. I then repeat the steps described above for each subsequent year in the projection period, each time assessing whether or not Purdue's projected cash balance at the year-end is positive. I conclude that Purdue had sufficient cash in each year to meet its obligations.

170. To summarize, as shown in **Exhibits 27a - 27i**, on each valuation date during the 2008-16 Period, I conduct a Cash Flow Test covering multiple future years. I conclude that Purdue was reasonably expected to have a positive cash balance at the end of each year of the projected period for each of the valuation dates. Across all Cash Flow Tests, the lowest year-end projected cash balance is in 2016 under the 2016 test. Even that lowest cash balance is projected to be nearly \$300 million. In all other years across all Cash Flow Tests, with the exception of the 2009 year-end balance of \$302 million under the 2009 test and the 2014 year-end balance of \$337 million under the 2014 test, the year-end projected cash balance would always exceed \$500 million, and in some years would be several billion dollars. This finding indicates that the at-issue cash distributions did not render Purdue insolvent on a cash flow basis during the 2008-16 Period.

VII. THE CAPITAL ADEQUACY TEST

171. The third test for solvency is the capital adequacy test, which examines whether “at the time of the transfer the debtor ‘was engaged in business or a transaction, or was about to engage in business or a transaction, for which any property remaining with the debtor was an unreasonably small capital.’ ... In general, unreasonably small capital ‘refer[s] to the inability to generate sufficient profits to sustain operations.’”²⁴⁰ More generally, the capital adequacy solvency test “essentially asks whether the firm is *unlikely* to become insolvent—under the balance sheet test or the ability-to-pay test.”²⁴¹

²⁴⁰ Stearn (2007), p. 385 (quoting 11 U.S.C. § 548(a)(1)(B)(ii)(II) and *Moody v. Sec. Pac. Bus. Credit, Inc.*, 971 F.2d 1056 (3d Cir. 1992) at 1070).

²⁴¹ Heaton (2007), p. 995.

172. The capital adequacy test is a stricter test than the cash flow or balance sheet tests in that it examines whether a firm would remain solvent even if it experiences some reasonably foreseeable, but unanticipated adversity.²⁴²

*Unlike the cash flow test, which looks directly at whether the company is able to meet its scheduled debt obligations as they come due, the adequate capital test is intended to analyze the company's robustness to the general economic uncertainty that all businesses face. That is...can the company survive if its actual performance is slightly below its projections, or if it takes slightly longer to achieve certain assumed changes in the business?*²⁴³

The capital adequacy test thus generally focuses on whether a firm would remain solvent even if the company experiences revenue shortfalls compared to its projections. That does not, however, imply that the company must be able to “withstand any and all setbacks to [its] business.”²⁴⁴

173. For the purposes of the capital adequacy test, courts have indicated that it is appropriate to take into account the firm's ability to raise new equity or debt capital in order to continue to operate.²⁴⁵ As is the case with the other solvency tests, the capital adequacy test is also typically based on information known at time of transfers.²⁴⁶ However, some courts have ruled that subsequent events can be considered and that a firm's ability to avoid bankruptcy for some period after an allegedly fraudulent transfer can be considered evidence of the adequacy of the firm's capital.²⁴⁷

²⁴² Heaton (2007), p. 999 (“...ability-to-pay solvency does not imply capital adequacy under the ability-to-pay capital adequacy test. A firm might have the ability to pay debts as they come due but only barely so.”); p. 1000 (“A firm may be going-concern balance-sheet solvent but only barely so, and thus will not have capital adequacy under a going-concern balance-sheet based capital-adequacy test.”).

²⁴³ Reilly and Schweihs (2000), at pp. 342 - 343.

²⁴⁴ Stearn (2007), p. 389 (quoting *Moody v. Sec. Pac. Bus. Credit, Inc.*, 127 B.R. 996 (W.D. Pa. 1991)).

²⁴⁵ Stearn (2007), p. 387 (“An analysis of adequacy of capital should take into account ‘all reasonably anticipated sources of operating funds, which may include new equity infusions, cash from operations, or cash from secured or unsecured loans over the relevant time period.’ Indeed, access to sufficient credit, *standing alone*, may be significant evidence of adequate capital,” quoting *Peltz v. Hatten*, 279 B.R. 710 (Bankr. D. Del. 2002) at 744-745) (emphasis in original).

²⁴⁶ See, e.g., *In re WRT Energy Corp.*, 282 B.R. at 414 (“Adequacy of capital and belief as to ability to pay debts must be judged by what was reasonably believed at the time of the transactions and not on the basis of hindsight informed by the unforeseeable losses of the third and fourth quarter.”); Stearn (2007), p. 386.

²⁴⁷ See, e.g., *In re Direct Access Partners, LLC*, 602 B.R. 495, 536 (Bankr. S.D.N.Y. 2019) (recognizing “[t]he fact that a business actually survived for a considerable period of time after a challenged transfer is a factor that a

174. In order to inform my opinion as to Purdue's capital adequacy, I utilize several categories of information:

- Purdue's projected value and cash flows in a stress-test scenario in which all of the firm's pipeline medicines fail to gain regulatory approval. Another way to state this is a scenario where a willing buyer ascribes no value to Purdue's pipeline medicines;
- Financial ratio analysis to assess Purdue's financial strength as of the end of each year of the 2008-16 Period; and
- Information related to Purdue's access to additional capital.
- As with the prior two tests, I conservatively use the high end of the estimated opioid litigation liability for 2013 through 2016.

A. Stress-test Scenario related to Purdue's Pipeline

175. In **Section III**, I estimated the value and cash flows of Purdue based on management's projections of future performance for Purdue's existing marketed drugs, as well as the expected performance of its development pipeline. For the purposes of the capital adequacy test, I instead utilize a stress-test scenario in which none of the drugs in Purdue's development pipeline ultimately succeed in gaining FDA approval (and therefore generate no future revenues) or assuming that a willing buyer ascribed no value to Purdue's pipeline. Management projections do not provide enough detail to precisely remove the value of the pipeline, so I adopt a methodology to estimate the proportion of the pipeline relative to the total value of Purdue's operating assets. To reflect a scenario where there is no value associated with the commercialization of these pipeline medications, I assume that Purdue's pre-tax earnings are reduced by a proportional amount equal to the proportion of management forecasted gross sales

court may consider in deciding whether the business had unreasonably low capital at the time of the transfer"); *In re Doctors Hospital of Hyde Park, Inc.*, 2007 WL 641399, at *859 ("Defendant correctly points out that events subsequent to the transfer period may be considered. This debtor survived for three years before filing its bankruptcy, and that may be considered in evaluating whether a company had unreasonably low capital at the time of the transfers."); *In re Joy Recovery Tech. Corp.*, 286 B.R. at 76 ("courts will not find that a company had unreasonably low capital if the company survives for an extended period after the subject transaction as Joy did.").

from drugs in development relative to total gross sales.²⁴⁸ In this stress scenario, I also assigned zero terminal value to Purdue's existing products following the projected loss of exclusivity for its existing products. This is also a conservative assumption in that it assumes Purdue's branded product sales would have no value after OxyContin loses exclusivity. This stress-test scenario thus is based only on the free cash flows Purdue is projected to earn on existing products through the loss of OxyContin exclusivity.

176. I summarize the value of Purdue under the stress-test scenario in **Figure 11** and **Exhibit 28**; the detailed calculations for Purdue's value and cash flows for each year in the 2008-16 Period are reported in **Exhibit D-10** to **Exhibit D-17**. Despite the conservative nature of this stress-test scenario, I find that the market value of Purdue's operating assets plus its excess cash still exceeded \$1.9 billion for all years in the 2008-16 Period (*see* **Figure 11** and **Exhibit 28**). This exceeds the face value of Purdue's liabilities during the 2008-16 Period by at least \$1.3 billion in all years. Similarly, in **Exhibits 29a to 29i**, I show that Purdue still passes the cash flow solvency test even based on the lower cash flows generated under this stress-test scenario.²⁴⁹

²⁴⁸ For example, given management projections that pipeline products would represent 25 percent of a given year's gross sales in its projections, I adjust that given year's forecast of Purdue's profit before tax (EBIT) to be 75 percent of management's forecast profit as of the valuation date.

²⁴⁹ I note that, although I did not value the operating assets as of January 2017, the excess cash would have been enough to satisfy total liabilities. I also reviewed the draft forecasts prepared as of January 2017 (*see* PPLPUCC9003546803), and although forecasted cash flows from operations were 13 percent lower than those forecasted as of June 2016, that does not change my conclusion since cash flows were still projected to be positive.

Figure 11. Purdue's Balance Sheet Test Under Stress-Test Scenario for Capital Adequacy

	Operating Assets Used in DCF Valuation	Operating Assets Under Stress- Test Scenario	Excess Cash	Liabilities	Solvency Cushion Under Stress-Test Scenario
	[i]	[ii]	[iii]	[iv]	[ii] + [iii] - [iv]
2008	9,157	5,748	386	342	5,792
2009	5,724	5,115	282	328	5,069
2010	7,457	4,752	232	331	4,653
2011	4,693	3,734	264	419	3,578
2012	4,590	3,221	349	245	3,326
2013	2,967	2,569	562	654	2,477
2014	1,377	1,377	568	694	1,251
2015	2,103	1,530	750	685	1,595
2016	1,625	1,285	693	641	1,337

B. Ratio Analysis of Purdue's Financial Health

177. In addition, I have also conducted an analysis of several financial ratios used to evaluate the financial health of companies to assess some basic indicators of Purdue's financial condition. For the purposes of this analysis, I utilize Purdue's actual financial results based on its consolidated financial statements as of the end of each calendar year rather than the firm's projected performance. These ratios thus reflect the financial condition of Purdue and its associated companies after all tax and non-tax distributions during the course of each year in the 2008-16 Period. I focus on three ratios:

- the current ratio is the ratio of a firm's current assets to its current liabilities and provides an indicator of a firm's liquidity and ability to satisfy its current liabilities.²⁵⁰ A ratio in excess of one indicates that the firm has adequate current assets to pay off its current liabilities.
- the quick ratio is similar to the current ratio, but deducts inventory from a firm's current assets, since a firm may not be able to liquidate inventory quickly.²⁵¹ Similar

²⁵⁰ Gallo, Amy, "A Refresher on Current Ratio," *Harvard Business Review*, September 14, 2015, available at <https://hbr.org/2015/09/a-refresher-on-current-ratio>.

²⁵¹ Gallo (2015).

to the current ratio, a quick ratio in excess of one indicates that a firm has sufficient liquid assets to pay off its current liabilities in full.

- the debt/equity ratio is the ratio of a firm's debt to its equity and is an indicator of the extent to which firm is financed with debt relative to equity.²⁵² The higher the debt-equity ratio, the more leveraged the company and the more likely it may have trouble servicing its debts, other things being equal.

178. As shown in **Exhibit 30**, Purdue's quick and current ratios were generally stable or rising throughout the 2008-16 Period and above 1.4 in all years. Similarly, Purdue's debt-equity ratio is zero for all years between 2009 and 2016 given that it had no outstanding debt throughout this period.²⁵³ As a result, this data provides no support for the allegation that Purdue's tax and non-tax distributions left the firm with "unreasonably small capital" that placed it in jeopardy of becoming bankrupt.

C. Purdue's Access to Capital

179. As discussed in **Section IV.B.4**, Purdue sought indicative credit ratings from both S&P and Moody's in 2016 related to a possible debt issuance to finance additional investments in the firm's pipeline. S&P provided an indicative corporate credit rating of 'BB', while Moody's provided an indicative corporate family rating of rated of Ba3.²⁵⁴ Both ratings are within the highest tier of non-investment grade ratings and would not be consistent with a financially distressed company that was on the verge of bankruptcy or unable to tap capital markets for funding.²⁵⁵ Indeed, both rating agencies based their indicative ratings on Purdue's healthy

²⁵² <https://corporatefinanceinstitute.com/resources/knowledge/finance/debt-to-equity-ratio-formula/>.


²⁵³ In 2008, Purdue Consolidated reported a \$39,978,000 loan payable by Lucien to Napp, which are foreign independent associated companies of Purdue Consolidated. See the "6-Loans P'ble" tab of PPLPUCC001704662.xls.

²⁵⁴ Indicative Ratings Letter, Standard & Poor's, April 7, 2016, PPLPUCC000360920-926 at 920; Indicative Ratings Letter, Moody's Investors Service, March 30, 2016, PPLPUCC003938943-946 at 943. S&P provided an indicative rat

²⁵⁵ Firms that are at imminent risk of bankruptcy are rated several tiers lower by both firms. For example, Moody's characterizes 'Ba'-rated obligations as being "speculative" and "subject to substantial credit risk." 'Caa'-rated bonds that are two rating tiers lower are "judged to be speculative of poor standing and are subject to very high credit risk." (Moody's Investor Service, "Rating Symbols and Definitions," January 26, 2021, p. 6., available at

financial condition. For example, Moody's noted that "[t]he low funded debt contemplated results in very strong interest coverage ratios, cash flow to debt coverage ratios and cash to debt ratios. This will allow the company to absorb considerable operating or legal setbacks with minimal risk of debt impairment."²⁵⁶ S&P similarly notes that Purdue's "historically conservative financial policy (this is the first debt placement) and very low leverage metrics support our 'minimal' financial risk assessment."²⁵⁷

180. Based on each of these factors, it is my opinion that Purdue met the capital adequacy test and was not insolvent on that basis.



Maureen Chakraborty, Ph.D.

https://www.moody.com/sites/products/AboutMoodyRatingsAttachments/MoodysRatingSymbolsandDefinitions.pdf?source=content_type%3Areact%7Cfirst_level_url%3Aarticle%7Csection%3Amain_content%7Cbutton%3Abody_link). S&P similarly notes that "An obligor rated 'B' is less vulnerable in the near term than other lower-rated obligors. However, it faces major ongoing uncertainties and exposure to adverse business, financial, or economic conditions which could lead to the obligor's inadequate capacity to meet its financial commitments." Issuers in the next lower tier are still considered able to service their debts, as S&P notes, "An obligor rated 'B' is more vulnerable than the obligors rated 'BB', but the obligor currently has the capacity to meet its financial commitments. Adverse business, financial, or economic conditions will likely impair the obligor's capacity or willingness to meet its financial commitments." (Standard & Poor's Rating Services, "Ratings Direct: Standard & Poor's Rating Definitions," November 20, 2014, p. 7., available at <https://www.spratings.com/documents/20184/86966/Standard+%26+Poor%27s+Ratings+Definitions/fd2a2a96-be56-47b8-9ad2-390f3878d6c6>)

²⁵⁶ Indicative Ratings Letter, Moody's Investors Service, March 30, 2016, PPLPUCC003938943-946 at 943.

²⁵⁷ Indicative Ratings Letter, Standard & Poor's, April 7, 2016, PPLPUCC000360920-926 at 922.

Exhibit 1
PPLP's Cash Distributions
AlixPartners Report
2008-2017
(\$ Millions)

Distribution Year	Partner Cash Distributions	Ex-U.S. Cash Distributions	Investment in Associated Companies	Tax Distributions	Total Distributions
2008	752	0	76	540	1,368
2009	899	0	112	711	1,721
2010	860	112	0	654	1,626
2011	554	113	0	556	1,223
2012	439	122	0	460	1,021
2013	298	234	0	401	934
2014	128	232	0	436	795
2015	129	297	0	366	792
2016	154	247	0	249	651
2017	0	0	0	187	187
Total	4,213	1,359	188	4,559	10,318


Notes:

- [1] PPLP recorded \$76 million in 2008 and \$112 million in 2009 as “Investment in Associated Companies.” This represents cash that flowed to an ex-U.S. affiliate entity through a wholly owned entity of Purdue.
- [2] Cash distributions do not include \$312.6 million of loans made to PRA L.P. in 2017, all of which have been repaid with full interest.
- [3] PPLP did not make any distributions after 2017.

Source:

- [A] *In re Purdue Pharma L.P. et al.*, Case No. 19-23649-rdd (U.S. Bankruptcy Court Southern District of New York) (ECF No. 654), Notice of Filing of Report of the Special Committee, Exhibit A, p. 25.

Exhibit 2 Pending Actions by Filing Date



Notes:

- [1] I understand from Counsel that the list of Pending Actions is based on the state, federal and tribal proceedings listed in Exhibits A, B and C to the Complaint for Injunctive *PPLP v. Commonwealth of Massachusetts*, Adv. Pro. No. 19-8289-rdd [Dkt. Nos. 1-1 and 1-2] and the exhibits to the preliminary injunction order now in effect [Dkt. No. 264 (18th Amended Order)].
- [2] For cases that have more than one filing date (e.g., an amended complaint is filed), the earliest filing date is used.

Source:

[A] **Appendix G.**

Exhibit 3a
Summary of PPLP's Cash Distributions
2008 - 2017

● **U.S. Partner Cash Distributions** ● **Ex-U.S. Cash Distributions** ● **Tax Distributions**




Exhibit 3a
Summary of PPLP's Cash Distributions
2008 - 2017

Notes:

- [1] PPLPUCC9011830859 and AlixPartners report the same \$10.318 billion amount of cash distributions from 2008 through 2017.
- [2] In 2017, PPLP made \$312.6 million in cash transfers to PRA L.P., which then transferred the amount to Ex-U.S. affiliated companies. PRA L.P. issued promissory notes for the \$312.6 million to PPLP, which it has since then paid back in full. AlixPartners treats this transfer as a loan to PRA L.P. and thus does not include it as an Ex-U.S. Cash Distribution. These are similarly omitted from the chart.
- [3] Negative distributions represent tax refunds, in addition to two adjustments dated April 30, 2016 described as “Correction of 2015 posting” and one adjustment dated December 31, 2011 described as “True-up to 2007 IRS Audit Payment”.

Sources:

- [A] PPLP Distributions Summary, PPLPUCC9011830859.
- [B] *In re Purdue Pharma L.P. et al.*, Case No. 19-23649-rdd (U.S. Bankruptcy Court Southern District of New York) (ECF No. 2907), Notice of Filing of Report of the Special Committee, pp. 25, 30.
- [C] **Appendix H.**

Exhibit 3b
Annual Summary of PPLP's Cash Distributions
2008 - 2017




Exhibit 3b
Annual Summary of PPLP's Cash Distributions
2008 - 2017

Notes:

- [1] AlixPartners categorizes \$187.7 million in distributions made in 2008 and 2009 out of the \$1.5 billion Ex-US Cash Distribution as "Investment in Associated Companies."
- [2] PPLPUCC9011830859 and AlixPartners report the same \$10.318 billion amount of cash distributions from 2008 through 2017.
- [3] In 2017, PPLP made \$312.6 million in cash transfers to PRA L.P., which then transferred the amount to Ex-U.S. affiliated companies. PRA L.P. issued promissory notes for the \$312.6 million to PPLP, which it has since then paid back in full. AlixPartners treats this transfer as a loan to PRA L.P. and thus does not include it as an Ex-U.S. Cash Distribution. These are similarly omitted from the chart.

Sources:

- [A] PPLP Distributions Summary, PPLPUCC9011830859.
- [B] *In re Purdue Pharma L.P. et al.*, Case No. 19-23649-rdd (U.S. Bankruptcy Court Southern District of New York) (ECF No. 2907), Notice of Filing of Report of the Special Committee, pp. 25, 30.
- [C] **Appendix H.**

Exhibit 4
Purdue's Gross Sales by Product
2008 - 2016




Exhibit 4
Purdue's Gross Sales by Product
2008 - 2016

Notes:

- [1] Sales numbers for 2015 are year-end estimates. Sales numbers for all other years are actuals.
- [2] Percentage at the top of each bar corresponds to the percentage of gross sales contributed by OxyContin in each year.
- [3] Other products include Betadine, Betasept, Colace, Dilaudid, Hydromorphone, Intermezzo, Peri-Colace, Morphine, MS Contin, OxyIR, Ryzolt, Senokot, Slow-Mag, Tramadol, Uniphyl, and other or discontinued products.

Sources:

- [A] Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453 at 376.
- [B] Purdue U.S. 2011 10-Year Plan, June 21, 2011, RSF00033012, at p. 98.
- [C] 2012 10-Year Plan, February 15, 2012, PPLPC053000063393-668, at 627.
- [D] 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 574.
- [E] 2014 10-Year Forecast and Trend, May 2014, PPLPUCC002545437-543 at 543.
- [F] Purdue Profit & Loss Account Summaries, November 2015, PPLPUCC001076695.
- [G] Purdue Profit & Loss Account Summaries, May 2017, PPLPUCC001075461.

Exhibit 5
Summary of Purdue Management Projections

No.	As-of Date	Bates Stamp	Document Title	Selected Projection	1. Non-Draft Document	2. Includes Income Stmt. & Cash Flow Stmt.	3. Projections Include LOE	4. Risk-Adjusted Projections Available	5. Projections Available for Existing Products
1.	4/18/2008	PPLPC012000179049	Board of Directors Meetings (U.S. Companies)	No	Yes	Yes	No	No	No
2.	4/18/2008	PPLPC063000023668	Five-Year Plan 2008-2013	Yes	Yes	Yes	No	No	No
3.	11/4/2008	PPLPUCC002538272	Purdue 10-Year Plan	No	No	No	Yes	No	No
4.	7/15/2009	PPLPC019000293027	Purdue 10-Year Plan	Yes	Yes	No	Yes	Yes	No
5.	9/21/2009	PPLPC051000080436	Purdue 10-Year Plan Supplemental Information	No	Yes	No	Yes	Yes	No
6.	11/1/2009	PPLPC062000002241	Ten Year Financial Projections	No	No	No	Yes	No	No
7.	12/31/2009	PPLPUCC001704662	Profit & Loss Account Summaries	No	No	Yes	Yes	No	No
8.	6/24/2010	PPLP004404330	Purdue Pharma 2010 10-Year Plan	Yes	Yes	Yes	Yes	Yes	Yes
9.	6/30/2010	PPLPUCC001053052	Profit & Loss Account Summaries	No	No	Yes	Yes	No	No
10.	6/30/2010	PPLPUCC9002975788	Purdue U.S. - Update Mid-Year Meetings	No	Yes	No	Yes	No	No
11.	12/31/2010	PPLPUCC001053705	Profit & Loss Account Summaries	No	No	Yes	Yes	No	No
12.	6/21/2011	RSF00033012	Purdue U.S. 2011 10-Year Plan	Yes	Yes	Yes	Yes	No	Yes
13.	6/21/2011	PPLPC063000000740	Purdue U.S. 2011 10-Year Plan	No	Yes	Yes	Yes	No	Yes
14.	12/31/2011	PPLPUCC001716854	Profit & Loss Account Summaries	No	No	Yes	Yes	No	No
15.	2/15/2012	PPLPC053000063393	Purdue 2012 10-Year Plan	Yes	Yes	Yes	Yes	Yes	Yes
16.	2/15/2012	PPLPC039000829545	Purdue 2012 10-Year Plan	No	Yes	Yes	Yes	No	No
17.	5/1/2013	PPLPC054000106338	Purdue 10-Year Plan	No	Yes	Yes	Yes	No	No
18.	5/9/2013	PPLPC063000003469	Purdue 2013 10-Year Plan	Yes	Yes	Yes	Yes	Yes	Yes

Exhibit 5
Summary of Purdue Management Projections

No.	As-of Date	Bates Stamp	Document Title	Selected Projection	1. Non-Draft Document	2. Includes Income Stmt. & Cash Flow Stmt.	3. Projections Include LOE	4. Risk-Adjusted Projections Available	5. Projections Available for Existing Products
19.	6/1/2013	PPLPC063000003593	Purdue Mid-Year Update	No	Yes	Yes	Yes	Yes	No
20.	6/1/2013	PPLPC034000795341	Purdue 2013 10-Year Plan	No	Yes	Yes	Yes	Yes	No
21.	11/6/2013	PPLPC053000089053	Purdue 5-Year Plan Update	No	Yes	Yes	Yes	No	No
22.	2014 (Exact date not specified)	RSF00126578	Purdue 2014 Finance Update	No	Yes	No	Yes	N/A	Yes
23.	2014 (Exact date not specified)	PPLPUCC9002452497	Purdue 2014 Finance Update	No	Yes	No	Yes	N/A	Yes
24.	5/1/2014	PPLPUCC002545437	2014 10-Year Forecast and Trend	Yes	Yes	Yes	Yes	N/A	Yes
25.	5/31/2014	PPLPC018000972178	Purdue - Finance Update Funds Available for Growth	No	Yes	Yes	Yes	N/A	Yes
26.	5/31/2014	PPLPC022000755894	Purdue - Finance Update Funds Available for Growth	No	Yes	Yes	Yes	N/A	Yes
27.	6/26/2014	PPLPC054000118010	Purdue U.S. Business and Financial Plans	No	No	Yes	Yes	N/A	Yes
28.	11/1/2014	RSF00016323	Budget Meeting	No	Yes	Yes	No	No	No
29.	11/30/2014	PPLPC063000008345	Purdue 2015 Budget Submission	No	Yes	No	No	No	No
30.	11/30/2014	PPLPUCC001074193	Profit & Loss Account Summaries	No	No	Yes	Yes	N/A	Yes
31.	2015 (Exact date not specified)	PPLPC011000036000	Purdue Mid-Year Strategic Review	No	No	Yes	Yes	Yes	Yes
32.	2015 (Exact date not specified)	RSF00178366	Cash Reserve Analyses	No	No	No	Yes	Yes	No
33.	2015 (Exact date not specified)	PPLPC051000258956	Purdue Mid-Year Strategic Review	No	No	Yes	Yes	Yes	Yes
34.	5/11/2015	PPLPC051000255338	Purdue Finance Update	No	No	Yes	Yes	Yes	Yes
35.	5/21/2015	PPLPC011000031720	Purdue Finance Update	No	Yes	Yes	Yes	Yes	Yes
36.	5/31/2015	RSF00178359	Cash Reserve Analyses	No	Yes	No	Yes	No	No

Exhibit 5
Summary of Purdue Management Projections

No.	As-of Date	Bates Stamp	Document Title	Selected Projection	1. Non-Draft Document	2. Includes Income Stmt. & Cash Flow Stmt.	3. Projections Include LOE	4. Risk-Adjusted Projections Available	5. Projections Available for Existing Products
37.	6/9/2015	PPLPC054000123288	Purdue Finance Update	Yes	Yes	Yes	Yes	Yes	Yes
38.	6/30/2015	PPLPC023000802126	10- & 5-Year Plans	No	No	No	Yes	Yes	No
39.	6/30/2015	PPLPUCC001074013	Profit & Loss Account Summaries	No	No	Yes	Yes	No	No
40.	12/31/2015	PPLPUCC001069623	Profit & Loss Account Summaries	No	No	Yes	Yes	No	No
41.	12/31/2015	PPLPUCC001076695	Profit & Loss Account Summaries	No	No	Yes	Yes	No	No
42.	6/8/2016	RSF00017771	Purdue Mid-Year Update	Yes	Yes	Yes	Yes	Yes	Yes
43.	6/8/2016	PPLPC063000016057	Purdue Financial Outlook	No	Yes	Yes	Yes	Yes	Yes
44.	6/30/2016	PPLPC023000885227	Purdue Financial Update	No	No	Yes	No	Yes	No
45.	10/5/2016	PPLPUCC001586350	Purdue Finance Update	No	No	No	No	No	No
46.	11/30/2016	PPLPUCC001746935	Purdue 2017 Budget	No	Yes	No	No	No	No

Notes:

[1] For 2008, 2009, and 2011, projections that meet all criteria were not available. *See Appendix D* for discussion of the projections used in these years and adjustments made.

[2] For 2014, 2015, and 2016, multiple projections meet all criteria. However, these projections were identical to one another.

[3] A value of "N/A" for Risk-Adjusted Projections Available indicates that projections do not include pipeline products.

Exhibit 6
Management Projections for Purdue's Net Sales
2008-2016

● Actual 2008 2009 2010 2011
2012 2013 2014 2015 2016

Net Sales
(\$ billions)




Exhibit 6
Management Projections for Purdue's Net Sales
2008-2016

Notes:

- [1] Net Sales projections provided here are risk-adjusted. Where risk-adjusted values were not available from the Management Projections, Net Sales were manually adjusted. The risk adjustments made to individual projections (where required) have been outlined in the notes below.
- [2] 2008 Net Sales provided in the Management Projections are non-risk adjusted and do not incorporate OxyContin's Loss of Exclusivity ("LOE"). Gross sales projections for OxyContin in 2008 include the impact of LOE. In order to risk adjust 2008 Net Sales projections, Gross Sales of individual pipeline drugs are multiplied to their corresponding success probabilities as listed in the July 2009 projections. *See* Purdue 10-Year Plan, July 15, 2009, PPLPC019000293027-65 at 28. The summation of risk-adjusted drug-level gross sales is then adjusted against Fee for Service, Discounts and Allowances, Rebates on Branded Products, and AG Income.
- [3] 2009 Net Sales provided in the Management Projections are non-risk adjusted. Risk adjusted projections are available at the Gross Sales level. In order to risk adjust 2009 Net Sales projections, the risk adjusted Gross Sales provided in the Management Projections are considered and adjusted against Fee for Service, Discounts and Allowances, Rebates on Branded Products, and AG Income.
- [4] 2011 Net Sales provided in the Management Projections are non-risk adjusted. Risk adjusted projections are available at the Gross Sales level. In order to risk adjust 2011 Net Sales projections, the risk adjusted Gross Sales provided in the Management Projections are considered and adjusted against Fee for Service, Discounts and Allowances, Patient Savings Card Discounts, Rebates on Branded Products, AG Income, and Third Party Royalty Income.
- [5] 2014 Net Sales projections are for Existing Products Only.

Sources:

- [A] Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 683 and 685.
- [B] Purdue 10-Year Plan, July 15, 2009, PPLPC019000293027-65 at 27 and 28.
- [C] Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453 at 380.
- [D] Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 98 and 107.
- [E] 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664.
- [F] 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526.
- [G] 2014 10-Year Forecast and Trend, May 2014, PPLPUCC002545437-543 at 440.
- [H] Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [I] Mid-Year Update, June 8, 2016, RSF00017771-921 at 892 and 910.
- [J] Purdue Pharma Inc. Board of Directors Meeting, Finance Update, March 7, 2019, PPLPUCC9002365418-440 at 423.

Exhibit 7
Summary of Purdue's Consolidated Income Statement
2008-2016




Exhibit 7
Summary of Purdue's Consolidated Income Statement
2008-2016

Notes:

- [1] Consolidated companies include Purdue Pharma L.P. and Associated Companies, PRA Holdings, Inc. and Subsidiaries, Pharma Associates Inc., Pharma Associates L.P., IKUWA Holdings Inc., Purdue Products Inc., Purdue Pharma Manufacturing Inc., Norwell Land Company, Avrio Health Inc., Purdue Pharmaceutical Products Inc., PharmIT Inc., Rhodes Pharmaceuticals Inc., Coventry Technologies L.P. and Associated Companies, Purdue Neuroscience Company, Millsaw Realty Inc., Millsaw Realty L.P., One Stamford Realty L.P., Laureate Pharma L.P., Laureate Pharma Inc., AB Generics L.P. and Bard Pharmaceuticals Inc.
- [2] Companies not listed as debtors include: PRA Holdings, Inc. and Subsidiaries, Pharma Associates Inc., Pharma Associates L.P., IKUWA Holdings Inc., Purdue Products Inc., Purdue Pharma Manufacturing Inc., Norwell Land Company, Avrio Health Inc., Purdue Pharmaceutical Products Inc., PharmIT Inc., Rhodes Pharmaceuticals Inc., Coventry Technologies L.P. and Associated Companies, Millsaw Realty Inc., Millsaw Realty L.P., One Stamford Realty L.P., Laureate Pharma L.P., Laureate Pharma Inc., AB Generics L.P. and Bard Pharmaceuticals Inc.
- [3] Other Expenses are reported as expenses that range from \$8 million to \$93 million in years 2008-2010 and as income that ranges from \$49,000 to \$2 million in years 2011-2016.
- [4] Income Tax Provisions range from \$901,000 to \$9.5 million.

Sources:

- [A] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697, at 663.
- [B] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991, at 955.
- [C] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583, at 541.
- [D] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLPC029000544175-219, at 179.
- [E] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174, at 140.
- [F] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664, at 620.
- [G] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPCO 11000090527, pp. 5-8.
- [H] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316, at 267.

Exhibit 8
Purdue's Consolidated Cash and Equivalents Balance
Purdue's Consolidated Free Cash Flows
2008-2016

■ Cash and Cash Equivalents ■ Free Cash Flows from Operations




Exhibit 8
Purdue's Consolidated Cash and Equivalents Balance
Purdue's Consolidated Free Cash Flows
2008-2016

Notes:

- [1] Consolidated companies include Purdue Pharma L.P. and Associated Companies, PRA Holdings, Inc. and Subsidiaries, Pharma Associates Inc., Pharma Associates L.P., IKUWA Holdings Inc., Purdue Products Inc., Purdue Pharma Manufacturing Inc., Norwell Land Company, Avrio Health Inc., Purdue Pharmaceutical Products Inc., PharmIT Inc., Rhodes Pharmaceuticals Inc., Coventry Technologies L.P. and Associated Companies, Purdue Neuroscience Company, Millsaw Realty Inc., Millsaw Realty L.P., One Stamford Realty L.P., Laureate Pharma L.P., Laureate Pharma Inc., AB Generics L.P. and Bard Pharmaceuticals Inc.
- [2] Companies not listed as debtors include: PRA Holdings, Inc. and Subsidiaries, Pharma Associates Inc., Pharma Associates L.P., IKUWA Holdings Inc., Purdue Products Inc., Purdue Pharma Manufacturing Inc., Norwell Land Company, Avrio Health Inc., Purdue Pharmaceutical Products Inc., PharmIT Inc., Rhodes Pharmaceuticals Inc., Coventry Technologies L.P. and Associated Companies, Millsaw Realty Inc., Millsaw Realty L.P., One Stamford Realty L.P., Laureate Pharma L.P., Laureate Pharma Inc., AB Generics L.P. and Bard Pharmaceuticals Inc.
- [3] Free Cash Flows are calculated as Income Before Taxes minus the sum of all interest accounts minus Income Tax Provisions plus Depreciation and Amortization minus increases in Working Capital minus Capital Expenditures.
- [4] Increases in Working Capital are calculated as the sum of the Changes in Operating Assets and Liabilities accounts within the Statements of Cash Flows: Accounts Receivable, Other Receivables, Inventories, Prepaid Expenses and Other Assets, Accounts Payable, and Accrued Expenses and Other Liabilities.
- [5] Cash and cash equivalents does not include restricted cash amounts listed on the balance sheet. Restricted cash is listed from years 2010-2014 and ranges from \$8 million to \$53 million.

Sources:

- [A] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697, at 662-665.
- [B] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991, at 954-957.
- [C] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583, at 540-543.
- [D] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLPC029000544175-219, at 178-181.
- [E] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174, at 139-142.
- [F] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664, at 619-622.
- [G] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPCO 11000090527, pp. 2-15.
- [H] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316, at 266-269.

Exhibit 9
Discount Rate for the DCF Valuation of Purdue's Operating Assets By Valuation Date

		<u>4/18/2008</u>	<u>7/15/2009</u>	<u>6/1/2010</u>	<u>6/21/2011</u>	<u>2/15/2012</u>	<u>5/3/2013</u>	<u>5/2/2014</u>	<u>6/9/2015</u>	<u>6/8/2016</u>
[1]	Risk Free Rate	4.50%	4.35%	4.05%	3.87%	2.70%	2.44%	3.16%	2.86%	2.10%
[2]	Equity Risk Premium	6.64%	6.10%	5.92%	6.35%	6.38%	6.40%	6.57%	6.60%	6.47%
[3]	Cash-Adjusted Unlevered Beta	<i>Lower Quartile</i>	0.65	0.72	0.76	0.75	0.80	0.88	0.91	1.08
		<i>Median</i>	0.86	0.83	0.88	0.96	0.96	0.98	1.20	1.24
		<i>Upper Quartile</i>	1.09	0.98	1.08	1.16	1.16	1.10	1.35	1.43
[4]	Discount Rate	<i>Lower Quartile</i>	8.81%	8.72%	8.55%	8.62%	7.79%	8.05%	9.17%	10.01%
		<i>Median</i>	10.19%	9.44%	9.25%	9.95%	8.85%	8.70%	11.04%	11.03%
		<i>Upper Quartile</i>	11.71%	10.36%	10.43%	11.26%	10.09%	9.48%	12.04%	11.25%
[5]	Number of Comparable Companies Included	20	20	21	20	19	16	14	9	8

Notes:

- [1] The Risk-Free Rate is the 20-year CMT yield from Bloomberg, L.P. and is measured one business day prior to the valuation date.
 [2] The Equity Risk Premium is the average of the Duff & Phelps Historical and Supply-Side equity risk premiums for the period from 1926 to the year end prior to the valuation date.
 [3] See **Appendix E** for Cash-Adjusted Unlevered Beta methodology.
 [4] The Discount Rate is calculated as [1] + [2]*[3]. I use the Upper Quartile Discount Rate.
 [5] The Number of Comparable Companies Included is based on availability of the data from Bloomberg, L.P. as needed for the methodology that is referenced in **Appendix E**.

Sources:

- [A] Bloomberg, L.P.
 [B] Duff & Phelps Cost of Capital Navigator, available at <https://costofcapital.duffandphelps.com/>.
 [C] Valuation Dates are from Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668; Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065; Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453 at 380; Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012; Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668; Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526; 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543; Finance Update, June 9, 2015, PPLPC054000123288; Purdue Mid-Year Update, June 8, 2016, RSF00017771-921.
 [D] See **Appendix E** for detailed methodology.

Exhibit 10
Sensitivity Analysis of DCF Valuation of Purdue's Operating Assets

2008					2009					2010				
Discount Rate	Long-Term Growth Rate				Discount Rate	Long-Term Growth Rate				Discount Rate	Long-Term Growth Rate			
	-4%	-2%	0%			-4%	-2%	0%			-4%	-2%	0%	
	9.71%	9,616	10,005	10,554		8.36%	6,078	6,078	6,078		8.43%	7,776	8,118	8,621
	11.71%	8,571	8,821	9,157		10.36%	5,724	5,724	5,724		10.43%	6,950	7,163	7,457
	13.71%	7,741	7,908	8,124		12.36%	5,404	5,404	5,404		12.43%	6,300	6,440	6,624
2011					2012					2013				
Discount Rate	Long-Term Growth Rate				Discount Rate	Long-Term Growth Rate				Discount Rate	Long-Term Growth Rate			
	-4%	-2%	0%			-4%	-2%	0%			-4%	-2%	0%	
	9.26%	4,976	4,976	4,976		8.09%	4,789	4,944	5,177		7.48%	3,137	3,152	3,175
	11.26%	4,693	4,693	4,693		10.09%	4,357	4,454	4,590		9.48%	2,945	2,954	2,967
	13.26%	4,436	4,436	4,436		12.09%	4,007	4,071	4,156		11.48%	2,777	2,782	2,790
2014					2015					2016				
Discount Rate	Long-Term Growth Rate				Discount Rate	Long-Term Growth Rate				Discount Rate	Long-Term Growth Rate			
	-4%	-2%	0%			-4%	-2%	0%			-4%	-2%	0%	
	10.04%	1,463	1,463	1,463		10.28%	2,220	2,281	2,367		9.25%	1,683	1,736	1,812
	12.04%	1,377	1,377	1,377		12.28%	2,011	2,050	2,103		11.25%	1,545	1,579	1,625
	14.04%	1,300	1,300	1,300		14.28%	1,841	1,867	1,901		13.25%	1,434	1,456	1,485

Notes:

[1] Valuations shaded in gray represent baseline DCF assumptions.

[2] Valuations for 2009, 2011, and 2014 do not include a terminal value, and therefore do not vary with a change in long-term growth rate.

Source:

[A] See Exhibits D-1 to D-9 for detailed sources for each DCF valuation.

Exhibit 11
Summary of Purdue's Excess Cash
(\$ millions)

Year	Cash & Cash Equivalents	Restricted Cash	Total Current Assets	Total Current Liabilities	Excess Cash^[1]
2008	425	0	675	290	386
2009	377	0	717	434	282
2010	378	22	767	513	232
2011	513	35	892	593	264
2012	621	17	987	620	349
2013	776	21	1,197	614	562
2014	938	14	1,238	656	568
2015	1,181	4	1,456	701	750
2016	1,189	0	1,341	648	693

Exhibit 11
Summary of Purdue's Excess Cash
(\$ millions)

Note:

- [1] Excess Cash is calculated as: Cash and Cash Equivalents - Max [Total Current Liabilities - (Total Current Assets - Cash and Cash Equivalents), 0] - Restricted Cash. Figures are calculated using actual year-end Purdue U.S. balance sheet figures to estimate Excess Cash as of the valuation date.

Sources:

- [A] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697, at 662.
- [B] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991, at 954.
- [C] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583, at 540.
- [D] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLPC029000544175-219, at 178.
- [E] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174, at 139.
- [F] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664, at 619.
- [G] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPCO11000090527, pp. 2-5.
- [H] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316, at 266.

Exhibit 12
Summary of DCF Valuation of Purdue's Assets
(\$ millions)

Valuation (\$ millions)			
Year	Value of Operating Assets	Excess Cash	Total
2008	9,157	386	9,543
2009	5,724	282	6,006
2010	7,457	232	7,689
2011	4,693	264	4,958
2012	4,590	349	4,939
2013	2,967	562	3,530
2014	1,377	568	1,945
2015	2,103	750	2,853
2016	1,625	693	2,318

Notes:

- [1] The value of Purdue's operating assets is determined using the DCF method, as described in **Section III** and **Appendix D** of my report.
- [2] Excess Cash is calculated as: Cash and Cash Equivalents - Max [Total Current Liabilities - (Total Current Assets - Cash and Cash Equivalents), 0] - Restricted Cash. Figures are calculated using actual year-end Consolidated Purdue Companies balance sheet figures to estimate Excess Cash as of the valuation date. *See Exhibit 11.*

Sources:

- [A] **Exhibits D-1 through D-9.**
- [B] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697, at 662.
- [C] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991, at 954.
- [D] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583, at 540.
- [E] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLPC029000544175-219, at 178.
- [F] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174, at 139.
- [G] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664, at 619.
- [H] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPCO 11000090527, pp. 2-5.
- [I] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316, at 266.

Exhibit 13a
Guideline Public Company Method - Comparable Companies Valuation
Enterprise Value / Next-Twelve-Months Revenue Multiple

	<u>2008</u>	<u>2009</u>	<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
Alkermes	3.5x	4.1x	5.1x	6.7x	5.2x	6.2x	10.6x	14.2x	8.3x
Allergan Inc.	3.9x	3.5x	3.6x	4.6x	4.8x	5.2x	5.2x		
AMAG	177.1x	12.5x	5.3x	2.3x	1.6x	3.8x	2.0x	5.0x	2.5x
Amylin	3.9x	2.3x	3.5x	3.6x	8.0x				
Celgene	10.7x	7.2x	5.9x	5.8x	6.0x	7.8x	7.4x	9.3x	7.3x
Cephalon	2.5x	2.0x	1.3x	2.0x					
Cubist	2.6x	1.5x	1.6x	2.4x	2.6x	2.4x	4.6x		
Forest	2.4x	1.1x	0.9x	1.5x	1.7x	2.1x	5.0x		
Hospira	2.4x	2.1x	2.7x	2.5x	1.8x	1.6x	2.0x	3.4x	
Jazz	1.8x	1.9x	2.4x	4.9x	5.2x	4.0x	7.1x	8.0x	5.6x
K-V	2.0x	0.7x	-	NM	-	-			
Medicines	2.5x	0.6x	0.6x	1.3x	1.4x	2.1x	2.2x	3.4x	13.7x
Medicis	1.4x	1.2x	1.2x	2.1x	2.5x				
Pharmacyclics	NM	7.5x	47.7x	86.7x	35.1x	-	17.1x	13.5x	
Questcor	-	2.3x	4.3x	7.5x	5.5x	2.5x	3.4x		
Regeneron	4.9x	3.3x	3.7x	9.5x	13.0x	9.0x	10.9x	13.6x	6.7x
Sepracor	1.5x	1.4x							
United Therapeutics	7.2x	5.7x	4.1x	3.4x	2.4x	2.5x	3.1x	4.8x	2.3x
Valeant	1.8x	3.2x	4.3x						
Vertex	12.7x	35.0x	43.0x	9.0x	4.1x	10.0x	26.5x	21.3x	10.7x
Viro Pharma	1.4x	1.3x	2.2x	2.3x	2.9x	3.4x			
Warner Chilcott	6.0x	4.1x	2.7x	3.8x	2.9x	2.9x			
Xstelos									
25th Percentile	2.0x	1.4x	2.0x	2.3x	2.4x	2.4x	3.1x	4.8x	4.8x
Median	2.6x	2.3x	3.5x	3.6x	3.5x	3.4x	5.1x	8.6x	7.0x
75th Percentile	5.2x	4.1x	4.5x	6.2x	5.5x	5.7x	9.8x	13.6x	8.9x
Count	20	22	20	19	18	15	14	10	8
(\$ millions)									
Purdue NTM Revenue	2,305	2,502	2,660	2,460	2,344	2,216	1,392	1,450	1,381
GPCM Valuation - 25th	4,537	3,559	5,428	5,677	5,592	5,392	4,367	6,988	6,648
GPCM Valuation - Median	5,959	5,762	9,432	8,834	8,233	7,453	7,135	12,534	9,679
GPCM Valuation - 75th	11,891	10,252	12,030	15,344	12,785	12,540	13,597	19,753	12,260
Purdue DCF Valuation	9,157	5,724	7,457	4,693	4,590	2,967	1,377	2,103	1,625
Purdue Implied Multiple	4.0x	2.3x	2.8x	1.9x	2.0x	1.3x	1.0x	1.5x	1.2x

Notes:

- [1] Analysis is conducted as of the same date of the DCF valuation for each year.
- [2] Multiples for comparable companies pulled on a quarterly basis as of quarter-end. Multiple from quarter-end date that is closest to the valuation date is used for each year.
- [3] The next-twelve-months (NTM) financial metric for Purdue as of the valuation date is estimated using management projections. Specifically, a weighted average of the current and next year figures (forecasted) is calculated to estimate the NTM.
- [4] NM indicates the calculated figure is not meaningful due to a negative number.

Sources:

- [A] All trading multiples for comparable companies are from S&P Capital IQ.
- [B] Purdue NTM figures are estimated using management projections. See **Appendix D** for detailed notes and sources and DCF Valuation.

Exhibit 13b
Guideline Public Company Method - Comparable Companies Valuation
Enterprise Value / Next-Twelve-Months EBITDA Multiple

	<u>2008</u>	<u>2009</u>	<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
Alkermes	40.8x	NM	NM	NM	25.8x	19.6x	108.7x	NM	NM
Allergan Inc.	14.4x	10.1x	10.9x	13.4x	13.8x	14.4x	14.2x		
AMAG	-	NM	NM	NM	NM	NM	NM	10.3x	4.7x
Amylin	NM	NM	83.1x	NM	NM				
Celgene	26.0x	17.1x	14.2x	12.5x	12.5x	15.9x	14.2x	17.7x	7.1x
Cephalon	8.0x	6.4x	4.0x	5.8x					
Cubist	11.7x	4.8x	4.8x	8.5x	8.9x	11.7x	38.1x		
Forest	8.0x	3.3x	2.7x	5.0x	8.9x	19.5x	17.4x		
Hospira	10.4x	10.0x	9.7x	9.1x	10.3x	9.8x	11.4x	15.8x	
Jazz	NM	26.8x	7.8x	9.8x	9.2x	7.3x	11.9x	13.3x	9.9x
K-V	6.0x	5.4x	-	-	-	-			
Medicines	39.0x	5.5x	9.7x	8.5x	7.6x	14.5x	79.3x	-	NM
Medicis	4.6x	4.4x	3.6x	5.3x	6.9x				
Pharmacyclics	-	-	NM	NM	NM	-	NM	87.5x	
Questcor	-	-	-	18.3x	12.2x	4.4x	6.0x		
Regeneron	NM	NM	NM	NM	NM	21.5x	28.4x	39.8x	21.9x
Sepracor	11.1x	5.4x							
United Therapeutics	30.0x	15.7x	10.5x	8.7x	5.0x	5.1x	6.9x	9.8x	3.9x
Valeant	8.3x	9.0x	10.2x						
Vertex	NM	NM	NM	46.6x	11.0x	NM	NM	249.7x	52.9x
Viro Pharma	3.4x	NM	-	4.3x	6.6x	18.7x			
Warner Chilcott	12.2x	7.7x	6.3x	7.2x	5.6x	5.7x			
Xstelos									
25th Percentile	8.0x	5.4x	4.8x	6.1x	7.1x	7.3x	11.6x	12.6x	5.3x
Median	11.1x	7.0x	9.7x	8.6x	9.1x	14.4x	14.2x	16.8x	8.5x
75th Percentile	20.2x	10.1x	10.5x	11.8x	11.9x	18.7x	33.2x	51.7x	18.9x
Count	15	14	13	14	14	13	11	8	6
(\$ millions)									
Purdue NTM EBITDA	1,581	1,483	1,559	1,157	915	926	344	396	241
GPCM Valuation - 25th	12,657	7,974	7,511	7,083	6,454	6,793	4,002	4,971	1,275
GPCM Valuation - Median	17,619	10,436	15,070	9,952	8,282	13,345	4,897	6,637	2,046
GPCM Valuation - 75th	31,911	14,985	16,407	13,700	10,896	17,334	11,425	20,454	4,552
Purdue DCF Valuation	9,157	5,724	7,457	4,693	4,590	2,967	1,377	2,103	1,625
Purdue Implied Multiple	5.8x	3.9x	4.8x	4.1x	5.0x	3.2x	4.0x	5.3x	6.8x

Notes:

- [1] Analysis is conducted as of the same date of the DCF valuation for each year.
- [2] Multiples for comparable companies pulled on a quarterly basis as of quarter-end. Multiple from quarter-end date that is closest to the valuation date is used for each year.
- [3] The next-twelve-months (NTM) financial metric for Purdue as of the valuation date is estimated using management projections. Specifically, a weighted average of the current and next year figures (forecasted) is calculated to estimate the NTM.
- [4] NM indicates the calculated figure is not meaningful due to a negative number.

Sources:

- [A] All trading multiples for comparable companies are from S&P Capital IQ.
- [B] Purdue NTM figures are estimated using management projections. See **Appendix D** for detailed notes and sources and DCF Valuation.

Exhibit 13c
Guideline Public Company Method - Comparable Companies Valuation
Enterprise Value / Next-Twelve-Months EBIT Multiple

	<u>2008</u>	<u>2009</u>	<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
Alkermes	67.4x	NM	NM	NM	NM	51.4x	NM	NM	NM
Allergan Inc.	16.5x	12.1x	12.3x	14.7x	15.2x	15.8x	15.4x		
AMAG	NM	NM	NM	NM	NM	NM	21.3x	9.6x	8.6x
Amylin	NM	NM	NM	NM	NM				
Celgene	26.6x	16.2x	13.6x	13.0x	13.0x	16.2x	14.9x	18.0x	7.2x
Cephalon	9.2x	7.0x	4.5x	5.9x					
Cubist	12.5x	5.4x	5.5x	10.1x	10.0x	12.5x	30.2x		
Forest	7.8x	3.5x	2.9x	5.5x	14.3x	58.2x	21.2x		
Hospira	14.1x	11.9x	13.2x	11.4x	14.6x	13.3x	15.5x	18.8x	
Jazz	NM	79.3x	11.3x	9.5x	10.9x	7.5x	13.1x	13.9x	9.6x
K-V	7.0x	NM	-	-	-	-			
Medicines	38.9x	7.8x	6.4x	7.5x	8.4x	16.9x	242.6x	NM	NM
Medicis	5.6x	5.3x	4.2x	6.0x	7.9x				
Pharmacyclics	0.3x	NM	NM	NM	NM	-	NM	89.4x	
Questcor	-	4.6x	9.2x	16.0x	9.9x	4.6x	5.7x		
Regeneron	NM	NM	NM	NM	NM	22.6x	28.4x	42.7x	25.5x
Sepracor	13.8x	6.1x							
United Therapeutics	29.5x	17.0x	12.9x	10.2x	5.4x	5.3x	7.1x	10.9x	3.5x
Valeant	15.7x	14.1x	12.6x						
Vertex	NM	NM	NM	56.8x	11.5x	NM	NM	NM	46.6x
Viro Pharma	3.4x	3.8x	7.8x	7.3x	7.7x	33.0x			
Warner Chilcott	22.4x	10.9x	11.0x	11.6x	6.2x	9.5x			
Xstelos									
25th Percentile	7.6x	5.3x	5.7x	7.4x	7.9x	9.5x	14.0x	12.4x	7.5x
Median	13.9x	7.8x	10.1x	10.2x	10.0x	15.8x	15.5x	18.0x	9.1x
75th Percentile	23.5x	13.1x	12.5x	12.6x	13.0x	22.6x	24.8x	30.7x	21.5x
Count	16	15	14	14	13	13	11	7	6
(\$ millions)									
Purdue NTM EBIT	1,550	1,449	1,523	1,126	881	894	311	365	212
GPCM Valuation - 25th	11,788	7,726	8,735	8,277	6,984	8,491	4,353	4,530	1,597
GPCM Valuation - Median	21,617	11,275	15,332	11,427	8,809	14,102	4,811	6,571	1,929
GPCM Valuation - 75th	36,384	18,982	19,072	14,226	11,483	20,170	7,720	11,214	4,566
Purdue DCF Valuation	9,157	5,724	7,457	4,693	4,590	2,967	1,377	2,103	1,625
Purdue Implied Multiple	5.9x	3.9x	4.9x	4.2x	5.2x	3.3x	4.4x	5.8x	7.7x

Notes:

- [1] Analysis is conducted as of the same date of the DCF valuation for each year.
- [2] Multiples for comparable companies pulled on a quarterly basis as of quarter-end. Multiple from quarter-end date that is closest to the valuation date is used for each year.
- [3] The next-twelve-months (NTM) financial metric for Purdue as of the valuation date is estimated using management projections. Specifically, a weighted average of the current and next year figures (forecasted) is calculated to estimate the NTM.
- [4] NM indicates the calculated figure is not meaningful due to a negative number.

Sources:

- [A] All trading multiples for comparable companies are from S&P Capital IQ.
- [B] Purdue NTM figures are estimated using management projections. See **Appendix D** for detailed notes and sources and DCF Valuation.

Exhibit 14
Summary of Purdue's Liabilities
2008-2016




Exhibit 14
Summary of Purdue's Liabilities
2008-2016

Notes:

- [1] Consolidated companies include Purdue Pharma L.P. and Associated Companies, PRA Holdings, Inc. and Subsidiaries, Pharma Associates Inc., Pharma Associates L.P., IKUWA Holdings Inc., Purdue Products Inc., Purdue Pharma Manufacturing Inc., Norwell Land Company, Avrio Health Inc., Purdue Pharmaceutical Products Inc., PharmIT Inc., Rhodes Pharmaceuticals Inc., Coventry Technologies L.P. and Associated Companies, Purdue Neuroscience Company, Millsaw Realty Inc., Millsaw Realty L.P., One Stamford Realty L.P., Laureate Pharma L.P., Laureate Pharma Inc., AB Generics L.P. and Bard Pharmaceuticals Inc.
- [2] Companies not listed as debtors include: PRA Holdings, Inc. and Subsidiaries, Pharma Associates Inc., Pharma Associates L.P., IKUWA Holdings Inc., Purdue Products Inc., Purdue Pharma Manufacturing Inc., Norwell Land Company, Avrio Health Inc., Purdue Pharmaceutical Products Inc., PharmIT Inc., Rhodes Pharmaceuticals Inc., Coventry Technologies L.P. and Associated Companies, Millsaw Realty Inc., Millsaw Realty L.P., One Stamford Realty L.P., Laureate Pharma L.P., Laureate Pharma Inc., AB Generics L.P. and Bard Pharmaceuticals Inc.
- [3] Other Liabilities include employee benefit liabilities, deferred income taxes, debt due to associated companies (current liability), accrued settlement expenses, and Infinity line of credit.
- [4] Long-Term Debt is only reported for 2014 at \$770,000.

Sources:

- [A] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697, at 662.
- [B] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991, at 954.
- [C] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583, at 540.
- [D] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLPC029000544175-219, at 178.
- [E] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174, at 139.
- [F] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664, at 619.
- [G] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPCO 11000090527, pp. 4-5.
- [H] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316, at 266.

Exhibit 15
Purdue Financial Statement Disclosures of OxyContin Civil Product Liability Litigation
Number of Pending and Actively Litigated Product Liability Lawsuits




Exhibit 15
Purdue Financial Statement Disclosures of OxyContin Civil Product Liability Litigation
Number of Pending and Actively Litigated Product Liability Lawsuits

Notes:

- [1] Figures are as reported in Purdue's annual Audited Combined Financial Statements.
- [2] Pending lawsuits include OxyContin civil Product liability lawsuits that are either 1) being actively litigated, 2) inactive, or 3) in settlement discussions.
- [3] Actively Litigated lawsuits for the years 2010-2011 through 2013-2014 include OxyContin civil Product liability lawsuits that are or will be engaged in discovery or substantive motion practice. These are not reported in the Audited Combined Financial Statements for the years 2007-2008 through 2009-2010 and are assumed to be equal to the number of Pending Lawsuits. Actively Litigated lawsuits for the years 2014-2015 through 2016-2017 include lawsuits whose claims are, according to the Audited Combined Financial Statements, being "actively pursu[ed]" by "plaintiffs in the matters."
- [4] Figures are as of March or April of each year following the second year covered by the Audited Combined Financial Statements. For example, the 2007-2008 financial statement is dated March 2009, and the 2009-2010 financial statement is dated April 2011.

Sources:

- [A] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2008 and 2007, PPLPC0120000221168-206, at 199.
- [B] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697, at 690-691.
- [C] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991, at 983-984.
- [D] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583, at 574-575.
- [E] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLP029000544175-219, at 208.
- [F] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174, at 166.
- [G] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664, at 655.
- [H] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPC021000890262-316, p. 42.
- [I] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316, at 304.

Exhibit 16
Purdue's Accrued Settlement Expenses and Legal Expenses
2006-2016




Exhibit 16
Purdue's Accrued Settlement Expenses and Legal Expenses
2006-2016

Notes:

- [1] Accrued Settlement Expenses are taken from EY audited combined financial statements which include Purdue Pharma L.P. and Associated Companies, PRA Holdings, Inc. and Subsidiaries, Pharma Associates Inc., Pharma Associates L.P., IKUWA Holdings Inc., Purdue Products Inc., Purdue Pharma Manufacturing Inc., Norwell Land Company, Avrio Health Inc., Purdue Pharmaceutical Products Inc., PharmIT Inc., Rhodes Pharmaceuticals Inc., Coventry Technologies L.P. and Associated Companies, Purdue Neuroscience Company, Millsaw Realty Inc., Millsaw Realty L.P., One Stamford Realty L.P., Laureate Pharma L.P., Laureate Pharma Inc., AB Generics L.P. and Bard Pharmaceuticals Inc.
- [2] Legal Expenses represent the actual legal expenses incurred by Purdue each year from 2006-2016.
- [3] The sharp increase in Accrued Settlement Expenses in 2006 is driven by a \$579 million accrual pertaining largely to Purdue's \$600 million settlement with the U.S. Attorney's Office for the Western District of Virginia in July 2007. Parts of this settlement were intended to be paid over the course of the following decade or kept as escrow and hence the full \$600 million amount was not incurred in 2006.

Sources:

- [A] Purdue Financial Statements, November 2007, PPLPC020000164902.
- [B] Purdue U.S. Financial Statements, December 2009, PPLPC042000019584.
- [C] Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 107.
- [D] 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664.
- [E] 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526.
- [F] Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [G] Mid-Year Update, June 8, 2016, RSF00017771-921 at 903.
- [H] 2017 Finance Update, July 11, 2017, PPLPC051000318806 at p. 4.
- [I] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2006 and 2005, PPLPC012000144598-636, at 614.
- [J] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2007 and 2006, PPLPMDL0040000379-417, at 394.
- [K] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2008 and 2007, PPLPC012000221168-206, at 185-186.
- [L] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697, at 677-678.
- [M] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991, at 970.
- [N] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583, at 558-559.
- [O] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLPC029000544175-219, at 193-194.
- [P] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174, at 153.
- [Q] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664, at 635.
- [R] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPCO 11000090527, pp. 25-26.
- [S] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316, at 282.
- [T] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2017 and 2016, PPLPC029000692681-739, at 702-703.

Exhibit 17
Management Projections for Purdue's Legal Expenses
2008-2016




Exhibit 17
Management Projections for Purdue's Legal Expenses
2008-2016

Note:

[1] Legal expenses from 2010 are estimated by subtracting the sum of non-redacted operating expenses from total operating expenses.

Sources:

- [A] Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 685.
- [B] Purdue Existing + New Products 10-Year Plan, July 15, 2009, PPLPC019000293027-65 at 27.
- [C] Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453 at 380.
- [D] Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 107.
- [E] 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664.
- [F] 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526.
- [G] 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 440.
- [H] Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [I] Mid-Year Update, June 8, 2016, RSF00017771-921 at 903.

Exhibit 18
New Case Filings Related to Pending Actions Over Time
Where Purdue Is Also a Named Defendant (Top 20 Co-Defendants)
2014-2019

	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>Total</u>
Purdue	2	1	2	344	1,486	884	2,719
Endo	2	1	1	339	1,475	837	2,655
Janssen	2	1	1	332	1,429	844	2,609
Teva	1	1	1	328	1,408	841	2,580
Cephalon	1	1	1	331	1,406	796	2,536
AmerisourceBergen	-	-	2	309	1,373	835	2,519
Johnson & Johnson	2	1	1	320	1,367	797	2,488
Cardinal Health	-	-	2	310	1,350	810	2,472
Actavis	2	1	-	313	1,313	763	2,392
Allergan	2	1	-	311	1,303	775	2,392
Watson	2	1	-	306	1,306	723	2,338
Mallinckrodt	-	-	1	249	1,238	812	2,300
McKesson	-	-	2	299	1,197	784	2,282
Noramco	-	-	-	202	838	459	1,499
Walmart	-	-	2	151	654	486	1,293
Insys	-	-	1	155	567	545	1,268
Walgreens	-	-	1	118	491	504	1,114
CVS Health	-	-	1	123	509	480	1,113
Par	-	-	1	109	378	391	879
Rite Aid	-	-	1	109	403	303	816
SpecGx	-	-	-	95	274	423	792

Exhibit 18
New Case Filings Related to Pending Actions Over Time
Where Purdue Is Also a Named Defendant (Top 20 Co-Defendants)
2014-2019

Notes:

- [1] I understand from Counsel that the list of Pending Actions is based on the state, federal and tribal proceedings listed in Exhibits A, B and C to the Complaint for Injunctive Relief, *PPLP v. Commonwealth of Massachusetts*, Adv. Pro. No. 19-8289-rdd [Dkt. Nos. 1-1 and 1-2] and the exhibits to the preliminary injunction order now in effect [Dkt. No. 264 (18th Amended Order)].
- [2] For cases that have more than one filing date (e.g., an amended complaint is filed), the earliest filing date is used.

Source:

[A] **Appendix G.**

Exhibit 19
Top 20 Most-Named Co-Defendants in the Pending Actions

No.	Name	Role	Business Description	Cases as Co-Defendant
1	Endo	Manufacturer	Endo International plc is a specialty pharmaceutical company that manufactures and sells generic and branded pharmaceuticals in the U.S. and internationally.	2,655
2	Janssen	Manufacturer	Janssen Pharmaceuticals, Inc. is a long-time subsidiary of Johnson & Johnson. Janssen manufactures and markets prescription pharmaceutical products. It provides medicines for health concerns in various therapeutic areas.	2,609
3	Teva	Manufacturer	Teva Pharmaceutical Industries Limited is a pharmaceutical company that develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products worldwide.	2,580
4	Cephalon	Manufacturer	Cephalon, Inc. has been a subsidiary of Teva since 2011, prior to which point it was a public company. Cephalon engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer.	2,536
5	AmerisourceBergen	Manufacturer	AmerisourceBergen Corporation sources and distributes pharmaceutical products worldwide. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals.	2,519
6	Johnson & Johnson	Distributor	Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices.	2,488

Exhibit 19
Top 20 Most-Named Co-Defendants in the Pending Actions

No.	Name	Role	Business Description	Cases as Co-Defendant
7	Cardinal Health	Manufacturer	Cardinal Health, Inc. operates as an integrated healthcare services and products company in the U.S. and internationally. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products.	2,472
8	Actavis	Distributor	Actavis Inc., a public company, acquired Allergan, also a public company, in 2015, and took on the Allergan name post-acquisition. Actavis Pharma, Inc., the Actavis generics business, was sold to Teva in 2016.	2,392
9	Allergan	Manufacturer	Allergan plc is a pharmaceutical company that develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. As of May 2020, operates as a subsidiary of AbbVie Inc.	2,392
10	Watson	Manufacturer	Watson Pharmaceuticals International, Ltd., a public company, acquired Actavis, a private company, in 2012, took on the Actavis name post-acquisition and continued to operate as a public company.	2,338
11	Mallinckrodt	Manufacturer	Mallinckrodt plc develops, manufactures, markets, and distributes specialty branded and generic pharmaceutical products and therapies in the U.S. and internationally. The company filed for Chapter 11 bankruptcy in October 2020.	2,300
12	McKesson	Distributor	McKesson Corporation provides pharmaceuticals and medical supplies worldwide. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products.	2,282

Exhibit 19
Top 20 Most-Named Co-Defendants in the Pending Actions

No.	Name	Role	Business Description	Cases as Co-Defendant
13	Noramco	Manufacturer	Noramco, Inc. was a subsidiary of Johnson & Johnson until March 2016, at which point it was sold to a private equity firm. It manufactures active pharmaceutical ingredients for pain management, as well as starting materials and key intermediates.	1,499
14	Walmart	Manufacturer	Walmart Inc. engages in the operation of retail, wholesale, and other units worldwide. The company operates supercenters, supermarkets, hypermarkets, warehouse clubs, cash and carry stores, and discount stores; membership-only warehouse clubs; e-commerce websites; and mobile commerce applications.	1,293
15	Insys	Pharmacy	Insys Therapeutics, Inc. was a specialty pharmaceutical company that focused on cannabinoids and drug delivery systems. The company filed for Chapter 11 bankruptcy in June 2019 and formally went out of business in February 2020.	1,268
16	Walgreens	Pharmacy	Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products. The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals.	1,114
17	CVS Health	Pharmacy	CVS Health Corporation provides health services in the U.S. The Pharmacy Services segment offers pharmacy benefit-management (PBM) solutions. The Retail/Long-Term Care segment sells prescription and over-the-counter drugs among other products.	1,113

Exhibit 19
Top 20 Most-Named Co-Defendants in the Pending Actions

No.	Name	Role	Business Description	Cases as Co-Defendant
18	Par	Manufacturer	Par Pharmaceutical Holdings, Inc. has been a subsidiary of Endo since 2015, prior to which point it was a private company. Par develops, licenses, manufactures, and distributes generic pharmaceutical and injectable products in the U.S.	879
19	Rite Aid	Manufacturer	Rite Aid Corporation operates a chain of retail drugstores in the U.S. The Retail Pharmacy segment sells prescription drugs and an assortment of other merchandise. The Pharmacy Services segment provides a range of pharmacy-related services.	816
20	SpecGx	Pharmacy	SpecGx LLC has been a subsidiary of Mallinckrodt since its incorporation in 2016. SpecGx manufactures, markets, and sells prescription opioid pain medications under brand names as well as generic drugs.	792

Notes:

- [1] I understand from Counsel that the list of Pending Actions is based on the state, federal and tribal proceedings listed in Exhibits A, B and C to the Complaint for Injunctive Relief, *PPLP v. Commonwealth of Massachusetts*, Adv. Pro. No. 19-8289-rdd [Dkt. Nos. 1-1 and 1-2] and the exhibits to the preliminary injunction order now in effect [Dkt. No. 264 (18th Amended Order)].
- [2] Role represents each company's primary role in the pharmaceutical supply chain, as described by the Business Description. A manufacturer develops, manufactures, and sells pharmaceutical drugs. A distributor delivers drug products to pharmacies, hospitals, and medical practices. A pharmacy dispenses prescription drugs to individual patients.
- [3] Business Descriptions are summarized from S&P Capital IQ. Additional information on history of mergers and acquisitions is sourced from Bloomberg L.P.

Sources:

- [A] See **Exhibit 18** for details on the number of cases for each co-defendant.
- [B] S&P Capital IQ.
- [C] Bloomberg L.P.

Exhibit 20
Share of Opioid Product Sales for the Litigation Comparables
As of 2013

Company	Opioid Product Sales (millions)	Total Sales (millions)	Share of Total Sales from Opioid Products		Description of Product Offerings
				Opioid Products	
[1] Endo International Plc	\$333.7	\$2,616.9	13%	Opana ER and Percocet. Excludes generic drugs in the Qualitest business.	We continue to operate across our diversified businesses in three key segments, Endo Pharmaceuticals, Qualitest and AMS, in key therapeutic areas including pain management, urology, oncology and endocrinology.
[2] Insys Therapeutics Inc	\$95.7	\$99.3	96%	Subsys	We are a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products: Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS.

Exhibit 20
Share of Opioid Product Sales for the Litigation Comparables
As of 2013

Company	Opioid Product Sales (millions)	Total Sales (millions)	Share of Total Sales from Opioid Products		Description of Product Offerings
				Opioid Products	
[3] Mallinckrodt Plc	\$546.3	\$2,204.5	25%	Oxycodone (API) and oxycodone-containing tablets; Hydrocodone (API) and hydrocodone-containing tablets; Other controlled substances; Exalgo, and Intrathecal products.	We conduct our business in the following two segments: Specialty Pharmaceuticals produces and markets branded and generic pharmaceuticals and API, comprised of medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients; and Global Medical Imaging develops, manufactures and markets contrast media and delivery systems ("CMDs") and radionuclide pharmaceuticals (nuclear medicine).
[4] Teva Pharmaceutical Inds Ltd	N/A	\$20,314	N/A	Fentora and Actiq	We operate our business in two segments: generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as our API business; and specialty products, which includes several core franchises, most significantly medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. Our specialty business also includes our emerging NTE activity.

Exhibit 20
Share of Opioid Product Sales for the Litigation Comparables
As of 2013


Notes:

- [1] Data is from Endo International Plc's fiscal year 2013 10-K.
- [2] Data is from Insys Therapeutics Inc's fiscal year 2013 10-K.
- [3] Data is from Mallinckrodt Plc's fiscal year 2013 10-K.
- [4] Teva Pharmaceutical Inds Ltd's fiscal year 2013 10-K does not contain data on opioid product sales. The company marketed opioids through its subsidiary Cephalon, and acquired Barr Pharmaceuticals in 2008.

Sources:

- [A] Endo Health Solutions Inc., SEC Form 10-K, for the fiscal year ended December 31, 2013, pp. 2, 30.
- [B] Insys Therapeutics, Inc., SEC Form 10-K, for the fiscal year ended December 31, 2013, pp. 2, 72.
- [C] Mallinckrodt plc, SEC Form 10-K, for the fiscal year ended September 27, 2013, pp. 4, 54.
- [D] Teva Pharmaceutical Industries Limited, SEC Form 10-K, for the fiscal year ended December 31, 2013, pp. 21, 31.


Exhibit 21a
Endo International Stock Price



Note: Price levels are indexed so that they are equal to the S&P 500 Pharmaceuticals Index price on January 2, 2008.

Source: Bloomberg L.P.

Exhibit 21b
Insys Therapeutics Stock Price




Notes:

[1] Price levels are indexed so that they are equal to the S&P 500 Pharmaceuticals Index price on May 1, 2013.

[2] Insys Therapeutics listed on the NASDAQ in May 2013. The company declared bankruptcy in June 2019 and the stock was delisted subsequently.

Source: Bloomberg L.P.

Exhibit 21c
Mallinckrodt Stock Price




Notes:

[1] Price levels are indexed so that they are equal to the S&P 500 Pharmaceuticals Index price on June 17, 2013.

[2] Mallinckrodt spun off from Covidien in June 2013 and started trading as an independent company in July 2013 on the NYSE.

Source: Bloomberg L.P.

Exhibit 21d
Teva Pharmaceuticals Stock Price



Note: Price levels are indexed so that they are equal to the S&P 500 Pharmaceuticals Index price on January 2, 2008.

Source: Bloomberg L.P.

Exhibit 22a Endo Credit Ratings 2010-2020




Exhibit 22a
Endo Credit Ratings
2010-2020

Notes:

- [1] Data includes Corporate Family/Issuer Ratings for Endo International plc. Moody's ratings also cover Endo Luxembourg Finance I Company S.a.r.l., a finance subsidiary of Endo International plc (collectively "Endo").
- [2] Credit rating data is not available prior to 2010.

Sources:

- [A] S&P Capital IQ.
- [B] Moody's Investors Service, Inc.
- [C] "Endo Pharmaceuticals Holdings Inc. Downgraded To 'BB' On Pending Acquisition Of AMS; Off CreditWatch," *S&P Global Ratings*, May 26, 2011, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/868852>.
- [D] "Endo Health Solutions Inc. Downgraded To 'BB-' On More Aggressive Financial Policies; Outlook Stable", *S&P Global Ratings*, June 17, 2013, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1146031>.
- [E] "Moody's affirms Endo's ratings; Ba3 CFR; negative outlook," *Moody's Investors Service*, May 1, 2014, available at https://www.moodys.com/research/Moodys-affirms-Endos-ratings-Ba3-CFR-negative-outlook--PR_298439.
- [F] "Endo International PLC Corporate Credit Rating Lowered To 'B+' From 'BB-'; Outlook Stable," *S&P Global Ratings*, January 20, 2015, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1379969>.
- [G] "Moody's Downgrades Endo's Ratings; CFR to B1; outlook negative," *Moody's Investors Service*, May 6, 2016, available at https://www.moodys.com/research/Moodys-Downgrades-Endos-Ratings-CFR-to-B1-outlook-negative--PR_348456.
- [H] "Moody's downgrades Endo's CFR to B2; assigns Ba2 to new secured debt," *Moody's Investors Service*, April 4, 2017, available https://www.moodys.com/research/Moodys-downgrades-Endos-CFR-to-B2-assigns-Ba2-to-new--PR_364464.
- [I] "Endo International PLC Downgraded To 'B' From 'B+', Outlook Stable; Debt Ratings Lowered," *S&P Global Ratings*, August 11, 2017, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1899766>.
- [J] "Moody's revises Endo's outlook to negative from stable; affirms ratings," *Moody's Investors Service*, November 29, 2017, available at https://www.moodys.com/research/Moodys-revises-Endos-outlook-to-negative-from-stable-affirms-ratings--PR_376112.
- [K] "Moody's downgrades Endo's CFR to B3; outlook revised to stable," *Moody's Investors Service*, July 1, 2019, available at https://www.moodys.com/research/Moodys-downgrades-Endos-CFR-to-B3-outlook-revised-to-stable--PR_404097.
- [L] "Endo International PLC Outlook Revised to Negative From Stable On Potential Costs Of Opioid Settlement; Ratings Affirmed," *S&P Global Ratings*, September 23, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2304689>.

Exhibit 22b Mallinckrodt Credit Ratings 2013-2020




Exhibit 22b
Mallinckrodt Credit Ratings
2013-2020

Notes:

- [1] Data includes Corporate Family/Issuer Ratings for Mallinckrodt International plc. Moody's ratings also cover Mallinckrodt International Finance SA (collectively "Mallinckrodt").
- [2] Credit rating data is not available prior to 2013.

Sources:

- [A] S&P Capital IQ.
- [B] Moody's Investors Service, Inc.
- [C] "Moody's downgrades Mallinckrodt's CFR to Ba3; stable outlook," *Moody's Investors Service*, February 20, 2014, available at https://www.moody's.com/research/Moodys-downgrades-Mallinckrodt's-CFR-to-Ba3-stable-outlook--PR_292951.
- [D] "Mallinckrodt plc Downgraded To 'BB-' From 'BBB-', Off Watch On Acquisition Of Cadence; Outlook Stable; New Debt Rated," *S&P Global Ratings*, February 20, 2014, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1261933>.
- [E] "Moody's confirms Mallinckrodt Ba3 CFR; outlook changed to negative," *Moody's Investors Service*, January 29, 2018, available at https://www.moody's.com/research/Moodys-confirms-Mallinckrodt-Ba3-CFR-outlook-changed-to-negative--PR_378601.
- [F] "S&P Global Ratings, Mallinckrodt PLC Downgraded To 'B+' From 'BB-'; Outlook Stable," *S&P Global Ratings*, May 14, 2018, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2037591>.
- [G] "Moody's Investors Service, Moody's downgrades Mallinckrodt's CFR to B1; outlook negative," *Moody's Investors Service*, April 24, 2019, available at https://www.moody's.com/research/Moodys-downgrades-Mallinckrodt's-CFR-to-B1-outlook-negative--PR_399335.
- [H] "Mallinckrodt PLC Downgraded To 'CCC' On Increased Distressed Exchange Risk; Outlook Negative," *S&P Global Ratings*, September 11, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2297098>.
- [I] "Mallinckrodt plc Downgraded To 'CC' On Exchange Offers; Ratings Placed On CreditWatch Negative," *S&P Global Ratings*, November 5, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2333340>.
- [J] "Mallinckrodt PLC Rating Lowered To 'SD' On Distressed Exchange," *S&P Global Ratings*, December 6, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2354541>.
- [K] "Moody's downgrades Mallinckrodt's CFR to Caa2; considers transaction a distressed exchange," *Moody's Investors Service*, December 9, 2019, available at https://www.moody's.com/research/Moodys-downgrades-Mallinckrodt's-CFR-to-Caa2-considers-transaction-a-distressed--PR_414289.
- [L] "Mallinckrodt PLC Upgraded To 'CCC' Following Distressed Exchange; Outlook Negative," *S&P Global Ratings*, December 10, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2355982>.
- [M] "Mallinckrodt PLC Downgraded To 'CCC-', On CreditWatch Negative On Possible Restructuring," *S&P Global Ratings*, August 6, 2020, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2491948>.
- [N] "Moody's downgrades Mallinckrodt's PDR to D-PD following Chapter 11 filing," *Moody's Investors Service*, October 12, 2020, available at https://www.moody's.com/research/Moodys-downgrades-Mallinckrodt's-PDR-to-D-PD-following-Chapter-11--PR_434415.
- [O] "Mallinckrodt PLC Downgraded To 'D' Following Announcement Of Voluntary Chapter 11 Proceedings," *S&P Global Ratings*, October 13, 2020, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2532935>.

Exhibit 22c
Teva Credit Ratings
2008-2020




Exhibit 22c
Teva Credit Ratings
2008-2020

Note:

- [1] Data includes Corporate Family/Issuer Ratings or Senior Long-Term Note Ratings for Teva Pharmaceutical Industries Limited and its subsidiaries. Where both rating types were available, the type with more observations was used.

Sources:

- [A] S&P Capital IQ.
- [B] Moody's Investors Service, Inc.
- [C] "Moody's Downgrades Teva's Rating to Baa1; Ratings on Review for Downgrade," *Moody's Investors Service*, July 27, 2015, available at https://www.moodys.com/research/Moodys-Downgrades-Texas-Rating-to-Baa1-Ratings-on-Review-for--PR_331025.
- [D] "Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BBB+' From 'A-' And Kept On CreditWatch Negative," *S&P Global Ratings*, July 28, 2015, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1424827>.
- [E] "Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BBB' From 'BBB+'; Outlook Stable," *S&P Global Ratings*, July 13, 2016, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1674013>.
- [F] "Moody's Investors Service, Moody's Downgrades Teva's ratings to Baa2; Outlook Stable," *Moody's Investors Service*, August 2, 2016, available at https://www.moodys.com/research/Moodys-Downgrades-Texas-ratings-to-Baa2-Outlook-Stable--PR_352868.
- [G] "Moody's downgrades Teva's ratings to Baa3 from Baa2; outlook negative," *Moody's Investors Service*, August 3, 2017, available at https://www.moodys.com/research/Moodys-downgrades-Texas-ratings-to-Baa3-from-Baa2-outlook-negative--PR_370853.
- [H] "Teva Pharmaceutical Industries Ltd. Downgraded To 'BBB-' From 'BBB' On Covenant Amendment; Outlook Stable," *S&P Global Ratings*, September 19, 2017, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1917630>.
- [I] "Moody's downgrades Teva to Ba2; outlook stable," *Moody's Investors Service*, January 12, 2018, available at https://www.moodys.com/research/Moodys-downgrades-Teva-to-Ba2-outlook-stable--PR_378074.
- [J] "Teva Pharmaceutical Industries Ltd. Downgraded To 'BB' On Continued Challenges To Business; Outlook Stable," *S&P Global Ratings*, February 8, 2018, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2009643>.
- [K] "Moody's affirms Teva's Ba2 CFR; outlook revised to negative," *Moody's Investors Service*, August 14, 2019, available at https://www.moodys.com/research/Moodys-affirms-Texas-Ba2-CFR-outlook-revised-to-negative--PR_406868.
- [L] "Teva Pharmaceutical Industries Ltd. 'BB' Rating Affirmed; Litigation Capacity Updated; Outlook Negative," *S&P Global Ratings*, September 23, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2304674>.
- [M] "Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BB-' On Rising Litigation Risks; Outlook Stable," *S&P Global Ratings*, September 3, 2020, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2508809>.

Exhibit 23a
Excerpts from Endo Credit Reports

Report Date	Agency	Report Title	Excerpt
5/26/2011	S&P	Endo Pharmaceuticals Holdings Inc. Downgraded To 'BB' On Pending Acquisition Of AMS; Off CreditWatch	The downgrade is in conjunction with the company's pending acquisition of American Medical Systems Inc. (AMS) for approximately \$2.9 billion, or an estimated 15x 2010 EBITDA. The acquisition, along with the refinancing of Endo's existing secured debt, and the payment of transaction fees will be funded with some \$363 million of cash (which includes \$110 million of acquired cash) and a \$3.1 billion debt financing. The \$2.7 billion of incremental debt will increase initial pro forma leverage by more than two turns, to approximately 3.9x.
6/17/2013	S&P	Endo Health Solutions Inc. Downgraded To 'BB-' On More Aggressive Financial Policies; Outlook Stable	"The rating action reflects our revised perception that Endo's financial policies, including our expectation of debt-financed acquisitions, will be indicative of an "aggressive" financial risk profile, with adjusted leverage rising to and sustained above 4x and funds from operations (FFO) to debt in the 12% to 20% range," said credit analyst Gail Hessol.
5/1/2014	Moody's	Moody's affirms Endo's ratings; Ba3 CFR; negative outlook	Endo increased its litigation accruals for mesh litigation by \$625 million in conjunction with reaching agreements in principle with plaintiff attorneys to settle approximately 20,000 cases.
1/20/2015	S&P	Endo International PLC Corporate Credit Rating Lowered To 'B+' From 'BB-'; Outlook Stable	The ratings on specialty pharmaceutical company Endo reflect our assessment of a "fair" business risk profile, highlighted by a sizable and diverse high-margin pharmaceutical portfolio offset by increased generic competition to lead product Lidoderm, and our assessment of a "highly leveraged" financial risk profile, given our expectations that leverage will remain over 5x over the next two years and that funds from operations (FFO) to adjusted debt will be below 12%.
5/6/2016	Moody's	Moody's Downgrades Endo's Ratings; CFR to B1; outlook negative	The downgrade of the Corporate Family Rating incorporates a number of negative developments over the last several months including generic competition on Voltaren Gel and a significant increase in vaginal mesh litigation accruals. More recently, competition and pricing pressure has intensified in Endo's generic business, particularly within legacy Qualitest opioid products. Moody's expectation that the company will generate strong free cash flow beyond 2017, once Endo has gotten past the bulk of its litigation-related payments.
4/4/2017	Moody's	Moody's downgrades Endo's CFR to B2; assigns Ba2 to new secured debt	The downgrade of the CFR to B2 reflects challenges in Endo's branded and generic segments at the same time that the company's free cash flow will be constrained by almost \$1 billion in cash outflows related to vaginal mesh litigation settlements.
8/11/2017	S&P	Endo International PLC Downgraded To 'B' From 'B+', Outlook Stable; Debt Ratings Lowered	Dublin, Ireland-based Endo International PLC (Endo) increased its mesh accrual by \$775 million, which removes much of the overhang from liabilities stemming from multiple lawsuits due to this device, but will result in increased adjusted leverage and payments that will burden cash flow over the next three years.

Exhibit 23a
Excerpts from Endo Credit Reports

Report Date	Agency	Report Title	Excerpt
11/29/2017	Moody's	Moody's revises Endo's outlook to negative from stable; affirms ratings	The negative outlook also reflects rising exposure to opioid-related litigation and declining opioid prescriptions volume trends.
7/1/2019	Moody's	Moody's downgrades Endo's CFR to B3; outlook revised to stable	The rating downgrades reflect Moody's expectation that Endo's financial leverage will remain elevated above 6.0 times through 2020. This incorporates the recently disclosed \$300 million revolver draw. It also reflects Moody's view that Endo will have limited revolver access going into a period of high uncertainty related to its large exposure to opioid-related litigation. The downgrade also reflects the risk that Endo uses cash to fund acquisitions. While acquisitions could be deleveraging, they would also reduce liquidity during this period of high litigation uncertainty.
9/23/2019	S&P	Endo International PLC Outlook Revised to Negative From Stable On Potential Costs Of Opioid Settlement; Ratings Affirmed	Our negative outlook reflects the risk that opioid litigation liability could exceed the \$1.5 billion to \$2 billion that we think Endo could absorb and still maintain the current ratings. We have also revised the outlook because we think Endo's business could weaken over the next year because of pricing pressure in generics and potential competition to the company's Vasostrict drug, which represents about 15% of total sales and, we think, an even higher share of EBITDA.

Sources:

- [A] "Endo Pharmaceuticals Holdings Inc. Downgraded To 'BB' On Pending Acquisition Of AMS; Off CreditWatch," *S&P Global Ratings*, May 26, 2011, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/868852>.
- [B] "Endo Health Solutions Inc. Downgraded To 'BB-' On More Aggressive Financial Policies; Outlook Stable", *S&P Global Ratings*, June 17, 2013, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1146031>.
- [C] "Moody's affirms Endo's ratings; Ba3 CFR; negative outlook," *Moody's Investors Service*, May 1, 2014, available at https://www.moodys.com/research/Moodys-affirms-Endos-ratings-Ba3-CFR-negative-outlook--PR_298439.
- [D] "Endo International PLC Corporate Credit Rating Lowered To 'B+' From 'BB-'; Outlook Stable," *S&P Global Ratings*, January 20, 2015, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1379969>.
- [E] "Moody's Downgrades Endo's Ratings; CFR to B1; outlook negative," *Moody's Investors Service*, May 6, 2016, available at https://www.moodys.com/research/Moodys-Downgrades-Endos-Ratings-CFR-to-B1-outlook-negative--PR_348456.
- [F] "Moody's downgrades Endo's CFR to B2; assigns Ba2 to new secured debt," *Moody's Investors Service*, April 4, 2017, available https://www.moodys.com/research/Moodys-downgrades-Endos-CFR-to-B2-assigns-Ba2-to-new--PR_364464.
- [G] "Endo International PLC Downgraded To 'B' From 'B+', Outlook Stable; Debt Ratings Lowered," *S&P Global Ratings*, August 11, 2017, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1899766>.
- [H] "Moody's revises Endo's outlook to negative from stable; affirms ratings," *Moody's Investors Service*, November 29, 2017, available at https://www.moodys.com/research/Moodys-revises-Endos-outlook-to-negative-from-stable-affirms-ratings--PR_376112.
- [I] "Moody's downgrades Endo's CFR to B3; outlook revised to stable," *Moody's Investors Service*, July 1, 2019, available at https://www.moodys.com/research/Moodys-downgrades-Endos-CFR-to-B3-outlook-revised-to-stable--PR_404097.
- [J] "Endo International PLC Outlook Revised to Negative From Stable On Potential Costs Of Opioid Settlement; Ratings Affirmed," *S&P Global Ratings*, September 23, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2304689>.

Exhibit 23b
Excerpts from Mallinckrodt Credit Reports

Report Date	Agency	Report Title	Excerpt
2/20/2014	Moody's	Moody's downgrades Mallinckrodt's CFR to Ba3; stable outlook	The downgrade of the Corporate Family Rating to Ba3 from Ba2 reflects a substantial increase in financial leverage relative to Moody's earlier expectations, with debt/EBITDA of roughly 5 times pro forma for the \$1.3 billion acquisition of Cadence Pharmaceuticals ("Cadence"). The downgrade of the senior unsecured notes further reflects the addition of a material amount of secured debt to Mallinckrodt's capital structure.
2/20/2014	S&P	Mallinckrodt plc Downgraded To 'BB-' From 'BBB-', Off Watch On Acquisition Of Cadence; Outlook Stable; New Debt Rated	The downgrades follow the company's debt-financed \$1.3 billion acquisition of Cadence Pharmaceuticals.
1/29/2018	Moody's	Moody's confirms Mallinckrodt Ba3 CFR; outlook changed to negative	The confirmation of Mallinckrodt's Ba3 Corporate Family Rating reflects Moody's expectation that leverage will be elevated but that the company will use a majority of its free cash flow to reduce gross debt/EBITDA to under 4 times within 18 months of the deal close. At the same time, Moody's has growing concerns regarding Acthar's revenue declines, as well as its opioid-related exposure.
5/14/2018	S&P	Mallinckrodt PLC Downgraded To 'B+' From 'BB-'; Outlook Stable	The ratings downgrade reflects our expectation that lower projected 2018-2019 EBITDA, along with potentially lower-than-expected proceeds from the sale of the generics business used to reduce debt, would likely result in Mallinckrodt's leverage sustained firmly above 5x in 2018-2019. The downgrade also reflects increasing operational risks, including potential competition for H.P. Acthar Gel and INOmax, the challenging reimbursement environment for H.P. Acthar Gel, and increasing opioid-related lawsuits against the company. The combination of these factors results in a weaker credit profile, making the company more similar to the 'B+' rated peers.
4/24/2019	Moody's	Moody's downgrades Mallinckrodt's CFR to B1; outlook negative	The downgrade of the CFR to B1 reflects Moody's view that debt/EBITDA will remain moderately high at over 4 times gross debt/EBITDA through 2020. This is high in the context of Mallinckrodt's business risks. These include revenue concentration in Mallinckrodt's largest product, Acthar, and opioid related litigation. Further, the company faces a number of headwinds over the next several years including the loss of patent exclusivity on Ofirmev in January 2021 and rising competitive pressures in Mallinckrodt's largest franchises.
9/11/2019	S&P	Mallinckrodt PLC Downgraded To 'CCC' On Increased Distressed Exchange Risk; Outlook Negative	The downgrade reflects our belief that incentives are aligned for a distressed debt exchange over the next 12 months. It also reflects our view that risks exist to the company's stated plan to use free cash flow to repay its April 2020 maturities, especially if the company incurs further litigation settlements or is required to make a large repayment to Medicare for past Acthar sales (this is not currently in our base case). Given uncertainty around the amount and timing of opioid related liabilities, we believe the company will have difficulty accessing debt markets at acceptable rates until opioid litigation is resolved.

Exhibit 23b
Excerpts from Mallinckrodt Credit Reports

Report Date	Agency	Report Title	Excerpt
11/5/2019	S&P	Mallinckrodt plc Downgraded To 'CC' On Exchange Offers; Ratings Placed On CreditWatch Negative	Our ratings reflect our view that Mallinckrodt's announced exchange offers and consent solicitations to unsecured lenders are distressed exchanges, based on our opinion that consenting lenders will receive less than the original promise of the debt at the close of the transaction.
12/6/2019	S&P	Mallinckrodt PLC Rating Lowered To 'SD' On Distressed Exchange	U.K.-headquartered specialty pharmaceutical manufacturer Mallinckrodt PLC has completed its limited offer to exchange various series of its unsecured notes maturing between 2020 and 2025 for a lesser principal of new 10% second-lien notes due in 2025. We view this transaction as a distressed exchange, in which lenders are receiving less than originally promised. We are lowering our long-term issuer credit rating to 'SD' (selective default) and our unsecured issue-level ratings to 'D'.
12/9/2019	Moody's	Moody's downgrades Mallinckrodt's CFR to Caa2; considers transaction a distressed exchange	The ratings downgrade reflects weak liquidity, highlighted by a sizable debt maturity in April 2020; the risk of additional distressed exchanges; and exposure to opioid litigation. In Moody's view, risks stemming from Mallinckrodt's exposure to opioid litigation are high, in both its branded and generics businesses, posing a challenge to capital market access. Moody's lowered its assumption for family recovery to 35% from 50% to reflect Moody's view of weaker than average recovery prospects on the unsecured debt in a liquidation scenario.
12/10/2019	S&P	Mallinckrodt PLC Upgraded To 'CCC' Following Distressed Exchange; Outlook Negative	We are raising our long-term issuer rating on Mallinckrodt to 'CCC' from 'SD' due to our view of heightened risk of a distressed exchange over the next year, before any large settlement of opioid claims.
8/6/2020	S&P	Mallinckrodt PLC Downgraded To 'CCC-', On CreditWatch Negative On Possible Restructuring	The downgrade and CreditWatch placement reflect our base-case scenario that Mallinckrodt will file for bankruptcy or negotiate a distressed exchange within the next six months. Earlier this year, the company proposed to pay \$1.6 billion over eight years as part of a settlement to address the majority of opioid litigation claims. Uncertainty around the ultimate settlement amount is a key credit risk. Mallinckrodt was ordered to pay \$640 million to CMS to settle a dispute regarding rebates associated with its Acthar Gel. The company has been unsuccessful in appealing the decision and we anticipate it will make the payment in coming months. We also anticipate the company will lose approximately \$90 million-\$100 million in annual revenue and EBITDA as a result of the ruling.
10/12/2020	Moody's	Moody's downgrades Mallinckrodt's PDR to D-PD following Chapter 11 filing	This follows Mallinckrodt's October 12, 2020 announcement that it filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code. Moody's downgraded Mallinckrodt's Corporate Family Rating ("CFR") to Caa3 from Caa2, senior secured revolver and term loans to Caa2 from Caa1, and unguaranteed unsecured notes to C from Ca.

Exhibit 23b
Excerpts from Mallinckrodt Credit Reports

Report Date	Agency	Report Title	Excerpt
10/13/2020	S&P	Mallinckrodt PLC Downgraded To 'D' Following Announcement Of Voluntary Chapter 11 Proceedings	We are lowering our ratings on Mallinckrodt PLC to 'D', including our long-term issuer credit rating and issue-level ratings, due to its recent filing of Chapter 11 petitions that include the parent entity, substantially all of its U.S. subsidiaries, and certain international subsidiaries. The company intends to use the Chapter 11 process to reduce its debt balance and resolve its opioid-related litigation and Acthar Gel-related disputes.

Sources:

- [A] "Moody's downgrades Mallinckrodt's CFR to Ba3; stable outlook," *Moody's Investors Service*, February 20, 2014, available at https://www.moodys.com/research/Moodys-downgrades-Mallinckrodt-CFR-to-Ba3-stable-outlook--PR_292951.
- [B] "Mallinckrodt plc Downgraded To 'BB-' From 'BBB-', Off Watch On Acquisition Of Cadence; Outlook Stable; New Debt Rated," *S&P Global Ratings*, February 20, 2014, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1261933>.
- [C] "Moody's confirms Mallinckrodt Ba3 CFR; outlook changed to negative," *Moody's Investors Service*, January 29, 2018, available at https://www.moodys.com/research/Moodys-confirms-Mallinckrodt-Ba3-CFR-outlook-changed-to-negative--PR_378601.
- [D] "S&P Global Ratings, Mallinckrodt PLC Downgraded To 'B+' From 'BB-'; Outlook Stable," *S&P Global Ratings*, May 14, 2018, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2037591>.
- [E] "Moody's Investors Service, Moody's downgrades Mallinckrodt's CFR to B1; outlook negative," *Moody's Investors Service*, April 24, 2019, available at https://www.moodys.com/research/Moodys-downgrades-Mallinckrodt-CFR-to-B1-outlook-negative--PR_399335.
- [F] "Mallinckrodt PLC Downgraded To 'CCC' On Increased Distressed Exchange Risk; Outlook Negative," *S&P Global Ratings*, September 11, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2297098>.
- [G] "Mallinckrodt plc Downgraded To 'CC' On Exchange Offers; Ratings Placed On CreditWatch Negative," *S&P Global Ratings*, November 5, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2333340>.
- [H] "Mallinckrodt PLC Rating Lowered To 'SD' On Distressed Exchange," *S&P Global Ratings*, December 6, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2354541>.
- [I] "Moody's downgrades Mallinckrodt's CFR to Caa2; considers transaction a distressed exchange," *Moody's Investors Service*, December 9, 2019, available at https://www.moodys.com/research/Moodys-downgrades-Mallinckrodt-CFR-to-Caa2-considers-transaction-a-distressed--PR_414289.
- [J] "Mallinckrodt PLC Upgraded To 'CCC' Following Distressed Exchange; Outlook Negative," *S&P Global Ratings*, December 10, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2355982>.
- [K] "Mallinckrodt PLC Downgraded To 'CCC-', On CreditWatch Negative On Possible Restructuring," *S&P Global Ratings*, August 6, 2020, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2491948>.
- [L] "Moody's downgrades Mallinckrodt's PDR to D-PD following Chapter 11 filing," *Moody's Investors Service*, October 12, 2020, available at https://www.moodys.com/research/Moodys-downgrades-Mallinckrodt-PDR-to-D-PD-following-Chapter-11--PR_434415.
- [M] "Mallinckrodt PLC Downgraded To 'D' Following Announcement Of Voluntary Chapter 11 Proceedings," *S&P Global Ratings*, October 13, 2020, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2532935>.

Exhibit 23c
Excerpts from Teva Credit Reports

Report Date	Agency	Report Title	Excerpt
7/27/2015	Moody's	Moody's Downgrades Teva's Rating to Baa1; Ratings on Review for Downgrade	The downgrade to Baa1 reflects Teva's demonstration of more aggressive financial policies, and willingness to tolerate a level of leverage that no longer support the A3 rating. The rating is constrained by challenges that Teva will face associated with the loss of patent exclusivity over the next several years of most of the company's key branded products including Copaxone, Treanda, Nuvigil, Azilect and ProAir. The rating is also constrained by the company's demonstrated appetite for large, leveraging acquisitions, as evidenced by its bid (now cancelled) for Mylan (Baa3) and the Allergan assets.
7/28/2015	S&P	Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BBB+' From 'A-' And Kept On CreditWatch Negative	However, the acquisition would also significantly increase debt leverage beyond our expectations within the current "modest" financial risk profile assessment on Teva. Management has had a track record of effectively integrating large acquisitions in the generic drug industry and rapidly delevering following acquisition-induced spikes in leverage. However, we are lowering our ratings on Teva to 'BBB+' based on our projection that leverage will likely exceed 4.0x following the acquisition of Allergan's generics unit and that leverage may remain in the 3x to 4x range over the next couple of years.
7/13/2016	S&P	Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BBB' From 'BBB+'; Outlook Stable	The acquisition strengthens Teva's leading position in the global generic pharmaceutical business, expanding its portfolio, pipeline, and geographic diversity. Following the debt- and equity-financed transaction, we estimated that long-term net leverage will be in the 3x-4x range over the next two years.
8/2/2016	Moody's	Moody's Downgrades Teva's ratings to Baa2; Outlook Stable	This rating action follows the Federal Trade Commission's clearance for Teva's acquisition of Allergan's generics business and the subsequent closing of the transaction on August 2, 2016. The rating is constrained by Teva's high financial leverage following the Allergan generics acquisition. Moody's estimates adjusted debt/EBITDA will approximate 4.7x on a pro forma basis. Moody's could upgrade the ratings if Teva successfully integrates the Allergan generics business and realizes significant synergies. Further, if Moody's believes that Teva will maintain adjusted debt to EBITDA below 3.0x, the ratings could be upgraded.
8/3/2017	Moody's	Moody's downgrades Teva's ratings to Baa3 from Baa2; outlook negative	"The downgrade to Baa3 from Baa2 reflects slower deleveraging than we anticipated as Teva contends with weakness in its US generics business and the looming threat of generic competition on Copaxone 40mg," said Morris Borenstein, a Moody's Assistant Vice President. "As a result, we believe debt/EBITDA will remain elevated above 4.0 times over the next 18 months. Pricing pressure and delays in new product launches will continue to be headwinds in its US generics business through 2018," continued Borenstein.

Exhibit 23c
Excerpts from Teva Credit Reports

Report Date	Agency	Report Title	Excerpt
9/19/2017	S&P	Teva Pharmaceutical Industries Ltd. Downgraded To 'BBB-' From 'BBB' On Covenant Amendment; Outlook Stable	In light of the revised covenants, we revised our forecast for 2017 and 2018. While we continue to recognize the company's commitment to reducing leverage, we believe it will take longer than previously expected due to ongoing pricing pressures in the generics industry that we project will continue well into 2018. We now expect 2018 leverage of about 4.6x, in contrast to our prior expectation that it would decline below 4x next year.
1/12/2018	Moody's	Moody's downgrades Teva to Ba2; outlook stable	"The downgrade of Teva's ratings to speculative grade reflects the challenge of managing its significant debt burden while facing a prolonged period of earnings erosion," commented Morris Borenstein, Moody's Assistant Vice President. "While Teva's cost restructuring program will help to partially offset declines, execution risk is high. In addition, we believe earnings declines from Copaxone and its US generics business will be severe, and that meaningful deleveraging to under 4 times gross debt/EBITDA will take several years to achieve," added Borenstein.
2/8/2018	S&P	Teva Pharmaceutical Industries Ltd. Downgraded To 'BB' On Continued Challenges To Business; Outlook Stable	The rating action on Teva reflects a series of lower-than-expected operating results following the 2016 acquisition of Actavis Generics for \$33.4 billion in cash and additional equity. We initially believed the acquisition would deliver a material boost to Teva's future generic first-to-market performance, as well as provide a level of scale that would give Teva a competitive advantage over peers like Mylan and Perrigo.
8/14/2019	Moody's	Moody's affirms Teva's Ba2 CFR; outlook revised to negative	The negative outlook reflects Moody's concern over Teva's persistently high leverage and large refinancing needs in light of its rising exposure to opioid-related litigation. It also reflects the minimal cushion in the rating for any negative developments in operating performance that will further delay deleveraging. These include: weak uptake of Teva's new migraine drug, AJOVY; acceleration of erosion of Copaxone; inability to stabilize profitability in the US generics business; or large cash outlays related to litigation.
9/23/2019	S&P	Teva Pharmaceutical Industries Ltd. 'BB' Rating Affirmed; Litigation Capacity Updated; Outlook Negative	We are raising our view of Teva's capacity for liabilities from a legal settlement (including opioid and price-fixing litigation) to \$2 billion (from \$1 billion) at the current rating, given our higher expectation for EBITDA following better-than-expected performance year to date. Our negative outlook reflects the risk that liabilities from ongoing litigation could exceed \$2 billion and also that the business could underperform over the next year given the extent of recent cost cutting and restructuring.

Exhibit 23c
Excerpts from Teva Credit Reports

Report Date	Agency	Report Title	Excerpt
9/3/2020	S&P	Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BB-' On Rising Litigation Risks; Outlook Stable	We are raising our estimate of legal liabilities (which we include in our measure of adjusted debt) to about \$2.5 billion to \$3 billion, (from \$1.6 billion recorded on the balance sheet in June 2020), following recent developments with plaintiffs. This creates further pressure on credit metrics which were already weak for the rating. Given already high debt leverage, we expect the substantial debt maturities and legal settlements over the next few years to absorb the company's free cash flow and constrain its ability to invest in growth opportunities. We expect this will weaken the company's competitive advantage.

Sources:

- [A] "Moody's Downgrades Teva's Rating to Baa1; Ratings on Review for Downgrade," *Moody's Investors Service*, July 27, 2015, available at https://www.moodys.com/research/Moodys-Downgrades-Tevas-Rating-to-Baa1-Ratings-on-Review-for-PR_331025.
- [B] "Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BBB+' From 'A-' And Kept On CreditWatch Negative," *S&P Global Ratings*, July 28, 2015, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1424827>.
- [C] "Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BBB' From 'BBB+'; Outlook Stable," *S&P Global Ratings*, July 13, 2016, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1674013>.
- [D] "Moody's Investors Service, Moody's Downgrades Teva's ratings to Baa2; Outlook Stable," *Moody's Investors Service*, August 2, 2016, available at https://www.moodys.com/research/Moodys-Downgrades-Tevas-ratings-to-Baa2-Outlook-Stable-PR_352868.
- [E] "Moody's downgrades Teva's ratings to Baa3 from Baa2; outlook negative," *Moody's Investors Service*, August 3, 2017, available at https://www.moodys.com/research/Moodys-downgrades-Tevas-ratings-to-Baa3-from-Baa2-outlook-negative-PR_370853.
- [F] "Teva Pharmaceutical Industries Ltd. Downgraded To 'BBB-' From 'BBB' On Covenant Amendment; Outlook Stable," *S&P Global Ratings*, September 19, 2017, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1917630>.
- [G] "Moody's downgrades Teva to Ba2; outlook stable," *Moody's Investors Service*, January 12, 2018, available at https://www.moodys.com/research/Moodys-downgrades-Teva-to-Ba2-outlook-stable-PR_378074.
- [H] "Teva Pharmaceutical Industries Ltd. Downgraded To 'BB' On Continued Challenges To Business; Outlook Stable," *S&P Global Ratings*, February 8, 2018, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2009643>.
- [I] "Moody's affirms Teva's Ba2 CFR; outlook revised to negative," *Moody's Investors Service*, August 14, 2019, available at https://www.moodys.com/research/Moodys-affirms-Tevas-Ba2-CFR-outlook-revised-to-negative-PR_406868.
- [J] "Teva Pharmaceutical Industries Ltd. 'BB' Rating Affirmed; Litigation Capacity Updated; Outlook Negative," *S&P Global Ratings*, September 23, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2304674>.
- [K] "Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BB-' On Rising Litigation Risks; Outlook Stable," *S&P Global Ratings*, September 3, 2020, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2508809>.

Exhibit 24
Abnormal Returns for Relevant Disclosure Dates

		Endo	Insys	Teva
Coefficients for Index Returns	S&P 500 Total Return Index	-0.355*	-0.131	0.00388
	S&P 500 Pharmaceutical Total Return Index	1.889***	1.601***	0.820***
Abnormal Returns on Disclosure Dates	11/15/2013	-1.5%		
	12/13/2013		-15.9%***	
	5/22/2014			0.1%
	9/15/2014		-2.5%	
Observations		1,007	925	1,007
R-squared		0.187	0.120	0.215

Notes:

- [1] Asterisks denote that coefficients are statistically significant based on a regression of stock price returns on: S&P 500 Total Return Index returns, S&P 500 Pharmaceutical Total Return Index returns, and the relevant Disclosure Date indicator variables during the 2013 - 2016 period. *** represents significance at the 1% level, ** represents significance at the 5% level, and * represents significance at the 10% level.
- [2] The regression uses log returns based on data adjusted for stock splits and dividends.
- [3] The reported values for the Index Returns are the coefficients from the regression model.
- [4] The reported values for the Abnormal Returns on Disclosure Dates are transformed regression coefficients using the exponential of the coefficients minus one. For example, for Insys's December 13, 2013 coefficient of -0.173, the abnormal return for Insys's stock price is -15.9% (*i.e.* , $\exp(-0.173) - 1$).

Exhibit 24
Abnormal Returns for Relevant Disclosure Dates

- [5] Insys Therapeutics listed on the NASDAQ in May 2013.
- [6] Teva's stock is an American Deposit Receipt.

Sources:

- [A] Bloomberg L.P.
- [B] Meier, Barry, "Chicago Said to Weigh Suit Over Marketing of Painkillers," *The New York Times*, November 15, 2013, available at <https://www.nytimes.com/2013/11/15/business/chicago-reviews-marketing-by-makers-of-narcotic-painkillers.html>, accessed June 14, 2021.
- [C] "Insys Therapeutics Receives Subpoena From Office of Inspector General," *GlobeNewswire*, December 12, 2013, available at <https://www.globenewswire.com/news-release/2013/12/12/1155914/0/en/Insys-Therapeutics-Receives-Subpoena-From-Office-of-Inspector-General.html>, accessed June 12, 2021.
- [D] Insys Therapeutics, Inc., SEC Form 8-K, September 12, 2014.
- [E] Glover, Scott, and Girion, Lisa, "Counties Sue Narcotics Makers, Alleging 'Campaign of Deception'," *Los Angeles Times*, May 21, 2014, available at <https://www.latimes.com/local/la-me-rx-big-pharma-suit-20140522-story.html>, accessed June 12, 2021.

Exhibit 25
Summary of Purdue's Liabilities
(\$ millions)

	Long-Term Debt	Other Liabilities	Estimated Opioid Litigation Liabilities - Low	Estimated Opioid Litigation Liabilities - High	Total Liabilities - Low	Total Liabilities - High
2008	0	142	200	200	342	342
2009	0	128	200	200	328	328
2010	0	131	200	200	331	331
2011	0	219	200	200	419	419
2012	0	226	19	19	245	245
2013	0	163	19	491	182	654
2014	1	202	19	491	222	694
2015	0	194	19	491	213	685
2016	0	169	0	472	169	641

Exhibit 25
Summary of Purdue's Liabilities
(\$ millions)

Notes:

- [1] Purdue's liabilities during the 2008-16 Period consist of Long-Term Debt (\$770,000 in 2014 only), "Other Liabilities," and Estimated Opioid Litigation Liabilities. While Purdue held current liabilities related to accrued settlement expenses and accrued rebate expenses on its balance sheet, these liabilities are already deducted in my DCF valuation of Purdue's operating assets and are not considered again in Purdue's recorded liabilities for the purpose of my solvency analysis. *See Section IV.A and Section IV.C* of my report.
- [2] Additional Liabilities for Pending Opioid Lawsuits/Investigations reflects potential future liabilities to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. This amount was resolved in 2015. Additionally, I estimate a maximum of \$472 million in liabilities associated with government investigations into Purdue's marketing practices for 2013 to 2016, which is the only remaining portion after the resolution of the \$19 million in 2015. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697, at 662.
- [B] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991, at 954.
- [C] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583, at 540.
- [D] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLPC029000544175-219, at 178.
- [E] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174, at 139.
- [F] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664, at 619.
- [G] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPCO 11000090527, pp. 2-5.

Exhibit 25
Summary of Purdue's Liabilities
(\$ millions)

[H] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316, at 266.

Exhibit 26
Summary of Purdue Balance Sheet Test
(\$ millions)

Year	Assets			Liabilities				Solvency Cushion
	Operating Assets	Excess Cash	Total Assets	Long-Term Debt	Other Liabilities	Estimated Opioid Litigation	Total	
						Litigation	Liabilities	
						Liabilities	Liabilities	
	[i]	[ii]	[iii] = [i] + [ii]	[iv]	[v]	[vi]	[vii] = [iv] + [v] + [vi]	[iii] - [vii]
2008	9,157	386	9,543	0	142	200	342	9,201
2009	5,724	282	6,006	0	128	200	328	5,678
2010	7,457	232	7,689	0	131	200	331	7,359
2011	4,693	264	4,958	0	219	200	419	4,538
2012	4,590	349	4,939	0	226	19	245	4,694
2013	2,967	562	3,530	0	163	491	654	2,876
2014	1,377	568	1,945	1	202	491	694	1,251
2015	2,103	750	2,853	0	194	491	685	2,168
2016	1,625	693	2,318	0	169	472	641	1,677

Exhibit 26
Summary of Purdue Balance Sheet Test
(\$ millions)

Notes:

- [1] The value of Purdue's operating assets is determined using the DCF method, as described in **Section III**, and **Appendix D** of my report.
- [2] Excess Cash is calculated as: Cash and Cash Equivalents - Max [Total Current Liabilities - (Total Current Assets - Cash and Cash Equivalents), 0] - Restricted Cash. Figures are calculated using actual year-end balance sheet figures from Purdue management's projections to estimate Excess Cash as of the valuation date. *See* **Exhibit 11**.
- [3] Purdue's liabilities during the 2008-16 Period consist of Long-Term Debt (\$770,000 in 2014 only), "Other Liabilities," and Estimated Opioid Litigation Liabilities. While Purdue held current liabilities related to accrued settlement expenses and accrued rebate expenses on its balance sheet, these liabilities are already deducted in my DCF valuation of Purdue's operating assets and are not considered again in Purdue's recorded liabilities for the purpose of my solvency analysis. *See* **Section IV.A** and **Section IV.C** of my report.
- [4] Estimated Opioid Litigation Liabilities reflects potential future liabilities to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. This amount was resolved in 2015. Additionally, I estimate \$472 million in liabilities associated with government investigations into Purdue's marketing practices for 2013 to 2016, which is the only remaining portion after the resolution of the \$19 million in 2015. *See* **Section IV.B** of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] **Section III**, **Section IV.A**, and **Section IV.C** of my report.
- [B] **Appendix D** and **Exhibits D-1** through **D-9**.
- [C] **Exhibit 11**.

Exhibit 27a
Cash Flow Test for Purdue as of 2008
(\$ Millions)

		<u>2008</u>	<u>2009</u>	<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
		(Partial Year)								
[1]=[13] from prior year	Starting Cash Balance	384	717	1,897	3,093	4,242	5,348	6,496	7,863	9,291
[2]	EBIT	974	1,938	1,915	1,954	1,984	2,145	2,351	2,451	1,684
[3]	Taxes	(384)	(810)	(770)	(800)	(844)	(945)	(940)	(980)	(674)
[4]	Depreciation and Amortization	21	35	35	36	39	40	39	39	39
[5]	Non-Cash P&L on Foreign Equity Investments	64	68	43	7	(34)	(43)	(38)	(38)	(38)
[6]	Changes in Net Working Capital	43	9	(13)	8	(2)	10	4	4	493
[7]	Capital Expenditures	(32)	(40)	(40)	(40)	(40)	(40)	(40)	(40)	(40)
[8]	Other Items	(33)	(1)	-	-	-	-	-	-	-
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	568	1,181	1,196	1,149	1,107	1,147	1,368	1,428	479
[10]	Payments for Other LT Liabilities on the Balance Sheet	(35)	-	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	917	1,897	3,093	4,242	5,348	6,496	7,863	9,291	9,770
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(200)	-	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	717	1,897	3,093	4,242	5,348	6,496	7,863	9,291	9,770

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 3/14/2008 and is sourced from Purdue's Weekly Cash Forecast, March 14, 2008, PPLPUCC001552391. The nearest available cash balance of \$527 million does not include restricted cash, which is listed at \$81.6 million. To adjust for the changes in cash between the nearest available cash balance date (3/14/2008) and the projection date (4/18/2008), at-issue cash distributions that occurred between this time period of \$142.5 million are then deducted from the nearest available cash balance.
- [2] EBIT (line item 2) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [3] Taxes (line item 3) is equal to the tax distributions from Purdue's projected Cash Flow Statement for each year of analysis where available. For years 2014-2016, where projected tax distributions are unavailable, the implied tax rate from 2013 of 40.0 percent is multiplied by EBIT. Implied tax rates are computed by dividing projected tax distributions from the Cash Flow Statement by projected profit before tax from the Income Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [4] Depreciation and Amortization (line item 4) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the DCF analysis and includes decreases in Long-Term Liabilities and an item listed as an Extraordinary Item Payout from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2007 from Purdue's Five Year Plan 2008-2013, April 18, 2008, PPLPC063000023668. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.

Exhibit 27a
Cash Flow Test for Purdue as of 2008
(\$ Millions)

[12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's Balance Sheet to account for management's expectation of future settlements of pending opioid litigation. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

[A] Five Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687.

[B] Purdue Weekly Cash Forecast, March 14, 2008, PPLPUCC001552391.

[C] Appendix H.

[D] Ten-Year Plan, July 15, 2009, PPLPC019000293027-65.

[E] 10-Year Plan, June 24, 2010, PPLP004404330-453.

[F] 10 Year Plan, February 15, 2012, PPLPC053000063393-668.

[G] 10-Year Plan, May 3, 2013, PPLPC063000003469-592.

Exhibit 27b
Cash Flow Test for Purdue as of 2009
(\$ Millions)

		<u>2009</u>	<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>
		(Partial Year)									
[1]=[13] from prior year	Starting Cash Balance	309	302	1,480	2,660	3,702	4,572	5,369	6,199	7,067	7,764
[2]	EBIT	545	1,678	1,570	1,370	1,181	1,142	1,260	1,318	1,088	(114)
[3]	Taxes	(219)	(675)	(631)	(551)	(475)	(459)	(507)	(530)	(437)	-
[4]	Depreciation and Amortization	14	36	38	39	39	36	36	36	36	33
[5]	Non-Cash P&L on Foreign Equity Investments	37	99	216	208	157	118	85	75	38	20
[6]	Changes in Net Working Capital	8	(78)	(32)	(16)	(5)	8	14	(0)	(4)	27
[7]	Capital Expenditures	(14)	(37)	(43)	(40)	(35)	(30)	(30)	(30)	(30)	(30)
[8]	Other Items	(16)	(2)	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	339	1,178	1,180	1,041	870	797	829	869	697	(119)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(146)	-	-	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	502	1,480	2,660	3,702	4,572	5,369	6,199	7,067	7,764	7,645
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(200)	-	-	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	302	1,480	2,660	3,702	4,572	5,369	6,199	7,067	7,764	7,645

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 6/30/2009 and is sourced from Purdue Financial Statements, June 2009, PPLPC042000017701. The nearest available cash balance of \$309 million does not include restricted cash, which is listed at \$82.5 million. To adjust for the changes in cash between the nearest available cash balance date (6/30/2009) and the projection date (7/15/2009), at-issue cash distributions that occurred between this time period are then deducted from the cash balance (zero distributions occur between the dates for this analysis).
- [2] EBIT (line item 2) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [3] Taxes (line item 3) are computed using the average implied tax rate from 2008 management projections used in 2008's DCF analysis. See Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668. This is due to tax distribution data limitations from the management projections used in 2009's DCF. Implied tax rates are computed by dividing projected tax distributions from the Cash Flow Statement by projected profit before tax from the Income Statement. This equates to a 40.2 percent tax rate. The average implied tax rate is then multiplied by EBIT for a given year to arrive at taxes for that year.
- [4] Depreciation and Amortization (line item 4) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the DCF analysis and includes decreases in long-term liabilities, deferred tax movement, profit/loss on disposal of fixed assets, Infinity common stock premium, Infinity line of credit, and other non-cash items. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year equal, which is the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2008 from Purdue Financial Statement, June 2009, PPLPC042000017701. These liabilities consist primarily of pension and post-retirement benefits.

Exhibit 27b
Cash Flow Test for Purdue as of 2009
(\$ Millions)

- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065.
- [B] Purdue Financial Statement, June 2009, PPLPC042000017701.
- [C] Appendix H.
- [D] Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662.
- [E] Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453.
- [F] Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668.
- [G] Purdue 2013 10-Year Plan, May 3, 2013, PPLPC063000003469-592.

Exhibit 27c
Cash Flow Test for Purdue as of 2010
(\$ Millions)

		<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>
		(Partial Year)								
[1]=[13] from prior year	Starting Cash Balance	445	698	1,757	2,626	3,462	4,384	5,311	6,389	7,353
[2]	EBIT	919	1,448	1,168	1,157	1,339	1,466	1,731	1,593	597
[3]	Taxes	(396)	(579)	(467)	(463)	(535)	(586)	(692)	(637)	(239)
[4]	Depreciation and Amortization	21	37	43	44	46	46	46	46	47
[5]	Non-Cash P&L on Foreign Equity Investments	83	148	147	123	88	40	38	41	35
[6]	Changes in Net Working Capital	22	(62)	(24)	(20)	(26)	(6)	2	37	117
[7]	Capital Expenditures	(22)	(54)	(44)	(43)	(39)	(42)	(40)	(40)	(40)
[8]	Other Items	0	(3)	(3)	(3)	(3)	(3)	(3)	(3)	(3)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	584	1,059	868	836	922	928	1,078	964	281
[10]	Payments for Other LT Liabilities on the Balance Sheet	(130)	-	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	898	1,757	2,626	3,462	4,384	5,311	6,389	7,353	7,634
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(200)	-	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	698	1,757	2,626	3,462	4,384	5,311	6,389	7,353	7,634

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 6/30/2010 and is sourced from Purdue Financial Statement, June 2010, PPLPC054000051935. The nearest available cash balance of \$445 million does not include restricted cash, which is listed at \$90 million. No further adjustment is made to the starting cash balance, as the cash balance date (6/30/2010) is after the projection date (6/1/2010) and therefore more conservative.
- [2] EBIT (line item 2) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). *See Appendix D* for a full list of DCF projections, notes, and sources.
- [3] Taxes (line item 3) are equal to tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). *See Appendix D* for a full list of DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). *See Appendix D* for a full list of DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). *See Appendix D* for a full list of DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). *See Appendix D* for a full list of DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the DCF analysis and includes decreases in Long-Term Liabilities and approximately \$350,000 listed as an Extraordinary Item Payout in 2010 from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). *See Appendix D* for a full list of DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2009 from Purdue 2010 10-Year Plan, June 24, 2010, PPLP004404330-453. These liabilities consist primarily of pension and post-retirement benefits.

Exhibit 27c
Cash Flow Test for Purdue as of 2010
(\$ Millions)

[11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.

[12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's Balance Sheet to account for management's expectation of future settlements of pending opioid litigation. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

[A] Purdue 2010 10-Year Plan, June 24, 2010, PPLP004404330-453.

[B] Purdue Financial Statement, June 2010, PPLPC054000051935.

[C] Appendix H.

Exhibit 27d
Cash Flow Test for Purdue as of 2011
(\$ Millions)

		<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>
		(Partial Year)							
[1]=[13] from prior year	Starting Cash Balance	582	613	1,341	2,103	2,866	3,728	4,644	5,266
[2]	EBIT	612	1,088	1,191	1,209	1,549	1,785	1,604	817
[3]	Taxes	(268)	(493)	(547)	(566)	(777)	(950)	(1,038)	(845)
[4]	Depreciation and Amortization	16	32	34	37	38	40	41	40
[5]	Non-Cash P&L on Foreign Equity Investments	65	120	135	98	73	58	43	28
[6]	Changes in Net Working Capital	41	(23)	11	(25)	(19)	(24)	(14)	111
[7]	Capital Expenditures	(19)	(40)	(40)	(40)	(40)	(40)	(40)	(40)
[8]	Other Items	(0)	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	364	728	762	762	862	916	622	(112)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(133)	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	813	1,341	2,103	2,866	3,728	4,644	5,266	5,154
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(200)	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	613	1,341	2,103	2,866	3,728	4,644	5,266	5,154

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 6/17/2011 and is sourced from Purdue Weekly Cash Forecast, June 17, 2011, PPLPUCC000638863. The nearest available cash balance of \$582 million does not include restricted cash, which is listed at \$71.7 million. To adjust for the changes in cash between the cash balance date (6/17/2011) and the projection date (6/21/2011), at-issue cash distributions that occurred between this time period are then deducted from the cash balance (zero distributions occurred between the dates for this analysis).
- [2] EBIT (line item 2) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [3] Taxes (line item 3) are equal to tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the DCF analysis and includes decreases in Long-Term Liabilities and an adjustment for Deferred Income Taxes of negative \$473,000 for 2011 from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011).

Exhibit 27d
Cash Flow Test for Purdue as of 2011
(\$ Millions)

- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2010 from Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's Balance Sheet to account for management's expectation of future settlements of pending opioid litigation. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012.
- [B] Purdue Weekly Cash Forecast, June 17, 2011, PPLPUCC000638863.
- [C] Appendix H.

Exhibit 27e
Cash Flow Test for Purdue as of 2012
(\$ Millions)

		<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>
		(Partial Year)						
[1]=[13] from prior year	Starting Cash Balance	605	935	1,569	2,078	2,712	3,478	4,173
[2]	EBIT	782	813	699	972	1,238	1,218	733
[3]	Taxes	(357)	(366)	(315)	(437)	(557)	(572)	(331)
[4]	Depreciation and Amortization	30	35	45	46	46	46	45
[5]	Non-Cash P&L on Foreign Equity Investments	201	166	123	70	48	43	38
[6]	Changes in Net Working Capital	53	(78)	(5)	(25)	(30)	(0)	208
[7]	Capital Expenditures	(31)	(90)	(46)	(40)	(40)	(40)	(40)
[8]	Other Items	(1)	(1)	(1)	(1)	-	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	570	634	509	634	766	695	235
[10]	Payments for Other LT Liabilities on the Balance Sheet	(221)	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	954	1,569	2,078	2,712	3,478	4,173	4,408
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(19)	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	935	1,569	2,078	2,712	3,478	4,173	4,408

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 12/31/2011 and is sourced from Purdue's 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668. The nearest available cash balance of \$606.5 million does not include restricted cash, which is listed at \$43 million. To adjust for the changes in cash between the cash balance date (12/31/2011) and the projection date (2/15/2012), at-issue cash distributions that occurred between this time period of \$1.7 million are then deducted from the nearest available cash balance.
- [2] EBIT (line item 2) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [3] Taxes (line item 3) are equal to tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). See **Appendix D** for a full list of DCF projections, notes, and sources.

Exhibit 27e
Cash Flow Test for Purdue as of 2012
(\$ Millions)

- [8] Other Items (line item 8) is sourced from the DCF analysis and includes an adjustment for Deferred Income Taxes of negative \$1.1 million for 2012 and decreases in Long-Term Liabilities from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). *See Appendix D* for a full list of DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2011 from PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's Balance Sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668.
- [B] Appendix H.

Exhibit 27f
Cash Flow Test for Purdue as of 2013
(\$ Millions)

		<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>
		(Partial Year)								
[1]=[13] from prior year	Starting Cash Balance	814	537	1,001	1,381	1,808	2,144	2,460	2,802	3,117
[2]	EBIT	691	597	539	721	611	683	757	696	192
[3]	Taxes	(304)	(299)	(270)	(368)	(330)	(402)	(455)	(395)	(96)
[4]	Depreciation and Amortization	21	33	41	42	42	42	42	40	38
[5]	Non-Cash P&L on Foreign Equity Investments	93	144	107	62	28	36	36	36	36
[6]	Changes in Net Working Capital	160	(65)	(5)	(9)	(18)	8	1	25	245
[7]	Capital Expenditures	(23)	(77)	(43)	(38)	(34)	(35)	(36)	(37)	(38)
[8]	Other Items	125	-	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	444	464	379	427	336	316	342	315	(114)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(230)	-	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	1,028	1,001	1,381	1,808	2,144	2,460	2,802	3,117	3,003
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(491)	-	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	537	1,001	1,381	1,808	2,144	2,460	2,802	3,117	3,003

- Notes:**
- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date. For this analysis, the nearest available cash balance is as of 5/10/2013 and is sourced from Purdue Weekly Cash Forecast, May 10, 2013, PPLUCC000638139. The nearest available cash balance of \$814 million does not include restricted cash, which is listed at \$42 million. No further adjustment is made to the starting cash balance, as the cash balance date (5/10/2013) is after the projection date (5/3/2013) and therefore more conservative.
- [2] EBIT (line item 2) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [3] Taxes (line item 3) are equal to tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the DCF analysis and includes decreases in Other Long-Term Liabilities and an Extraordinary Item Payout of \$125 million associated with the sale of Infinity Stock in 2013 from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balances of year-end 2013 from PPLP 10-Year Plan, May 3, 2013, PPLPC06300003469-592. These liabilities consist primarily of pension and post-retirement benefits.

Exhibit 27f
Cash Flow Test for Purdue as of 2013
(\$ Millions)

- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. Additionally, I estimate \$472 million in liabilities associated with government investigations into Purdue's marketing practices for 2013 to 2016 to reach a total of \$491 million. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. See **Section IV.B** of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] PPLP 10-Year Plan, May 3, 2013, PPLPC063000003469-592.
- [B] Purdue Weekly Cash Forecast, May 10, 2013, PPLPUCC000638139.
- [C] Appendix H.

Exhibit 27g
Cash Flow Test for Purdue as of 2014
(\$ Millions)

		<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>
		(Partial Year)							
[1]=[13] from prior year	Starting Cash Balance	957	337	634	943	1,203	1,464	1,727	1,974
[2]	EBIT	258	157	256	330	393	435	450	215
[3]	Taxes	(103)	(77)	(127)	(163)	(195)	(216)	(224)	(106)
[4]	Depreciation and Amortization	22	32	33	32	27	27	26	26
[5]	Non-Cash P&L on Foreign Equity Investments	126	192	144	82	58	29	26	24
[6]	Changes in Net Working Capital	226	(22)	(25)	(3)	0	(11)	8	189
[7]	Capital Expenditures	(40)	(28)	(21)	(21)	(21)	(21)	(22)	(12)
[8]	Other Items	-	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	37	298	309	261	260	263	248	(44)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(166)	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	828	634	943	1,203	1,464	1,727	1,974	1,930
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(491)	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	337	634	943	1,203	1,464	1,727	1,974	1,930

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date. For this analysis, the nearest available cash balance is as of 5/9/2014 and is sourced from Purdue Weekly Cash Forecast, May 13, 2014, PPLPUCC9003551645. The nearest available cash balance of \$957 million does not include restricted cash, which is listed at \$37.4 million. No further adjustment is made to the starting cash balance, as the cash balance date (5/9/2014) is after the projection date (5/2/2014) and therefore more conservative.
- [2] EBIT (line item 2) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [3] Taxes (line item 3) is equal to the tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the DCF analysis and includes decreases in Long-Term Liabilities from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of DCF projections, notes, and sources.

Exhibit 27g
Cash Flow Test for Purdue as of 2014
(\$ Millions)

- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2013 from PPLP 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. Additionally, I estimate \$472 million in liabilities associated with government investigations into Purdue's marketing practices for 2013 to 2016 to reach a total of \$491 million. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. See **Section IV.B** of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] PPLP 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543.
- [B] Purdue Weekly Cash Forecast, May 13, 2014, PPLPUCC9003551645.
- [C] Appendix H.

Exhibit 27h
Cash Flow Test for Purdue as of 2015
(\$ Millions)

		<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>	<u>2022</u>	<u>2023</u>
		(Partial Year)								
[1]=[13] from prior year	Starting Cash Balance	1,396	702	1,086	1,377	1,702	2,026	2,369	2,710	2,958
[2]	EBIT	210	352	344	485	568	643	657	582	365
[3]	Taxes	(74)	(175)	(171)	(241)	(283)	(320)	(327)	(289)	(181)
[4]	Depreciation and Amortization	16	33	36	36	34	33	32	30	23
[5]	Non-Cash P&L on Foreign Equity Investments	89	165	102	65	22	(5)	(37)	(50)	(53)
[6]	Changes in Net Working Capital	224	(36)	(13)	(6)	(9)	(9)	(35)	7	444
[7]	Capital Expenditures	(28)	(23)	(29)	(21)	(23)	(18)	(18)	(18)	(8)
[8]	Other Items	2	(4)	(4)	(4)	(4)	(0)	(0)	(0)	(0)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	(9)	384	292	325	324	343	341	248	(298)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(194)	-	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	1,192	1,086	1,377	1,702	2,026	2,369	2,710	2,958	2,660
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(491)	-	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	702	1,086	1,377	1,702	2,026	2,369	2,710	2,958	2,660

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 5/31/2015 and is sourced from Purdue Finance Flash Report, May 2015, RSF00016745, slide 10. The nearest available cash balance of \$1,396 million is unrestricted cash (the restricted cash amount is not specified). To adjust for the difference between the cash balance date (5/31/2015) and the projection date (6/9/2015), at-issue cash distributions that occurred between this time period are then deducted from the cash balance (zero distributions occurred between the dates for this analysis).
- [2] EBIT (line item 2) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [3] Taxes (line item 3) are equal to tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the DCF analysis and includes decreases in Long-Term Liabilities and an adjustment for Deferred Income Taxes of \$2.9 million in 2015 from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2014 from PPLP Finance Update, June 9, 2015, PPLPC054000123288. These liabilities consist primarily of pension and post-retirement benefits.

Exhibit 27h
Cash Flow Test for Purdue as of 2015
(\$ Millions)

- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. Additionally, I estimate \$472 million in liabilities associated with government investigations into Purdue's marketing practices for 2013 to 2016 to reach a total of \$491 million. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. See **Section IV.B** of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] PPLP Finance Update, June 9, 2015, PPLPC054000123288.
- [B] Purdue Finance Flash Report, May 2015, RSF00016745, slide 10.
- [C] Appendix H.

Exhibit 27i
Cash Flow Test for Purdue as of 2016
(\$ Millions)

		<u>2016</u>	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>	<u>2022</u>	<u>2023</u>
		(Partial Year)							
[1]=[13] from prior year	Starting Cash Balance	864	286	612	870	1,157	1,446	1,735	1,994
[2]	EBIT	108	238	238	353	436	509	597	324
[3]	Taxes	-	(147)	(134)	(180)	(212)	(248)	(290)	(158)
[4]	Depreciation and Amortization	15	32	32	32	32	30	29	23
[5]	Non-Cash P&L on Foreign Equity Investments	135	182	115	72	39	(32)	(50)	(48)
[6]	Changes in Net Working Capital	143	(51)	(29)	(34)	(13)	(49)	10	617
[7]	Capital Expenditures	(20)	(29)	(21)	(23)	(18)	(18)	(17)	(8)
[8]	Other Items	(5)	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	91	326	258	287	289	290	259	(485)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(198)	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	757	612	870	1,157	1,446	1,735	1,994	1,509
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(472)	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	286	612	870	1,157	1,446	1,735	1,994	1,509

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 5/1/2015 and is sourced from PPLP Mid-Year Update, June 8, 2016, RSF00017771-921 at 908. The nearest available cash balance of \$1,131 million may or may not include restricted cash as the source does not specify. To adjust for changes in cash between the cash balance date (5/1/2016) and the projection date (6/8/2016), at-issue distributions that occurred between this time period of \$10 million are then deducted from the nearest available cash balance. Since 2016 is the last year of the solvency period, the at-issue cash distributions for the remainder of the year totaling \$257 million are also deducted.
- [2] EBIT (line item 2) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [3] Taxes (line item 3) are not deducted from EBIT in 2016 due to the inclusion of \$123 million in tax distributions within the \$257 million at-issue distributions mentioned in Note 1. For years 2017-2020, tax distributions from Purdue's projected Cash Flow Statement for each year of analysis are used. For years 2021-2023, where projected tax distributions are unavailable, the implied tax rate from 2020 is used. Implied tax rates are computed by dividing projected tax distributions from the Cash Flow Statement by projected profit before tax from the Income Statement. This equates to a 48.6 percent tax rate.
- [4] Depreciation and Amortization (line item 4) is sourced from the DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). See **Appendix D** for a full list of DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). See **Appendix D** for a full list of DCF projections, notes, and sources.

Exhibit 27i
Cash Flow Test for Purdue as of 2016
(\$ Millions)

-
- [8] Other Items (line item 8) is sourced from the DCF analysis and includes decreases in Other Long-Term Liabilities from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). *See Appendix D* for a full list of DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2015 from PPLP Mid-Year Update, June 8, 2016, RSF00017771-921. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. This amount was resolved in 2015. Additionally, I estimate \$472 million in liabilities associated with government investigations into Purdue's marketing practices for 2013 to 2016, which is the only remaining portion after the resolution of the \$19 million in 2015. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

[A] PPLP Mid-Year Update, June 8, 2016, RSF00017771-921.

[B] PPLP Finance Update, June 9, 2015, PPLPC054000123288.

[C] Appendix H.

Exhibit 28
Summary of Purdue Balance Sheet Test Under Stress-Test Scenario for Capital Adequacy
(\$ millions)

	Operating Assets Used in DCF Valuation	Operating Assets Under Stress- Test Scenario	Excess Cash	Liabilities	Solvency Cushion Under Stress-Test Scenario
	[i]	[ii]	[iii]	[iv]	[ii] + [iii] - [iv]
2008	9,157	5,748	386	342	5,792
2009	5,724	5,115	282	328	5,069
2010	7,457	4,752	232	331	4,653
2011	4,693	3,734	264	419	3,578
2012	4,590	3,221	349	245	3,326
2013	2,967	2,569	562	654	2,477
2014	1,377	1,377	568	694	1,251
2015	2,103	1,530	750	685	1,595
2016	1,625	1,285	693	641	1,337

Notes:

- [1] The Stress-Test Scenario multiplies the Earnings Before Interest and Taxes (EBIT) used in the DCF valuation of Purdue's operating assets by the proportion of Sales for Existing Products to Total Sales. It keeps all other cash adjustments the same. *See Section VII and Appendix D* of my report.
- [2] Excess Cash is calculated as: Cash and Cash Equivalents - Max [Total Current Liabilities - (Total Current Assets - Cash and Cash Equivalents), 0] - Restricted Cash. Figures are calculated using actual year-end Consolidated Purdue Companies balance sheet figures to estimate Excess Cash as of the valuation date. *See Exhibit 11.*
- [3] Liabilities during the Solvency Period consist of Long-Term Debt (\$770,000 in 2014 only), "Other Liabilities," and Estimated Opioid Litigation Liabilities. *See Sections IV.A and IV.C* of my report and **Exhibit 25**.

Sources:

- [A] **Section IV.A, Section IV.C, and Section VII** of my report.
- [B] **Appendix D and Exhibits D-1 to D-17.**
- [C] **Exhibit 11 and Exhibit 25.**

Exhibit 29a
Capital Adequacy Cash Flow Test for Purdue as of 2008
(\$ Millions)

		<u>2008</u>	<u>2009</u>	<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
		(Partial Year)								
[1]=[13] from prior year	Starting Cash Balance	384	717	1,897	3,040	4,013	4,777	5,406	6,355	7,305
[2]	EBIT	974	1,938	1,862	1,778	1,641	1,627	1,653	1,654	675
[3]	Taxes	(384)	(810)	(770)	(800)	(844)	(945)	(661)	(662)	(270)
[4]	Depreciation and Amortization	21	35	35	36	39	40	39	39	39
[5]	Non-Cash P&L on Foreign Equity Investments	64	68	43	7	(34)	(43)	(38)	(38)	(38)
[6]	Changes in Net Working Capital	43	9	(13)	8	(2)	10	4	4	493
[7]	Capital Expenditures	(32)	(40)	(40)	(40)	(40)	(40)	(40)	(40)	(40)
[8]	Other Items	(33)	(1)	-	-	-	-	-	-	-
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	568	1,181	1,143	973	764	629	949	950	(127)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(35)	-	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	917	1,897	3,040	4,013	4,777	5,406	6,355	7,305	7,178
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(200)	-	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	717	1,897	3,040	4,013	4,777	5,406	6,355	7,305	7,178

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 3/14/2008 and is sourced from Purdue Weekly Cash Forecast, March 14, 2008, PPLUCC001552391. The nearest available cash balance of \$527 million does not include restricted cash, which is listed at \$81.6 million. To adjust for the changes in cash between the nearest available cash balance date (3/14/2008) and the projection date (4/18/2008), at-issue cash distributions that occurred between this time period of \$142.5 million are then deducted from the nearest available cash balance.
- [2] EBIT (line item 2) is sourced from the capital adequacy DCF analysis and reflects a stressed scenario by multiplying EBIT (from the DCF Model) by the fraction equal to Net Sales (Existing Products) divided by Net Sales (Existing and Pipeline Products). The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [3] Taxes (line item 3) equals tax distributions from Purdue's projected Cash Flow Statement for each year of analysis where available. For years 2014-2016, where projected tax distributions are unavailable, the implied tax rate from 2013 of 40.0 percent is multiplied by EBIT. Implied tax rates are computed by dividing projected tax distributions from the Cash Flow Statement by projected profit before tax from the Income Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [4] Depreciation and Amortization (line item 4) is sourced from the capital adequacy DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the capital adequacy DCF analysis and comprises of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the DCF analysis and includes decreases in Long-Term Liabilities and an item listed as an Extraordinary Item Payout from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (4/18/2008 - 12/31/2008).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2007 from Purdue's Five Year Plan 2008-2013, April 18, 2008, PPLPC063000023668. These liabilities consist primarily of pension and post-retirement benefits.

Exhibit 29a
Capital Adequacy Cash Flow Test for Purdue as of 2008
(\$ Millions)

- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's Balance Sheet to account for management's expectation of future settlements of pending opioid litigation. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. See **Section IV.B** of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] Five Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687.
- [B] Purdue Weekly Cash Forecast, March 14, 2008, PPLPUCC001552391.
- [C] Appendix H.
- [D] Ten-Year Plan, July 15, 2009, PPLPC019000293027-65.
- [E] 10-Year Plan, June 24, 2010, PPLP004404330-453.
- [F] 10 Year Plan, February 15, 2012, PPLPC053000063393-668.
- [G] 10-Year Plan, May 3, 2013, PPLPC063000003469-592.

Exhibit 29b
Capital Adequacy Cash Flow Test for Purdue as of 2009
(\$ Millions)

		<u>2009</u>	<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>
		(Partial Year)									
[1]=[13] from prior year	Starting Cash Balance	309	302	1,465	2,604	3,579	4,378	5,052	5,650	6,192	6,580
[2]	EBIT	545	1,653	1,500	1,259	1,062	934	873	773	572	(22)
[3]	Taxes	(219)	(665)	(603)	(506)	(427)	(376)	(351)	(311)	(230)	-
[4]	Depreciation and Amortization	14	36	38	39	39	36	36	36	36	33
[5]	Non-Cash P&L on Foreign Equity Investments	37	99	216	208	157	118	85	75	38	20
[6]	Changes in Net Working Capital	8	(78)	(32)	(16)	(5)	8	14	(0)	(4)	27
[7]	Capital Expenditures	(14)	(37)	(43)	(40)	(35)	(30)	(30)	(30)	(30)	(30)
[8]	Other Items	(16)	(2)	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	339	1,163	1,138	975	799	673	598	542	388	(27)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(146)	-	-	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	502	1,465	2,604	3,579	4,378	5,052	5,650	6,192	6,580	6,553
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(200)	-	-	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	302	1,465	2,604	3,579	4,378	5,052	5,650	6,192	6,580	6,553

- Notes:**
- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 6/30/2009 and is sourced from Purdue Financial Statement, June 2009, PPLPC042000017701. The nearest available cash balance of \$309 million does not include restricted cash, which is listed at \$82.5 million. To adjust for the changes in cash between the nearest available cash balance date (6/30/2009) and the projection date (7/15/2009), at-issue cash distributions that occurred between this time period are then deducted from the cash balance (zero distributions occurred between the dates for this analysis).
- [2] EBIT (line item 2) is sourced from the capital adequacy DCF analysis and reflects a stressed scenario by multiplying EBIT (from the DCF Model) by the fraction equal to Net Sales (Existing Products) divided by Net Sales (Existing and Pipeline Products). The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [3] Taxes (line item 3) are computed using the average implied tax rate from 2008 management projections used in 2008's capital adequacy DCF analysis. See Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668. This is due to tax distribution data limitations from the management projections used in 2009's DCF. Implied tax rates are computed by dividing projected tax distributions from the Cash Flow Statement by projected profit before tax from the Income Statement. This equates to a 40.2% tax rate. The average implied tax rate is then multiplied by EBIT for a given year to arrive at taxes for that year.
- [4] Depreciation and Amortization (line item 4) is sourced from the capital adequacy DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the capital adequacy DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the capital adequacy DCF analysis and includes decreases in long-term liabilities, deferred tax movement, profit/loss on disposal of fixed assets, Infinity common stock premium, Infinity line of credit, and other non-cash items. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year equal, which is the fraction of the projection year that is included in the projection period (7/15/2009 - 12/31/2009).

Exhibit 29b
Capital Adequacy Cash Flow Test for Purdue as of 2009
(\$ Millions)

- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2008 from Purdue Financial Statement, June 2009, PPLPC042000017701. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. See **Section IV.B** of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065.
- [B] Purdue Financial Statement, June 2009, PPLPC042000017701.
- [C] Appendix H.
- [D] Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662.
- [E] Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453.
- [F] Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668.
- [G] Purdue 2013 10-Year Plan, May 3, 2013, PPLPC063000003469-592.

Exhibit 29c
Capital Adequacy Cash Flow Test for Purdue as of 2010
(\$ Millions)

		<u>2010</u>	<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>
		(Partial Year)								
[1]=[13] from prior year	Starting Cash Balance	445	698	1,724	2,517	3,184	3,803	4,334	4,809	5,268
[2]	EBIT	919	1,415	1,093	988	1,036	1,068	1,128	1,088	191
[3]	Taxes	(396)	(579)	(467)	(463)	(535)	(586)	(692)	(637)	(239)
[4]	Depreciation and Amortization	21	37	43	44	46	46	46	46	47
[5]	Non-Cash P&L on Foreign Equity Investments	83	148	147	123	88	40	38	41	35
[6]	Changes in Net Working Capital	22	(62)	(24)	(20)	(26)	(6)	2	37	117
[7]	Capital Expenditures	(22)	(54)	(44)	(43)	(39)	(42)	(40)	(40)	(40)
[8]	Other Items	0	(3)	(3)	(3)	(3)	(3)	(3)	(3)	(3)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	584	1,026	793	667	619	530	476	459	(125)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(130)	-	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	898	1,724	2,517	3,184	3,803	4,334	4,809	5,268	5,143
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(200)	-	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	698	1,724	2,517	3,184	3,803	4,334	4,809	5,268	5,143

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 6/30/2010 and is sourced from Purdue Financial Statement, June 2010, PPLPC054000051935. The nearest available cash balance of \$445 million does not include restricted cash, which is listed at \$90 million. No further adjustment is made to the starting cash balance, as the cash balance date (6/30/2010) is after the projection date (6/1/2010) and therefore more conservative.
- [2] EBIT (line item 2) is sourced from the capital adequacy DCF analysis and reflects a stressed scenario by multiplying EBIT (from the DCF Model) by the fraction equal to Net Sales (Existing Products) divided by Net Sales (Existing and Pipeline Products). The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [3] Taxes (line item 3) are equal to tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the capital adequacy DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the capital adequacy DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the capital adequacy DCF analysis and includes decreases in Long-Term Liabilities and approximately \$350,000 listed as an Extraordinary Item Payout in 2010. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (6/1/2010 - 12/31/2010).

Exhibit 29c
Capital Adequacy Cash Flow Test for Purdue as of 2010
(\$ Millions)

[10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2009 from Purdue 2010 10-Year Plan, June 24, 2010, PPLP004404330-453. These liabilities consist primarily of pension and post-retirement benefits.

[11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.

[12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's Balance Sheet to account for management's expectation of future settlements of pending opioid litigation. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

[A] Purdue 2010 10-Year Plan, June 24, 2010, PPLP004404330-453

[B] Purdue Financial Statement, June 2010, PPLPC054000051935.

[C] Appendix H.

Exhibit 29d
Capital Adequacy Cash Flow Test for Purdue as of 2011
(\$ Millions)

		<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>
		(Partial Year)							
[1]=[13] from prior year	Starting Cash Balance	582	609	1,313	2,002	2,637	3,119	3,422	3,225
[2]	EBIT	608	1,064	1,117	1,082	1,170	1,172	784	94
[3]	Taxes	(268)	(493)	(547)	(566)	(777)	(950)	(1,038)	(845)
[4]	Depreciation and Amortization	16	32	34	37	38	40	41	40
[5]	Non-Cash P&L on Foreign Equity Investments	65	120	135	98	73	58	43	28
[6]	Changes in Net Working Capital	41	(23)	11	(25)	(19)	(24)	(14)	111
[7]	Capital Expenditures	(19)	(40)	(40)	(40)	(40)	(40)	(40)	(40)
[8]	Other Items	(0)	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	360	704	688	635	483	303	(198)	(835)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(133)	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	809	1,313	2,002	2,637	3,119	3,422	3,225	2,389
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(200)	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	609	1,313	2,002	2,637	3,119	3,422	3,225	2,389

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 6/17/2011 and is sourced from Purdue Weekly Cash Forecast, June 17, 2011, PPLUCC000638863. The nearest available cash balance of \$582 million does not include restricted cash, which is listed at \$71.7 million. To adjust for the changes in cash between the cash balance date (6/17/2011) and the projection date (6/21/2011), at-issue cash distributions that occurred between this time period are then deducted from the cash balance (zero distributions occurred between the dates for this analysis).
- [2] EBIT (line item 2) is sourced from the capital adequacy DCF analysis and reflects a stressed scenario by multiplying EBIT (from the DCF Model) by the fraction equal to Net Sales (Existing Products) divided by Net Sales (Existing and Pipeline Products). The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [3] Taxes (line item 3) are equal to tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the capital adequacy DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the capital adequacy DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.

Exhibit 29d
Capital Adequacy Cash Flow Test for Purdue as of 2011
(\$ Millions)

- [8] Other Items (line item 8) is sourced from the capital adequacy DCF analysis and includes decreases in Long-Term Liabilities and an adjustment for Deferred Income Taxes of approximately negative \$473,000 for 2011 from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011). *See Appendix D* for a full list of capital adequacy DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (6/21/2011 - 12/31/2011).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2010 from Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's Balance Sheet to account for management's expectation of future settlements of pending opioid litigation. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012.
- [B] Purdue Weekly Cash Forecast, June 17, 2011, PPLPUCC000638863.
- [C] Appendix H.

Exhibit 29e
Capital Adequacy Cash Flow Test for Purdue as of 2012
(\$ Millions)

		<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>
		(Partial Year)						
[1]=[13] from prior year	Starting Cash Balance	605	935	1,569	2,070	2,641	3,233	3,597
[2]	EBIT	782	813	692	909	1,064	887	288
[3]	Taxes	(357)	(366)	(315)	(437)	(557)	(572)	(331)
[4]	Depreciation and Amortization	30	35	45	46	46	46	45
[5]	Non-Cash P&L on Foreign Equity Investments	201	166	123	70	48	43	38
[6]	Changes in Net Working Capital	53	(78)	(5)	(25)	(30)	(0)	208
[7]	Capital Expenditures	(31)	(90)	(46)	(40)	(40)	(40)	(40)
[8]	Other Items	(1)	(1)	(1)	(1)	-	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	570	634	501	571	592	363	(210)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(221)	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	954	1,569	2,070	2,641	3,233	3,597	3,386
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(19)	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	935	1,569	2,070	2,641	3,233	3,597	3,386

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 12/31/2011 and is sourced from Purdue's 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668. The nearest available cash balance of \$606.5 million does not include restricted cash, which is listed at \$43 million. To adjust for the changes in cash between the cash balance date (12/31/2011) and the projection date (2/15/2012), at-issue cash distributions that occurred between this time period of \$1.7 million are then deducted from the nearest available cash balance.
- [2] EBIT (line item 2) is sourced from the capital adequacy DCF analysis and reflects a stressed scenario by multiplying EBIT (from the DCF Model) by the fraction equal to Net Sales (Existing Products) divided by Net Sales (Existing and Pipeline Products). The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [3] Taxes (line item 3) are equal to tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the capital adequacy DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the capital adequacy DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.

Exhibit 29e
Capital Adequacy Cash Flow Test for Purdue as of 2012
(\$ Millions)

-
- [7] Capital Expenditures (line item 7) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). *See Appendix D* for a full list of capital adequacy DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the capital adequacy DCF analysis and includes an adjustment for Deferred Income Taxes of negative \$1.1 million for 2012 and decreases in Long-Term Liabilities from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012). *See Appendix D* for a full list of capital adequacy DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (2/15/2012 - 12/31/2012).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2011 from PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's Balance Sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668.
- [B] Appendix H.

Exhibit 29f
Capital Adequacy Cash Flow Test for Purdue as of 2013
(\$ Millions)

		<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>
		(Partial Year)								
[1]=[13] from prior year	Starting Cash Balance	814	537	1,001	1,361	1,703	1,929	2,073	2,218	2,395
[2]	EBIT	691	597	519	636	501	512	561	558	64
[3]	Taxes	(304)	(299)	(270)	(368)	(330)	(402)	(455)	(395)	(96)
[4]	Depreciation and Amortization	21	33	41	42	42	42	42	40	38
[5]	Non-Cash P&L on Foreign Equity Investments	93	144	107	62	28	36	36	36	36
[6]	Changes in Net Working Capital	160	(65)	(5)	(9)	(18)	8	1	25	245
[7]	Capital Expenditures	(23)	(77)	(43)	(38)	(34)	(35)	(36)	(37)	(38)
[8]	Other Items	125	-	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	444	464	359	343	225	144	145	177	(241)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(230)	-	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	1,028	1,001	1,361	1,703	1,929	2,073	2,218	2,395	2,154
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(491)	-	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	537	1,001	1,361	1,703	1,929	2,073	2,218	2,395	2,154

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date. For this analysis, the nearest available cash balance is as of 5/10/2013 and is sourced from Purdue Weekly Cash Forecast, May 10, 2013, PPLPUCC000638139. The nearest available cash balance of \$814 million does not include restricted cash, which is listed at \$42 million. No further adjustment is made to the starting cash balance, as the cash balance date (5/10/2013) is after the projection date (5/3/2013) and therefore more conservative.
- [2] EBIT (line item 2) is sourced from the capital adequacy DCF analysis and reflects a stressed scenario by multiplying EBIT (from the DCF Model) by the fraction equal to Net Sales (Existing Products) divided by Net Sales (Existing and Pipeline Products). The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [3] Taxes (line item 3) are equal to tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the capital adequacy DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the capital adequacy DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the capital adequacy DCF analysis and includes decreases in Other Long-Term Liabilities and an Extraordinary Item Payout of \$125 million associated with the sale of Infinity Stock in 2013. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (5/3/2013 - 12/31/2013).

Exhibit 29f
Capital Adequacy Cash Flow Test for Purdue as of 2013
(\$ Millions)

- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term liabilities (line item 10) to become payable in the first year of the test period using the initial balances of year-end 2013 from PPLP 10-Year Plan, May 3, 2013, PPLPC063000003469-592. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. Additionally, I estimate \$472 million in liabilities associated with government investigations into Purdue's marketing practices for 2013 to 2016 to reach a total of \$491 million. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] PPLP 10-Year Plan, May 3, 2013, PPLPC063000003469-592.
- [B] Purdue Weekly Cash Forecast, May 10, 2013, PPLPUCC000638139.
- [C] Appendix H.

Exhibit 29g
Capital Adequacy Cash Flow Test for Purdue as of 2014
(\$ Millions)

		<u>2014</u>	<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>
		(Partial Year)							
[1]=[13] from prior year	Starting Cash Balance	957	337	634	943	1,203	1,464	1,727	1,974
[2]	EBIT	258	157	256	330	393	435	450	215
[3]	Taxes	(103)	(77)	(127)	(163)	(195)	(216)	(224)	(106)
[4]	Depreciation and Amortization	22	32	33	32	27	27	26	26
[5]	Non-Cash P&L on Foreign Equity Investments	126	192	144	82	58	29	26	24
[6]	Changes in Net Working Capital	226	(22)	(25)	(3)	0	(11)	8	189
[7]	Capital Expenditures	(40)	(28)	(21)	(21)	(21)	(21)	(22)	(12)
[8]	Other Items	-	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	37	298	309	261	260	263	248	(44)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(166)	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	828	634	943	1,203	1,464	1,727	1,974	1,930
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(491)	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	337	634	943	1,203	1,464	1,727	1,974	1,930

- Notes:**
- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date. For this analysis, the nearest available cash balance is as of 5/9/2014 and is sourced from Purdue Weekly Cash Forecast, May 13, 2014, PPLPUCC9003551645. The nearest available cash balance of \$957 million does not include restricted cash, which is listed at \$37.4 million. No further adjustment is made to the starting cash balance, as the cash balance date (5/9/2014) is after the projection date (5/2/2014) and therefore more conservative.
- [2] EBIT (line item 2) is sourced from the capital adequacy DCF analysis and reflects a stressed scenario by multiplying EBIT (from the DCF Model) by the fraction equal to Net Sales (Existing Products) divided by Net Sales (Existing and Pipeline Products). The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [3] Taxes (line item 3) equal to tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the capital adequacy DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the capital adequacy DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the capital adequacy capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.

Exhibit 29g
Capital Adequacy Cash Flow Test for Purdue as of 2014
(\$ Millions)

- [8] Other Items (line item 8) is sourced from the capital adequacy DCF analysis and includes decreases in Long-Term Liabilities from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (5/2/2014 - 12/31/2014).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2013 from PPLP 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. Additionally, I estimate \$472 million in liabilities associated with government investigations into Purdue's marketing practices for 2013 to 2016 to reach a total of \$491 million. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. See **Section IV.B** of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] PPLP 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543.
- [B] Purdue Weekly Cash Forecast, May 13, 2014, PPLPUCC9003551645.
- [C] Appendix H.

Exhibit 29h
Capital Adequacy Cash Flow Test for Purdue as of 2015
(\$ Millions)

		<u>2015</u>	<u>2016</u>	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>	<u>2022</u>	<u>2023</u>
		(Partial Year)								
[1]=[13] from prior year	Starting Cash Balance	1,396	702	1,085	1,360	1,632	1,894	2,165	2,442	2,603
[2]	EBIT	210	351	328	433	507	571	593	495	236
[3]	Taxes	(74)	(175)	(171)	(241)	(283)	(320)	(327)	(289)	(181)
[4]	Depreciation and Amortization	16	33	36	36	34	33	32	30	23
[5]	Non-Cash P&L on Foreign Equity Investments	89	165	102	65	22	(5)	(37)	(50)	(53)
[6]	Changes in Net Working Capital	224	(36)	(13)	(6)	(9)	(9)	(35)	7	444
[7]	Capital Expenditures	(28)	(23)	(29)	(21)	(23)	(18)	(18)	(18)	(8)
[8]	Other Items	2	(4)	(4)	(4)	(4)	(0)	(0)	(0)	(0)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	(9)	383	275	273	262	270	277	161	(427)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(194)	-	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	1,192	1,085	1,360	1,632	1,894	2,165	2,442	2,603	2,176
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(491)	-	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	702	1,085	1,360	1,632	1,894	2,165	2,442	2,603	2,176

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 5/31/2015 and is sourced from Purdue Finance Flash Report, May 2015, RSF00016745, slide 10. The nearest available cash balance of \$1,396 million is unrestricted cash (the restricted cash amount is not specified). To adjust for the difference between the cash balance date (5/31/2015) and the projection date (6/9/2015), at-issue cash distributions that occurred between this time period are then deducted from the cash balance (zero distributions occurred between the dates for this analysis).
- [2] EBIT (line item 2) is sourced from the capital adequacy DCF analysis reflect a stressed scenario by multiplying EBIT (from the DCF Model) by the fraction equal to Net Sales (Existing Products) divided by Net Sales (Existing and Pipeline Products). The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [3] Taxes (line item 3) are equal to tax distributions from Purdue's projected Cash Flow Statement for each year of analysis.
- [4] Depreciation and Amortization (line item 4) is sourced from the capital adequacy DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the capital adequacy DCF analysis and is comprise of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [7] Capital Expenditures (line item 7) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the capital adequacy DCF analysis and includes decreases in Long-Term Liabilities and an adjustment for Deferred Income Taxes of \$2.9 million in 2015 from Purdue's Cash Flow Statements. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (6/9/2015 - 12/31/2015).

Exhibit 29h
Capital Adequacy Cash Flow Test for Purdue as of 2015
(\$ Millions)

- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2014 from PPLP Finance Update, June 9, 2015, PPLPC054000123288. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities in addition to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. Additionally, I estimate \$472 million in liabilities associated with government investigations into Purdue's marketing practices for 2013 to 2016 to reach a total of \$491 million. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] PPLP Finance Update, June 9, 2015, PPLPC054000123288.
- [B] Purdue Finance Flash Report, May 2015, RSF00016745, slide 10.
- [C] Appendix H.

Exhibit 29i
Capital Adequacy Cash Flow Test for Purdue as of 2016
(\$ Millions)

		<u>2016</u>	<u>2017</u>	<u>2018</u>	<u>2019</u>	<u>2020</u>	<u>2021</u>	<u>2022</u>	<u>2023</u>
		(Partial Year)							
[1]=[13] from prior year	Starting Cash Balance	864	286	612	870	1,157	1,444	1,731	1,983
[2]	EBIT	108	238	238	353	435	504	584	273
[3]	Taxes	-	(147)	(134)	(180)	(212)	(245)	(284)	(133)
[4]	Depreciation and Amortization	15	32	32	32	32	30	29	23
[5]	Non-Cash P&L on Foreign Equity Investments	135	182	115	72	39	(32)	(50)	(48)
[6]	Changes in Net Working Capital	143	(51)	(29)	(34)	(13)	(49)	10	617
[7]	Capital Expenditures	(20)	(29)	(21)	(23)	(18)	(18)	(17)	(8)
[8]	Other Items	(5)	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[9]=[2]+[3]+[4]+[5]-[6]+[7]+[8]	Free Cash Flows	91	326	258	287	288	287	252	(511)
[10]	Payments for Other LT Liabilities on the Balance Sheet	(198)	-	-	-	-	-	-	-
[11]=[1]+[9]+[10]	Cash Available Before Considering Add'l Liabilities	757	612	870	1,157	1,444	1,731	1,983	1,472
[12]	Add'l Liabilities for Pending Opioid Lawsuits/Investigations	(472)	-	-	-	-	-	-	-
[13]=[11]+[12]	Ending Cash Balance	286	612	870	1,157	1,444	1,731	1,983	1,472

Notes:

- [1] Starting Cash Balance (line item 1) is calculated using the nearest available cash balance around the time of the projection date adjusted for cash distributions between the nearest available date and the projection date. For this analysis, the nearest available cash balance is as of 5/1/2015 and is sourced from PPLP Mid-Year Update, June 8, 2016, RSF00017771-921 at 908. The nearest available cash balance of \$1,131 million may or may not include restricted cash as the source does not specify. To adjust for changes in cash between the cash balance date (5/1/2016) and the projection date (6/8/2016), at-issue distributions that occurred between this time period of \$10 million are then deducted from the nearest available cash balance. Since 2016 is the last year of the solvency period, the at-issue cash distributions for the remainder of the year totaling \$257 million are also deducted.
- [2] EBIT (line item 2) is sourced from the capital adequacy DCF analysis and reflects a stressed scenario by multiplying EBIT (from the DCF Model) by the fraction equal to Net Sales (Existing Products) divided by Net Sales (Existing and Pipeline Products). The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [3] Taxes (line item 3) are not deducted from EBIT in 2016 due to the inclusion of \$123 million in tax distributions within the \$257 million at-issue distributions mentioned in Note 1. For years 2017-2020, tax distributions from Purdue's projected Cash Flow Statement for each year of analysis are used. For years 2021-2023, where projected tax distributions are unavailable, the implied tax rate from 2020 is used. Implied tax rates are computed by dividing projected tax distributions from the Cash Flow Statement by projected profit before tax from the Income Statement. This equates to a 48.6 percent tax rate.
- [4] Depreciation and Amortization (line item 4) is sourced from the capital adequacy DCF analysis. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [5] Non-Cash P&L on Foreign Equity Investments (line item 5) is sourced from the capital adequacy DCF analysis and is comprised of items listed under non-cash changes to net income on the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.
- [6] Changes in Net Working Capital (line item 6) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. As the leftmost column indicates, this line item is subtracted and reflects increases in working capital. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). See **Appendix D** for a full list of capital adequacy DCF projections, notes, and sources.

Exhibit 29i
Capital Adequacy Cash Flow Test for Purdue as of 2016
(\$ Millions)

-
- [7] Capital Expenditures (line item 7) is sourced from the capital adequacy DCF analysis and is listed in the projected Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). *See Appendix D* for a full list of capital adequacy DCF projections, notes, and sources.
- [8] Other Items (line item 8) is sourced from the capital adequacy DCF analysis and includes decreases in Long-Term Liabilities from Purdue's Cash Flow Statement. The first year is multiplied by a partial year factor equal to the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016). *See Appendix D* for a full list of capital adequacy DCF projections, notes, and sources.
- [9] The first year Free Cash Flow (line item 9) reflects the resulting cash flow for the partial year, which is the fraction of the projection year that is included in the projection period (6/8/2016 - 12/31/2016).
- [10] I assume an acceleration of the entire outstanding balance of Other Long-Term Liabilities (line item 10) to become payable in the first year of the test period using the initial balance as of year-end 2015 from PPLP Mid-Year Update, June 8, 2016, RSF00017771-921. These liabilities consist primarily of pension and post-retirement benefits.
- [11] Cash Available Before Considering Add'l Liabilities (line item 11) reflects the resulting cash balance after adding Free Cash Flows to the Starting Cash Balance and paying in full the Other Long-Term Liabilities on Purdue's Balance Sheet.
- [12] Add'l Liabilities for Pending Opioid Lawsuits/Investigations (line item 12) reflects potential future liabilities to the liabilities reported on Purdue's balance sheet to account for management's expectation of future settlements of pending opioid litigation. Between 2008 and 2011, Purdue incurred \$181 million in accrued settlement expenses out of the existing \$200 million in future liabilities. Thus, \$19 million remained after 2011 when the majority of the product liability cases were settled. This amount was resolved in 2015. Additionally, I estimate \$472 million in liabilities associated with government investigations into Purdue's marketing practices for 2013 to 2016, which is the only remaining portion after the resolution of the \$19 million in 2015. I assume an acceleration of the entire potential future liability that pays this amount in full in the first year of the test period. *See Section IV.B* of this report for a full description of Purdue's opioid litigation liabilities.

Sources:

- [A] PPLP Mid-Year Update, June 8, 2016, RSF00017771-921.
- [B] PPLP Finance Update, June 9, 2015, PPLPC054000123288.
- [C] Appendix H.

Exhibit 30
Purdue Current and Quick Ratios
2008-2016




Exhibit 30
Purdue Current and Quick Ratios
2008-2016

Notes:

- [1] Consolidated companies include Purdue Pharma L.P. and Associated Companies, PRA Holdings, Inc. and Subsidiaries, Pharma Associates Inc., Pharma Associates L.P., IKUWA Holdings Inc., Purdue Products Inc., Purdue Pharma Manufacturing Inc., Norwell Land Company, Avrio Health Inc., Purdue Pharmaceutical Products Inc., PharmIT Inc., Rhodes Pharmaceuticals Inc., Coventry Technologies L.P. and Associated Companies, Purdue Neuroscience Company, Millsaw Realty Inc., Millsaw Realty L.P., One Stamford Realty L.P., Laureate Pharma L.P., Laureate Pharma Inc., AB Generics L.P. and Bard Pharmaceuticals Inc.
- [2] Current Ratio is calculated as the ratio of Current Assets to Current Liabilities.
- [3] Quick Ratio is calculated as the ratio of the difference between Current Assets and Inventories to Current Liabilities.

Sources:

- [A] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697, at 662.
- [B] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991, at 954.
- [C] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583, at 540.
- [D] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLPC029000544175-219, at 178.
- [E] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174, at 139.
- [F] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664, at 619.
- [G] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPCO 11000090527, pp. 2-4.
- [H] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316, at 266.
- [I] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2017 and 2016, PPLPC029000692681-739, at 685.

Appendix A

Maureen M. Chakraborty, Ph.D.

Curriculum Vitae

Appendix A

MAUREEN M. CHAKRABORTY, PH.D. Managing Principal

Phone: 212 492 8105
Fax: 212 492 8188
maureen.chakraborty@analysisgroup.com

151 West 42nd Street
23rd Floor
New York, NY 10036

Dr. Chakraborty is an economist with an extensive background in economics, finance, accounting, and valuation. She has been retained both as an expert witness and as a consultant in a number of matters involving equity and fixed income securities, valuation, solvency, fraudulent conveyance, and economic damages. Dr. Chakraborty has conducted analyses in matters involving bankruptcy, mergers and acquisitions (M&A), tax and transfer pricing, international arbitrations, and fraud. Her work has involved the development of financial and economic models, the evaluation of large datasets, and the application of statistical methods to a variety of complex problems. She has worked on matters involving companies in many industries, including financial services, energy, retail, and pharmaceuticals.

EDUCATION

Ph.D. Economics, University of Notre Dame, Notre Dame, IN
B.A. Economics, Colby College, Waterville, ME

PROFESSIONAL EXPERIENCE

2003–Present Analysis Group, Inc., New York, NY
1995–2003 PricewaterhouseCoopers LLP, Dallas, TX
Dispute Analysis & Investigations (1997–2003)
Dispute Analysis & Corporate Recovery Group (1995–1997)

SELECTED CONSULTING EXPERIENCE

Securities

- Evaluated issues related to loss causation, market efficiency, class certification, and damages in a number of securities litigation cases involving both equity and fixed income securities. Provided assistance with settlement discussions and mediations, as well as filed expert reports and provided testimony.
- Constructed a stream of counterfactual share prices based on counterfactual market disclosures.
- Examined trading strategies, statistical patterns in trading activities, the timing of information disclosure (public and non-public) relative to trading patterns and securities prices, and the impact of large volume trades on securities prices.
- Assessed the market efficiency for traded securities.

- Valued a number of complex securities, including tranches of collateralized loan obligations, executive stock options, mortgage-backed and other asset-backed structured securities, auction rate securities, credit linked notes, and sovereign debt.
- Analyzed and valued derivative securities including futures, forwards, options, and swaps.
- Evaluated the risk of auction rate failure, the liquidity of auction rate securities, and the ultimate collapse of the auction rate securities market.
- Investigated and analyzed many economic issues arising from the 2008 financial crisis, including the causes and foreseeability of the severity of the economic crisis, the effect of the crisis on hedge fund strategy and performance, and the impact of the crisis on repo financing, leverage, margin, and asset values.

Valuation / Mergers & Acquisitions

- Valued numerous privately held companies using discounted cash flow and market multiple approaches in a variety of industries including energy, telecom, pharmaceutical, retail, and banks and other financial institutions.
- Developed models to assess forecasting uncertainty, majority and minority holding positions, illiquidity and blockage discounts.
- Evaluated the reasonableness of financial projections and cash flows prepared for purposes of assessing value.
- Evaluated the economic fairness of deal terms in the contexts of acquisitions and hostile bids, including disputes in the Delaware Court of Chancery.
- Assisted a special committee with topics related to valuation for purposes of evaluating a proposed acquisition offer.
- Assessed the reasonableness of the defensive measures taken by a board of directors in a hostile bid.
- Analyzed the economic circumstances and valuation implications arising from material adverse change (MAC) and material adverse events (MAE).
- Analyzed the financial implications of a proposed merger on a company's creditworthiness, liquidity, and ability to raise capital.

Bankruptcy and Solvency Analysis

- Assessed the solvency of numerous companies based on their balance sheet assets and liabilities, ability to pay debts as they come due, and their capital adequacy.
- Assessed companies' access to liquidity and capital, their ability to monetize or sell assets, and their ability to restructure debt.
- Analyzed the reasonable equivalent value of assets disposed in periods leading up to an event of insolvency or bankruptcy.
- Evaluated the price impact of asset sales in distressed situations.
- Performed an analysis of a hypothetical liquidation of a large international retail company for purposes of supporting a large global settlement.
- Prepared oil price forecasts and evaluated conditions affecting the supply and demand for oil and gas for purposes of evaluating corporate restructuring plans.

- Provided financial analysis to evaluate the reinstatement of senior debt proposed in the *Joint Plan of Reorganization of Spectrum Jungle Labs Corporation, et al., Debtors* (the Plan). Provided analysis demonstrating that the Plan would violate certain provisions of the Senior Secured Lenders' Credit Agreement. Analysis Group affiliate Robert Grien testified in deposition and in bankruptcy court.

Tax and Transfer Pricing

- Assessed an arm's length royalty rate using the comparable profits method and the comparable uncontrolled transaction method to inform the economic reasonableness of a profit split between corporate functions for tax purposes.
- Valued the outbound transfer of a customer relationship intangible from a large global securities custody business to a foreign subsidiary following the merger of two financial companies.
- Valued the transfer of intangible property associated with a foreign owned branch of a global custody and collateral management business to a newly established foreign bank subsidiary.
- Assessed the fair market value of Class A common units in a partnership for trust administration and tax compliance purposes.
- Provided economic and financial analysis on behalf of GlaxoSmithKline in a long-running transfer pricing dispute with the Internal Revenue Service (IRS). Supported experts in the valuation of pharmaceutical drugs at various stages of development and sales cycles, the valuation of a sales and marketing team, and a study of M&A activity in the pharmaceutical industry.
- Quantified the expected tax benefits relating to various research and development (R&D) activities on behalf of a large airline.

Economic Damages

- Provided analysis and testimony on damages in raiding claims, as well as in claims related to violations of non-compete and non-solicitation agreements.
- Quantified economic damages in a variety of disputes arising from employment disputes, contract disputes, investment allegations, and fraud claims.
- Evaluated alleged economic harm from a failed merger.

Antitrust

- In a high-profile debate over the effects of market power in the online advertising market, provided analytical and empirical support to academic affiliate Susan Athey in an examination of the ways in which online search platforms compete for advertising; an analysis of the online advertising auction pricing mechanism and the ability to exert monopoly power over pricing in the relevant market; and the development of a framework to assess the effects of monopoly power on consumer surplus, output, and quality. Professor Athey testified before the Department of Justice (DOJ) on issues relating to competition among search advertising platforms.
- Evaluated a damages claim from alleged price discrimination in a major pharmaceutical industry Robinson-Patman Act litigation matter. Analysis involved a critique of a theoretical economic model and the damage model used to quantify the alleged damages. Other tasks involved researching market trends, defining and calculating the incremental costs of operating chain store and grocery store pharmacies, and analyzing non-discriminatory prices for the industry.

PUBLICATIONS

“Calculating Damages in Broker Raiding Cases,” with John D. Finnerty and Michael J. McAlister, *Stanford Journal of Law, Business & Finance*, Vol 11, No. 2, 261–297 (Spring 2006)

Appendix B

Maureen M. Chakraborty, Ph.D.

Testimony in Past Four Years

Appendix B
Prior Testimony List
2017– 2021

DEPOSITION TESTIMONY

- ***NMR E-Tailing LLC v. Oak Investment Partners, et al.***
Supreme Court of the State of New York, New York County (2020)
- ***US Securities and Exchange Commission v. Mathias Francisco Sandoval Herrera, et al.***
US District Court, Southern District of Florida (2018)

Appendix C

Materials Considered

APPENDIX C
MATERIALS CONSIDERED

Bates-Numbered Documents and Files

1. PAZ000115626
2. PDD9316314303
3. PKY183397026
4. PNY000620892
5. POK003285615
6. PPLP003421407
7. PPLP004031287
8. PPLP004399675
9. PPLP004399813
10. PPLP004399909
11. PPLP004399952
12. PPLP004399991
13. PPLP004400043
14. PPLP004400527
15. PPLP004400551
16. PPLP004400562
17. PPLP004400572
18. PPLP004400597
19. PPLP004400663
20. PPLP004400864
21. PPLP004401017
22. PPLP004401143
23. PPLP004401328
24. PPLP004401340
25. PPLP004401475
26. PPLP004402088
27. PPLP004402136
28. PPLP004402162
29. PPLP004402229
30. PPLP004402377
31. PPLP004402432
32. PPLP004402584
33. PPLP004402697
34. PPLP004402709
35. PPLP004402802
36. PPLP004402881
37. PPLP004403059
38. PPLP004403418
39. PPLP004403588
40. PPLP004403707
41. PPLP004403811
42. PPLP004404073
43. PPLP004404330
44. PPLP004404454
45. PPLP004404478

APPENDIX C
MATERIALS CONSIDERED

46. PPLP004404619
47. PPLP004404784
48. PPLP004404901
49. PPLP004405427
50. PPLP004405511
51. PPLP004405607
52. PPLP004405789
53. PPLP004405858
54. PPLP004405990
55. PPLP004406095
56. PPLP004406301
57. PPLP004406668
58. PPLP004406761
59. PPLP004406952
60. PPLP004406990
61. PPLP004407542
62. PPLP004407735
63. PPLP004407765
64. PPLP004407956
65. PPLP004408065
66. PPLP004408301
67. PPLP004409073
68. PPLP004409271
69. PPLP004409377
70. PPLP004409476
71. PPLP004409601
72. PPLP004409708
73. PPLP004409774
74. PPLP004409781
75. PPLP004409890
76. PPLP004409973
77. PPLP004410504
78. PPLP004410516
79. PPLP004410692
80. PPLP004410816
81. PPLP004410817
82. PPLP004411049
83. PPLP004411233
84. PPLP004411288
85. PPLP004411368
86. PPLP004411807
87. PPLP004411894
88. PPLP004412123
89. PPLP004412226
90. PPLP004412371
91. PPLP004412555

APPENDIX C
MATERIALS CONSIDERED

92. PPLP004412586
93. PPLP004413180
94. PPLP004413348
95. PPLP004413452
96. PPLP004413791
97. PPLP004413815
98. PPLP004413871
99. PPLP004414090
100. PPLP004414342
101. PPLP004414567
102. PPLP004414881
103. PPLP004415256
104. PPLP004416667
105. PPLP004416787
106. PPLP004417012
107. PPLP004417130
108. PPLP004417222
109. PPLP004417632
110. PPLP004473667
111. PPLP004473709
112. PPLP004473738
113. PPLPC011000025791
114. PPLPC011000031720
115. PPLPC011000036000
116. PPLPC011000047666
117. PPLPC011000090527
118. PPLPC011000091243
119. PPLPC011000118657
120. PPLPC011000139651
121. PPLPC011000155040
122. PPLPC012000111317
123. PPLPC012000144598
124. PPLPC012000157378
125. PPLPC012000179049
126. PPLPC012000221168
127. PPLPC012000222077
128. PPLPC012000265396
129. PPLPC012000270659
130. PPLPC012000308899
131. PPLPC012000318963
132. PPLPC012000319924
133. PPLPC012000323951
134. PPLPC012000432399
135. PPLPC013000252864
136. PPLPC016000262496
137. PPLPC016000326080

APPENDIX C
MATERIALS CONSIDERED

138. PPLPC018000066140
139. PPLPC018000137301
140. PPLPC018000154015
141. PPLPC018000157428
142. PPLPC018000480936
143. PPLPC018000650253
144. PPLPC018000650273
145. PPLPC018000916505
146. PPLPC018000972178
147. PPLPC018001437163
148. PPLPC019000217660
149. PPLPC019000293027
150. PPLPC019001355808
151. PPLPC020000164902
152. PPLPC020000766504
153. PPLPC021000796266
154. PPLPC021000890262
155. PPLPC021000905780
156. PPLPC022000755894
157. PPLPC022000838293
158. PPLPC023000802126
159. PPLPC023000885227
160. PPLPC023000973973
161. PPLPC025000206753
162. PPLPC028000235587
163. PPLPC029000544175
164. PPLPC029000589136
165. PPLPC029000643588
166. PPLPC029000692681
167. PPLPC030000417143
168. PPLPC031001424670
169. PPLPC032000390447
170. PPLPC032000398822
171. PPLPC034000795341
172. PPLPC037000102197
173. PPLPC037000119373
174. PPLPC037000209682
175. PPLPC039000358902
176. PPLPC039000829545
177. PPLPC039000919953
178. PPLPC039000984972
179. PPLPC039001044053
180. PPLPC039001203005
181. PPLPC039001208828
182. PPLPC039001210740
183. PPLPC039001212792

APPENDIX C
MATERIALS CONSIDERED

184. PPLPC039001213357
185. PPLPC041000014543
186. PPLPC041000017540
187. PPLPC042000015996
188. PPLPC042000016991
189. PPLPC042000017426
190. PPLPC042000017701
191. PPLPC042000017723
192. PPLPC042000018672
193. PPLPC042000018926
194. PPLPC042000019584
195. PPLPC042000023642
196. PPLPC042000023702
197. PPLPC042000023782
198. PPLPC042000024638
199. PPLPC042000025595
200. PPLPC044000010048
201. PPLPC044000023970
202. PPLPC044000041897
203. PPLPC045000013384
204. PPLPC045000014401
205. PPLPC045000014752
206. PPLPC045000015554
207. PPLPC045000015926
208. PPLPC045000016023
209. PPLPC045000016076
210. PPLPC045000018249
211. PPLPC046000054971
212. PPLPC046000055719
213. PPLPC046000071895
214. PPLPC049000070397
215. PPLPC051000064746
216. PPLPC051000080436
217. PPLPC051000121037
218. PPLPC051000150959
219. PPLPC051000193984
220. PPLPC051000255338
221. PPLPC051000255339
222. PPLPC051000258956
223. PPLPC051000262706
224. PPLPC051000265076
225. PPLPC051000267849
226. PPLPC051000310803
227. PPLPC051000314340
228. PPLPC051000318806
229. PPLPC051000329512

APPENDIX C
MATERIALS CONSIDERED

230. PPLPC051000332001
231. PPLPC051000332793
232. PPLPC051000332795
233. PPLPC053000019122
234. PPLPC053000020583
235. PPLPC053000035655
236. PPLPC053000035664
237. PPLPC053000038938
238. PPLPC053000043567
239. PPLPC053000048718
240. PPLPC053000063393
241. PPLPC053000064469
242. PPLPC053000064478
243. PPLPC053000089053
244. PPLPC053000111461
245. PPLPC053000112705
246. PPLPC053000122044
247. PPLPC053000125367
248. PPLPC054000040595
249. PPLPC054000040618
250. PPLPC054000042825
251. PPLPC054000042936
252. PPLPC054000042941
253. PPLPC054000042942
254. PPLPC054000046697
255. PPLPC054000046698
256. PPLPC054000046707
257. PPLPC054000051141
258. PPLPC054000051159
259. PPLPC054000051928
260. PPLPC054000051935
261. PPLPC054000066016
262. PPLPC054000066023
263. PPLPC054000086946
264. PPLPC054000087872
265. PPLPC054000087876
266. PPLPC054000106326
267. PPLPC054000106338
268. PPLPC054000115001
269. PPLPC054000115013
270. PPLPC054000115020
271. PPLPC054000115153
272. PPLPC054000118010
273. PPLPC054000123288
274. PPLPC054000126428
275. PPLPC054000134819

APPENDIX C
MATERIALS CONSIDERED

276. PPLPC054000135804
277. PPLPC054000137280
278. PPLPC054000138358
279. PPLPC054000141918
280. PPLPC054000142611
281. PPLPC054000143628
282. PPLPC056000133811
283. PPLPC056000580977
284. PPLPC056000595779
285. PPLPC057000003777
286. PPLPC057000003803
287. PPLPC057000003811
288. PPLPC057000003812
289. PPLPC057000003874
290. PPLPC057000003875
291. PPLPC057000003938
292. PPLPC057000004015
293. PPLPC057000006469
294. PPLPC057000006470
295. PPLPC057000007061
296. PPLPC057000007310
297. PPLPC057000009447
298. PPLPC057000009955
299. PPLPC057000010335
300. PPLPC057000010344
301. PPLPC057000010420
302. PPLPC057000011183
303. PPLPC057000014605
304. PPLPC057000014790
305. PPLPC057000020613
306. PPLPC057000020678
307. PPLPC061000026971
308. PPLPC062000002128
309. PPLPC062000002130
310. PPLPC062000002133
311. PPLPC062000002241
312. PPLPC062000002333
313. PPLPC063000000016
314. PPLPC063000000740
315. PPLPC063000001518
316. PPLPC063000001791
317. PPLPC063000003207
318. PPLPC063000003469
319. PPLPC063000003593
320. PPLPC063000008345
321. PPLPC063000008617

APPENDIX C
MATERIALS CONSIDERED

322. PPLPC063000014681
323. PPLPC063000015093
324. PPLPC063000016057
325. PPLPC063000017048
326. PPLPC063000018767
327. PPLPC063000018836
328. PPLPC063000023434
329. PPLPC063000023668
330. PPLPCO11000090527
331. PPLPMDL0040000025
332. PPLPMDL0040000052
333. PPLPMDL0040000083
334. PPLPMDL0040000118
335. PPLPMDL0040000153
336. PPLPMDL0040000189
337. PPLPMDL0040000213
338. PPLPMDL0040000379
339. PPLPMDL0040000537
340. PPLP-NRF-000016462
341. PPLPUCC000252943
342. PPLPUCC000356670
343. PPLPUCC000360920
344. PPLPUCC000362162
345. PPLPUCC000385191
346. PPLPUCC000440006
347. PPLPUCC000510542
348. PPLPUCC000636347
349. PPLPUCC000636597
350. PPLPUCC000638139
351. PPLPUCC000638154
352. PPLPUCC000638863
353. PPLPUCC000695299
354. PPLPUCC000701839
355. PPLPUCC000802252
356. PPLPUCC000802254
357. PPLPUCC000810110
358. PPLPUCC001018217
359. PPLPUCC001048962
360. PPLPUCC001049075
361. PPLPUCC001053052
362. PPLPUCC001053705
363. PPLPUCC001065701
364. PPLPUCC001069623
365. PPLPUCC001074013
366. PPLPUCC001074193
367. PPLPUCC001075461

APPENDIX C
MATERIALS CONSIDERED

368. PPLPUCC001076695
369. PPLPUCC001137514
370. PPLPUCC001138489
371. PPLPUCC001145139
372. PPLPUCC001165339
373. PPLPUCC001552368
374. PPLPUCC001552370
375. PPLPUCC001552391
376. PPLPUCC001552397
377. PPLPUCC001552413
378. PPLPUCC001554158
379. PPLPUCC001557605
380. PPLPUCC001559111
381. PPLPUCC001560499
382. PPLPUCC001560512
383. PPLPUCC001560514
384. PPLPUCC001586350
385. PPLPUCC001653408
386. PPLPUCC001684294
387. PPLPUCC001704662
388. PPLPUCC001716854
389. PPLPUCC001746935
390. PPLPUCC002434005
391. PPLPUCC002536767
392. PPLPUCC002538272
393. PPLPUCC002545437
394. PPLPUCC002595029
395. PPLPUCC002683256
396. PPLPUCC003938943
397. PPLPUCC9002310385
398. PPLPUCC9002310410
399. PPLPUCC9002364573
400. PPLPUCC9002365418
401. PPLPUCC9002452497
402. PPLPUCC9002641325
403. PPLPUCC9002790025
404. PPLPUCC9002964468
405. PPLPUCC9002975788
406. PPLPUCC9003110059
407. PPLPUCC9003152030
408. PPLPUCC9003546781
409. PPLPUCC9003546837
410. PPLPUCC9003546978
411. PPLPUCC9003551645
412. PPLPUCC9004063788
413. PPLPUCC9004115230

APPENDIX C
MATERIALS CONSIDERED

414. PPLPUCC9004368683
415. PPLPUCC9004696169
416. PPLPUCC9004737104
417. PPLPUCC9011830859
418. PWG004346733
419. PWG004346740
420. PWG004347562
421. PWG004347777
422. PWG004347832
423. PWG004347984
424. PWG004348097
425. PWG004348109
426. PWG004349878
427. PWG004350770
428. PWG004351884
429. PWG004351934
430. PWG004353617
431. PWG004355938
432. RSF_OLK00011007
433. RSF_OLK00016977
434. RSF_OLK00034552
435. RSF00735509
436. RSF00016323
437. RSF00016745
438. RSF00016746
439. RSF00017639
440. RSF00017771
441. RSF00018245
442. RSF00018287
443. RSF00018611
444. RSF00031260
445. RSF00031266
446. RSF00031267
447. RSF00032539
448. RSF00033012
449. RSF00039785
450. RSF00039814
451. RSF00073087
452. RSF00073089
453. RSF00098652
454. RSF00098883
455. RSF00104721
456. RSF00126578
457. RSF00127584
458. RSF00127591
459. RSF00127592

APPENDIX C
MATERIALS CONSIDERED

460. RSF00130738
461. RSF00135763
462. RSF00142160
463. RSF00175922
464. RSF00175923
465. RSF00175924
466. RSF00176105
467. RSF00176106
468. RSF00176108
469. RSF00176112
470. RSF00177987
471. RSF00178359
472. RSF00178364
473. RSF00178366
474. RSF00179870
475. RSF00180663
476. RSF00180668
477. RSF00180669
478. RSF00188431
479. RSF00189284
480. RSF00197479
481. RSF00197509
482. RSF00366273
483. RSF00411664
484. RSF00491015
485. PPLPC01300025286
486. PPLPC05700000401
487. PPLPC012000372436
488. PPLPUCC9002892662

Depositions

1. Deposition of Edward B. Mahony, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Sept. 6, 2019).

SEC Filings

1. Endo Pharmaceuticals Holdings, SEC Form 10-K/A, for the fiscal year ended December 31, 2007.
2. Endo Pharmaceuticals Holdings, SEC Form 10-K, for the fiscal year ended December 31, 2008.
3. Endo Pharmaceuticals Holdings, SEC Form 10-K, for the fiscal year ended December 31, 2009.
4. Endo Pharmaceuticals Holdings, SEC Form 10-K, for the fiscal year ended December 31, 2010.
5. Endo Pharmaceuticals Holdings, SEC Form 10-K, for the fiscal year ended December 31, 2011.
6. Endo Health Solutions Inc., SEC Form 10-K, for the fiscal year ended December 31, 2012.
7. Endo Health Solutions Inc., SEC Form 10-K, for the fiscal year ended December 31, 2013.
8. Endo International plc, SEC Form 10-K, for the fiscal year ended December 31, 2014.
9. Endo International plc, SEC Form 424(b)(5), June 5, 2015.

APPENDIX C
MATERIALS CONSIDERED

10. Endo International plc, SEC Form 10-K, for the fiscal year ended December 31, 2015.
11. Endo International plc, SEC Form 10-K, for the fiscal year ended December 31, 2016.
12. Endo International plc, SEC Form 10-K, for the fiscal year ended December 31, 2017.
13. Insys Therapeutics, Inc., SEC Form 10-K, for the fiscal year ended December 31, 2013.
14. Insys Therapeutics, Inc., SEC Form 8-K, dated September 12, 2014.
15. Insys Therapeutics, Inc., SEC Form 10-K, for the fiscal year ended December 31, 2014.
16. Insys Therapeutics, Inc., SEC Form 10-K, for the fiscal year ended December 31, 2015.
17. Insys Therapeutics, Inc., SEC Form 10-K, for the fiscal year ended December 31, 2016.
18. Insys Therapeutics, Inc., SEC Form 10-K, for the fiscal year ended December 31, 2017.
19. Mallinckrodt plc, SEC Form 10-K, for the fiscal year ended September 27, 2013.
20. Mallinckrodt plc, SEC Form 10-K, for the fiscal year ended September 26, 2014.
21. Mallinckrodt plc, SEC Form 10-K, for the fiscal year ended September 25, 2015.
22. Mallinckrodt plc, SEC Form 10-K, for the fiscal year ended September 30, 2016.
23. Mallinckrodt plc, SEC Form 10-K, for the fiscal year ended December 29, 2017.
24. Teva Pharmaceutical Industries Limited, SEC Form 20-F, for the fiscal year ended December 31, 2014.
25. Teva Pharmaceutical Industries Limited, SEC Form 424(b)(5) (54,000,000 American Depositary Shares), December 3, 2015.
26. Teva Pharmaceutical Industries Limited, Form 20-F, for the fiscal year ended December 31, 2015.
27. Teva Pharmaceutical Industries Limited, SEC Form 6-K, July 21, 2016.
28. Teva Pharmaceutical Industries Limited, Form 20-F, for the fiscal year ended December 31, 2016.
29. Teva Pharmaceutical Industries Limited, Form 20-F, for the fiscal year ended December 31, 2017.
30. Teva Pharmaceutical Industries Limited, SEC Form 10-K, for the fiscal year ended December 31, 2017.

Books

1. Bonbright, James C., *Valuation of Property*, 1937.
2. Brealey, Richard A., et al., *Principles of Corporate Finance*, McGraw-Hill Irwin, Tenth Edition, 2011.
3. Damodaran, Aswath, *Investment Valuation Tools and Techniques for Determining the Value of Any Asset*, John Wiley & Sons, Inc., Third Edition, 2006.
4. Duff and Phelps, *2019 Cost of Capital: Annual U.S. Guidance and Examples*, 2019.
5. Koller, Tim, Marc Goedhart, and David Wessels, *Valuation: Measuring and Managing the Value of Companies*, McKinsey & Company, John Wiley & Sons, Inc., Fifth Edition, 2010.
6. Pratt, Shannon, *Valuing a Business: The Analysis and Appraisal of Closely Held Companies*, McGraw Hill, Fifth Edition, 2008.
7. Pratt, Shannon P. and Roger J. Grabowski, *Cost of Capital: Applications and Examples*, John Wiley & Sons, Inc., Fourth Edition, 2010.
8. Reilly, Robert F., and Robert P. Schweihs, *The Handbook of Advanced Business Valuation*, McGraw-Hill, 2000.
9. Weil, Roman L., Lentz, Daniel G., and Evans, Elizabeth A., *Litigation Services Handbook The Role of the Financial Expert*, Sixth Edition, 2017.

APPENDIX C
MATERIALS CONSIDERED

Academic Articles

1. Schippel, Bahar A., “Boilerplate Tax Distribution Provisions Can Get You Into Hot Water,” *Tax Management Real Estate Journal*, Vol. 32, 2, February 3, 2016.
2. Brav, Alon and J.B. Heaton, “Event Studies in Securities Litigation: Low Power, Confounding Effects, and Bias,” *Washington University Law Review*, Vol. 93, No. 2, 2015, pp. 583-614.
3. Heaton, J.B., “Solvency Tests,” *The Business Lawyer*, Vol. 62, No. 3, 2007, pp. 983-1006.
4. Page, Benjamin, Rohaly, Jeffrey, Matheson, Thornton, and Boddupalli, Aravind, “Tax Incentives For Pass-Through Income,” Tax Policy Center, Urban Institute and Brookings Institution, July 15, 2020.
5. MacKinlay, Craig A., “Event Studies in Economics and Finance,” *Journal of Economics Literature*, Vol. 35, 1997, pp. 13-39.
6. Schwartz, Michael W., and Bryan, David C., “Campbell, Iridium, and the Future of Valuation Litigation,” *The Business Lawyer*, Vol 67, no. 4, 2012, pp. 939 - 955.
7. Stearn Jr., Robert J., “Proving Solvency: Defending Preference and Fraudulent Transfer Litigation,” *The Business Lawyer*, Vol. 62, February 2007, pp. 359 - 395.

Legal Filings

1. Complaint for Injunctive Relief, *Purdue Pharma L.P. et al., v. Commonwealth of Massachusetts*, Adv. Pro. No. 19-8289-rdd [Dkt. Nos. 1-1 and 1-2].
2. Eighteenth Amended Order Pursuant To 11 U.S.C. § 105(a) Granting Motion For a Preliminary Injunction, *Purdue Pharma L.P. et al., v. Commonwealth of Massachusetts*, Adv. Pro. No. 19-8289-rdd [Dkt. No. 264].
3. Disclosure Statement for Fifth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors, *In re Purdue Pharma L.P.*, No. 19-23649-rdd (Bankr. S.D.N.Y. June 2, 2021), ECF No. 2969.
4. Debtors’ Disclosure Statement for Fifth Amended Plan of Reorganization, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y.) (ECF No. 2983).
5. Disclosure Statement for Fourth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. May 26, 2021), ECF No. 2937.
6. Fourth Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. May 26, 2021), ECF No. 2935.
7. Disclosure Statement for Third Amended Joint Chapter 11 Plan of Reorganization of Purdue Pharma L.P. and Its Affiliated Debtors, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. May 24, 2021), ECF No. 2907.
8. Exhibit A, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. May 29, 2020), Doc No. 1194-1.
9. Notice of Filing of Appendix F to the Disclosure Statement, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Mar. 16, 2021), ECF No. 2491.
10. Notice of Hearing on Debtors’ Motion To Approve (I) The Adequacy of Information in the Disclosure Statement, (II) Solicitation and Voting Procedures, (III) Forms of Ballots, Notices and Notice Procedures In Connection Therewith, and (IV) Certain Dates with Respect Thereto, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Mar. 16, 2021), ECF No. 2489.
11. Disclosure Statement for Chapter 11 Plan for Purdue Pharma L.P. and Its Affiliated Debtors, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Mar. 15, 2021). ECF No. 2488.
12. Second Amended Raymond Sackler Family’s Opposition to the Official Committee of Unsecured Creditors’ Exceptions Motions, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Dec. 22, 2020), ECF No. 2191.

APPENDIX C
MATERIALS CONSIDERED

13. Sur-Reply Memorandum of Objection of Mortimer Sackler Initial Covered Sackler Persons to the Official Committee of Unsecured Creditors' Motion to Compel Production of Purportedly Privileged Documents, or For In Camera Review, Based on Good Cause, Crime Fraud, and At Issue Exceptions To Claims of Privilege, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N. Y. Dec. 9, 2020, ECF No. 2095).
14. The Raymond Sackler Family's Surreply in Further Support of Its Opposition to the Official Committee of Unsecured Creditors' Exceptions Motion, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Dec. 9, 2020, ECF No. 2093).
15. Official Committee of Unsecured Creditors' Reply in Support of its Motion to Compel Production of Purportedly Privileged Documents, or for *In Camera* Review, Based on Good Cause, Crime Fraud, and At Issue Exceptions To Claims of Privilege, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Nov. 18, 2020), ECF No. 2014.
16. Objection of Mortimer Sackler Initial Covered Sackler Persons to the Official Committee of Unsecured Creditors' Motion to Compel Production of Purportedly Privileged Documents, or for *In Camera* Review, Based on Good Cause, Crime Fraud, and At Issue Exceptions to Claims of Privilege, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Oct. 14, 2020), ECF No. 1804.
17. Official Committee of Unsecured Creditors' Motion to Compel Production of Purportedly Privileged Documents or For *In Camera* Review, Based on Good Cause, Crime Fraud, and At Issue Exceptions to Claims of Privilege, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Sept. 29, 2020), ECF. No. 1753.
18. Notice of Filing of Report by the Special Committee, *In re Purdue Pharma L.P.*, Case No. 7:19-bk-23649-rdd (Bankr. S.D.N.Y. May 29, 2020), ECF No. 1194.
19. Notice of Filing of Report of the Special Committee, *In re Purdue Pharma L.P. et al.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Dec. 16, 2019).
20. Debtors' Informational Brief, *In re Purdue Pharma L.P.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Sept. 15, 2019, ECF No. 17).
21. Plan Support Letter, *In re Purdue Pharma L.P. et al.*, Case No. 19-23649-rdd (U.S. Bankruptcy Court Southern District of New York).
22. Memorandum Opinion and Order, *City of Chicago v. Purdue Pharma L.P. et al.*, Case No. 14-cv-4361 (N.D. Ill. May 8, 2015), ECF No. 288.
23. Complaint, *County of Suffolk v. Purdue Pharma L.P. et al.*, Index No. 613760/2016 (Sup. Ct. Suffolk Cnty. Aug. 31, 2016), NYSCEF No. 1.
24. Memorandum Opinion and Order, *City of Chicago v. Purdue Pharma L.P. et al.*, Case No. 14-cv-4361 (N.D. Ill. Sept. 29, 2016, ECF No. 471).
25. Minute Order, *Orange County v. Purdue Pharma L.P. et al.*, Case No. 30-2014-00725287-CU-BT-CXC (Cal. Super. Ct. Oct. 19, 2016), Doc. No. 630.
26. Minute Order, *Orange County v. Purdue Pharma L.P. et al.*, Case No. 30-2014-00725287-CU-BT-CXC (Cal. Super. Ct. Aug. 27, 2015), Doc. No. 501.
27. Order and Opinion of the Court, *State v. Purdue Pharma L.P. et al.*, Case No. 25CH1:15-cv-001814 (Miss. Cir. Ct. Feb. 13, 2017).
28. Order, *In re Opioid Litigation*, Index No. 400000/2017 (Sup. Ct. Suffolk Cnty. June 18, 2018), NYSCEF No. 454.
29. Memorandum of Law in Support of the United States' Motion to Dismiss Relator's Complaint, *United States of America, et al. ex rel. Robert E. Manchester v. Purdue Pharma L.P. et al.*, Case No. 1:16-cv-10947 MLW (D. Mass. Aug. 24, 2018), ECF No. 47.
30. Declaration of Jon Lowne in Support of the Debtors' Chapter 11 Petitions and First Day Pleadings, *In re Purdue Pharma L.P. et al.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Sep. 16, 2019), ECF No. 3.
31. Complaint for Injunctive Relief, *In re Purdue Pharma L.P. et al.*, Case No. 19-23649-rdd (Bankr. S.D.N.Y. Sept. 18, 2019), ECF No. 74.

APPENDIX C
MATERIALS CONSIDERED

32. *State ex rel. Stenehjem v. Purdue Pharma L.P. et al.* , Case No. 08-2018-CV-01300, 2019 WL 2245743 (N.D. Dist. Ct. May 10, 2019).
33. Amended Declaration of Mara Leventhal and Associated Exhibits, No. 19-23649-rdd (Bankr. S.D.N.Y. Oct. 14, 2020).
34. Declaration of Jasmine Ball and Associated Exhibits, No. 19-23649-rdd (Bankr. S.D.N.Y. Oct. 14, 2020).
35. Declaration of Mitchell Hurley and Associated Exhibits, No. 19-23649-rdd (Bankr. S.D.N.Y. Sept. 29, 2020).
36. Declaration of Arik Preis and Associated Exhibits, No. 19-23649-rdd (Bankr. S.D.N.Y. Nov. 18, 2020).
37. Supplemental Declaration of Jasmine Ball and Associated Exhibits, No. 19-23649-rdd (Bankr. S.D.N.Y. Dec. 9, 2020).
38. Declaration of Mara Leventhal and Associated Exhibits, No. 19-23649-rdd (Bankr. S.D.N.Y. Dec. 9, 2020).
39. Assurance of Discontinuance Under Executive Law Section 63, Subdivision 16, Assurance No. 15-151, *In re Purdue Pharma L.P.* (N.Y. Att’y Gen. Aug. 19, 2015).
40. Complaint, *State v. Sackler* , Case No. 19CV22185 (Or. Cir. Ct. May 16, 2019).
41. First Amended Complaint, *State ex rel. Stumbo v. Purdue Pharma, L.P.* , Case No. 07-CI-01303 (Ky. Cir. Ct. Oct. 10, 2007).
42. *United States v. Purdue Frederick Co.* , 495 F. Supp. 2d 569 (W.D. Va. 2007).
43. Plea Agreement as to The Purdue Frederick Company, Inc., *United States v. Purdue Frederick Co.* , Case No. 1:07-cr-00029 (W.D. Va. May 10, 2007, ECF Doc. No. 6).
44. Civil Settlement Agreement (Exhibit D to Information), *United States v. Purdue Frederick Co.* , Case No. 1:07-cr-00029 (W.D. Va. May 10, 2007), ECF No. 5-4.
45. Agreed Statement of Facts (Exhibit B to Information), *United States v. Purdue Frederick Co.* , Case No. 1:07-cr-00029-JPJ (W.D. Va. May 10, 2007, ECF No. 5-2).
46. *VFB LLC v. Campbell Soup Co.* , 482 F.3d 624 (3d Cir. 2007).
47. *In re Doctors Hosp. of Hyde Park, Inc.* , 360 B.R. 787 (Bankr. N.D. Ill. 2007).
48. *Del. Open MRI Radiology Assocs. v. Kessler* , 898 A.2d 290 (Del. Ch. 2006).
49. *In re Med Diversified, Inc.* , 334 B.R. 89 (Bankr. E.D.N.Y. 2005).
50. *In re Commercial Fin. Servs., Inc.* , 350 B.R. 520 (Bankr. N.D. Okla. 2005).
51. *VFB LLC v. Campbell Soup Co.* , Case No. 1:02-cv-137-KAJ, 2005 WL 2234606 (D. Del. Sept. 13, 2005).
52. *Lippe v. Bairnco Corp.* , 99 F. App’x 274 (2d Cir. 2004).
53. *Lippe v. Bairnco Corp.* , 249 F. Supp. 2d 357 (S.D.N.Y. 2003).
54. *Lippe v. Bairnco Corp.* , 288 B.R. 678 (S.D.N.Y. 2003).
55. *In re Joy Recovery Tech. Corp.* , 286 B.R. 54 (Bankr. N.D. Ill. 2002).
56. *In re WRT Energy Corp.* , 282 B.R. 343 (Bankr. W.D. La. 2001).
57. *In re Trans World Airlines, Inc.* , 134 F.3d. 188 (3d Cir. 1998).
58. *In re Direct Access Partners, LLC* , 602 B.R. 495, 536 (Bankr. S.D.N.Y. 2019).
59. *In re Longview Aluminum, L.L.C.* , 2005 Bankr. LEXIS 1312.
60. *Moody v. Sec. Pacific Bus. Credit, Inc.* , 971 F.2d 1056 (3d Cir. 1992).

APPENDIX C
MATERIALS CONSIDERED

Publicly Available Materials

1. "1Q14 Results: Revenue Misses, But Rx's Still Strong," *Oppenheimer*, May 14, 2014.
2. "2Q Takeaways: Despite Strategic Actions, 2017/2018 Setup Remains Challenging," *J.P. Morgan*, August 7, 2017.
3. "2Q15 Results: Subsys Beat Not Enough," *Oppenheimer*, August 7, 2015.
4. "4Q15 Results: Mesh Liability and Generic Weakness Lead to Share Declines," *Oppenheimer*, March 1, 2016.
5. Allston, Maggie, Dieguez, Gabriela, and Tomicki, Samantha, "A primer on prescription drug rebates: Insights into why rebates are a target for reducing prices," *Milliman*, May 21, 2018, available at <https://www.milliman.com/en/insight/a-primer-on-prescription-drug-rebates-insights-into-why-rebates-are-a-target-for-reducing>, accessed June 12, 2021.
6. ASC 450-20-20.
7. ASC 450-20-25-2.
8. ASC 450-20-25-5.
9. ASC 450-20-30-1.
10. ASC 450-20-50-3.
11. ASC 450-20-50-4.
12. ASC 450-20-50-6.
13. ASC 450-20-55-14.
14. ASC 450-20-55-15.
15. Bankruptcy Code 11 U.S.C. § 101(32)(A).
16. Bankruptcy Code 11 U.S.C. § 101(32)(B).
17. Bankruptcy Code 11 U.S.C. § 548(a)(1)(B)(ii)(II).
18. Bennett, Johanna, "3 Small Biotech Stocks with Cash, Hot Pipelines," *Barron's*, June 3, 2015.
19. Berezow, Alex, "Clinical Trial Success Rates By Phase and Therapeutic Area," *American Council on Science and Health*, June 11, 2020, available at <https://www.acsh.org/news/2020/06/11/clinical-trial-success-rates-phase-and-therapeutic-area-14845>, accessed May 27, 2021.
20. DeRuiter, Jack, and Pamela L. Holston, "Drug Patent Expirations and the 'Patent Cliff'," *U.S. Pharmacist*, June 20, 2012, available at <https://www.uspharmacist.com/article/drug-patent-expirations-and-the-patent-cliff>, accessed June 3, 2021.
21. "Development & Approval Process | Drugs," U.S. Food and Drug Administration, available at <https://www.fda.gov/drugs/development-approval-process-drugs#:~:text=Developed%20and%20Approved,-,FDA%20Approval%3A%20What%20it%20means,risks%20for%20the%20intended%20population.,> accessed May 27, 2021.
22. "Diamonds in the Rough," *Morgan Stanley*, November 29, 2017.
23. Doughman, Elizabeth, "Impending Patent Cliff Threatens Billions of Global Prescription Drug Sales," *Pharmaceutical Processing World*, June 6, 2019, available at <https://www.pharmaceuticalprocessingworld.com/impending-patent-cliff-threatens-billions-of-global-prescription-drug-sales/>, accessed June 3, 2021.
24. Duff & Phelps Cost of Capital Navigator, available at <https://costofcapital.duffandphelps.com/>.
25. "Economic Outlook No. 109 - May 2021," OECD, available at <https://stats.oecd.org/Index.aspx?DataSetCode=EO#>, accessed June 4, 2021.
26. "Endo Health Solutions Inc. Downgraded To 'BB-' On More Aggressive Financial Policies; Outlook Stable," *S&P Global Ratings*, June 17, 2013, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1146031>.
27. "Endo International PLC Corporate Credit Rating Lowered To 'B+' From 'BB-'; Outlook Stable," *S&P Global Ratings*, January 20, 2015, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1379969>.

APPENDIX C
MATERIALS CONSIDERED

28. “Endo International PLC Downgraded To ‘B’ From ‘B+’, Outlook Stable; Debt Ratings Lowered,” *S&P Global Ratings*, August 11, 2017, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1899766>.
29. “Endo International PLC Outlook Revised to Negative From Stable On Potential Costs Of Opioid Settlement; Ratings Affirmed,” *S&P Global Ratings*, September 23, 2019.
30. “Endo Pharmaceuticals Holdings Inc. Downgraded To ‘BB’ On Pending Acquisition Of AMS; Off CreditWatch,” *S&P Global Ratings*, May 26, 2011, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/868852>.
31. “Examining the Impact of ENDP’s Additional Mesh Liability,” *Oppenheimer & Co. Inc.*, July 23, 2017.
32. “FDA Analysis of Long-Term Trends in Prescription Opioid Analgesic Products: Quantity, Sales, and Price Trends,” U.S. Food and Drug Administration, March 1, 2018, available at <https://www.fda.gov/media/111695/download>, accessed June 10, 2021.
33. “FDA Drug Approval Package,” U.S. Food and Drug Administration, available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021306_butrans_toc.cfm, accessed May 28, 2021.
34. “FedBizOpps Award Notice,” U.S. Department of Veteran Affairs, available as an attachment at <https://sam.gov/opp/f92c522315d70836f6bf4eab75c113ca/view>, accessed June 13, 2021.
35. “Frequently Asked Questions on Patents and Exclusivity,” U.S. Food and Drug Administration, available at https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity#What_is_the_difference_between_patents_a, accessed May 27, 2021.
36. Gallo, Amy, “A Refresher on Current Ratio,” *Harvard Business Review*, September 14, 2015, available at <https://hbr.org/2015/09/a-refresher-on-current-ratio>, accessed June 10, 2021.
37. “Ghost from the past haunting MNK?” *Barclays*, September 21, 2015.
38. Glover, Scott and Girion, Lisa, “Counties Sue Narcotics Makers, Alleging ‘Campaign of Deception,’” *The Los Angeles Times*, May 21, 2014, <https://www.latimes.com/local/la-me-rx-big-pharma-suit-20140522-story.html>, accessed June 14, 2021.
39. Harris, Gardiner, “Judge Says Maker Of OxyContin Misled Officials To Win Patents,” *The New York Times*, available at <https://www.nytimes.com/2004/01/06/business/judge-says-maker-of-oxycontin-misled-officials-to-win-patents.html>, accessed June 12, 2021.
40. “Information Page: FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties,” U.S. Food and Drug Administration, available at <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-page-fda-approves-extended-release-single-entity-hydrocodone-product-abuse-deterrent>, accessed May 28, 2021.
41. “Inomax reaction overblown; legal fight not over,” *Canaccord Genuity*, September 5, 2017.
42. “INSY: Lowering Estimates And Valuation Range But Remaining Positive On The Stock,” *Wells Fargo Securities*, May 14, 2014.
43. “INSY: Michigan Neurologist Investigation Poses Risks But Sales Contribution Appears Modest,” *Wells Fargo Securities*, May 12, 2014.
44. Insys Therapeutics Receives Subpoena From Office of Inspector General, *GlobeNewswire*, December 12, 2013, available at <https://www.globenewswire.com/news-release/2013/12/12/1155914/0/en/Insys-Therapeutics-Receives-Subpoena-From-Office-of-Inspector-General.html>, accessed June 12, 2021.
45. “Justice Department Recovers \$2 Billion for Fraud Against the Government in Fy 2007; More Than \$20 Billion Since 1986,” U.S. Department of Justice, November 1, 2007, available at https://www.justice.gov/archive/opa/pr/2007/November/07_civ_873.html, accessed June 3, 2021.
46. “Laquinimod Not Looking So Good,” *UBS*, August 1, 2011.
47. Lowrey, Brandon, “Kentucky AG Settles OxyContin, Risperdal Suits For \$39.5M,” *Law360*, December 23, 2015.

APPENDIX C
MATERIALS CONSIDERED

48. "Mallinckrodt PLC Downgraded To 'B+' From 'BB-', Outlook Stable," *S&P Global Ratings*, May 14, 2018, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2037591>.
49. "Mallinckrodt plc Downgraded To 'BB-' From 'BBB-', Off Watch On Acquisition Of Cadence; Outlook Stable; New Debt Rated," *S&P Global Ratings*, February 20, 2014, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1261933>.
50. "Mallinckrodt PLC Downgraded To 'CCC-', On CreditWatch Negative On Possible Restructuring," *S&P Global Ratings*, August 6, 2020, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2491948>.
51. "Mallinckrodt PLC Downgraded To 'CCC' On Increased Distressed Exchange Risk; Outlook Negative," *S&P Global Ratings*, September 11, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2297098>.
52. "Mallinckrodt plc Downgraded To 'CC' On Exchange Offers; Ratings Placed On CreditWatch Negative," *S&P Global Ratings*, November 5, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2333340>.
53. "Moody's downgrades Mallinckrodt's PDR to D-PD following Chapter 11 filing," *Moody's Investors Service*, October 12, 2020, available at https://www.moodys.com/research/Moodys-downgrades-Mallinckrodt's-PDR-to-D-PD-following-Chapter-11--PR_434415.
54. "Mallinckrodt PLC Rating Lowered To 'SD' On Distressed Exchange," *S&P Global Ratings*, December 6, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2354541>.
55. "Mallinckrodt PLC Downgraded To 'D' Following Announcement Of Voluntary Chapter 11 Proceedings," *S&P Global Ratings*, October 13, 2020, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2532935>.
56. "Mallinckrodt PLC Upgraded To 'CCC' Following Distressed Exchange; Outlook Negative," *S&P Global Ratings*, December 10, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2355982>.
57. Meier, Barry, "Chicago Said to Weigh Suit Over Marketing of Painkillers," *The New York Times*, November 15, 2013, available at <https://www.nytimes.com/2013/11/15/business/chicago-reviews-marketing-by-makers-of-narcotic-painkillers.html>, accessed June 14, 2021.
58. Meier, Barry, "Court Says OxyContin Patent Is Invalid," *The New York Times*, June 8, 2005, available at <https://www.nytimes.com/2005/06/08/business/court-says-oxycontin-patent-is-invalid.html>, accessed June 8, 2021.
59. Meier, Barry, "F.D.A. Bars Generic OxyContin," *The New York Times*, April 16, 2013, available at <https://www.nytimes.com/2013/04/17/business/fda-bars-generic-oxycontin.html>, accessed June 14, 2021.
60. "MNK: Is divestiture a prelude to a settlement?" *Barclays*, September 10, 2019.
61. "Moody's affirms Endo's ratings; Ba3 CFR; negative outlook," *Moody's Investors Service*, May 1, 2014, available at https://www.moodys.com/research/Moodys-affirms-Endo's-ratings-Ba3-CFR-negative-outlook--PR_298439.
62. "Moody's affirms Teva's Ba2 CFR; outlook revised to negative," *Moody's Investors Services*, August 14, 2019, available at https://www.moodys.com/research/Moodys-affirms-Teva's-Ba2-CFR-outlook-revised-to-negative--PR_406868, accessed June 2, 2021.
63. "Moody's confirms Mallinckrodt Ba3 CFR; outlook changed to negative," *Moody's Investors Services*, January 29, 2018, available at https://www.moodys.com/research/Moodys-confirms-Mallinckrodt-Ba3-CFR-outlook-changed-to-negative--PR_378601, accessed June 2, 2021.

APPENDIX C
MATERIALS CONSIDERED

64. "Moody's downgrades Endo's CFR to B2; assigns Ba2 to new secured debt," *Moody's Investors Service*, April 4, 2017, available https://www.moody's.com/research/Moodys-downgrades-Endos-CFR-to-B2-assigns-Ba2-to-new--PR_364464.
65. "Moody's downgrades Endo's CFR to B3; outlook revised to stable," *Moody's Investors Services*, July 1, 2019, available at https://www.moody's.com/research/Moodys-downgrades-Endos-CFR-to-B3-outlook-revised-to-stable--PR_404097, accessed June 2, 2021.
66. "Moody's Downgrades Endo's Ratings; CFR to B1; outlook negative," *Moody's Investors Service*, May 6, 2016, available at https://www.moody's.com/research/Moodys-Downgrades-Endos-Ratings-CFR-to-B1-outlook-negative--PR_348456.
67. "Moody's downgrades Mallinckrodt's CFR to B1; outlook negative," *Moody's Investors Services*, April 24, 2019, *Moody's Investors Service*, April 24, 2019, available at https://www.moody's.com/research/Moodys-downgrades-Mallinckrodts-CFR-to-B1-outlook-negative--PR_399335.
68. "Moody's downgrades Mallinckrodt's CFR to Ba3; stable outlook," *Moody's Investors Services*, February 20, 2014, available at https://www.moody's.com/research/Moodys-downgrades-Mallinckrodts-CFR-to-Ba3-stable-outlook--PR_292951.
69. "Moody's downgrades Mallinckrodt's CFR to Caa2; considers transaction a distressed exchange," *Moody's Investors Services*, December 9, 2019, available at https://www.moody's.com/research/Moodys-downgrades-Mallinckrodts-CFR-to-Caa2-considers-transaction-a-distressed--PR_414289.
70. "Moody's Downgrades Teva's Rating to Baa1; Ratings on Review for Downgrade," *Moody's Investors Services*, July 27, 2015, available at https://www.moody's.com/research/Moodys-Downgrades-Texas-Rating-to-Baa1-Ratings-on-Review-for--PR_331025, accessed June 2, 2021.
71. "Moody's Downgrades Teva's ratings to Baa2; Outlook Stable," *Moody's Investors Service*, August 2, 2016, available at https://www.moody's.com/research/Moodys-Downgrades-Texas-ratings-to-Baa2-Outlook-Stable--PR_352868.
72. "Moody's downgrades Teva's ratings to Baa3 from Baa2; outlook negative," *Moody's Investors Service*, August 3, 2017, available at https://www.moody's.com/research/Moodys-downgrades-Texas-ratings-to-Baa3-from-Baa2-outlook-negative--PR_370853.
73. "Moody's downgrades Teva to Ba2; outlook stable," *Moody's Investors Service*, January 12, 2018, available at https://www.moody's.com/research/Moodys-downgrades-Teva-to-Ba2-outlook-stable--PR_378074.
74. "Moody's revises Endo's outlook to negative from stable; affirms ratings," *Moody's Investors Services*, November 29, 2017, available at https://www.moody's.com/research/Moodys-revises-Endos-outlook-to-negative-from-stable-affirms-ratings--PR_376112, accessed June 2, 2021.
75. "More Than \$20 Billion Since 1986," U.S. Department of Justice, November 1, 2007, available at https://www.justice.gov/archive/opa/pr/2007/November/07_civ_873.html, accessed June 3, 2021.
76. "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations," U.S. Food and Drug Administration, available at <https://www.accessdata.fda.gov/scripts/cder/ob/>, accessed June 9, 2021.
77. "Our ECTRIMS Slide Deck Thoughts, Detailed Conf Planner and CONFIRM Expectations," *RBC Capital Markets*, October 12, 2011.
78. "OxyContin Abuse Deterrent Formulation (ADF)," FDA Briefing Document, Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC), FDA, September 10-11, 2020.
79. "Pain Survey Points to Strong Demand for Xartemis XR," *Jefferies*, May 12, 2014.

APPENDIX C
MATERIALS CONSIDERED

80. "Pharmaceutical & Medical Device Manufacturers: Recent Settlements and Investigations Related to Marketing, Pricing and Associated Activities, Public Settlements & Investigations," *Epstein Becker & Green*, October 16, 2009.
81. "Plunging off the patent cliff," *Healthcare Global*, May 17, 2020, available at <https://healthcareglobal.com/medical-devices-and-pharma/plunging-patent-cliff>, accessed June 8, 2021.
82. "Quick thoughts on Generic sale speculation," *Deutsche Bank*, May 30, 2017.
83. "Ratings Direct: Standard & Poor's Rating Definitions," *Standard & Poor's Rating Services*, available at <https://www.spratings.com/documents/20184/86966/Standard+%26+Poor%27s+Ratings+Definitions/fd2a2a96-be56-47b8-9ad2-390f3878d6c6>, accessed June 14, 2021.
84. "Rating Symbols and Definitions," *Moody's Investor Service*, January 26, 2021, available at https://www.moodys.com/sites/products/AboutMoodysRatingsAttachments/MoodysRatingSymbolsandDefinitions.pdf?source=content_type%3Areact%7Cfirst_level_url%3Aarticle%7Csection%3Amain_content%7Cbutton%3Abody_link, accessed June 14, 2021.
85. "Recent insider share purchases are encouraging; have we hit a valuation floor?" *Canaccord Genuity*, November 13, 2017.
86. Silverman, Ed, "J&J and Purdue Pharma settle with Kentucky for \$40M over marketing claims," *Stat*, December 23, 2015, available at <https://www.statnews.com/pharmalot/2015/12/23/20818/>, accessed June 9, 2021.
87. "Staying on the Sidelines for Now, But Pipeline Remains Potential Source of LT Upside," *Oppenheimer*, January 17, 2017.
88. Stempel, Jonathan, "Insys to pay \$225 million, Plead Guilty in U.S. Over Opioid Kickbacks," *Reuters*, June 5, 2019, available at <https://www.reuters.com/article/us-insys-opioids-settlement/insys-to-pay-225-million-plead-guilty-in-u-s-over-opioid-kickbacks-idUSKCN1T62QY>, accessed June 14, 2021.
89. "Subsys Continues to Face Challenges," *Oppenheimer*, April 11, 2016.
90. "Teva Pharmaceutical Industries Estimates, price target down again," *Barclays*, November 3, 2017.
91. "Teva Pharmaceutical Industries Ltd. 'BB' Rating Affirmed; Litigation Capacity Updated; Outlook Negative," *S&P Global Ratings*, September 23, 2019, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2304689>.
92. "Teva Pharmaceutical Industries Ltd. Downgraded To 'BB' On Continued Challenges To Business; Outlook Stable," *S&P Global Ratings*, February 8, 2018, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2009643>.
93. "Teva Pharmaceutical Industries Ltd. Downgraded To 'BBB-' From 'BBB' On Covenant Amendment; Outlook Stable," *S&P Global Ratings*, September 19, 2017, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1917630>.
94. "Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BB-' On Rising Litigation Risks; Outlook Stable," *S&P Global Ratings*, September 3, 2020, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/2508809>.
95. "Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BBB' From 'BBB+'; Outlook Stable," *S&P Global Ratings*, July 13, 2016, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1674013>.
96. "Teva Pharmaceutical Industries Ltd. Ratings Lowered To 'BBB+' From 'A-' And Kept On CreditWatch Negative," *S&P Global Rating*, July 28, 2015, available at <https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/1424827>.
97. "The Writing Is On The Wall For Insys; Reiterating Underweight," *Piper Jaffray*, May 12, 2019.
98. "Top Drug Patent Losses in 2017," *PBA Health*, January 13, 2017, available at https://www.pbahealth.com/portal_news/top-drug-patent-losses-in-2017/, accessed June 4, 2021.
99. United States Patent No. US RE41571-E, August 24, 2010.

APPENDIX C
MATERIALS CONSIDERED

100. “What Could Make ENDP Work,” *Deutsche Bank*, June 1, 2018.
101. “What is Butrans,” Butrans, available at <https://butrans.com/patient/what-is-butrans.html>, accessed June 4, 2021.
102. “What is the Debt to Equity Ratio,” Corporate Finance Institute, available at <https://corporatefinanceinstitute.com/resources/knowledge/finance/debt-to-equity-ratio-formula/>, accessed June 6, 2021.
103. Yang, Y. Tony, Brian Chen, and Charles L. Bennett, “FDA Approval of Extended Release OxyCodone for Children with Severe Pain,” *Pediatrics*, April 2016, available at <https://pediatrics.aappublications.org/content/early/2016/04/16/peds.2016-0205#:~:text=In%20a%20highly%20controversial%20decision,alternative%20treatment%20options%20are%20inadequate.%E2%80%9D>.

Other Produced Documents

1. Raymond-side Informational Presentation, November 22, 2019.
2. Defense Presentation Part 4: Fraudulent Transfer, *In re Purdue Pharma L.P. et al.*, April 27, 2021.

Appendix D

Discounted Cash Flow Method

Supplemental Information

Appendix D

Discounted Cash Flow Method: Supplemental Information

1. In my report, I provide an overview of the DCF Method I use to estimate the fair market value of Purdue's operating assets. In this appendix and in **Appendix E**, I provide additional discussion that describes how I implemented the DCF, the assumptions used in the analysis, and management projections that I relied upon.
2. The DCF models as of each date I value Purdue's operating assets during the 2008-16 Period are presented in **Exhibits D-1 to D-9**. These exhibits include detailed notes that provide the sources upon which I rely, and other information relevant to the calculations. The results of my sensitivity analysis pertaining to the DCF analyses are provided in **Exhibit 10**.
3. A separate set of exhibits (**Exhibits D-10 to D-17**) present the models used to estimate Purdue's operating assets under a stress test scenario for purposes of the capital adequacy test for all years during the 2008-16 Period.¹

A. Projections of Purdue's Performance

4. As discussed in **Section III.C**, I have utilized projections of financial performance that Purdue's management prepared in the ordinary course of business (*see Exhibit 5*). I also outlined the criteria I used to evaluate the available financial projections in order to identify those that would be most reliable for the purposes of the valuations in my report. Based on my review of the available management projections for the 2008-16 Period, I identified one set of projections that met all of these criteria for the years 2010, 2012, 2013, and 2015.² Although I was provided projections for the years 2008, 2009, 2011, 2014, and 2016, none of them met all of the same criteria as those prepared for years 2010, 2012, 2013, and 2015. However, I

¹ As discussed in the report, 2014 projections did not incorporate projections of future contributions from Purdue's pipeline products. As a result, I do not include a terminal value in my 2014 valuation of Purdue's operating assets. My baseline valuation for 2014 is therefore equivalent to this stress test scenario.

² I identified two projections in 2013 (May and June 2013) that met all criteria (*See* Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592; and Purdue 2013 10-Year Plan, June 2013, PPLPC034000795341). Although there were minor differences in some line items (such as forecasts of settlement expense and incentives), these differences would not have a material impact on my concluded value.

determined that these projections were reasonable to rely upon, with certain adjustments that I discuss below.³

1. 2008

5. For 2008, I utilize projections presented in a five-year plan dated April 18, 2008.^{4, 5} These projections are not risk-adjusted and they do not project expenses beyond 2013. They do however, project gross sales for some products through 2016, the first year of generic entry and competition with OxyContin. However, no forecasts modeling the expected impact of the full loss of exclusivity are provided in 2008. I am not able to infer the impact from prior year forecasts given that patent litigation had not yet been resolved in those years.⁶ Therefore, I make the following adjustments to the five-year plan dated April 18, 2008:

- I sum the projected product-level gross sales presented in the 2008 Projections to compute the company-level gross sales projections for 2016 or 2017.⁷

³ The notes for all DCF exhibits include additional details regarding the methodology and assumptions used for each individual year.

⁴ See Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 (“2008 Projections”).

⁵ The only other unique set of projections prepared in 2008 did not include a Cash Flow Statement and appears to be a draft rather than final document. See Purdue, 10-Year Plan, November 4, 2008, PPLPUCC002538272.

⁶ Starting in 1999, Purdue was involved in a series of patent infringement lawsuits against competitors such as Endo and Teva, who had filed for FDA approvals to sell generic controlled-release oxycodone products. In one such lawsuit involving Endo in 2004, the Federal District court in Manhattan ruled that the OxyContin patent was unenforceable, which led to Purdue losing exclusivity over OxyContin. See “Judge Says Maker Of OxyContin Misled Officials To Win Patents,” *The New York Times*, January 6, 2004. Further, in 2005, United States Court of Appeals for the Federal Circuit in Washington upheld this judgement. See “Court Says OxyContin Patent Is Invalid,” *The New York Times*, June 8, 2005. Subsequently, between 2006 and 2008, Purdue entered into settlements with many of its competitors, which affirmed the validity and enforceability of the OxyContin patents. Further, in January 2008, in a patent infringement litigation involving KV Pharmaceuticals, Actavis, and Apotex, the U.S. District Court for the Southern District of New York upheld the validity and enforceability of the OxyContin patents, finding that Purdue had not engaged in conduct that invalidated these patents. See Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the Years Ended December 31, 2008 and 2007, PPLPC012000221168-1206 at 1201, 1202.

⁷ See 2008 Projections, PPLPC063000023668-687 at 672, 675, 678, 680 and 683. The 2008 Projections document includes gross sales projections for OxyContin and Butrans only through 2016 and projections for OXN/Targin and Hydrocodone TR Q24h through 2017. Gross Sales for Purdue’s remaining drugs, which mainly comprise over-the-counter (OTC) products, were available only from 2008 through 2013. I assume that those sales will remain constant over the 2014 to 2017 period.

- I risk adjust the sales projections for Purdue's pipeline drugs, using management's July 2009 estimates of the probability of launch of each drug.⁸ The July 2009 probabilities are the closest estimates in time to April 2008.
- I was not able to risk adjust pipeline expense projections for the 2008 forecast. Therefore, I conservatively use the full amount of forecasted non-risk-adjusted expenses. Using non-risk-adjusted expenses will understate Purdue's value and cash flows since it effectively assumes that Purdue will incur the full amount of expected R&D and sales and promotion expenses on pipeline products, regardless of whether those products receive regulatory approval.
- I then extend projected net sales, gross profit, and operating profit projections beyond 2013 to 2014 and 2015. To do so, I assume that net sales as a percentage of gross sales, and gross profits and operating expenses as a percentage of net sales, will be the same as 2013.
- To forecast the impact of OxyContin's projected loss of exclusivity at the end of 2015 on sales and profits, I extend my estimate of 2015 net sales by two additional years to 2017 and estimate a gross margin that reflects the loss of exclusivity in 2016 and 2017. My estimates are based on the projected impact of OxyContin's loss of exclusivity in the two years after loss of exclusivity in management's 2010, 2012, and 2013 projections.⁹ Specifically:
 - Using the 2010, 2012, and 2013 projections, I first calculate the year-over-year change in OxyContin sales, net sales margins, total gross margins, and total operating expenses margins in the two years after the introduction of generic competition.
 - I then calculate the average year-over-year change across the 2010, 2012, and 2013 projections to estimate an adjustment factor that captures the expected financial impact of the introduction of generic competition. I

⁸ See Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 028. The probability of launch is also referred to as the "probability of regulatory and technical success" or PTRS in other projections.

⁹ See Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453; Purdue 2012 10-Year Plan, February 15, 2012, PPLPC053000063393-668; Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592.

separately estimate the impact of generic competition on performance metrics in the first and second years after the introduction of generic competition.

- Finally, I apply these estimates of the impact of generic competition to the 2015 forecasted financials. For example, to estimate 2016 OxyContin sales, I multiply 2015 OxyContin sales by the adjustment factor for the first year of generic competition.¹⁰ To estimate 2017 OxyContin sales, I apply the adjustment factor for the second year after introduction of generic competition to the projected 2016 OxyContin sales.
- While this adjustment utilizes information from future years to arrive at an estimate for both sales and margins, the general relationship between loss of exclusivity and a pharmaceutical company's financial performance is well established.¹¹ Using information across multiple years of projections is conservative, as Purdue's management became more pessimistic over time about the impact that OxyContin's loss of exclusivity would have on OxyContin sales.¹²

2. 2009

6. None of the available projections prepared in 2009 include projections of risk-adjusted expenses and only one incorporates a Cash Flow Statement.¹³ I therefore utilize information

¹⁰ I compute projected 2016 and 2017 net sales margins, gross margins, and operating margins in the same way.

¹¹ See DeRuiter, Jack, and Pamela L. Holston, "Drug Patent Expirations and the 'Patent Cliff'," *U.S. Pharmacist*, June 20, 2012; Doughman, Elizabeth, "Impending Patent Cliff Threatens Billions of Global Prescription Drug Sales," *Pharmaceutical Processing World*, June 6, 2019; "Plunging off the Patent Cliff," *Healthcare Global*, May 17, 2020.

¹² For example, Purdue's management projected that OxyContin sales would fall 80.4% between 2017 and 2019 in the firm's 2010 projections, compared to the 93.9% decline projected for the same period in the 2012 projections. In the 2013 projections, Purdue's management projected that OxyContin sales would fall 97.2% between 2020 and 2022, when OxyContin was expected to lose exclusivity at the end of 2020. See Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453 at 358; Purdue 2012 10-Year Plan, February 15, 2012, PPLPC053000063393-668 at 506; Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 574.

¹³ I evaluated a set of projections from September 2009 (Purdue 10-Year Plan, Supplemental Information, September 21, 2009, PPLPC051000080436-469 at 451 and 453). While these projections are notionally risk-adjusted, the projections use a probability of launch of 100% for several early stage drugs, which is inconsistent with both other management projections and the risks of the drug development process more generally.

from two sets of projections for my DCF analysis: 1) Purdue's 10-Year Plan prepared as of July 15, 2009,¹⁴ which includes 10-year projections of Purdue's Income Statement and management's estimates of the probability of launch for Purdue's pipeline; and 2) a non-risk-adjusted Cash Flow Statement from projections dated December 31, 2009.¹⁵ In addition, both projections only extend one year beyond OxyContin's expected loss of exclusivity. As in the prior year, I conservatively utilize non-risk adjusted expenses in my DCF analysis. In order to model the impact of OxyContin's expected loss of exclusivity, I extend management's projections one additional year using the same method described above.

7. Given the conservative inclusion of non-risk adjusted expenses, projected cash flows from operations in the final year of the forecast are negative. I therefore do not include a terminal value in my estimate of the value of Purdue's operating assets in 2009. This result does not imply that Purdue does not have value after 2019 or that Purdue has inadequate cash flow (*See Section VI* where I discuss my cash flow test). Rather, the result is reflective of the conservative nature of my assumptions, which underestimates the value of Purdue's pipeline products.¹⁶

3. 2011

8. The only set of projections prepared in 2011 that are not "drafts" are from the Purdue U.S. 10-Year Plan dated June 21, 2011.¹⁷ The projected financial statements in the 2011 Projections provide risk-adjusted projections of gross sales, but not expenses.¹⁸ Similar to other years that do not provide risk-adjusted expenses, I conservatively use the full amounts of the forecasted non-risk-adjusted expenses. As in 2009, the final year cash flows are negative, and I therefore do not calculate a terminal value, thus underestimating the value of Purdue's operations.

¹⁴ See Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 027.

¹⁵ See Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at Schedule 8, Cash Flow Statement. While it would be preferable to only utilize information from a single projection date, that was not possible in 2009. I therefore rely on the July 2009 projections for net profit and pipeline drugs' launch probabilities and the December 2009 projections for non-cash adjustments to EBIT in the DCF model.

¹⁶ The comparison of my baseline valuation to the capital adequacy test of balance sheet solvency for 2009 reflects the understatement of the implied value of pipeline drugs. (*See Exhibit 28*).

¹⁷ See Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 ("2011 Projections"). This is identical to the non-native file PPLPC063000000740-853.

¹⁸ See 2011 Projections, RSF00033012 at p. 98.

4. 2014

9. I utilize management's forecasts from Purdue's "2014 10-Year Forecast and Trend" dated May 2014.¹⁹ I observe that none of the forecasts prepared in 2014 that were provided to me include projected sales for pipeline products, which appears to reflect management's increasing pessimism about the prospects for the company's pipeline. In the May 2014 projection, management noted that "[p]rofitable growth will require significant investment in new products, acquisitions, and more,"²⁰ and, in the following month, that, "Purdue is executing an aggressive diversification and growth strategy, which includes transforming from internally driven R&D toward increased licensing and M&A."²¹ Therefore, for the 2014 valuation of Purdue's operating assets, I only value the existing products and attribute no value to Purdue's pipeline. I also do not ascribe additional value from the existing products beyond the loss of exclusivity.²²

5. 2016

10. For my 2016 valuation of Purdue's operating assets, I utilize Purdue's "Mid-Year Update" dated June 8, 2016.²³ While these projections include ten years of risk-adjusted net sales, they do not include projections of expenses beyond five years. I therefore project Purdue's expenses from 2021 to 2025, to cover the period when OxyContin was projected to lose exclusivity.

- In order to project operating expense for 2021 to 2025, I utilize the Finance Update dated June 9, 2015 that provides projections through 2025.²⁴ I apply the 2015 projected year-over-year percentage change in gross margin and operating expenses to estimate gross margins and operating expenses for the same years as of 2016. For Ex-U.S. / Other expenses and the Ex-U.S. non-cash adjustment to EBIT, I apply

¹⁹ See 2014 10-Year Forecast and Trend, May 2014, PPLPUCC002545437-543 ("2014 Projections"). The projections in this file appear to be identical to the other documents containing projections that are either undated or dated May 2014.

²⁰ See Purdue - Finance Update: Funds Available for Growth, May 2014, PPLPC018000972178 at p. 2.

²¹ See Purdue U.S. Business and Financial Plans, June 26, 2014, PPLPC054000118010-065 at 011.

²² Because my valuation of Purdue's operating assets does not cover any pipeline products, nor does it include a terminal value, I do not conduct a separate capital adequacy test of balance sheet solvency for 2014. My baseline valuation is equivalent to the stress test scenario.

²³ See Purdue Mid-year update, June 8, 2016, RSF00017771-921.

²⁴ See Purdue Finance Update, June 9, 2015, PPLPC054000123288 ("2015 Projections") at p. 52.

forecasted 2015 margins as a percentage of Net Sales to the forecasted Net Sales in the 2016 DCF model.²⁵

²⁵ I take this approach because the small magnitude of these figures in the 2015 projections leads to extraordinarily large year-over-year percentage changes and nonsensical line-item projections for the 2016 DCF model.

Exhibit D-1
2008 Discounted Cash Flow Valuation of Purdue's Operating Assets^[1]

Notes:

- [1] Purdue management projections relied upon for the 2008 valuation of Purdue's operating assets are from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687. These projections contain non-risk adjusted Income Statement, Balance Sheet and Cash Flow Statement forecasts for the six-year period from 2008 through 2013, and do not incorporate OxyContin's loss of exclusivity ("LOE"). However, Purdue management provides projections as of 2008 that include the impact of OxyContin's LOE, only at the Gross Sales level.
- [2] As of Date matches the date of the Purdue management projections used, April 18, 2008. Cash flows shown for 2008 are full-year estimates. The present value of the 2008 cash flows is multiplied by a factor of 0.70, representing the fraction of the year remaining from April 18, 2008, to December 31, 2008.
- [3] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2008.
- [4] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [5] Long-Term Growth Rate assumed to be zero percent based upon flat to slightly negative growth for existing products and positive growth for pipeline products.
- [6] Gross Sales is the summation of Purdue's Pipeline and Existing Gross Sales, and includes the Gross Sales of OxyContin, Butrans, Targin, Hydrocodone TR, POA, and Other products. Of these drugs, Butrans, Targin, Hydrocodone TR, and POA are a part of Purdue's pipeline. Gross Sales for all products for 2008 through 2017 are from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 672, 675, 678, 680 and 683. As specified in Note [1], these Gross Sales values are non-risk adjusted. Risk adjustment to Gross Sales is made by multiplying success probabilities for pipeline drugs from the July 2009 projections (See **10-Year Plan, July 15, 2009, PPLPC019000293027-65 at 28**) to their corresponding 2008 Gross Sales projections. In order to better capture the impact of OxyContin's patent cliff in 2015, the Gross Sales of OxyContin and Butrans, which are through 2016 in Purdue management's forecasts, are extended by an additional year. Specifically, Gross Sales of OxyContin and Butrans are multiplied by the average year-over-year change in Gross Sales for these drugs between the first and the second year following OxyContin's LOE per the 2010, 2012 and 2013 projections. Similarly, the Gross Sales of Other Products are also extended from 2014 through 2017 and are assumed to equal Gross Sales in 2013.
- [7] Net Sales for 2008 through 2013 are from Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 685, accounting for the risk adjustments described in Note [6]. For the years 2014 and 2015 (the years prior to OxyContin's LOE), Net Sales Margin ([7] Net Sales / [6] Gross Sales) is assumed to be equal to that in the year 2013; this margin is then multiplied by Gross Sales to compute Net Sales. For the year 2016, the Net Sales Margin from 2015 is multiplied by the average year-over-year change in Net Sales Margin between the year of LOE and the first year after LOE, per the 2010, 2012, and 2013 projections. For the year 2017, the Net Sales Margin from 2016 is multiplied by the average year-over-year change in Net Sales Margin between the first and second years after LOE, per the 2010, 2012, and 2013 projections. In 2016 and 2017, the estimated Net Sales Margin values are multiplied by Gross Sales to calculate Net Sales.
- [8] Gross Profit for 2008 through 2013 is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 685, accounting for the risk adjustments described in Note [6]. For the years 2014 and 2015 (the years prior to OxyContin's LOE), Gross Margin ([8] Gross Profit / [7] Net Sales) is assumed to be equal to the Gross Margin from 2013; this margin is then multiplied by Net Sales to compute Gross Profit. For the year 2016, the Gross Margin from 2015 is multiplied by the average year-over-year change in Gross Margin between the year of LOE and the first year after LOE, per the 2010, 2012, and 2013 projections. For the year 2017, the Gross Margin from 2016 is multiplied by the average year-over-year change in Gross Margin between the first and second years after LOE, per the 2010, 2012, and 2013 projections. In 2016 and 2017, the estimated Gross Margin values are multiplied by Net Sales to calculate Gross Profit.
- [9] Gross Margins for 2008 through 2013 are calculated as [8] Gross Profit divided by [7] Net Sales. Thereafter, Gross Margins are projected as described in Note [8].
- [10] General and Administrative expenses for 2008 through 2013 are from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 685.
- [11] Research and Development expenses for 2008 through 2013 are from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 685.
- [12] Sales and Promotion expenses for 2008 through 2013 are from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 685.
- [13] Other - U.S. expenses for 2008 through 2013 are from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 685.

Exhibit D-1
2008 Discounted Cash Flow Valuation of Purdue's Operating Assets^[1]

- [14] Incentives and Settlements expenses for 2008 through 2013 are from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 685.
- [15] Legal expenses for 2008 through 2013 are from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 685.
- [16] Ex-U.S. / Other expenses for 2008 through 2013 are from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 685.
- [17] Operating Expenses for 2008 through 2013 are calculated as the sum of items [10] through [16]. For the years 2014-2015 (the years prior to OxyContin's LOE), Operating Expenses Margin ([17] Operating Expenses / [7] Net Sales) is assumed to be equal to that in the year 2013; this margin is then multiplied by Net Sales to compute Operating Expenses. For the year 2016, the Operating Expenses Margin from 2015 is multiplied by the average year-over-year change in Operating Expenses Margin between the year of LOE and the first year after LOE, per the 2010, 2012, and 2013 projections. For the year 2017, the Operating Expenses Margin from 2016 is multiplied by the average year-over-year change in Operating Expenses Margin between the first and second years after LOE, per the 2010, 2012, and 2013 projections. In 2016 and 2017, the estimated Operating Expenses Margin values are multiplied by Net Sales to calculate Operating Expenses.
- [18] Operating Expenses Margin for 2008 through 2013 is calculated as [17] Operating Expenses divided by [7] Net Sales. Thereafter, it is projected as described in Note [17].
- [19] EBIT is calculated as [8] Gross Profit less [17] Operating Expenses.
- [20] Taxes are calculated as [19] EBIT multiplied by [4] Tax Rate.
- [21] Depreciation and Amortization for 2008 through 2013 is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 through 2017, Depreciation and Amortization is kept constant, and equal to the average of the 2012 and 2013 values.
- [22] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. For 2008 through 2013, is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 through 2017, the Ex-U.S. adjustment is kept constant, and equal to the average of the 2012 and 2013 values.
- [23] Increase in Working Capital for 2008 through 2013 is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 and 2015, Increase in Working Capital is kept constant, and equal to the average of the 2012 and 2013 values. Thereafter, the average margin from 2010, 2012 and 2013 projections (Increase in Working Capital / Net Sales) one year after the LOE is multiplied with the Increase in Working Capital forecast for the year 2015 to compute the 2016 forecast. Similarly, the average margin from 2010, 2012 and 2013 projections (Increase in Working Capital / Net Sales) two years after the LOE is multiplied with the Increase in Working Capital forecast for the year 2016 to compute the 2017 forecast.
- [24] Capital Expenditures for 2008 through 2013 is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 through 2017, Capital Expenditures are kept constant, and equal to the average of the 2012 and 2013 values.
- [25] Extraordinary Item Payout for 2008 through 2013 is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 through 2017, Extraordinary Item Payout is kept constant, and equal to the average of the 2012 and 2013 values.
- [26] Decrease in Long-Term Liabilities for 2008 through 2013 is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 through 2017, Decrease in Long-Term Liabilities is kept constant, and equal to the average of the 2012 and 2013 values.
- [27] Cash Flows calculated as [19] EBIT plus [21] Depreciation & Amortization and [22] Ex-U.S., less [20] Taxes, [23] Increase in Working Capital, [24] Capital Expenditures, [25] Extraordinary Item Payout, and [26] Decrease in Long-Term Liabilities.
- [28] Terminal Value in Year 10 is calculated as [27] Cash Flow in Year 10 multiplied by $(1 + [4] \text{ Long-Term Growth Rate})$, divided by $([3] \text{ Discount Rate} - [5] \text{ Long-Term Growth Rate})$.
- [29] Discount Factor is equal to 1 divided by the following expression: $(1 + [3] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [2] As of Date. For 2008, the partial year cash flow is discounted from the halfway point between the [2] As of Date and December 31, 2008. For all other years, the cash flow is discounted from June 30 of the projection year.
- [30] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2008, due to the mid-year [2] As of Date. The 2008 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.

Exhibit D-1
2008 Discounted Cash Flow Valuation of Purdue's Operating Assets^[1]

- [31] Present Value of Cash Flows is calculated as [27] Cash Flows multiplied by [29] Discount Factor and [30] Partial Year Factor.
[32] Present Value of Terminal Value is calculated as [28] Terminal Value multiplied by [29] Discount Factor.
[33] Valuation is equal to the sum of all [31] Present Value of Cash Flows (years 1-10) and [32] Present Value of Terminal Value, as of April 18, 2008.

Sources:

- [A] Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668.
[B] Ten-Year Plan, July 15, 2009, PPLPC019000293027-65.
[C] 10-Year Plan, June 24, 2010, PPLP004404330-453.
[D] 10 Year Plan, February 15, 2012, PPLPC053000063393-668.
[E] 10-Year Plan, May 3, 2013, PPLPC063000003469-592.

2009 Discounted Cash Flow Valuation of Purdue's Operating Assets^[1]

[illegible]

Exhibit D-2

2009 Discounted Cash Flow Valuation of Purdue's Operating Assets^[1]

Notes:

- [1] Purdue management projections relied upon for the 2009 valuation of Purdue's operating assets are from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 and the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662. The first set of projections contains a non-risk-adjusted Income Statement for the ten-year period 2009 through 2018, one year after OxyContin loss of exclusivity ("LOE"), as well as risk-adjusted Gross Sales projections for the same time period. The second set of projections contains a non-risk-adjusted Cash Flow Statement for the same time period, the only projected Cash Flow Statement available for 2009. The 2009 valuation of Purdue's operating assets does not include a terminal value because [26] Cash Flow in the last year of the projection period is negative.
- [2] As of Date matches the date of the Purdue management projections used, July 15, 2009. Cash flows shown for 2009 are full-year estimates. The present value of the 2009 cash flows is multiplied by a factor of 0.46, representing the fraction of the year remaining from July 15, 2009, to December 31, 2009.
- [3] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2009.
- [4] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [5] Gross Sales - Risk-Adjusted is the summation of Purdue's Pipeline and Existing Gross Sales, and includes Gross Sales of OxyContin, Butrans, Targin, HTR, HYD, POA, TRPV1, and Other products. Of these drugs, Butrans, Targin, HTR, HYD, POA, and TRPV1 are a part of Purdue's pipeline. Gross Sales for all products from 2009 through 2018 are from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 028. In order to better capture the impact of OxyContin's patent cliff in 2015, the Gross Sales of all products are extended by an additional year. Specifically, 2018 Gross Sales of OxyContin is multiplied by the average year-over-year change in Gross Sales for OxyContin between the first and the second year following OxyContin's LOE per the 2010, 2012 and 2013 projections. Similarly, the Gross Sales of all other products are extended an additional year and are assumed to equal Gross Sales in 2018.
- [6] Net Sales for 2009 through 2018 are from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 027, accounting for the risk adjustments of [5] Gross Sales. For 2019, Net Sales are calculated as the Net Sales Margin ([6] Net Sales divided by [5] Gross Sales) from 2018 multiplied by the average year-over-year change in Net Sales Margin between the first and second years after LOE, per the 2010, 2012, and 2013 projections, and then multiplied by [5] Gross Sales in 2019.
- [7] Gross Profit for 2009 through 2018 is non-risk-adjusted and is from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 027, accounting for the risk adjustments of [5] Gross Sales. For the year 2019, the Gross Margin ([7] Gross Profit divided by [6] Net Sales) from 2018 is multiplied by the average year-over-year change in Gross Margin between the first and second years after LOE, per the 2010, 2012, and 2013 projections, and then multiplied by [6] Net Sales in 2019.
- [8] Gross Margins for 2009 through 2018 are calculated as [7] Gross Profit divided by [6] Net Sales. For 2019, Gross Margin is projected as described in Note [7].
- [9] General and Administrative expenses for 2009 through 2018 are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 027.
- [10] Research and Development expenses for 2009 through 2018 are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 027.
- [11] Sales and Promotion expenses for 2009 through 2018 are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 027.
- [12] Other - U.S. expenses for 2009 through 2018 are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 027.
- [13] Incentives and Settlements expenses for 2009 through 2018 are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 027.
- [14] Legal expenses for 2009 through 2018 are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 027.
- [15] Ex-U.S. / Other expenses for 2009 through 2018 are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 027.
- [16] Operating Expenses for 2009 through 2018 are calculated as the sum of items [9] through [15]. For the year 2019, the Operating Expense Margin ([16] Operating Expenses divided by [6] Net Sales) from 2018 is multiplied by the average year-over-year change in Operating Expense Margin between the first and second years after LOE, per the 2010, 2012, and 2013 projections, and then multiplied by [6] Net Sales.
- [17] Operating Expense / Net Sales (%) for 2009 through 2018 is calculated as [16] Operating Expenses divided by [6] Net Sales. For 2019, this Operating Expense Margin is projected as described in Note [16].
- [18] EBIT is calculated as [7] Gross Profit less [16] Operating Expenses.

Exhibit D-2

2009 Discounted Cash Flow Valuation of Purdue's Operating Assets^[1]

- [19] Taxes are calculated as [18] EBIT multiplied by [4] Tax Rate.
- [20] Depreciation and Amortization for 2009 through 2018 are non-risk-adjusted and are from the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. For 2019, it is assumed equal to its value in 2018.
- [21] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. For 2009 through 2018 it is non-risk-adjusted and is from the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. For 2019, it is assumed equal to its value in 2018.
- [22] Increase in Working Capital for 2009 through 2018 is non-risk-adjusted and is from the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. The Increase in Working Capital for 2018 is due to a decline in accrued rebates following Purdue's loss of exclusivity for OxyContin in 2017. For 2019, it is assumed equal to its value in 2018.
- [23] Capital Expenditures for 2009 through 2018 are non-risk-adjusted and are from the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. For 2019, it is assumed equal to its value in 2018.
- [24] Decrease in Long-Term Liabilities represents the change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liabilities. For 2009 through 2018 it is non-risk-adjusted and from Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. For 2019, it is assumed equal to its value in 2018.
- [25] Other Items include Deferred Tax Movement, (Profit) / Loss on Disposal of Fixed Assets, Infinity Common Stock Premium, Infinity Line of Credit, and Other Non-Cash Items. For 2009 through 2018 they are non-risk-adjusted and are from the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. For 2019, it is assumed equal to its value in 2018.
- [26] Cash Flows calculated as [18] EBIT plus [20] Depreciation & Amortization, [21] Ex-U.S., and [25] Other Items, less [19] Taxes, [22] Increase in Working Capital, [23] Capital Expenditures, and [24] Decrease in Long-Term Liabilities.
- [27] Discount Factor is equal to 1 divided by the following expression: $(1 + [3] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [2] As of Date. For 2009, the partial year cash flow is discounted from the halfway point between the [2] As of Date and December 31, 2009. For all other years, the cash flow is discounted from June 30 of the projection year.
- [28] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2009, due to the mid-year [2] As of Date. The 2009 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [29] Present Value of Cash Flows is calculated as [26] Cash Flows multiplied by [27] Discount Factor and [28] Partial Year Factor.
- [30] Valuation is equal to the sum of all [29] Present Value of Cash Flows (years 1-11). No terminal value is included because [26] Cash Flow in the last year of the projection period is negative.

Sources:

- [A] Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065.
- [B] Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662.
- [C] Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453.
- [D] Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668.
- [E] Purdue 2013 10-Year Plan, May 3, 2013, PPLPC063000003469-592.

Exhibit D-3
2010 Discounted Cash Flow Valuation of Purdue's Operating Assets

Notes:

- [1] As of Date matches the date of the Purdue management projections used, June 24, 2010. Management projections are provided for the ten-year period 2010 through 2019. Cash flows shown for 2010 are full-year estimates. The present value of the 2010 cash flows is multiplied by a factor of 0.52, representing the fraction of the year remaining from June 24, 2010 to December 31, 2010.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2010.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Long-Term Growth Rate assumed to be zero percent based upon flat to slightly negative growth for existing products and positive growth for pipeline products.
- [5] Net Sales correspond to Net Sales for Purdue's Existing and Pipeline Products, and are from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 380.
- [6] Gross Profit is from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 380.
- [7] Gross Margins are calculated as [6] Gross Profit divided by [5] Net Sales.
- [8] General and Administrative expenses are from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 380.
- [9] Research and Development expenses are from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 380.
- [10] Sales and Promotion expenses are from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 380.
- [11] Other - U.S. expenses are from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 380.
- [12] Incentives and Settlements expenses are from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 380.
- [13] Ex-U.S. / Other expenses are from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 380.
- [14] Redacted Expenses represent the expenses which were redacted in the income statement and are calculated as the difference between Operating Expenses line item as stated in the Income Statement and the summation of the individual components making up the Operating Expenses. See Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 380.
- [15] Operating Expenses are calculated as the sum of items [8] through [14].
- [16] Calculated as [15] Operating Expenses divided by [5] Net Sales.
- [17] EBIT is calculated as [6] Gross Profit less [15] Operating Expenses.
- [18] Taxes are calculated as [17] EBIT multiplied by [3] Tax Rate.
- [19] Depreciation and Amortization is from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384.
- [20] Extraordinary Item Payout is from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384.
- [21] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. It is from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384.
- [22] Increase in Working Capital is from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384. The Increase in Working Capital for 2018 is due to a decline in accrued rebates following Purdue's loss of exclusivity for OxyContin in 2017.
- [23] Decrease in Long-Term Liabilities represents change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liabilities. It is from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384.
- [24] Capital Expenditures are from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384.

Exhibit D-3

2010 Discounted Cash Flow Valuation of Purdue's Operating Assets

- [25] Cash Flows calculated as [17] EBIT plus [19] Depreciation & Amortization, [20] Extraordinary Item Payout, and [21] Ex-U.S., less [18] Taxes, [22] Increase in Working Capital, [23] Decrease in Long-Term Liabilities, and [24] Capital Expenditures.
- [26] Terminal Value in Year 10 is calculated as [25] Cash Flow in Year 10 multiplied by $(1 + [4] \text{ Long-Term Growth Rate})$, divided by $([2] \text{ Discount Rate} - [4] \text{ Long-Term Growth Rate})$.
- [27] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [1] As of Date. For 2010, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2010. For all other years, the cash flow is discounted from June 30 of the projection year.
- [28] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2010, due to the mid-year [1] As of Date. The 2010 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [29] Present Value of Cash Flows is calculated as [25] Cash Flows multiplied by [27] Discount Factor and [28] Partial Year Factor.
- [30] Present Value of Terminal Value is calculated as [26] Terminal Value multiplied by [27] Discount Factor.
- [31] Valuation is equal to the sum of all [29] Present Value of Cash Flows (years 1-10) and [30] Present Value of Terminal Value.

Source:

[A] Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453.

Exhibit D-4
2011 Discounted Cash Flow Valuation of Purdue's Operating Assets

[1]	<div>As of Date: June 21, 2011 Discount Rate: 11.26% Tax Rate: 35.0%</div>										
[2]											
[3]		Financial Projections									
	(\$ millions)	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
[4]	Gross Sales - Risk-Adjusted	3,072	3,234	3,441	3,646	4,439	5,133	5,269	3,447	3,680	1,517
[5]	Net Sales	2,418	2,506	2,685	2,830	3,393	3,804	3,798	2,877	2,860	1,214
[6]	Gross Profit	2,105	2,184	2,313	2,405	2,851	3,195	3,134	2,262	2,141	597
[7]	Gross Margin	87%	87%	86%	85%	84%	84%	83%	79%	75%	49%
[8]	General and Administrative	(151)	(158)	(165)	(172)	(180)	(187)	(195)	(204)	(213)	(178)
[9]	Research and Development	(291)	(357)	(265)	(283)	(351)	(408)	(453)	(354)	(402)	(253)
[10]	Sales and Promotion	(312)	(420)	(482)	(558)	(602)	(646)	(706)	(710)	(808)	(636)
[11]	Other - U.S.	(31)	(17)	(18)	(20)	(21)	(26)	(39)	(43)	(24)	(26)
[12]	Incentives and Settlements	(35)	(38)	(39)	(41)	(44)	(46)	(48)	(50)	(52)	(54)
[13]	Legal	(66)	(64)	(56)	(57)	(65)	(67)	(70)	(75)	(78)	(70)
[14]	Ex-U.S. / Other	(60)	(41)	(97)	(65)	(39)	(30)	(20)	(9)	2	13
[15]	Operating Expenses	(947)	(1,095)	(1,123)	(1,196)	(1,302)	(1,410)	(1,530)	(1,445)	(1,575)	(1,204)
[16]	Operating Expenses/Net Sales (%)	-39%	-44%	-42%	-42%	-38%	-37%	-40%	-50%	-55%	-99%
[17]	EBIT	1,159	1,088	1,191	1,209	1,549	1,785	1,604	817	566	(607)
[18]	- Taxes	(406)	(381)	(417)	(423)	(542)	(625)	(561)	(286)	(198)	-
[19]	+ Depreciation and Amortization	30	32	34	37	38	40	41	40	39	39
[20]	+ Ex-U.S.	124	120	135	98	73	58	43	28	13	(2)
[21]	- Increase in Working Capital	(77)	23	(11)	25	19	24	14	(111)	29	(24)
[22]	- Capital Expenditures	(36)	(40)	(40)	(40)	(40)	(40)	(40)	(40)	(40)	(40)
[23]	- Deferred Income Taxes	(1)	-	-	-	-	-	-	-	-	-
[24]	- Decrease in Long-Term Liabilities	-	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[25]	Cash Flows	793	841	892	905	1,096	1,241	1,099	447	408	(636)
[26]	Discount Factor	97%	90%	81%	72%	65%	58%	53%	47%	42%	38%
[27]	Partial Year Factor	0.53	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
[28]	Present Value of Cash Flows	407	754	719	655	713	726	578	211	173	(243)
[29]	Valuation (\$ millions)	4,693									

Exhibit D-4
2011 Discounted Cash Flow Valuation of Purdue's Operating Assets

Notes:

- [1] As of Date matches the date of the Purdue management projections used, June 21, 2011. Cash flows shown for 2011 are full-year estimates. The present value of the 2011 cash flows is multiplied by a factor of 0.53, representing the fraction of the year remaining from June 21, 2011, to December 31, 2011. Detailed projections for the ten-year period 2011 through 2020 are only provided on a non-risk-adjusted basis. In addition, risk-adjusted Gross Sales projections are provided for 2011 through 2020.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2011.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Gross Sales - Risk-Adjusted correspond to Gross Sales for Purdue's Existing and Pipeline Products on a risk-adjusted basis, and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 98.
- [5] Net Sales are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 107, accounting for the risk adjustments of [4] Gross Sales.
- [6] Gross Profit is non-risk-adjusted and is from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 107, accounting for the risk adjustments of [4] Gross Sales.
- [7] Gross Margins are calculated as [6] Gross Profit divided by [5] Net Sales.
- [8] General and Administrative expenses are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 107.
- [9] Research and Development expenses are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 107.
- [10] Sales and Promotion expenses are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 107.
- [11] Other - U.S. expenses are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 107 and include Pharmacy Fee.
- [12] Incentives and Settlements expenses are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 107.
- [13] Legal expenses are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 107.
- [14] Ex-U.S. / Other expenses are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 107.
- [15] Operating Expenses are calculated as the sum of items [8] through [14].
- [16] Calculated as [15] Operating Expenses divided by [5] Net Sales.
- [17] EBIT is calculated as [6] Gross Profit less [15] Operating Expenses.
- [18] Taxes are calculated as [17] EBIT multiplied by [3] Tax Rate.
- [19] Depreciation and Amortization are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111.
- [20] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. It is non-risk-adjusted and is from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111.
- [21] Increase in Working Capital is non-risk-adjusted and is from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111. The Increase in Working Capital for 2018 is due to a decline in accrued rebates following Purdue's loss of exclusivity for OxyContin in 2017.
- [22] Capital Expenditures are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111.
- [23] Deferred Income Taxes are non-risk-adjusted and are from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111.

Exhibit D-4
2011 Discounted Cash Flow Valuation of Purdue's Operating Assets

- [24] Decrease in Long-Term Liabilities represents change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liabilities. It is non-risk-adjusted and is from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111.
- [25] Cash Flows are calculated as [17] EBIT plus [19] Depreciation & Amortization and [20] Ex-U.S., less [18] Taxes, [21] Increase in Working Capital, [22] Capital Expenditures, [23] Deferred Income Taxes, and [24] Decrease in Long-Term Liabilities.
- [26] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [1] As of Date. For 2011, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2011. For all other years, the cash flow is discounted from June 30 of the projection year.
- [27] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2011, due to the mid-year [1] As of Date. The 2011 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [28] Present Value of Cash Flows is calculated as [25] Cash Flows multiplied by [26] Discount Factor and [27] Partial Year Factor.
- [29] Valuation is equal to the sum of all [28] Present Value of Cash Flows (years 1-10). No terminal value is included because [25] Cash Flow in the last year of the projection period is negative.

Source:

[A] Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012.

Exhibit D-5
2012 Discounted Cash Flow Valuation of Purdue's Operating Assets

[1]	<div>As of Date: February 15, 2012 Discount Rate: 10.09% Tax Rate: 35.0% Long-Term Growth Rate: 0.0%</div>									
[2]										
[3]										
[4]										
			Financial Projections							
	(\$ millions)	2012	2013	2014	2015	2016	2017	2018	2019	2020
[5]	Net Sales	2,353	2,282	2,176	2,533	2,905	2,888	2,150	2,127	1,042
[6]	Gross Profit	2,051	1,970	1,839	2,135	2,403	2,398	1,738	1,697	791
[7]	Gross Margin	87%	86%	85%	84%	83%	83%	81%	80%	76%
[8]	General and Administrative	(167)	(169)	(174)	(177)	(180)	(178)	(132)	(123)	(57)
[9]	Research and Development	(341)	(347)	(322)	(326)	(340)	(348)	(229)	(229)	(103)
[10]	Sales and Promotion	(359)	(381)	(418)	(486)	(487)	(480)	(478)	(477)	(213)
[11]	Other - U.S.	(37)	(33)	(34)	(32)	(36)	(51)	(52)	(23)	(18)
[12]	Incentives and Settlements	(39)	(42)	(43)	(46)	(47)	(47)	(43)	(41)	(14)
[13]	Legal	(63)	(56)	(58)	(59)	(60)	(59)	(55)	(51)	(23)
[14]	Ex-U.S. / Other	(154)	(131)	(91)	(37)	(16)	(16)	(16)	(14)	(14)
[15]	Operating Expenses	(1,161)	(1,158)	(1,140)	(1,163)	(1,166)	(1,180)	(1,005)	(959)	(441)
[16]	Operating Expenses/Net Sales (%)	-49%	-51%	-52%	-46%	-40%	-41%	-47%	-45%	-42%
[17]	EBIT	890	813	699	972	1,238	1,218	733	737	350
[18]	- Taxes	(312)	(284)	(245)	(340)	(433)	(426)	(256)	(258)	(122)
[19]	+ Depreciation and Amortization	34	35	45	46	46	46	45	43	42
[20]	+ Deferred Income Taxes	(1)	-	-	-	-	-	-	-	-
[21]	+ Ex-U.S.	229	166	123	70	48	43	38	23	18
[22]	- Increase in Working Capital	(60)	78	5	25	30	0	(208)	48	(78)
[23]	- Decrease in Long-Term Liabilities	-	(1)	(1)	(1)	-	(1)	(1)	(1)	(1)
[24]	- Capital Expenditures	(36)	(90)	(46)	(40)	(40)	(40)	(40)	(40)	(40)
[25]	Cash Flows	745	715	579	731	890	840	309	552	168
[26]	Terminal Value									1,667
[27]	Discount Factor	96%	88%	80%	72%	66%	60%	54%	49%	45%
[28]	Partial Year Factor	0.88	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
[29]	Present Value of Cash Flows	627	627	461	529	584	501	168	272	75
[30]	Present Value of Terminal Value									745
[31]	Valuation (\$ millions)	4,590								

Exhibit D-5

2012 Discounted Cash Flow Valuation of Purdue's Operating Assets

Notes:

- [1] As of Date for DCF valuation matches the date of the management projections used, February 15, 2012. Cash flows shown for 2012 are full-year estimates. The present value of the 2012 cash flows is multiplied by a factor of 0.88, representing the fraction of the year remaining from February 15, 2012 to December 31,
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for corresponding value for 2012.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Long-Term Growth Rate assumed to be zero percent based upon flat to slightly negative growth for existing products and positive growth for pipeline products.
- [5] Net Sales for 2012 through 2020 are from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664.
- [6] Gross Profit for 2012 through 2020 is from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664.
- [7] Gross Margins are calculated as [6] Gross Profit divided by [5] Net Sales.
- [8] General and Administrative expenses are from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664.
- [9] Research and Development expenses are from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664.
- [10] Sales and Promotion expenses are from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664.
- [11] Other - U.S. expenses are from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664 and include Pharmacy Fee (Health Reform).
- [12] Incentives and Settlements expenses are from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664.
- [13] Legal expenses are from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664.
- [14] Ex-U.S. / Other expenses are from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 664.
- [15] Operating Expenses calculated as the sum of items [8] through [14].
- [16] Calculated as [15] Operating Expenses divided by [5] Net Sales.
- [17] EBIT is calculated as [6] Gross Profit less [15] Operating Expenses.
- [18] Taxes are calculated as [17] EBIT multiplied by [3] Tax Rate.
- [19] Depreciation and Amortization is from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [20] Deferred Income Taxes are from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [21] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. It is from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [22] Increase in Working Capital is from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [23] Decrease in Long-Term Liabilities represents change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liability. It is from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [24] Capital Expenditures are from the Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [25] Cash Flows calculated as [17] EBIT plus [19] Depreciation & Amortization, [20] Deferred Income Taxes and [21] Ex-U.S., less [18] Taxes, [22] Increase in Working Capital, [23] Decrease in Long-Term Liabilities and [24] Capital Expenditures.
- [26] Terminal Value in Year 9 is calculated as [25] Cash Flow in Year 9 multiplied by $(1 + [4] \text{ Long-Term Growth Rate})$, divided by $([2] \text{ Discount Rate} - [4] \text{ Long-Term Growth Rate})$.

Exhibit D-5

2012 Discounted Cash Flow Valuation of Purdue's Operating Assets

- [27] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [1] As of Date. For 2012, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2012. For all other years, the cash flow is discounted from June 30 of the projection year.
- [28] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2012, due to the mid-year [1] As of Date. The 2012 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [29] Present Value of Cash Flows is calculated as [25] Cash Flows multiplied by [27] Discount Factor and [28] Partial Year Factor.
- [30] Present Value of Terminal Value is calculated as [26] Terminal Value multiplied by [27] Discount Factor.
- [31] Valuation is equal to the sum of all [29] Present Value of Cash Flows (years 1-10) and [30] Present Value of Terminal Value, as of February 15, 2012.

Source:

[A] Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668.

Exhibit D-6
2013 Discounted Cash Flow Valuation of Purdue's Operating Assets

Notes:

- [1] As of Date matches the date of the Purdue management projections used, May 3, 2013. Management projections are provided for the ten-year period 2013 through 2022. Cash flows shown for 2013 are full-year estimates. The present value of the 2013 cash flows is multiplied by a factor of 0.66, representing the fraction of the year remaining from May 3, 2013, to December 31, 2013.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2013.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Long-Term Growth Rate assumed to be zero percent based upon flat to slightly negative growth for existing products and positive growth for pipeline products.
- [5] Net Sales correspond to Net Sales for Purdue's Existing and Pipeline Products, and are from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526.
- [6] Gross Profit is from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526.
- [7] Gross Margins are calculated as [6] Gross Profit divided by [5] Net Sales.
- [8] General and Administrative expenses are from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526.
- [9] Research and Development expenses are from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526.
- [10] Sales and Promotion expenses are from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526.
- [11] Other - U.S. expenses are from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526 and include Pharmacy Fee (Health Reform).
- [12] Incentives and Settlements expenses are from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526.
- [13] Legal expenses are from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526.
- [14] Ex-U.S. / Other expenses are from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526.
- [15] Operating Expenses are calculated as the sum of items [8] through [14].
- [16] Calculated as [15] Operating Expenses divided by [5] Net Sales.
- [17] EBIT is calculated as [6] Gross Profit less [15] Operating Expenses.
- [18] Taxes are calculated as [17] EBIT multiplied by [3] Tax Rate.
- [19] Depreciation and Amortization is from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528.
- [20] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. It is from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528.
- [21] Extraordinary Item Payout represents reduction in (distribution from) Infinity stock. It is from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528.
- [22] Increase in Working Capital is from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528. The Increase in Working Capital for 2021 is due to a decline in accrued rebates following Purdue's loss of exclusivity for OxyContin in 2020.
- [23] Capital Expenditures are from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528.
- [24] Decrease in Long-Term Liabilities represents the change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liabilities. It is from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528.
- [25] Cash Flows calculated as [17] EBIT plus [19] Depreciation & Amortization, [20] Ex-U.S., and [21] Extraordinary Item Payout, less [18] Taxes, [22] Increase in Working Capital, [23] Capital Expenditures, and [24] Decrease in Long-Term Liabilities.

Exhibit D-6

2013 Discounted Cash Flow Valuation of Purdue's Operating Assets

- [26] Terminal Value in Year 10 is calculated as [25] Cash Flow in Year 10 multiplied by $(1 + [4] \text{ Long-Term Growth Rate})$, divided by $([2] \text{ Discount Rate} - [4] \text{ Long-Term Growth Rate})$.
- [27] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [1] As of Date. For 2013, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2013. For all other years, the cash flow is discounted from June 30 of the projection year.
- [28] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2013, due to the mid-year [1] As of Date. The 2013 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [29] Present Value of Cash Flows is calculated as [25] Cash Flows multiplied by [27] Discount Factor and [28] Partial Year Factor.
- [30] Present Value of Terminal Value is calculated as [26] Terminal Value multiplied by [27] Discount Factor.
- [31] Valuation is equal to the sum of all [29] Present Value of Cash Flows (years 1-10) and [30] Present Value of Terminal Value as of May 3, 2013.

Source:

- [A] Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592.

Exhibit D-7
2014 Discounted Cash Flow Valuation of Purdue's Operating Assets

[1]	As of Date: May 2, 2014											
[2]	Discount Rate: 12.04%											
[3]	Tax Rate: 35.0%											
[4]	Long-Term Growth Rate: 0.0%											
		Financial Projections										
	(\$ millions)	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	
[5]	Net Sales - Existing Products	1,524	1,129	1,060	1,041	1,062	1,074	1,107	600	289	184	
[6]	Gross Profit - Existing Products	1,323	956	915	901	930	943	975	523	218	141	
[7]	Gross Margin - Existing Products	87%	85%	86%	87%	88%	88%	88%	87%	75%	77%	
[8]	General and Administrative	(132)	(110)	(107)	(104)	(102)	(100)	(99)	(80)	(50)	(40)	
[9]	Research and Development	(216)	(149)	(76)	(55)	(50)	(50)	(40)	(28)	(23)	(23)	
[10]	Sales and Promotion	(240)	(238)	(236)	(236)	(235)	(236)	(237)	(127)	(29)	(9)	
[11]	Other - U.S.	(52)	(31)	(29)	(26)	(25)	(19)	(19)	(20)	(10)	(8)	
[12]	Incentives and Settlements	(34)	(22)	(21)	(20)	(21)	(21)	(22)	(12)	(6)	(4)	
[13]	Legal	(45)	(43)	(43)	(42)	(42)	(42)	(43)	(22)	(22)	(22)	
[14]	Ex-U.S. / Other	(215)	(208)	(149)	(87)	(62)	(39)	(65)	(21)	(1)	(3)	
[15]	Operating Expenses - Existing Products	(934)	(800)	(659)	(571)	(537)	(507)	(525)	(309)	(140)	(109)	
[16]	Operating Expenses/Net Sales (%)	-61%	-71%	-62%	-55%	-51%	-47%	-47%	-51%	-49%	-59%	
[17]	EBIT	389	157	256	330	393	435	450	215	77	32	
[18]	- Taxes	(136)	(55)	(90)	(115)	(138)	(152)	(158)	(75)	(27)	(11)	
[19]	+ Depreciation and Amortization	33	32	33	32	27	27	26	26	25	23	
[20]	+ Ex-U.S.	190	192	144	82	58	29	26	24	21	19	
[21]	- Increase in Working Capital	(340)	22	25	3	(0)	11	(8)	(189)	(22)	(36)	
[22]	- Decrease in Long-Term Liabilities	-	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)	
[23]	- Capital Expenditures	(61)	(28)	(21)	(21)	(21)	(21)	(22)	(12)	(6)	(4)	
[24]	Cash Flows	75	320	345	309	318	327	314	(13)	68	22	
[25]	Discount Factor	96%	88%	78%	70%	62%	56%	50%	44%	40%	35%	
[26]	Partial Year Factor	0.66	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
[27]	Present Value of Cash Flows	48	280	270	215	198	182	156	(6)	27	8	
[28]	Valuation (\$ millions)	1,377										

Exhibit D-7
2014 Discounted Cash Flow Valuation of Purdue's Operating Assets

Notes:

- [1] As of Date matches the date of the Purdue management projections used, May 2, 2014. Management projections are provided for the ten-year period 2014 through 2023 and include Purdue's Existing Products only, and no Pipeline Products. As a result, the 2014 valuation of Purdue's operating assets does not include a terminal value. Cash flows shown for 2014 are full-year estimates. The present value of the 2014 cash flows is multiplied by a factor of 0.66, representing the fraction of the year remaining from 5/2/2014 to 12/31/2014.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2014.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Long-Term Growth Rate assumed to be zero percent.
- [5] Net Sales of Existing Products are from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 440.
- [6] Gross Profit of Existing Products is from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 440.
- [7] Gross Margins are calculated as [6] Gross Profit divided by [5] Net Sales.
- [8] General and Administrative expenses of Existing Products are from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 440.
- [9] Research and Development expenses of Existing Products are from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 440.
- [10] Sales and Promotion expenses of Existing Products are from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 440.
- [11] Other - U.S. expenses of Existing Products are from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 440 and include Health Care
- [12] Incentives and Settlements expenses of Existing Products are from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 440.
- [13] Legal expenses of Existing Products are from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 440.
- [14] Ex-U.S. / Other expenses of Existing Products are from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 440. This item includes ex-U.S. expenses and other one-time charges.
- [15] Operating Expenses - Existing Products are calculated as the sum of items [8] through [14].
- [16] Calculated as [15] Operating Expenses divided by [5] Net Sales.
- [17] EBIT is calculated as [6] Gross Profit - Existing Products less [15] Operating Expenses - Existing Products.
- [18] Taxes are calculated as [17] EBIT multiplied by [3] Tax Rate.
- [19] Depreciation and Amortization is from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 541.
- [20] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. It is from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 541.
- [21] Increase in Working Capital is from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 541.
- [22] Decrease in Long-Term Liabilities represents the change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liabilities. It is from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 541.
- [23] Capital Expenditures are from the 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543 at 541.
- [24] Cash Flows are calculated as [17] EBIT plus [19] Depreciation & Amortization and [20] Ex-U.S., less [18] Taxes, [21] Increase in Working Capital, [22] Decrease in Long-Term Liabilities and [23] Capital Expenditures.
- [25] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [1] As of Date. For 2014, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2014. For all other years, the cash flow is discounted from June 30 of the projection year.

Exhibit D-7

2014 Discounted Cash Flow Valuation of Purdue's Operating Assets

- [26] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2014, due to the mid-year [1] As of Date. The 2014 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [27] Present Value of Cash Flows is calculated as [24] Cash Flows multiplied by [25] Discount Factor and [26] Partial Year Factor.
- [28] Valuation is equal to the sum of all [27] Present Value of Cash Flows (years 1-10), as of May 2, 2014.

Source:

- [A] 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543.

Exhibit D-8
2015 Discounted Cash Flow Valuation of Purdue's Operating Assets

[illegible]

Exhibit D-8
2015 Discounted Cash Flow Valuation of Purdue's Operating Assets

Notes:

- [1] As of Date matches the date of the Purdue's management projections used, June 9, 2015. Cash flows shown for 2015 are full-year estimates. The present value of the 2015 cash flows is multiplied by a factor of 0.56, representing the fraction of the year remaining from June 9, 2015, to December 31, 2015.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2015.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Long-Term Growth Rate assumed to be zero percent based upon flat to slightly negative growth for existing products and positive growth for pipeline products.
- [5] Net Sales for 2015 through 2025 are from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [6] Gross Profit for 2015 through 2025 are from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [7] Gross Margins are calculated as [6] Gross Profit divided by [5] Net Sales.
- [8] General and Administrative expenses for 2015 through 2025 are from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [9] Research and Development expenses for 2015 through 2025 are from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [10] Sales and Promotion expenses for 2015 through 2025 are from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [11] Other - U.S. expenses for 2015 through 2025 are from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [12] Incentives and Settlements expenses for 2015 through 2025 are from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [13] Legal expenses for 2015 through 2025 are from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [14] Ex-U.S. / Other expenses for 2015 through 2025 are from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 52.
- [15] Operating Expenses are calculated as the sum of items [8] through [14].
- [16] Calculated as [15] Operating Expenses divided by [5] Net Sales.
- [17] EBIT is calculated as [6] Gross Profit less [15] Operating Expenses.
- [18] Taxes are calculated as [17] EBIT multiplied by [3] Tax Rate.
- [19] Depreciation and Amortization for 2015 through 2025 is from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56.
- [20] Ex-U.S. represents non-cash loss (gain) in foreign equity investments. For 2015 through 2025, it is from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56.
- [21] Deferred Income Taxes for 2015 through 2025 is from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56.
- [22] Increase in Working Capital for 2015 through 2025 is from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56. Large increase in 2023 due to decline in accrued rebates (current liability) following OxyContin, Butrans, and Hysingla's loss of exclusivity in 2022.
- [23] Decrease in Long-Term Liabilities represents change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liability. It is from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56.
- [24] Capital Expenditures for 2015 through 2025 are from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56.
- [25] Cash Flows calculated as [17] EBIT plus [19] Depreciation & Amortization, [20] Ex-U.S., and [21] Deferred Income Taxes, less [18] Taxes, [22] Increase in Working Capital, [23] Decrease in Long-Term Liabilities and [24] Capital Expenditures.
- [26] Terminal Value in Year 11 is calculated as [25] Cash Flow in Year 11 multiplied by $(1 + [4] \text{ Long-Term Growth Rate})$, divided by $([2] \text{ Discount Rate} - [4] \text{ Long-Term Growth Rate})$.
- [27] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [1] As of Date. For 2015, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2015. For all other years, the cash flow is discounted from June 30 of the projection year.
- [28] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2015, due to the mid-year [1] As of Date. The 2015 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [29] Present Value of Cash Flows is calculated as [25] Cash Flows multiplied by [27] Discount Factor and [28] Partial Year Factor.
- [30] Present Value of Terminal Value is calculated as [26] Terminal Value multiplied by [27] Discount Factor.
- [31] Valuation is equal to the sum of all [29] Present Value of Cash Flows (years 1-11) and [30] Present Value of Terminal Value, as of June 9, 2015.

Exhibit D-8
2015 Discounted Cash Flow Valuation of Purdue's Operating Assets

Source:

[A] Finance Update, June 9, 2015, PPLPC054000123288.

Exhibit D-9

2016 Discounted Cash Flow Valuation of Purdue's Operating Assets

Notes:

- [1] As of Date matches the date of the Purdue management projections used, June 8, 2016. Management projections are provided for the ten-year period 2016 through 2025. Cash flows shown for 2016 are full-year estimates. The present value of the 2016 cash flows is multiplied by a factor of 0.56, representing the fraction of the year remaining from June 8, 2016 to December 31, 2016. Detailed risk-adjusted projections are provided for the five-year period 2016 through 2020, but only risk-adjusted Net Sales projections are provided for the ten-year period 2016 through 2025.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for corresponding value in 2016.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Long-Term Growth Rate assumed to be zero percent based upon flat to slightly negative growth for existing products and positive growth for pipeline products.
- [5] Net Sales correspond to Net Sales for Purdue's Existing and Pipeline Products, and are from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 892 and 910.
- [6] Gross Profits for 2016 through 2020 are from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 903. Gross Profits for 2021 through 2025 are calculated as [5] Net Sales multiplied by [7] Gross Margin (see note [7] below).
- [7] Gross Margins for 2016 through 2020 are calculated as [6] Gross Profit divided by [5] Net Sales. Gross Margins for 2021 through 2025 are estimated by applying the year-over-year percentage change in Gross Margin from the 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 52) to the previous year's Gross Margin provided in the 2016 DCF Model.
- [8] General and Administrative ("G&A") expenses for 2016 through 2020 are from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 903. G&A expenses for 2021 through 2025 are estimated by applying the year-over-year percentage change in G&A expenses from the 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 52) to the previous year's G&A expenses provided in the 2016 DCF Model.
- [9] Research and Development (R&D) expenses for 2016 through 2020 are from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 903. R&D expenses for 2021 through 2025 are estimated by applying the year-over-year percentage change in R&D expenses from the 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 52) to the previous year's R&D expense provided in the 2016 DCF Model.
- [10] Sales and Promotion expenses for 2016 through 2020 are from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 903. Sales and Promotion expenses for 2021 through 2025 are estimated by applying the year-over-year percentage change in Sales and Promotion expenses from the 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 52) to the previous year's Sales and Promotion expense provided in the 2016 DCF Model.
- [11] Other - U.S. expenses for 2016 through 2020 are from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 903. Other - U.S. expenses for 2021 through 2025 are estimated by applying the year-over-year percentage change in Other - U.S. expenses from the 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 52) to the previous year's Other - U.S. expense provided in the 2016 DCF Model.

Exhibit D-9

2016 Discounted Cash Flow Valuation of Purdue's Operating Assets

- [12] Incentives and Settlements expenses for 2016 through 2020 are from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 903. Incentives and Settlements expenses for 2021 through 2025 are estimated by applying the year-over-year percentage change in Incentives and Settlements expenses from the 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 52) to the previous year's Incentives and Settlements expense provided in the 2016 DCF Model.
- [13] Legal expenses for 2016 through 2020 are from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 903. Legal expenses for 2021 through 2025 are estimated by applying the year-over-year percentage change in Legal Expenses from the 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 52) to the previous year's Legal expense provided in the 2016 DCF Model.
- [14] Ex-U.S. / Other expenses for 2016 through 2020 are from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 903. Ex-U.S. / Other expenses for 2021 through 2025 are calculated using the margin (as a percentage of Net Sales) from 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 52).
- [15] Operating Expenses calculated as the sum of items [8] through [14].
- [16] Calculated as [15] Operating Expenses divided by [5] Net Sales.
- [17] EBIT is calculated as [6] Gross Profit less [15] Operating Expenses.
- [18] Taxes are calculated as [17] EBIT multiplied by [3] Tax Rate.
- [19] Depreciation and Amortization ("D&A") for 2016 through 2020 is from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 907. D&A for 2021 through 2025 is estimated by applying the year-over-year percentage change in D&A from 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 56) to the previous year's D&A provided in the 2016 DCF Model.
- [20] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. For 2016 through 2020, it is from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 907. Ex-U.S. for 2021 through 2025 is calculated using the margin (as a percentage of Net Sales) from 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 52 and 56).
- [21] Increase in Working Capital for 2016 through 2020 is from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 907. Increase in Working Capital for 2021 through 2025 is estimated by applying the year-over-year percentage change in Increase in Working Capital from 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 56) to the previous year's Increase in Working Capital provided in the 2016 DCF Model. The Increase in Working Capital for 2023 is due to a decline in accrued rebates following PPLP's loss of exclusivity for OxyContin, Butrans, and Hysingla in 2022.
- [22] Capital Expenditures for 2016 through 2020 are from Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 907. Capital Expenditures for 2021 through 2025 are estimated by applying the year-over-year percentage change in Capital Expenditures from 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 56) to the previous year's Capital Expenditures provided in the 2016 DCF Model.
- [23] Decrease in Long-Term Liabilities represents change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liability. For 2016 through 2020 it is from Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 907. For 2021 through 2025 it is estimated by applying the year-over-year percentage change in Long-Term Assets and Liabilities from 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 56) to the previous year's value provided in the 2016 DCF Model.

Exhibit D-9

2016 Discounted Cash Flow Valuation of Purdue's Operating Assets

- [24] Cash Flows calculated as [17] EBIT plus [19] Depreciation & Amortization and [20] Ex-U.S., less [18] Taxes, [21] Increase in Working Capital, [22] Capital Expenditures, and [23] Decrease in Long-Term Liabilities.
- [25] Terminal Value in Year 10 is calculated as [24] Cash Flow in Year 10 multiplied by $(1 + [4] \text{ Long-Term Growth Rate})$, divided by $([2] \text{ Discount Rate} - [4] \text{ Long-Term Growth Rate})$.
- [26] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [1] As of Date. For 2016, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2016. For all other years, the cash flow is discounted from June 30 of the projection year.
- [27] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2016, due to the mid-year [1] As of Date. The 2016 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [28] Present Value of Cash Flows is calculated as [24] Cash Flows multiplied by [26] Discount Factor and [27] Partial Year Factor.
- [29] Present Value of Terminal Value is calculated as [25] Terminal Value multiplied by [26] Discount Factor.
- [30] Valuation is equal to the sum of all [28] Present Value of Cash Flows (years 1-10) and [29] Present Value of Terminal Value, as of June 8, 2016.

Sources:

- [A] Purdue Mid-Year Update, June 8, 2016, RSF00017771-921.
- [B] Purdue Finance Update, June 9, 2015, PPLPC054000123288.

Exhibit D-10
2008 Cash Flows for Capital Adequacy Test^[1]

[2]	<div> <div>As of Date: April 18, 2008</div> <div>Discount Rate: 11.71%</div> <div>Tax Rate: 35.0%</div> </div>										
[3]											
[4]		Stress Test Financial Projections									
	(\$ millions)	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
[5]	Gross Sales (Existing and Pipeline Products)	2,672	3,559	3,713	3,892	4,169	4,579	5,018	5,231	3,166	2,823
[6]	Gross Sales (Existing Products)	2,672	3,559	3,611	3,542	3,450	3,472	3,529	3,531	1,269	852
[7]	<i>EBIT Stress (%) = [6]/[5]</i>	<i>100%</i>	<i>100%</i>	<i>97%</i>	<i>91%</i>	<i>83%</i>	<i>76%</i>	<i>70%</i>	<i>68%</i>	<i>40%</i>	<i>30%</i>
[8]	EBIT (from the DCF Model)	1,386	1,938	1,915	1,954	1,984	2,145	2,351	2,451	1,684	1,146
[9]	EBIT (Capital Adequacy) = [8]*[7]	1,386	1,938	1,862	1,778	1,641	1,627	1,653	1,654	675	346
[10]	- Taxes	(485)	(678)	(652)	(622)	(574)	(569)	(579)	(579)	(236)	(121)
[11]	+ Depreciation and Amortization	30	35	35	36	39	40	39	39	39	39
[12]	+ Ex-U.S.	91	68	43	7	(34)	(43)	(38)	(38)	(38)	(38)
[13]	- Increase in Working Capital	(61)	(9)	13	(8)	2	(10)	(4)	(4)	(493)	(38)
[14]	- Capital Expenditures	(46)	(40)	(40)	(40)	(40)	(40)	(40)	(40)	(40)	(40)
[15]	- Extraordinary Item Payout	(35)	-	-	-	-	-	-	-	-	-
[16]	- Decrease in Long-Term Liabilities	(12)	(1)	-	-	-	-	-	-	-	-
[17]	Cash Flows	868	1,313	1,261	1,150	1,034	1,005	1,032	1,033	(93)	148
[18]	Discount Factor	96%	88%	78%	70%	63%	56%	50%	45%	40%	36%
[19]	Partial Year Factor	0.70	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
[20]	Present Value of Cash Flows	587	1,150	989	807	649	565	519	465	(38)	53
[21]	Valuation (\$ millions)	5,748									

Exhibit D-10
2008 Cash Flows for Capital Adequacy Test^[1]

Notes:

- [1] Purdue management projections relied upon for the 2008 valuation of Purdue's operating assets are from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687. These projections contain non-risk adjusted Income Statement, Balance Sheet and Cash Flow Statement forecasts for the six-year period from 2008 through 2013, and do not incorporate OxyContin's loss of exclusivity ("LOE"). However, Purdue management provides projections as of 2008 that include the impact of OxyContin's LOE, only at the Gross Sales level.
- [2] As of Date matches the date of the Purdue management projections used, April 18, 2008. Cash flows shown for 2008 are full-year estimates. The present value of the 2008 cash flows is multiplied by a factor of 0.70, representing the fraction of the year remaining from April 18, 2008, to December 31, 2008.
- [3] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2008.
- [4] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [5] Gross Sales (Existing and Pipeline Products) is taken from the DCF model and represents the Gross Sales corresponding to all of Purdue's products.
- [6] Gross Sales (Existing Products) represents the Gross Sales of Existing Products and is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 672 and 683.
- [7] EBIT Stress (%) represents the fraction equal to the [6] Gross Sales (Existing Products) / [5] Gross Sales (Existing and Pipeline Products).
- [8] EBIT (from the DCF Model) refers to the EBIT as calculated in the 2008 DCF Model.
- [9] EBIT (Capital Adequacy) is a stressed version of [8] EBIT (from the DCF Model), in order to simulate a downside scenario. Specifically, EBIT for each year is scaled down by a factor equal to [7] EBIT Stress (%).
- [10] Taxes are calculated as [9] EBIT (Capital Adequacy) multiplied by [4] Tax Rate.
- [11] Depreciation and Amortization for 2008 through 2013 is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 through 2017, Depreciation and Amortization is kept constant, and equal to the average of the 2012 and 2013 values.
- [12] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. For 2008 through 2013, is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 through 2017, the Ex-U.S. adjustment is kept constant, and equal to the average of the 2012 and 2013 values.
- [13] Increase in Working Capital for 2008 through 2013 is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 and 2015, Increase in Working Capital is kept constant, and equal to the average of the 2012 and 2013 values. Thereafter, the average margins from 2010, 2012 and 2013 projections (Increase in Working Capital / Net Sales) one year and two years after the LOE are used to compute the Increase in Working Capital for 2016 and 2017, respectively.
- [14] Capital Expenditures for 2008 through 2013 is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 through 2017, Capital Expenditures are kept constant, and equal to the average of the 2012 and 2013 values.
- [15] Extraordinary Item Payout for 2008 through 2013 is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 through 2017, Extraordinary Item Payout is kept constant, and equal to the average of the 2012 and 2013 values.
- [16] Decrease in Long-Term Liabilities for 2008 through 2013 is from the Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668-687 at 687. For the years 2014 through 2017, Decrease in Long-Term Liabilities is kept constant, and equal to the average of the 2012 and 2013 values.
- [17] Cash Flows calculated as [9] EBIT (Capital Adequacy) plus [11] Depreciation & Amortization and [12] Ex-U.S., less [10] Taxes, [13] Increase in Working Capital, [14] Capital Expenditures, [15] Extraordinary Item Payout, and [16] Decrease in Long-Term Liabilities.
- [18] Discount Factor is equal to 1 divided by the following expression: $(1 + [3] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [2] As of Date. For 2008, the partial year cash flow is discounted from the halfway point between the [2] As of Date and December 31, 2008. For all other years, the cash flow is discounted from June 30 of the projection year.
- [19] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2008, due to the mid-year [2] As of Date. The 2008 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [20] Present Value of Cash Flows is calculated as [17] Cash Flows multiplied by [18] Discount Factor and [19] Partial Year Factor.
- [21] Valuation is equal to the sum of all [20] Present Value of Cash Flows, as of April 18, 2008.

Exhibit D-10
2008 Cash Flows for Capital Adequacy Test^[1]

Sources:

- [A] Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668.
- [B] Ten-Year Plan, July 15, 2009, PPLPC019000293027-65.
- [C] 10-Year Plan, June 24, 2010, PPLP004404330-453.
- [D] 10 Year Plan, February 15, 2012, PPLPC053000063393-668.
- [E] 10-Year Plan, May 3, 2013, PPLPC063000003469-592.

Exhibit D-11
2009 Cash Flows for Capital Adequacy Test^[1]

[2]	As of Date: July 15, 2009											
[3]		Discount Rate: 10.36%										
[4]		Tax Rate: 35.0%										
		Stress Test Financial Projections										
	(\$ millions)	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
[5]	Gross Sales (Existing and Pipeline Products)	2,883	3,248	3,748	3,635	3,409	3,453	3,692	4,278	4,668	3,178	3,001
[6]	Gross Sales (Existing Products)	2,883	3,200	3,582	3,341	3,066	2,826	2,559	2,508	2,454	604	427
[7]	EBIT Stress (%) = [6]/[5]	100%	99%	96%	92%	90%	82%	69%	59%	53%	19%	14%
[8]	EBIT (from the DCF Model)	1,182	1,678	1,570	1,370	1,181	1,142	1,260	1,318	1,088	(114)	(203)
[9]	EBIT (Capital Adequacy) = [8]*[7]	1,182	1,653	1,500	1,259	1,062	934	873	773	572	(22)	(29)
[10]	- Taxes	(414)	(579)	(525)	(441)	(372)	(327)	(306)	(270)	(200)	-	-
[11]	+ Depreciation and Amortization	30	36	38	39	39	36	36	36	36	33	33
[12]	+ Ex-U.S.	79	99	216	208	157	118	85	75	38	20	20
[13]	- Increase in Working Capital	(17)	78	32	16	5	(8)	(14)	0	4	(27)	(27)
[14]	- Capital Expenditures	(30)	(37)	(43)	(40)	(35)	(30)	(30)	(30)	(30)	(30)	(30)
[15]	- Decrease in Long-Term Liabilities	(41)	-	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[16]	+ Other Items	8	(2)	-	-	-	-	-	-	-	-	-
[17]	Cash Flows	797	1,249	1,217	1,041	855	722	644	583	418	(27)	(34)
[18]	Discount Factor	98%	91%	82%	75%	68%	61%	56%	50%	46%	41%	37%
[19]	Partial Year Factor	0.46	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
[20]	Present Value of Cash Flows	359	1,136	1,003	777	578	443	358	293	191	(11)	(13)
[21]	Valuation (\$ millions)	5,115										

Exhibit D-11
2009 Cash Flows for Capital Adequacy Test^[1]

Notes:

- [1] Purdue management projections relied upon for the 2009 valuation of Purdue's operating assets are from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 and the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662. The first set of projections contains a non-risk-adjusted Income Statement for the ten-year period 2009 through 2018, one year after OxyContin loss of exclusivity ("LOE"), as well as risk-adjusted Gross Sales projections for the same time period. The second set of projections contains a non-risk-adjusted Cash Flow Statement for the same time period, the only projected Cash Flow Statement available for 2009. The 2009 valuation of Purdue's operating assets does not include a terminal value because [26] Cash Flow in the last year of the projection period is negative.
- [2] As of Date matches the date of the Purdue management projections used, July 15, 2009. Cash flows shown for 2009 are full-year estimates. The present value of the 2009 cash flows is multiplied by a factor of 0.46, representing the fraction of the year remaining from July 15, 2009, to December 31, 2009.
- [3] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2009.
- [4] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [5] Gross Sales (Existing and Pipeline Products) is taken from the DCF model and represents the Gross Sales corresponding to all of Purdue's products.
- [6] Gross Sales (Existing Products) represents the Gross Sales of Existing Products and is from the Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065 at 28.
- [7] EBIT Stress (%) represents the fraction equal to the [6] Gross Sales (Existing Products) / [5] Gross Sales (Existing and Pipeline Products).
- [8] EBIT (from the DCF Model) refers to the EBIT as calculated in the 2009 DCF Model.
- [9] EBIT (Capital Adequacy) is a stressed version of [8] EBIT (from the DCF Model), in order to simulate a downside scenario. Specifically, EBIT for each year is scaled down by a factor equal to [7] EBIT Stress (%).
- [10] Taxes are calculated as [9] EBIT (Capital Adequacy) multiplied by [4] Tax Rate.
- [11] Depreciation and Amortization for 2009 through 2018 are non-risk-adjusted and are from the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. For 2019, it is assumed equal to its value in 2018.
- [12] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. For 2009 through 2018 it is non-risk-adjusted and is from the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. For 2019, it is assumed equal to its value in 2018.
- [13] Increase in Working Capital for 2009 through 2018 is non-risk-adjusted and is from the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. The Increase in Working Capital for 2018 is due to a decline in accrued rebates following Purdue's loss of exclusivity for OxyContin in 2017. For 2019, it is assumed equal to its value in 2018.
- [14] Capital Expenditures for 2009 through 2018 are non-risk-adjusted and are from the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. For 2019, it is assumed equal to its value in 2018.
- [15] Decrease in Long-Term Liabilities represents the change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liabilities. For 2009 through 2018 it is non-risk-adjusted and from Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. For 2019, it is assumed equal to its value in 2018.
- [16] Other Items include Deferred Tax Movement, (Profit) / Loss on Disposal of Fixed Assets, Infinity Common Stock Premium, Infinity Line of Credit, and Other Non-Cash Items. For 2009 through 2018 they are non-risk-adjusted and are from the Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662 at 8-CashFlow. For 2019, it is assumed equal to its value in 2018.
- [17] Cash Flows calculated as [9] EBIT (Capital Adequacy) plus [11] Depreciation & Amortization, [12] Ex-U.S., and [16] Other Items, less [10] Taxes, [13] Increase in Working Capital, [14] Capital Expenditures, and [15] Decrease in Long-Term Liabilities.
- [18] Discount Factor is equal to 1 divided by the following expression: $(1 + [3] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [2] As of Date. For 2009, the partial year cash flow is discounted from the halfway point between the [2] As of Date and December 31, 2009. For all other years, the cash flow is discounted from June 30 of the projection year.

Exhibit D-11
2009 Cash Flows for Capital Adequacy Test^[1]

- [19] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2009, due to the mid-year [2] As of Date. The 2009 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [20] Present Value of Cash Flows is calculated as [17] Cash Flows multiplied by [18] Discount Factor and [19] Partial Year Factor.
- [21] Valuation is equal to the sum of all [20] Present Value of Cash Flows (years 1-11).

Sources:

- [A] Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065.
- [B] Purdue U.S. Profit & Loss Account Summary, December 31, 2009, PPLPUCC001704662.
- [C] Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453.
- [D] Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668.
- [E] Purdue 2013 10-Year Plan, May 3, 2013, PPLPC063000003469-592.

Exhibit D-12
2010 Cash Flows for Capital Adequacy Test

Notes:

- [1] As of Date for Capital Adequacy Test matches the date of the Purdue management projections used, June 24, 2010. Cash flows shown for 2010 are full-year estimates. The present value of the 2010 cash flows is multiplied by a factor of 0.52, representing the fraction of the year remaining from June 24, 2010 to December 31, 2010.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2010.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Gross Sales (Existing and Pipeline Products) is taken from the DCF model and represents the Gross Sales corresponding to all of Purdue's products.
- [5] Gross Sales (Existing Products) represents the Gross Sales of Existing Products and is from Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 381.
- [6] EBIT Stress (%) represents the fraction equal to the [5] Gross Sales (Existing Products) / [4] Gross Sales (Existing and Pipeline Products).
- [7] EBIT (from the DCF Model) refers to the EBIT as calculated in the 2010 DCF Model.
- [8] EBIT (Capital Adequacy) is a stressed version of [7] EBIT (from the DCF Model), in order to simulate a downside scenario. Specifically, EBIT for each year is scaled down by a factor equal to [6] EBIT Stress (%).
- [9] Taxes are calculated as [8] EBIT (Capital Adequacy) multiplied by [3] Tax Rate.
- [10] Depreciation and Amortization is from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384.
- [11] Extraordinary Item Payout is from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384.
- [12] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. It is from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384.
- [13] Increase in Working Capital is from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384.
- [14] Decrease in Long-Term Liabilities represents change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liability. It is from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384.
- [15] Capital Expenditures are from the Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453, at 384.
- [16] Cash Flows calculated as [8] EBIT (Capital Adequacy) plus [10] Depreciation & Amortization, [11] Extraordinary Item Payout, and [12] Ex-U.S., less [9] Taxes, [13] Increase in Working Capital, [14] Decrease in Long-Term Liabilities and [15] Capital Expenditures.
- [17] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})^{\text{distance in years between the middle of the projection year and [1] As of Date}}$. For 2010, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2010. For all other years, the cash flow is discounted from June 30 of the projection year.
- [18] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2010, due to the mid-year [1] As of Date. The 2010 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [19] Present Value of Cash Flows is calculated as [16] Cash Flows multiplied by [17] Discount Factor and [18] Partial Year Factor.
- [20] Valuation is equal to the sum of all [19] Present Value of Cash Flows (years 1-10).

Source:

- [A] Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453.

Exhibit D-13
2011 Cash Flows for Capital Adequacy Test

[1]	<div> As of Date: June 21, 2011 Discount Rate: 11.26% Tax Rate: 35.0% </div>										
[2]											
[3]		<div>Stress Test Financial Projections</div>									
	(\$ millions)	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
[4]	Gross Sales (Existing and Pipeline Products)	3,072	3,234	3,441	3,646	4,439	5,133	5,269	3,447	3,680	1,517
[5]	Gross Sales (Existing Products)	3,053	3,163	3,228	3,262	3,353	3,370	2,576	395	296	240
[6]	EBIT Stress (%) = [5]/[4]	99%	98%	94%	89%	76%	66%	49%	11%	8%	16%
[7]	EBIT (from the DCF Model)	1,159	1,088	1,191	1,209	1,549	1,785	1,604	817	566	(607)
[8]	EBIT (Capital Adequacy) = [7]*[6]	1,152	1,064	1,117	1,082	1,170	1,172	784	94	46	(96)
[9]	- Taxes	(403)	(373)	(391)	(379)	(410)	(410)	(274)	(33)	(16)	-
[10]	+ Depreciation and Amortization	30	32	34	37	38	40	41	40	39	39
[11]	+ Ex-U.S.	124	120	135	98	73	58	43	28	13	(2)
[12]	- Increase in Working Capital	(77)	23	(11)	25	19	24	14	(111)	29	(24)
[13]	- Capital Expenditures	(36)	(40)	(40)	(40)	(40)	(40)	(40)	(40)	(40)	(40)
[14]	- Deferred Income Taxes	(1)	-	-	-	-	-	-	-	-	-
[15]	- Decrease in Long-Term Liabilities	-	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[16]	Cash Flows	788	825	844	822	850	843	566	(23)	70	(125)
[17]	Discount Factor	97%	90%	81%	72%	65%	58%	53%	47%	42%	38%
[18]	Partial Year Factor	0.53	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
[19]	Present Value of Cash Flows	404	740	680	595	553	493	298	(11)	30	(48)
[20]	Valuation (\$ millions)	3,734									

Exhibit D-13
2011 Cash Flows for Capital Adequacy Test

Notes:

- [1] As of Date matches the date of the PPLP management projections used, June 21, 2011. Cash flows shown for 2011 are full-year estimates. The present value of the 2011 cash flows is multiplied by a factor of 0.53, representing the fraction of the year remaining from June 21, 2011, to December 31, 2011. Detailed projections for the ten-year period 2011 through 2020 are only provided on a non-risk-adjusted basis. In addition, risk-adjusted Gross Sales projections are provided for 2011 through 2020.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2011.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Gross Sales (Existing and Pipeline Products) is taken from the DCF model and represents the Gross Sales corresponding to all of Purdue's products.
- [5] Gross Sales (Existing Products) represents the Gross Sales of Existing Products and is from the Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 108.
- [6] EBIT Stress (%) represents the fraction equal to the [5] Gross Sales (Existing Products) / [4] Gross Sales (Existing and Pipeline Products).
- [7] EBIT (from the DCF Model) refers to the EBIT as calculated in the 2011 DCF Model.
- [8] EBIT (Capital Adequacy) is a stressed version of [7] EBIT (from the DCF Model), in order to simulate a downside scenario. Specifically, EBIT for each year is scaled down by a factor equal to [6] EBIT Stress (%).
- [9] Taxes are calculated as [8] EBIT (Capital Adequacy) multiplied by [3] Tax Rate.
- [10] Depreciation and Amortization are non-risk-adjusted and from Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111.
- [11] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. It is non-risk-adjusted and from Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111.
- [12] Increase in Working Capital is non-risk-adjusted and from Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111. The Increase in Working Capital for 2018 is due to a decline in accrued rebates following Purdue's loss of exclusivity for OxyContin in 2017.
- [13] Capital Expenditures are non-risk-adjusted and from Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111.
- [14] Deferred Income Taxes are non-risk-adjusted and from Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111.
- [15] Decrease in Long-Term Liabilities represents change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liability. It is non-risk-adjusted and from Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012 at p. 111.
- [16] Cash Flows calculated as [8] EBIT (Capital Adequacy) plus [10] Depreciation & Amortization, and [11] Ex-U.S., less [9] Taxes, [12] Increase in Working Capital, [13] Capital Expenditures, [14] Deferred Income Taxes, and [15] Decrease in Long-Term Liabilities.
- [17] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [1] As of Date. For 2011, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2011. For all other years, the cash flow is discounted from June 30 of the projection year.
- [18] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2011, due to the mid-year [1] As of Date. The 2011 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [19] Present Value of Cash Flows is calculated as [16] Cash Flows multiplied by [17] Discount Factor and [18] Partial Year Factor.
- [20] Valuation is equal to the sum of all [19] Present Value of Cash Flows (years 1-10).

Source:

- [A] Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012.

Exhibit D-14
2012 Cash Flows for Capital Adequacy Test

[1]	<div> <div>As of Date: February 15, 2012</div> <div>Discount Rate: 10.09%</div> <div>Tax Rate: 35.0%</div> </div>	Stress Test Financial Projections								
[2]										
[3]										
	(\$ millions)	2012	2013	2014	2015	2016	2017	2018	2019	2020
[4]	Gross Sales (Existing and Pipeline Products)	3,168	3,087	3,233	3,678	4,150	4,218	2,265	2,401	1,026
[5]	Gross Sales (Existing Products)	3,168	3,087	3,196	3,440	3,566	3,070	889	796	302
[6]	<i>EBIT Stress (%) = [5]/[4]</i>	<i>100%</i>	<i>100%</i>	<i>99%</i>	<i>94%</i>	<i>86%</i>	<i>73%</i>	<i>39%</i>	<i>33%</i>	<i>29%</i>
[7]	EBIT (from the DCF Model)	890	813	699	972	1,238	1,218	733	737	350
[8]	EBIT (Capital Adequacy) = [7]*[6]	890	813	692	909	1,064	887	288	244	103
[9]	- Taxes	(312)	(284)	(242)	(318)	(372)	(310)	(101)	(86)	(36)
[10]	+ Depreciation and Amortization	34	35	45	46	46	46	45	43	42
[11]	+ Deferred Income Taxes	(1)	-	-	-	-	-	-	-	-
[12]	+ Ex-U.S.	229	166	123	70	48	43	38	23	18
[13]	- Increase in Working Capital	(60)	78	5	25	30	0	(208)	48	(78)
[14]	- Decrease in Long-Term Liabilities	-	(1)	(1)	(1)	-	(1)	(1)	(1)	(1)
[15]	- Capital Expenditures	(36)	(90)	(46)	(40)	(40)	(40)	(40)	(40)	(40)
[16]	Cash Flows	745	715	574	690	776	625	20	231	8
[17]	Discount Factor	96%	88%	80%	72%	66%	60%	54%	49%	45%
[18]	Partial Year Factor	0.88	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
[19]	Present Value of Cash Flows	627	627	457	499	510	373	11	114	3
[20]	Valuation (\$ millions)	3,221								

Exhibit D-14
2012 Cash Flows for Capital Adequacy Test

Notes:

- [1] As of Date for DCF valuation matches the date of the management projections used, February 15, 2012. Cash flows shown for 2012 are full-year estimates. The present value of the 2012 cash flows is multiplied by a factor of 0.88, representing the fraction of the year remaining from February 15, 2012 to December 31, 2012.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for corresponding value for 2012.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Gross Sales (Existing and Pipeline Products) is taken from the DCF model and represents the Gross Sales corresponding to all of Purdue's products.
- [5] Gross Sales (Existing Products) represents the Gross Sales of Existing Products and is from the PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 665.
- [6] EBIT Stress (%) represents the fraction equal to the [5] Gross Sales (Existing Products) / [4] Gross Sales (Existing and Pipeline Products).
- [7] EBIT (from the DCF Model) refers to the EBIT as calculated in the 2012 DCF Model.
- [8] EBIT (Capital Adequacy) is a stressed version of [7] EBIT (from the DCF Model), in order to simulate a downside scenario. Specifically, EBIT for each year is scaled down by a factor equal to [6] EBIT Stress (%).
- [9] Taxes are calculated as [8] EBIT (Capital Adequacy) multiplied by [3] Tax Rate.
- [10] Depreciation and Amortization is from the PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [11] Deferred Income Taxes are from the PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [12] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. It is from the PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [13] Increase in Working Capital is from the PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [14] Decrease in Long-Term Liabilities represents change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liability. It is from the PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [15] Capital Expenditures are from the PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668, at 668.
- [16] Cash Flows calculated as [8] EBIT (Capital Adequacy) plus [10] Depreciation & Amortization, [11] Deferred Income Taxes, and [12] Ex-U.S., less [9] Taxes, [13] Increase in Working Capital, [14] Decrease in Long-Term Liabilities, and [15] Capital Expenditures.
- [17] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [1] As of Date. For 2012, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2012. For all other years, the cash flow is discounted from June 30 of the projection year.
- [18] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2012, due to the mid-year [1] As of Date. The 2012 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [19] Present Value of Cash Flows is calculated as [16] Cash Flows multiplied by [17] Discount Factor and [18] Partial Year Factor.
- [20] Valuation is equal to the sum of all [19] Present Value of Cash Flows (years 1-9), as of February 15, 2012.

Source:

- [A] PPLP 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668.

Exhibit D-15
2013 Cash Flows for Capital Adequacy Test

[1]	As of Date: May 3, 2013										
[2]	Discount Rate: 9.48%										
[3]	Tax Rate: 35.0%	Stress Test Financial Projections									
	(\$ millions)	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
[4]	Gross Sales (Existing and Pipeline Products)	3,190	3,044	3,007	3,198	3,208	3,244	3,320	3,049	823	467
[5]	Gross Sales (Existing Products)	3,190	3,044	2,894	2,824	2,629	2,430	2,458	2,443	276	166
[6]	<i>EBIT Stress (%) = [5]/[4]</i>	<i>100%</i>	<i>100%</i>	<i>96%</i>	<i>88%</i>	<i>82%</i>	<i>75%</i>	<i>74%</i>	<i>80%</i>	<i>33%</i>	<i>36%</i>
[7]	EBIT (from the DCF Model)	1,046	597	539	721	611	683	757	696	192	1
[8]	EBIT (Capital Adequacy) = [7]*[6]	1,046	597	519	636	501	512	561	558	64	1
[9]	- Taxes	(366)	(209)	(182)	(223)	(175)	(179)	(196)	(195)	(22)	(0)
[10]	+ Depreciation and Amortization	32	33	41	42	42	42	42	40	38	38
[11]	+ Ex-U.S.	141	144	107	62	28	36	36	36	36	36
[12]	+ Extraordinary Item Payout	190	-	-	-	-	-	-	-	-	-
[13]	- Increase in Working Capital	(242)	65	5	9	18	(8)	(1)	(25)	(245)	(21)
[14]	- Capital Expenditures	(35)	(77)	(43)	(38)	(34)	(35)	(36)	(37)	(38)	(39)
[15]	- Decrease in Long-Term Liabilities	-	-	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)
[16]	Cash Flows	765	554	447	488	379	367	404	376	(168)	14
[17]	Discount Factor	97%	90%	82%	75%	69%	63%	57%	52%	48%	44%
[18]	Partial Year Factor	0.66	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
[19]	Present Value of Cash Flows	491	499	368	367	260	230	231	197	(80)	6
[20]	Valuation (\$ millions)	2,569									

Exhibit D-15
2013 Cash Flows for Capital Adequacy Test

Notes:

- [1] As of Date for Capital Adequacy Test matches the date of the Purdue management projections used, May 3, 2013. Cash flows shown for 2013 are full-year estimates. The present value of the 2013 cash flows is multiplied by a factor of 0.66, representing the fraction of the year remaining from May 3, 2013, to December 31, 2013.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for the corresponding value in 2013.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Gross Sales (Existing and Pipeline Products) is taken from the DCF model and represents the Gross Sales corresponding to all of Purdue's products.
- [5] Gross Sales (Existing Products) represents the Gross of Existing Products and is from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 520.
- [6] EBIT Stress (%) represents the fraction equal to the [5] Gross Sales (Existing Products) / [4] Gross Sales (Existing and Pipeline Products).
- [7] EBIT (from the DCF Model) refers to the EBIT as calculated in the 2013 DCF Model.
- [8] EBIT (Capital Adequacy) is a stressed version of [7] EBIT (from the DCF Model), in order to simulate a downside scenario. Specifically, EBIT for each year is scaled down by a factor equal to [6] EBIT Stress (%).
- [9] Taxes are calculated as [8] EBIT (Capital Adequacy) multiplied by [3] Tax Rate.
- [10] Depreciation and Amortization are from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528.
- [11] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. It is from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528.
- [12] Extraordinary Item Payout represents reduction in (distribution from) Infinity stock. It is from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528.
- [13] Increase in Working Capital is from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528. The Increase in Working Capital for 2021 is due to a decline in accrued rebates following Purdue's loss of exclusivity for OxyContin in 2020.
- [14] Capital Expenditures are from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528.
- [15] Decrease in Long-Term Liabilities represents change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liability. It is from the Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 528.
- [16] Cash Flows calculated as [8] EBIT (Capital Adequacy) plus [10] Depreciation & Amortization, [11] Ex-U.S., and [12] Extraordinary Item Payout, less [9] Taxes, [13] Increase in Working Capital, [14] Capital Expenditures, and [15] Decrease in Long-Term Liabilities.
- [17] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})^{\text{the distance in years between the middle of the projection year and [1] As of Date}}$. For 2013, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2013. For all other years, the cash flow is discounted from June 30 of the projection year.
- [18] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2013, due to the mid-year [1] As of Date. The 2013 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [19] Present Value of Cash Flows is calculated as [16] Cash Flows multiplied by [17] Discount Factor and [18] Partial Year Factor.
- [20] Valuation is equal to the sum of all [19] Present Value of Cash Flows (years 1-10) as of May 3, 2013.

Source:

- [A] Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592.

Exhibit D-16
2015 Cash Flows for Capital Adequacy Test

[1]	<div>As of Date: June 9, 2015 Discount Rate: 12.28% Tax Rate: 35.0%</div>											
[2]												
[3]		Stress Test Financial Projections										
	(\$ millions)	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
[4]	Net Sales (Existing and Pipeline Products)	1,446	1,454	1,372	1,432	1,442	1,442	1,418	1,413	737	549	600
[5]	Net Sales (Existing Products)	1,445	1,450	1,306	1,278	1,285	1,280	1,279	1,202	476	212	191
[6]	<i>EBIT Stress (%) = [5]/[4]</i>	<i>100%</i>	<i>100%</i>	<i>95%</i>	<i>89%</i>	<i>89%</i>	<i>89%</i>	<i>90%</i>	<i>85%</i>	<i>65%</i>	<i>39%</i>	<i>32%</i>
[7]	EBIT (from the DCF Model)	375	352	344	485	568	643	657	582	365	263	288
[8]	EBIT (Capital Adequacy) = [7]*[6]	375	351	328	433	507	571	593	495	236	102	92
[9]	- Taxes	(131)	(123)	(115)	(151)	(177)	(200)	(208)	(173)	(83)	(36)	(32)
[10]	+ Depreciation and Amortization	29	33	36	36	34	33	32	30	23	21	19
[11]	+ Ex-U.S.	158	165	102	65	22	(5)	(37)	(50)	(53)	(76)	(66)
[12]	+ Deferred Income Taxes	5	-	-	-	-	-	-	-	-	-	-
[13]	- Increase in Working Capital	(399)	36	13	6	9	9	35	(7)	(444)	(2)	0
[14]	- Decrease in Long-Term Liabilities	(2)	(4)	(4)	(4)	(4)	(0)	(0)	(0)	(0)	(0)	(0)
[15]	- Capital Expenditures	(50)	(23)	(29)	(21)	(23)	(18)	(18)	(18)	(8)	(8)	(8)
[16]	Cash Flows	(15)	435	331	362	367	391	396	277	(328)	1	4
[17]	Discount Factor	97%	88%	79%	70%	62%	56%	50%	44%	39%	35%	31%
[18]	Partial Year Factor	0.56	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
[19]	Present Value of Cash Flows	(8)	385	261	254	230	217	197	123	(129)	0	1
[20]	Valuation (\$ millions)	1,530										

Exhibit D-16
2015 Cash Flows for Capital Adequacy Test

Notes:

- [1] As of Date matches the date of the Purdue management projections used, June 9, 2015. Management projections are provided for the eleven-year period 2015 through 2025. Cash flows shown for 2015 are full-year estimates. The present value of the 2015 cash flows is multiplied by a factor of 0.56, representing the fraction of the year remaining from June 9, 2015 to December 31, 2015.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for corresponding value in 2015.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Net Sales (Existing and Pipeline Products) is taken from the DCF model and represents the Net Sales corresponding to all of Purdue's products.
- [5] Net Sales (Existing Products) represents the Net Sales of Existing Products and is from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 55.
- [6] EBIT Stress (%) represents the fraction equal to the [5] Net Sales (Existing Products) / [4] Net Sales (Existing and Pipeline Products).
- [7] EBIT (from the DCF Model) refers to the EBIT as calculated in the 2015 DCF Model.
- [8] EBIT (Capital Adequacy) is a stressed version of [7] EBIT (from the DCF Model), in order to simulate a downside scenario. Specifically, EBIT for each year is scaled down by a factor equal to [6] EBIT Stress (%).
- [9] Taxes are calculated as [8] EBIT (Capital Adequacy) multiplied by [3] Tax Rate.
- [10] Depreciation and Amortization for 2015 through 2025 is from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56.
- [11] Ex-U.S. represents non-cash loss (gain) in foreign equity investments. For 2015 through 2025, it is from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56.
- [12] Deferred Income Taxes for 2015 through 2025 is from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56.
- [13] Increase in Working Capital for 2015 through 2025 is from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56. Large increase in 2023 due to decline in accrued rebates (current liability) following OxyContin, Butrans, and Hysingla's loss of exclusivity in 2022.
- [14] Decrease in Long-Term Liabilities represents change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liabilities. It is from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56.
- [15] Capital Expenditures for 2015 through 2025 are from the Finance Update, June 9, 2015, PPLPC054000123288, at p. 56.
- [16] Cash Flows calculated as [8] EBIT (Capital Adequacy) plus [10] Depreciation & Amortization, [11] Ex-U.S., and [12] Deferred Income Taxes, less [9] Taxes, [13] Increase in Working Capital, [14] Decrease in Long-Term Liabilities, and [15] Capital Expenditures.
- [17] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [1] As of Date. For 2016, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2016. For all other years, the cash flow is discounted from June 30 of the projection year.
- [18] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2016, due to the mid-year [1] As of Date. The 2016 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [19] Present Value of Cash Flows is calculated as [16] Cash Flows multiplied by [17] Discount Factor and [18] Partial Year Factor.
- [20] Valuation is equal to the sum of all [19] Present Value of Cash Flows (years 1-11), as of June 9, 2015.

Source:

- [A] Finance Update, June 9, 2015, PPLPC054000123288.

Exhibit D-17
2016 Cash Flows for Capital Adequacy Test

Notes:

- [1] As of Date matches the date of the Purdue management projections used, June 8, 2016. Management projections are provided for the ten-year period 2016 through 2025. Cash flows shown for 2016 are full-year estimates. The present value of the 2016 cash flows is multiplied by a factor of 0.56, representing the fraction of the year remaining from June 8, 2016 to December 31, 2016. Detailed risk-adjusted projections are provided for the five-year period 2016 through 2020, but only risk-adjusted Net Sales projections are provided for the ten-year period 2016 through 2025.
- [2] See **Appendix E** for the calculation of the discount rate and **Exhibit 9** for corresponding value in 2016.
- [3] Tax Rate assumed to be the U.S. effective corporate tax rate of 35 percent.
- [4] Net Sales (Existing and Pipeline Products) is taken from the DCF model and represents the Net Sales corresponding to all of Purdue's products.
- [5] Net Sales (Existing Products) represents the Net Sales of Existing Products, namely OxyContin, Butrans, Hysingla and Other Products; and is from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 892 and 911.
- [6] EBIT Stress (%) represents the fraction equal to the [5] Net Sales (Existing Products) / [4] Net Sales (Existing and Pipeline Products).
- [7] EBIT (from the DCF Model) refers to the EBIT as calculated in the 2016 DCF Model.
- [8] EBIT (Capital Adequacy) is a stressed version of [7] EBIT (from the DCF Model), in order to simulate a downside scenario. Specifically, EBIT for each year is scaled down by a factor equal to [6] EBIT Stress (%).
- [9] Taxes are calculated as [8] EBIT (Capital Adequacy) multiplied by [3] Tax Rate.
- [10] Depreciation and Amortization ("D&A") for 2016 through 2020 is from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 907. D&A for 2021 through 2025 is estimated by applying the year-over-year percentage change in D&A from 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 56) to the previous year's D&A provided in the 2016 DCF Model.
- [11] Ex-U.S. represents non-cash loss (gain) on foreign equity investments. For 2016 through 2020, it is from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 907. Ex-U.S. for 2021 through 2025 is calculated using the margin (as a percentage of Net Sales) from 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 52 and 56).
- [12] Increase in Working Capital for 2016 through 2020 is from the Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 907. Increase in Working Capital for 2021 through 2025 is estimated by applying the year-over-year percentage change in Increase in Working Capital from 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 56) to the previous year's Increase in Working Capital provided in the 2016 DCF Model. The Increase in Working Capital for 2023 is due to a decline in accrued rebates following PPLP's loss of exclusivity for OxyContin, Butrans, and Hysingla in 2022.
- [13] Capital Expenditures for 2016 through 2020 are from Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 907. Capital Expenditures for 2021 through 2025 are estimated by applying the year-over-year percentage change in Capital Expenditures from 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 56) to the previous year's Capital Expenditures provided in the 2016 DCF Model.

Exhibit D-17
2016 Cash Flows for Capital Adequacy Test

- [14] Decrease in Long-Term Liabilities represents change in Other Long-Term Obligations on the Balance Sheet, which mostly consists of pension and retirement benefits liability. For 2016 through 2020 it is from Purdue Mid-Year Update, June 8, 2016, RSF00017771-921 at 907. For 2021 through 2025 it is estimated by applying the year-over-year percentage change in Long-Term Assets & Liabilities from 2015 management projections (Purdue Finance Update, June 9, 2015, PPLPC054000123288 at p. 56) to the previous year's value provided in the 2016 DCF Model.
- [15] Cash Flows calculated as [8] EBIT (Capital Adequacy) plus [10] Depreciation & Amortization and [11] Ex-U.S., less [9] Taxes, [12] Increase in Working Capital, [13] Capital Expenditures, and [14] Decrease in Long-Term Liabilities.
- [16] Discount Factor is equal to 1 divided by the following expression: $(1 + [2] \text{ Discount Rate})$ raised to the power of: the distance in years between the middle of the projection year and [1] As of Date. For 2016, the partial year cash flow is discounted from the halfway point between the [1] As of Date and December 31, 2016. For all other years, the cash flow is discounted from June 30 of the projection year.
- [17] Partial Year Factor is equal to the fraction of each projection year that is included in the projection period. The only partial year factor that is not equal to 1.00 is 2016, due to the mid-year [1] As of Date. The 2016 full-year estimated cash flow is ultimately multiplied by the partial year factor to estimate the cash flow for the remaining portion of the year.
- [18] Present Value of Cash Flows is calculated as [15] Cash Flows multiplied by [16] Discount Factor and [17] Partial Year Factor.
- [19] Valuation is equal to the sum of all [18] Present Value of Cash Flows (years 1-10), as of June 8, 2016.

Sources:

- [A] Purdue Mid-Year Update, June 8, 2016, RSF00017771-921.
- [B] Purdue Finance Update, June 9, 2015, PPLPC054000123288.

Appendix E

Estimation of Purdue's Discount Rate

Appendix E

Estimation of Purdue's Discount Rate

1. As discussed in **Section III.E.2** of this report, the DCF model requires a discount rate to calculate the present value of Purdue's expected future cash flows as of each valuation date. I estimate this discount rate using the CAPM, a simple and widely used model for deriving a firm's cost of equity capital. In this appendix, I provide a detailed explanation of how I derive each of the inputs used to estimate Purdue's cost of equity as of each valuation date between 2008 and 2016.
2. The formula to estimate the discount rate from the CAPM is:

$$\text{Cost of Equity} = \underbrace{r_f}_{\text{Risk-free Return}} + \underbrace{\beta * (\text{Expected Return}_{\text{Market}} - r_f)}_{\text{Non-diversifiable Risk Premium}}$$

I discuss each of these inputs below.

A. Risk-Free Rate (r_f)

3. For the risk-free rate, I use the 20-year constant maturity U.S. Treasury yield from Bloomberg. This is appropriate for a U.S.-based company such as Purdue given that Treasury debt is considered to have little default risk.¹ A 20-year maturity is commonly used to account for the long-term investments that businesses make.² As shown in **Exhibit 9**, the risk-free rate ranges from a low of 2.10% as of June 8, 2016 to a high of 4.50% as of April 18, 2008.

B. Beta (β)

1. Selection of Comparable Companies

4. A beta measures the sensitivity of the return of an investment (such as a company's stock) to the return of the broad stock market. Because Purdue is a privately held company whose stock is not publicly listed and traded, I am not able to directly observe the beta of Purdue's stock.

¹ Damodaran (2012), p. 155.

² See, e.g., Pratt, Shannon P. and Roger J. Grabowski, *Cost of Capital: Applications and Examples*, John Wiley & Sons, Inc., 4th Ed., 2010, p. 90.

Therefore, I benchmark Purdue's beta to that of publicly-traded companies that have comparable risks to Purdue.

5. To identify companies that are comparable to Purdue, I started with the firms in the Compustat database that share the same industry code.³ As described in **Exhibit E-1**, I then impose a series of restrictions related to the characteristics of each company and data availability to ensure that the data necessary to estimate the beta are available for at least a portion of the 2008-16 Period. I restrict the list of comparable firms based on size to exclude firms that are significantly larger or smaller than Purdue. Specifically, I include only firms that have annual sales of between \$500 million and \$5 billion in at least one year between 2008 and 2016. I also restrict the list of comparable firms to those that are primarily engaged in the development and sale of branded prescription drugs. I identify those firms based on a review of each remaining firm's business description. I exclude companies based on the following terms: "generic," "bioequivalent," "animal," "device," "outsource," "nutrition," "over-the-counter," or "OTC." After imposing these restrictions, 23 comparable companies remain. **Exhibit E-2** provides a list of the comparable companies I include for purposes of estimating Purdue's discount rate and indicates the valuation dates for which I had sufficient data for inclusion.⁴

2. Estimation of Purdue's Beta

6. I collected the betas of each of the comparable companies over the 2008-16 Period from Bloomberg. Bloomberg derives the beta by regressing the return of each company's stock against the return of the S&P 500, a widely used benchmark index for U.S. stocks. Bloomberg reports betas based on different lengths of regression periods (*e.g.*, one year to three years) as well as in different return intervals (*e.g.*, daily or weekly). The trade-off between using short versus long regression periods is that while longer periods use more data such that the result might be more robust, they could be less representative of a firm's risk characteristics as of the

³ Purdue is classified under SIC code 2834 (Pharmaceutical Preparations) and NAICS code 325412 (Pharmaceutical Preparation Manufacturing). Firms classified under either industry code are considered potentially comparable. I retrieved the SIC code from S&P Capital IQ and the NAICS code from a federal contract that Purdue had from the Department of Veteran Affairs. *See* "FedBizOpps Award Notice," U.S. Department of Veteran Affairs, available as an attachment at <https://sam.gov/opp/f92c522315d70836f6bf4eab75c113ca/view>, accessed June 13, 2021.

⁴ One of the comparable companies, Xstelos Holdings, did not have sufficient data to estimate its beta as of any of the valuation dates and therefore is not used in my analysis of Purdue's discount rate.

valuation date if the risk profile of the company changed over time.⁵ Similarly, there is also a trade-off between using various return intervals, where more frequent return intervals increase the number of observations for estimating the beta, but could result in a downward biased beta estimate for small firms with no or little trading in a measurement interval. Given these considerations, I collect six Bloomberg beta estimates for each comparable company using weekly and daily intervals over one, two, and three-year regression periods for each of the nine valuation dates. A comparable company is not included in the discount rate calculation for a specific valuation date if there is not at least three years of trailing stock price information. As a result, the entire set of comparable firms is not used in all of the discount rate calculations.⁶

7. The observed betas from Bloomberg reflect the risk of using debt in financing a company's business and therefore represent the levered betas of the comparable companies. All else being equal, use of debt (in other words, financial leverage) increases the risk to equity investors.⁷ Because Purdue did not finance itself using appreciable long-term debt, the appropriate beta should correspond to all-equity financing (*i.e.*, no financial leverage) and therefore should be lower than the observed betas I obtain from Bloomberg. Thus, for each of the comparable companies, I "unlever" the betas collected from Bloomberg using the following formula:⁸

$$\text{Unlevered Beta} = \frac{\text{Levered Beta}}{1 + (1 - \text{tax rate}) \times \frac{\text{Debt}}{\text{Equity}}}$$

8. I obtain each company's debt-to-equity ratio from Bloomberg and estimate the average ratio over the period corresponding to the length of the regression period used to estimate the beta.⁹ I do not include a comparable company in my estimation of Purdue's discount rate for a particular valuation date if the company does not have at least one quarter of debt-to-equity data for each of the associated one-year, two-year, and three-year backward-looking periods. I assume a U.S. corporate tax rate of 35%.
9. To estimate an unlevered beta from the set of comparable companies, I compute the medians of the levered betas and debt-to-equity ratios across those companies. I then calculate the

⁵ Damodaran (2012), p. 188.

⁶ See **Exhibit E-2**.

⁷ Damodaran (2012), p. 195.

⁸ Damodaran (2012), p. 197.

⁹ For example, for a two-year beta for the April 18, 2008 valuation date, the debt-to-equity ratio is calculated as the average quarterly debt-to-equity ratio over the two-year period ending March 31, 2008.

median unlevered beta by using the median of the levered betas, the median of the debt-to-equity ratios, and the assumed tax rate.¹⁰

10. I make one additional adjustment to the estimated unlevered betas to control for the cash holdings of the comparable firms. The unlevered betas reflect both the beta of a company's operating assets and cash. However, cash has a beta of close to zero. As a result, if comparable companies are holding differing levels of cash, this will tend to distort estimates of the beta of operating assets.¹¹ To isolate the beta for the operating assets of the firm, I use the following equation:¹²

$$\text{Cash} - \text{Adjusted Unlevered Beta} = \frac{\text{Unlevered Beta}}{1 - \frac{\text{Total Cash}}{\text{Total Capital}}}$$

11. For the purpose of this calculation, I obtain data to estimate cash as a percentage of total capital for each comparable company from Bloomberg.¹³ In order to implement the cash-adjusted unlevered beta, I follow an approach that is consistent with how I unlevered the betas.¹⁴ For each valuation date, I calculate the median cash adjustment factor across the comparable companies and then adjust the unlevered beta by this factor. I do this to adjust each of the six unlevered betas calculated over different estimation periods.

¹⁰ When calculating the upper quartile or bottom quartile unlevered beta for Purdue, I still utilize the median debt-to-equity ratio, as doing otherwise would tend to distort the distribution of unlevered betas. An alternative approach for calculating unlevered betas would be to calculate the unlevered beta for each comparable company and then use the median (or some other measure of the distribution) across those comparable companies to estimate the unlevered beta of the company being valued. However, some scholars argue the approach I am using is better suited to dealing with potential measurement errors when estimating levered betas or debt-to-equity ratios. See, e.g., Damodaran (2012), p. 197.

¹¹ See, e.g., McKinsey (2010), p. 145.

¹² Damodaran, Aswath, "Variables Used in Datasets," available at http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/variable.htm, accessed on May 29, 2021.

¹³ I obtain data on cash and near-cash items, short- and long-term debt, and market capitalization from Bloomberg. Total Capital is calculated as short- and long-term debt plus market capitalization, while Total Cash is equal to cash plus near-cash items. I conservatively use total cash rather than an estimate of excess cash for the comparable companies, as higher cash amounts will result in higher cash-adjusted unlevered betas and discount rates, as well as lower valuations, all else equal.

¹⁴ I calculate adjustment ratios based on quarterly data averaged over the length of the regression period for the beta and do not include comparable companies if they do not have at least one quarter of data for each of the associated backward looking periods. When calculating the upper quartile or bottom quartile cash-adjusted unlevered beta for Purdue, I still utilize the median cash adjustment ratio, as I did with the debt-to-equity ratio when I unlevered the CAPM betas.

12. I then calculate the median and interquartile range of cash-adjusted unlevered betas by using the median of cash-adjusted unlevered betas across the six combinations of regression period and return interval. As shown in **Exhibit 9**, the median cash-adjusted beta ranges between 0.83 and 1.34, while the upper quartile ranges between 0.98 and 1.43.

C. Market Risk Premium ($Expected\ Return_{Market} - r_f$)

13. The U.S. market risk premium estimates the extra return over and above the risk-free interest rate that an investor would demand in order to compensate them for making a riskier equity investment.¹⁵
14. A common method of estimating the U.S. market risk premium is based on the excess return of a broad equity market (such as the S&P 500 Index) relative to the risk-free rate of return (such as the return on the 20-year U.S. Treasury bonds) using historical data.¹⁶ Duff and Phelps publishes a number of such historical estimates over different time periods. For the historical U.S. market risk premium, the longest estimate period is based on data starting in 1926.¹⁷ I use a start year of 1926 and choose an end year equal to the year prior to the valuation date, as this would represent the last known estimate as of the valuation date. The historical equity risk premiums range from a low of 6.47% for the 1926-2008 period to a high of 7.06% for the 1926-2007 period.¹⁸
15. The historical approach, however, assumes that historical returns are the best possible predictor of future returns. Some practitioners instead consider alternative estimates of the market risk premium, which account for other factors in addition to historical returns. One of the most commonly used alternatives is the supply-side market risk premium developed by Ibbotson and Chen.¹⁹ Like the historical approach, this method calculates the market risk premium using historical returns, but also factors equity market price-to-earnings ratios into the estimate. For each valuation date, I use a supply-side equity risk premium calculated over the period between

¹⁵ Damodaran (2012), p. 159.

¹⁶ Damodaran (2012), p. 161.

¹⁷ Duff and Phelps explain that “long-term historical returns have shown surprising stability,” and that using “short-term observations [instead] may lead to illogical forecasts.” Duff and Phelps, *2019 Cost of Capital: Annual U.S. Guidance and Examples*, p. 41.

¹⁸ Duff & Phelps Cost of Capital Navigator, available at <https://costofcapital.duffandphelps.com/>.

¹⁹ Duff and Phelps, *2019 Cost of Capital: Annual U.S. Guidance and Examples*, p. 45; Damodaran (2012), p. 161.

1926 and the year prior to the valuation date, the last known estimate as of the valuation date. Over the range of valuation dates in my sample, the supply-side equity risk premium from Duff & Phelps varies from a low of 5.18% for the 1926-2009 period to a high of 6.23% for the 1926-2007 period.²⁰

16. I take the average of the historical equity risk premium and the supply-side equity risk premium as my measure of the equity risk premium in a given year. As shown in **Exhibit 9**, the estimated equity risk premium ranges between 5.92% and 6.64%.

D. Estimation of Purdue's Discount Rate

17. Based on my estimates of the risk-free rate, cash-adjusted unlevered beta, and equity risk premium, I calculate Purdue's discount rate and report these figures in **Exhibit 9**. For the purposes of my DCF valuations, I use discount rates drawn from the upper quartile of the estimated discount rates, which vary from 9.48% to 12.28%.

²⁰ Duff & Phelps Cost of Capital Navigator, available at <https://costofcapital.duffandphelps.com/>.

Exhibit E-1
Filtering for the Comparable Companies from Compustat

<u>Restriction</u>	<u>Number of Potential Comparable Companies</u>
[1] Same industry as Purdue (<i>i.e.</i> , SIC of 2834 or NAICS of 325412)	2,150
[2] Are publicly traded	1,116
[3] Restrict to the primary stock issues on U.S. exchanges	1,028
[4] Have monthly stock price information between 2008 and 2016	587
[5] Have financial statement data between 2008 and 2016	377
[6] Annual sales value between \$500M and \$5B for at least one year between 2008 and 2016	40
[7] Companies with a primary focus on branded pharmaceuticals	23

Notes:

- [1] Purdue is classified under SIC code 2834 (Pharmaceutical Preparations) and NAICS code 325412 (Pharmaceutical Preparation Manufacturing). *See* Source [B] for the SIC code and Source [C] for the NAICS code.
- [2] Publicly traded companies include those that are not traded on a major exchange.
- [3] Companies with a first issue on a U.S. exchange.
- [4] Companies with monthly stock price information for some portion of the 2008 to 2016 period.
- [5] Domestic companies with consolidated and standardized financial statement data available for at least some portion of the 2008 to 2016 period.
- [6] Companies with an annual net sales between \$500M and \$5B for at least some portion of the 2008 to 2016 period. The non-USD records that were excluded were reviewed and would not have met the criteria if converted to USD.
- [7] I restrict to companies with a primary focus on branded pharmaceuticals by removing companies that have any of the following keywords in their descriptions: “generic,” “bioequivalent,” “animal,” “device,” “outsource,” “nutrition,” “over-the-counter,” or “OTC.”

Sources:

- [A] Standard & Poor's Compustat, accessed on June 11, 2021.
- [B] S&P Capital IQ.
- [C] “FedBizOpps Award Notice,” U.S. Department of Veteran Affairs, available as an attachment at <https://sam.gov/opp/f92c522315d70836f6bf4eab75c113ca/view>, accessed June 13, 2021.

Exhibit E-2
Valuation Dates Each Comparable Company Will Be Represented in the Discount Rate

										# of Valuation Dates
Company	4/18/2008	7/15/2009	6/1/2010	6/21/2011	2/15/2012	5/3/2013	5/2/2014	6/9/2015	6/8/2016	Included
1 Alkermes Plc	X	X	X	X	X	X	X	X	X	9
2 Allergan Inc.	X	X	X	X	X	X	X			7
3 AMAG Pharmaceuticals Inc	X	X	X	X	X	X	X	X	X	9
4 Amylin Pharmaceuticals Inc	X	X	X	X	X					5
5 Celgene Corp	X	X	X	X	X	X	X	X	X	9
6 Cephalon Inc	X	X	X	X						4
7 Cubist Pharmaceuticals Inc	X	X	X	X	X	X	X			7
8 Forest Laboratories Inc	X	X	X	X	X	X	X			7
9 Hospira Inc	X	X	X	X	X	X	X	X		8
10 Jazz Pharmaceuticals Plc			X	X	X	X	X	X	X	7
11 K-V Pharmaceutical Co	X	X	X	X	X					5
12 Medicines Co (The)	X	X	X	X	X	X	X	X	X	9
13 Medicis Pharmaceutical Corp	X	X	X	X	X					5
14 Pharmacyclics Inc	X	X	X	X	X	X	X			7
15 Questcor Pharmaceuticals Inc.	X	X	X	X	X	X	X			7
16 Regeneron Pharmaceuticals Inc	X	X	X	X	X	X	X	X	X	9
17 Sepracor Inc.	X	X								2
18 United Therapeutics Corp	X	X	X	X	X	X	X	X	X	9
19 Valeant Pharmaceuticals International	X	X	X							3
20 Vertex Pharmaceuticals Inc	X	X	X	X	X	X	X	X	X	9
21 ViroPharma Inc	X	X	X	X	X	X				6
22 Warner Chilcott Plc			X	X	X	X				4
Total Number of Comparable Companies Included in Each Discount Rate	20	20	21	20	19	16	14	9	8	

Exhibit E-2

Valuation Dates Each Comparable Company Will Be Represented in the Discount Rate

Sources:

- [A] Valuation Dates are from Five-Year Plan 2008-2013, April 18, 2008, PPLPC063000023668; Purdue U.S. 10-Year Plan, July 15, 2009, PPLPC019000293027-065; Purdue Pharma 2010 10-Year Plan, June 24, 2010, PPLP004404330-453 at 380; Purdue U.S. 10-Year Plan, June 21, 2011, RSF00033012; Purdue 2012 10 Year Plan, February 15, 2012, PPLPC053000063393-668; Purdue 2013 10-Year Plan, May 9, 2013, PPLPC063000003469-592 at 526; 2014 10 Year Forecast and Trend, May 2, 2014, PPLPUCC002545437-543; Finance Update, June 9, 2015, PPLPC054000123288; Purdue Mid-Year Update, June 8, 2016, RSF00017771-921.
- [B] Bloomberg, L.P.
- [C] See **Appendix E** for detailed methodology.

Appendix F

Excerpts from Financial Statements

Related to Opioid Litigation Risk

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[1] Audited Combined Financial Statements for the years ended 2008 and 2007	<i>OxyContin® Tablets Litigation - Civil Product Liability Lawsuits</i> . Numerous individuals have made product liability claims related to OxyContin against certain of the Companies. ... To the extent that product liability claims remain after the settlements, including claimants that elect to opt out of the settlement offers, or have been brought after the settlements, the defendant Companies are confident that they will prevail on the merits of those individual claims. ... As of March 27, 2009, 326 OxyContin product liability lawsuits are pending against the defendant Companies in the United States. In addition, there are 6 product liability putative class action lawsuits against the defendant Companies in Canada, collectively advancing claims on behalf of all Canadians who have been prescribed and/or used OxyContin. The defendant Companies have also maintained agreements to toll the statutes of limitations of potential claims on behalf of approximately 300 or more individuals not subject to the settlements. The defendant Companies believe they have meritorious defenses with respect to such claims and will vigorously defend them.
[2] Audited Combined Financial Statements for the years ended 2008 and 2007	<i>OxyContin® Tablets Litigation - Consumer Protection Claims</i> . Two consumer protection claims have been filed against certain of the Companies by third party payors. ... Although defendant Companies in each of these actions contest the allegations and have raised meritorious defenses with respect to these claims, the parties have tentatively entered into a settlement disposing of both actions, which was preliminarily approved by the Southern District in December 2008.

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[3] Audited Combined Financial Statements for the years ended 2008 and 2007	<i>OxyContin® Tablets Litigation - Regulatory, Law Enforcement and Governmental Matters</i> . On July 20, 2007 the U.S. District Court in the Western District of Virginia approved a settlement between certain of the Companies and the U.S. Attorney's Office for the Western District of Virginia to end a pending investigation. As part of this resolution, The Purdue Frederick Company Inc. pled guilty to a single felony count of misbranding based upon misstatements made in the promotion of OxyContin to healthcare professionals that occurred prior to July 2001. As part of the agreement with the government and based upon their senior positions with such Companies, one executive and two former executives also pled guilty to a single "strict liability" misdemeanor for misbranding based upon the misconduct of other employees while the executives held their positions of responsibility. ... In May 2007, in connection with investigations involving activities related to certain of the Companies and their promotion of OxyContin, such Companies signed consent judgments to settle investigations with twenty-seven State Attorneys General. In addition, such Companies settled separately with the Attorneys General for the State of Mississippi and the State of Florida.
[4] Audited Combined Financial Statements for the years ended 2008 and 2007	On October 4, 2007, the Attorney General of the Commonwealth of Kentucky and Pike County, Kentucky filed a claim against certain of the Companies in state court alleging such Companies' improper promotion of OxyContin caused the plaintiffs to pay for excessive costs related to the usage of OxyContin, as well as the costs arising from misuse and addiction. ... In 2004, certain of the Companies settled claims raised by the West Virginia Attorney General, based mostly on consumer protection assertions.

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[5] Audited Combined Financial Statements for the years ended 2009 and 2008	OxyContin® Tablets ("OxyContin ") Litigation - Civil Product Liability Lawsuits. Numerous individuals have made product liability claims related to OxyContin against certain of the Companies. Most of those claimants allege that (1) they suffered bodily injury from the use of OxyContin, including addiction, (2) the defendant Companies failed to adequately warn them about the risks of addiction and (3) the defendant Companies "over-promoted" and aggressively and/or fraudulently marketed OxyContin. The claimants seek various forms of relief, including compensatory and punitive damages, interest and costs, and attorneys' fees. ... As of March 31, 2010, 476 OxyContin product liability lawsuits are either currently pending against the defendant Companies or the defendant Companies in the United States have been notified they will be pending. ... In addition, there are nine product liability putative class action lawsuits against the defendant Companies in Canada, collectively advancing claims on behalf of all Canadians who have been prescribed and/or used OxyContin. ... The defendant Companies believe they have meritorious defenses with respect to such claims and will vigorously defend them.
[6] Audited Combined Financial Statements for the years ended 2009 and 2008	<i>OxyContin® Tablets Litigation - Consumer Protection Claims</i> . In 2007, two consumer protection claims were filed against certain of the Companies by third party payors alleging improper promotion of OxyContin caused them to pay for unnecessary and excessive usage of OxyContin. Both actions were consolidated in the U.S. District Court for the Southern District of New York (the "Southern District"). ... The parties entered into a settlement disposing of both actions, which was approved by the Southern District at a Fairness Hearing on May 15, 2009. Pursuant to the terms of the settlement, the two actions were dismissed with prejudice.

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

Document

Excerpt

- | | |
|---|---|
| [7] Audited Combined Financial Statements for the years ended 2009 and 2008 | <p><i>OxyContin® Tablets Litigation - Regulatory, Law Enforcement and Governmental Matters</i> . On July 20, 2007 the U.S. District Court for the Western District of Virginia (the "WDVA") approved a settlement between certain of the Companies and the U.S. Attorney's Office for the WDVA to end a pending investigation. ... In May 2007, in connection with investigations involving activities related to certain of the Companies and their promotion of OxyContin, such Companies signed consent judgments to settle investigations with twenty-seven State Attorneys General. In addition, such Companies settled separately with the Attorneys General for the State of Florida and the State of Mississippi. ... On October 4, 2007, the Attorney General of the Commonwealth of Kentucky and Pike County, Kentucky filed a claim against certain of the Companies in state court alleging such Companies' improper promotion of OxyContin caused the plaintiffs to pay for excessive costs related to the usage of OxyContin, as well as the costs arising from misuse and addiction. ... The defendant Companies in this action believe they have meritorious defenses with respect to these claims and will vigorously defend them.</p> |
|---|---|

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[8] Audited Combined Financial Statements for the years ended 2010 and 2009	<p><i>OxyContin Litigation - Civil Product Liability Lawsuits</i>. Numerous individuals have made product liability claims related to OxyContin against certain of the Companies. Most of those claimants allege that (1) they suffered bodily injury from the use of OxyContin, including addiction, (2) the defendant Companies failed to adequately warn them about the risks of addiction, and (3) the defendant Companies "over-promoted" and aggressively and/or fraudulently marketed OxyContin. The claimants seek various forms of relief, including compensatory and punitive damages, interest and costs, and attorneys' fees. ... As of April 13, 2011, approximately 299 OxyContin product liability lawsuits involving approximately 471 user plaintiffs are either currently pending against the defendant Companies or the defendant Companies in the United States have been notified they will be pending. These class actions subsequently settled in March, 2010 and have been dismissed against the defendant Companies. ... The defendant Companies have reached an agreement to settle 274 OxyContin cases brought in Staten Island, New York by New York and non-New York residents. The law firm representing the plaintiffs in these matters, Sanders Viener, is in the process of obtaining from its clients approval of the settlement agreement. ... In addition, there are nine product liability putative class action lawsuits against the defendant Companies in Canada, collectively advancing claims on behalf of all Canadians who have been prescribed and/or used OxyContin. ... On August 24, 2010, the defendant Companies signed a settlement agreement that will potentially resolve the claims of up to 155 of such claimants. As of April 13, 2011, nearly all of those claimants have agreed to participate in the settlement. The defendant Companies believe they have meritorious defenses with respect to such claims and will vigorously defend them.</p>

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

Document

Excerpt

- | | |
|---|---|
| [9] Audited Combined Financial Statements for the years ended 2010 and 2009 | <i>OxyContin Tablets Litigation - Consumer Protection Claims</i> . In 2007, two consumer protection claims were filed against certain of the Companies by third party payors alleging improper promotion of OxyContin caused them to pay for unnecessary and excessive usage of OxyContin. Both actions were consolidated in the U.S. District Court for the Southern District of New York (the "Southern District"). The parties entered into a settlement disposing of both actions, which was approved by the Southern District at a Fairness Hearing on May 15, 2009. Pursuant to the terms of the settlement, the two actions were dismissed with prejudice. ... On September 9, 2010, a putative nationwide consumer class action was filed against certain of the Companies by a California consumer alleging improper promotion of OxyContin caused consumers to pay an excessive price for the medication. The case is pending in the U.S. District Court for the Eastern District of California. The defendant Companies believe they have meritorious defenses and intend to vigorously defend the claims. |
|---|---|

Appendix F-1

Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[10] Audited Combined Financial Statements for the years ended 2010 and 2009	<i>OxyContin Tablets Litigation - Regulatory, Law Enforcement and Governmental Matters</i> . On July 20, 2007 the U.S. District Court for the Western District of Virginia (the "WDVA") approved a settlement between certain of the Companies and the U.S. Attorney's Office for the WDVA to end a pending investigation. As part of this resolution, The Purdue Frederick Company Inc. pled guilty to a single felony count of misbranding based upon misstatements made in the promotion of OxyContin to healthcare professionals that occurred prior to July 2001. ... In May 2007, in connection with investigations involving activities related to certain of the Companies and their promotion of OxyContin, such Companies signed consent judgments to settle investigations with twenty-seven State Attorneys General. In addition, such Companies settled separately with the Attorneys General for the State of Florida and the State of Mississippi. ... On October 4, 2007, the Attorney General of the Commonwealth of Kentucky and Pike County, Kentucky filed a claim against certain of the Companies in state court alleging such Companies' improper promotion of OxyContin caused the plaintiffs to pay for excessive costs related to the usage of OxyContin, as well as the costs arising from misuse and addiction. ... The defendant Companies in this action believe they have meritorious defenses with respect to these claims and will vigorously defend them.

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

Document

Excerpt

- | | |
|--|---|
| [11] Audited Combined Financial Statements for the years ended 2011 and 2010 | <p><i>OxyContin® Tablets Litigation - Civil Product Liability Lawsuits</i>. Numerous individuals have made product liability claims related to OxyContin® tablets ("OxyContin") against certain of the Companies. Most of those claimants allege that (1) they suffered bodily injury from the use of OxyContin, including addiction, (2) the defendant Companies failed to adequately warn them about the risks of addiction, and (3) the defendant Companies "over-promoted" and aggressively and/or fraudulently marketed OxyContin. The claimants seek various forms of relief, including compensatory and punitive damages, interest and costs, and attorneys' fees. ... As of April 5, 2012, approximately 24 OxyContin product liability lawsuits are pending in the United States against the defendant Companies. Only three of those lawsuits are being actively litigated (e.g., the parties are engaged in discovery or substantive motion practice). The remaining lawsuits are inactive or the claimants are in the process of determining whether or not to participate in previously negotiated group settlements. ... Since the beginning of 2011, the defendant Companies have entered into three settlements to resolve OxyContin personal injury claims. ... The defendant Companies have also maintained agreements to toll the statutes of limitations of potential claims on behalf of approximately several hundred individuals not subject to the settlements. On August 24, 2010, the defendant Companies signed a settlement agreement that will potentially resolve the claims of up to 155 of such claimants. As of April 5, 2012, nearly all of those claimants have agreed to participate in the settlement. ... The defendant Companies believe they have meritorious defenses with respect to such claims and will vigorously defend them.</p> |
|--|---|

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[12] Audited Combined Financial Statements for the years ended 2011 and 2010	<i>OxyContin® Tablets Litigation - Consumer Protection Claims</i> . In 2007, two consumer protection claims were filed against certain of the Companies by third party payors alleging improper promotion of OxyContin caused them to pay for unnecessary and excessive usage of OxyContin. Both actions were consolidated in the U.S. District Court for the Southern District of New York (the "Southern District"). The parties entered into a settlement disposing of both actions, which was approved by the Southern District at a Fairness Hearing on May 15, 2009. Pursuant to the terms of the settlement, the two actions were dismissed with prejudice. ... On September 9, 2010, a putative nationwide consumer class action was filed against certain of the Companies by a California consumer alleging improper promotion of OxyContin caused consumers to pay an excessive price for the medication. ... On May 19, 2011, the plaintiff voluntarily dismissed without prejudice her claims ... In the event plaintiff should re-file her claims, the defendant Companies believe they would continue to vigorously assert their meritorious defenses.

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

Document

Excerpt

- | | |
|--|--|
| [13] Audited Combined Financial Statements for the years ended 2011 and 2010 | <p><i>OxyContin® Tablets Litigation - Regulatory, Law Enforcement and Governmental Matters</i>. On July 20, 2007, the U.S. District Court for the Western District of Virginia (the "WDVA") approved a settlement between certain of the Companies and the U.S. Attorney's Office for the WDVA to end a pending investigation. As part of this resolution, The Purdue Frederick Company Inc. pled guilty to a single felony count of misbranding based upon misstatements made in the promotion of OxyContin to healthcare professionals that occurred prior to July 2001. As part of the agreement with the government and based upon their senior positions with such Companies, three former executives also pled guilty to a single "strict liability" misdemeanor for misbranding based upon the misconduct of other employees while the executives held their positions of responsibility. ... In May 2007, in connection with investigations involving activities related to certain of the Companies and their promotion of OxyContin, such Companies signed consent judgments to settle investigations with 27 State Attorneys General. In addition, such Companies settled separately with the Attorneys General for the State of Florida and the State of Mississippi. ... On October 4, 2007, the Attorney General of the Commonwealth of Kentucky and Pike County, Kentucky filed a claim against certain of the Companies in state court alleging such Companies' improper promotion of OxyContin caused the plaintiffs to pay for excessive costs related to the usage of OxyContin, as well as the costs arising from misuse and addiction. ... On October 24, 2011, the Second Circuit granted the defendant Companies a temporary stay of the Southern District's remand order pending the Second Circuit's determination of the appeal. As of April 5, 2012, the appeal is still pending. The defendant Companies in this action believe they have meritorious defenses with respect to these claims and will vigorously defend them.</p> |
|--|--|

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[14] Audited Combined Financial Statements for the years ended 2012 and 2011	<i>OxyContin® Tablets Litigation - Civil Product Liability Lawsuits</i> . Numerous individuals have made product liability claims related to OxyContin® tablets ("OxyContin") against certain of the Companies. Most of those claimants allege that (1) they suffered bodily injury from the use of OxyContin, including addiction, (2) the defendant Companies failed to adequately warn them about the risks of addiction, and (3) the defendant Companies "over-promoted" and aggressively and/or fraudulently marketed OxyContin. The claimants seek various forms of relief, including compensatory and punitive damages, interest and costs, and attorneys' fees. ... As of March 29, 2013, approximately 21 OxyContin product liability lawsuits are pending in the United States against the defendant Companies. Only three of those lawsuits are being actively litigated (e.g., the parties are now or soon will be engaged in discovery or substantive motion practice). The remaining lawsuits are inactive or the claimants are in the process of determining whether or not to participate in previously negotiated group settlements. ... [Description of events related to lawsuits.] The defendant Companies believe they have meritorious defenses with respect to such claims and will vigorously defend them.
[15] Audited Combined Financial Statements for the years ended 2012 and 2011	<i>OxyContin® Tablets Litigation - Consumer Protection Claims</i> . On September 9, 2010, a putative nationwide consumer class action was filed against certain of the Companies by a California consumer alleging improper promotion of OxyContin caused consumers to pay an excessive price for the medication. On May 19, 2011, the plaintiff voluntarily dismissed without prejudice her claims after the defendant Companies filed motions to dismiss the claims and strike the class allegations. In the event plaintiff should re-file her claims, the defendant Companies believe they have meritorious defenses with respect to such claims and would vigorously defend them.

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

Document

Excerpt

- | | |
|--|---|
| [16] Audited Combined Financial Statements for the years ended 2012 and 2011 | <i>OxyContin® Tablets Litigation - Regulatory, Law Enforcement and Governmental Matters</i> . On July 20, 2007, the U.S. District Court for the Western District of Virginia (the "WDVA") approved a settlement between certain of the Companies and the U.S. Attorney's Office for the WDVA to end a pending investigation. As part of this resolution, The Purdue Frederick Company Inc. pled guilty to a single felony count of misbranding based upon misstatements made in the promotion of OxyContin to healthcare professionals that occurred prior to July 2001. ... In May 2007, in connection with investigations involving activities related to certain of the Companies and their promotion of OxyContin, such Companies signed consent judgments to settle investigations with 27 State Attorneys General. In addition, such Companies settled separately with the Attorneys General for the State of Florida and the State of Mississippi. ... The defendant Companies in this action believe they have meritorious defenses with respect to these claims and will vigorously defend them. |
| [17] Audited Combined Financial Statements for the years ended 2013 and 2012 | <i>OxyContin® Tablets Litigation - Civil Product Liability Lawsuits</i> . Numerous individuals have made product liability claims related to OxyContin® tablets ("OxyContin") against certain of the Companies. Most of those claimants allege that (1) they suffered bodily injury from the use of OxyContin, including addiction, (2) the defendant Companies failed to adequately warn them about the risks of addiction, and (3) the defendant Companies "overpromoted" and aggressively and/or fraudulently marketed OxyContin. The claimants seek various forms of relief, including compensatory and punitive damages, interest and costs, and attorneys' fees. ... The defendant Companies believe they have meritorious defenses with respect to such claims and will vigorously defend them. |

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[18] Audited Combined Financial Statements for the years ended 2013 and 2012	<i>OxyContin® Tablets Litigation - Regulatory, Law Enforcement and Governmental Matters</i> . On July 20, 2007, the U.S. District Court for the Western District of Virginia (the "WDVA") approved a settlement between certain of the Companies and the U.S. Attorney's Office for the WDVA to end a pending investigation. As part of this resolution, The Purdue Frederick Company Inc. pled guilty to a single felony count of misbranding based upon misstatements made in the promotion of OxyContin to healthcare professionals that occurred prior to July 2001. As part of the agreement with the government and based upon their senior positions with such Companies, three former executives also pled guilty to a single "strict liability" misdemeanor for misbranding based upon the misconduct of other employees while the executives held their positions of responsibility. [Description of other related lawsuits.] The defendant Companies in this action believe they have meritorious defenses with respect to the Commonwealth's [and other claimants'] claims and will vigorously defend them.
[19] Audited Combined Financial Statements for the years ended 2014 and 2013	<i>OxyContin Tablets Litigation - Civil Product Liability Lawsuits</i> . Numerous individuals have made product liability claims related to OxyContin tablets against certain of the Companies. Most of those claimants allege that (1) they suffered bodily injury from the use of OxyContin, including addiction, (2) the defendant Companies failed to adequately warn them about the risks of addiction, and (3) the defendant Companies "over-promoted" and aggressively and/or fraudulently marketed OxyContin. The claimants seek various forms of relief, including compensatory and punitive damages, interest and costs, and attorneys' fees. ... The defendant Companies believe they have meritorious defenses with respect to such claims and will vigorously defend them.

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[20] Audited Combined Financial Statements for the years ended 2014 and 2013	<i>OxyContin Tablets Litigation - Regulatory, Law Enforcement and Governmental Matters</i> . On October 4, 2007, the Attorney General of the Commonwealth of Kentucky and Pike County, Kentucky filed a claim against certain of the Companies in Pike County Circuit Court alleging such Companies violated the Kentucky Medicaid Fraud Statute and various tort law claims, including a claim for public nuisance. ... The defendant Companies in this action believe they have meritorious defenses with respect to the Commonwealth's claims and will vigorously defend them.

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

Document

Excerpt

[21] Audited Combined Financial Statements for the years ended 2014 and 2013	In December 2013, PPLP received a subpoena from the New York Attorney General's office that requested a broad array of documents and items related to the marketing of OxyContin and certain other PPLP programs and websites. PPLP is cooperating and producing responsive materials on a rolling basis. In September 2014, PPLP received a Request for Information from the Tennessee Attorney General seeking documents related to the marketing of OxyContin, certain programs and the content of some of its websites. In August, 2014, PPLP received a request for documents from the California Attorney General pursuant to the prior Consent Judgment filed in May, 2007. ... On May 21, 2014, two counties in the State of California (the California plaintiff) filed a complaint in state court against certain of the Companies and five other pharmaceutical companies alleging false and deceptive marketing practices. ... The defendant Companies moved to dismiss the amended complaint, which is now fully briefed on both sides. The defendant Companies in these actions believe they have meritorious defenses with respect to both the California plaintiff and the Chicago plaintiff's claims and will vigorously defend them. ... In March 2015, certain of the Companies received a Civil Investigative Demand from the Massachusetts Attorney General seeking documents and materials related to the marketing of OxyContin, payments to healthcare professionals in Massachusetts, and information the Companies allegedly knew about abuse, misuse and addiction to OxyContin. The Companies anticipate producing materials and cooperating with the investigation.
--	--

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[22] Audited Combined Financial Statements for the years ended 2015 and 2014	<i>OxyContin® Tablets Litigation - Civil Product Liability Lawsuits</i> . Numerous individuals have made product liability claims related to OxyContin® tablets (OxyContin) against certain of the Companies. Most of those claimants allege that (1) they suffered bodily injury from the use of OxyContin, including addiction, (2) the defendant Companies failed to adequately warn them about the risks of addiction, and (3) the defendant Companies “over-promoted” and aggressively and/or fraudulently marketed OxyContin. The claimants seek various forms of relief, including compensatory and punitive damages, interest and costs, and attorneys’ fees. ... Of the more than 18,000 OxyContin personal injury claims brought against certain of the Companies since 2001, approximately 18 OxyContin product liability lawsuits are pending in the United States against the defendant Companies. None of the plaintiffs in those pending lawsuits is actively pursuing his or her claim, and the Companies expect that the cases will remain dormant. ... The defendant Companies believe they have meritorious defenses with respect to such claims and will vigorously defend them.
[23] Audited Combined Financial Statements for the years ended 2015 and 2014	<i>OxyContin® Tablets Litigation – Regulatory, Law Enforcement and Governmental Matters</i> . On October 4, 2007, the Attorney General of the Commonwealth of Kentucky and Pike County, Kentucky filed a claim against certain of the Companies in Pike County Circuit Court alleging such Companies violated the Kentucky Medicaid Fraud Statute and various tort law claims, including a claim for public nuisance. On June 4, 2013, the defendant Companies settled Pike County’s claim for \$4 million. On December 18, 2015, the defendant Companies settled the Commonwealth of Kentucky’s claim for \$24 million, with a portion of those payments due in installments over the next 8 years.

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[24] Audited Combined Financial Statements for the years ended 2015 and 2014	Opioid Litigation. Beginning in May 2014, certain state and local governments commenced litigation against certain of the Companies and five other manufacturers of opioid analgesics making similar allegations of false and deceptive marketing practices. On May 21, 2014, Santa Clara County and Orange County, California filed a complaint in California state court against the defendants. The defendants filed various demurrers or motions to dismiss or stay that complaint. On August 27, 2015, the Court stayed the action pursuant to the doctrine of primary jurisdiction and the court's inherent authority to manage its own cases. ... The defendant Companies believe they have meritorious defenses with respect to the claims asserted in the California, Chicago, and Mississippi actions and are vigorously defending them.
[25] Audited Combined Financial Statements for the years ended 2016 and 2015	<i>OxyContin® Tablets Litigation - Civil Product Liability Lawsuits</i> . Numerous individuals have made product liability claims related to OxyContin® tablets (OxyContin) against certain of the Companies. The claimants seek various forms of relief, including compensatory and punitive damages, interest and costs, and attorneys' fees. Currently, approximately 19 OxyContin product liability lawsuits are pending in the United States against the defendant Companies. None of the plaintiffs in those pending lawsuits is actively pursuing his or her claim, and the Companies expect that the cases will remain dormant. ... In addition, there are ten product liability putative class action lawsuits against the defendant Companies in Canada, collectively advancing claims on behalf of all Canadians who have been prescribed and/or used OxyContin or OxyNEO®. As of February, 2017, the defendant Companies entered into a settlement of all of the claims in all of these lawsuits, and they have notified the four provincial courts. Court approval of the settlement by these courts are expected in the first half of 2018.

Appendix F-1

Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

Document

Excerpt

- | | |
|--|--|
| [26] Audited Combined Financial Statements for the years ended 2016 and 2015 | <i>OxyContin® Tablets Litigation - Regulatory, Law Enforcement and Governmental Matters</i> . On October 4, 2007, the Attorney General of the Commonwealth of Kentucky (Kentucky AG) and Pike County, Kentucky filed a claim against certain of the Companies in Pike County Circuit Court alleging such Companies violated the Kentucky Medicaid Fraud Statute and various tort law claims, including a claim for public nuisance. On June 4, 2013, the defendant Companies settled Pike County's claim for \$4 million. On December 18, 2015, the defendant Companies settled the Kentucky AG's claims for \$24 million, with a portion of those payments due in installments over the next 8 years. |
| [27] Audited Combined Financial Statements for the years ended 2016 and 2015 | <i>Opioid Litigation</i> . Beginning in May 2014, certain state and local governments commenced litigation against certain of the Companies and several other manufacturers of opioid analgesics (collectively, the defendants) making similar allegations of false and deceptive marketing practices. ... [Description of various related lawsuits.] The defendant Companies believe they have meritorious defenses with respect to the claims asserted in the California, Chicago, Mississippi, Suffolk County, Everett, Erie County and Broome County actions and are vigorously defending them. |

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[28] Audited Combined Financial Statements for the years ended 2017 and 2016	<i>OxyContin® Tablets Litigation - Civil Product Liability Lawsuits</i> . Numerous individuals have made product liability claims related to OxyContin® tablets ("OxyContin") against certain of the Companies. The claimants seek various forms of relief, including compensatory and punitive damages, interest and costs and attorneys' fees. Currently, approximately 19 OxyContin product liability lawsuits are pending in the United States against the defendant Companies. None of the plaintiffs in those pending lawsuits is actively pursuing his or her claim, and the Companies expect that the cases will remain dormant. In addition, there are ten product liability putative class action lawsuits against the defendant Companies in Canada, collectively advancing claims on behalf of all Canadians who have been prescribed and/or used OxyContin or OxyNEO®. As of February 2017, the defendant Companies entered into a settlement agreement for all of the claims in all of these lawsuits, and have notified the four provincial courts. Approval of the settlement by these courts is expected in the first half of 2018.

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

<u>Document</u>	<u>Excerpt</u>
[29] Audited Combined Financial Statements for the years ended 2017 and 2016	<p><i>Opioid Litigation</i> . Beginning in May 2014, certain state and local governments commenced litigation against PPLP, Purdue Pharma Inc., and/or The Purdue Frederick Company Inc. (collectively, the "Purdue Entities") and several other manufacturers of opioid analgesics, making similar allegations of false and deceptive marketing practices. ... As of March 29, 2018, there are approximately 620 lawsuits pending against the Purdue Entities in federal and state courts around the United States, most of which were filed in 2017 and 2018. In general, these lawsuits, which have been brought by state Attorneys General, municipalities, and third-party health care providers, allege that the Purdue Entities engaged in unfair or deceptive marketing practices related to the promotions and sale of their opioid medications. The lawsuits seek compensatory, treble and punitive damages, and/or various forms of injunctive relief. [Description of related cases.] The Purdue Entities believe they have meritorious defenses with respect to the claims asserted in the various state and federal actions and are vigorously defending against them. Unfavorable outcomes in such actions could have a material adverse effect on the Companies' financial position, operations and cash flows. ... The Companies are cooperating with these investigations. The Companies cannot predict the outcome of these investigations; however, unfavorable outcomes could have a material adverse effect on the Companies' financial position, operations and cash flows.</p>
[30] Audited Combined Financial Statements for the years ended 2017 and 2016	<p><i>OxyContin® Tablets Litigation - Regulatory, Law Enforcement and Governmental Matters</i> . On October 4, 2007, the Attorney General of the Commonwealth of Kentucky ("Kentucky AG") and Pike County, Kentucky filed a claim against certain of the Companies in Pike County Circuit Court alleging such Companies violated the Kentucky Medicaid Fraud Statute and various tort law claims, including a claim for public nuisance. On June 4, 2013, the defendant Companies settled Pike County's claim for \$4 million. On December 18, 2015, the defendant Companies settled the Kentucky AG's claims for \$24 million, with a portion of those payments due in installments over the next eight years.</p>

Appendix F-1
Excerpts from Purdue's Audited Combined Financial Statements Related to Opioid Litigation Risk

Sources:

- [1] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2008 and 2007, PPLPC0120000221168-206 at 199.
- [2] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2008 and 2007, PPLPC0120000221168-206 at 200.
- [3] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2008 and 2007, PPLPC0120000221168-206 at 200.
- [4] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2008 and 2007, PPLPC0120000221168-206 at 201.
- [5] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697 at 690-691.
- [6] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697 at 691.
- [7] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2009 and 2008, PPLPC012000270659-697 at 691-692.
- [8] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991 at 983-984.
- [9] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991 at 984.
- [10] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2010 and 2009, PPLPC012000323951-991 at 985.
- [11] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583 at 574-575.
- [12] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583 at 575-576.
- [13] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2011 and 2010, PPLPMDL0040000537-583 at 576-577.
- [14] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLPC029000544175-219 at 207-209.
- [15] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLPC029000544175-219 at 209.
- [16] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2012 and 2011, PPLPC029000544175-219 at 209-210.
- [17] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174 at 166.
- [18] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2013 and 2012, PPLPC029000589136-174 at 167.
- [19] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664 at 654.
- [20] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664 at 655.
- [21] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2014 and 2013, POK003285615-664 at 661-662.
- [22] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPCO 11000090527, p. 43.
- [23] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPCO 11000090527, p. 44.
- [24] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2015 and 2014, PPLPCO 11000090527, p. 51.
- [25] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316 at 304.
- [26] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316 at 305.
- [27] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2016 and 2015, PPLPC021000890262-316 at 312-313.
- [28] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2017 and 2016, PPLPC029000692681-739 at 726.
- [29] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2017 and 2016, PPLPC029000692681-739 at 734-736.
- [30] Purdue Pharma L.P. and Associated Companies, Audited Combined Financial Statements for the years ended 2017 and 2016, PPLPC029000692681-739 at 734.

Appendix F-2
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Mallinckrodt

<u>Document</u>	<u>Excerpt</u>
[1] Form 10-K, for the fiscal year ended September 27, 2013	<i>Risk Evaluation and Mitigation Strategies</i> . For certain drug products or classes, such as transmucosal immediate-release fentanyl products and extended-release and long-acting opioids, the FDA has the authority to require the manufacturer to provide a REMS that is intended to ensure that the benefits of a drug product (or class of drug products) outweigh the risks of harm. The FDA may require that a REMS include elements to ensure safe use to mitigate a specific serious risk of harm, such as requiring that prescriber have particular training or experience or that the drug product is dispensed in certain healthcare settings. The FDA has the authority to impose civil penalties on or take other enforcement action against any drug manufacturer who fails to properly implement an approved REMS program.
[2] Form 10-K, for the fiscal year ended September 27, 2013	From a compliance standpoint, the DEA continues to increase its efforts to hold manufacturers, distributors and pharmacies accountable through various enforcement actions as well as the implementation of compliance practices for controlled substances, including SOM activities for Schedule II opioids.
[3] Form 10-K, for the fiscal year ended September 26, 2014	For all pharmaceuticals sold in the U.S., the FDA also regulates sales and marketing to ensure that drug product claims made by manufacturers are neither false nor misleading. Manufacturers are required to file copies of all product-specific promotional materials to the FDA's Office of Prescription Drug Promotion prior to their first use. In general, such advertising does not require FDA prior approval. Failure to implement a robust internal company review process and comply with FDA regulations regarding advertising and promotion increases the risk of enforcement action by either the FDA or the U.S. Department of Justice.

Appendix F-2
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Mallinckrodt

<u>Document</u>	<u>Excerpt</u>
[4] Form 10-K, for the fiscal year ended September 26, 2014	<i>Risk Evaluation and Mitigation Strategies ("REMS")</i> . For certain drug products or classes, such as transmucosal immediate-release fentanyl products and extended-release and long-acting opioids, the FDA has the authority to require the manufacturer to provide a REMS that is intended to ensure that the benefits of a drug product (or class of drug products) outweigh the risks of harm. ... The FDA has the authority to impose civil penalties on or take other enforcement action against any drug manufacturer who fails to properly implement an approved REMS program.
[5] Form 10-K, for the fiscal year ended September 26, 2014	To meet its responsibilities, the DEA conducts periodic inspections of registered establishments that handle controlled substances. ... Failure to maintain compliance, particularly as manifested in loss or diversion, can result in regulatory action that could have a material adverse effect on our competitive position, business, financial condition, results of operations and cash flows. The DEA may seek civil penalties, refuse to renew necessary registrations or initiate proceedings to revoke those registrations. In certain circumstances, violations could lead to criminal proceedings.
[6] Form 10-K, for the fiscal year ended September 26, 2014	From a compliance standpoint, the DEA continues to increase its efforts to hold manufacturers, distributors and pharmacies accountable for the abuse, overdose and diversion of controlled substances through various enforcement actions as well as the implementation of compliance practices for controlled substances, including suspicious ordering monitoring activities for Schedule II opioids.

Appendix F-2
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Mallinckrodt

<u>Document</u>	<u>Excerpt</u>
[7] Form 10-K, for the fiscal year ended September 25, 2015	For all pharmaceuticals sold in the U.S., the FDA also regulates sales and marketing to ensure that drug product claims made by manufacturers are neither false nor misleading. Manufacturers are required to file copies of all product-specific promotional materials to the FDA's Office of Prescription Drug Promotion prior to their first use. In general, such advertising does not require FDA prior approval. Failure to implement a robust internal company review process and comply with FDA regulations regarding advertising and promotion increases the risk of enforcement action by either the FDA or the U.S. Department of Justice.
[8] Form 10-K, for the fiscal year ended September 25, 2015	The FDA has the authority to impose civil penalties on or take other enforcement action against any drug manufacturer who fails to properly implement an approved REMS program. Separately, a drug manufacturer cannot use an approved REMS program to delay generic competition.
[9] Form 10-K, for the fiscal year ended September 25, 2015	We are or may be involved in various legal proceedings and certain government inquiries and investigations, including with respect to, but not limited to, patent infringement, product liability, antitrust matters, securities class action lawsuits, breach of contract, Medicare and Medicaid reimbursement claims, promotional practices and compliance with laws relating to the manufacturing and sale of controlled substances, such as those relating to the operation of a suspicious order monitoring program. ... With respect to product liability and clinical trial risks, in the ordinary course of business we are subject to liability claims and lawsuits, including potential class actions, alleging that our marketed products or products in development have caused, or could cause, serious adverse events or other injury.

Appendix F-2
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Mallinckrodt

<u>Document</u>	<u>Excerpt</u>
[10] Form 10-K, for the fiscal year ended September 30, 2016	<i>Risk Evaluation and Mitigation Strategies ("REMS")</i> . For certain drug products or classes, such as transmucosal immediate-release fentanyl products and extended-release and long-acting opioids, the FDA has the authority to require the manufacturer to provide a REMS that is intended to ensure that the benefits of a drug product (or class of drug products) outweigh the risks of harm. ... The FDA has the authority to impose civil penalties on or take other enforcement action against any drug manufacturer who fails to properly implement an approved REMS program. Separately, a drug manufacturer cannot use an approved REMS program to delay generic competition.
[11] Form 10-K, for the fiscal year ended December 29, 2017	Risk Evaluation and Mitigation Strategies. For certain drug products or classes, such as transmucosal immediate-release fentanyl ("TIRF") products and extended-release and long-acting opioids, the FDA has the authority to require the manufacturer to provide a REMS that is intended to ensure that the benefits of a drug product (or class of drug products) outweigh the risks of harm. [...] The FDA has the authority to impose civil penalties on or take other enforcement action against any drug manufacturer who fails to properly implement an approved REMS program.

Appendix F-2
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Mallinckrodt

<u>Document</u>	<u>Excerpt</u>
[12] Form 10-K, for the fiscal year ended December 29, 2017	We are or may be involved in various legal proceedings and certain government inquiries and investigations, including with respect to, but not limited to, patent infringement, product liability, personal injury, antitrust matters, securities class action lawsuits, breach of contract, Medicare and Medicaid reimbursement claims, opioid related matters, promotional practices and compliance with laws relating to the manufacture and sale of controlled substances. For example, we, along with other opioid manufacturers and, often, distributors, have been named in lawsuits related to the manufacturing, distribution, marketing and promotion of opioids. In addition, we have also received various subpoenas and requests for information related to the distribution, marketing and sale of our opioid products. ... With respect to product liability and clinical trial risks, in the ordinary course of business we are subject to liability claims and lawsuits, including potential class actions, alleging that our marketed products or products in development have caused, or could cause, serious adverse events or other injury.
[13] Form 10-K, for the fiscal year ended December 29, 2017	<i>Opioid Related Matters . Multidistrict Litigation .</i> The Company has been named in lawsuits court brought by various counties, cities, Native American tribes, hospitals, third-party payers and others against opioid manufacturers and, often, distributors. In general, the lawsuits assert claims of public nuisance, negligence, civil conspiracy, fraud, violations of the Racketeer Influenced and Corrupt Organizations Act or similar state laws, consumer fraud, deceptive trade practices, insurance fraud, unjust enrichment and other common law claims arising from defendants' manufacturing, distribution, marketing and promotion of opioids and seek restitution, damages, injunctive and other relief and attorneys' fees and costs.

Appendix F-2
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Mallinckrodt

Sources:

- [1] Mallinckrodt plc, Form 10-K, for the fiscal year ended September 27, 2013, p. 17.
- [2] Mallinckrodt plc, Form 10-K, for the fiscal year ended September 27, 2013, p. 30.
- [3] Mallinckrodt plc, Form 10-K, for the fiscal year ended September 26, 2014, p. 13.
- [4] Mallinckrodt plc, Form 10-K, for the fiscal year ended September 26, 2014, p. 15.
- [5] Mallinckrodt plc, Form 10-K, for the fiscal year ended September 26, 2014, p. 16.
- [6] Mallinckrodt plc, Form 10-K, for the fiscal year ended September 26, 2014, p. 24.
- [7] Mallinckrodt plc, Form 10-K, for the fiscal year ended September 25, 2015, p. 12.
- [8] Mallinckrodt plc, Form 10-K, for the fiscal year ended September 25, 2015, p. 14.
- [9] Mallinckrodt plc, Form 10-K, for the fiscal year ended September 25, 2015, p. 30.
- [10] Mallinckrodt plc, Form 10-K, for the fiscal year ended September 30, 2016, p. 13.
- [11] Mallinckrodt plc, Form 10-K, for the fiscal year ended December 29, 2017, p. 15.
- [12] Mallinckrodt plc, Form 10-K, for the fiscal year ended December 29, 2017, p. 32.
- [13] Mallinckrodt plc, Form 10-K, for the fiscal year ended December 29, 2017, p. 124.

Appendix F-3
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Endo International

<u>Document Title</u>	<u>Excerpt</u>
[1] Form 10-K/A, for the fiscal year ended December 31, 2007	Most of our core products contain narcotic ingredients. Misuse or abuse of such drugs can lead to physical or other harm. For example, in the past two years, reportedly widespread misuse or abuse of OxyContin®, a product of Purdue Pharma L.P., or Purdue, containing the narcotic oxycodone, resulted in the strengthening of warnings on its labeling. In addition, we believe that Purdue, the manufacturer of OxyContin®, faces or did face numerous lawsuits, including class action lawsuits, related to OxyContin® misuse or abuse. On June 7, 2005, we began commercial sale of our oxycodone extended-release tablets, 10mg, 20mg, 40mg and 80mg strengths, each bioequivalent versions of OxyContin®. Pursuant to a settlement agreement with Purdue, all sales of our oxycodone extended-release tablets ceased as of December 31, 2006. However, we may be subject to litigation similar to the OxyContin® suits related to our generic version of OxyContin® or any other narcotic containing product that we market.
[2] Form 10-K, for the fiscal year ended December 31, 2008	Most of our core products contain narcotic ingredients. Misuse or abuse of such drugs can lead to physical or other harm. For example, in the past, reportedly widespread misuse or abuse of OxyContin®, a product of Purdue Pharma L.P., or Purdue, containing the narcotic oxycodone, resulted in the strengthening of warnings on its labeling. In addition, we believe that Purdue, the manufacturer of OxyContin®, faces or did face numerous lawsuits, including class action lawsuits, related to OxyContin® misuse or abuse. On June 7, 2005, we began commercial sale of our oxycodone extended-release tablets, 10mg, 20mg, 40mg and 80mg strengths, each bioequivalent versions of OxyContin®. Pursuant to a settlement agreement with Purdue, all sales of our oxycodone extended-release tablets ceased as of December 31, 2006. However, we may be subject to litigation similar to the OxyContin® suits related to any narcotic-containing product that we market.

Appendix F-3
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Endo International

<u>Document Title</u>	<u>Excerpt</u>
[3] Form 10-K, for the fiscal year ended December 31, 2009	Many of our core products contain narcotic ingredients. Misuse or abuse of such drugs can lead to physical or other harm. For example, in the past, reportedly widespread misuse or abuse of OxyContin®, a product of Purdue Pharma L.P., or Purdue, containing the narcotic oxycodone, resulted in the strengthening of warnings on its labeling. In addition, we believe that Purdue, the manufacturer of OxyContin®, faces or did face numerous lawsuits, including class action lawsuits, related to OxyContin® misuse or abuse. On June 7, 2005, we began commercial sale of our oxycodone extended-release tablets, 10mg, 20mg, 40mg and 80mg strengths, each bioequivalent versions of OxyContin®. Pursuant to a settlement agreement with Purdue, all sales of our oxycodone extended-release tablets ceased as of December 31, 2006. However, we may be subject to litigation similar to the OxyContin® suits related to any narcotic-containing product that we market.
[4] Form 10-K, for the fiscal year ended December 31, 2010	Many of our core products contain narcotic ingredients. Misuse or abuse of such drugs can lead to physical or other harm. For example, in the past, reportedly widespread misuse or abuse of OxyContin®, a product of Purdue Pharma L.P., or Purdue, containing the narcotic oxycodone, resulted in the strengthening of warnings on its labeling. In addition, we believe that Purdue, the manufacturer of OxyContin®, faces or did face numerous lawsuits, including class action lawsuits, related to OxyContin® misuse or abuse. We may be subject to litigation similar to the OxyContin® suits related to any narcotic-containing product that we market.

Appendix F-3
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Endo International

<u>Document Title</u>	<u>Excerpt</u>
[5] Form 10-K, for the fiscal year ended December 31, 2011	Many of our core products contain narcotic ingredients. Misuse or abuse of such drugs can lead to physical or other harm. For example, in the past, reportedly widespread misuse or abuse of OxyContin®, a product of Purdue Pharma L.P., or Purdue, containing the narcotic oxycodone, resulted in the strengthening of warnings on its labeling. In addition, we believe that Purdue, the manufacturer of OxyContin®, faces or did face numerous lawsuits, including class action lawsuits, related to OxyContin® misuse or abuse. We may be subject to litigation similar to the OxyContin® suits related to any narcotic-containing product that we market.
[6] Form 10-K, for the fiscal year ended December 31, 2012	Many of our core products contain narcotic ingredients. Misuse or abuse of such drugs can lead to physical or other harm. For example, in the past, reportedly widespread misuse or abuse of OxyContin®, a product of Purdue Pharma L.P., or Purdue, containing the narcotic oxycodone, resulted in the strengthening of warnings on its labeling. In addition, we believe that Purdue, the manufacturer of OxyContin®, faces or did face numerous lawsuits, including class action lawsuits, related to OxyContin® misuse or abuse. We may be subject to litigation similar to the OxyContin® suits related to any narcotic-containing product that we market.
[7] Form 10-K, for the fiscal year ended December 31, 2013	Many of our core products contain narcotic ingredients. Misuse or abuse of such drugs can lead to physical or other harm. For example, in the past, reportedly widespread misuse or abuse of OxyContin®, a product of Purdue Pharma L.P., or Purdue, containing the narcotic oxycodone, resulted in the strengthening of warnings on its labeling. In addition, we believe that Purdue, the manufacturer of OxyContin®, faces or did face numerous lawsuits, including class action lawsuits, related to OxyContin® misuse or abuse. We may be subject to litigation similar to the OxyContin® suits related to any narcotic-containing product that we market.

Appendix F-3
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Endo International

<u>Document Title</u>	<u>Excerpt</u>
[8] Form 10-K, for the fiscal year ended December 31, 2013	In March 2013, the Company received an Investigative Subpoena from the Corporation Counsel for the City of Chicago seeking documents and information regarding the sales and marketing of opioids, including Opana®. Following discussion with the Company, in May 2013, the Corporation Counsel for the city of Chicago served the Company with a revised Investigative Subpoena seeking the same documents and information. In September 2013, the Company received a subpoena from the State of New York Office of Attorney General seeking documents and information regarding the sales and marketing of Opana® The Company is cooperating with the Corporation Counsel for the City of Chicago, the State of New York Office of Attorney General and the Office of the United States Attorney for the Eastern District of Pennsylvania in their respective investigations. At this time, the Company cannot predict the outcome of these matters or reasonably estimate the amount or range of amounts or fines and penalties, if any, that might result from any adverse outcome but will explore all options as appropriate in the best interests of EPI and the Company.
[9] Form 10-K, for the fiscal year ended December 31, 2014	Many of our core products contain narcotic ingredients. Misuse or abuse of such drugs can lead to physical or other harm. For example, in the past, reportedly widespread misuse or abuse of OxyContin®, a product of Purdue Pharma L.P., or Purdue, containing the narcotic oxycodone, resulted in the strengthening of warnings on its labeling. In addition, we believe that Purdue, the manufacturer of OxyContin®, faces or did face numerous lawsuits, including class action lawsuits, related to OxyContin® misuse or abuse. We may be subject to litigation similar to the OxyContin® suits related to any narcotic-containing product that we market.

Appendix F-3
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Endo International

<u>Document Title</u>	<u>Excerpt</u>
[10] Form 10-K, for the fiscal year ended December 31, 2014	In September 2013, the Company received a subpoena from the State of New York Office of Attorney General seeking documents and information regarding the sales and marketing of Opana® and in October 2014 received a Subpoena Ad Testificandum seeking testimony regarding the sales and marketing of Opana®. In January 2014, the Company received a set of informal document requests from the Office of the United States Attorney for the Eastern District of Pennsylvania seeking documents and information regarding the sales and marketing of Opana® ER. In September 2014, the Company received a Request for Information from the State of Tennessee Office of the Attorney General and Reporter seeking documents and information regarding the sales and marketing of opioids, including Opana® ER.
[11] Form 10-K, for the fiscal year ended December 31, 2014	In March 2013, the Company's subsidiary, Endo Health Solutions Inc. received an Investigative Subpoena from the Corporation Counsel for the City of Chicago seeking documents and information regarding the sales and marketing of opioids, including Opana®. ... In May 2014, a lawsuit was filed in California Superior Court (Orange County) in the name of the People of the State of California, acting by and through County Counsel for Santa Clara County and the Orange County District Attorney, against multiple defendants, including the Company. ... The amended complaint asserts violations of California's statutory Unfair Competition and False Advertising laws, as well as asserting a claim for public nuisance, based on alleged misrepresentations in connection with sales and marketing of opioids, including Opana®. On July 14, 2014, the case was removed to the United States District Court for the Central District of California. Plaintiff seeks declaratory relief, restitution, civil penalties (including treble damages), abatement, an injunction, and attorneys' fees and costs.

Appendix F-3
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Endo International

<u>Document Title</u>	<u>Excerpt</u>
[12] Form 10-K, for the fiscal year ended December 31, 2015	<i>Opioid-Related Litigations, Subpoenas and Document Requests</i> . In June 2014, Corporation Counsel for the City of Chicago filed suit in Illinois state court against multiple defendants, including our subsidiaries, Endo Health Solutions Inc. (EHSI) and EPI, for alleged violations of city ordinances and other laws relating to defendants' alleged opioid sales and marketing practices. [...] In May 2014 and in June 2014, a lawsuit was filed in California Superior Court (Orange County) in the name of the People of the State of California [...] based on alleged misrepresentations in connection with sales and marketing of opioids, including OPANA®. [...] Descriptions of various related litigation and subpoenas. [...] The cost of those penalties has been incorporated into our legal loss contingency reserve. With respect to the litigations brought on behalf of the City of Chicago, the People of the State of California and the State of Mississippi, we intend to contest those matters vigorously. We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interest.
[13] Form 10-K, for the fiscal year ended December 31, 2016	<i>Opioid-Related Litigations, Subpoenas and Document Requests</i> . [Descriptions of opioid related lawsuits from 2014-2017] ... With respect to the litigations brought on behalf of the City of Chicago, the People of the State of California, the State of Mississippi and the Counties of Suffolk, Broome and Erie, we intend to contest those matters vigorously. We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interests.

Appendix F-3
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Endo International

<u>Document Title</u>	<u>Excerpt</u>
[14] Form 10-K, for the fiscal year ended December 31, 2016	In addition, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical and medical device companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical and medical device products, including state investigations of the Company regarding the Company's vaginal mesh devices and investigations and litigation by certain government entities regarding the Company's marketing of opioid products.
[15] Form 10-K, for the fiscal year ended December 31, 2017	In addition, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical and medical device companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceutical and medical device products, including state investigations of the Company regarding the Company's vaginal mesh devices and investigations and litigation by certain government entities regarding the Company's marketing of opioid products.

Appendix F-3
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Endo International

<u>Document Title</u>	<u>Excerpt</u>
[16] Form 10-K, for the fiscal year ended December 31, 2017	Our business exposes us to significant potential risk from product liability claims, other significant litigation matters, government investigations or product recalls, including, but not limited to, such matters associated with the testing, manufacturing, marketing and sale of our products. We have been, continue to be and may be subject to various product liability cases, other significant litigations and government investigations. For example, we, along with other manufacturers of prescription opioid medications, are the subject of lawsuits and have received subpoenas and other requests for information from various state and local government agencies regarding the sales and marketing of opioid medications. ... For these or other reasons, any significant product liability or mass tort litigation in which we are a defendant could have a larger number of plaintiffs than such actions have seen historically and we could also see an increase in number of cases filed against us because of the increasing use of widespread and media-varied advertising.
[17] Form 10-K, for the fiscal year ended December 31, 2017	<i>Opioid-Related Matters</i> . Since 2014, multiple U.S. states, counties, other governmental persons or entities and private plaintiffs have filed suit against our subsidiaries EHSI and EPI, in some instances the Company and/or our subsidiary Par Pharmaceutical, Inc. (PPI), and/or various other manufacturers, distributors and/or others, asserting claims relating to defendants' alleged sales, marketing and/or distribution practices with respect to prescription opioid medications, including certain of our products. ... We will continue to vigorously defend the foregoing matters and to explore other options as appropriate in our best interests. Similar matters may be brought by others or the foregoing matters may be expanded. We are unable to predict the outcome of these matters or to estimate the possible range of any losses that could be incurred. ...

Appendix F-3
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Endo International

Sources:

- [1] Endo Pharmaceuticals Holdings, Form 10-K/A, for the fiscal year ended December 31, 2007, p. 9.
- [2] Endo Pharmaceuticals Holdings, Form 10-K, for the fiscal year ended December 31, 2008, pp. 38-39.
- [3] Endo Pharmaceuticals Holdings, Form 10-K, for the fiscal year ended December 31, 2009, pp. 28-29.
- [4] Endo Pharmaceuticals Holdings, Form 10-K, for the fiscal year ended December 31, 2010, p. 42.
- [5] Endo Pharmaceuticals Holdings, Form 10-K, for the fiscal year ended December 31, 2011, p. 44.
- [6] Endo Health Solutions Inc., Form 10-K, for the fiscal year ended December 31, 2012, p. 35.
- [7] Endo Health Solutions Inc., Form 10-K, for the fiscal year ended December 31, 2013, p. 33.
- [8] Endo Health Solutions Inc., Form 10-K, for the fiscal year ended December 31, 2013, p. F-56.
- [9] Endo International plc, Form 10-K, for the fiscal year ended December 31, 2014, p. 28.
- [10] Endo International plc, Form 10-K, for the fiscal year ended December 31, 2014, pp. F-58-F-59.
- [11] Endo International plc, Form 10-K, for the fiscal year ended December 31, 2014, pp. F-58-F-59.
- [12] Endo International plc, Form 10-K, for the fiscal year ended December 31, 2015, p. F-60.
- [13] Endo International plc, Form 10-K, for the fiscal year ended December 31, 2016, pp. F-52-F-53.
- [14] Endo International plc, Form 10-K, for the fiscal year ended December 31, 2016, p. 19.
- [15] Endo International plc, Form 10-K, for the fiscal year ended December 31, 2016, p. F-53.
- [16] Endo International plc, Form 10-K, for the fiscal year ended December 31, 2017, p. 15.
- [17] Endo International plc, Form 10-K, for the fiscal year ended December 31, 2017, p. 20.
- [18] Endo International plc, Form 10-K, for the fiscal year ended December 31, 2017, pp. F-50-F-51.

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

<u>Document</u>	<u>Excerpt</u>
[1] Form 10-K, for the fiscal year ended December 31, 2013	In addition, products used to treat and manage pain, especially in the case of controlled substances, are from time to time subject to negative publicity, including illegal use, overdoses, abuse, diversion, serious injury and death. These events have led to heightened regulatory scrutiny. Controlled substances are classified by the DEA as Schedule I through V substances, with Schedule I substances being prohibited for sale in the United States, Schedule II substances considered to present the highest risk of abuse and Schedule V substances being considered to present the lowest relative risk of abuse. Subsys contains fentanyl, an opioid, and is regulated as a Schedule II controlled substance, and our Dronabinol SG Capsule is regulated as a Schedule III controlled substance, and despite the strict regulations on the marketing, distributing, prescribing and dispensing of such substances, illicit use and abuse of controlled substances is well-documented.
[2] Form 10-K, for the fiscal year ended December 31, 2013	The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including substantial monetary penalties and criminal prosecution. For example, we received a subpoena dated December 9, 2013 from the U.S. Department of Health and Human Services, Office of Inspector General. The subpoena primarily requests documents relating to the marketing of Subsys. We are cooperating in responding to the subpoena.

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

<u>Document</u>	<u>Excerpt</u>
[3] Form 10-K, for the fiscal year ended December 31, 2014	In addition, products used to treat and manage pain, especially in the case of controlled substances, are from time to time subject to negative publicity, including illegal use, overdoses, abuse, diversion, serious injury and death. ... Subsys contains fentanyl, an opioid, and is regulated as a Schedule II controlled substance, and our Dronabinol SG Capsule is regulated as a Schedule III controlled substance, and despite the strict regulations on the marketing, distributing, prescribing and dispensing of such substances, illicit use and abuse of controlled substances is well-documented. Thus, the marketing of Subsys, Dronabinol SG Capsule and, if approved, our product candidates that contain controlled substances, may generate public controversy that may adversely affect market acceptance of Subsys and Dronabinol SG Capsule and, if approved, such product candidates.
[4] Form 10-K, for the fiscal year ended December 31, 2014	The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including substantial monetary penalties and criminal prosecution. For example, we received subpoenas dated December 9, 2013 and September 8, 2014 from the U.S. Department of Health and Human Services, Office of Inspector General and the U.S. District Attorney's Office for the District of Massachusetts, respectively. The subpoenas primarily request documents relating to the marketing of Subsys. We are cooperating in responding to the subpoenas.

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

Document

Excerpt

- | | |
|--|--|
| [5] Form 10-K, for the fiscal year ended December 31, 2015 | The commercial use of our products and clinical use of our product candidates expose us to the risk of product liability claims. This risk exists even if a product is approved for commercial sale by the FDA and manufactured in facilities licensed and regulated by the FDA, such as the case with Subsys and our discontinued Dronabinol SG Capsule, or an applicable foreign regulatory authority. Our products and product candidates are designed to affect important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with Subsys or Dronabinol SG Capsule or our product candidates could result in injury to a patient or even death. For example, because our sublingual spray technology is designed to be self-administered by patients, it is possible that a patient could fail to follow instructions and as a result apply a dose in a manner that results in injury or death. In addition, Subsys is an opioid pain reliever that contains fentanyl, and Dronabinol SG Capsule is a synthetic cannabinoid, which are regulated “controlled substances” under the CSA and could result in harm to patients relating to its potential for abuse. In addition, a liability claim may be brought against us even if our products or product candidates merely appear to have caused an injury. Product liability claims may be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products or product candidates, among others. If we cannot successfully defend ourselves against product liability claims we will incur substantial liabilities. |
|--|--|

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

<u>Document</u>	<u>Excerpt</u>
[6] Form 10-K, for the fiscal year ended December 31, 2015	The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including substantial monetary penalties and criminal prosecution. For example, we have received subpoenas from the HHS, Office of Inspector General, the U.S. District Attorney's Office for the District of Massachusetts and other attorney generals from several states. The subpoenas primarily request documents relating to the marketing of Subsys. We are cooperating in responding to the subpoenas.
[7] Form 10-K, for the fiscal year ended December 31, 2015	<i>Heightened attention on the use of opioids, including government litigation changes in policies, legislation and leadership at the federal and state level could hinder or prevent the commercial success of our current fentanyl-based product and any potential future opioid product candidates .</i> Many federal and governmental agencies are focused on the abuse of opioids in the United States and agencies such as the HHS have expressed their belief that the United States is in the midst of a prescription opioid abuse epidemic. Common prescription drugs that contain opioids are drugs such as oxycodone, hydrocodone, and fentanyl. Our product, Subsys, is fentanyl based product in the TIRF class. To the extent that the healthcare community, regulatory bodies and governmental agencies associate us with, or determine that we are a part of, this perceived opioid abuse epidemic then this may negatively affect our stock price and our business in various ways including from a marketing, sales and public relations standpoint and these perceptions may also negatively affect our ongoing governmental investigations.

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

Document

Excerpt

- | | |
|--|--|
| [8] Form 10-K, for the fiscal year ended December 31, 2015 | Opoid Litigation. Many federal and governmental agencies are focused on the abuse of opioids in the United States and agencies such as the HHS have expressed their belief that the United States is in the midst of a prescription opioid abuse epidemic. Common prescription drugs that contain opioids are drugs such as oxycodone, hydrocodone, and fentanyl. Our product, Subsys, is fentanyl based product in the TIRF class. Certain stakeholders in the healthcare community, regulatory bodies and governmental agencies may associate us with, or determine that we are a part of, this perceived opioid abuse epidemic. Like all TIRF products, our product is part of the mandatory TIRF REMS program which is designed “to ensure informed risk-benefit decisions before initiating treatment, and while patients are treated to ensure appropriate use of TIRF medicines” and “to mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors with the use of TIRF medicines.” Nevertheless, from d these perceptions may also negatively affect our ongoing governmental investigations.ear to have caused an injury or because our commercial activities are alleged to have impaired a prescriber’s ability to independently act in the best interest of the patient. Product liability claims may be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products or product candidates, among others. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities.estigation. potentially resolve the claims of up to 155 of such claimants. As of April 13, 2011, nearly all of those claimants have agreed to participate in the settlement. The defendant C |
|--|--|

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

<u>Document</u>	<u>Excerpt</u>
[9] Form 10-K, for the fiscal year ended December 31, 2016	The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including substantial monetary penalties and criminal prosecution. For example, we have received subpoenas from the HHS, Office of Inspector General, the U.S. District Attorney's Office for the District of Massachusetts and other attorney generals from several states. The subpoenas primarily request documents relating to the marketing of SUBSYS®. We are cooperating in responding to the subpoenas.
[10] Form 10-K, for the fiscal year ended December 31, 2016	<i>State Related Investigations</i> . We have received Civil Investigative Demands ("CIDs") or subpoenas, as the case may be, from each of the Office of the Attorney General (or similarly named and authorized office) of the State of Arizona, Colorado, Florida, Illinois, Massachusetts, Maryland, Minnesota, New Hampshire, New Jersey, New York, Oregon, Pennsylvania and Washington. Moreover, we have received an administrative subpoena from the California Insurance Commissioner. In addition, we understand that numerous physicians practicing within several of the aforementioned states have received subpoenas from each applicable state Attorney General or Department of Justice office in connection with interactions with us. Generally, these CIDs and subpoenas request documents regarding SUBSYS®, including our sales and marketing practices related to SUBSYS® in the applicable state, as well as our patient services hub. We are cooperating with each of these investigations and have produced documents in response to these CIDs, subpoenas and related requests for information from each office.

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

Document

Excerpt

- | | |
|---|---|
| [11] Form 10-K, for the fiscal year ended December 31, 2016 | <p><i>Opioid Litigation</i> . Many federal and governmental agencies are focused on the abuse of opioids in the United States and agencies such as the HHS have expressed their belief that the United States is in the midst of a prescription opioid abuse epidemic. Common prescription drugs that contain opioids are drugs such as oxycodone, hydrocodone and fentanyl. Our product, SUBSYS®, is a fentanyl-based product in the TIRF class. Certain stakeholders in the healthcare community, regulatory bodies and governmental agencies may associate us with, or determine that we are a part of, this perceived opioid abuse epidemic. Like all TIRF products, our product is part of the mandatory TIRF REMS program which is designed “to ensure informed risk-benefit decisions before initiating treatment, and while patients are treated to ensure appropriate use of TIRF medicines” and “to mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors with the use of TIRF medicines.” Nevertheless, from time to time, we may be included in litigation or investigations that are directed at the abuse of opioids in the United States.</p> |
|---|---|

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

<u>Document</u>	<u>Excerpt</u>
[12] Form 10-K, for the fiscal year ended December 31, 2016	With the exception of the investigations by the ODOJ, the State of New Hampshire and the State of Massachusetts which we have quantified above, and the investigations by the Department of Health and Human Services and HIPAA for which we have responded to subpoenas as requested, we believe a loss from an unfavorable outcome of these governmental proceedings is reasonably possible and an estimate of the amount or range of loss from an unfavorable outcome is not determinable at these stages. We believe we have meritorious legal positions and will continue to represent our interests vigorously in these matters. However, responding to government investigations has and could continue to burden us with substantial legal costs in connection with defending any claims raised. Any potential resulting fines, restitution, damages and penalties, settlement payments, pleas or exclusion from federal health care programs or other administrative actions, as well as any related actions brought by shareholders or other third parties, could have a material adverse effect on our financial position, results of operations or cash flows. Additionally, these matters could also have a negative impact on our reputation and divert the attention of our management from operating our business.

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

<u>Document</u>	<u>Excerpt</u>
[13] Form 10-K, for the fiscal year ended December 31, 2017	<i>Multi-District Prescription Opioid Litigation</i> . We have been named along with various other opioid manufacturers, opioid distributors, prescribers and others in complaints focused on the national opioid epidemic filed by various cities, counties, states, and third-party payers in many state and federal courts in Alabama, Connecticut, Florida, Georgia, Kentucky, Louisiana, Maryland, Michigan, Minnesota, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oregon, Tennessee, Texas and West Virginia. We are involved in more than 100 of these cases, over 70 of which have been consolidated into multi-district litigation (No. 2804) in the Northern District of Ohio. The cases in the multi-district litigation are presently stayed while the Court seeks to facilitate a resolution. On March 1, 2018, the United States filed a statement of interest in the multi-district litigation, in which it requested a period of thirty days to evaluate whether to participate in the multi-district litigation proceedings at this stage.
[14] Form 10-K, for the fiscal year ended December 31, 2017	<i>Congressional and Other Inquiries</i> . Many federal agencies and branches are focused on the abuse of opioids in the United States and agencies such as the HHS have expressed their belief that the United States is in the midst of a prescription opioid abuse epidemic. Moreover, President Trump has declared the opioid crisis to be a public health emergency and has made it a priority to address this crisis.

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

Document

Excerpt

[15] Form 10-K, for the fiscal year ended December 31, 2017	Members of our U.S. Congress have been conducting hearings and other inquiries into causes and solutions to the national opioid epidemic that have involved inquiries in our company's practices. For example, on March 28, 2017, the Ranking Member of the Committee on Homeland Security and Governmental Affairs of the United States Senate distributed a letter to five manufacturers of opioid products, including us, requesting documents and information intended to aid such committee in understanding the challenges industry practices pose to efforts to curb opioid addiction and stem rising prescription drug costs for the federal government. This letter requests documents regarding our business, including the commercialization of SUBSYS®. This inquiry continues and has resulted in at least two reports that mention or address our company. We continue to cooperate with this inquiry.
---	--

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

<u>Document</u>	<u>Excerpt</u>
[16] Form 10-K, for the fiscal year ended December 31, 2017	With the exception of the investigations by the ODOJ, the State of New Hampshire, the State of Illinois, the State of Massachusetts, and the DOJ, which we have quantified above, we believe a loss from an unfavorable outcome of these federal and state governmental proceedings is reasonably possible and an estimate of the amount or range of loss from an unfavorable outcome is not determinable at these stages. We believe we have meritorious legal positions and will continue to represent our interests vigorously in these matters. However, responding to government investigations has and could continue to burden us with substantial legal costs in connection with defending any claims raised. Any potential resulting fines, restitution, damages and penalties, settlement payments, pleas or exclusion from federal health care programs or other administrative actions, as well as any related actions brought by stockholders or other third parties, could have a material adverse effect on our financial position, results of operations or cash flows. Additionally, these matters could also have a negative impact on our reputation and divert the attention of our management from operating our business.

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

Document

Excerpt

- | | |
|---|---|
| [17] Form 10-K, for the fiscal year ended December 31, 2017 | The continuing and heightened publicity surrounding the national opioid epidemic continues to result in heightened sensitivity by many health care professionals to prescribe, and pharmacies to dispense, opioids. In part, this sensitivity by health care professionals and pharmacies is the result of third-party payers, such as insurance companies, and regulatory and government agencies increasingly scrutinizing the indications and uses for which health care professionals are prescribing, and pharmacies are dispensing, opioids. Other high-profile initiatives, such as President Trump's declaration of the opioid crisis as a public health emergency will likely add to this sensitivity. Moreover, ongoing state and federal investigations into our sales, marketing and other commercial practices and developments and media reports that may arise in connection with such investigations may negatively affect our relationships with health care professionals and pharmacies and their prescribing or dispensing habits. Furthermore, widespread litigation focused on opioids, including multi-district litigation, has focused an enormous amount of scrutiny on the prescribing of opioids. Consequently, these current and potential future events have affected, and will likely continue to affect, the manner in which, and the situations when, SUBSYS® is being prescribed, dispensed and approved for coverage. |
|---|---|

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

<u>Document</u>	<u>Excerpt</u>
[18] Form 10-K, for the fiscal year ended December 31, 2017	<p>In addition, products used to treat and manage pain, especially in the case of controlled substances, are from time to time subject to negative publicity, including illegal use, overdoses, abuse, diversion, serious injury and death. These events have led to heightened regulatory scrutiny and in certain circumstances the FDA might even consider action to remove or revoke a product's approval. Controlled substances are classified by the DEA as Schedule I through V substances, with Schedule I substances being prohibited for sale in the United States, Schedule II substances considered to present the highest risk of abuse and Schedule V substances being considered to present the lowest relative risk of abuse. SUBSYS® contains fentanyl, an opioid, and is regulated as a Schedule II controlled substance, and despite the strict regulations on the marketing, distributing, prescribing and dispensing of such substances, illicit use and abuse of controlled substances is well-documented. Thus, the marketing of SUBSYS®, SYNDROS® and, if approved, our product candidates that contain controlled substances, may generate public controversy that may adversely affect market acceptance of SUBSYS®, SYNDROS® and, if approved, such product candidates.</p>

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

Document

Excerpt

[19] Form 10-K, for the
fiscal year ended
December 31, 2017

For instance, because SUBSYS® is an opioid, we face significant risk of product liability for this product even though this product is approved for commercial sale by the FDA and manufactured in facilities licensed and regulated by the FDA. Our products and product candidates are designed to affect important bodily functions and processes, but side effects, manufacturing defects, misuse or abuse associated with SUBSYS®, SYNDROS®, or our product candidates could result in injury to a patient or even death. For example, because our sublingual spray technology is designed to be self-administered by patients, it is possible that a patient could fail to follow instructions and as a result apply a dose in a manner that results in injury or death. In addition, SUBSYS® is an opioid pain reliever that contains fentanyl, and SYNDROS® is a synthetic cannabinoid, which are both regulated “controlled substances” under the CSA and could result in harm to patients relating to its potential for abuse. In addition, a liability claim may be brought against us even if our products or product candidates merely appear to have caused an injury or because our commercial activities are alleged to have impaired a prescriber’s ability to independently act in the best interest of the patient. Product liability claims may be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products or product candidates, among others. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities.

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

<u>Document</u>	<u>Excerpt</u>
[20] Form 10-K, for the fiscal year ended December 31, 2017	The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability, including substantial monetary penalties and criminal prosecution. For example, we have received subpoenas from the HHS, Office of Inspector General, the U.S. District Attorney's Office for the District of Massachusetts and other attorney generals from several states. The subpoenas primarily request documents relating to the marketing of SUBSYS®. We are cooperating in responding to the subpoenas.

Appendix F-4
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Insys Therapeutics

Sources:

- [1] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2013, p. 25.
- [2] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2013, p. 47.
- [3] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2014, p. 23.
- [4] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2014, p. 45.
- [5] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2015, p. 37.
- [6] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2015, p. 42.
- [7] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2015, p. 45.
- [8] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2015, p. 86.
- [9] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2016, p. 46.
- [10] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2016, p. 100.
- [11] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2016, p. 101.
- [12] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2016, p. 101.
- [13] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2017, p. 105.
- [14] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2017, p. 105.
- [15] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2017, p. 105.
- [16] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2017, p. 105.
- [17] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2017, p. 6.
- [18] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2017, p. 26.
- [19] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2017, p. 27.
- [20] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2017, p. 43.
- [21] Insys, Inc., Form 10-K, for the fiscal year ended December 31, 2017, p. 48.

Appendix F-5
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Teva

<u>Document Title</u>	<u>Excerpt</u>
[1] Form 20-F, for the fiscal year ended December 31, 2014	On May 21, 2014, counsel for Santa Clara County and Orange County, purportedly on behalf of the People of California, filed a complaint in the Superior Court for Orange County, California against Teva and Cephalon, along with several other pharmaceutical companies, contending that defendants allegedly engaged in off-label promotion in the sale of opioids, including Actiq® and Fentora®. On June 2, 2014, the City of Chicago filed a similar complaint against Teva and Cephalon in the Circuit Court of Cook County, Illinois, which has been removed to the Northern District of Illinois. Both complaints assert claims under state law based upon alleged off-label promotion in the sale of opioids, and both seek a variety of damages, including restitution, civil penalties, disgorgement of profits, treble damages, attorneys' fees and injunctive relief. Neither complaint specifies the exact amount of damages at issue. Teva and Cephalon have not yet responded to the complaint in the California action and have filed a motion to dismiss in the Chicago action.
[2] Form 20-F, for the fiscal year ended December 31, 2015	Teva and Cephalon filed motions to dismiss in both the California and Chicago actions. In the California action, in August 2015, the Court granted the defendants' demurrer, or motion to dismiss, on primary jurisdiction grounds and the case has been stayed. In the Chicago action, all claims against Teva and Cephalon were dismissed without prejudice. In August 2015, the City of Chicago filed a second amended complaint and defendants have filed motions to dismiss the second amended complaint.

Appendix F-5
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Teva

<u>Document Title</u>	<u>Excerpt</u>
[3] Form 20-F, for the fiscal year ended December 31, 2015	In December 2015, the Mississippi Attorney General filed a lawsuit against Teva Pharmaceuticals USA, Inc. and Cephalon along with the same defendants named in the California and Chicago actions described above. The Mississippi complaint is similar to the California and Chicago complaints, asserts claims under Mississippi state law based upon alleged improper marketing of opioids, including Actiq® and Fentora®, and seeks a variety of damages including restitution, civil penalties, disgorgement of profits, treble damages, attorneys' fees and injunctive relief. The complaint does not specify the exact amount of damages at issue. Teva and Cephalon intend to move to dismiss the complaint.
[4] Form 20-F, for the fiscal year ended December 31, 2016	On August 31, 2016, Suffolk County, New York filed a complaint in the Supreme Court of New York against Teva USA and Cephalon along with the most of the same defendants named in the California, Chicago and Mississippi actions described above. The Suffolk County complaint, which is similar to the complaints filed in California, Chicago and Mississippi, asserts claims under New York state law for improper marketing of opioids, including Actiq® and Fentora®, and seeks a variety of damages including compensatory damages, civil penalties, disgorgement of profits, treble damages, and attorneys' fees. A motion to dismiss was filed on January 23, 2017. On February 1, 2017, Erie and Broome Counties in the State of New York filed a suit against Teva USA and other defendants that is substantially similar to the Suffolk County suit.

Appendix F-5
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Teva

<u>Document Title</u>	<u>Excerpt</u>
[5] Form 20-F, for the fiscal year ended December 31, 2017	We operate around the world in complex legal and regulatory environments, and any failure to comply with applicable laws, rules and regulations may result in civil and/or criminal legal proceedings. As those rules and regulations change or as interpretations of those rules and regulations evolve, our prior conduct or that of companies we have acquired may be called into question. In the United States, we are currently responding to federal investigations into our marketing practices with regard to several of our specialty pharmaceutical products, which could result in civil litigation brought on behalf of the federal government.
[6] Form 10-K, for the fiscal year ended December 31, 2017	Beginning in May 2014 various complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties and states across the country. ... The complaints, asserting claims under similar provisions of different state law, generally contend that the defendants allegedly engaged in improper marketing of opioids, including ACTIQ® and FENTORA and seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages, attorneys' fees and injunctive relief. None of the complaints specifies the exact amount of damages at issue. Teva and its affiliates that are defendants in the various lawsuits deny all allegations asserted in these complaints and have filed or will be filing motions to dismiss where possible. In addition, a number of State Attorneys General, including a coordinated multistate effort, have initiated investigations into sales and marketing practices of Teva and its affiliates with respect to opioids. Teva is cooperating with these investigations, which are ongoing, and cannot predict at this time the outcome.

Appendix F-5
Excerpts from Litigation Comparables' SEC Filings Related to Opioid Litigation Risk
Teva

Sources:

- [1] Teva Pharmaceutical Industries Limited, Form 20-F, for the fiscal year ended December 31, 2014, p. F-37.
- [2] Teva Pharmaceutical Industries Limited, Form 20-F, for the fiscal year ended December 31, 2015, p. F-41.
- [3] Teva Pharmaceutical Industries Limited, Form 20-F, for the fiscal year ended December 31, 2015, p. F-42.
- [4] Teva Pharmaceutical Industries Limited, Form 20-F, for the fiscal year ended December 31, 2016, p. F-55.
- [5] Teva Pharmaceutical Industries Limited, Form 10-K, for the fiscal year ended December 31, 2017, p. 46.
- [6] Teva Pharmaceutical Industries Limited, Form 10-K, for the fiscal year ended December 31, 2017, p. 163.

Appendix G

Produced in Native Format - Appendix G.xlsx

Case Name	Transferor or State Court	Purdue Entity Defendants	Non-Purdue Co-Defendants	Filed	Filing Year
A.M.H., individually and in her capacity as legal custodian of Baby C.E., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	W.D.N.Y./1:18-cv-01018 (removed from Sup. Ct. Niagara Cnty. (N.Y.)/E165792-2018)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Insys; Endo; Allergan; Watson; Actavis	8/22/2018	2018
Accomack County, Virginia v. Purdue Pharma L.P., et al.	E.D. Va./2:19-cv-00184	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
Ada County v. Purdue Pharma L.P., et al.	D. Ida./1:19-cv-00216	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Rhodes; SpecGx; Teva; Watson	6/14/2019	2019
Adair County, et al. v. Purdue Pharma L.P., et al.	S.D. Iowa./4:18-cv-00011-JAJ-HCA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman and Lynn Webster	1/5/2018	2018
Adams County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00894-MHW-KAJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/13/2017	2017

Adams County v. Purdue Pharma L.P., et al.	E.D. Pa./2:19-cv-04438 (removed from C.P. Adams Cnty. (Pa.)/2019-sv-923)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; McKesson; Endo; Cardinal; AmerisourceBergen; Rhodes; Allergan; Watson; Actavis; Par; Mallinckrodt; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart; Kroger; Insys; H.D. Smith; Miami-Luken	8/5/2019	2019
Adams County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01533-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Adams County, Blaine County, Boise County, Bonneville County, Caribou County, Cassia County, Elmore County, Latah County, Minidoka County, Owyhee County, and Payette County v. Purdue Pharma L.P., et al.	D. Ida./1:18-cv-00360-BLW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; Sandoz; SpecGx; West-Ward; SuperValu; Albertsons; Auburn; Henry Schein; Smith Foods; Thrifty; Rhodes	8/17/2018	2018
Adams County, Mississippi v. AmerisourceBergen Drug Corp., et al	S.D. Miss./5:18-cv-00066-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/22/2018	2018

Alamance County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:19-cv-00594	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/13/2019	2019
Alaska Native Tribal Health Consortium v. Purdue Pharma L.P., et al.	D. Alaska/3:18-cv-00269-SLG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Janssen; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Abbott; Amneal; KVK; Cardinal; AmerisourceBergen; Anda; McKesson; Henry Shein	11/13/2018	2018
Aleutian Pribilof Islands Association, Inc. v. Purdue Pharma L.P., et al.	D. Alaska/3:18-cv-00294-SLG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Janssen; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Abbott; Amneal; KVK; Cardinal; AmerisourceBergen; Anda; McKesson; Henry Shein	12/17/2018	2018
Alexander County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./5:18-cv-00169-RJC-DSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/15/2018	2018
Alicia Simonson, individually and as next friend and guardian of Baby M.S., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45479-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/15/2019	2019

Allamakee County v. Purdue Pharma L.P., et al.	S.D. Iowa/4:18-cv-00245- RP-CFB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken	8/2/2018	2018
Allegany County v. Purdue Pharma L.P., et al.	E.D.N.Y./2:19-cv-04891- KAM-ST	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Rhodes; Mallinckrodt; Par; CVS; Anda; Rite Aid; Walgreens; Wal-Mart	N/A	2019
Allegany County, Maryland v. AmerisourceBergen Drug Corp., et al.	D. Md./1:18-cv-01382- ELH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	5/11/2018	2018
Alleghany County v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 46019-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	8/14/2018	2018

Alleghany County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./7:19-cv-00275-EKD (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
Allen County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/3:18-cv-00815	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	4/10/2018	2018
Alyssa Lyle, individually and as next friend and guardian of Baby A.W. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45524-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Amalgamated Union Local 450-A Welfare Fund v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-04949-NGG-VMS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; Anda; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	8/29/2019	2019

Amanda Gibson, individually and as next friend and guardian of Baby B.A. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45515-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Amanda Hanlon and Amy Gardner v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45206-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Endo; Watson	3/28/2019	2019
Amanda Muffley, individually and as next friend and guardian of Baby M.S. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45507-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019
Amel Eiland, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	D. Colo./1:18-cv-02894- CMA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	11/9/2018	2018
American Federation of State, County and Municipal Employees District Council 37 Health & Security Plan v. Purdue Pharma L.P. et al	N.D. Ohio/1:17-cv-02585- CAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Insys	12/12/2017	2017

American Resources Insurance Company, Inc. v. Purdue Pharma L.P., et al.	S.D. Ala./1:18-cv-00145-KU-MU	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Actavis; Cephalon; Johnson & Johnson; Janssen; Endo; Qualitest; Allergan; Watson; Actavis; Mallinckrodt; Par; West-Ward; KVK; Rhodes; UCB; Sun; Alvogen; Aurolife; Specgx; Lupin; Tris; Amneal; Impax; Mylan; McKesson; Cardinal; AmerisourceBergen	3/27/2018	2018
Amite County, Miss. v. AmerisourceBergen Drug Corp., et al.	W.D. Miss./5:18-cv-00009-DCB-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	1/9/2018	2018
A-MMED Ambulance, Inc. v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00953-BAJ-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
Amy Shepard, individually and as next friend and guardian of Baby E.S. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45536-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Andrew G. Riling and Beverly Riling, as next friends of A.P. Riling, a minor under the age of 18 v. Purdue Pharma L.P., et al.	S.D. WV/2:18-cv-01390	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; Endo; Mallinckrodt	10/29/2018	2018

Androscoggin County v. Purdue Pharma L.P., et al.	D. Me./2:19-cv-00012-NT (removed from Super. Ct. Androscoggin Cnty. (Me.)/CV-18-156)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	11/21/2018	2018
Andy Brown, in his capacity as the Sheriff for Jackson Parish v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45926-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; AmerisourceBergen; McKesson; Cardinal	8/6/2018	2018
Angel Bolton and Christopher Bolton, as surviving children of Kevi Bolton, deceased v. Frank Byne, Jr., et al.	S.D. Ga./4:18-cv-00136 (removed from Chathan Cnty. State Ct./STCV1800266)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Frank H. Byne, Jr., MD; Curtis v. Coomer Primary Health Care; Pembroke Pharmacy; Willie C. Conley Jr.; AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/6/2018	2018
Angela Cherry, individually and as next friend and guardian of Baby Z.C.T., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45490-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/16/2019	2019

Anson County v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./3:18-cv-00651-FDW-DCK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	12/6/2018	2018
ApolloMD Business Services, LLC, a Georgia Limited Liability Company v. Attain Med, Inc., et al.	N.D. Ga./1:18-cv-01662-SCJ (removed from Fulton County (GA)/18EV001062)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Attain; Bloodworth; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/8/2018	2018
April Berzinski, individually and as next friend and guardian of Baby A.Z. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45503-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019
Aracya Johnson, individually and as next friend and guardian of Baby R.H. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45521-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Arizona Counties Insurance Pool v. Purdue Pharma L.P., et al.	D. Ariz./2:18-cv-01439-DJH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; John and Jane Does 1 through 100, inclusive	5/10/2018	2018

Arizona Municipal Risk Retention Pool v. Purdue Pharma L.P., et al.	D. Ariz./2:18-cv-00354-DLR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; John and Jane Does 1 Through 100 Inclusive	2/1/2018	2018
Aroostook Band of Micmacs v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op-45349-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/28/2019	2019
Aroostook County v. Purdue Pharma L.P., et al.	D. Me./1:19-cv-00018-NT (removed from Super. Ct. Aroostook Cnty. (Me.)/CARSC-CV-2018-179)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	11/21/2018	2018
Asbestos Workers Local 6 Health and Welfare Fund and Massachusetts Bricklayers & Masons Trust Funds v. Purdue Pharma L.P., et al.	D. Mass./1:18-cv-10799	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo	4/24/2018	2018
Ascension Parish Government v. Purdue Pharma L.P., et al.	M.D. La./3:18-cv-01088 (removed from 23rd Judicial District, Parish of Ascension (LA)/123831)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Morris & Dickson Co.	11/13/2018	2018
Ashe County v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./5:18-cv-00168	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/12/2018	2018

Ashland County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:17-cv-02569- SO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	12/8/2017	2017
Ashland County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01644- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/28/2017; 3/15/2019	2017
Assoc. of Ark. Counties, Assoc. of Ark. Counties Risk Mgmt. Fund and Assoc. of Ark. Counties WC Trust v. Purdue Pharma L.P., et al.	E.D. Ark./4:17-cv-00831- JLH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	12/14/2017	2017
Atchison County, Missouri v. AmerisourceBergen Drug Corp., et al.	W.D. Mo./5:18-cv-06086- GAF	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/13/2018	2018
Athens County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:18-cv-00216- EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/14/2018	2018
Atkinson County, Georgia v. Purdue Pharma L.P., et al.	S.D. Ga./5:19-cv-00016- LGW-BWC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Noramco; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	2/21/2019	2019

Audrain County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46265-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal- Mart; McQueary; Amneal	11/20/2018; 3/7/2019 (Am.)	2018
Auglaize County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45570-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/14/2018	2018
Augusta, GA v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./1:18-cv-00029- JRH-BKE	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	2/13/2018	2018
Autauga County, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./2:19-cv-00100- MHT-SMD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	2/4/2019	2019
Bacon County Hospital Foundation, Inc. d/b/a Bacon County Hospital and Health System v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./5:18-cv-00020- LGW-RSB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/9/2018	2018
Bacon County, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./5:18-cv-00069- LGW-BWC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	9/7/2018	2018

Bad River Band of Lake Superior Chippewa v. Purdue Pharma L.P., et al.	W.D. Wi./3:18-cv-01017 (removed from Cir. Ct. Ashland County (Wi.)/2018CV000182)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	11/5/2018	2018
Baldwin County, Alabama v. AmerisourceBergen Drug Corp., et al.	S.D. Ala./1:18-cv-00010-CG-N	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	1/12/2018	2018
Baltimore County, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:18-cv-01215-MJG	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	4/25/2018	2018
Banks County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ga./2:18-cv-00024-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/16/2018	2018
Bannock County v. Purdue Pharma L.P., et al.	D. Ida./1:19-cv-00151-CWD	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters	4/24/2019	2019

Baptist Healthcare System, Inc. d/b/a Baptist Health Corbin, Baptist Health La Grange, Baptist Health Lexington, Baptist Health Louisville, Baptist Health Paducah, and Baptist Health Floyd; Baptist Health Madisonville, Inc. d/b/a Baptist Health Madisonville; Baptist Health Richmond, Inc. d/b/a Baptist Health Richmond; Bowling Green Warren County Community Hospital Corporation d/b/a The Medical Center at Bowling Green d/b/a The Medical Center at Caverna d/b/a The Medical Center at Scottsville; The Medical Center at Clinton County, Inc. d/b/a The Medical Center at	W.D. Ky./3:18-cv-00558-CHB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Walgreens Boots Alliance; CVS; Wal-Mart; Miami-Luken	8/17/2018	2018
Baptist Hospital Inc. and Jay Hospital v. McKesson Corp., et al.	N.D. Fla./3:17-cv-00816-MCR-CJK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; TEVA; Cephalon; Johnson & Johnson; Janssen; Pharmaceuticals; Endo; Allergan; Watson; Actavis	11/21/2017	2017
Barbara Rivers, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ill./1:18-cv-03116	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	5/2/2018	2018
Barbour County, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./2:18-cv-00121-MHT-GMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/20/2018	2018

Barnes County v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00110-DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
Barron County, La Crosse County, Lafayette County and Menominee County v. Purdue Pharma L.P., et al.	E.D. Wi./2:18-cv-00360-WED	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	3/7/2018; 5/25/2018; 3/15/2019	2018
Bartow County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ga./4:19-cv-00007-ODE	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Rite Aid; Walgreens; JM Smith	1/16/2019	2019
Battle Mountain of the Te-Moak Tribe of Western Shoshone Indians v. McKesson Corp., et al.	N.D. Ohio/1:18-op-46017-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	8/31/2018	2018
Bay County v. AmerisourceBergen Drug Corp., et al.	N.D. Fla./5:18-cv-00086-RH-GRJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/4/2018	2018

Bay Mills Indian Community v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45287-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Insys; Malinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Kroger; Rite Aid; H.D. Smith	4/19/2019	2019
Bayfield County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01645- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/28/2017; 3/15/2019	2017
Beaufort County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./4:18-cv-0044	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/2/2018	2018
Beauregard Parish Police Jury v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00819- BAJ-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Mallinckrodt	9/4/2018	2018
Belmont County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00663- EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/11/2017	2017

Beltrami County, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-02295- WMW-LIB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	7/15/2019	2019
Ben Hill County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45505-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/23/2018	2018
Benson County v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00113- DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
Benton County v. Purdue Pharma L.P., et al.	N.D. Ind./4:18-cv-00074	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	10/4/2018	2018
Benton County, Miss. v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./3:18-cv- 00007-MPM-RP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	1/8/2018	2018
Benton Fire Protection District No. 4 v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00970- BAJ-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018

Bergen County v. Purdue Pharma L.P., et al.	D.N.J./2:18-cv-08845	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; CVS; Walgreens; Cotsco; Ride Aid	5/4/2018	2018
Berkeley County Council v. Purdue Pharmaceutical Products L.P., et al.	N.D. WV/3:17-cv-00143-GMG	Purdue Pharmaceutical Products LP; Purdue Pharma L.P.; The Purdue Frederick Company Inc.	Actavis; Allergan; Cephalon; Janssen; Johnson & Johnson; TEVA; Mallinckrodt; AmerisourceBergen; Cardinal; CVS Indiana; Endo; H.D. Smith Wholesale Drug Co.; McKesson; Rite Aid of MD, Inc.; Wal-Mart; Walgreen; American Sales; Associated Pharm.; Auburn Pharm.; Bellco; Bloodworth; CVS; Harvard Drug; Masters; Parmed; LRSJ; Walmart; Amneal; Anda; Food Lion; Indivior; Mylan; Rite Aid; Target; Medicap; Weis Markets; Sears Holding; Giant Food	11/21/2017; 5/25/2018; 3/15/2019	2017
Berlin, New Hampshire v. Purdue Pharma L.P., et al.	D.N.H./1:18-cv-00721	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Rite Aid; Walgreens; Walmart	8/17/2018	2018
Berrien County, Georgia v. Purdue Pharma L.P., et al.	M.D. Ga./7:18-cv-00083-HL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Depomed; Endo; Allergan; Actavis; Watson; Avis; Watson; Avis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	6/8/2018	2018
Bertie County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./2:19-cv-00025-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	8/3/2019	2019

Bibb County, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./7:18-cv-00473-LSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/26/2018	2018
Big Bend Community Based Care Inc.; Lutheran Services Florida Inc.; Central Florida Cares health System Inc; Southeast Florida Behavioral Health Network Inc; Central Florida Behavioral Health Network Inc. v. Purdue Pharma L.P., et al.	N.D. FLA./4:18-cv-00183-MW-CAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Janssen; Johnson & Johnson; Cephalon; TEVA; Allergan; Watson; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal	4/4/2018	2018
Big Sandy Rancheria of Western Mono Indians v. McKesson Corp., et al.	N.D. Cal./3:18-cv-02537 (removed from San Francisco County Super Ct. (CA)/CGC-18-564736)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	3/2/2018	2018
Big Valley Band of Pomo Indians of the Big Valley Rancheria v. McKesson Corp.	N.D. Cal./3:18-cv-02536 (removed from San Francisco County Super. Ct. (CA)/CGC-18-564282)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	2/13/2018	2018
Billie Ivie, individually and as next friend and guardian of Baby A.I., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45489-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/16/2019	2019

Bingham County v. Purdue Pharma L.P., et al.	D. Ida./1:19-cv-00294-BLW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Janssen; Normaco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Amneal; KVK; Mylan; Par; Sandoz; SpecGx; West-Ward; Advantage Logistics; Albertsons; Anda; Associated Pharmacies; Auburn; Henry Schein; Smith's Food & Drug; Thrifty; Rhodes; Pfizer	7/26/2019	2019
Black Hawk County, Des Moines County, Harrison County, Howard County, Jasper County, Lyon County, Mills County, Tama County, Union County, Worth County v. Purdue Pharma L.P., et al.	S.D. Iowa./4:18-cv-00072-JAJ-HCA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen	3/8/2018	2018
Blackford County, Indiana v. AmerisourceBergen Drug Corp., et al.	N.D. Ind./1:18-cv-00380-WCL-SLC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	11/20/2018	2018
Bladen County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./7:19-cv-00104-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/5/2019	2019
Bland County, Virginia v. AmerisourceBergen Drug Corp., et al.	W.D. Va./7:18-cv-00307-EKD-PMS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Anda; Par; Sandoz; SpecGx; Sun Pharm.; West-Ward; Rhodes	6/28/2018; 3/14/2019	2018

Blount County v. Purdue Pharma L.P., et al.	N.D. Ala./2:18-cv-00492-RDP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/28/2018	2018
Blount County, Tennessee and Jefferson County, Tennessee v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45132-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; McKesson; Cardinal; AmerisourceBergen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; Walgreens; CVS; Walmart; Smith Drug Co.; SpecGx; Par; Amneal; Indivior; Mylan; Sandoz	3/12/2019; 3/15/2019	2019
Board Commissioners of Fulton County, Ohio v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45440-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; Par; Mylan; Sandoz; Omnicare; Prescription Supply; Rhodes	6/13/2019	2019
Board of Commissioners for Lucas County, Ohio; Mental Health & Recovery Services Board of Lucas County; Lucas County Children Services Board of Trustees v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46177-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Anda; CVS; Cardinal; Cephalon; Endo; H.D. Smith; Health Mart; Insys; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; Par; Rite Aid; SpecGx; TEVA; Walgreens; Wal-Mart; Watson; Mylan; Sandoz; Omnicare; Prescription Supply	10/23/2018; 3/15/2019	2018

Board of Commissioners of Barber County, Kansas v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-457815	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; CVS; Cardinal; Cephalon; Endo; H.D. Smith; Health Mart; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; TEVA; Walgreens; Walmart	9/11/2019	2019
Board of Commissioners of Leavenworth County, Kansas v. AmerisourceBergen Drug Corp., et al.	D. Kan./2:19-cv-02316-CM-TJJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	6/14/2019	2019
Board of County Commissioners for Dewey County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00736 (removed from D. Ct. Dewey Cnty. (OK)/CJ-2019-5)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Walgreens	2/22/2019	2019
Board of County Commissioners for San Miguel County v. Purdue Pharma L.P., et al.	D.N.M./1:19-cv-00400 (removed from San Miguel Dist. Ct. (NM)/D-412-CV-2018-00711)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; AmerisourceBergen; Cardinal; McKesson; CVS; Walgreens; Walmart	12/28/2018	2018
Board of County Commissioners of Atoka County v. Purdue Pharma L.P., et al.	E.D. Okla./6:19-cv-00279-RAW (removed from D. Ct. Atoka Cnty. (OK)/CJ-19-10)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	2/25/2019	2019

Board of County Commissioners of Caddo County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00710-R (removed from D. Ct. Caddo Cnty. (OK)/CJ-2019-4)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Walgreens; CVS	1/14/2019	2019
Board of County Commissioners of Cherokee County, Kansas v. AmerisourceBergen Drug Corp., et al.	D. Kan./6:18-cv-01110	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	4/5/2018	2018
Board of County Commissioners of Cimarron County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00776-F (removed from D. Ct. Cimarron Cnty. (OK)/CJ-19-4)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	2/25/2019	2019
Board of County Commissioners of Cowley County, Kansas v. AmerisourceBergen Drug Corp., et al.	D. Kan./6:18-cv-01204-JWB-KGG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Insys; CVS; Walgreens; Wal-Mart	7/13/2018	2018

Board of County Commissioners of Crawford County, Kansas v. AmerisourceBergen Drug Corp., et al.	D. Kan./2:18-cv-02246-JAR-TJJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Insys; H.D. Smith; Miami-Luken; Harvard Drug Co.	5/11/2018	2018
Board of County Commissioners of Finney County, Kansas and Thomas Burgardt, Finney County Counselor v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45387-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
Board of County Commissioners of Grady County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00703 (removed from D. Ct. Grady Cnty. (OK)/CJ-2019-12)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Walgreens; CVS	1/14/2019	2019
Board of County Commissioners of Harper County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00735-D (removed from D. Ct. Harper Cnty. (OK)/CJ-2019-8)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Walgreens	2/22/2019	2019

Board of County Commissioners of Haskell County v. Purdue Pharma L.P., et al.	E.D. Okla./6:19-cv-00280-RAW (removed from D. Ct. Haskell Cnty. (OK)/CJ-19-8)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	2/25/2019	2019
Board of County Commissioners of Jefferson County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00721-D (removed from D. Ct. Jefferson Cnty. (OK)/CJ-19-1)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	1/14/2019	2019
Board of County Commissioners of Johnston County v. Purdue Pharma L.P., et al.	E.D. Okla./6:19-cv-00261-SPS (removed from D. Ct. Johnston Cnty. (OK)/CJ-2019-10)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Walgreens	2/22/2019	2019

Board of County Commissioners of Kay County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00884-D (removed from D. Ct. Kay Cnty. (OK)/CJ-2019-56)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	3/11/2019	2019
Board of County Commissioners of Latimer County v. Purdue Pharma L.P., et al.	E.D. Okla./6:19-cv-00282-KEW (removed from D. Ct. Latimer Cnty. (OK)/CJ-19-9)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	2/25/2019	2019
Board of County Commissioners of Love County v. Purdue Pharma L.P., et al.	E.D. Okla./6:19-cv-00320 (removed from D. Ct. Love Cnty. (OK)/CJ-2019-8)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	2/22/2019	2019

Board of County Commissioners of Major County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00879 (removed from D. Ct. Major Cnty. (OK)/CJ-2019-5)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Walgreens	2/22/2019	2019
Board of County Commissioners of Morton County, Kansas and Eric Witcher, Morton County Counselor v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45393-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
Board of County Commissioners of Neosho County, Kansas v. AmerisourceBergen Drug Corp., et al.	D. Kan./2:18-cv-02497-DDC-TJJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Insys; H.D. Smith; Miami-Luken	9/14/2018	2018
Board of County Commissioners of Pittsburg County v. Purdue Pharma L.P., et al.	E.D. Okla./6:19-cv-00100-KEW (removed from D. Ct. Pittsburg Cnty. (OK)/CJ-19-46)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Walgreens	2/25/2019	2019

Board of County Commissioners of Pottawatomie County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00880 (removed from D. Ct. Pottawatomie Cnty. (OK)/CJ-19-18)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Walgreens	2/22/2019	2019
Board of County Commissioners of Pratt County, Kansas v. AmerisourceBergen Drug Corp., et al.	D. Kan./6:18-cv-01109	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	4/5/2018	2018
Board of County Commissioners of Seward County, Kansas and Russell Hasenbank, Seward County Counselor v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45391-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
Board of County Commissioners of Stephens County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00728-SLP (removed from D. Ct. Stephens Cnty. (OK)/ CJ-2019-7R)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Abolghasem Rezaei; Russell Portenoy; Perry Fine; Lynn Webster	1/14/2019	2019

Board of County Commissioners of the County of Adams; Board of County Commissioners of the County of Arapahoe; City of Aurora; City of Black Hawk; Board of County Commissioners of the County of Boulder; City and County of Broomfield; City of Commerce City; City and County of Denver; Board of County Commissioners of the County of Fremont; Town of Hudson; Board of County Commissioners of County of Larimer; City of Northglenn; Board of County Commissioners of the County of Teller; City of Westminster; Tri-County Health Department v. Purdue	D. Colo./1:19-cv-00114	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	1/11/2019	2019
Board of County Commissioners of the County of Bernadillo v. AmerisourceBergen Drug Corp., et al.	D.N.M./1:19-cv-00342-SMV-JHR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	4/12/2019	2019
Board of County Commissioners of the County of Catron v. AmerisourceBergen Drug Corp., et al.	D.N.M./2:19-cv-00370	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	4/23/2019	2019
Board of County Commissioners of the County of Cibola v. AmerisourceBergen Drug Corp., et al.	D.N.M./1:19-cv-00371	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	4/23/2019	2019

Board of County Commissioners of the County of Curry v. AmerisourceBergen Drug Corp., et al.	D.N.M./2:19-cv-00414	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	5/6/2019	2019
Board of County Commissioners of the County of Dona Ana, New Mexico v. AmerisourceBergen Drug Corp., et al.	D.N.M./2:18-cv-00959	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	10/15/2018	2018
Board of County Commissioners of the County of Lea v. AmerisourceBergen Drug Corp., et al.	D.N.M./2:19-cv-00222	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	3/15/2019	2019
Board of County Commissioners of the County of Lincoln v. AmerisourceBergen Drug Corp., et al.	D.N.M./2:19-cv-00462-SMV-GBW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	5/20/2019	2019
Board of County Commissioners of the County of McKinley v. AmerisourceBergen Drug Corp., et al.	D.N.M./1:19-cv-00023	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	1/11/2019	2019

Board of County Commissioners of the County of Otero v. AmerisourceBergen Drug Corp., et al.	D.N.M./2:19-cv-00208-KRS-SMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	3/12/2019	2019
Board of County Commissioners of the County of Santa Fe v. Purdue Pharma L.P., et al.	D.N.M./1:18-cv-00534-KK-JHR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; RiteAid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	6/8/2018	2018
Board of County Commissioners of the County of Sierra v. AmerisourceBergen Drug Corp., et al.	D.N.M./2:19-cv-00372	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	4/23/2019	2019
Board of County Commissioners of the County of Socorro v. AmerisourceBergen Drug Corp., et al.	D.N.M./2:19-cv-00374	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	4/23/2019	2019
Board of County Commissioners of the County of Taos v. AmerisourceBergen Drug Corp., et al.	D.N.M./1:19-cv-00056-LF-JHR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	1/18/2019	2019

Board of County Commissioners of the County of Valencia v. AmerisourceBergen Drug Corp., et al.	D.N.M./1:19-cv-00375	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart	4/23/2019	2019
Board of County Commissioners of Tulsa County v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv-00205-GFK-FHM (removed from D. Ct. Tulsa Cnty. (OK)/CJ-2019-01116)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Tamerlane Rozsa; Roger Kinney; Joshua Livingston; Joseph Knight; Christopher Moses; Jeremy Thomas	3/18/2019	2019
Board of County Commissioners of Washington County, Maryland v. AmerisourceBergen Drug Corp., et al.	D. Md./1:18-cv-02592-GLR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Walgreens; Wal-Mart; Anda	8/21/2018	2018
Board of Kiowa Commissioners of Kiowa County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00730-PRW (removed from D. Ct. Kiowa Cnty. (OK)/CJ-2019-9)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Walgreens	2/22/2019	2019

Board of Miami County Commissioners, on behalf of Miami County, Ohio v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45335-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco	5/20/2019	2019
Board of Supervisors, Prince William County v. Purdue Pharma L.P., et al.	E.D. Va./1:19-cv-00365	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
Board of Woods Commissioners of Woods County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00878 (removed from D. Ct. Woods Cnty. (OK)/CJ-2019-6)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Walgreens	2/22/2019	2019
Bobbie Lou Moore, individually and as next friend and guardian of minor of minor R.R.C., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	S.D. WV/2:18-cv-01231	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Linden Care; Kroger; H.D. Smith; Linden; Kroger; Rhodes	8/15/2018; 3/16/2019	2018

Bobby Guidroz, duly elected Sheriff of St. Landry Parish, Louisiana, in his capacity as Ex Officio of the St. Landry Parish's Office and the St. Landry Parish Law Enforcement District v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46051-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Andia; CVS; Rite Aid; Walgreens; Walmart; Amneal; Indivior; Mylan; Hikma; Louisiana Wholesale Drug Co; Albertsons; Morris & Dickson; Rhodes	9/7/2018	2018
Bon Secours Health System, Inc.; Our Lady of Bellefonte; and Bellefonte Physician Services, Inc. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45822-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Noramco; Endo; Watson; Allergan; Actavis; Depomed; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Collegium; Miami-Luken	7/11/2018	2018
Boone County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45375-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Par; SpecGx; Insys; CVS; Walmart; Wagreens; H.D. Smith; Kroger	6/6/2019	2019
Bossier City v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00817-BAJ-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Mallinckrodt	9/4/2018	2018
Bossier Parish Emergency Medical Services Ambulance District v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00971-SDD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018

Bossier Parish v. Cardinal Health, Inc.	M.D. LA/3:17-cv-01815-BAJ-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cardinal, McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	12/29/2017	2017
Boulder City v. Purdue Pharma L.P., et al.	D. Nev./2:19-cv-01057-RFB-GWF	Purdue Pharma L.P.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; Insys; Omnicare; Masters	6/20/2019	2019
Bourbon County, Kansas v. AmerisourceBergen Drug Corp., et al.	D. Kan./2:18-cv-02312	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	6/12/2018	2018
Bradford County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./3:19-cv-00702-BJD-JBT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Publix; Walgreen	6/11/2019	2019
Brandi Brumbarger, individually and as next friend and guardian of Baby J.B.B., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45469-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/14/2019	2019
Brantley County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45714-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	6/13/2018	2018

Brazos County v. Purdue Pharma L.P., et al.	S.D. Texas/4:18-cv-02314	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Does 1-100 Inclusive	7/5/2018; 3/16/2019	2018
Bridge House Corporation v. Purdue Pharma L.P., et al.	E.D. La./2:18-cv-07821-EEF-JCW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	8/16/2018	2018
Bristol Township, Pennsylvania v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45434-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger; H.D. Smith	6/12/2019	2019
Brittany Flach, individually and as next friend and guardian of Babies A.B. and G.B., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45488-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/16/2019	2019
Brooks County, Georgia v. Purdue Pharma L.P., et al.	M.D. Ga./7:18-cv-00118-WLS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	8/3/2018	2018

Broward Behavioral Health Coalition v. Purdue Pharma L.P., et al.	S.D. Fla./0:19-cv-61172-UU	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Health Mart; H.D. Smith; CVS; Walgreen; Wal-Mart	5/8/2019	2019
Broward County, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./0:18-cv-60535-BB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; CVS; Walgreens; Wal-Mart	3/12/2018	2018
Brown County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00664-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/12/2017	2017
Brown County, et al. v. Purdue Pharma L.P., et al.	E.D. Wi./2:18-cv-00022-DEJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	1/5/2018; 5/25/2018; 3/15/2019	2018
Brunswick County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./7:18-cv-00021-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/2/2018	2018

Buchanan County v. Purdue Pharma L.P., et al.	W.D. Va./1:18-cv-00047-EKD (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	9/6/2018	2018
Buchanan County, Missouri v. AmerisourceBergen Drug Corp., et al.	W.D. Mo./5:17-cv-06141-FJH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	11/29/2017	2017
Buffalo County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01647-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Building Trades Welfare Benefit Fund v. Purdue Pharma L.P., et al.	E.D.N.Y./2:19-cv-05254	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; Anda; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	9/13/2019	2019

Bulloch County, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./6:18-cv-00031- JRH-GRS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/21/2018	2018
Bullock County, Alabama v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./2:18-cv-00119- MHT-GMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/15/2018	2018
Buncombe County v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./1:17-cv-00310- MR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	11/14/2017	2017
Burke County v. AmerisourceBergen Drug Corp., et al.	W.D.NC/1:18-vc-00020	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	1/31/2018	2018
Burke County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45207-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/28/2019	2019
Burleigh County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00107- DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019

Burnett County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01648-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Butler County Board of Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-01024-EAS-KAJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Allergan; Watson; Actavis; AmerisourceBergen	11/22/2017	2017
Butler County, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./2:18-cv-00362-WC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/20/2018	2018
Butler County, Cape Girardeau County, Christian County, City of Independence, City of Joplin, Crawford County, Dent County, Dunklin County, Greene County, Iron County, Jasper County, Madison County, Perry County, Ste. Genevieve County, Stone County, Taney County, Texas County, and Washington County v. Dannie E. Williams, M.D., et al.	E.D. Mo./4:19-cv-00157-RLW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Dannie E. William, M.D.; Delmar Primary Care; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Express; Wal-Mart; Target; Walgreens; CVS; Caremark; Mylan; Depomed; Insys; United Health; Optum	1/29/2019	2019

Butts County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45490-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/19/2018	2018
Cabarrus County v. Purdue Pharma L.P., et al.	M.D.N.C./1:18-cv-00474- TDS-LPA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; RiteAid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	6/4/2018	2018
Cabell County Commission v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:17-op- 45053-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; TEVA; Watson; CVS; Insys; Noramco; Walgreens; Walmart; Rite Aid; SpecGx	3/9/2017	2017
Caddo Fire Protection District No. 1 v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00975- BAJ-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
Caddo Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00936- JWD-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/23/2018	2018

Cahto Indian Tribe of the Laytonville Rancheria; Cher-Ae Heights Indian Community of the Trinidad Rancheria; Ewiiapaayp Band of Kumeyaay Indians; Koi Nation of Northern California; Manchester Band of Pomo Indians of the Manchester Rancheria; Potter Valley Tribe; Resighini Rancheria v. McKesson Corp., et al.	N.D. Ohio/1:19-op-45038-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	1/28/2019	2019
Caldwell County v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./5:18-cv-00039-MOC-DCK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/6/2018	2018
Caldwell Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00929-JWD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/19/2018	2018
Calhoun County, Alabama v. Cardinal Health Inc., et al.	N.D. Ala./1:18-cv-00159-JEO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cardinal; AmerisourceBergen; McKesson; Actavis; Allergan; Cephalon; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; Noramco; TEVA; Watson; John and Jane Does 1-101	1/31/2018	2018
Calhoun County, Florida v. AmerisourceBergen Drug Corp., et al.	N.D. Fla./3:18-cv-00067-RH-GRJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/16/2018	2018

Calhoun County, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:19-cv- 00438	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Par; Mallinckrodt; SpecGx; Allergan; Insys; AmerisourceBergen; Cardinal; McKesson; Walgreen; Walmart; Kroger; Rite Aid; CVS	6/7/2019	2019
Calhoun County, South Carolina v. AmerisourceBergen Drug Corp., et al	D.S.C./5:18-cv-01526- MDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	6/5/2018	2018
Callaway County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45378-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Par; SpecGx; Insys; CVS; Walmart; Wagreens; H.D. Smith; Kroger	6/6/2019	2019
Calumet County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01649- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017

Camas County, Idaho v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45407-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/7/2019	2019
Camden County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45717-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	6/13/2018	2018
Camden County, NJ v. Purdue Pharma L.P., et al.	D.N.J./1:18-cv-11983-JHR-AMD (removed from Super. Ct. of NJ, Law Division/CAM-L-000695-18)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; CVS; Walgreens; Cotsco; Rite Aid	2/21/2018	2018
Cameron Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:19-cv-00390-BAJ-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Mallinckrodt	6/14/2019	2019
Campbell County, TN v. AmerisourceBergen Drug Corp., et al.	E.D. Tenn./3:18-cv-00006-JRG-HBG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Masters; SpecGx; Par; Amneal; Rite Aid; CVS; Walgreens; Walmart	1/4/2018; 3/6/2019	2018
Candler County, GA v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./6:18-cv-00011-JRH-GRS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	1/29/2018	2018

Canyon County v. Purdue Pharma L.P., et al.	D. Ida./1:18-cv-00479-BLW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken	10/29/2018	2018
Cape May County, New Jersey v. Purdue Pharma L.P., et al.	D.N.J./1:19-cv-05416 (removed from Super. Ct. NJ, Cape May Cnty/CPM-L-000261-18)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen	7/3/2018	2018
Carbon County, Utah v. Purdue Pharma Inc., et al.	D. Ut./2:18-cv-00863-BCW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; SpecGx; Par; Amneal	11/1/2018; 3/14/2019	2018
Carbon County, Wyoming v. Purdue Pharma L.P., et al.	D. Wyo./1:18-cv-00074-ABJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; AmerisourceBergen; Insys; H.D. Smith; Walmart; Associated Pharm.; SpecGx; Par; Amneal; West-Ward; Mylan; Rhodes	5/8/2018; 3/15/2019	2018
Carlton County, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01573-SRN-LIB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	6/14/2019	2019
Carmen Siebler, as Personal Representative of the Estate of George Siebler, deceased v. Purdue Pharma L.P., et al.	S.D. Fla./1:18-cv-023684-UU	Purdue Pharma L.P.; Purdue Pharma Inc.	Same as "Purdue Entities Named as Defendants"	9/7/2018	2018

Carol Lively, individually and as next friend and guardian of Baby L.L. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45523-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Caroline VonCannon, individually and as next friend and guardian of Babies C.W. and S.W. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45540-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Carpenter Hospice of Northwest Louisiana, LLC; St. Joseph Hospice, LLC; St. Joseph Hospice of Acadiana, LLC; St. Joseph Hospice of Bayou Region, LLC; St. Joseph Hospice of Cenla, LLC; St. Joseph Hospice & Palliative Care of Monroe, LLC; Grace Hospice of New Orleans, LLC; St. Joseph Hospice & Palliative Care-Northshore, LLC; St. Joseph Hospice of Southern Mississippi, LLC; St. Joseph Hospice of Houston, LLC; St. Joseph Hospice of South Alabama, LLC; St. Joseph Hospice of Southwest Louisiana, LLC; Stat Home Health, LLC; Stat Home Health-North, LLC; Stat-Home Health-West, LLC; Bellator	M.D. La./3:19-cv-00385-SDD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Morris & Dickson Co.; SpecGx	6/12/2019	2019

Carroll County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-46079-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	9/18/2018	2018
Carroll County v. Purdue Pharma L.P., et al.	N.D. Ga./3:18-cv-00131-TCB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Depomed; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; McKesson; Cardinal	11/2/2018	2018
Carroll County, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./4:19-cv-00034-DMB-RP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	3/1/2019	2019
Carroll County, Virginia v. AmerisourceBergen Drug Corp., et al.	W.D. Va./7:18-cv-00308-EKD-PMS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS; North Carolina Wholesale Drug Co; JM Smith; Walgreens; Walmart; Amneal; Mylan; Par; SpecGx; West-Ward; Rhodes	6/28/2018; 3/14/2019	2018
Carteret County, North Carolina v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./4:18-cv-00082-H	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/27/2018	2018
Carver County, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-02388	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	8/29/2019	2019

Casper, Wyoming v. Purdue Pharma L.P., et al.	D. Wyo./1:19-cv-00024-ABJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; AmerisourceBergen; Insys; Caredinal; Walgreens; Walmart; Rhodes; SpecGx; Par; Amneal; West-Ward; Mylan	2/4/2019; 4/3/2019	2019
Cass County, Missouri v. AmerisourceBergen Drug Corp., et al.	W.D. Mo./4:18-cv-00495-ODS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/26/2018	2018
Cass County, North Dakota and City of Grand Forks, North Dakota, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00055-DLH-ARS	Purdue Pharma L.P.; The Purdue Frederick Company Inc.; Purdue Pharmaceutical Products L.P.; Purdue Products L.P.	Rhodes; Endo; Par; Janssen; TEVA; Cephalon; Allergan; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/26/2019	2019
Caswell County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:18-cv-00595-TDS-LPA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	7/6/2018	2018
Catahoula Parish Police Jury v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00943-BAJ-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/24/2018	2018
Catawba County, NC v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./5:18-cv-00007	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	1/11/2018	2018

Catoosa County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ga./4:18-cv-00088- HLM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/10/2018	2018
Cecil County, Maryland v. AmerisourceBergen Drug Corp., et al.	D. Md./1:18-cv-00063- GLR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	1/9/2018	2018
Center Point, Inc. v. McKesson Corporation, et al.	N.D. Cal./3:18-cv-02535 (removed from San Francisco County Super Ct. (CA)/CGC-18-564833)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal- Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	3/6/2018	2018
Central States, Southeast and Southwest Areas Health & Welfare Fund v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45623-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	5/30/2018	2018
Chambers County, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./3:18-cv-00361- WKW-CSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/20/2018	2018
Champaign County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-01132- JLG-CMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/21/2017	2017

Charleston County, South Carolina v. Purdue Pharma L.P., et al.	D.S.C./2:19-cv-02099- MDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Johnson & Johnson; Normaco; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; CVS; Walgreens; Walmart	7/26/2019	2019
Charlotte County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./4:19-cv-00029	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
Charlton County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45713-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	6/13/2018	2018
Charter Township of Canton; City of Livonia; Charter Township of Northville; City of Romulus; Charter Township of Van Buren; City of Wayne; and Charter Township of Huron, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./2:18-cv- 12938-DPH-RSW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Par; Mallinckrodt; SpecGx; Allergan; Insys; AmerisourceBergen; Cardinal; McKesson; Walgreen; Walmart; Kroger; Rite Aid; CVS	9/19/2018	2018
Charter Township of Clinton, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./4:18-cv- 12950-MFL-MKM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Par; Mallinckrodt; SpecGx; Allergan; Insys; AmerisourceBergen; Cardinal; McKesson; Walgreen; Walmart; Kroger; Rite Aid; CVS	9/20/2018	2018

Charter Township of Harrison v. The Pain Center USA, PLLC, et al.	E.D. Mich./2:19-cv-11681-DML-RSW (removed from 16th Jud. Cir. Ct., Macomb Cnty. (Mich.)/19-1562-CZ)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	The Pain Center; Interventional Pain Center; Rhodes; Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal	4/24/2019	2019
Charter Township of Pittsfield, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./2:19-cv-11703-NGE-DRG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Par; Mallinckrodt; SpecGx; Allergan; Insys; AmerisourceBergen; Cardinal; McKesson; Walgreen; Walmart; Kroger; Rite Aid; CVS	6/7/2019	2019
Chatham County Hospital Authority, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./4:19-cv-00086-CLR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/18/2019	2019
Chatham County Hospital Authority, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./4:19-cv-00159-RSB-CLR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	7/3/2019	2019
Chatham County, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./4:18-cv-00042-WTM-GRS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/6/2018	2018
Chelan County v. Purdue Pharma L.P., et al.	E.D. Wa./2:18-cv-00285-SAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; SpecGx; Par; Mylan; West-Ward; Hikma; KVK; Walgreens; Walmart	9/7/2018; 3/13/2019	2018

Cherokee County v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./1:18-cv-00215-MOC-DLH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	7/30/2018	2018
Cherokee County, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./4:18-cv-00172-SGC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
Cherokee County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45174-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/25/2019	2019
Cheshire County v. Purdue Pharma L.P., et al.	D.N.H./1:19-cv-00328 (removed from Cheshire Super. Ct. (NH)/213-2018-CV-00168)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Rite-Aid; Walgreens; Walmart; Dr. Michael Dipre; Dr. Mark Weinreb; Christopher Clough; Ayman A. Jacobs	9/19/2018	2018
Chester County, Pennsylvania, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	E.D. Pa./2:19-cv-01018-PBT	Purdue Pharma L.P.; The Purdue Frederick Company Inc.; Purdue Pharmaceutical Products L.P.; Purdue Products L.P.	Rhodes; Endo; Par; Janssen; TEVA; Cephalon; Allergan; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/11/2019	2019
Cheyenne & Arapaho Tribes v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00039-SLP (removed from D. Ct. Canadian Cnty. (OK)/CJ2018677)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	12/14/2018	2018
Cheyenne River Sioux Tribe v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45114-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; Johnson & Johnson; Janssen; Endo; CVS; Walmart	3/6/2019	2019

Cheyenne, Wyoming v. Purdue Pharma L.P., et al.	D. Wyo./1:19-cv-00049	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; AmerisourceBergen; Insys; Caredinal; Walgreens; Walmart	3/8/2019	2019
Chickasaw County, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:19-cv-00044-MPM-RP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	3/1/2019	2019
Chickasaw Nation v. Purdue Pharma L.P., et al.	E.D. Okla./6:18-cv-00356-KEW (removed from D. Ct. Pontotoc Cnty. (OK)/CJ-18-136)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Allergan; Watson; Actavis; Endo	8/2/2018	2018
Chilton County, Alabama v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./2:18-cv-00547-MHT-WC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	6/1/2018	2018
Chippewa County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01650-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Chippewa Cree Tribe of the Rocky Boy's Reservation v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45395-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith; Kroger; Rite Aid	6/6/2019	2019

Chitimacha Tribe of Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45825-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Morris & Dickson	7/16/2018	2018
Chloe Paul, individually and as next friend and guardian of Baby A.R.P., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45467-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/14/2019	2019
Choctaw Nation v. Purdue Pharma L.P., et al.	E.D. Okla./6:18-cv-00355-RAW (removed from D. Ct. Bryan Cnty. (OK)/CJ-2018-114)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Allergan; Actavis; Watson; Endo	8/1/2018	2018
Chowan County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./2:18-cv-00051-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	9/27/2018	2018
Chris Steverson in his official capacity as the Sherriff of Telfair County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45313-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	5/9/2019	2019

Christina Delancey, individually and as next friend and guardian of Baby A.J.W., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45480-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/15/2019	2019
Chuck Smith in his official capacity as the Sherriff of Meriwether County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45306-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	5/7/2019	2019
City of Eureka; The People of the State of California, acting by and through Interim Eureka City Attorney, Robert Norris Black v. Purdue Pharma L.P., et al.	N.D. Cal./1:18-cv-05353-RMI	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; John and Jane Does 1 through 100, inclusive	8/30/2018	2018
City of Abbeville, AL v. Purdue Pharma L.P., et al.	M.D. Ala./1:18-cv-00363-TFM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/20/2018	2018
City of Aberdeen, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02016-ELH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019

City of Ada v. Purdue Pharma L.P., et al.	E.D. Okla./6:19-cv-00034-RAW (removed from D. Ct. Pontotoc Cnty. (OK)/CJ-2019-3)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; William Valuck; Harvey Jenkins; Russell Portenoy; Perry Fine; Lynn Webster	1/9/2019	2019
City of Adel, Georgia v. Purdue Pharma L.P., et al.	M.D. Ga./7:19-cv-00061-HL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Noramco; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	4/26/2019	2019
City of Albany, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./1:18-cv-00221-LJA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Rite Aid; Walgreens; JM Smith	11/20/2018	2018
City of Alexander City, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./3:19-cv-00630-ECM-SMD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	8/30/2019	2019
City of Alexandria v. Purdue Pharma L.P., et al.	E.D. Va./1:18-cv-01536 (removed from Cir. Ct. City of Alexandria (VA))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Does 1-100	3/12/2018	2018

City of Alexandria, City of Elwood and Madison County v. Purdue Pharma L.P., et al.	S.D. Ind./1:18-cv-00123-TWP-MJD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	1/15/2018	2018
City of Alexandria, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46050-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Anda; CVS; Rite Aid; Walgreens; Walmart; Amneal; Indivior; Mylan; Hikma; Louisiana Wholesale Drug Co; Albertsons; Morris & Dickson; Rhodes	9/7/2018	2018
City of Allentown, Pennsylvania v. AmerisourceBergen Drug Corp., et al.	E.D. Pa./5:19-cv-03884-EGS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; Endo; TEVA; Cephalon; Par; Allergan; Watson; Actavis; Mallinckrodt; SpecGx	8/27/2019	2019
City of Alma, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./5:18-cv-00041-LGW-RSB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Attain; Bloodworth; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/11/2018	2018
City of Amory, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:19-cv-00106-SA-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/3/2019	2019

City of Anacortes and Sedro-Woolley School District v. Purdue Pharma L.P., et al.	W.D. Wa./2:18-cv-01853-BAT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; SpecGx; Par; West-Ward; Hikma; Amneal; Impax; Walgreens; Thrifty; Par; Rite Aid	12/21/2018; 3/15/2019	2018
City of Anadarko v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00815-F (removed from D. Ct. Caddo Cnty. (OK)/CJ-2019-23)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	3/15/2019	2019
City of Annapolis, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-01162-GLR (removed from Cir. Ct. Anne Arundel Cnty. (MD)/C-02-CV-19-000594)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Cardinal McKesson; AmerisourceBergen; William Tham, M.D.; Physical Medicine and Pain Management Associates, PC; Kofi Shaw-Taylor; Happiness Aguzie; Tomarco Harris; Minnie Ndem; Starlife Wellness Center LLC; Lawrence Vidaver, M.D.; Maryland Healing Waters, LLC	2/26/2019	2019
City of Anniston, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./1:18-cv-00398-VEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/14/2018	2018

City of Argo, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./4:19-cv-01270-KOB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	8/8/2019	2019
City of Ashland, Ohio v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46203-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; SpecGx; Par; Amneal; KVK; Discount Drug Mart; CVS; Rite Aid; Walmart	10/31/2018; 3/14/2019	2018
City of Atlanta v. Purdue Pharma L.P., et al.	N.D. Ga./1:18-cv-03508-SCJ (removed from Fulton Cnty. St. Ct. (Ga.)/18EV002561)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Kroger; CVS; Walgreens; Wal-Mart; RiteAid; Perry Fine; Scott Fishman; Lynn Webster; Medicine Center Pharmacy; Amarc; J.M. Smith; PSS; Attain; Bloodworth	5/31/2018	2018
City of Auburn v. Purdue Pharma L.P., et al.	D. Me./2:19-cv-00013-NT (removed from Super. Ct. Adroscoggin Cnty. (Me.)/CV-18-155)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	11/21/2018	2018

City of Augusta v. Purdue Pharma L.P., et al.	D. Me./1:19-cv-00017-NT (removed from Super. Ct. Kennebec Cnty. (Me.)/CV-2018-201)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	11/21/2018	2018
City of Austin v. Purdue Pharma L.P., et al.	S.D. Ind./4:19-cv-00155-JMS-DML (removed from Scott Cnty. Super. Ct. (Ind.)/72D01-1906-PL-000030)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Samantha Beaver; Kevin L. Foster; Brittany Berkshire; Jesse Bobb; Michael White; Glenn Michael Fields; Claude Holt, Jr.; Lloyd E. McNear	6/14/2019	2019
City of Bainbridge, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./1:18-cv-00065-WLS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/22/2018	2018
City of Bangor v. Purdue Pharma L.P., et al.	D. Me./1:18-cv-00298-NT (removed from Super. Ct. Penobscot Cnty. (Me.)/18002818)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	6/27/2018; 7/31/2018 (Am.)	2018

City of Bastrop, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45771-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Andia; CVS; Rite Aid; Walgreens; Walmart; Mylan; Sandoz; Hikma; West- Ward; Morris & Dickson; Harco; Rhodes	7/2/2018	2018
City of Baton Rouge, Parish of East Baton Rouge v. AmerisourceBergen Drug Corp., et al.	M.D. LA/3:18-cv-00047- BAJ-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	1/23/2018	2018
City of Beech Grove, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-02757- TWP-TAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	9/6/2018	2018
City of Bel Air, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02020- TDC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019

City of Belknap v. Purdue Pharma L.P., et al.	D.N.H./1:19-cv-00326 (removed from Belknap Super. Ct. (NH)/211-2018-CV-00240)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Rite-Aid; Walgreens; Walmart; Dr. Michael Dipre; Dr. Mark Weinreb; Christopher Clough; Dr. Erik L. Knight	9/18/2018	2018
City of Belmont v. Purdue Pharma L.P., et al.	D.N.H./1:19-cv-00326 (removed from Belknap Super. Ct. (NH)/211-2018-CV-00241)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Rite-Aid; Walgreens; Walmart; Dr. Michael Dipre; Dr. Mark Weinreb; Christopher Clough	9/19/2018	2018
City of Benham v. Purdue Pharma L.P., et al.	E.D. Ky./6:19-cv-00048-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Knoll; Abbvie; Wal-Mart; Walgreens; CVS	2/14/2019	2019
City of Berlin, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02021-PX	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019

City of Bethany v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00804-D (removed from D. Ct. Oklahoma Ctny. (OK)/CJ-2019-4271)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	8/1/2019	2019
City of Beverly, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-10398	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	3/4/2019	2019
City of Biddeford, a municipality in York County, State of Maine v. Purdue Pharma L.P., et al.	D. Me./2:19-cv-00092-NT (removed from Super. Ct. York Cnty. (Me.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.	1/18/2019	2019
City of Birmingham, Alabama, et al. v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./2:17-cv-01360-JEO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	8/14/2017; 11/1/2017 (Am.)	2017

City of Bismarck v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00106- DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
City of Blackshear, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./5:19-cv-00071- LGW-BWC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	8/22/2019	2019
City of Blakely, Georgia; City of Arlington, Georgia; City of Demascus, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op- 45129-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; McKesson; Cardinal; AmerisourceBergen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; Walgreens; CVS; Walmart; Smith Drug Co.; SpecGx; Par; Amneal; Indivior; Mylan; Sandoz; Anda	3/12/2019; 3/15/2019	2019
City of Bloomington and Monroe County v. Purdue Pharma L.P., et al.	S.D. Ind./1:18-cv-00378- SEB-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	2/9/2018	2018
City of Bogalusa, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46297-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; PSS World; CVS; Walgreens; Walmart; Rite Aid; Par; SpecGx; Mylan; Rhodes; Miami-Luken; Noramco; Anda; John N. Kapoor	12/5/2018; 3/18/2019	2018

City of Boise v. Purdue Pharma L.P., et al.	D. Ida./1:18-cv-00500- BLW	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters	11/8/2018	2018
City of Bradenton v. AmerisourceBergen Drug Corp., et al.	M.D. Fla./8:18-cv-02861- JSM-SPF	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	11/20/2018	2018
City of Brighton v. Purdue Pharma L.P., et al.	D. Colo./1:19-cv-01048- SKC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Par; Mylan; Hikma; Walmart; Smith Drug	4/9/2019	2019
City of Bristol, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./1:19-op-45719 (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019

City of Broken Arrow v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv-00047 (removed from D. Ct. Tulsa Cnty. (OK)/CJ-2019-63)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Joshua Livingston; Russell Portenoy; Perry Fine; Lynn Webster	1/7/2019	2019
City of Brunswick, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./2:18-cv-00023-LGW-RSB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/6/2018	2018
City of Buckhorn v. Purdue Pharma L.P., et al.	E.D. Ky./6:19-cv-00045-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Knoll; Abbvie; Wal-Mart; Walgreens; CVS	2/12/2019	2019
City of Cambridge, Maryland v. Purdue Pharma L.P., et al.	D. Md./8:19-cv-01737-PX	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Insys	6/13/2019	2019
City of Canton, a municipal corporation; Chatham County, North Carolina, and all others similarly situated	N.D. Ohio/1:19-op-45462-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Depomed; Endo; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	6/14/2019	2019

City of Central Falls, RI v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00142-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
City of Charles Town v. AmerisourceBergen Drug Corp., et al.	N.D. WV/3:19-cv-00040-GMG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Bellco; Cardinal; Harvard Drug; Parmed; McKesson; Masters; TEVA; Cephalon; Anda; Allergan; Watson; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; SpecGx; Insys; Rite Aid; Walmart; American Sales; West-Ward; Amneal; Indivior; Mylan; Giant Food Stores; Walgreen; TopRx; Smith Drug Co	3/20/2019	2019
City of Charleston, Miss. v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./3:18-cv-00076-MPM-RP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/26/2018	2018
City of Charlestown, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02022-PX	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019

City of Chelsea v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-10994	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018
City of Chester, South Carolina v. Purdue Pharma L.P., et al.	D.S.C./0:19-cv-01704-MDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Johnson & Johnson; Normaco; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; CVS; Walgreens	6/12/2019	2019
City of Chicago v. Purdue Pharma L.P., at al.	N.D. Ill./1:14-cv-04361 (Removed from Cir. Ct. Cook Cnty. (Ill)/2014L005854)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson	6/11/2014; 11/10/2014 (1st Amend.); 11/5/2015 (2nd Amend.); 10/25/2016 (3rd Amend.)	2014
City of Chubbuck v. Purdue Pharma L.P., et al.	D. Ida./4:19-cv-00278-DCN	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters	7/17/2019	2019
City of Chula Vista, California, a municipal corporation v. Purdue Pharma L.P., et al.	S.D. Cal./3:19-cv-01115-DMS-MSB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Insys; CVS; Kroger; Rite Aid; Thrifty; Walgreens; Wal-Mart	6/14/2019	2019
City of Cincinnati v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00713-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	9/22/2017	2017
City of Clanton, Alabama, a municipal corporation v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./2:18-cv-00761-WC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	8/27/2018	2018

City of Claremont v. Purdue Pharma L.P., et al.	D.N.H./1:19-cv-00331 (removed from Sullivan Super. Ct. (NH)/220-2018-CV-00127)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Rite-Aid; Walgreens; Walmart; Dr. Michael Dipre; Dr. Mark Weinreb; Christopher Clough; Dr. Erik L. Knight	9/18/2018	2018
City of Clarksdale v. Purdue Pharma L.P., et al.	N.D. Miss./3:19-cv-00128-NBB-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Insys	6/14/2019	2019
City of Clearwater in the County of Pinellas v. Purdue Pharma L.P., et al.	M.D. Fla./8:18-cv-03084-MSS-JSS (removed from Cir. Ct. Pinellas Cnty. (Fla.)/18-007492-CI)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; Cephalon; TEVA; Allergan; Actavis; AmerisourceBergen; Cardinal; McKesson; Mallinckrodt; Walgreens	11/15/2018	2018
City of Cleveland v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45132	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/6/2018	2018
City of Coatesville, Pennsylvania v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45396-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
City of Columbia, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./2:19-cv-00008-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	1/16/2019	2019

City of Columbus, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:18-cv-00204-SA-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	11/13/2018	2018
City of Concord, New Hampshire and City of Dover, New Hampshire v. Purdue Pharma L.P., et al.	D.N.H./1:18-cv-00328	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	4/24/2018	2018
City of Connersville and Fayette County v. Purdue Pharma L.P., et al.	S.D. Ind./1:18-cv-00175-WTL-TAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	1/22/2018	2018
City of Coon Rapids, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-02379-NEB-TNL	Purdue Pharma L.P.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Omnicare; Masters	8/29/2019	2019
City of Costa Mesa, and The People of the State of California, by and through Costa Mesa City Attorney Kimberly Hall Barlow v. Purdue Pharma L.P., et al.	N.D. Cal./3:19-cv-02320 (removed from San Francisco County Super. Ct. (Cal.)/CGC-19-574865)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Actavis; Watson; Allergan; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson	3/28/2019	2019
City of Covington v. Purdue Pharma L.P., et al.	E.D. La./2:18-cv-04789-JTM-KWR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; AmerisourceBergen; McKesson; Cardinal	5/9/2018	2018
City of Covington, Kentucky v. Purdue Pharma L.P., et al.	E.D. Ky./2:18-cv-00131-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Insys; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; Walmart	7/24/2018	2018

City of Covington, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./7:19-cv-00372	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
City of Cranston, RI v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00149- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
City of Cullman, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./5:19-cv-00444- HNJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	3/14/2019	2019
City of Cumberland, Maryland v. AmerisourceBergen Drug Corp., et al.	D. Md./1:18-cv-01368- RDB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	5/11/2018	2018
City of Dadeville, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./3:19-cv-00567- ECM-WC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	8/7/2019	2019

City of Daleville, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./3:19-cv-00566- ECM-WC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	8/7/2019	2019
City of Danville v. AmerisourceBergen Drug Corp., et al.	W.D. Va./4:19-cv-00025- EKD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Rite Aid; Thrifty; Walgreens; Wal-Mart	6/6/2019	2019
City of Dawson, Georgia v. Purdue Pharma L.P., et al.	M.D. Ga./1:19-cv-00104- LAG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Noramco; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	6/19/2019	2019
City of Daytona Beach Shores, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./6:19-cv-01094	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/13/2019	2019
City of Daytona Beach, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./6:19-cv-01103- RBD-TBS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/13/2019	2019
City of Decatur, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./5:18-cv-00173- HNJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018

City of Deerfield Beach, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./0:18-cv-63076-CMA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Health Mart; H.D. Smith; CVS; Walgreen	12/17/2018	2018
City of Delray Beach v. Purdue Pharma L.P., et al.	S.D. Fla./9:17-cv-81384-DMM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	12/21/2017	2017
City of Deltona, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./3:19-cv-01092-BJD-JBT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/13/2019	2019
City of Demopolis, Alabama v. AmerisourceBergen Drug Corp., et al.	S.D. Ala./2:18-cv-00044-N	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
City of Demorest, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ga./2:18-cv-00161-LGW-BWC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	9/7/2018	2018
City of Detroit v. Purdue Pharma L.P., et al.	E.D. Mich./2:17-cv-14075-LVP-SDD	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	12/18/2017	2017

City of Diamondhead, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./1:19-cv-00427-LG-RHW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	8/2/2019	2019
City of Donaldsonville v. Purdue Pharma L.P., et al.	M.D. La./3:18-cv-01089 (removed 23rd Judicial District, Parish of Ascension (LA)/123834)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Morris & Dickson Co.	11/13/2018	2018
City of Dover, a municipal corporation of the State of Delaware; City of Seaford, a municipal corporation of the State of Delaware; and Kent County, a political subdivision of the State of Delaware v. Purdue Pharma L.P., et al.	D. De./1:19-cv-01749-UNA (removed from Super. Ct. Of Delaware/K19C-06-022 JJC)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; Mylan; Assertio; McKesson; Cardinal; AmerisourceBergen; Anda; H.D. Smith; CVS; Rite Aid; Walgreens	6/14/2019	2019
City of Duluth, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01077	Purdue Pharma L.P.	Insys; TEVA; Johnson & Johnson; Janssen; Cephalon; Endo; Mallinckrodt; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Omnicare; Masters	4/19/2019	2019
City of East Cleveland, OH v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45448	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; Miami-Luken; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; CVS; Walgreens; Wal-Mart; Perry Fine; Scott Fishman; Lynn Webster	4/17/2018	2018

City of East Lansing, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45902-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	7/31/2018	2018
City of East Providence v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00140- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
City of Easthampton, Mass. v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30041	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	3/15/2018	2018
City of Edmond v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv- 00149-HE (removed from D. Ct. Oklahoma Cnty. (OK)/CJ-2019-158)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; William Valuck; Harvey Jenkins; Russell Portenoy; Perry Fine; Lynn Webster	1/10/2019	2019

City of Emporia, Virginia v. Purdue Pharma L.P., et al.	E.D. Va./3:19-cv-00513- MHL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
City of Enid v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv- 00351 (removed from D. Ct. Garfield Cnty. (OK)/CJ- 2019-63-01)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Tamerlane Rozsa; Perry Fine; Lynn Webster; GCP	3/18/2019	2019
City of Enterprise, Alabama v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./1:18-cv-00068- WC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
City of Escanaba, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./2:17-cv- 00208	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	12/19/2017	2017

City of Eunice, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46328-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; H.D. Smith; Ando; CVS; Rite Aid; Walgreens; Walmart; Amenal; Indivior; Mylan; Sandoz; Hikma; West-Ward; Louisiana Wholesale Drug; Morris & Dickson; K&B Louisiana Corp; Rhodes	12/14/2018; 3/14/2019; 3/16/2019	2018
City of Evansville, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./3:18-cv-00086- RLY-MPB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	4/30/2018	2018
City of Everett v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-10660	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	4/5/2018	2018
City of Everett v. Purdue Pharma, et al.	W.D. Wa./2:17-cv-00209- RSM (removed from Sup. Ct. Snohomish Cnty. (WA)/17-00002-00469- 31)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	SpecGx; Par; KVK; West- Ward; CVS; Rite Aid; Walgreens; Walmart; Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Johnson & Johnson; Mallinckrodt; TEVA; Watson	1/19/2017; 10/25/2017; 3/6/2019	2017
City of Evergreen, Alabama v. Purdue Pharma L.P., et al.	S.D. Ala./1:18-cv-00212- MU	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/15/2018	2018

City of Fairfield, Ohio v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/1:19-cv-00589-TSB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	7/22/2019	2019
City of Fauquier, Virginia v. Purdue Pharma L.P., et al.	E.D. Va./1:19-cv-00364	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
City of Fayetteville v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./5:18-cv-00230-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/23/2018	2018
City of Federal Heights v. Purdue Pharma L.P., et al.	D. Colo./1:19-cv-01704-KLM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Par; Mylan; Hikma; Walmart; Smith Drug	6/11/2019	2019
City of Fishers, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-01925-JMS-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	6/22/2018	2018

City of Fitzgerald, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45603-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/21/2018	2018
City of Flint, Michigan, a municipal corporation v. Purdue Pharma L.P., et al.	E.D. Mich./2:19-cv- 10488-DML-DRG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	2/18/2019	2019
City of Florence v. Purdue Pharma L.P., et al.	E.D. Ky./2:19-cv-00007- GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Walgreens; Insys	2/5/2019	2019
City of Florida City, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./1:19-cv-22476- UU	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/14/2019	2019
City of Fort Cobb v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv- 00816-F (removed from D. Ct. Kay Cnty. (OK)/CJ- 2019-22)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	3/15/2019	2019

City of Fort Lauderdale, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./0:18-cv-62830-WPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Health Mart; H.D. Smith; CVS; Walgreen	11/20/2018	2018
City of Fort Payne, Alabama, et al. v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./4:17-cv-01877-VEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	11/8/2017	2017
City of Fort Pierce, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./2:19-cv-14203-RLR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/13/2019	2019
City of Fostoria v. Purdue Pharma L.P., et al.	N.D. Ohio/3:18-cv-00850 (removed from C.P. Seneca Cnty./18CV0066)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	3/12/2018	2018
City of Franklin v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00944-JWD-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/24/2018	2018
City of Franklin, New Hampshire v. AmerisourceBergen Drug Corp., et al.	D.N.H./1:18-cv-00417	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/22/2018	2018

City of Franklin, Town of Pendleton, and City of Richmond v. Purdue Pharma L.P., et al.	S.D. Ind./1:18-cv-03174-JMS-DLP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	10/12/2018	2018
City of Fredericksburg, Virginia v. Purdue Pharma L.P., et al.	E.D. Va./3:19-cv-00457	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
City of Frostburg, Maryland v. AmerisourceBergen Drug Corp., et al.	D. Md./1:18-cv-01383-GLR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	5/11/2018	2018
City of Fullerton, and The People of the State of California, by and through Fullerton City Attorney Richard D. Jones v. Purdue Pharma L.P., et al.	N.D. Cal./3:19-cv-02321 (removed from San Francisco County Super. Ct. (Cal.)/CGC-19-574867)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Actavis; Watson; Allergan; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson	3/28/2019	2019
City of Gadsden, Alabama, et al. v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./4:17-cv-01800-KOB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	10/25/2017	2017

City of Galax v. Purdue Pharma L.P., et al.	W.D. Va./7:18-cv-00617 (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	8/27/2018	2018
City of Garfield Heights v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45993 (removed from C.P. Cuyahoga County (OH)/CV18-901104)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; RiteAid; Miami- Luken; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West- Ward; Mylan; Rhodes; John N. Kapoor; Noramco; Anda	7/11/2018	2018
City of Gary, Indiana v. Purdue Pharma L.P., et al.	N.D. Ind./2:18-cv-00117 (removed from Super Ct. Lake Cnty./45D041801CT000 20)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Endo; Insys; McKesson; Cardinal; AmerisourceBergen; CVS Indiana; Russell Portnoy; Perry Fine; Lynn Webster; Midwest Pain Clinic; Paul C. Madison, M.D.	1/29/2018	2018

City of Geneva, New York v. Purdue Pharma L.P., et al.	N.D.N.Y./6:19-cv-06186	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Cephalon; TEVA; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Insys; Hikma; West-Ward; Indivior; Mylan; Amneal; Sandoz; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; Walgreen; Walmart; CVS; Associated Pharmacies; Keysource	3/13/2019	2019
City of Georgiana, AL v. Purdue Pharma L.P., et al.	M.D. Ala./2:18-cv-00341-TFM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/19/2018	2018
City of Grand Rapids, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv-00327	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/22/2018	2018
City of Grantsville, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02023-TDC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019

City of Grayson v. Purdue Pharma L.P., et al.	E.D. Ky./0:19-cv-00014-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Walgreens; Insys	2/5/2019	2019
City of Great Falls, County of Anaconda-Deer Lodge, County of Lake, and City of Missoula v. Purdue Pharma L.P., et al.	D. Mt./4:19-cv-00008-BMM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS	2/6/2019	2019
City of Greenfield v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:17-cv-30175	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	12/14/2017	2017
City of Greensboro v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:19-cv-00383	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	4/8/2019	2019
City of Greensboro, AL v. Actavis LLC	S.D. Ala./2:18-cv-00142	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/27/2018	2018
City of Greenville, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./2:17-cv-00836-WC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/13/2017	2017
City of Greenwood, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-00047-JMS-TAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	1/8/2018	2018

City of Greenwood, Mississippi v. AmerisourceBergen Drug Corp., et al	S.D. Miss./4:18-cv-00143-DMB-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	7/12/2018	2018
City of Grenada v. Purdue Pharma L.P., et al.	N.D. Miss./3:19-cv-00129-SA-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Insys	6/14/2019	2019
City of Gretna v. Purdue Pharma L.P., et al.	E.D. La./2:19-cv-00329-NJB-MBN	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen	1/16/2019	2019
City of Guin, AL v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./6:18-cv-00531-LSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/4/2018	2018
City of Guthrie County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00158 (removed from D. Ct. Logan Cnty. (OK)/ CJ-2019-8)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Abolghasem Rezaei; Russell Portenoy; Perry Fine; Lynn Webster	1/14/2019	2019
City of Hagerstown, Maryland v. AmerisourceBergen Drug Corp., et al.	D. Md./1:18-cv-01367-ELH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	5/11/2018	2018

City of Hamilton, AL v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./6:18-cv-00532-LSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/4/2018	2018
City of Hamilton, Ohio v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/1:18-cv-00577-MRB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	8/14/2018	2018
City of Hammond, et al. v. Purdue Pharma L.P., et al.	N.D. Ind./2:17-cv-00431	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	11/16/2017	2017
City of Harlan v. Purdue Pharma L.P., et al.	E.D. Ky./6:19-cv-00049-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Knoll; Abbvie; Wal-Mart; Walgreens; CVS	2/14/2019	2019
City of Harrisburg, Illinois v. Purdue Pharma L.P., et al.	S.D. Ill./3:18-cv-01068	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	5/5/2018	2018
City of Harrisonville, Cass County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45369-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019

City of Hartford, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-01872- SEB-TAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	6/19/2018	2018
City of Hartselle, Alabama, a municipal corporation v. Purdue Pharma L.P., et al.	N.D. Ala./5:18-cv-00805- MHH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	5/25/2018	2018
City of Harvey; Village of Broadview; Village of Chicago Ridge; Village of Dolton; Village of Hoffman Estates; Village of Maywood; Village of Marrionette Park; Village of North Riverside; Village of Orland Park; City of Peoria; Village of Posen; Village of River Grove; Village of Stone Park; Orland Fire Protection District v. Purdue Pharma L.P., et al.	N.D. Ill./1:18-cv-05756 (removed from Cir. Ct. Cook Cnty (Ill.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Paul Madison; William McMahon; Joseph Giacchino	7/19/2018	2018
City of Hattiesburg, MS v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./2:18-cv-00068- KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	4/17/2018	2018
City of Havre De Grace, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02018- PJM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019

City of Hazleton, Pennsylvania v. Purdue Pharma L.P., et al.	M.D. Pa./3:19-cv-01398- MEM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.; PLP Associates Holdings; PLP Associates Holdings Inc.; Purdue Holdings; BR Holdings Associates Inc.; BR Holdings Associates L.P.	Rhodes; Cephalon; TEVA; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Insys; Hikma; West-Ward; Indivior; Mylan; Amneal; Sandoz; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Andia; Rite Aid; Walgreen; CVS; Associated; Masters; Keysource; Qualitest	8/13/2019	2019
City of Henderson County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./5:18-cv-00278- H	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/13/2018	2018
City of Henderson, Kentucky v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./4:18-cv-00169- TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	10/30/2018	2018
City of Henderson, Kentucky, on behalf of themselves and all other similarly situated home rule cities v. Purdue Pharmna L.P.,et al.	E.D. Ky./3:19-cv-00067 (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Abbott; TEVA; Cephalon; Allergan; Actavis; Watson; Endo; Par; SpecGx; Mallinckrodt; Johnson & Johnson; Janssen; Noramco; Amneal; Mylan; West-Ward; KVK; Assertio; Depomed; AmerisourceBergen; H.D. Smith; Andia; CVS; Rite Aid; Smith Drug; Kroger; Walgreens; Walmart; Fred's	9/13/2019	2019
City of Hickory v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./5:18-cv-00184- FDW-DSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	11/19/2018	2018

City of Holyoke v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30067	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/14/2018	2018
City of Hoover, a municipal corporation v. Purdue Pharma L.P., et al.	N.D. Ala./2:19-cv-01256-GMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson; Par; SpecGx	8/6/2019	2019
City of Hopewell, Virginia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45433-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Endo; Par; Janssen; Johnson & Johnson; Noramco; Insys; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Anda; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Walmart; Rhodes	6/11/2019	2019
City of Huntington, Indiana v. AmerisourceBergen Drug Corp., et al.	N.D. Ind./1:18-cv-00399-TLS-SLC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	11/30/2018	2018
City of Huntington, West Virginia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:17-op-45054-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; TEVA; Watson; CVS; Insys; Noramco; Walgreens; Walmart; Rite Aid; SpecGx	3/9/2017	2017

City of Huron, Ohio v. Cardinal Health, Inc., et al.	N.D. Ohio/1:18-op-45431-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cardinal; McKesson; Miami-Luken; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; Walgreens; Wal-Mart; Perry Fine; Scott Fishman; Lynn Webster	4/13/2018	2018
City of Hyden v. Purdue Pharma L.P., et al.	E.D. Ky./6:19-cv-00042-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Knoll; Abbvie; Wal-Mart; Walgreens; CVS	2/12/2019	2019
City of Indianapolis, et al. v. Purdue Pharma L.P., et al.	S.D. Ind./1:17-cv-04231-JMS-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	11/14/2017	2017
City of Indianola v. Purdue Pharma L.P., et al.	N.D. Miss./4:19-cv-00091-DMB-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Insys	6/14/2019	2019
City of Iron Mountain, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./2:18-cv-00037	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
City of Ironton, Ohio v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/1:18-cv-00579-TSB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	8/14/2018	2018

City of Irvine, and The People of the State of California, by and through Irvine City Attorney Jeffrey Melching v. Purdue Pharma L.P., et al.	N.D. Cal./3:19-cv-02323 (removed from San Francisco County Super. Ct. (Cal.)/CGC-19-574866)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Actavis; Watson; Allergan; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson	3/28/2019	2019
City of Iuka, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:18-cv-00182-DMB-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	9/27/2018	2018
City of Jackson, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45904-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	7/31/2018	2018
City of Jacksonville v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./7:18-cv-00002-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	1/4/2017	2017
City of Jacksonville, a Florida Municipal Corporation v. Purdue Pharma L.P., et al.	M.D. Fla./3:18-cv-00751-TJC-PDB (removed from Cir. Ct. Duval Cnty. (Fla.)/16-2018-001233)	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; John Kapoor; Michael Babich; Alec Burlakoff; Karen Hill; Joseph Rowan	2/27/2018	2018
City of Jasper, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./3:18-cv-00140-RLY-MPB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	8/10/2018	2018

City of Jeffersonville, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-02122-JMS-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	7/12/2018	2018
City of Jenks v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv-00380-JED-FHM (removed from D. Ct. Tulsa Cnty. (OK)/CJ-2019-02431)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care	6/14/2019	2019
City of Jersey City, New Jersey v. Purdue Pharma L.P., et al.	D.N.J./2:18-cv-11210-ES-CLW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; CVS; Walgreens; Costco; Rite Aid	6/28/2018	2018
City of Jonestown v. Purdue Pharma L.P., et al.	N.D. Miss./3:19-cv-00130-SA-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Insys	6/14/2019	2019
City of Kansas City, Missouri v. Purdue Pharma L.P., et al.	W.D. Mo./4:18-cv-00605-DGK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	8/9/2018	2018

City of Keene, NH v. Purdue Pharma L.P., et al.	D.N.H./1:18-cv-00293	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Mallinckrodt; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	4/11/2018	2018
City of Kenner v. AmerisourceBergen Drug Corp., et al.	E.D. La./2:19-cv-01174-SM-JCW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Noramco	10/29/2018	2018
City of Kent v. Purdue Pharma L.P., et al.	W.D. Wa./2:18-cv-00618	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Mylan; Par; Walgreens; West-Ward; Hikma	4/27/2018; 3/15/2019	2018
City of Kent, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-00001-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Insys; Mallinckrodt; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Par; Noramco; SpecGx; Anda; Walmart; Rhodes; Mylan; Novartis; Sandoz	1/3/2019; 3/16/2019	2019
City of Kingman v. Purdue Pharma L.P., et al.	D. Ariz./3:18-cv-08191-DLR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; John and Jane Does 1 through 100, inclusive	8/16/2018	2018

City of Kokomo, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-00060- JMS-TAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	1/8/2018	2018
City of Lackawanna, New York v. Purdue Pharma L.P., et al.	W.D.N.Y./1:19-cv-00485	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Cephalon; TEVA; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Insys; Hikma; West-Ward; Indivior; Mylan; Amneal; Sandoz; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; Walgreen; Walmart; CVS; Associated Pharmacies; Keysource	4/15/2019	2019
City of Laconia, New Hampshire v. AmerisourceBergen Drug Corp., et al.	D.N.H./1:18-cv-00347	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/27/2018	2018
City of Lafayette, et al. v. Purdue Pharma L.P., et al.	N.D. Ind./4:17-cv-00091- RL-JEM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	11/29/2017	2017
City of Laguna Beach, California v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45447-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; CVS; Cardinal; Endo; H.D. Smith; Cephalon; Health Mart; Janssen; Johnson & Johnson; Mallinckrodt; Rite Aid; TEVA; Walgreens; Walmart	6/13/2019	2019

City of Lake Charles v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45449-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Endo; Par; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Mylan; West-Ward; Hikma; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; Smith's Food & Drug; H.D. Smith; CVS; Anda; Warner Chilcott; Sandoz	6/13/2019	2019
City of Lakeland, Georgia v. Purdue Pharma L.P., et al.	M.D. Ga./7:19-cv-00089-HL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Noramco; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Par; SpecGx; Amneal; West-Ward; Hikma; Mylan; Smith Drug; American Associated Pharmacies; Associated Pharmacies; JM Smith	6/19/2019	2019
City of Lakewood v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00502	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	3/5/2018	2018
City of Lakewood v. Purdue Pharma L.P., et al.	W.D. Wa./3:19-cv-05173	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; SpecGx	3/6/2019	2019
City of Lansing v. Purdue Pharma L.P., et al.	W.D. Mich./1:17-cv-01114	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	12/19/2017	2017

City of Laurel, Maryland v. Purdue Pharma L.P., et al.	D. Md./8:19-cv-02019- PX	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019
City of Laurel, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./2:18-cv-00173- KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	9/27/2018	2018
City of Lawrence, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-01836- TWP-MPB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	6/15/2018	2018
City of Lawton v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv- 00078-D (removed from D. Ct. Comanche Cnty. (OK)/CJ-2018-725)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Abolghasem Rezaei; Russell Portenoy; Perry Fine; Lynn Webster	11/8/2018	2018
City of Leominster v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40080- TSH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018

City of Lewiston v. Purdue Pharma L.P., et al.	D. Me./2:18-cv-00310-NT (removed from Super. Ct. Adroscoggin Cnty. (Me.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	7/11/2018; 7/26/2018 (Am.)	2018
City of Lexington, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./6:19-cv-00021	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
City of Lima v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/3:18-cv-00755	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	4/3/2018	2018
City of Lincoln, Alabama, a municipal corporation v. Cardinal Health, Inc., et al.	N.D. Ala./1:18-cv-00819	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	5/29/2018	2018

City of Lisbon v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00172-PDW-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS	8/13/2019	2019
City of Locust Fork, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./2:19-cv-01286-JEO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	8/12/2019	2019
City of Logansport v. Purdue Pharma L.P., et al.	N.D. Ind./3:18-cv-00367	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	5/18/2018	2018
City of London v. Purdue Pharma L.P., et al.	E.D. Ky./6:19-cv-00050-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Knoll; Abbvie; Wal-Mart; Walgreens; CVS	2/14/2019	2019
City of Los Angeles, California v. Purdue Pharma L.P., et al.	C.D. Cal./2:18-cv-03712	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	5/3/2018	2018
City of Lowell v. AmerisourceBergen Drug Corp., et al	D. Mass./1:18-cv-10729	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	4/16/2018	2018

City of Loyall v. Purdue Pharma L.P., et al.	E.D. Ky./6:19-cv-00046-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Knoll; Abbvie; Wal-Mart; Walgreens; CVS	2/12/2019	2019
City of Lumberton, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./2:18-cv-00185-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Par	10/26/2018	2018
City of Lynch v. Purdue Pharma L.P., et al.	E.D. Ky./6:19-cv-00043-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Knoll; Abbvie; Wal-Mart; Walgreens; CVS	2/12/2019	2019
City of Lyndhurst v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45636-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Noramco; Actavis; Mallinckrodt; Insys; Miami-Luken; CVS; Walgreens; Wal-Mart; Perry Fine; Scott Fishman; Lynn Webster	6/1/2018	2018
City of Lynn v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11219-FDS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/11/2018	2018

City of Macedonia, OH v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45447	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; Miami-Luken; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; CVS; Walgreens; Wal-Mart; Perry Fine; Scott Fishman; Lynn Webster	4/17/2018	2018
City of Madison, Indiana, a political subdivision of the State of Indiana, located in Jefferson County, Indiana, by and through its Mayor and Common Council v. Purdue Pharma L.P., et al.	S.D. Ind./4:19-cv-00156-JMS-DML (removed from Jefferson Cnty. Super. Ct. (Ind.)/39C01-1906-PL-00565)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Samantha Beaver; Kevin L. Foster; Brittany Berkshire; Joe Gay, Jr.; Jesse Bobb; Michael White; Elsa Marie Neace; Glenn Michael Fields; Claude Holt, Jr.; James Coomer; Lloyd E. McNear; Christopher C. Smith; Joel E. Barrett, Jr.	6/18/2019	2019
City of Malden v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-10602	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	3/29/2018	2018
City of Manchester v. Purdue Pharma L.P., et al.	D.N.H./1:17-cv-00507-AJ (removed from NH Superior Court, Northern District Hillsborough/216-2017-cv-00649)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	9/1/2017	2017
City of Manchester v. Purdue Pharma L.P., et al.	E.D. Ky./6:19-cv-00062-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Knoll; Abbvie; Wal-Mart; Walgreens; CVS	2/28/2019	2019

City of Mandeville v. Purdue Pharma L.P., et al.	E.D. La./2:19-cv-11726-SSV-JVM (removed from 22nd Judicial District Court, Parish of St. Tammany (LA)/201912787)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Actavis; Watson; Warner Chilcott; TEVA; Cephalon; Janssen; Johnson & Johnson; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Indivior; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Morris & Dickson	5/31/2019	2019
City of Mansfield v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00797 (removed from C.P. Richland Cnty. (OH)/18CV168)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; Amerisource; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	3/8/2018	2018
City of Marion, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./2:18-cv-00053-MU	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/2/2018	2018
City of Martinsville, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-00878-WTL-MPB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	3/19/2018	2018
City of Melrose v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11411	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	7/6/2018	2018

City of Memphis v. Purdue Pharma L.P., et al.	W.D. Tenn./2:19-cv- 02159-SHL-dkv	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/7/2019	2019
City of Meridian v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./3:18-cv-00486- HTW-LRA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	7/24/2018	2018
City of Mesquite v. Purdue Pharma L.P., et al.	D. Nev./2:19-cv-01058- JCM-BNW	Purdue Pharma L.P.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; Insys; Omnicare; Masters	6/20/2019	2019
City of Methuen v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-10035- MAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	1/8/2018	2018
City of Metropolis, Illinois v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45537-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/7/2018	2018
City of Miami Gardens, Florida v. AmerisourceBergen Drug Corp., et al.	S.D. Fla./1:18-cv-22182- FAM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	6/1/2018	2018

City of Middletown v. Purdue Pharma L.P., et al.	D. Conn./3:19-cv-00919 (removed from Middlesex State Super. Ct. (CT))	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	John Kapoor; McKesson; Cardinal; AmerisourceBergen; CVS; Rite Aid; Walgreens; Walmart; Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Insys	4/24/2019	2019
City of Midfield, Alabama v. Purdue Pharma L.P., et al.	S.D. Ala./2:18-cv-00482-JEO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/27/2018	2018
City of Midwest City v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00345-HE (removed from D. Ct. Oklahoma Cnty. (OK)/CJ-2019-1596)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; William Vladuck; Harvey Jenkins; Reagan Nichols	3/22/2019	2019
City of Millington, Tennessee v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45474-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/14/2019	2019

City of Minneapolis, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:18-cv-01825 (removed from 4th Jud. Dist. Hennepin Cnty. (Minn.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Cardinal; Mallinckrodt; McKesson; AmerisourceBergen; Walgreens	6/19/2018	2018
City of Mobile, Alabama v. AmerisourceBergen., et al.	S.D. Ala./1:17-cv-00564- C	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/27/2017	2017
City of Monroe, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45732-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Andia; CVS; Rite Aid; Walgreens; Walmart; Mylan; Sandoz; Hikma; West- Ward; Morris & Dickson; Harco; Rhodes	6/13/2018	2018
City of Montpelier, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-01866- SEB-MJD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	6/18/2018	2018
City of Montgomery, AL v. Purdue Pharma L.P., et al.	M.D. Ala./2:18-cv-00402- MHT-GMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	4/9/2018	2018

City of Morehead v. Purdue Pharma L.P., et al.	E.D. Ky./0:19-cv-00020-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Knoll; Abbvie; Wal-Mart; Walgreens; CVS	2/14/2019	2019
City of Moulton, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./5:18-cv-00174-HNJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
City of Mound Bayou, Mississippi v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45422-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Andax; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
City of Mountain Lake Park, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02024-PWG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019

City of Mustang v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00339-R (removed from D. Ct. Canadian Cnty. (OK)/CJ-2019-189)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; William Vladuck; Harvey Jenkins; Reagan Nichols	3/22/2019	2019
City of Nanticoke, Pennsylvania v. Purdue Pharma L.P., et al.	M.D. Pa./3:19-cv-00190-MEM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; CVS; Rite Aid; Walgreens; Wal-Mart; Value Drug Co; Generics Bidco	2/4/2019	2019
City of Nashville, Georgia v. Purdue Pharma L.P., et al.	M.D. Ga./7:19-cv-00090-HL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Noramco; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Par; SpecGx; Amneal; West-Ward; Hikma; Mylan; Smith Drug; American Associated Pharmacies; Associated Pharmacies; JM Smith; Harco	6/19/2019	2019
City of Nettleton, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:19-cv-00050-NBB-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	3/1/2019	2019

City of New Albany, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./4:18-cv-00198	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	10/26/2018	2018
City of New Albany, Mississippi v. AmerisourceBergen Drug Corp., et al	S.D. Miss./3:18-cv-00159- MPM-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	7/12/2018	2018
City of New Bedford, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-11266- PBS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/6/2019	2019
City of New Castle v. Purdue Pharma L.P., et al.	E.D. Pa./2:18-cv-00952- TJS (removed from C.P. Philadelphia (PA)/001036)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; SpecGx; Par; Amneal; West-Ward; Indivior; Mylan; Sandoz; CVS; Walgreens; Walmart; Kroger; Miami-Luken	2/13/2018; 3/15/2019	2018
City of New Iberia v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00954- SDD-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
City of New Orleans v. Purdue Pharma L.P., et al.	E.D. La./2:18-cv-11486- JCZ-DEK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Morris and Dickson Co.	10/18/2018	2018

City of New Roads, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45011-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Insys; SpecGx; Amneal; West-Ward; Indivior; Mylan; Sandoz; Walmart; Winn-Dixie	1/16/2019; 3/15/2019	2019
City of Newburyport v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11017	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/18/2018	2018
City of Newport, RI v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00156- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
City of Noblesville, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-00048- WTL-TAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	1/7/2018	2018
City of Norfolk v. AmerisourceBergen Drug Corp., et al.	E.D. Va./2:19-cv-00299- HCM-RJK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Rite Aid; Thrifty; Walgreens; Wal-Mart	6/6/2019	2019

City of North Adams v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30072	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/18/2018	2018
City of North East, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02025-GJH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019
City of North Miami, Florida v. AmerisourceBergen Drug Corp., et al.	S.D. Fla./1:18-cv-22133-FAM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/30/2018	2018
City of North Royalton, OH v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45427-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; Miami-Luken; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; CVS; Walgreens; Wal-Mart; Perry Fine; Scott Fishman; Lynn Webster	4/13/2018	2018
City of Northampton v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30042	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	3/16/2018	2018

City of Norton, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./2:18-cv-00050- EKD (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	10/22/2018	2018
City of Norwalk v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46351 (removed from C.P. Huron County (OH)/CVC20180936)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Perry Fine; Scott Fishman; Lynn Webster	11/27/2018	2018
City of Norwich v. Purdue Pharma L.P., et al.	D. Conn./3:19-cv-00770- MPS (removed from New London State Super. Ct. (CT))	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	John Kapoor; McKesson; Cardinal; AmerisourceBergen; CVS; Rite Aid; Walgreens; Walmart; Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Insys	4/9/2019	2019
City of Oakland, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02026- GJH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019

City of Ocala, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./5:19-cv-00440-JSM-PRL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Publix; Walgreen	9/5/2019	2019
City of Oklahoma City v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00076-C (removed from D. Ct. Oklahoma Cnty. (OK)/CJ-2018-6179)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; William Valuck; Harvey Jenkins; Russell Portenoy; Perry Fine; Lynn Webster	11/8/2018	2018
City of Olympia v. Purdue Pharma L.P., et al.	W.D. Wa./3:18-cv-05560-RBL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; SpecGx; Par; Mylan; Thrify; Rite Aid; West-Ward; Hikma; Walgreens	7/16/2018; 3/13/2019	2018

City of Opelousas, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45685	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Actavis; Allergan; AmerisourceBergen; Amneal; Anda; CVS; Cardinal; Cephalon; Endo; H.D. Smith; Health Mart; Hikma; Indivior; Insys; Janssen; Johnson & Johnson; KVK; Louisiana Wholesale Drug Co; Mallinckrodt; McKesson; Morris & Dickson; Mylan; Noramco; Par; Rhodes; Rite Aid; Sandoz; SpecGx; Sun Pharm.; TEVA; Walgreens; Walmart; Watson	7/31/2019	2019
City of Opp, Alabama v. AmerisourceBergen Drug Corporation et al	M.D. Ala./2:17-cv-00840- GMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/14/2017	2017
City of Orange Beach, Alabama v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45784	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; TEVA; Watson	9/10/2019	2019
City of Orangeburg, South Carolina v. Purdue Pharma L.P., et al.	D.S.C./5:19-cv-01692- MDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Johnson & Johnson; Normaco; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; CVS; Walgreens	6/12/2019	2019
City of Overland Park, Kansas v. AmerisourceBergen Drug Corp., et al.	D. Kan./2:18-cv-02609	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	11/14/2018	2018

City of Oviedo, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./6:19-cv-01095-RBD-DCI	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/13/2019	2019
City of Owasso v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv-00171-GKF-JFJ (removed from D. Ct. Tulsa Cnty. (OK)/CJ-2019-00784)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Joshua Livingston; Jeremy David Thomas; Walgreens	2/22/2019	2019
City of Oxford, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./1:19-cv-01401-KOB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	8/27/2019	2019
City of Ozark, Alabama v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./1:18-cv-00073-CSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
City of Paducah, Kentucky v. Purdue Pharma, L.P. et al.	N.D. Ohio/1:18-op-45592-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	5/16/2018	2018

City of Palm Bay v. Purdue Pharma L.P., et al.	M.D. Fla./6:18-cv-01554 (removed from Brevard Cnty. Cir. Ct. 05-2018-CA- 028116-XXXX-XX)	Purdue Pharma L.P.	Cephalon; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Russell Portenoy; Scott Fishman; Lynn Webster; John Gayden; Ibem Borges; Victor Thiagaraj Selvaraj; Edge Pharmacy	5/14/2018	2018
City of Palmetto v. Purdue Pharma L.P., et al.	M.D. Fla./8:18-cv-02036- CEH-CPT	Purdue Pharma L.P.	Cephalon, TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	8/16/2018	2018
City of Patterson v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00946- SDD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/24/2018	2018
City of Pawtucket, RI v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00139- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
City of Peabody v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11408	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	7/5/2018	2018

City of Pembroke Pines, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./0:18-cv-62995-RNS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Health Mart; H.D. Smith; CVS; Walgreen	12/6/2018	2018
City of Pensacola v. AmerisourceBergen Drug Corp., et al.	N.D. Fla./3:18-cv-00417-MCR-GRJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/13/2018	2018
City of Perryville, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02027-PWG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019
City of Peru, Indiana v. AmerisourceBergen Drug Corp., et al.	N.D. Ind./3:18-cv-00463-RLM-MGG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	6/15/2018	2018
City of Philadelphia, Miss. v. Purdue Pharma L.P., et al.	S.D. Miss./3:18-cv-00143-LG-LRA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Does 1-100, Inclusive	3/7/2018	2018
City of Phoenix v. Purdue Pharma L.P., et al.	D. Ariz./2:18-cv-01150-DMF	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	4/13/2018	2018

City of Pinellas Park v. AmerisourceBergen Drug Corp., et al.	M.D. Fla./8:18-cv-01454-EAK-AEP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	6/15/2018	2018
City of Pineville, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45037-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; Rite Aid; Walgreens; Walmart; Amneal; Indivior; Mylan; Sandoz; Hikma; West-Ward; Louisiana Wholesale Drug; Morris & Dickson; K&B; Albertsons; Rhodes	1/28/2019; 3/14/2019; 3/16/2019	2019
City of Pippa Passes v. Purdue Pharma L.P., et al.	E.D. Ky./7:19-cv-00023-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Knoll; Abbvie; Wal-Mart; Walgreens; CVS	2/28/2019	2019
City of Pittsfield v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30040	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	3/15/2018	2018
City of Pocatello v. Purdue Pharma L.P., et al.	D. Ida./4:19-cv-00189-BLW	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters	5/23/2019	2019

City of Ponca City v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00160 (removed from D. Ct. Kay Cnty. (OK)/ CJ-2019-9)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Abolghasem Rezaei; Russell Portenoy; Perry Fine; Lynn Webster	1/10/2019	2019
City of Pooler, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./4:18-cv-00061-WTM-GRS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/20/2018	2018
City of Port St. Lucie, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./2:19-cv-14207-RLR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/14/2019	2019
City of Portland and Jay County v. Purdue Pharma L.P., et al.	N.D. Ind./1:18-cv-00290-TLS-SLC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	9/14/2018	2018

City of Portland v. Purdue Pharma L.P., et al.	D. Me./2:18-cv-00282-NT (removed from Super. Ct. Cumberland Cnty. (Me.)/CV-18-140)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	4/5/2018	2018
City of Portland, Oregon v. AmerisourceBergen Drug Corp., et al.	D. Or./3:18-cv-00817-SB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco; Smith Food & Drug; SpecGx; Par; KVK; Albertsons; CVS; Rite Aid; Walgreens; Walmart	5/10/2018; 3/13/2019	2018
City of Portsmouth v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00723-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	8/16/2017; 10/26/2017 (Am.)	2017
City of Portsmouth v. Purdue Pharma L.P., et al.	E.D. Va./2:19-cv-00331 (removed from Cir. Ct. City of Portsmouth (VA))	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	John Kapoor; McKesson; Cardinal; AmerisourceBergen; CVS; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Insys	1/11/2019	2019
City of Prattville, Alabama v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45783	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; TEVA; Watson	9/10/2019	2019

City of Preston v. Purdue Pharma L.P., et al.	D. Ida./1:19-cv-00031-BLW	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters	1/25/2019	2019
City of Prichard, Alabama v. Purdue Pharma L.P., et al.	S.D. Ala./1:18-cv-00230-CG-B	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	5/16/2018	2018
City of Princeton, Illinois v. Purdue Pharma L.P., et al.	C.D. Ill./4:18-cv-04088-SLD-JEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	5/5/2018	2018
City of Proctor, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-02190	Purdue Pharma L.P.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Omnicare; Masters	8/9/2019	2019
City of Providence v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00360-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; TEVA	6/28/2018	2018
City of Radford, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./7:19-cv-00525-EKD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-	N/A	2019

City of Rainsville, Alabama and Town of Hammondville, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op- 45135-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; McKesson; Cardinal; AmerisourceBergen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; Walgreens; CVS; Walmart; Smith Drug Co.; SpecGx; Par; Amneal; Indivior; Mylan; Sandoz; Anda	3/14/2019; 3/15/2019	2019
City of Red Bay, Alabama; City of Russellville, Alabama; City of Sheffield, Alabama; Town of Leighton, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op- 45136-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; McKesson; Cardinal; AmerisourceBergen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; Bloodworth; SpecGx; Par; West- Ward; Mylan; Indivior; Par; Smith Drug Co.	3/14/2019; 3/15/2019	2019
City of Revere v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-10124- GAO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	1/22/2018	2018
City of Richmond Hill, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./4:18-cv-00047- JRS-GRS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/9/2018	2018
City of Richmond v. AmerisourceBergen Drug Corp., et al.	E.D. Va./3:19-cv-00404- HEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Rite Aid; Thrifty; Walgreens; Wal-Mart	5/29/2019	2019

City of Roanoke, Virginia v. Purdue Pharma L.P., et al.	E.D. Va./2:19-cv-00183	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
City of Roanoke, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./7:19-cv-00272- EKD (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
City of Rochester and County of Merrimack v. Purdue Pharma L.P., et al.	D.N.H./1:18-cv-00808	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	9/6/2018	2018
City of Rochester, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01317- PJS-ECW	Purdue Pharma L.P.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Omnicare; Masters	5/20/2019	2019
City of Rockford, an Illinois Municipal Corporation v. AmerisourceBergen Drug Corp., et al.	N.D. Ill./3:18-cv-50092	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/12/2018	2018

City of Rockland, State of Maine v. Purdue Pharma L.P., et al.	D. Me./2:19-cv-00373 (removed from Super. Ct. Knox Cnty. (Me.)/CV-19-15)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Douglas J. Jorgensen; Mark E. Cieniawski; Michael B. Bruehl	5/10/2019	2019
City of Rome, Floyd County, Chattooga County, Whitfield County and City of Catersville v. Purdue Pharma L.P., et al.	N.D. Ga./4:18-cv-00052-HLM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Depomed; Endo; Allergan; Actavis; Watson; Avis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	3/2/2018	2018
City of Rome, New York v. Purdue Pharma L.P., et al.	N.D.N.Y./6:19-cv-06187	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Cephalon; TEVA; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Insys; Hikma; West-Ward; Indivior; Mylan; Amneal; Sandoz; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; Walgreen; Walmart; CVS; Associated Pharmacies; Keysource	3/28/2019	2019

City of Saco v. Purdue Pharma L.P., et al.	D. Me./2:19-cv-00143-NT (removed from Super. Ct. York Cnty. (Me.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	2/1/2019	2019
City of Saint Martinville v. AmerisourceBergen Drug Corp., et al.	W.D. La./6:18-cv-01635-TAD-CBW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Morris & Dickson Co.	12/19/2018	2018
City of Salem, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./7:19-cv-00273-EKD (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
City of San Antonio, Texas v. AmerisourceBergen Drug Corp., et al.	W.D. Texas/5:19-cv-01089-OLG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS; Kroger; Walgreens; Walmart	9/10/2019	2019

City of San Clemente, and The People of the State of California, by and through San Clemente City Attorney Scott C. Smith v. Purdue Pharma L.P., et al.	N.D. Cal./3:19-cv-02326 (removed from San Francisco County Super. Ct. (Cal.)/CGC-19-574868)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Actavis; Watson; Allergan; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson	3/28/2019	2019
City of San Jose, a political subdivision of California, the People of the State of California, acting by and through the City of San Jose v. AmerisourceBergen Drug Corp., et al.	N.D. Cal./5:19-cv-04529-NC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Insys; CVS; Kroger; Rite Aid; Thrifty; Walgreens; Wal-Mart	8/2/2019	2019
City of Sandusky v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45788 (removed from C.P. Erie Cnty. (OH)/2018CV0315)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; Rite Aid; Miami-Luken; Perry Fine; Scott Fishman; Lynn Webster	6/6/2018	2018
City of Sanford v. Purdue Pharma L.P., et al.	D. Me./2:19-cv-00146-NT (remmoved from Super. Ct. Sanford Cnty. (Me.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	2/1/2019	2019

City of Sanford, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./6:19-cv-01098-PGB-TBS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/13/2019	2019
City of Santa Ana, and The People of the State of California, by and through Santa Ana City Attorney Sonia R. Carvalho v. Purdue Pharma L.P., et al.	N.D. Cal./3:19-cv-02324 (removed from San Francisco County Super. Ct. (Cal.)/CGC-19-574872)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Actavis; Watson; Allergan; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson	3/28/2019	2019
City of Sarasota v. Purdue Pharma L.P., et al.	M.D. Fla./8:18-cv-00859-VMC-CPT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon, TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	4/11/2018	2018
City of Sault Ste. Marie, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45928-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	8/6/2018	2018
City of Seattle v. Purdue Pharma, et al.	W.D. Wa./2:17-cv-01577-TSZ (removed from Sup. Ct. King Cty. (WA))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Seattle Pain Center; AmerisourceBergen; Cardinal; Cephalon; Hikma; Mylan; Par; TEVA; Walgreens; West-Ward	9/28/2017; 5/25/2018; 3/15/2019	2017
City of Selma, Alabama v. Actavis LLC, et al.	S.D. Ala./2:18-cv-00042	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018

City of Seminole v. Purdue Pharma L.P., et al.	E.D. Okla./6:19-cv-00291-RAW (removed from D. Ct. Seminole Cnty. (OK)/CJ-2019-67)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	7/30/2019	2019
City of Seven Hills, Ohio v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45413-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Andia; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
City of Seymour, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./4:18-cv-00082-RLY-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	5/11/2018	2018
City of Shannon, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:19-cv-00047-GHD-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	3/1/2019	2019

City of Shawnee v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv- 00711-SLP (removed from D. Ct. Pottawatomie Cnty. (OK)/CJ-2019-4)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; William Valuck; Harvey Jenkins; Russell Portenoy; Perry Fine; Lynn Webster	1/7/2019	2019
City of Shelbyville, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-02119- TWP-DLP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	7/12/2018	2018
City of Sheridan v. Purdue Pharma L.P., et al.	D. Colo./1:19-cv-01701- CMA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Par; Mylan; Hikma; Walmart; Smith Drug	6/11/2019	2019
City of Shreveport v. Purdue Pharma L.P., et al.	W.D. La./5:18-cv-01021- SMH-MLH (removed from 1st Judicial District Court for the Parish of Caddo (LA)/605608C)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; LA Wholesale Drug Co.; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; Par; West- Ward; Walmart; Wagreens; CVS; Rhodes; John N. Kapoor; Mallinckrodt; Noramco; Anda; Rite Aid; Miami- Luken	12/19/2017	2017

City of Slidell v. Purdue Pharma L.P., et al.	E.D. La./2:19-cv-11771-SSV-KWR (removed from 22nd Judicial District Court, Parish of St. Tammany (LA)/201913022)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Actavis; Watson; Warner Chilcott; TEVA; Cephalon; Janssen; Johnson & Johnson; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Indivior; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Morris & Dickson; Amneal; West-Ward; Hikma; Norvatis; Sandoz; Andia; H.D. Smith; Smith Drug; JM Smith; CVS; Rite Aid; Louisiana Wholesale Drug; Impax	6/12/2019	2019
City of Somerville v. Purdue Pharma L.P., et al.	D. Mass./1:19-cv-11009 (removed from Super. Ct. Middlesex Cnty. (Mass.)/1981CV00285)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Cardinal; Mallinckrodt; SpecGx; McKesson; AmerisourceBergen; Walgreens	1/30/2019	2019
City of South Bend, Indiana v. AmerisourceBergen Drug Corp., et al.	N.D. Ind./3:18-cv-00206	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	3/22/2018	2018
City of South Sioux City, Nebraska, a municipal corporation v. AmerisourceBergen Drug Corp., et al	D. Ne./8:19-cv-00244-LSC-SMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Insys; Allergan; Watson; Actavis; Mallinckrodt; Noramco	6/5/2019	2019
City of Springfield, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45199-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/27/2019	2019

City of St. Albans, VT v. AmerisourceBergen Drug Corp., et al.	D. Vt./5:19-cv-00098-gwc	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Rite Aid; Thrifty; Walgreens; Wal-Mart	6/10/2019	2019
City of St. Augustine, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./3:19-cv-00714-TJC-MCR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/13/2019	2019
City of St. Joseph, Missouri v. AmerisourceBergen Drug Corp., et al.	W.D. Mo./5:18-cv-06087-ODS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/13/2018	2018
City of St. Louis v. Purdue Pharma L.P., et al.	E.D. Mo./4:18-cv-01882	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	11/5/2018	2018
City of St. Mary's Ohio v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45638-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Noramco; Actavis; Mallinckrodt; Insys	6/1/2018	2018
City of St. North Paul, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01995-JNE-SER	Purdue Pharma L.P.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Omnicare; Masters	7/29/2019	2019

City of St. Paul, Minnesota v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45424-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami- Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
City of Starkville, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:19-cv- 00046-GHD-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	3/1/2019	2019
City of Sterling Heights v. The Pain Center USA, PLLC, et al.	E.D. Mich./2:19-cv- 11685-VAR-DRG (removed from 16th Jud. Cir. Ct., Macomb Cnty. (Mich.)/19-1563-CZ)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	The Pain Center; Interventional Pain Center; Rhodes; Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal	4/24/2019	2019
City of Superior v. Purdue Pharma L.P., et al.	W.D. Wi./3:19-cv-00340	Purdue Pharma L.P.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; Omnicare; Maters	4/30/2019	2019

City of Syracuse, New York v. Purdue Pharma L.P., et al.	N.D.N.Y./5:18-cv-01184-GTS-DEP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Depomed; Par; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Insys; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; KPH; Walmart; Rhodes; Hikma; West-Ward; Indivior; Mylan; Amneal; Sandoz; Anda; CVA; Omnicare; Associated Pharmacies; Coram	10/3/2018; 3/7/2019 (Am.)	2018
City of Tacoma v. Purdue Pharma L.P., et al.	W.D. Wa./3:17-cv-05737-JRC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Seattle Pain CenterAmerisourceBergen; Cardinal; Cephalon; Hikma; Mylan; Par; TEVA; Walgreens; West-Ward	9/13/2017; 5/25/2018; 3/15/2019	2017
City of Tallahassee v. AmerisourceBergen Drug Corp., et al.	N.D. Fla./4:18-cv-00484-MW-MJF	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	10/25/2018	2018
City of Thornton v. Purdue Pharma L.P., et al.	D. Colo./1:19-cv-00112	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	1/11/2019	2019
City of Traverse City, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45901-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	7/31/2018	2018

City of Trenton v. Purdue Pharma L.P., et al.	D.N.J./3:19-cv-17155-MAS-DEA (removed from Super. Ct. NJ, Mercer Cnty./MER-L001167-19)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; SpecGx; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; John Kapoor; CVS; Rite Aid; Walgreens; Walmart	6/14/2019	2019
City of Troy, Alabama v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./2:18-cv-00677-MHT-GMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	7/19/2018	2018
City of Tucson, a municipal corporation v. Purdue Pharma L.P., et al.	D. Ariz./4:19-cv-00166-CKJ (removed from Super. Ct. Pima Cnty. (Ariz.)/C20190272)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; H.D. Smith; Anda	1/17/2019	2019
City of Tupelo, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op-45491-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Noramco	6/14/2019	2019
City of Tuscaloosa, Alabama v. Cardinal Health Inc., et al.	N.D. Ala./7:18-cv-00630-LSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	4/20/2018	2018
City of Tuskegee, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./3:18-cv-00423	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	4/20/2018	2018

City of Twin Falls v. Purdue Pharma L.P., et al.	D. Ida./4:19-cv-00303-CWD	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters	8/2/2019	2019
City of Union Springs, Alabama v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./2:18-cv-00071-MHT-GMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
City of Utica, New York v. Purdue Pharma L.P., et al.	N.D.N.Y./6:18-cv-01394-BKS-ATB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Depomed; Par; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Insys; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; KPH; Walmart; Rhodes; Hikma; West-Ward; Indivior; Mylan; Amneal; Sandoz; Anda; CVA; Omnicare; Associated Pharmacies	11/30/2018; 3/5/2019 (Am.)	2018
City of Van Wert v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-46345-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Walmart; Par; Mylan; West-Ward; CVS	12/19/2018; 3/16/2019	2018
City of Verona, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:19-cv-00048-SA-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	3/1/2019	2019

City of Vestavia Hills, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op- 45141-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; McKesson; Cardinal; AmerisourceBergen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; Bloodworth; SpecGx; Par; West- Ward; Mylan; Indivior; Par; Smith Drug Co.	3/14/2019; 3/15/2019	2019
City of Vienna, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02028- PX	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019
City of Virginia Beach and Sheriff of the City of Virginia Beach v. AmerisourceBergen Drug Corp., et al.	E.D. Va./2:18-cv-00485- HCM-RJK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Kroger; RiteAid; Walgreens; Wal- Mart; Thrifty; Advantage Logistics; Eckerd; SpecGx; Par; Amneal	9/10/2018; 3/9/2019	2018
City of Warren v. Purdue Pharma L.P., et al.	N.D. Ohio/4:18-cv-00852 (removed from C.P. Trumbull Cnty./2018CV496)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Miami-Luken; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Walgreens; CVS; Rhodes; Mallinckrodt; John N. Kapoor; Anda; Rite Aid; Wal-Mart; Rhodes	3/9/2018	2018

City of Warren v. The Pain Center USA, PLLC, et al.	E.D. Mich./2:19-cv-11687-GAD-DRG (removed from 16th Jud. Cir. Ct., Macomb Cnty. (Mich.)/19-1561-CZ)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	The Pain Center; Interventional Pain Center; Rhodes; Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal	4/24/2019	2019
City of Warwick, Georgia v. Purdue Pharma L.P., et al.	M.D. Ga./1:19-cv-00105-LAG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Noramco; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	6/20/2019	2019
City of Warwick, RI v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00136-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
City of Waterville v. Purdue Pharma L.P., et al.	D. Me./1:19-cv-00014-NT (removed Super. Ct. Kennebec Cnty. (Me.)/CV-2018-202)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	11/21/2018	2018

City of Weaver, Alabama v. Actavis LLC, et al.	N.D. Ala./1:18-cv-00612-VEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	4/17/2018	2018
City of West Lafayette v. Purdue Pharma L.P., et al.	N.D. Ind./4:18-cv-00013	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	3/12/2018	2018
City of West Monroe, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46133	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Andia; CVS; Rite Aid; Walgreens; Walmart; Amneal; Indivior; Mylan; Hikma; Louisiana Wholesale Drug Co.; Morris & Dickson; K&B Louisiana Corp.; CVS; Walgreens; Alberstons; Rhodes	10/5/2018; 3/14/2019; 3/26/2019	2018
City of Westfield, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-02576-JMS-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	8/21/2018	2018
City of Westland, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45903-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	7/31/2018	2018

City of Westminster, and The People of the State of California, by and through Westminster City Attorney Rick Olivarez v. Purdue Pharma L.P., et al.	N.D. Cal./3:19-cv-02325 (removed from Westminster County Super. Ct. (Cal.)/CGC-19-574864)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Actavis; Watson; Allergan; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson	3/28/2019	2019
City of Whitesburg v. Purdue Pharma L.P., et al.	E.D. Ky./7:19-cv-00026-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Knoll; Abbvie; Wal-Mart; Walgreens; CVS	3/13/2019	2019
City of Wickliffe v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45637-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Noramco; Actavis; Mallinckrodt; Insys; Miami-Luken; CVS; Walgreens; Wal-Mart; Perry Fine; Scott Fishman; Lynn Webster	6/1/2018	2018
City of Wiggins, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./1:19-cv-00308-LG-RHW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/7/2019	2019
City of Wilkes-Barre, Pennsylvania v. Purdue Pharma L.P., et al.	M.D. Pa/3:18-cv-00857-MEM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Mallinckrodt; Watson; McKesson; Cardinal; AmerisourceBergen; Noramco; Eckerd; Value Drug Co.; SpecGx; Par; CVS; Walmart; Walgreens; Anda; Eckerd; Value Drug	4/20/2018; 3/5/2019	2018

City of Wilmington v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./7:18-cv-00081-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/16/2018	2018
City of Winchester v. Purdue Pharma L.P., et al.	E.D. Ky./5:18-cv-00627-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Walgreens	11/28/2018	2018
City of Woburn v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-10032-MAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	1/8/2018	2018
City of Woodbury, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45575-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	5/15/2018	2018
City of Youngstown v. Actavis Pharma, Inc., et al.	N.D. Ohio/1:19-op-45722	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	8/22/2019	2019

City of Yukon v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv- 00280 (removed from D. Ct. Canadian Cnty. (OK)/CJ-2019-119)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; William Valuck; Harvey Jenkins; Russell Portenoy; Perry Fine; Lynn Webster	2/28/2019	2019
Claiborne County, Miss v. Purdue Pharma L.P., et al.	S.D. Miss./5:17-cv-00150- DCB-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/20/2017	2017
Claiborne County, Tennessee v. AmerisourceBergen Drug Corp., et al.	E.D. Tenn./3:19-cv- 00231	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	6/21/2019	2019
Claiborne Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00872- SDD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	9/28/2018	2018
Clallam County v. Purdue Pharma L.P., et al.	W.D. Wa./3:18-cv-05361	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; Cephalon; Hikma; Mylan; Par; TEVA; Walgreens; West- Ward; KVK; Thrifty; Walmart; Rite Aid	5/8/2018; 5/13/2019	2018

Clark County v. Purdue Pharma L.P., et al.	W.D. Wa./3:18-cv-05241	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; Cephalon; Hikma; Mylan; Par; TEVA; Walgreens; West-Ward; KVK; Thrifty; Walmart; Rite Aid	5/27/2018; 3/15/2019	2018
Clark County v. Purdue Pharma L.P., et al.	D. Nev./2:19-cv-01616-KJD-VCF (removed from District Ct. Clark County (NV))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; AmerisourceBergen; McKesson; Cardinal; Masters; C&R; Does 1-100	12/6/2017	2017
Clark County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01651-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Clarke County, Mississippi v. Purdue Pharma L.P., et al.	S.D. Miss./2:18-cv-00036-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Does 1-100, Inclusive	3/7/2018	2018
Clay County, Alabama v. Cardinal Health, Inc., et al.	N.D. Ala./1:18-cv-00275-VEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cardinal; AmerisourceBergen; McKesson; Actavis; Cephalon; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; Noramco; TEVA; Watson	2/19/2018	2018

Clay County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./3:19-cv-00712-BJD-JBT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/13/2019	2019
Clay County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45194-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/27/2019	2019
Clayton County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46298-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; PSS World; CVS; Walgreens; Walmart; Rite Aid; West-Ward; Hikma; Mylan; Eckerd; Rhodes; John N. Kapoor; Miami-Luken; Noramco; Anda	12/6/2018; 3/18/2019	2018
Cleburne County, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./1:18-cv-00606-VEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	4/17/2018	2018
Clermont County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00662-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/9/2017	2017
Cleveland Bakers and Teamsters Health and Welfare Fund and Pipe Fitters Local Union No. 120 Insurance Fund v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00854	Purdue Pharma L.P.; The Purdue Frederick Company Inc.; Purdue Pharmaceutical Products, LP; Purdue Products L.P.	AmerisourceBergen; Cardinal; Cephalon; Endo; Johnson & Johnson; Mallinckrodt; McKesson; TEVA	4/13/2018	2018

Cleveland County v. Purdue Pharma L.P., et al.	W.D.N.C./1:18-cv-00061-MR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen	3/7/2018	2018
Cleveland Teachers Union, Local 279 v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00241	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Noramco; Insys	1/30/2018	2018
CLHG-ACADIAN, LLC D/B/A ACADIAN MEDICAL CENTER, EUNICE; ALLEGIANCE HEALTH CENTER OF MONROE; ALLEGIANCE HEALTH CENTER OF RUSTON; CLHG-AVOYELLES, LLC D/B/A AVOYELLES HOSPITAL, MARKSVILLE;BIENVILLE MEDICAL CENTER, ARCADIA; CLHG-LEESVILLE D/B/A BYRD REGIONAL HOSPITAL, LEESVILLE; CLHG-VILLE PLATTE, LLC D/B/A MERCY REGIONAL MEDICAL CENTER, VILLE PLATTE; CLHG-MINDEN, LLC D/B/A MINDEN MEDICAL CENTER, MINDEN; CLHG-OAKDALE, LLC OAKDALE COMMUNITY HOSPITAL, OAKDALE; SABINE	W.D. La./5:19-cv-00756-TAD-MLH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Morris & Dickson Co.; SpecGx	6/14/2019	2019
Clinch County Hospital Authority v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./7:18-cv-00051-HL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	4/4/2018	2018
Clinch County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45197-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/27/2019	2019

Clinton County Board of Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-01117-GCS-CMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Allergan; Watson; Actavis; AmerisourceBergen	12/20/2017	2017
Cloverdale Rancheria of Pomo Indians v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46241-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Insys	11/16/2018	2018
CMGH Minden LLC v. Purdue Pharma L.P., et al.	W.D. La./5:19-cv-00750-SMH-MLH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Rhodes; Par Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; RiteAid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	6/13/2019	2019
Cobb County v. Purdue Pharma L.P., et al.	N.D. Ga./1:18-cv-02865-MLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Health Mart	6/12/2018	2018
Coeur Dalene Tribe v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45115	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Health Mart	3/8/2019	2019
Coffee County, Alabama v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./1:18-cv-00069-CSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018

Cole County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46189-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-Mart; McQueary; Amneal; Hy-Vee	10/26/2018; 3/7/2019	2018
Columbia County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01538-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Columbia County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45607-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/21/2018	2018
Columbia County, PA v. Purdue Pharma L.P., et al.	M.D. Pa./4:17-cv-02067	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Mallinckrodt; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; Value Drug; SpecGx; Par; Amneal; CVS	11/9/2017; 3/13/2019	2017

Columbiana County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00883-EAS-KAJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/10/2017	2017
Columbus County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./7:18-cv-00113-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/22/2018	2018
Columbus Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./4:18-cv-00079-GL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Attain; Bloodworth; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/25/2018	2018
Commissioners of St. Mary's County, Maryland v. AmerisourceBergen Drug Corp., et al.	D. Md./8:18-cv-03597-TDC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Walgreens; Wal-Mart; Anda	11/23/2018	2018
Community Based Care of Brevard, Inc. d/b/a Brevard Family Partnership v. McKesson Corporation	N.D. Ohio/1:18-op-46240-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	11/15/2018	2018
Community Partnership for Children, Inc. v. McKesson Corp., et al.	N.D. Ohio/1:18-op-46005-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	8/28/2018	2018

Concordia Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00914-BAJ-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/16/2018	2018
Conecuh County, Alabama v. AmerisourceBergen Drug Corp., et al.	S.D. Ala./1:18-cv-00309-CG-M	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	7/12/2018	2018
Conejos County, Las Animas County, Chaffee County, Otero County, Alamosa County, The City of Alamosa v. Purdue Pharma L.P., et al.	D. Colo./1:18-cv-01316	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt	5/29/2018	2018
Confederated Salish and Kootenai Tribes of the Flathead Reservation; Fort Belknap Indian Community of the Fort Belknap Indian Reservation of Montana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45364-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; McKesson; Cardinal; AmerisourceBergen; Walgreens; Walmart; CVS	6/5/2019	2019
Confederated Tribe of Warm Springs v. Purdue Pharma L.P., et al.	D. Or./3:19-cv-00125-SI	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Rite Aid; Health Mart; Walmart; Walgreens	1/25/2019	2019
Confederated Tribes and Bands of the Yakama Nation v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46202-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Par; Insys; SpecGx; Health Mart	10/31/2018	2018

Confederated Tribes of the Colville Reservation v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45312-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Insys; Malinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Kroger; Rite Aid; H.D. Smith; Health Mart	5/8/2019	2019
Confederated Tribes of the Grand Ronde Community of Oregon v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45097-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart	2/27/2019	2019
Confederated Tribes of the Umatilla Indian Reservation v. Purdue Pharma L.P., et al.	D. Or./2:18-cv-00674-SU	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	4/19/2018	2018
Consolidated Tribal Health Project, Inc. v. McKesson Corporation, et al.	N.D. Cal./3:18-cv-02534 (removed from San Francisco County Superior Ct. (CA)/CGC-18-564743)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	3/2/2018	2018
Cook County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./3:18-cv-00040-HL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/9/2018	2018
Coos County, Oregon v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46300-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; PSS World; CVS; Walgreens; Walmart; Rite Aid; Miami-Luken; SpecGx; Par; West-Ward; Hikma; Mylan; John N. Kapoor; Noramco; Anda	12/9/2018; 3/15/2019	2018

Corey Means, individually and as next friend and guardian of Baby E.D.J., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45470-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/14/2019	2019
Coshocton County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-01105- GCS-KAJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/18/2017	2017
County Commision of McDowell County v. McKesson Corporation, et al.	N.D. Ohio/1:17-op- 45066-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; TEVA; Watson; H.D. Smith; Miami-Luken; WV Board of Pharmacy	N/A	2017
County Commission of Clay County v. Purdue Pharma L.P., et al.	S.D. WV/2:18-cv-00413 (removed from Cir. Ct. Clay Cty. (WV)/18-C-2)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Johnson & Johnson; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Miami-Luken; RiteAid; WV Board of Pharmacy; Rhodes; Walmart	2/8/2018; 3/15/2019	2018
County Commissioners of Calvert County, Maryland v. Purdue Pharma L.P., et al.	D. Md./8:19-cv-01735- GJH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Insys	6/13/2019	2019

County Commissioners of Charles County, Maryland v. Purdue Pharma L.P., et al.	D. Md./8:19-cv-00336-PJM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Insys	2/4/2019	2019
County of Alachua v. Purdue Pharma L.P., et al.	N.D. Fla./1:18-cv-00086-MW-GRJ (removed from Cir. Ct. Alachua County (FL)/2018CA000322)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Actavis; Endo; McKesson; Cardinal; AmerisourceBergen; Andia; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Walgreens; CVS; Rhodes; Miami-Luken; John N. Kapoor; Mallinckrodt; Noramco; Rite Aid	1/30/2018	2018
County of Alameda, and The People of the State of California, by and through Alameda County Attorney Donna Ziegler v. Purdue Pharma L.P., et al.	N.D. Cal./3:19-cv-02307 (removed from Alameda County Super. Ct. (Cal.)/R919012661)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Actavis; Watson; Allergan; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson	3/28/2019	2019
County of Alcona, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./1:18-cv-10820-GCS-PTM	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Alger, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./2:18-cv-00032	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	3/12/2018	2018

County of Amador, a political subdivision of the State of California, The People of the State of California, acting by and through the County of Amador v. Purdue Pharma L.P., et al.	E.D. Cal./2:18-cv-02299-WBS-KJN	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Rite Aid; Thrift; Walgreens; Wal-Mart	8/22/2018	2018
County of Angelina v. Purdue Pharma L.P., et al.	S.D. Texas/4:18-cv-04707 (removed from Angelina Cnty. Dist. Ct. (Tex.)/CV-00785-18-11)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	11/14/2018	2018
County of Angelina v. Purdue Pharma L.P., et al.	S.D. Texas/4:19-cv-03590 (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; AmerisourceBergen; Par; McKesson; Cardinal; CVS; Walgreens; Morris & Dickson; SpecGx; Amneal; Atlas; Walmart	12/11/2018	2018
County of Anoka, MN	D. Minn./0:18-cv-00062-WMW-LIB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	1/9/2018	2018
County of Antrim, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv-00265	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/12/2018	2018
County of Arenac, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./1:18-cv-10821-TLL-PTM	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018

County of Ashtabula v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00100	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; AmerisourceBergen; McKesson; Cardinal; Miami-Luken; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	1/12/2018	2018
County of Baraga, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./2:18-cv-00033	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/12/2018	2018
County of Bay, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45228-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Mallinckrodt; SpecGx; Allergan; Watson; Warner Chilcott; Actavis; Cardinal; McKesson; AmerisourceBergen; Walgreens; Rite Aid	4/3/2019	2019
County of Benzie, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv-00266	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/12/2018	2018
County of Berkeley, South Carolina v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45436-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Endo; Par; Janssen; Johnson & Johnson; Noramco; Insys; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Anda; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Walmart; Rhodes	6/12/2019	2019

County of Berrien, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45887-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	7/26/2018	2018
County of Blanco v. Purdue Pharma L.P., et al.	S.D. Texas/4:18-cv- 04705 (removed from Blanco Cnty. Dist. Ct. (Tex.)/CV08563)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	11/5/2018	2018
County of Bowie v. Purdue Pharma L.P. et al.	E.D. Texas/5:17-cv- 00168-RWS-CMC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Hikma; West-Ward; Indivior; Morris & Dickson; Par; Qualitest; SpecGx; Walgreens; Walmart	10/2/2017; 3/14/2019	2017
County of Branch v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv- 00983-JTN-ESC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Insys; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Andia; Rite Aid; Walmart	8/31/2018	2018
County of Brevard, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./6:19-cv-00145- ACC-TBS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Health Mart; H.D. Smith; CVS; Walgreen; Walmart	1/23/2019	2019
County of Burleson v. Purdue Pharma L.P., et al.	S.D. Texas/4:19-cv- 03845 (removed from Burleson Cnty. Dist. Ct. (Tex.)/29267)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	4/12/2018	2018

County of Burlington, NJ v. Purdue Pharma L.P., et al.	D.N.J./1:19-cv-13684- JHR-JS (removed from Super. Ct. Burlington Cnty. (NJ))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; SpecGx; Par; Andia; Insys; H.D. Smith; Miami- Luken; John N. Kapoor; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; American Pain Foundation; The Academy of Integrative Pain Management; CVS; Walgreens; Walmart; Kroger	5/8/2019	2019
County of Butte, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Butte v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01151- JAM-CMK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/9/2018	2018
County of Calaveras, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Calaveras v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./1:18-at-00339	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/9/2018	2018
County of Camp v. Purdue Pharma L.P., et al.	S.D. Texas/2:18-cv- 00002-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Amneal; CVS; Hikma; Morris & Dickson; Mylan; Par; SpecGx; Smith Drug	1/5/2018; 3/14/2019	2018

County of Carbon v. Purdue Pharma L.P., et al.	E.D. Pa./2:18-cv-05625 (removed from C.P. Carbon Cnty. (Pa.)/18-0990)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Scott Fishman; Perry Fine; Lynn Webster; Noramco; Endo; Par; McKesson; AmerisourceBergen; Cardinal; Rhodes; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Kroger; Insys; H.D. Smith; Miami-Luken	4/2/2018; 11/14/2018 (Am.)	2018
County of Cascade v. Purdue Pharma L.P., et al.	D. Mt./4:17-cv-00130-BMM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; Does 1-100	11/29/2017	2017
County of Charlevoix, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45897-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	7/30/2018	2018
County of Cheboygan v. Purdue Pharma L.P., et al.	E.D. Mich./1:19-cv-11769-TLL-PTM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Endo; Par; Janssen; Noramco; Johnson & Johnson; Insys; Mallinckrodt; SpecGx; Allergan; Actavis; AmerisourceBergen; Cardinal; McKesson	6/13/2019	2019
County of Cherokee v. Purdue Pharma L.P. et al.	E.D. Texas/6:17-cv-00659-RWS-JDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Hikma; Morris & Dickson; Mylan; Par; SpexGx; Walgreens; Walmart	11/20/2017; 3/14/2019	2017

County of Childress v. Purdue Pharma L.P., et al.	N.D. Texas/2:18-cv- 00031-D	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; SpecGx; Mallinckrodt; Mylan; Par; Sandoz; United Pharm.; Walmart; West- Ward; Morris & Dickson	2/13/2018; 3/15/2019	2018
County of Chippewa v. Purdue Pharma L.P., et al.	W.D. Mich./2:17-cv- 00206	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	12/19/2017	2017
County of Clackamas, County of Lane and County of Washington v. Purdue Pharma L.P., et al.	D. Or./3:18-cv-00520- MO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Allergan; Actavis; Mallinckrodt; Insys; McKesson; AmerisourceBergen; Cardinal; Indivior; KVK; Mylan; Par; SpecGx; West-Ward; Advantage Logistics; Anda; Kaiser; Kroger; Smiths Food & Drug; Fred Meyer Stores; Rite Aid; Thrifty; Walgreens; Walmart; Albertsons; Bi-Mart; Cotsco; Safeway; Target	3/27/2018; 6/8/2018; 3/16/2019	2018
County of Clay v. Purdue Pharma L.P., et al.	N.D. Texas/7:18-cv- 00017-O	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Watson; Sandoz; CVS; Walgreens; Walmart; Albertsons; Watson; Indivior	1/30/2018; 3/15/2019	2018

County of Clinton, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45888-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	7/27/2018	2018
County of Cochise v. Purdue Pharma L.P., et al.	D. Ariz./4:18-cv-00316- JR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; John and Jane Does 1 through 100, inclusive	6/29/2018	2018
County of Contra Costa, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Contra Costa v. AmerisourceBergen Drug Corp., et al.	N.D. Cal./3:18-cv-02705- JSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	5/8/2018	2018
County of Crawford, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./5:18-cv- 01077-JEL-PTM	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	1/8/2018	2018
County of Curry v. Purdue Pharma L.P., et al.	D. Or./1:19-cv-00815-CL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Allergan; Mallinckrodt; Actavis; McKesson; Insys; AmerisourceBergen; Cardinal	5/24/2019	2019

County of DeKalb v. Purdue Pharma L.P., et al.	N.D. Ga./1:18-cv-01498 (removed from DeKalb County, GA)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; Medicine Center Pharmacy; Amrac; J.M. Smith; Vaxserve; PSS World; Attain; Bloodworth	12/20/2017	2017
County of Del Norte, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Del Norte v. AmerisourceBergen Drug Corp., et al.	N.D. Cal./1:18-cv-02732-RMI	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	5/9/2018	2018
County of Delta v. Purdue Pharma L.P., et al.	W.D. Mich./2:17-cv-00207	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	12/19/2017	2017
County of Dickinson, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./2:18-cv-00036	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Douglas, State of Nebraska v. Purdue Pharma L.P., et al.	D. Ne./8:19-cv-00049	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; Noramco; TEVA; Cephalon; Actavis; Allergan; Watson; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken	1/31/2019	2019

County of Duval v. Purdue Pharma L.P., et al.	S.D. Tex./4:19-cv-02504	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Abbott; Knoll; Allergan; Watson; McKesson; Actavis; Cardinal; Mallinckrodt; Covidien; Abbvie; CVS; Walmart; Rite Aid; Walgreens; AmerisourceBergen	6/6/2019	2019
County of Eaton v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv-00823	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Insys; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; Walmart	7/25/2018	2018
County of El Dorado, a political subdivision of the State of California; the People of the State of California, acting by and through the County of El Dorado v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01157-KJM-DB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/9/2018	2018
County of Fannin v. Rite Aid of Georgia, Inc., et al.	N.D. Ga./2:18-cv-00220-RWS (removed from Super. Ct. Fannin Cnty. (Ga.)/SUV2018000119)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Noramco; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; AttainMed; Just In Time Meds, LLC; Medicine Center Pharmacy; Amarc	3/22/2018	2018
County of Franklin v. Purdue Pharma L.P., et al.	S.D. Texas/5:18-cv-00002-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Amneal; Hikma; Sandoz; SepcGx; Par	1/5/2018; 3/14/2019	2018

County of Freestone v. Purdue Pharma L.P., et al.	S.D. Texas/4:19-cv-03983 (removed from Freestone Cnty. Dist. Ct. (Tex.)/CV18-148-B)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/15/2018	2018
County of Fresno, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Fresno v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./1:18-cv-00634-LJO-SAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/9/2018	2018
County of Galveston v. Purdue Pharma L.P., et al.	S.D. Texas/4:18-cv-04708 (removed from Galveston Cnty. Dist. Ct. (Tex.)/18-CV-1572)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	11/13/2018	2018
County of Galveston v. Purdue Pharma L.P., et al.	S.D. Texas/3:18-cv-00077	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Endo; Abbott; Allergan; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Insys	3/16/2018	2018
County of Glenn, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Glenn v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01139-JAM-AC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	5/8/2018	2018
County of Grand Traverse v. Purdue Pharma L.P., et al.	W.D. Mich./1:17-cv-01115	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	12/19/2017	2017

County of Gratiot, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./1:18-cv- 10810-GCS-PTM	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Wal-Mart; Costco	3/12/2018	2018
County of Grenada v. Purdue Pharma L.P., et al.	N.D. Miss./4:18-cv- 00212-DMB-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; AbbVie; Knoll; Walgreens; Wal-Mart; CVS	10/30/2018	2018
County of Hardin v. Purdue Pharma L.P., et al.	S.D. Texas/4:19-cv- 00114 (removed from Hardin Cnty. Dist. Ct. (Tex.)/59921)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	12/7/2018	2018
County of Harrison v. Purdue Pharma L.P. et al.	W.D. Texas/2:17-cv- 00748-JRG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; Pfizer; McKesson; Cardinal; AmerisourceBergen; Does 1 - 100 Inclusive	11/17/2017	2017
County of Harvey v. Purdue Pharma L.P., et al.	D. Kan./6:18-cv-01179- JTM-KGG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Insys	6/22/2018	2018
County of Henderson, Texas v. Purdue Pharma L.P., et al.	S.D. Tex./6:19-cv-00309	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Abbott; Knoll; Allergan; Watson; McKesson; Actavis; Cardinal; Mallinckrodt; Covidien; Abbvie; CVS; Walmart; Rite Aid; Walgreens; AmerisourceBergen; Kroger	7/10/2019	2019

County of Hillsdale, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv- 00275	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Hudson, NJ v. Purdue Pharma L.P., et al.	D.N.J./2:18-cv-09029 (removed from Super. Ct. NJ. Hudson Cnty./HUD-L-001272)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; John N. Kapoor; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; American Pain Foundation; Academy of Integrative Pain Management; American Academy of Pain Management; CVS; Walgreens; Rite Aid; Wal- Mart	4/3/2018; 4/26/2018	2018
County of Imperial, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Imperial v. AmerisourceBergen Drug Corp., et al.	S.D. Cal./3:18-cv-00892- LAB-BLM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018
County of Inyo, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Inyo v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./1:18-at-00340	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/9/2018	2018

County of Iosco, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./1:18-cv- 10823-TLL-PTM	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Isabella, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./1:18-cv- 10864-TLL-PTM	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Jasper v. Purdue Pharma L.P., et al.	S.D. Texas/4:18-cv- 04706 (removed from Jasper Cnty. Dist. Ct. (Tex.)/37653)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	11/5/2018	2018
County of Jefferson v. Purdue Pharma L.P., et al.	S.D. Ohio/2:18-cv-00037- ALM-CMV (removed from C.P. Jefferson Cnty (OH)/17CV00554)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; AmerisourceBergen; McKesson; Cardinal; Miami-Luken; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/13/2017	2017
County of Jefferson, New York v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45437-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Abbott; Abbvie; Mallinckrodt; SpecGx; Endo; Par; TEVA; Cephalon; Watson; Actavis; Johnson & Johnson; Janssen; Allergan; Noramco; Mylan; Hikma; Sandoz; McKesson; Cardinal; Kinray; AmerisourceBergen; Rochester Drug; Anda; Walgreens; Walmart; CVS; Caremark; Express; ESI Mail; UnitedHealth; Optum	6/12/2019	2019

County of Jim Hogg v. Purdue Pharma L.P., et al.	S.D. Tex./4:19-cv-02816 (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Abbott; Knoll; Allergan; Watson; McKesson; Actavis; Cardinal; Mallinckrodt; Covidien; Abbvie; CVS; Walmart; Rite Aid; Walgreens; AmerisourceBergen	6/14/2019	2019
County of Jones v. Purdue Pharma L.P., et al.	N.D. Texas/1:18-cv- 00003-C	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Does 1-100 Does	1/16/2018	2018
County of Kaua'i, a political subdivision of the State of Hawaii, for themselves individually, and on behalf of all similarly situated persons, and on behalf of the general public, as a class v. Purdue Pharma L.P., et al.	D. Haw./1:19-cv-00377- LEK-KJM (removed from 3rd Cir. Ct. of Hawaii/19- 1-156)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Rhodes; Par; Mallinckrodt; SpecGx; Mylan; Sandoz; West- Ward; Amneal; Noramco; John N. Kapoor; Rudolph B. Puana, M.D.; Big Island Pain Center LLC; Puana Pain LLC; Bellco; American Medical Distributors; Blenhrim; Eveready; Kinray; PSS World; Rochester Drug; Darby; Discount Drug Mart; Anda; HBC; Morris & Dickson; Publix; Smith Drug; SAJ; Value Drug; CVS; Rite Aid; Walmart; Miami-Luken; Walgreens; Kroger; Henry Schein; Harold B. Charles Spears, M.D.	5/17/2019	2019
County of Kinney v. Purdue Pharma L.P., et al.	W.D. Texas/2:18-cv- 00011	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Does 1 - 100 Inclusive	2/14/2018	2018

County of Kleberg v. Purdue Pharma L.P., et al.	S.D. Tex./4:19-cv-02815 (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Abbott; Knoll; Allergan; Watson; McKesson; Actavis; Cardinal; Mallinckrodt; Covidien; Abbvie; CVS; Walmart; Rite Aid; Walgreens; AmerisourceBergen	6/14/2019	2019
County of Knox, State of Nebraska v. McKesson Corporation, et al.	D. Ne./8:18-cv-00181-JFB-GRZ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Insys; Allergan; Watson; Actavis; Mallinckrodt; Walgreens	4/25/2018	2018
County of La Salle v. Purdue Pharma L.P., et al.	S.D. Texas/5:18-cv-00021	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Amneal; Indivior; Mallinckrodt; Mylan; Par; Sandoz; SpecGx; West-Ward	2/13/2018; 3/15/2019	2018
County of Lake v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00089 (removed from C.P. Lake Cnty (OH)/17CV001972)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; AmerisourceBergen; McKesson; Cardinal; Miami-Luken; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/11/2017	2017
County of Lake, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv-00267	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/12/2018	2018

County of Lamar v. Purdue Pharma L.P. et al.	E.D. Texas/4:17-cv-00814	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Amneal; CVS; Hikma; Indivior; Kroger; Morris & Dickson; Mylan; Par; Sandoz; SpecGx; Walgreens; Walmart	11/20/2017; 3/14/2019	2017
County of Lassen, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Lassen v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-at-00660	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018
County of Leelanau, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv-00030	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	1/8/2018	2018
County of Lenawee, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./2:18-cv-10835-LJM-SDD	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Leon v. Purdue Pharma L.P. et al.	W.D. Texas/6:17-cv-00318-RP-JCM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; Pfizer; McKesson; Cardinal; AmerisourceBergen; Does 1 - 100 Inclusive	11/14/2017	2017

County of Leon v. Purdue Pharma L.P., et al.	S.D. Texas/4:18-cv- 04709 (removed from 4:18-cv-04709 (removed from Leon Cnty. Dist. Ct. (Tex.)/18-0415CV)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	11/13/2018	2018
County of Lorain v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00145 (removed from C.P. Lorain Cnty (OH)/17CV194035)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; RiteAid; Miami- Luken; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West- Ward; Mylan; Rhodes; John N. Kapoor; Noramco; Anda	12/13/2017	2017
County of Luce, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./2:18-cv- 00034	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/12/2018	2018
County of Lycoming, Pennsylvania v. Purdue Pharma L.P., et al.	M.D. Pa./4:19-cv-01039	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.; PLP Associates Holdings; PLP Associates Holdings Inc.; Purdue Holdings; BR Holdings Associates Inc.; BR Holdings Associates L.P.	Rhodes; Cephalon; TEVA; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Insys; Hikma; West-Ward; Indivior; Mylan; Amneal; Sandoz; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; Walgreen; CVS; Associated; Masters; Keysource; Qualitest	6/19/2019	2019

County of Macomb v. Purdue Pharma L.P., et al.	E.D. Mich./4:17-cv-14077-LVP-APP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	12/19/2017	2017
County of Madera, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Madera v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./1:18-at-00343	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/9/2018	2018
County of Manistee, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv-00033	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	1/8/2018	2018
County of Maricopa v. Purdue Pharma L.P., et al.	D. Ariz./2:18-cv-04866-SMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; John and Jane Does 1 through 100, inclusive	12/21/2018	2018
County of Marin v. Purdue Pharma L.P., et al.	N.D. Cal./3:18-cv-02730-JCS	Purdue Pharma L.P.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; Insys	5/9/2018	2018
County of Mariposa, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Mariposa v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./1:18-cv-00626-LJO-BAM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/7/2018	2018

County of Marquette, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./2:18-cv-00001	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	1/8/2018	2018
County of Mason, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv-00032	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	1/8/2018	2018
County of McCracken County, Kentucky v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45611-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	5/29/2018	2018
County of McLennan v. Purdue Pharma L.P. et al.	W.D. Texas/6:17-cv-00298-RP-JCM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; Pfizer; McKesson; Cardinal; AmerisourceBergen; SpexGx; Mallinckrodt; Par; West-Ward; Indivior; Mylan; Sandoz; HEB; Walmart; Morris & Dickson; CVS; Albertsons; Target; Walgreens	10/31/2017; 3/15/2019	2017
County of Mendocino, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Mendocino v. AmerisourceBergen Drug Corp., et al.	N.D. Cal./1:18-cv-02712-RMI	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	5/8/2018	2018

County of Merced, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Merced v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./1:18-at-00338	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018
County of Mitchell, Texas v. Purdue Pharma L.P., et al.	N.D. Texas/1:17-cv-00197-C	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; FNU 1-100 Does	12/27/2017	2017
County of Modoc, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Modoc v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01141-JAM-CMK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018
County of Mohave v. Purdue Pharma L.P., et al.	D. Ariz./3:19-cv-08048-DMF	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; SpecGx; John and Jane Does 1 through 100, inclusive	2/15/2019	2019
County of Mono, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Mono v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01149-JAM-KJN	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/9/2018	2018
County of Monroe v. Purdue Pharma L.P., et al.	E.D. Mich./2:18-cv-10251-GCS-DRG	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen	1/22/2018	2018

County of Monterey, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Monterey v. AmerisourceBergen Drug Corp., et al.	N.D. Cal./7:18-cv-02693	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018
County of Montgomery v. Purdue Pharma L.P., et al.	S.D. Texas/4:17-cv-03756	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; H.D. Smith; Indivior; Kroger; Mallinckrodt; Mylan; Par; Sandoz; SpecGx; Walgreens; Walmart	12/13/2017; 3/14/2019	2017
County of Montmorency, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./1:18-cv-10834-TLL-PTM	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Mora v. Purdue Pharma L.P., et al.	D.N.M./1:17-cv-01044 (transferred from Mora Cnty. (NM)/D-430-CV-2017-00067)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; Pawankumar K. Jain; William P. Gaspar; Rhodes; Par; SpecGx; CVS; Mallinckrodt; John N. Kapoor; Miami-Luken; Insys; Noramco; Anda; Walmart; Rite Aid; Walgreens	8/28/2017; 9/12/2017; 10/16/2017	2017

County of Morris v. Purdue Pharma L.P. et al.	E.D. Texas/2:17-cv-00725-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Amneal; Par; SpecGx; Smith Drug; Qualitest; Walgreen; JM Smith	11/3/2017; 3/14/2019	2017
County of Multnomah v. Purdue Pharma L.P., et al.	D. Or./3:17-cv-02010-JE (removed from Multnomah Cnty. (OR)/17CV33413)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; INSYS; McKesson; AmerisourceBergen; Cardinal; Julie Ann DeMille; Fusion Wellness Clinic; Roy Blackburn; Oregon TLC; Pacific Medical Evaluation and Review Co.; James Gallant; Corvallis Internal Medicine; Stuart Rosenblum; Does 1 through 100	8/3/2017	2017
County of Napa, California v. Purdue Pharma L.P., et al.	N.D. Cal./4:18-cv-03374-KAW	Purdue Pharma L.P.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; Insys	6/7/2018	2018
County of Navajo v. Purdue Pharma L.P., et al.	D. Ariz./3:19-cv-08070-BSB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; SpecGx; John and Jane Does 1 through 100, inclusive	3/12/2019	2019
County of Nevada, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Nevada v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01152-WBS-DB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/9/2018	2018

County of Newaygo, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46187-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Par; Noramco; Anda; Walmart; Rhodes; Mylan; Novartis; Woodward CVS	10/25/2018; 3/16/2019	2018
County of Newton v. Purdue Pharma L.P., et al.	S.D. Texas/4:19-cv- 00117 (removed from Newton Cnty. Dist. Ct. (Tex.)/14467)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	12/7/2018	2018
County of Nolan, Texas v. Purdue Pharma L.P., et al.	N.D. Texas/1:17-cv- 00196-C	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; FNU 1-100 Does	12/27/2017	2017
County of Northumberland, Pennsylvania v. Purdue Pharma L.P., et al.	M.D. Pa./4:19-cv-00945- MWB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.; PLP Associates Holdings; PLP Associates Holdings Inc.; Purdue Holdings; BR Holdings Associates Inc.; BR Holdings Associates L.P.	Rhodes; Cephalon; TEVA; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Insys; Hikma; West-Ward; Indivior; Mylan; Amneal; Sandoz; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; Walgreen; CVS; Associated; Masters; Keysource; Qualitest	6/3/2019	2019

County of Ocean, New Jersey v. Purdue Pharma L.P., et al.	D.N.J./3:19-cv-17138-MAS-DEA (removed from Super. Ct. NJ, Ocean Cnty./OCN-L-001474019)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; SpecGx; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; John Kapoor; CVS; Rite Aid; Walgreens; Walmart; Noramco; H.D. Smith; Andia; Russell Portenoy, M.D.; Perry Fine, M.D.; Scott Fishman; Lynn Webster, M.D.; American Pain Foundation; The Academy of Integrative Pain Management; The American Academy of Pain Management; Kroger	6/13/2019	2019
County of Oceana, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv-00274	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Ogemaw, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./1:18-cv-10839-JEL-PTM	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Ontonagon, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45893-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	7/30/2018	2018

County of Osceola, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv- 00271	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Ostego, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./1:18-cv- 10828-MOB-PTM	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Placer, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Placer v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01143- KJM-CKD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018
County of Plumas, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Plumas v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01146- TLN-EFB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018

County of Polk, Texas v. Purdue Pharma L.P., et al.	E.D. Texas/9:17-cv-00213	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; CVS; Kroger; Rite Aid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; Rhodes; SpecGx; West-Ward; SuperValu; Dakota Drug; Omnicare; Hy-Vee; Pharmacy Buying Assoc.; SAJ; Rhodes	12/27/2017; 5/25/2018; 3/15/2019	2017
County of Presque Isle, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45894-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	7/30/2018	2018
County of Red River v. Purdue Pharma L.P. et al.	E.D. Texas/5:17-cv-00185-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; Pfizer; McKesson; Cardinal; AmerisourceBergen; Amneal; Hikma; Indivior; Morris & Dickson; Mylan; Par; Qualitest; Sandoz; SpecGx; TopRx	11/2/2017; 3/14/2019	2017
County of Reno v. Purdue Pharma L.P., et al.	D. Kan./6:18-cv-01144	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys	5/18/2018	2018

County of Riverside, a political subdivision of the State of California, The People of the State of California, acting by and through the County of Riverside v. Purdue Pharma L.P., et al.	C.D. Cal./5:18-cv-01372	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	6/27/2018	2018
County of Rockland, New York v. Purdue Pharma L.P., et al.	S.D.N.Y./7:19-cv-05588	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mallinckrodt; SpecGx; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; AmerisourceBergen; Cardinal; McKesson; Rochester Drug; CVS; Caremark; Walgreens; Rite Aid	6/14/2019	2019
County of Roscommon, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./5:18-cv-01078-TLL-PTM	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	1/8/2018	2018
County of Rusk v. Purdue Pharma L.P. et al.	E.D. Texas/6:17-cv-00634-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Hikma; West-Ward; Kroger; Morris & Dickson; Mylan; Par; Qualitest; SpecGx; Walgreen; Walmart	11/7/2017; 3/14/2019	2017
County of Sacramento, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Sacramento v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01135-JAM-DB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018

County of Saginaw v. Purdue Pharma L.P., et al.	E.D. Mich./1:17-cv-14076-LVP-PTM	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	12/19/2017	2017
County of San Bernardino, a political subdivision of the State of California, The People of the State of California, acting by and through the County of San Bernardino v. Purdue Pharma L.P., et al.	C.D. Cal./5:18-cv-01527-DSF-SP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	7/19/2018	2018
County of San Diego, a political subdivision of the State of California; the People of the State of California, acting by and through the County of San Diego v. AmerisourceBergen Drug Corp., et al.	S.D. Cal./3:18-cv-00882-WQH-NLS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/7/2018	2018
County of San Joaquin, et. al. v. Purdue Pharma L.P., et al.	E.D. Cal/2:17-cv-01485-MCE-GGH (removed from STK-CV-UBT-2017-5325)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Does 1-100	5/25/2017	2017
County of San Luis Obispo, California v. Purdue Pharma L.P., et al.	C.D. Cal./2:18-cv-09516	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Endo; Par; Janssen; Noramco; Johnson & Johnson; Insys; Mallinckrodt; SpecGx; Allergan; Actavis; AmerisourceBergen; Cardinal; McKesson	11/9/2018	2018
County of San Mateo v. Purdue Pharma L.P., et al.	N.D. Cal./3:19-cv-00949-DMR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Products L.P.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; Insys	2/21/2019	2019

County of Sanilac, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./4:18-cv- 10812-BAF-RSW	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Wal-Mart; Costco	3/12/2018	2018
County of Santa Barbara; The People of the State of California v. Purdue Pharma L.P., et al.	C.D. Cal./2:19-cv-01186- PA-JPR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	2/15/2019	2019
County of Santa Cruz, California v. Purdue Pharma L.P., et al.	N.D. Cal./5:18-cv-02803- HRL	Purdue Pharma L.P.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; Insys	5/11/2018	2018
County of Shasta, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Shasta v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-at-00672	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018
County of Shiawassee, Michigan v. Purdue Pharma L.P., et al.	E.D. Mich./4:18-cv- 10811-LJM-EAS	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Wal-Mart; Costco	3/12/2018	2018
County of Siskiyou, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Siskiyou v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01167- KJM-CMK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	5/9/2018	2018

County of Smith v. Purdue Pharma L.P., et al.	E.D. Texas/6:17-cv-00699	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Hikma; Morris & Dickson; Mylan; Omnicare; Par; Sandoz; SpexGx; Walgreens; Walmart	12/19/2017; 3/14/2019	2017
County of Sonoma, California v. Purdue Pharma L.P., et al.	N.D. Cal./3:18-cv-03806-MEJ	Purdue Pharma L.P.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; Insys	6/26/2018	2018
County of St. Clair, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45896-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	7/30/2018	2018
County of Summit, Ohio, et al. v. Purdue Pharma L.P., et al.	N.D. Ohio/5:18-cv-00170 (removed from C.P. Summit County (OH)/CV-2017-12-5235)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Cardinal; McKesson; AmerisourceBergen; Jane Does 1-50	12/20/2017	2017
County of Sutter, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Sutter v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01140-MCE-EFB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018

County of Tarrant v. Purdue Pharma L.P., et al.	N.D. Texas/3:18-cv-00518-D	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Rhodes; SpecGx; Mylan; Walgreens; CVS; Morris & Dickson; Walmart; H.D. Smith; Indivior; Hikma; Mylan	3/5/2018; 3/15/2019	2018
County of Tehama, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Tehama v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01221-KJM-CMK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	5/14/2018	2018
County of Throckmorton v. Purdue Pharma L.P., et al.	N.D. Texas/1:18-cv-00004-C	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Does 1-100 Does	1/16/2018	2018
County of Titus v. Purdue Pharma L.P. et al.	E.D. Texas/5:17-cv-00189-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Hikma; West-Ward; Indivior; Morris & Dickson; Par; Qualitest; SpecGx; Walgreens; Walmart	11/8/2017; 3/14/2019	2017
County of Trinity, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Trinity v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01147-MCE-CMK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018

County of Trumbull v. Purdue Pharma L.P., et al.	N.D. Ohio/4:18-cv-00147 (removed from C.P. Trumbull Cnty (OH)/2017CV2266)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; RiteAid; Miami-Luken; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Rhodes; John N. Kapoor; Noramco; Anda	12/13/2017	2017
County of Tuolumne, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Tuolumne v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-00630-JAM-DB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018
County of Upshur v. Purdue Pharma L.P. et al.	E.D. Texas/2:17-cv-00672-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Hikma; West-Ward; Kroger; Morris & Dickson; Mylan; Par; Qualitest; SpecGx; Walgreen; Walmart; JM Smith; Pharmacy Buying Assoc.; Sandoz; Smith Drug	9/29/2017; 3/14/2019	2017
County of Ventura v. Purdue Pharma L.P., et al.	C.D. Cal./2:19-cv-06799	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; Mallinckrodt; Walgreens; AmersourceBergen; McKesson; Cardinal; Allergan; Watson; Actavis	8/6/2019	2019

County of Volusia, Florida v. AmerisourceBergen Drug Corp., et al.	M.D. Fla./6:18-cv-00944- GKS-KRS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	6/15/2018	2018
County of Walker v. Abbott Laboratories, Inc., et al.	S.D. Tex./4:19-cv-01767 (removed from Walker Cnty. Dist. Ct. (Tex.)/1929076)	Purdue Pharma L.P.; Purdue Pharma Inc.; Purdue Pharmaceuticals, L.P.	Abbott; Abbvie; Actavis; Advanced Pharma; Allergan; Alpharma; AmerisourceBergen; Watson; Apotex; Aveva; Cardinal; Caremark; Cephalon; CuraScript; CVS; Depomed; Endo; Express; Fresenius; H.D. Smith; ICU Med. Sales; Impax; Insys; Janssen; JM Smith; Johnson & Johnson; Knoll; Mallinckrodt; McKesson; Medco; Mission Pharmaceutical; Mylan; Navitus; Neos; Neshier; Noven; Optum; Paddock; Par; Perrigo; Prime; TEVA; UnitedHealth; Zogenix; Zydus	1/11/2019	2019
County of Wayne & County of Oakland v. Purdue Pharma L.P., et al.	E.D. Mich./4:17-cv- 13334-MFL-EAS	Purdue Pharma L.P.	TEVA; Cephalon; Janssen; Endo; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Insys	10/12/2017	2017
County of Webb v. Purdue Pharma L.P., et al.	S.D. Texas/5:18-cv- 00011	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Johnson & Johnson; Janssen; Watson; Allergan; Actavis; Insys; McKesson; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum RX; Navitus; Rhodes; Abbvie; SpecGx; Mylan; Hikma; Caremart; ESI Mail Pharm.; Express; Walmart	1/25/2018; 9/17/2018; 3/16/2019	2018

County of Wexford, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv- 00273	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco	3/13/2018	2018
County of Wichita, Texas v. Purdue Pharma L.P., et al.	N.D. Texas/7:17-cv- 00173-M	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Knoll; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Albertsons; Allergan; CVS; Indivior; Mallinckrodt; Morris & Dickson; Mylan; Par; SpecGx; Walgreens; Walmart; West-Ward	12/22/2017; 3/15/2019	2017
County of Wicomico, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02029- TDC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Walmart; Rite Aid; Covidien Kroger	7/9/2019	2019
County of Wilcox, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45506-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	4/27/2018	2018
County of Williamson v. Purdue Pharma L.P., et al.	S.D. Tex./4:19-cv-03299 (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Abbott; Knoll; Allergan; Watson; McKesson; Actavis; Cardinal; Mallinckrodt; CVS; Walmart; Walgreens; AmerisourceBergen	6/14/2019	2019

County of Yolo, a political subdivision of California, the People of the State of California, acting by and through the Yolo County Counsel v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:19-cv-00813-JAM-DB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Insys; CVS; Kroger; Rite Aid; Thrifty; Walgreens; Wal-Mart	5/7/2019	2019
County of Yuba, a political subdivision of the State of California; the People of the State of California, acting by and through the County of Yuba v. AmerisourceBergen Drug Corp., et al.	E.D. Cal./2:18-cv-01145-WBS-KJN	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Ride Aid; Thrifty; Walgreens; Wal-Mart	5/8/2018	2018
County of Yuma v. Purdue Pharma L.P., et al.	D. Ariz./2:19-cv-04410-ESW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Endo; Par; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Mylan; West-Ward; Hikma; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; Smith's Food & Drug	6/7/2019	2019
Courtney Herring, individually and as next friend and guardian of Baby M.T. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45519-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Coushatta Tribe of Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45438-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Walgreens; SpecGx; Par; Morris & Dickson; Louisiana Wholesale Drug; CVS	6/13/2019	2019

Covington County, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./2:19-cv-00544-MHT-SMD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	7/31/2019	2019
Covington County, Mississippi v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45417-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
Cow Creek Band of Umpqua Tribe of Indians v. Purdue Pharma L.P., et al.	D. Or./6:18-cv-00535-AA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/28/2018	2018
Coyote Valley Band of Pomo Indians v. McKesson Corp., et al.	N.D. Cal./3:18-cv-02533-MEJ (removed from San Francisco County Super. Ct. (CA)/CGC-18-563933)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	1/29/2018	2018
Craven County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./4:18-cv-00090-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/11/2018	2018
Crawford County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00975-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	11/6/2017	2017

Crisp County, GA v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./1:18-cv-00036-WLS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	2/14/2018	2018
Crockett County, TN v. AmerisourceBergen Drug Corp., et al.	W.D. Tenn./1:18-cv-01026	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Quest; Par; SpecGx; Amneal	2/2/2018; 3/8/2019	2018
Cullen Talton in his official capacity as the Sherriff of Houston County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45308-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	5/8/2019	2019
Cullman County, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./5:18-cv-00230-UJH-AKK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/9/2018	2018
Culpeper County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./3:19-cv-00037	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-	N/A	2019

Cumberland County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./5:18-cv-00399-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	8/14/2018	2018
Cumberland County, State of Maine v. Purdue Pharma L.P., et al.	D. Me./2:19-cv-00093 (removed from Super. Ct. Cumberland Cnty. (Me.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.	1/18/2019	2019
Cumberland County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./6:19-cv-00054-EKD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
Currituck County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./2:18-cv-00052-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	9/27/2018	2018

CWA Local 1182 & 1183 Health & Welfare Funds v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-04903-NGG-ST	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; And; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	8/27/2019	2019
Dakota County, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:18-cv-02612 (removed from 1st Jud. Dist. Ct., Dakota Cnty. (Minn.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo	8/16/2018	2018
Dale County, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./1:18-cv-00433-GMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	4/24/2018	2018
Dane County, Wisconsin v. AmerisourceBergen Drug Corp., et al.	W.D. Wi./3:18-cv-00455-jdp	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; RiteAid; Walgreens; Wal-Mart; SpecGx; Par; Hy-Vee	6/14/2018; 3/13/2019	2018
Daniel Wilson v. Purdue Pharma L.P., et al.	E.D. Pa./2:18-cv-05595-JD	Purdue Pharma L.P.; Purdue Pharma Inc.	N/A	12/27/2018	2018
Danville Regional Medical Center, LLC v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45788-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Abbott; Cephalon; Depomed; Endo; Janssen; Johnson & Johnson; Mallinckrodt; Noramco; SpecGx; TEVA; Watson	9/13/2019	2019
Darcy C. Sherman, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	D. Minn./0:18-cv-03335	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	12/6/2018	2018

Dare County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./4:18-cv-00091-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/11/2018	2018
Darke County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-01064-EAS-CMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	12/9/2017	2017
Darren and Elena Flanagan, individually and as adoptive parents and next friends of Baby K.L.F., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	W.D. Tenn./2:18-cv-02194-TLP-DKV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Linden Care; Kroger; H.D. Smith; Rhodes; Anda	3/21/2018; 3/8/2019	2018
David J. Davis, in his official capacity as the Sherriff of Bibb County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45360-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; SpecGx; Anda; JM Smith	5/31/2019	2019
Davidson County v. Purdue Pharma L.P., et al.	M.D.N.C./1:18-cv-00983	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Insys; Walgreens; Walmart; Kroger; CVS; Rite Aid; H.D. Smith; Miami-Luken	11/27/2018	2018

Davie County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./2:18-cv-00061-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	12/6/2018	2018
Davie County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:18-cv-00874	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/15/2018	2018
Dawson County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45210-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/28/2019	2019
Deborah Green-Kuchta, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	D.S.D./4:18-cv-04132-KES	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	10/15/2018	2018
Debra Dawsey, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	W.D. Mich./1:19-cv-00094	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Insys	2/6/2019	2019
Decatur County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./1:18-cv-00055-WLS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/16/2018	2018
Delaware County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:18-cv-00172-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/28/2018	2018

Delaware County v. Purdue Pharma L.P., et al.	S.D. Ind./1:18-cv-02044-WTL-TAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	7/5/2018	2018
Delaware County, Pennsylvania v. Purdue Pharma L.P., et al.	E.D. Pa./2:18-cv-05627 (removed from C.P. Delaware Cnty (Pa.)/CV-2017-008095)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Scott Fishman; Perry Fine; Lynn Webster; Noramco; Endo; Par; McKesson; AmerisourceBergen; Cardinal; Rhodes; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Kroger; Insys; H.D. Smith; Miami-Luken	9/21/2017; 11/14/2018	2017
Deric Rees and Ceonda Rees, individually and as next friend and guardian of baby T.W.B. on behalf of themselves and all others similarly situated v. McKesson Corp.	S.D. Ill./3:18-cv-00511	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis	2/28/2018	2018
Desiree Carlson, individually and as next friend and guardian of Baby J.S., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45487-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/16/2019	2019

Desiree Warren, individually and as next friend and guardian of Baby A.W., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45486-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/16/2019	2019
DeSoto County, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./3:19-cv- 00115-GHD-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/3/2019	2019
Desoto Fire Protection District No. 8 v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00972- BAJ-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
Detroit Wayne Mental Health Authority v. Purdue Pharma L.P., et al.	E.D. Mich./2:18-cv- 13645-SFC-SDD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Endo; Par; Janssen; Noramco; Johnson & Johnson; Insys; Mallinckrodt; SpecGx; Allergan; Actavis; AmerisourceBergen; Cardinal; McKesson	11/21/2018	2018
Devils Lake v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00105- DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019

Dickenson County v. Purdue Pharma L.P., et al.	W.D. Va./2:18-cv-00048-EKD (Removed from Cir. Ct. Dickenson Cnty. (VA)/CL18-155)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Does 1-100	3/14/2018	2018
Dixie County, Florida v. Purdue Pharma L.P., et al.	N.D. Fla./1:19-cv-00107-MW-GRJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/14/2019	2019
Dodge County Hospital Authority d/b/a Dodge County Hospital v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./3:18-cv-00048-DHB-BKE	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Noramco	6/22/2018	2018
Dodge County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01653-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Dooly County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45712-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	6/13/2018	2018

Door County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01541- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Dora Lawrence, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	S.D. Texas/4:18-cv- 02889	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	8/21/2018	2018
Dorchester County, Maryland v. Purdue Pharma L.P., et al.	D. Md./8:19-cv-01736- PX	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Insys	6/13/2019	2019
Dougherty County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45491-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/19/2018	2018

Douglas Anderson, Sheriff of Avoyelles Parish v. Purdue Pharma L.P., et al.	W.D. LA/1:17-cv-01567 (removed from 12th Judicial District Court, Parish of Avoyelles/2017- 4682B)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal- Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	9/18/2017	2017
Douglas County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01545- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Douglas County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45386-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Par; SpecGx; Insys; CVS; Walmart; Wagreens; H.D. Smith; Kroger	6/6/2019	2019
Douglas County, MN v. Purdue Pharma L.P. et al	D. Minn./0:18-cv-00829- DWF-LIB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/26/2018	2018

Douglas Herbert III, duly executed Sheriff of Allen Parish v. Purdue Pharma L.P., et al.	W.D. LA/2:18-cv-00055 (removed from 33rd Judicial District Court, Allen Parish (LA)/C-2017-462)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal-Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	11/22/2017	2017
Doyle T. Wooten, in his Official Capacity as the Sheriff of Coffee County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45145-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019
Drew Memorial Hospital Inc. v. Purdue Pharma L.P., et al.	E.D. Ark./5:18-cv-00010-DPM (removed from Cir. Ct. Drew Cnty. (Ark.)/CV-2017-221-3)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Dr. Richard Jones; John Doe Defendants 1 through 9	12/14/2017; 1/2/2018 (Am.)	2017
Drywall Tapers Insurance Fund v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-04952	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; Anda; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	8/29/2019	2019
Dunn County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00115-DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019

Dunn County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01656-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Duplin County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./7:19-cv-00012-D	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	1/18/2019	2019
Durham County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:19-cv-00491	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	5/10/2019	2019
Dusty Gates, in his capacity as the Sheriff for Union Parish v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45927-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; AmerisourceBergen; McKesson; Cardinal	8/6/2018	2018
E. Neal Jump, in his Official Capacity as the Sheriff of Glynn County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45155-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019

Early County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45180-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/26/2019	2019
Eastern Aleutian Tribes v. Purdue Pharma L.P., et al.	D. Alaska/3:19-cv-00234	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; Walgreen; Kroger; Albertsons; Walmart; CVS	8/30/2019	2019
Eastern Band of Cherokee Indians v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./1:18-cv-00004-MR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	1/4/2017	2017
Eastern Shoshone Tribe v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45412-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger; H.D. Smith	6/7/2019	2019
Eau Claire County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01551-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017

Echols County, Georgia v. Purdue Pharma L.P., et al.	M.D. Ga./7:18-cv-00174-HL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Noramco; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	10/15/2018	2018
Edna House for Women, Inc.; Treatment Works Inc. d/b/a Absolute House; K.I.S.S. Foundation Inc. d/b/a Lia House; Lantern; Primary Purpose Center Inc.; and John T. Foundation d/b/a Jack Mulhall Center for Sober Living v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46209-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	11/1/2018	2018
Edrick Soileau, Sherriff of Evangeline Parish v. Purdue Pharma L.P., et al.	W.D. LA/6:18-cv-00125 (removed from 13th Judicial District Court for the Parish of Evangeline (LA)/77278-A)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal-Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	12/15/2017	2017
Edward Grace, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	D. Mass./1:18-cv-10857-MPK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	5/2/2018	2018
Effingham County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45178-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/26/2019	2019

El Campo Memorial Hospital and West Wharton County Hospital District v. McKesson Corporation, et al.	S.D. Texas/4:18-cv-00751	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; John Does 1-100	3/8/2018	2018
Elbert County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./3:18-cv-00038-CDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/22/2018	2018
Eli Medina, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	D. Ida./1:18-cv-00369	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	8/21/2018	2018
Elizabeth Kommer, individually and as next friend and guardian of Baby C.K. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45522-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Ellis County v. Purdue Pharma L.P., et al.	S.D. Tex./4:19-cv-02256 (removed from Ellis Cnty. Dist. Ct. (Tex.)/100921)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Wal-Mart; Dr. Richard Andrews; Dr. Theodore Okechuku; Dr. Nicolas Padron	5/3/2019	2019

Ely Shoshone Tribe of Nevada v. McKesson Corp., et al.	N.D. Ohio/1:18-op-46003-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS; Walgreens; Walmart	8/27/2018	2018
Emanuel County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45209-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/28/2019	2019
Employer-Teamsters Local Nos. 175 & 505 Health & Welfare Fund; Employer-Teamsters Local Nos. 175 & 505 Retiree Health & Welfare Fund; Ohio Conference of Teamsters & Industry Health & Welfare Fund; Teamsters Local No. 348 Health & Welfare Fund; Teamsters Union Local No. 52 Health & Welfare Fund v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45446	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; Miami-Luken; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; CVS; Walgreens; Wal-Mart; Perry Fine; Scott Fishman; Lynn Webster; Abbott; Express; UnitedHealth; International Brotherhood of Teamsters; Caremark; Optum; Noramco	4/17/2018	2018
Erie County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00918-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/20/2017	2017
Erin Doyle, individually and as Mother and Custodian of Baby D.F., on behalf of themselves and all others similarly situated v. Actavis LLC	S.D. Ohio/2:18-cv-00719-MHW-CMV (removed from C.P. Ross Cnty. (OH)/18CI201)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Endo; Janssen; Johnson & Johnson; McKesson; TEVA; Watson; Cephalon	5/9/2018	2018

Escambia County, Florida v. AmerisourceBergen Drug Corp., et al.	N.D. Fla./3:18-cv-01370-MCR-CJK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/22/2018	2018
Esperanza Ellis, individually and as next friend and guardian of Baby S.O.D., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45464-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/14/2019	2019
Essex County, New Jersey v. Purdue Pharma L.P., et al.	D.N.J./2:18-cv-12313	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; CVS; Walgreens; Costco; Rite Aid	6/29/2018	2018
Estill County Emergency Medical Services v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:18-cv-00590-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	10/26/2018	2018
Evangeline Parish Police Jury v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45450-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Endo; Par; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Mylan; West-Ward; Hikma; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; Smith's Food & Drug; H.D. Smith; CVS; Anda; Warner Chilcott; Sandoz	6/13/2019	2019

Evans Memorial Hospital, Inc. v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./6:18-cv-00070-JRH-GRS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Noramco	6/22/2018	2018
F. Kirk Hopkins, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	D. Ariz./2:18-cv-02646	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	8/21/2018	2018
Fairfax County Board Of Supervisors v. Purdue Pharma L.P., et al.	E.D. Va./1:19-cv-00544	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
Fairfield County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-01012-MHW-CMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	11/17/2017	2017
Fairview Township, Pennsylvania v. Purdue Pharma L.P., et al.	M.D. Pa./3:19-cv-00795-MEM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; CVS; Rite Aid; Walgreens; Wal-Mart; Value Drug Co; Generics Bidco	5/9/2019	2019

Family Practice Clinic of Booneville, Inc. and Family Health Care Clinic, PSC v. Purdue Pharma L.P., et al.	E.D. Ky./6:18-cv-00087-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Depomed; Endo; Johnson & Johnson; Mallinckrodt; TEVA; Watson; Collegium	3/21/2018	2018
Farrah Williams, individually and as next friend and guardian of Baby A.W., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45485-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/16/2019	2019
Fayette County, Alabama; City of Fayette, Alabama and Rodney Ingle, Sheriff of Fayette County, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./7:18-cv-00200-LSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	2/5/2018	2018
Fayette County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45293-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; McKesson; Cardinal; AmerisourceBergen; Rhodes; SpecGx; Mylan; Amneal; Novartis; Sandoz; West-Ward; Hikma; KVK-Tech; JM Smith; CVS; Kroger; Rite Aid; Harco; Walgreens; Walmart	4/25/2019; 6/19/2019	2019

Feather River Tribal Health, Inc. v. Purdue Pharma L.P., et al.	C.D. Cal./5:19-cv-00823	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Endo; Par; Johnson & Johnson; Janssen; TEVA; Noramco; Cephalon; Allergan; Watson; Warner Chilcott; Actavis; Insys; SpecGx; Mallinckrodt; Mylan; West-Ward; AmerisourceBergen; Anda; Cardinal; CVS; McKesson; Walgreens; Walmart; H.D. Smith; Thrifty	5/2/2019	2019
Fentress County, TN v. AmerisourceBergen Drug Corp., et al.	M.D. Tenn./2:18-cv-00028	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; JM Smith; Morris & Dickson; Top Tx; Par; SpexGx; H.D. Smith; Walgreens; Walmart	3/27/2018; 3/8/2019	2018
Fiscal Court of Allen County, on Behalf of Allen County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./1:17-cv-00196-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/1/2017	2017
Fiscal Court of Anderson County, on Behalf of Anderson County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./3:17-cv-00070-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	9/12/2017; 10/3/2017 (Am.)	2017
Fiscal Court of Bell County, on Behalf of Bell County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./6:17-cv-00246-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	9/12/2017; 10/3/2017 (Am.)	2017
Fiscal Court of Boone County, on Behalf of Boone County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./2:17-cv-00157-GFVT-CJS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	9/12/2017; 10/3/2017 (Am.)	2017

Fiscal Court of Boyd County, on Behalf of Boyd County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./0:17-cv-00104-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	9/25/2017; 10/3/2017 (Am.)	2017
Fiscal Court of Boyle County, on Behalf of Boyle County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:17-cv-00367-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	9/12/2017; 10/3/2017 (Am.)	2017
Fiscal Court of Bullitt County, on Behalf of Bullitt County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./3:17-cv-00727-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/1/2017	2017
Flandreau Santee Sioux Tribe, Rosebud Sioux Tribe, and Sisseton-Wahpeton Oyate v. Purdue Pharma L.P., et al.	D.S.D./4:18-cv-04003-KES	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	1/8/2018	2018
Flint Plumbing and Pipefitting Industry Health Care Fund, on behalf of itself and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45430-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger; H.D. Smith; Rite Aid; Kroger	6/10/2019	2019

Florence County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01554- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Floyd County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./7:19-cv-00371	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
Fond Du Lac Band of Lake Superior Chippewa v. Purdue Pharma L.P., et al.	D. Minn./0:18-cv-03181- JNE-LIB (removed from 6th Jud. Dist. Ct., Carlton Cnty. (Minn.)/09-CV-18- 1882)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	10/9/2018	2018

Fond du Lac County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01543-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Forest County Potawatomi Community v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46342-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	12/18/2018	2018
Forest County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01658-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Forrest County, Miss. v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./2:18-cv-00009-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	1/18/2018	2018

Forsyth County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45420-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami- Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
Four Winds Tribe Louisiana Cherokee v. Purdue Pharma L.P., et al.	W.D. La./2:19-cv-00760- UDJ-KK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Morris & Dickson Co.; SpecGx	6/14/2019	2019
Franklin County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:18-cv-00077- GCS-KAJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	1/30/2018	2018
Franklin County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./5:18-cv-00500- D	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/22/2018	2018
Franklin County v. Purdue Pharma L.P., et al.	E.D. Wa./4:18-cv-05116	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; SpecGx; Par; Mylan; Thrifty; Rite Aid; West- Ward; Hikma; Walgreens; Amneal; Thrifty; Impax	7/11/2018; 3/15/2019	2018

Franklin County, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./5:19-cv-00053-DCB-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/6/2019	2019
Franklin County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./7:19-cv-00302	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
Franklin Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00915-BAJ-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/17/2018	2018
Freeborn County, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01850-JNE-DTS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	7/15/2019	2019
Gallia County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00768-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/9/2017	2017

Gary Gilley v. Purdue Pharma L.P., et al.	W.D. La./3:18-cv-01604-TAD-KLH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; Allergan; Watson; TEVA; Cephalon; Noramco; Cephalon; Insys; Mallinckrodt; Cardinal; McKesson; CVS; Kroger; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	12/12/2018	2018
Gary Landford, in his Official Capacity as the Sheriff of Murray County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45164-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019
Gasconade County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46190-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-Mart; McQuery; Amneal	10/26/2018; 3/8/2019	2018
Gaston County v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./3:18-cv-00045	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	1/28/2018	2018
Geauga County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-cv-00605	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/15/2018	2018

Gena Patterson, individually and as next friend and guardian of Baby F.P. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45534-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Gene Scarborough, in his Official Capacity as the Sheriff of Tift County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45168-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019
Genesee County v. Purdue Pharma L.P., et al.	E.D. Mich./4:17-cv-14074-TGB-MKM	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Rite Aid; Costco; Insys	12/18/2017	2017
George County, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./1:19-cv-00120-LG-RHW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	3/1/2019	2019
Georgetown City, South Carolina v. Purdue Pharma L.P., et al.	D.S.C./2:19-cv-01696-MDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Johnson & Johnson; Normaco; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; CVS; Walgreens	6/12/2019	2019
Georgetown County, South Carolina v. Purdue Pharma L.P., et al.	D.S.C./5:19-cv-01695-MDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Johnson & Johnson; Normaco; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; CVS; Walgreens	6/12/2019	2019

Gila River Indian Community; Pascua Yaqui Tribe; and San Carlos Apache Tribe v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45366-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; McKesson; Cardinal; AmerisourceBergen; Walgreens; Walmart; CVS	6/5/2019	2019
Gilchrist County, Florida v. Purdue Pharma L.P., et al.	N.D. Fla./1:19-cv-00109-MW-GRJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/14/2019	2019
Giles County v. Purdue Pharma L.P., et al.	W.D. Va./7:18-cv-00618-EKD (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	12/12/2018	2018
Glascoc County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45175-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/25/2019	2019
Glenn Golden, Gretta Golden and Michael Christy, individually, and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	E.D. La./2:19-cv-01048	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen	2/6/2019	2019

Glorida Cruz, individually and as next friend and guardian of Baby C.E.L., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45466-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/14/2019	2019
Glynn County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46115-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Amneal; Walgreens; CVS; Walmart; Indivior; Smith Drug Co.; J.M. Smith; West-Ward; Wal-Mart; Hikma; SpecGx	10/16/2018; 3/15/2019; 3/18/2019	2018
Gonzales Healthcare Systems v. McKesson Corporation, et al.	N.D. Ohio/1:18-op-45867-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Endo; Allergan; Watson; Actavis; Mallinckrodt	7/24/2018	2018
Gooding County, Idaho v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45404-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/7/2019	2019

Grady County, Georgia v. Purdue Pharma L.P., et al.	M.D. Ga./1:18-cv-00224-LJA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Noramco; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	11/26/2018	2018
Grafton County v. Purdue Pharma L.P., et al.	D.N.H./1:19-cv-00332 (removed from Grafton Super. Ct. (NH)/215-2018-CV-00323)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Rite-Aid; Walgreens; Walmart; Dr. Michael Dipre; Dr. Mark Weinreb; Christopher Clough; Dr. Erik Knight; Christopher S. Manfred	9/18/2018	2018
Grand Forks County v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00123-DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
Grant County v. Pharma L.P., et al.	E.D. Wi./2:17-cv-01557-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017

Grant County, New Mexico v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45108-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Miami-Luken; Mallinckrodt; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreen; Wal-Mart; Rite Aid; Amneal; Par; SpecGx; West-Ward; Hikma; Mylan; KVK; Sandoz; Albertsons; Medicine Shoppe; Rhodes; John N. Kapoor; Noramco; Anda	3/4/2019; 3/18/2019	2019
Grant Parish, Louisiana, by and through its duly elected Police Jury v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45277-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Endo; Par; Janssen; TEVA; Cephalon; Allergan; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Hikma; Indivior; Health Mart; H.D. Smith; Anda; Louisiana Wholesale Drug; Morris & Dickson; CVS; Rite Aid; Walgreens; Walmart	4/12/2019	2019
Grayson County, Virginia v. AmerisourceBergen Drug Corp., et al.	W.D. Va./7:18-cv-00309-EKD-PMS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS; North Carolina Wholesale Drug Co; JM Smith; Walgreens; Walmart; Amneal; Mylan; Par; SpecGx; West-Ward; Rhodes	6/28/2018; 3/14/2019	2018

Green County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01535-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Green Lake County, Taylor County and Vilas County v. Purdue Pharma L.P., et al.	E.D. Wi./2:18-cv-00819-PP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; RiteAid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; Sandoz; SpecGx; West-Ward; Dakota Drug; Omnicare; TopRx; Rhodes	5/29/2018; 3/15/2019	2018
Green River, Wyoming v. Purdue Pharma L.P., et al.	D. Wyo./1:19-cv-00155-SWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; AmerisourceBergen; Insys; Amneal; West-Ward; Mylan; Walgreens; Walmart	7/24/2019	2019
Greenbrier County Commission v. AmerisourceBergen Drug Corp., et al.	S.D. WV/5:19-cv-00084	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Mallinckrodt; SpecGx; Wal-Mart; RiteAid; CVS; Kroger; Insys; Anda; Generics Bidco; Bellco; Qualitest; H.D. Smith	2/4/2019	2019

Greene County, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./7:18-cv-00169-C	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
Greene County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45203-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/28/2019	2019
Greene County, North Carolina v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./4:18-cv-00085-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/27/2018	2018
Greene County, TN v. AmerisourceBergen Drug Corp., et al.	E.D. Tenn./2:18-cv-00002	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; JM Smith; Harvard Drug; SpecGx; Par; Rite Aid; CVS; Walgreens; Walmart	1/4/2018; 3/8/2019	2018
Greenville County, Virginia v. Purdue Pharma L.P., et al.	E.D. Va./3:19-cv-00459	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-	N/A	2019

Greenwood Leflore Hospital v. McKesson Corporation, et al.	N.D. Miss./4:18-cv-00091-NBB-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/17/2018	2018
Guernsey County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00886-GCS-CMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/11/2017	2017
Guidiville Rancheria of California v. McKesson Corp.	N.D. Cal./3:18-cv-02532-EDL (removed from San Francisco County Super. Ct. (CA)/CGC-18-564281)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	2/13/2018	2018
Guildford County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:19-cv-00468-TDS-LPA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	5/4/2019	2019
Gulf County v. AmerisourceBergen Drug Corp., et al.	M.D. Fla./5:18-cv-00162-RH-GRJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	7/11/2018	2018
Gwinnett County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ga./1:18-cv-02078-ELR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Depomed; Endo; Allergan; Actavis; Watson; Avis; Watson; Avis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	5/11/2018	2018

H.W. "Billy" Hancock, in his official capacity as the Sheriff of Crisp County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45562-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	6/26/2019	2019
Habersham County Medical Center v. AmerisourceBergen Drug Corp., et al.	N.D. Ga./2:18-cv-00162-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	9/7/2018	2018
Habersham County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ga./2:18-cv-00041-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	4/4/2018	2018
Hale County, Alabama v. Actavis LLC et al.	S.D. Ala./2:18-cv-00483	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/27/2018	2018
Halifax County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./4:18-cv-00049-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/12/2018	2018
Halifax County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./6:19-cv-00021-EKD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-	N/A	2019

Hall County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ga./3:18-cv-00040-HL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/9/2018	2018
Hamilton County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/1:18-cv-00150-WOB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/1/2018	2018
Hamilton County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./3:19-cv-00710-TJC-MCR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/13/2019	2019
Hamilton County, TN v. Purdue Pharma L.P., et al.	E.D. Tenn./1:18-cv-00061	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; JM Smith	4/12/2018; 3/15/2019	2018
Hancock County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45572-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco; Insys	5/14/2018	2018
Hancock County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45535-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/4/2018	2018
Hancock County, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./1:18-cv-00200-HSO-JCG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/12/2018	2018

Hancock County, TN v. AmerisourceBergen Drug Corp., et al.	E.D. Tenn./2:18-cv-00010	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; JM Smith; Harco; Par; SpecGx; Rite Aid	1/18/2018; 3/8/2019	2018
Hanover Township, Pennsylvania v. Purdue Pharma L.P., et al.	M.D. Pa./3:19-cv-01055-MEM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.; PLP Associates Holdings; PLP Associates Holdings Inc.; Purdue Holdings; BR Holdings Associates Inc.; BR Holdings Associates L.P.	Rhodes; Cephalon; TEVA; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Insys; Hikma; West-Ward; Indivior; Mylan; Amneal; Sandoz; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; Walgreen; CVS; Associated; Masters; Keysource; Qualitest	6/21/2019	2019
Hardin County Fiscal Court, on behalf of Hardin County; Breckinridge County Fiscal Court, on behalf of Breckinridge County; Green County Fiscal Court, on behalf of Green County; Meade County Fiscal Court, on behalf of Meade County; Ohio County Fiscal Court, on behalf of Ohio County; on behalf of themselves and all other similarly situated counties (Fiscal Courts) v. Purdue Pharmna L.P., et al.	E.D. Ky./3:19-cv-00068 (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Abbott; TEVA; Cephalon; Allergan; Actavis; Watson; Endo; Par; SpecGx; Mallinckrodt; Johnson & Johnson; Janssen; Noramco; Amneal; Mylan; West-Ward; KVK; Assertio; Depomed; AmerisourceBergen; H.D. Smith; Anda; CVS; Rite Aid; Smith Drug; Kroger; Walgreens; Walmart; Fred's	9/13/2019	2019

Harris County v. Purdue Pharma L.P., et al.	S.D. Texas/4:18-cv- 00490 (removed from District Ct. Harris Cnty. (TX)/201782618)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; Janssen; Endo; Abbott; Allergan; Insys; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; Advanced Pharma; NexGen; Neos Therapeutics Brands; Mission Pharmacal; Fresenius; ICU Medical Sales; Mylan; Dr. Gazelle Craig; Dr. Arun Sharma; Dr. Karin Sharma; Dr. Richard Arthur Evans; and pharmacist David Devido	12/13/2017	2017
Harrison County Board of County Commissioners v. Purdue Pharma L.P., et al.	S.D. Ohio/2:18-cv-00359 (removed from C.P. Harrison Cnty. (OH)/CVH- 2018-0024)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; Insys; Miami-Luken	3/20/2018	2018
Harrison County, Mississippi v. McKesson Corp., et al.	N.D. Ohio/1:19-op- 45113-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt; Insys; SpecGx; Par; Amneal; Indivior; Mylan; Smith Drug; Morris & Dickson; Hikma; West- Ward	3/5/2019; 3/15/2019	2019

Hartford County, Maryland; Caroline County, Maryland; Garrett County, Maryland; Frederick County, Maryland; Talbot County, Maryland; City of Frederick, Maryland; The Mayor and Common Council of Westminster, Maryland; City of Bowie, Maryland; The Mayor and Council of Rockville, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:18-cv-01913-GJH	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Johnson & Johnson; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	6/25/2018	2018
Haskell County, Texas v. Purdue Pharma L.P., et al.	N.D. Texas/1:18-cv-00023-C	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Amneal; Indivior; Mallinckrodt; Mylan; Par; Sandoz; SpecGx; West-Ward	2/9/2018; 3/15/2019	2018
Hawkins County, TN v. AmerisourceBergen Drug Corp., et al.	E.D. Tenn./2:18-cv-00030-TAV-MCLC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; JM Smith; Par; SpecGx; CVS; Walgreens; Walmart	3/8/2018; 3/11/2019	2018
Haywood County v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./1:18-cv-00363	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	12/17/2018	2018

Haywood County, TN v. AmerisourceBergen Drug Corp., et al.	W.D. Tenn./2:18-cv-02016	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; SAJ; Associated Pharm; SpecGx; Amneal; Walgreens; Walmart	1/4/2018; 3/11/2019	2018
Health Care Authority of the City of Huntsville d/b/a HH Health System d/b/a Huntsville Hospital d/b/a Madison Hospital d/b/a Huntsville Hospital for Women and Children; HH Health System-Morgan, LLC d/b/a Decatur Morgan Hospital d/b/a Decatur Morgan Hospital-Parkway; Health Care Authority of Morgan County-City of Decatur; HH Health System-Shoals, LLC d/b/a Helen Keller Hospital d/b/a Red Bay Hospital; HH Health System-Athens Limestone, LLC d/b/a Athens Limestone Hospital; Attentus Moulton, LLC d/b/a Lawrence Medical Center	N.D. Ohio/1:19-op-45143-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; McKesson; Cardinal; AmerisourceBergen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	3/15/2019	2019
Heard County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op-45130-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; McKesson; Cardinal; AmerisourceBergen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; Bloodworth; SpecGx; Par; West-Ward	3/12/2019; 3/15/2019	2019
Heather Enders, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	S.D. Ohio/2:19-cv-00448-GCS-KAJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt; Insys	2/11/2019	2019

Heather Goss, individually and as next friend and guardian of Babies C.B. and V.B. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45518-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Heather Puckett, individually and as next friend and guardian of Baby C.M.B. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45539-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Henderson County, TN v. AmerisourceBergen Drug Corp., et al.	W.D. Tenn./1:18-cv- 01048	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; SAJ; Par; Amneal; KVK; Walgreens; Walmart	3/21/2018 3/8/2019	2018
Hennepin County, MN v. Purdue Pharma L.P., et al.	D. Minn./0:18-cv-00350 (removed from 4th Jud. Dist., County of Hennepin (MN))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Jane Does 1-100	1/31/2018	2018
Henry County, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./1:18-cv-00418- GMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	4/17/2018	2018

Henry County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ga./1:18-cv-03899-AT (removed from Henry Cnty. Sup. Ct. (Ga.)/18CV650EDB)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; Rite Aid; Narendra Nagareddy; Perry Fine; Scott Fishman; Lynn Webster; Par; West-Ward; Mylan; Sandoz; Publix; Rhodes; Miami-Luken; John N. Kapoor; Noramco; Andia; Rite Aid; Mallinckrodt	7/11/2018	2018
Henry County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./4:18-cv-00071-EKD (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	10/3/2018	2018
Hernando County v. AmerisourceBergen Drug Corp., et al.	M.D. Fla./8:19-cv-01388-MSS-CPT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	6/6/2019	2019
Hillsborough County, a political subdivision of the State of Florida v. Purdue Pharma L.P., et al.	M.D. Fla./8:18-cv-02716-MSS-AEP (removed from Cit. Ct. Hillsborough Cnty. (Fla.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; H.D. Smith; Andia; CVS; Walgreens	8/14/2018	2018

Hillsborough County, New Hampshire v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46353	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; PSS World; CVS; Walgreens; Walmart; Rite Aid; Miami-Luken; SpecGx; Par; West-Ward; Hikma; Mylan; John N. Kapoor; Noramco; Anda	12/24/2018	2018
Hocking County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00769- EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/12/2017	2017
Holmes County v. AmerisourceBergen Drug Corp., et al.	N.D. Fla./5:18-cv-00087- RH-JRG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/4/2018	2018
Holmes County, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./3:18-cv-00403- CWR-FKB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/20/2018	2018
Hopland Band of Pomo Indians v. McKesson Corp., et al.	N.D. Cal./3:18-cv-02528 (removed from San Francisco County Super Ct. (CA)/CGC-18-564491)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal- Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	2/21/2018	2018
Hospital Authority of Bainbridge and Decatur County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./1:18-cv-00066- LJA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/22/2018	2018

Hospital Authority of Baxley and Appling County d/b/a Appling Health Care System v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./2:18-cv-00115-LGW-BWC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	9/24/2018	2018
Hospital Authority of Bleckley County d/b/a Bleckley Memorial Hospital v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./5:18-cv-00366-MTT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	10/4/2018	2018
Hospital Authority of Valdosta and Lowndes County, Georgia d/b/a South Georgia Medical Center v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45133-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; McKesson; Cardinal; AmerisourceBergen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	3/12/2019	2019
Hospital Service District No. 1 of the Parish of LaSalle, State of Louisiana d/b/a Hardtner Medical Center v. Purdue Pharma L.P. et al	N.D. Ohio/1:18-op-46150-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Anda; CVS; Rite Aid; Walgreens; Walmart; Amneal; Indivior; Mylan; Hikma; Louisiana Wholesale Drug Co.; Morris & Dickson; K&B Louisiana Corp.; CVS; Walgreens; Alberstons; Rhodes	10/15/2018	2018
Houlton Band of Maliseet Indians v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op-45315-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/9/2019	2019

Houston County v. Purdue Pharma L.P., et al.	M.D. Ga./5:18-cv-00248-MTT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; H.D. Smith; Miami-Luken	7/11/2018	2018
Houston County, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./1:17-cv-00838-GMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Fictitious Defendants 1-100	12/14/2017	2017
Howard County, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-00242-JMS-TAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	1/26/2018	2018
Howard County, Maryland v. Purdue Pharma L.P., et al.	D. Md./1:19-cv-02116-GLR (removed from Cir. Ct. Howard Cnty. (MD)/C-13-19-000501)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; John N. Kapoor; Cardinal; Mallinckrodt; SpecGx; Walgreen; Rite Aid; AmerisourceBergen	5/17/2019	2019
Howell County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45368-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
Hualapai Tribe v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45004-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	1/10/2019	2019

Huerfano County v. Purdue Pharma L.P., et al.	D. Colo./1:18-cv-00219	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	1/28/2018	2018
Humboldt County v. Purdue Pharma L.P., et al.	N.D. Cal./1:18-cv-04375-RMI	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; John and Jane Does 1 through 100, inclusive	7/18/2018	2018
Humphreys County, Miss. V. Purdue Pharma L.P., et al.	N.D. Miss./4:17-cv-00190-DMB-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/20/2017	2017
Huntington Beach v. Purdue Pharma L.P.	C.D. Cal./8:18-cv-00735 (removed from Orange County Super. Ct. (CA)/No. 30-2018-00971989-CU-MC-CXC)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardina; AmerisourceBergen; Does 1 Through 100, Inclusive	2/5/2018	2018
Huron County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00891-GCS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/12/2017	2017
Iberia Parish School Board v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00960-BAJ-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
Iberia Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00940-BAJ-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/23/2018	2018

Iberville Parish Council, a Louisiana governmental entity v. Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware), Limited Partnership	M.D. La./3:19-cv-00121 (removed from 18th Jud. Dist. Ct. for Parish of Iberville (LA)78598)	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware), Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Hanssen; Endo; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Anda; John Kapoor; Michael Babich; Alec Berlakoff; Joseph Rowan	1/16/2019	2019
IBEW Local 38 Health and Welfare Fund v. Purdue Pharma L.P., et al.	N.D. Ohio/1:17-cv-02171-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen	10/13/2017	2017
IBEW Local 90 Benefits Plan v. Purdue Pharma L.P., et al.	CT/3:17-cv-02095-JCH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Qualitest; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Abbott; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/18/2017	2017
I-Kare Treatment Center, LLC v. Purdue Pharma L.P., et al.	E.D. Pa./2:19-cv-03899-ER	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	Rhodes; Endo; Par; Janssen; TEVA; Cephalon; Allergan; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; John N. Kapoor; Anda; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; American Pain Foundation; The American Academy of Integrative Pain Management; CVS; Walgreens; Rite Aid	8/28/2019	2019

Illinois Public Risk Fund v. Purdue Pharma L.P., et al.	N.D. Ill./1:19-cv-03210	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; American Academy of Pain Medicine; American Geriatric Society; American Pain Society; Cardinal; AmerisourceBergen; McKesson; Paul Madison; Joseph Giacchino	5/10/2019	2019
Indian Health Council, Inc. v. Purdue Pharma L.P., et al.	S.D. Cal./3:18-cv-02626- WQH-JLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Abbott; Amneal; KVK; Cardinal; AmerisourceBergen; Anda; McKesson; Henry Shein	11/15/2018	2018
Indiana County, PA v. Purdue Pharma L.P., et al.	W.D. Pa./2:18-cv-00211- NBF	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Mallinckrodt; Watson; McKesson; Cardinal; AmerisourceBergen; Noramco; Value Drug; SpecGx; Par; Amneal; KVK; CVS; Rite Aid; Walmart	2/20/2018; 3/6/2019	2018
Intergovernmental Risk Management Agency and Intergovernmental Personnel Benefit Cooperative v. McKesson Corp., et al.	N.D. Ill./1:18-cv-06959 (removed from Cook Cnty. (Ill.)/2018-CH- 12828)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Paul Madison; William McMahon; Joseph Giacchino; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	10/15/2018	2018

International Union of Operating Engineers, Local 150; Midwest Operating Engineers Health and Welfare Fund; Chicago Regional Council of Carpenter; and Chicago Regional Council of Carpenters Welfare Fund v. Purdue Pharma L.P., et al.	N.D. Ill./1:19-cv-00811 (removed from State Court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Endo; Janssen; Johnson & Johnson; Insys; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Paul Madison; William McMahon; Joseph Giacchino; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	2/7/2019	2019
International Union of Painters and Allied Trades 1974 v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-05257	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; Anda; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	9/13/2019	2019
Iowa County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01539-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017

Iredell County v. Purdue Pharma L.P., et al.	W.D.N.C./5:18-cv-00090-MOC-DLH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; RiteAid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	6/4/2018	2018
Irwin County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./7:18-cv-00041-HL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/9/2018	2018
Isabelle Nadine Hublot (deceased) by and through her father, Chaude Hublot, Joshua Holley (deceased) by and through his mother, Wendy Hoover, Gretchen M. Scott, James Matthew Davis, Jr, Miranda Strickland, Melissa Bond, Brian L. Williams, Sr, Henry William Ford, Amanda Lynne Cox, Amy Michele Tackett, Chad Julius Contranchis (deceased) by and through his mother, Brenda Contranchis, Jason McCrocklin, Jennifer Elizabeth Howard Price, Kimberly Ann Vandevander-Morgan, Brandon Wade Freeman, by and through his mother and power of attorney, Darla Storey,	N.D. Ohio/1:19-op-45767	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	8/30/2019	2019

Island County v. Purdue Pharma L.P., et al.	W.D. Wa./2:18-cv-01127	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Amnea; Hikma; Impax; Mylan; Par; Rite Aid; Walmart; West-Ward; Thrifty; KVK	8/1/2018; 3/13/2019	2018
Itasca County, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:18-cv-02084 (removed from 9th Jud. Dist., Itasca Cnrt. (Minn.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt	7/9/2018	2018
Itawamba County, Miss. v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:18-cv-00055-SA-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/26/2018	2018
Ivy Woods, Sheriff of Jefferson Davis Parish v. Purdue Pharma L.P., et al.	W.D. LA/2:18-cv-00002 (removed from 31st Judicial District Court, Parish of Jefferson Davis/C-638-17)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal-Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	9/18/2017	2017
J. Paul Jones Hospital v. McKesson Corp., et al.	S.D. Ala./2:18-cv-00029	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	1/24/2018	2018
Jackson County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00680-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/12/2017	2017

Jackson County Health Care Authority v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45134-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; McKesson; Cardinal; AmerisourceBergen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	3/14/2019	2019
Jackson County v. AmerisourceBergen Drug Corp., et al.	N.D. Fla./4:19-cv-00149-RH-CAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/2/2019	2019
Jackson County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01544-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Jackson County, Alabama; City of Bridgeport, Alabama; City of Henagar, Alabama; City of New Hope, Alabama; City of Scottsboro, Alabama; Town of Geraldine, Alabama; Town of Woodville, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45634-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Noramco; Actavis; Mallinckrodt; Insys	6/1/2018	2018
Jackson County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45581-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/15/2018	2018

Jackson County, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./4:18-cv-00054-RLY	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	3/30/2018	2018
Jackson County, Missouri v. Purdue Pharma L.P., et al.	W.D. Mo./4:18-cv-00571-BP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken; Rhodes; West-Ward; Mylan; Sandoz; SuperValu	7/25/2018	2018
Jackson Parish Police Jury v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00973-BAJ-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
Jacquelynn Martinez, individually and as next friend and guardian of Baby J.M., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45484-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/16/2019	2019

Jamie Johnson, individually and as next friend and guardian of Babies K.D. and J.D. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45504-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019
Jamie Gilson, as next friend and guardian of Baby M.M.D. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45461-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/14/2019	2019
Janna Lowry, as Spouse of Decedent, Brian Lowry v. Purdue Pharma Inc., et al.	E.D. Mo./4:19-cv-01223 (removed from Cir. Ct. St. Louis City (MO)/18SL-CC00300)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mylan Bertek Pharmaceuticals, Inc.; KVK; West-Ward; Par; Advanced Pain Specialists; Comprehensive Pain Specialists; Dr. Christopher Creighton	1/17/2018	2018
Jason Reynolds, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	D. Or./3:18-cv-01911-MO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	11/1/2018	2018
Jasper County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45504-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/23/2018	2018

Jay Brodsky v. Purdue Pharma L.P., et al.	E.D.N.Y./2:18-cv-02788-JS-AYS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Depomed; Janssen; Endo; Allergan; Actavis	5/7/2018	2018
Jay Russell, Sheriff of Ouachita Parish v. Purdue Pharma L.P., et al.	W.D. LA/3:18-cv-00094 (removed from 4th Judicial District Court, Parish of Oachita (LA)/C-20173279)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal-Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	10/5/2017	2017
Jean Lafitte Town v. Purdue Pharma L.P., et al.	E.D. La./2:19-cv-00374-JCZ-JVM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen	1/17/2019	2019
Jeff Davis County, GA v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./2:18-cv-00014-LGW-RSB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	2/15/2018	2018
Jefferson County Commission v. Purdue Pharmaceutical Products L.P., et al.	N.D. WV/3:17-cv-00144-GMG	Purdue Pharmaceutical Products LP; Purdue Pharma L.P.; The Purdue Frederick Company Inc.	Actavis; Allergan; Cephalon; Janssen; Johnson & Johnson; TEVA; Mallinckrodt; AmerisourceBergen; Cardinal; CVS Indiana; Endo; H.D. Smith Wholesale Drug Co.; McKesson; Rite Aid of MD, Inc.; Wal-Mart; Walgreen; Anda; Amneal; Indivior; J.M. Smith; Masters; Mylan; Par; Rite Aid; Harvard; Walmart; Weis Markets; American Sales; Bellco; Top Rx; Giant Food	11/21/2017; 5/25/2018; 3/15/2019	2017

Jefferson County v. Purdue Pharma L.P., et al.	W.D. Wa./3:18-cv-05661	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	8/14/2018	2018
Jefferson County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01546-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Jefferson County, AL; Mike Hale, in his capacity as Sherriff of Jefferson County, Alabama; City of Pleasant Grove, AL; City of Hueytown, AL; and City of Mountain Brook, AL v. Purdue Pharma L.P., et al.	N.D. Ala./2:18-cv-00626-UJB-VEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Mallinckrodt; Insys; McKesson; Cardinal; AmerisouceBergen; Steven Hefter; Ernest Clayborn; Perry Fine; Scott Fishman; Lynn Webster	3/15/2018	2018
Jefferson County, Mississippi v. AmerisourceBergen Drug Corp., et al	S.D. Miss./5:18-cv-00067-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/25/2018	2018
Jefferson Davis County, Miss. V. AmerisourceBergen Drug Corp., et al.	S.D. Miss./2:17-cv-00200-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/13/2017	2017

Jefferson Davis Parish Police Jury v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00879- SDD-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/2/2018	2018
Jenni Goldman, individually and as next friend and guardian of Babies J.K.W. and M.J.R. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45516-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Jennifer Artz, individually and as next friend and guardian of Baby I.A.A., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45459-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019
Jennifer Thomas, individually and as next friend and guardian of Baby A.S. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45542-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019

Jennings County v. Purdue Pharma L.P., et al.	S.D. Ind./4:18-cv-00006-RLY-TAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	1/8/2018	2018
Jenny Scully, individually and as next friend and guardian of Baby I.S. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45544-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Jerry Philley, sherriff of West Carroll Parish v. Purdue Pharma L.P., et al.	W.D. La./3:18-cv-00264 (removed from 5th Judicial Court for the Parish of West Carroll/31178-C)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal-Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	1/9/2018	2018
Jessica Collier, individually and as next friend and guardian of Baby A.P. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45506-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019

<p>Jessica Hampel, individually and as next friend and guardian of Baby A.M.H., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.</p>	<p>N.D. Ohio/1:19-op- 45473-DAP</p>	<p>Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.</p>	<p>McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes</p>	<p>6/14/2019</p>	<p>2019</p>
<p>Jessica Perkins, individually and as next friend and guardian of Babies P.A. and R.A. v. Purdue Pharma L.P., et al.</p>	<p>N.D. Ohio/1:19-op- 45535-DAP</p>	<p>Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.</p>	<p>McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes</p>	<p>6/20/2019</p>	<p>2019</p>
<p>Jessica Rodriguez, individually and as next friend and guardian of Baby M.A.P., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.</p>	<p>N.D. Ohio/1:19-op- 45463-DAP</p>	<p>Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.</p>	<p>McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes</p>	<p>6/14/2019</p>	<p>2019</p>

Jessica Taylor, individually and as next friend and guardian of Baby D.S. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45528-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Jodi Shaffer, individually and as next friend and guardian of minor R.C., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	S.D. WV/2:18-cv-01448	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; Allergan; R.C. Son; Noramco	11/15/2018	2018
Joel Bishop, Dean Colman, and Pete Lavite v. Purdue Pharma L.P., et al.	S.D. Ill./3:19-cv-00442-NJR-GCS (removed from Madison Cnty. (Ill.)/2019L000444)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; TEVA; Cephalon; Endo; Janssen; Johnson & Johnson; Noramco; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens	3/27/2019	2019
John Craft (Vernon Parish) v. Purdue Pharma L.P., et al.	W.D. LA/2:18-cv-00053 (removed from 30th Judicial District Court, Parish of Vernon/95086)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal-Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	10/5/2017	2017
John Doe, by and through Jane Does, his parent and natural guardian, on behalf of himself and all others similarly situated v. Purdue Pharma L.P., et al.	E.D. Pa./2:18-cv-03637-MMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Mallinckrodt; Watson; McKesson; Cardinal; AmerisourceBergen; Noramco	8/24/2018	2018

John E. Ballance, in his capacity as the Sheriff for Bienville Parish v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45925-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; AmerisourceBergen; McKesson; Cardinal	8/6/2018	2018
John G. Carter, in his Official Capacity as the Sheriff of Wayne County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45170-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019
John Pohlmann, Sheriff of St. Bernard Parish, Louisiana in his capacity as officer ex officio of the St. Bernard Parish Sheriff's Office and the St. Bernard Parish Law Enforcement District v. Purdue Pharma L.P., et al.	E.D. La./2:18-cv-09557-SSV-MBN (removed 24th Judicial District Court, Parish of St. Bernard (LA)/18-1218)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Morris & Dickson Co.	8/31/2018	2018
Johnson County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45716-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	6/13/2018	2018
Johnson County, Kansas v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45443-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/13/2019	2019

Johnson County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45363-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/5/2019	2019
Johnson County, TN v. AmerisourceBergen Drug Corp., et al.	E.D. Tenn./2:18-cv- 00003	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; JM Smith; Harco; Par; SpecGx; Amneal; Rite Aid	1/4/2018; 3/8/2019	2018
Jones County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./4:19-cv-00029- D	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	1/16/2019	2019
Jones County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45424-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/13/2018	2018
Jordan Chu v. Purdue Pharma L.P., et al.	N.D. Cal./3:18-cv-02576	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	5/2/2018	2018
Jorge A. Martinez v. Purdue Pharma Inc., et al.	N.D. Ohio/1:19-op- 45353-DAP	Pudue Pharma Inc.; Purdue Pharma L.P.	Michael Friedman; Dr. Paul Goldenheim; Ronald F. McBride; Kevin Crane; Jim Harper; Jeffrey Carren; Dr. David J. Haddox	5/24/2019	2019
Joseph P. Lopinto, III, in his capacity as Sherriff on behalf of the Jefferson Parish Sherriff's Office	E.D. La./2:18-cv-10021- JTM-KWR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/25/2018	2018

Kalamazoo County, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:19-cv- 00439	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Par; Mallinckrodt; SpecGx; Allergan; Insys; AmerisourceBergen; Cardinal; McKesson; Walgreen; Walmart; Kroger; Rite Aid; CVS McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/7/2019	2019
Katherine Whittington, individually and as next friend and guardian of Babies S.W. and A.W. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45541-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Kaufman County v. Purdue Pharma L.P., et al.	N.D. Texas/3:18-cv- 02270-M	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal- Mart; Kroger	8/27/2018; 3/16/2019	2018
Kayla Shockley, individually and as next friend and guardian of Baby M.G.L. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45527-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019

Kenaitze Indian Tribe; Asa' Carsamiut Tribe; Akiak Native Community; Native Village of Port Heiden; and Native Village of Afognak, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	D. Alaska/3:18-cv-00273-HRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; Walgreen; Kroger; Albertsons; Walmart; CVS	11/16/2018	2018
Kennebec County, State of Maine v. Purdue Pharma L.P., et al.	D. Me./1:19-cv-00096 (removed from Super. Ct. Kennebec Cnty. (Me.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.	1/18/2019	2019
Kenosha County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01659-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Kentucky League of Cities Insurance Services v. Purdue Pharma L.P., et al.	E.D. Ky./5:18-cv-00471-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Walgreens Boots Alliance	7/26/2018	2018

Kentucky River District Health Department, on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45050-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Anda; Amneal; Cardinal; Cephalon; Depomed; Endo; H.D. Smith; Hikma; Indivior; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Mylan; Noramco; Omnicare; Par; Quest; Richie; Sandoz; SpecGx; TEVA; Watson; Associated Pharm.; Auburn; CVS; Forest; Harvard Drug; Keysource; Kroher; Miami-Luken; Morris Dickson; Pfizer; Rhodes; River City; SAJ; Smith Drug; Schwarz Pharma; Walgreens; Walmart; West-Ward	2/6/2019; 3/15/2019	2019
Kevin Schwartz and Stephanie Schwartz v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46354-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Endo	12/20/2018	2018
Kevin Wilk, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	E.D.N.C./5:18-cv-00517-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Insys; Allergan; Watson; Actavis; AmerisourceBergen McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	10/30/2018	2018
Kiana Hutchins, individually and as next friend and guardian of Baby T.E. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45505-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.		6/17/2019	2019

Kickapoo Tribe in Kansas v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45381-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith; Kroger	6/6/2019	2019
Kids First of Florida, Inc. v. McKesson Corp., et al.	N.D. Ohio/1:18-op- 46101-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	9/26/2018	2018
Kimberly Brand, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	W.D. Mo./4:18-cv-00653	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	8/21/2018	2018
Kimberly Martin, individually and as next friend and guardian of Baby A.M. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45510-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019
King County v. Purdue Pharma L.P., et al.	W.D. Wa./2:18-cv-00025 (removed from Super. Ct. King Cnty./18-cv- 00570-1 SEA)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; Cephalon; Hikma; Mylan; Par; TEVA; Walgreens; West- Ward	1/5/2018; 5/25/2018; 3/15/2019	2018

Kingston Borough, Pennsylvania v. Purdue Pharma L.P., et al.	M.D. Pa./3:19-cv-00998- RDM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; CVS; Rite Aid; Walgreens; Wal-Mart; Value Drug Co; Generics Bidco	6/11/2019	2019
Kinloch Fire Protection District of St. Louis County, Missouri v. Purdue Pharma L.P., et al.	E.D. Mo./4:19-cv-01700- PLC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	6/14/2019	2019
Kitsap County v. Purdue Pharma L.P., et al.	W.D. Wa./4:18-cv-05116	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Hikma; Mylan; Par; Rite Aid; Walgreens; Walmart; West-Ward; Thrifty	7/23/2018; 3/13/2019	2018
Kittitas County v. Purdue Pharma L.P., et al.	E.D. Wa./1:18-cv-03151	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Amnea; Hikma; Mylan; Par; Rite Aid; Thrifty; KVK; Anda; Smith Drug	8/9/2018; 3/14/2019	2018
Kjellsi Meinecke, individually and as next friend and guardian of Baby J.B., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45493-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019

Knox County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:18-cv-00466-MHW-CMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/11/2018	2018
Knox County, State of Maine, individually, and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	D. Me./2:19-cv-00371-DBH (removed from Super. Ct. Knox Cnty. (Me.)/CV-19-14)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Douglas J. Jorgensen; Mark E. Cieniawski; Michael B. Bruehl	5/13/2019	2019
Kodiak Area Native Association v. Purdue Pharma L.P., et al.	D. Alaska/3:18-cv-00243-JWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Janssen; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Abbott; Amneal; KVK; Cardinal; AmerisourceBergen; Anda; McKesson; Henry Shein	10/15/2018	2018
Kootenai Tribe of Idaho v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46153-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	10/16/2018	2018
Kris Koechley, Administrator of the Estate of James P. Koechley, Deceased v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46165 (removed from C.P. Lucas County (OH)/G-4801-CI-0201803741-000)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Deca; Comprehensive Centers for Pain Mgmt; Toledo Pain Services	9/17/2018	2018

Krista Gauthier, Angela Sawyers, and Jessica Springborn, individually and as next friends and guardians of Babies D.L.D., M.A.S., and N.S., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45478-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/15/2019	2019
Krystle Kirk, individually and as next friend and guardian of Baby B.K. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45509-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019
La Posta Band of Diegueno Mission Indians of the La Posta Indian Reservation v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45397-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith; Kroger; Rite Aid	6/6/2019	2019
Laborers 17 Health Benefit Fund v. Purdue Pharma L.P., et al.	S.D.N.Y./1:17-cv-09877	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Qualitest; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Abbott; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/18/2017	2017

Laborers Local 1298 of Nassau & Suffolk Counties Welfare Fund v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-04976	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; Anda; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	8/30/2019	2019
Laborers Local 235 Welfare Fund v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-04915-NGG-JO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; Anda; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	8/28/2019	2019
Lac Courte Oreilles Band of Lake Superior Chippewa Indians vs. McKesson Corporation, et al.	W.D. WI./3:18-cv-00286-jdp (removed from Cir. Ct. Sawyer Cnty. (WI))/2018CV000040)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	3/16/2018	2018
Lac du Flambeau Band of Chippewa Indians v. McKesson Corp., et al.	W.D. WI./3:18-cv-00228	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; John Does 1-100	3/30/2018	2018
Lac Vieux Desert Band of Lake Superior Chippewa Indians v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46239-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	11/14/2018	2018

Lafayette County, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./3:19-cv-00095-MPM-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	5/6/2019	2019
Lafayette General Health System, Inc. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46082-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Anda; CVS; Rite Aid; Walgreens; Walmart; Amneal; Indivior; Mylan; Hikma; Louisiana Wholesale Drug Co.; Morris & Dickson; K&B Louisiana Corp.; CVS; Walgreens; Alberstons; Rhodes	9/21/2018	2018
Lake County v. Purdue Pharma L.P., et al.	N.D. Ind./2:18-cv-00024	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	1/19/2018	2018
Lake County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./5:19-cv-00294-JSM-PRL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/13/2019	2019
Lakeview Center, Inc. v. McKesson Corporation, et al.	N.D. Fla./3:18-cv-00867-MCR-CJK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/20/2018	2018

Lamar County, Alabama; City of Vernon, Alabama and Hal Allred, Sheriff of Lamar County, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./7:18-cv-00199-LSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	2/5/2018	2018
LaMoure County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00171-PDW-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS	8/13/2019	2019
Langlade County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01550-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Lanier County, Georgia v. Purdue Pharma L.P., et al.	M.D. Ga./7:18-cv-00135-HL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	8/24/2018	2018
LaPorte County v. Purdue Pharma L.P., et al.	N.D. Ind./3:18-cv-00169	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	3/7/2018	2018

Larry H. Dean, in his Official Capacity as the Sheriff of Laurens County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45163-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019
Lasalle Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00880-SDD-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/2/2018	2018
Lauderdale County, TN v. AmerisourceBergen Drug Corp., et al.	W.D. Tenn./2:18-cv-02806-SHL-dkv	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; H.D. Smith; Par; SpecGx; Amneal; Walmart	11/19/2018; 3/8/2019	2018
Laurens County, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./3:18-cv-00052-DHB-BKE	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Noramco ; Insys; CVS; Kroger; Rite Aid; Walgreens; Wal-Mart; J.M. Smith	7/10/2018	2018
Lawrence County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00770-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/11/2017	2017
Lawrence County v. Purdue Pharma L.P., et al.	S.D. Ind./4:18-cv-00187-RLY-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	10/8/2018	2018

Lawrence County, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./5:18-cv-00243-HNJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/12/2018	2018
Lawrence County, Miss. V. AmerisourceBergen Drug Corp., et al.	S.D. Miss./2:17-cv-00199-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/13/2017	2017
Lee County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:19-cv-00384	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	4/8/2019	2019
Lee County v. Purdue Pharma L.P., et al.	W.D. Va./2:18-cv-00049-EKD (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	10/22/2018	2018
Lee County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./2:19-cv-00471-UA-MRM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Qualitest; Knoll; Allergan; Watson; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; Walgreens; Wal-Mart; CVS; Rite Aid; Kroger	7/9/2019	2019

Lee County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./1:18-cv-00187-LJA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Rite Aid; Walgreens; JM Smith	9/27/2018	2018
Lee County, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:19-cv-00045-SA-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	3/1/2019	2019
Leflore County, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./4:19-cv-00086-DMB-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/3/2019	2019
Lenoir County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./4:18-cv-00134-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	7/30/2018	2018
Leon County, Florida v. AmerisourceBergen Drug Corp., et al.	N.D. Fla./4:18-cv-00485-MW-MJF	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	10/25/2018	2018
Levy County v. Purdue Pharma L.P., et al.	N.D. Fla./1:18-cv-00100 (removed from Cir. Ct. Levy Cnty. (Fla.)/2018CA000283)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Actavis; Endo; McKesson; Cardinal; AmerisourceBergen; Anda; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; Walmart; Walgreens; Health Mart; SpecGx; Par; West-Ward; Amneal; Rhodes; Noramco; Miami-Luken; Rite Aid; Mallinckrodt	4/9/2018	2018

Lewis County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46263-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal- Mart; Anda; SpecGX; West-Ward	11/20/2018; 3/14/2019	2018
Lewis County, Washington v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46301-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; PSS World; CVS; Walgreens; Walmart; Rite Aid; Miami-Luken; SpecGx; Par; West-Ward; Hikma; Mylan; John N. Kapoor; Noramco; Anda	12/9/2018; 3/15/2019	2018
Lewis S. Walker, in his Official Capacity as the Sheriff of Crawford County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45146-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019
Lexington, TN v. AmerisourceBergen Drug Corp., et al.	W.D. Tenn./2:18-cv- 02220-GDB-EGB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; SAJ; SpecGx; Par; Amneal; KVK; Walgreens; Walmart	4/3/2018; 3/8/2019	2018
Lexington-Fayette Urban County Government v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:17-cv-00442- GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis, Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	11/9/2017	2017

Liberty County , Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45200-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/27/2019	2019
Licking County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00904- ALM-KAJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/18/2017	2017
Limestone County, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./5:18-cv-00396- HNJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/14/2018	2018
Lincoln County v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./5:18-cv-00085	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/23/2018	2018
Lincoln County v. Purdue Pharma L.P., et al.	D. Me./2:19-cv-00021- NT (removed from Super. Ct. Lincoln Cnty. (Me.)/CV-2018-43)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal- Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	11/21/2018	2018

Lincoln County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01555-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Lincoln County, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./1:18-cv-0069-JRH-BKE	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/11/2018	2018
Lincoln County, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./5:18-cv-00057-DCB-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	5/23/2018	2018
Livingston County, Missouri v. AmerisourceBergen Drug Corp., et al.	W.D. Mo./5:18-cv-06146-FJG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	10/3/2018	2018
Local 22 Health Benefit Fund v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-04964	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; Anda; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	8/30/2019	2019

Local 8A-28A Welfare Fund v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-04961-DLI-RER	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; And; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	8/29/2019	2019
Local Initiative Health Authority for Los Angeles County, <i>a California local public agency operating as L.A. Care Health Plan</i> v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45212-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Qualitest; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisouceBergen; CVS; Walgreens; Rite Aid; Health Mart; H.D. Smith	3/29/2019	2019
Logan County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-01097-ALM-CMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/15/2017	2017
Long County , Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45196-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/27/2019	2019
Loretto Hospital of Chicago v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45455-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; McKesson; Cardinal; TEVA; Cephalon; And; H.D. Smith; Henry Schein; Depomed; Johnson & Johnson; Janssen; Noramco; Mallinckrodt; SpecGx; Endo; Insys; Allergan; Watson; Actavis; Miami-Luken	6/13/2019	2019

Lori Taylor, individually and as next friend and guardian of Baby M.T. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45529-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Lou Sardella, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	D.N.J./3:18-cv-08706-MAS-DEA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	5/2/2018	2018
Loudoun County, Virginia v. Purdue Pharma L.P., et al.	E.D. Va./1:19-cv-00778	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
Louis M. Ackal, duly elected Sheriff of Iberia Parish, Louisiana, in his capacity as Ex Officio of the Iberia Parish Sheriff's Office and the Iberia Parish Law Enforcement District v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46052-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Anda; CVS; Rite Aid; Walgreens; Walmart	9/10/2018	2018

Louisa County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./3:19-cv-00027	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
Louisiana Assessors' Insurance Fund a/k/a The Insurance Committee of the Assessors' Insurance Fund v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00950- JWD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/25/2018	2018
Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana, and HMO Louisiana Inc. v. Purdue Pharma L.P., et al.	M.D. LA/3:17-cv-01766- JWD-RLB (removed from 19th Judicial District Court, Parish of East Baton Rouge)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; and Frederick Floyd	11/7/2017	2017
Louisville/Jefferson County Government v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./3:17-cv-00508- TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	8/21/2017; 10/5/2017 (Am.)	2017
Lovelace Health Systems, Inc. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45458-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Noramco; H.D. Smith; Anda; Miami-Luken; SpecGx	6/14/2019	2019

Lower Brule Sioux Tribe v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op-45350-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Par; SpecGx; Insys; CVS; Walmart; Wagreens	5/28/2019	2019
Lower Sioux Indian Community in the State of Minnesota v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45976-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Actavis; Allergan; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	8/16/2018	2018
Lowndes County, Alabama v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./2:18-cv-00070-MHT-WC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
Lowndes County, Georgia v. Purdue Pharma L.P., et al.	M.D. Ga./7:18-cv-00090-HL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Noramco	6/15/2018	2018
Lumpkin County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45211-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/28/2019	2019
Luzerne County, PA v. Purdue Pharma L.P., et al.	M.D. Pa./3:17-cv-02043	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Mallinckrodt; Watson; McKesson; Cardinal; AmerisourceBergen; Anda; Eckerd; Value Drug; SpecGx; Par; Amneal; Rite Aid; CVS; Walmart; Walgreens	11/8/2017; 3/13/2019	2017

Lytton Band of Pomo Indians v. AmerisourceBergen Drug Corp., et al.	N.D. Cal./3:19-cv-03224	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Mallinckrodt; SpecGx; Insys; Walmart; Walgreen	6/7/2019	2019
Macon County, Georgia v. Purdue Pharma L.P.	N.D. Ohio/1:18-op-45577-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	5/15/2018	2018
Madison County v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-46067-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	8/23/2018	2018
Madison County, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./5:18-cv-02024-HNJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson; CVS; Kroger; Walgreens; Wal-Mart	12/10/2018	2018
Madison County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./3:18-cv-00031-CDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/9/2018	2018
Madison County, TN v. AmerisourceBergen Drug Corp., et al.	W.D. Tenn./1:18-cv-01047	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; SAJ; Morris & Dickson; JM Smith; SpecGx; Par; Kroger; Walmart; CVS; Walgreens	3/21/2018; 3/8/2019	2018

Madison County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./3:19-cv-00028	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
Manatee County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./8:19-cv-00143- VMC-AEP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Publix; Walgreen	1/18/2019	2019
Manitowoc County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01660- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017

Marathon County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01536-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Marengo County, Alabama v. AmerisourceBergen Drug Corp., et al.	S.D. Ala./2:18-cv-00043-C	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
Maria Ortiz, individually and as next friend and guardian of Baby A.O., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45492-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019
Maries County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46194-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-Mart	10/26/2018	2018

Marijha Hamawi, individually and as next friend and guardian of Babies K.L.H. and N.A.W., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45477-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/15/2019	2019
Marinette County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01661- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Marion County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45529-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/3/2018	2018
Marion County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./5:19-cv-00165- JSM-PRL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Publix; Walgreen	4/3/2019	2019

Marion County, Miss. V. AmerisourceBergen Drug Corp., et al.	S.D. Miss./2:17-cv-00202-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/14/2017	2017
Marion County; Pickens County; Walker County; City of Dora; City of Jasper; City of Sumiton v. Purdue Pharma L.P., et al.	N.D. Ala./6:18-cv-00143-LSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Actavis; McKesson; Cardinal; AmerisourceBergen; Insys	1/29/2018	2018
Mark Garber, Sheriff of Lafayette Parish v. Purdue Pharma L.P., et al.	W.D. LA/6:17-cv-01583 (removed from 15th Judicial District Court, Parish of Lafayette/20175337L)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal-Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	9/18/2017	2017
Mark Melton in his offical capacity as the Sherriff of Appling County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45307-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	5/8/2019	2019
Mark Tilley, as next friend of K.B. Tilley, a minor child under the age of 18 v. Purdue Pharma L.P., et al.	S.D. WV/2:19-cv-00566	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	McKesson; AmerisourceBergen; Endo; Par; Mallinckrodt; SpecGx; Actavis; Rhodes	8/2/2019	2019
Marketing Services of Indiana, Inc., individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	S.D. Ind./1:18-cv-02778-RLY-TAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; AmerisourceBergen; Janssen; Endo; Actavis; Watson; McKesson; Cardinal	9/10/2018	2018

Marlin N. Gusman, Sheriff of Orleans Parish v. Purdue Pharma L.P., et al.	E.D. La./2:18-cv-04828- KDE-DEK (removed from Parish of Orleans (LA)/2018-01918)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; Frederick Floyd; CVS; Walgreens; Wal-Mart	3/28/2018; 4/9/2018	2018
Marquette County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01662- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Marshall County, AL; City of Albertville, AL; Arab, AL; City of Boaz, AL; City of Guntersville, AL; City of Douglas, AL; and Town of Grant, AL v. Purdue Pharma L.P., et al.	N.D. Ala./4:18-cv-00226- VEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Actavis; McKesson; Cardinal; AmerisourceBergen; Insys	2/8/2018	2018
Marshall County, Miss. v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./3:18-cv- 00075-SA-RP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/26/2018	2018
Martin County, NC v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./4:18-cv-00071- FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/16/2018	2018

Mashantucket (Western) Pequot Tribe v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45405-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger; H.D. Smith	6/7/2019	2019
Masmoud Bamdad, M.D., o.b.o. State of CA v. Purdue Pharma L.P., et al.	C.D. Cal./2:18-cv-03662 (removed from Los Angeles County (Central Div.) Super Ct. (CA)/BC695309)	Purdue Pharma L.P.; Purdue Products L.P.	Named Defendants: Purdue Pharma L.P.; Purdue Pharma Products, L.P.; Craig Landau; Paul Medeiros; Marv Kelly	2/26/2018	2018
Maverick County, Texas v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45426-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
Maxwell A. Newman and Caroline S. Newman v. Purdue Pharma L.P., et al.	E.D. La./2:19-cv-01594-MVL-JVM (removed from Civil Dist. Ct. for Parish of Orleans (LA)/2018-8229)	Purdue Pharma L.P.	B&B Drugs; All for Jen; Jefferson Family Pharmacy; Dua Tran	8/17/2018	2018
Mayor Charles Sparks, on behalf of the Town of Kermit v. Purdue Pharma L.P., et al.	N.D. Ohio/1:17-op-45058-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; TEVA; Watson; H.D. Smith; Miami-Luken; WV Board of Pharmacy	N/A	2017
Mayor David Adkins, o.b.o. The Town of Hamlin v. Purdue Pharma L.P., et al.	S.D. WV/2:18-cv-00477 (removed from Cir. Ct. Lincoln Cnty. (WV)/18-C-9)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Miami-Luken; Rite Aid; WV Board of Pharmacy; Chip RX; George W. Chapman III; Rhodes; Walmart	1/31/2018; 3/15/2019	2018

Mayor Farris Burton, o.b.o. The Town of West Hamlin v. Purdue Pharma L.P., et al.	S.D. WV/2:18-cv-00478 (removed from Cir. Ct. Lincoln Cnty. (WV)/18-C- 8)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Miami-Luken; Rite Aid; WV Board of Pharmacy; Chip RX; George W. Chapman III; Rhodes; Walmart	1/13/2018; 3/15/2019	2018
Mayor Raimee Barker, on behalf of the The Town of Chapmanville v. Purdue Pharma L.P., et al.	N.D. Ohio/1:17-op- 45055-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; TEVA; Watson; H.D. Smith; Miami-Luken; WV Board of Pharmacy	N/A	2017
Mayor Reba Jonaker, on behalf of the The City of Welch v. Purdue Pharma L.P., et al.	N.D. Ohio/1:17-op- 45065	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; TEVA; Watson; H.D. Smith; Miami-Luken; WV Board of Pharmacy	N/A	2017
Mayor Robert Carlton, on behalf of the The City of Williamson v. Purdue Pharma L.P., et al.	N.D. Ohio/1:17-op- 45057-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; TEVA; Watson; H.D. Smith; Miami-Luken; WV Board of Pharmacy	N/A	2017
Mayor Vivian Livinggood, on behalf of the The Town of Gilbert v. Purdue Pharma L.P., et al.	N.D. Ohio/1:17-op- 45059-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; TEVA; Watson; H.D. Smith; Miami-Luken; WV Board of Pharmacy	N/A	2017
McDowell County, NC v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./1:18-cv-00100	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/17/2018	2018

McDuffie County, Georgia v. Purdue Pharma L.P., et al.	S.D. Ga./1:18-cv-00070-JRH-BKE	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/11/2018	2018
McIntosh County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45173-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/25/2019	2019
McKenzie County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00119-DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
McLean County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00116-DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
McLeod County v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01202	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; McKesson; AmerisourceBergen; Walgreens	5/3/2019	2019

Mechelle Gauthier, individually and as next friend and guardian of Baby B.L. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45514-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Mechoopda Indian Tribe of Chico Rancheria v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45403-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger; H.D. Smith	6/7/2019	2019
Mecklenburg County v. Purdue Pharma L.P., et al.	W.D.N.C./3:18-cv-00071- FDW-DSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Endo; McKesson; Cardinal; AmerisourceBergen	2/8/2018	2018
Medical Mutual of Ohio v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00716	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Actavis; Allergan; AmerisourceBergen; CVS; Cardinal; Cephalon; Endo; Johnson & Johnson; Mallinckrodt; McKesson; Rite Aid; TEVA; Walgreens; Watson	3/28/2018	2018
Meeker County v. Purdue Pharma L.P., et al.	D .Minn./0:19-cv-01211	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; McKesson; AmerisourceBergen; Walgreens	5/6/2019	2019
Meigs County, Ohio v. Cardinal Health Inc., et al.	S.D. Ohio/2:18-cv-01582 (removed from C.P. Meigs County (OH)/18CV083)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cardinal; Kroger; Miami- Luken; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mylan; Rite Aid; Walgreen; McKesson; AmerisourceBergen; CVS; Wal-Mart	11/8/2018	2018

Melanie Massey, individually and as next friend and guardian of Babies S.L.M. and K.D.R. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45525-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019
Melba Alexander, individually and as next friend and guardian of Baby B.H.R. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45502-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019
Melissa Ambrosio, individually and as next friend of Baby G.A., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	C.D. Cal./2:18-cv-02201	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis	3/16/2018	2018
Mennonite General Hospital, Inc.; Hospital Menonita Caguas, Inc.; Hospital Menonita Gauyama, Inc. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45109-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; Insys; Cardinal; McKesson; AmerisourceBergen; Par; SpecGx; Amneal; KVK; Sun; Sandoz; Unither; Mylan; Hospira; Ethex; Kremers; West-Ward; Anda; Drogueria Betances; JM Blanco; FMC Dist; Walgreen; Jose Ferrari, Inc.; Cesar Castillo, Inc.; Axiscare; Luis Garraton, LLC	3/4/2019; 3/15/2019	2019

Mental Health & Recovery Services Board of Allen, Auglaize and Hardin Counties v. Purdue Pharma L.P. et al	N.D. Ohio/1:18-op-46344-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; SpecGx; H.D. Smith; Anda; Discount Drug Mart; Prescription Supply; CVS; HBC; Rite Aid; Walgreens; Walmart; Mylan; Kroger; Amenal; West-Ward	12/19/2018	2018
Mercer County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-46094-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	9/24/2018	2018
Mercer County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00122-DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
Mercy House Teen Challenge, a non-for-profit Corporation on behalf of itself and all others similarly situated v. Purdue Pharma L.P., et al.	S.D. Miss./3:18-cv-00584-HTW-LRA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	8/23/2018	2018
Meriwether County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45305-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	5/7/2019	2019

Mescalero Apache Tribe v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45317-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Insys; Malinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Kroger; Rite Aid; H.D. Smith; Health Mart	5/10/2019	2019
MetroHealth System v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46004-DAP	Purdue Pharma L.P., d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; Insys; John Kapoor	8/28/2018	2018
Metropolitan Government of Nashville and Davidson County, Tennessee v. Purdue Pharma L.P., et al.	M.D. Tenn./3:17-cv-01605	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; AmerisourceBergen; McKesson; Cardinal; Par; SpecGx; Walgreens; West-Ward; Kroger; JM Smith; Rhodes	12/22/2017; 3/18/2019	2017
Miami-Dade County, Florida v. AmerisourceBergen Drug Corp., et al.	S.D. Fla./1:18-cv-21608	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	4/23/2018	2018
Miccosukee Tribe of Indians of Florida v. AmerisourceBergen Drug Corp., et al.	S.D. Fla./1:19-cv-20618-DPG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Insys; Mallinckrodt; Walgreen; CVS; Actavis	2/15/2019	2019
Michael Espinosa v. Jane Joiner, M.D., et al.	D. Mass./1:18-cv-12196 (removed from Super. Ct. Middlesex Cnty. (Mass.))	Purdue Pharma L.P.; Purdue Pharma Inc.	Jane H. Joinder; Charles River Medical Associates; Endo; Allergan	9/11/2018	2018

Michael Klodzinski individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	S.D.N.Y./1:18-cv-03927	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	5/2/2018	2018
Michael Konig, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	S.D. Fla./0:18-cv-61960-FAM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	8/21/2018	2018
Michael Lopez, <i>individually and on behalf of all others similarly situated v.</i> Purdue Pharma L.P., et al.	D. Ut./2:18-cv-00719-DB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	9/12/2018	2018
Michael Masiowski, M.D., on behalf of himself and all others similarly situated v. AmerisourceBergen Drug Corp., et al.	D.S.C./2:18-cv-02080-MDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	7/26/2018	2018
Michael Ray Lewis, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	W.D. Ark./5:17-cv-05118-TLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Johnson & Johnson; Janssen ; Endo; Watson; Actavis	6/29/2017	2017
Mike Jolley, in his Official Capacity as the Sheriff of Harris County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45147-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019
Mike Kile, in his Official Capacity as the Sheriff of Screven County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45167-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019
Mike Stone, in his capacity as the Sheriff for Lincoln Parish v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45920-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; AmerisourceBergen; McKesson; Cardinal	8/3/2018	2018

Milwaukee County, Wisconsin v. AmerisourceBergen Drug Corp., et al.	E.D. Wi./2:18-cv-00403-JPS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; SpecGx; Par; Amneal; KVK	3/14/2018; 3/13/2019	2018
Minute Men, Inc. and Minute Men Select, Inc. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00688 (removed from C.P. Cuyahoga County (OH)/CV18-893314)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	2/21/2018	2018
Mississippi Band of Choctaw Indians v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45279-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; McKesson; Cardinal; AmerisourceBergen; Walgreens; Walmart; CVS	4/16/2019	2019
Missoula County v. Purdue Pharma L.P., et al.	D. Mt./9:19-cv-00015-DWM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; SpecGx	1/22/2019	2019
Mitchell County v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./1:19-cv-00176	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/5/2019	2019
Moapa Band of Paiute Indians v. Purdue Pharma L.P., et al.	D. Nev./2:19-cv-01059-RFB-CWH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; Insys	6/20/2019	2019
Mobile County Emergency Medical Services Rescue Squad, Inc., a nonprofit corporation v. AmerisourceBergen Drug Corp., et al.	S.D. Ala./1:18-cv-00016	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	1/16/2018	2018

Moniteau County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46352-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-Mart; Andia; McQuery; Amneal	12/21/2018; 3/15/2019	2018
Monmouth County v. Purdue Pharma L.P., et al.	D.N.J./3:18-cv-10901 (removed from Super. Ct. Middlesex Cnty. (N.J.)/MID-L-003010-18)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen; Watson; Actavis; Insys; Mallinckrodt; Abbvie; Abbott	5/15/2018	2018
Monroe County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:18-cv-00433-EAS-KAJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/3/2018	2018
Monroe County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01663-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
Monroe County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./5:18-cv-00167-MTT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/16/2018	2018

Monroe County, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:18-cv- 00183-SA-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	9/27/2018	2018
Montgomery County v. Purdue Pharma L.P., et al.	W.D. Va./7:18-cv-00619- EKD (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	12/6/2018	2018
Montgomery County, AL v. Purdue Pharma L.P., et al.	M.D. Ala./2:18-cv-00381- MHT-CSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	4/2/2018	2018
Montgomery County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45292-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; McKesson; Cardinal; AmerisourceBergen; Rhodes; SpecGx; Mylan; Amneal; Novartis; Sandoz; West-Ward; Hikma; KVK-Tech; JM Smith; CVS; Kroger; Rite Aid; Harco; Walgreens; Walmart	4/25/2019; 6/19/2019	2019
Montgomery County, Kansas v. AmerisourceBergen Drug Corp., et al.	D. Kan./2:18-cv-02311	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	6/11/2018	2018

Montgomery County, Maryland v. Purdue Pharma L.P., et al.	D. Md./8:18-cv-00377-DKC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Insys	2/6/2018	2018
Montgomery County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46197-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-Mart; Amneal	10/29/2018; 3/8/2019	2018
Montgomery County, TN v. AmerisourceBergen Drug Corp., et al.	M.D. Tenn./3:18-cv-00314	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Morris & Dickson; SpecGx; Par; Amneal; Rite Aid; Kroger; Publix; Walmart; Walgreens	3/26/2018; 3/6/2019	2018
Moore County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:18-cv-00703	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	8/14/2018	2018
Morehouse Parish Police Jury v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45452-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Endo; Par; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Mylan; West-Ward; Hikma; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; Smith's Food & Drug; H.D. Smith; CVS; Anda	6/13/2019	2019

Morgan City v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00942- JWD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/24/2018	2018
Morgan County Commission v. Purdue Pharmaceutical Products L.P., et al.	N.D. WV/3:18-cv-00044- GMG	Purdue Pharmaceutical Products LP; Purdue Pharma L.P.; The Purdue Frederick Company Inc.	Actavis; Allergan; Cephalon; Janssen; Johnson & Johnson; TEVA; Mallinckrodt; AmerisourceBergen; Anda; Auburn; Bellco; Cardinal; Healthcare; Endo; Keysource; Masters; McKesson; Parmed; Rite Aid; Toprx; Anda; Indivior; Mylan; Par; Rite Aid; American Medical Distributors; West Ward; Amneal; SpecGx; DIT Healthcare	3/29/2018; 5/25/2018; 3/15/2019	2018
Morgan County v. Purdue Pharma L.P., et al.	S.D. Ind./1:18-cv-01731- WTL-MPB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	6/7/2018	2018
Morgan County, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./5:18-cv-00170- HNJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
Morgan County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45367-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/5/2019	2019

Morgan County, TN v. Purdue Pharma L.P., et al.	E.D. Tenn./3:19-cv-00036-RLJ-DCP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Mylan; Rhodes	1/22/2019; 3/18/2019	2019
Morrison County, MN v. Purdue Pharma L.P. et al	D. Minn./0:18-cv-00831-MJD-LIB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/26/2018	2018
Morrisville Borough, Pennsylvania v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45435-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger; H.D. Smith	6/12/2019	2019
Morrow County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-01126-MHW-KAJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/21/2017	2017
Mountrail County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00121-DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
Mower County, MN v. Purdue Pharma L.P., et al.	D. Minn./0:17-cv-05263-SRN-KMM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	11/29/2017	2017

MSI Corporation, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	W.D. Pa./2:18-cv-01109-CB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	8/21/2018	2018
MSP Recovery Claims, Services LLC v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00040-PAG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Qualitest; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Abbott; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	1/5/2018	2018
MSPA Claims 1, LLC; MAO-MSO Recovery II, LLC; and MSP Recovery Claims, Series LLC v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00130	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	1/17/2018	2018
MSPA Claims I, LLC; MAO-MSO Recovery II, LLC; MSP Recovery Claims Series LLC v. Anda Inc., et al.	S.D. FLA./1:18-cv-21391	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Anda; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Qualitest; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Abbott; Russell Portenoy; Scott Fishman; Lynn Webster	2/16/2018	2018
Muckleshoot Indian Tribe v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45213-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Qualitest; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Rite Aid; Health Mart; H.D. Smith	3/29/2019	2019

Municipality of Arroyo, Puerto Rico, et al. v. Purdue Pharma L.P., et al.	PR/3:19-cv-01816-GAG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; McKesson; Cardinal; AmerisourceBergen; Rhodes; Allergan; Watson; Actavis; Par; Mallinckrodt; SpecGx; Anda; Insys; H.D. Smith; Miami-Luken	8/29/2019	2019
Municipality of Bayamon, Puerto Rico, et al. v. Purdue Pharma L.P., et al.	PR/3:19-cv-01815-ADC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; McKesson; Cardinal; AmerisourceBergen; Rhodes; Allergan; Watson; Actavis; Par; Mallinckrodt; SpecGx; Anda; Insys; H.D. Smith; Miami-Luken	8/29/2019	2019
Municipality of Caguas, Puerto Rico, et al. v. Purdue Pharma L.P., et al.	PR/3:19-cv-01814-FAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; McKesson; Cardinal; AmerisourceBergen; Rhodes; Allergan; Watson; Actavis; Par; Mallinckrodt; SpecGx; Anda; Insys; H.D. Smith; Miami-Luken	8/29/2019	2019
Municipality of Canovanas, Puerto Rico v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46018-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; SpecGx; Mallinckrodt; Cardinal; McKesson; Health Mart; AmerisourceBergen; Rite Aid; H.D. Smith; Walgreen; Walmart	8/31/2018	2018
Municipality of Catano, Puerto Rico, et al. v. Purdue Pharma L.P., et al.	PR/3:19-cv-01824-GAG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; McKesson; Cardinal; AmerisourceBergen; Rhodes; Allergan; Watson; Actavis; Par; Mallinckrodt; SpecGx; Anda; Insys; H.D. Smith; Miami-Luken	8/30/2019	2019

Municipality of Ceiba, Puerto Rico, et al. v. Purdue Pharma L.P., et al.	PR/3:19-cv-01818-ADC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; McKesson; Cardinal; AmerisourceBergen; Rhodes; Allergan; Watson; Actavis; Par; Mallinckrodt; SpecGx; Anda; Insys; H.D. Smith; Miami-Luken	8/30/2019	2019
Municipality of Coamo, Puerto Rico, et al. v. Purdue Pharma L.P., et al.	PR/3:19-cv-01819-JAG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; McKesson; Cardinal; AmerisourceBergen; Rhodes; Allergan; Watson; Actavis; Par; Mallinckrodt; SpecGx; Anda; Insys; H.D. Smith; Miami-Luken	8/30/2019	2019
Municipality of Guayama, Puerto Rico v. Purdue Pharma L.P., et al.	PR/3:17-cv-02356-JAG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Miami-Luken; CVS; Walgreens; Walmart; Insys; Kroger; Droguera Betances; Axis; JM Blanco; SpecGx; Par; Amneal; Sun; Kremer; Unither	12/18/2017; 3/15/2019	2017
Municipality of Guayanilla, Puerto Rico v. Purdue Pharma L.P., et al.	PR/3:17-cv-02364	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Miami-Luken; CVS; Walgreens; Walmart; Insys; Kroger; SpecGx; Par; JM Blanco	12/20/2017; 3/15/2019	2017
Municipality of Isla de Vieques, Puerto Rico v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op-45752	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	8/28/2019	2019

Municipality of Juncos, Puerto Rico v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45994-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; SpecGx; Mallinckrodt; Cardinal; McKesson; Health Mart; AmerisourceBergen; Rite Aid; H.D. Smith; Walgreen; Walmart	8/22/2018	2018
Municipality of Loiza, Puerto Rico v. Purdue Pharma L.P., et al.	PR/3:17-cv-02371	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Miami-Luken; CVS; Walgreens; Walmart; Insys; Kroger; Droguera Betances; Axis; JM Blanco; SpecGx; Par; Amneal; Sun; Kremer; Unither	12/27/2017; 3/15/2019	2017
Municipality of Rio Grande, Puerto Rico v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45895-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; SpecGx; Mallinckrodt; Cardinal; McKesson; Health Mart; AmerisourceBergen; Rite Aid; H.D. Smith; Walgreen; Walmart	7/30/2018	2018
Municipality of Sabana Grande, Puerto Rico, et al. v. Purdue Pharma L.P., et al.	PR/3:17-cv-02380-JAG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018

Municipality of Vega Alta, Puerto Rico v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46011-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; SpecGx; Mallinckrodt; Cardinal; McKesson; Health Mart; AmerisourceBergen; Rite Aid; H.D. Smith; Walgreen; Walmart	8/29/2018	2018
Municipality of Villalba, Puerto Rico, et al. v. Purdue Pharma L.P., et al.	PR/3:19-cv-01821-FAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; McKesson; Cardinal; AmerisourceBergen; Rhodes; Allergan; Watson; Actavis; Par; Mallinckrodt; SpecGx; Andia; Insys; H.D. Smith; Miami-Luken	8/30/2019	2019
Municipality of Yabucoa, Puerto Rico v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45731-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; SpecGx; Mallinckrodt; Cardinal; McKesson; Health Mart; AmerisourceBergen; Rite Aid; H.D. Smith; Walgreen; Walmart	6/13/2018	2018
Musette Chancey, individually and as next friend and guardian of Babies D.C.1. and D.C.2. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45533-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Andia; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Muskegon County, Michigan v. Purdue Pharma L.P., et al.	W.D. Mich./1:18-cv-01155	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Par; Mallinckrodt; SpecGx; Allergan; Insys; AmerisourceBergen; Cardinal; McKesson; Walgreen; Walmart; Kroger; Rite Aid; CVS	10/9/2018	2018

Muskingum County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:18-cv-00040-ALM-KAJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	1/15/2018	2018
Nadja Streiter, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	CT/3:18-cv-01425-SRU	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	8/21/2018	2018
Naomi Wright, individually and as next friend and guardian of Baby M.W. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45543-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Nassau University Medical Center v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-04972	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; Anda; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	8/30/2019	2019
National Roofers Union & Employers Joint Health & Welfare Fund v. Purdue Pharma L.P., et al	D. Ariz./2:18-cv-01949-BSB	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	6/21/2018	2018
Neshoba County, Mississippi v. AmerisourceBergen Drug Corp., et al	S.D. Miss./3:18-cv-00423-HTW-LRA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/28/2018	2018

New Hanover County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./7:17-cv-00241-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	12/14/2017	2017
New Orleans Mission, Inc. v. McKesson Corporation, et al.	E.D. La./2:18-cv-07353-EEF-JCW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis	8/2/2018	2018
Newman's Medical Services, Inc. v. AmerisourceBergen Drug Corp., et al.	S.D. Ala./1:18-cv-00358-KD-M	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	8/14/2018	2018
Newton County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45578-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/15/2018	2018
Nez Pierce Tribe v. Purdue Pharma L.P., et al.	D. Ida./3:18-cv-00222-REB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; John and Jane Does 1 through 100, inclusive	5/18/2018	2018
Nichole Tindall, individually and as next friend and guardian of Baby L.M. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45530-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019

Nicole Tuttle, individually and as next friend and guardian of Baby A.T., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45476-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/15/2019	2019
Niola Lechuga, individually and as next friend and guardian of Babies Q.H.L. and A.G.L., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45468-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/14/2019	2019
Noble County, Ohio v. Cardinal Health Inc., et al.	S.D. Ohio/2:18-cv-01379- GCS-KAJ (removed from C.P. Noble County (OH)/218-0089)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cardinal; Kroger; Miami- Luken; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mylan; Walgreen; McKesson; AmerisourceBergen; CVS; Wal-Mart	10/3/2018	2018
Nodaway County, Missouri v. AmerisourceBergen Drug Corp., et al.	W.D. Mo./5:18-cv-06085- SWH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/13/2018	2018

NOITU Insurance Trust Fund v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-04958	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; Anda; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	8/29/2019	2019
North Caddo Hospital Service District d/b/a North Caddo Medical Center v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00959-SDD-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
North Mississippi Medical Center Inc.; Clay County Medical Corporation; Pontonoc Health Services, Inc.; Webster Health Services, Inc.; Tishomingo Health Services; and Marion Regional Medical Center, Inc. v. McKesson Corporation, et al.	N.D. Miss./1:18-cv-00078-SA-DAS (removed from Cir. Ct. Lee Cnty. (Miss.)/CV18-031(P)L)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	3/19/2018	2018
Northeast Ambulance and Fire Protection District of St. Louis County, Missouri v. Purdue Pharma L.P., et al.	E.D. Mo./4:19-cv-01699-DD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	6/14/2019	2019
Northeast Carpenters Funds v. Purdue Pharma L.P., et al.	D.N.J./2:18-cv-09973 (removed from Super. Ct. NJ. Middlesex Cnty./MID-L-002078-18)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen	4/9/2018	2018
Northern Arapaho Tribe v. Purdue Pharma L.P., et al.	D. Wyo./2:18-cv-00057-ABJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; AmerisourceBergen	4/2/2018; 4/24/2018	2018

Northern Cheyenne Tribe v. Purdue Pharma L.P., et al.	D. Mt./9:18-cv-00182- DLC-JCL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	10/26/2018	2018
Northumberland County, Virginia v. Purdue Pharma L.P., et al.	E.D. Va./3:19-cv-00246	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
Northwest Arizona Employee Benefit Trust v. Purdue Pharma L.P., et al.	D. Ariz./3:18-cv-08190- JZB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; John and Jane Does 1 through 100, inclusive	8/16/2018	2018
Norton Sound Health Corporation v. Purdue Pharma L.P., et al.	D. Alaska/3:18-cv-00247- JWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Janssen; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Abbott; Amneal; KVK; Cardinal; AmerisourceBergen; Anda; McKesson; Henry Shein	10/17/2018	2018
Nye County, Nevada v. AmerisourceBergen Drug Corp., et al.	D. Nev./2:18-cv-02050- MMD-VCF	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Kroger; Walgreens; Wal-Mart	10/25/2018	2018

Ochiltree County Hospital District v. McKesson Corporation, et al.	N.D. Ohio/1:18-op-45869-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Endo; Allergan; Watson; Actavis; Mallinckrodt	7/24/2018	2018
Oconee County, GA v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./3:18-cv-00016-CDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/8/2018	2018
Oconto County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01542-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Odyssey House Louisiana, Inc. v. Morris & Dickson Co. LLC, et al.	E.D. La./2:18-cv-05620 (removed from Civ. Dist. Ct. Parish of New Orleans (LA)/18-1197)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Morris & Dickson; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/7/2018	2018
Oglala Lakota Sioux Tribe v. Purdue Pharma L.P., et al.	D.S.D./5:18-cv-05021-JLV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	3/16/2018	2018
Oglethorpe County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./3:18-cv-00027-CDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/2/2018	2018

Ohio Carpenters Health Fund v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45072-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; Insys; Cardinal; McKesson; AmerisourceBergen; Walgreens; CVS; H.D. Smith; Rite Aid; Wal-Mart; SpecGx; Par; West-Ward; Hikma; Mylan; Amneal; Sandoz; KVK; Smith Food & Drugs; Discount Drug Mart; Kroger; Harvard Drug; HBC; Anda; Value Drug; Prescription Supply; Omnicare; Eckerd; Apotex; Rochester Drug; Rhodes; Keysource; John N. Kapoor	2/14/2019; 3/18/2019	2019
Olmsted County, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01483	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	6/6/2019	2019
Oneida County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01559-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Oneida Nation v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-46034-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	9/4/2018	2018

Onslow County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./7:18-cv-00001-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	1/4/2017	2017
Opelousas General Hospital Authority d/b/a Opelousas General Health System	N.D. Ohio/1:18-op-46083-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Anda; CVS; Rite Aid; Walgreens; Walmart	9/21/2018	2018
Orange County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./4:18-cv-00049-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/12/2018	2018
Orange County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./6:19-cv-01700-CEM-DCI	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Publix; Walgreen	8/29/2019	2019
Orange County, Indiana v. Purdue Pharma L.P., et al.	S.D. Ind./4:19-cv-00103-TWP-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	5/13/2019	2019
Orleans Parish Hospital Service District - District A v. Purdue Pharma L.P., et al.	E.D. La./2:18-cv-09383	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen	10/9/2018	2018

Osage County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46191-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal- Mart; SAI; McQuery; Amneal; West-Ward	10/26/2018; 3/8/2019	2018
Osage Nation v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv- 00485-GKF-JFJ (removed from D. Ct. Osage Cnty. (OK)/CJ-2019-135)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Mylan; Sandoz; McKesson; Cardinal; AmerisourceBergen; Walgreens; Morris & Dickson; Walmart; SAI; McQuery	7/26/2019	2019
Otoe-Missouria Tribe of Indians v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45402-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger; H.D. Smith	6/7/2019	2019
Ottawa County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/3:17-cv-02570- JGC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	12/8/2017	2017
Overton County, TN v. AmerisourceBergen Drug Corp., et al.	M.D. Tenn./2:18-cv- 00031	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; JM Smith; Morris & Dickson; Par; SpecGx; Walgreens	4/17/2018; 3/11/2019	2018

Ozark County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46198-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal- Mart; J.M.Smith; McQuery; Pharmacy Buying Assoc.; Amneal; Mylan	10/29/2018; 3/14/2019	2018
Page County v. Purdue Pharma L.P., et al.	W.D. Va./5:18-cv-00147- EKD (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	9/21/2018	2018
Painting Industry Insurance Fund v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-04940	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; Anda; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	8/29/2019	2019
Paiute-Shoshone Tribe of the Fallon Reservation and Colony v. McKesson Corporation, et al.	N.D. Ohio/1:18-op- 45697	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; CVS; Cardinal; Cephalon; Johnson & Johnson; McKesson; TEVA; Wal- Mart; Walgreens	6/1/2018	2018
Pala Band of Mission Indians v. Purdue Pharma L.P., et al.	S.D. Cal./3:18-cv-02673- BAS-BLM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Noramco; Insys	11/26/2018	2018

Palm Beach County v. Purdue Pharma L.P., et al.	S.D. Fla./9:18-cv-80749-BB (removed from Cir. Ct. Palm Beach Cnty.)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Actavis; Endo; McKesson; Cardinal; AmerisourceBergen; Andia; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; Walmart; Walgreens; Health Mart	4/5/2018	2018
Pamlico County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./4:19-cv-00010-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	1/16/2019	2019
Panama City, Florida v. AmerisourceBergen Drug Corp., et al.	N.D. Fla./5:18-cv-00068-MCR-GRJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/16/2018	2018
Panola County, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./3:19-cv-00045-MPM-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	3/1/2019	2019
Parish of DeSoto v. Purdue Pharma L.P., et al.	E.D. La./5:19-cv-00153	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Noramco	2/6/2019	2019
Pasco County v. AmerisourceBergen Drug Corp., et al.	M.D. Fla./8:18-cv-01558-VMC-AEP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	6/27/2018	2018

Pasquotank County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./2:18-cv-00038-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	7/30/2018	2018
Passaic County, New Jersey v. Purdue Pharma L.P., et al.	D.N.J./2:19-cv-15809-ES-CLW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; CVS; Walgreens; Costco; Rite Aid	7/25/2019	2019
Passamaquoddy Tribe-Indian Township v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45876-DAP	Purdue Pharma L.P.	TEVA; Cephalon; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreens; Walmart	7/25/2018	2018
Passamaquoddy Tribe-Pleasant Point v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45100-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Janssen; Johnson & Johnson; Insys; Mallinckrodt; Allergan; Actavis; Omnicare; Masters	2/28/2019	2019
Patients' Choice Medical Center of Claiborne, LLC v. Purdue Pharma L.P., et al.	S.D. Miss./5:19-cv-00030-DCB-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Insys	4/15/2019	2019
Patients' Choice Medical Center of Erin, Tennessee v. Purdue Pharma L.P., et al.	W.D. Tenn./2:19-cv-02231	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Janssen; Johnson & Johnson; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; Walgreens; Walmart; CVS	4/16/2019	2019
Patients' Choice Medical Center of Erin, Tennessee v. Purdue Pharma L.P., et al.	W.D. Tenn./3:19-cv-00370	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Janssen; Johnson & Johnson; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; Walgreens; Walmart; CVS	5/2/2019	2019

Patients' Choice Medical Center of Humphreys County, LLC v. Purdue Pharma L.P., et al.	N.D. Miss./4:19-cv-00051-DMB-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Insys	4/15/2019	2019
Patricia Kuepfer, Individually and as Surviving Mother of Kristeen Oettle, Deceased v. Mallinckrodt PLC, et al.	E.D. Mo./4:19-cv-02633 (removed from state court)	Purdue Pharma L.P.; The Purdue Frederick Company Inc.	Mallinckrodt; SpecGx; TEVA; Janssen; Johnson & Johnson; Noramco; Allergan; Actavis; Mylan; Depomed; Insys	2/11/2019	2019
Patrick County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./4:19-cv-00032-EKD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
Paula Watson, individually and as next friend and guardian of Baby D.M. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45545-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Peach County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45579-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	5/15/2018	2018

Pearl River County Hospital & Nursing Home v. McKesson Corp., et al.	N.D. Ohio/1:19-op-45659	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; CVS; Walgreens; Walmart	7/23/2019	2019
Pearl River County, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./1:19-cv-00304-LG-RHW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/1/2019	2019
Pembina County v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00138-DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	7/9/2019	2019
Penny Martin, individually and as next friend and guardian of Baby D.M. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45508-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019

Penobscot County v. Purdue Pharma L.P., et al.	D. Me./1:19-cv-00019-NT (removed from Super. Ct. Penobscot Cnty. (Me.)/CV-2018-157)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	11/21/2018	2018
People of the State of Illinois, Calhoun County v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46294-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-Mart; McQuery; Amneal	12/3/2018; 3/6/2019	2018
People of the State of Illinois, Jefferson County v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45539-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/7/2018	2018
People of the State of Illinois, Lee County v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45606-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/23/2018	2018
People of the State of Illinois, Livingston County v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45527-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/3/2018	2018

People of the State of Illinois, Marion County v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45532	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/4/2018	2018
People of the State of Illinois, Saline County v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45528-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/3/2018	2018
People of the State of Illinois, the People of Effingham County, and County of Effingham v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45499-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/19/2018	2018
People of the State of Illinois, the People of Lawrence County, and County of Lawrence v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45518	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/1/2018	2018
People of the State of Illinois, the People of Massac County, and County of Massac v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45519	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/1/2018	2018
Perry County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:18-cv-00158-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/23/2018	2018
Perry County, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./2:18-cv-00089-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	5/23/2018	2018

Person County v. AmerisourceBergen Drug Corp., et al.	N.D. NC/1:18-cv-00158	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/2/2018	2018
Pettis County, Mississippi v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45416-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami- Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
Phelps County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46195-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal- Mart; McQuery; Amneal	10/26/2018; 3/8/2019	2018
Phenix City, Alabama v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./3:18-cv-00072- CSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
Philadelphia Federation of Teachers Health and Welfare Fund, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	E.D. Pa./2:17-cv-04746- TJS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott	10/23/2017	2017

Pickett County, TN v. AmerisourceBergen Drug Corp., et al.	M.D. Tenn./2:18-cv-00020	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; JM Smith; Morris & Dickson; Top Tx; Par; SpexGx	2/16/2018; 3/11/2019	2018
Pierce County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00137-DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	7/9/2019	2019
Pierce County v. Purdue Pharma L.P., et al.	W.D. Wa./3:18-cv-05086	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Seattle Pain Center AmerisourceBergen; Cardinal; Cephalon; Hikma; Mylan; Par; TEVA; Walgreens; West-Ward	1/25/2018; 5/25/2018; 3/15/2019	2018
Pierce County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01547-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017

Pierce County, Georgia v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./5:18-cv-00068-LGW-BWC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	9/7/2018	2018
Pike County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00696-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/9/2017	2017
Pike County, Alabama v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./2:18-cv-00582-MHT-CSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	6/15/2018	2018
Pike County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45179-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/26/2019	2019
Pima County, a political subdivision of the State of Arizona v. Purdue Pharma L.P., et al.	D. Ariz./4:19-cv-00167-JAS (removed from Super. Ct. Pima Cnty. (Ariz.)/C20190269)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; H.D. Smith; Anda	1/17/2019	2019
Pine County, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01907-DWF-LIB	Purdue Pharma L.P.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Omnicare; Masters	7/19/2019	2019
Pinellas County, Florida v. AmerisourceBergen Drug Corp., et al.	M.D. Fla./8:18-cv-01211-CEH-TGW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/18/2018	2018

<p>Pioneer Telephone Cooperative, Inc. Employee Benefits Plan; Bios Companies, Inc. Welfare Plan; Pioneer Telephone Cooperative, Inc. as plan sponsor and fiduciary of Pioneer Telephone Cooperative, Inc. Employee Benefits Plan; and Bios Companies, Inc. as plan sponsor and fiduciary of Bios Companies, Inc. Welfare Plan, all individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.</p>	<p>W.D. Okla./5:18-cv-00994-G</p>	<p>Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.</p>	<p>Endo; Par; Janssen; Johnson & Johnson; TEVA; Cephalon; Noramco; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Anda; Cardinal; McKesson</p>	<p>10/9/2018</p>	<p>2018</p>
<p>Pitt County v. AmerisourceBergen Drug Corp., et al.</p>	<p>E.D.N.C./4:18-cv-00018-FL</p>	<p>Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.</p>	<p>AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt</p>	<p>2/2/2018</p>	<p>2018</p>
<p>Pittsylvania County v. Purdue Pharma L.P., et al.</p>	<p>W.D. Va./4:18-cv-00070-EKD (removed from state court)</p>	<p>Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.</p>	<p>Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-</p>	<p>9/25/2018</p>	<p>2018</p>

Plains Township, Pennsylvania v. Purdue Pharma L.P., et al.	M.D. Pa./3:18-cv-02025- RDM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Mallinckrodt; Watson; McKesson; Cardinal; AmerisourceBergen; Noramco; Insys; CVS; Rite Aid; Walgreens; Wal- Mart; Value Drug Co.; Generics Bidco; Anda; Eckerd; SpecGx; Par; Amneal	10/18/2018; 3/13/2019	2018
Plumbers & Steamfitters Local 166 Health and Welfare Fund v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45432	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith; Rite Aid	6/10/2019	2019
Plumbers Local Union No. 1 Welfare Fund v. Purdue Pharma L.P., et al.	S.D.N.Y./1:18-cv-04750- UA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Products L.P.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	5/30/2018	2018
Pocahontas County Commission v. Purdue Pharmaceutical Products L.P., et al.	N.D. WV/2:18-cv-00034- JPB	Purdue Pharmaceutical Products LP; Purdue Pharma L.P.; The Purdue Frederick Company Inc.	Actavis; Allergan; Cephalon; Janssen; Johnson & Johnson; TEVA; Mallinckrodt; AmerisourceBergen; Anda; Auburn; Bellco; Cardinal; Healthcare; Endo; Keysource; Masters; McKesson; Parmed; Rite Aid; Toprx; SpecGx; Par; West Ward; Amneal; Indivior; Rhodes; Sandoz	3/29/2018; 3/15/2019	2018
Pointe Coupee Parish Health Services District Number 1 v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45019-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Insys; SpecGx; Amneal; West-Ward; Indivior; Mylan; Sandoz	1/18/2019; 3/15/2019	2019

Police Jury of the Parish of Pointe Coupee, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45012-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Insys; SpecGx; Amneal; West-Ward; Indivior; Mylan; Sandoz; Walmart; Winn-Dixie	1/18/2019; 3/15/2019	2019
Polk County v. Purdue Pharma L.P., et al.	S.D. Iowa./4:18-cv-00010-JAJ-HCA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman and Lynn Webster	1/5/2018	2018
Polk County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./8:18-cv-01814 (removed from Cir. Ct. Polk Cnty. (Fla.)/2018-CA-001882)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; Cephalon; TEVA; Allergan; Actavis; AmerisourceBergen; Cardinal; McKesson; Mallinckrodt; Walgreens; Insys	5/22/2018	2018
Polk County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ga./4:19-cv-00008-HLM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Rite Aid; Walgreens; JM Smith	1/16/2019	2019
Ponca Tribe of Indians of Oklahoma v. Purdue Pharma L.P., et al.	W.D. Okla./5:18-cv-00221-M	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Physician Total Care; Pd-Rx	3/13/2018	2018
Ponca Tribe of Nebraska v. McKesson Corporation, et al.	D. Ne./8:18-cv-00180-LSC-SMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Insys; Allergan; Watson; Actavis; Mallinckrodt	4/25/2018	2018
Port Gamble S'Klallam Tribe, Suquamish Tribe, and Jamestown S'Klallam Tribe v. Purdue Pharma L.P., et al.	W.D. Wa./3:18-cv-05173	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/5/2018	2018

Porter County v. Purdue Pharma L.P., et al.	N.D. Ind./2:19-cv-00050-JTM-JEM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	2/1/2019	2019
Prairie Island Indian Community v. Purdue Pharma L.P. et al	N.D. Ohio/1:18-op-45975	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	8/31/2018	2018
Prarie Island Indian Community v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45975-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Actavis; Allergan; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	8/16/2018	2018
Prentiss County, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:18-cv-00097-SA-RP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	5/23/2018	2018
Preston Bohannon, in his Official Capacity as the Sheriff of Jeff Davis County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45161-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019

Price County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01556- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Prince George County, Virginia v. Purdue Pharma L.P., et al.	E.D. Va./3:19-cv-00458	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
Prince George's County, Maryland v. Purdue Pharma L.P., et al.	D. Md./8:18-cv-00870 (removed from Cir. Ct. Prince George's Cnty. (MD)/CAL-18-02008)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; Rite Aid; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	1/23/2018	2018

Pueblo County v. Purdue Pharma L.P., et al.	D. Colo./1:18-cv-01479-PAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	6/14/2018	2018
Pulaski County v. Purdue Pharma L.P., et al.	S.D. Ind./3:18-cv-00709-PPS-MGG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	8/31/2018	2018
Pulaski County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45176-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/26/2019	2019
Pulaski County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46192-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-MartMcQueary; Amneal	10/26/2018; 3/8/2019	2018
Pulaski County, Virginia v. AmerisourceBergen Drug Corp., et al.	W.D. Va./7:18-cv-00343-EKD-PMS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; North Carolina Mutual Wholesale Drug; Rite Aid; Walmart; Par; SpecGx; West-Ward; Rhodes; CVS; Walgreens; JM Smith	7/16/2018; 3/14/2019	2018

Puyallup Tribe of Indians, a/k/a Puyallup Tribe of the Puyallup Reservation v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45660	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; CVS; Cardinal; Endo; McKesson; Walmart; Walgreens	7/25/2019	2019
Quapaw Tribe of Oklahoma v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op-45460-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Noramco	6/14/2019	2019
Quinault Indian Nation v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46154-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	10/17/2018	2018
Quincy Weatherwax, individually and as next friend and guardian of Baby L.W., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45483-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/16/2019	2019
R. Chris Nevils v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45296-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	Rhodes; Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Health Mart; H.D. Smith; CVS; Walgreen; Wal-Mart; Amneal; West-Ward; Hikma; Sandoz; Mylan; Louisiana Wholesale Drug Cop.; Morris & Dickson	5/3/2019; 5/30/2019	2019

R.D. Burns v. Purdue Pharma L.P., et al.	C.D. Cal./8:18-cv-00745 (removed from Orange County Super Ct. (CA)/30-2018-00932342-CU-P-P-CKC)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Janssen; Johnson & Johnson; Endo; American Academy of Pain Medicine; American Pain Society; American Pain Foundation; American Chronic Pain Association; and Does 1 through 100, Inclusive	3/27/2018	2018
R.N. "Butch" Reece, in his Official Capacity as the Sheriff of Jones County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45162-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019
Rabun County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45177-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/26/2019	2019
Rachel Wood, individually and as next friend and adopted mother of Baby O.W., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	E.D. Mo./4:18-cv-00352	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis	3/3/2018	2018
Ramsey Bennett, in his Official Capacity as the Sheriff of Pierce County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45166-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019
Ramsey County v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00111-DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019

Ramsey County, MN v. Purdue Pharma L.P., et al.	D. Minn./0:17-cv-05285-PAM-FLN	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	11/30/2017	2017
Randolph County v. AmerisourceBergen Drug Corp., et al.	N.D. NC/1:18-cv-00157	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/2/2018	2018
Randolph County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45202-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/28/2019	2019
Randolph County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45409-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Par; SpecGx; Insys; CVS; Walmart; Wagreens; H.D. Smith; Kroger	6/7/2019	2019
Randy F. Royal, in his Official Capacity as the Sheriff of Ware County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45169-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019

Randy Seal, Sheriff of Washington Parish v. Purdue Pharma L.P., et al.	E.D. LA/2:17-cv-17722 (removed from 22nd Judicial District Court, Parish of Washington)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal-Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	10/5/2017	2017
Randy Smith, Sheriff of St. Tammany Parish, Louisiana in his capacity as officer ex officio of the St. Tammany Parish Sheriff's Office and the St. Tammany Parish Law Enforcement District v. Purdue Pharma L.P., et al.	E.D. La./2:18-cv-09357 (removed from 22nd Judicial District Court, Parish of St. Tammany (LA)/2018-13666)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Morris & Dickson Co.	7/27/2018	2018
Ransom County v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00117-DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
Reannan Howell, individually and as next friend and guardian of Baby N.J.D. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45520-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019

Rebecca Goforth, individually and as next friend and guardian of Babies A.S. and N.S. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45532-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Red Cliff Band of Lake Superior Chippewa Indians vs. McKesson Corporation, et al.	W.D. Wi./3:18-cv-00380- jdp (removed from Cir. Ct. Bayfield Cnty. (WI))/2018CV000036)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal- Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	4/13/2018	2018
Red Lake Chippewa Band of Chippewa Indians v. AmerisourceBergen Drug Corp., et al.	D. Minn./0:18-cv-02107	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	7/23/2018	2018
Red River Fire Protection District v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00974- SDD-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
Red River Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00949- SDD-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/25/2018	2018

Redwood Valley or Little River Band of Pomo Indians of the Redwood Valley Rancheria v. McKesson Corp., et al.	N.D. Cal./3:18-cv-02531-MEJ (removed from San Francisco County Superior Ct. (CA)/CGC-18-564489)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	2/21/2018	2018
Regina Hapgood, Individually and on behalf of the Estate of Richard Coelho v. Purdue Pharma L.P., et al.	D. Mass./1:18-cv-10010	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Cardinal; AmerisourceBergen	1/2/2018	2018
Reno-Sparks Indian Colony v. McKesson Corporation, et al.	N.D. Ohio/1:18-op-45699-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	6/8/2018	2018
Reynolds County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46193-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-Mart; McQuery; Pharmacy Buying Assoc.; Harvard Drug; Amneal; Mylan	10/26/2018; 3/8/2019	2018
Rhonda Belcher and Ella Louise Johnson as Administratrix of the Estate of Mackenzie Paige Hays v. Purdue Pharma L.P., et al.	E.D. Ky./6:18-cv-00246-GFVT (removed from Cir. Ct. Leslie Cnty. (Ky.)/18-CI-00134)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Endo; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; Magna; Xanodyne; Richie; Alyssa Noble	8/15/2018	2018

Richland County Children's Services v. Purdue Pharma L.P., et al.	N.D. Ohio/1:17-cv-02185 (removed from Richland Cnty./2017-CV-0662)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Walgreens; Walmart; CVS; Miami-Luken; Rite Aid; Kroger; H.D. Smith; Rhodes; John N. Kapoor; Insys; Mallinckrodt; Noramco; Anda	9/12/2017	2017
Richland County v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00114- DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS: Rite Aid; Kroger	6/14/2019	2019
Richland County, South Carolina v. Purdue Pharma L.P., et al.	D.S.C./3:19-cv-01207- BHH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Johnson & Johnson; Normaco; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; CVS; Walgreens	4/25/2019	2019
Richland Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00952- BAJ-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
Richmond County, North Carolina v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:18-cv-00350	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/27/2018	2018

Rincon Band of Luiseno Indians v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46151-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	10/16/2018	2018
Ripley County v. Purdue Pharma L.P., et al.	S.D. Ind./4:18-cv-00175-SEB-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	9/24/2018	2018
Ripley County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46262-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-Mart; Quest; Amneal	11/20/2018; 3/14/2019	2018
Risk Management, Inc. v. Purdue Pharma L.P., et al.	M.D. La./3:18-cv-00670-JWD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; Walgreens	7/10/2018	2018
Riverside-San Bernadino County Indian Health, Inc. v. Purdue Pharma L.P., et al.	C.D. Cal./5:19-cv-00005	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	1/2/2019	2019

Riverton, Wyoming v. Purdue Pharma L.P., et al.	D. Wyo./1:19-cv-00109-ABJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; AmerisourceBergen; Insys; Caredinal; Walgreens; Walmart	5/28/2019	2019
Roanoke County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./7:19-cv-00271-EKD (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
Robeson County v. Purdue Pharma L.P., et al.	E.D.N.C./7:18-cv-00163-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; CVS; Endo; H.D. Smith; Insys; Janssen; Johnson & Johnson; Kroger; Mallinckrodt; McKesson; Miami-Luken; Noramco; Rite Aid; TEVA; Walmart; Walgreens; Watson	9/4/2018	2018
Robinson Rancheria v. McKesson Corporation, et al.	N.D. Cal./3:18-cv-02525 (removed from San Francisco County Superior Ct. (CA)/CGC-18-564739)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	3/2/2018	2018

Rock County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01549- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Rock Springs, Wyoming v. Purdue Pharma L.P., et al.	D. Wyo./1:19-cv-00056- ABJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; AmerisourceBergen; Insys; Caredinal; Walgreens; Walmart	3/19/2019	2019
Rockbridge County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./6:19-cv-00025- EKD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-	N/A	2019

Rockdale County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46296-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; PSS World; CVS; Walgreens; Walmart; Rite Aid; Par; SpecGx; West-Ward; Hikma; Mylan; Sandoz; Omnicare; Smith Drug; Kroger; Eckerd; Rhodes; Miami-Luken; Noramco; Anda; John N. Kapoor	12/4/2018; 3/15/2019	2018
Rockingham County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:17-cv-01114	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	12/12/2017	2017
Rockingham County v. Purdue Pharma L.P., et al.	D.N.H./1:19-cv-00333 (Rockingham Super. Ct. (NH)/218-2018-CV-01100)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Rite-Aid; Walgreens; Walmart; Dr. Michael Dipre; Dr. Mark Weinreb; Christopher Clough; Ayman A. Jacobs; Dr. Greg Thompson	9/18/2018	2018
Rockwall County v. Purdue Pharma L.P., et al.	S.D. Tex./4:19-cv-02181 (removed from Rockwall Cnty. Dist. Ct. (Tex.)/1-19-0503)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; SpecGx; Abbvie; CVS; Walgreens; Wal-Mart; Dr. Richard Andrews; Dr. Theodore Okechuku; Dr. Nicolas Padron	4/10/2019; 6/17/2019 (Am.)	2019

Rolette County v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00118-DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
Ronald D. Stracener, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	S.D. Ala./1:19-cv-00086-CG-M	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson; Insys	2/25/2019	2019
Ronald Richardson, duly executed Sheriff of Sabine Parish v. Purdue Pharma L.P., et al.	W.D. LA/5:18-cv-00054 (removed from 11th Judicial District Court, Parish of Sabine (LA)/68465)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal-Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	10/5/2017	2017
Roofers Local 149 Security Benefit Trust Fund, on behalf of itself and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45429-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger; H.D. Smith; Rite Aid; Kroger	6/10/2019	2019
Rosary Hall and St. Vincent Charity Medical Center	N.D. Ohio/1:18-op-45610-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisouceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Insys; Allergan; Actavis; Watson; Mallinckrodt; CVS; Kroger; Rite Aid; Walgreens; Wal-Mart	5/29/2018	2018

Roseau County v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01212-JNE-LIB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; McKesson; AmerisourceBergen; Walgreens	5/6/2019	2019
Ross County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00704-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/12/2017	2017
Round Valley Indian Tribes and Round Valley Indian Health Center, Inc. v. McKesson Corporation, et al.	N.D. Cal./3:18-cv-02530 (removed from San Francisco County Superior Ct. (CA)/CGC-18-564741)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	3/2/2018	2018
Rowan County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:18-cv-00524-TDS-LPA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/20/2018	2018
Roxie Whitley, individually and as next friend of Baby Z.B.D.; Chris and Diane Denson, individually and as next friends of Baby L.D.L, on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	W.D. Tenn./2:18-cv-02290 (removed from Cir. Ct. Fayette Cnty. (TN))/24CCI-2018-CV-14)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Fred's Stores; Depomed; Mallinckrodt; SpecGx; Par; Insys; Noramco; Indivior; CVS; Rite Aid; Wagreens; Walmart; Miami-Luken; Costco; Linden; Kroger; H.D. Smith; Anda; Rhodes	3/16/2018; 5/25/2018; 3/16/2019	2018
Rush Health Systems, Inc. v. McKesson, et al.	S.D. Miss./3:17-cv-01012-TSL-RHW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis	12/13/2017	2017

Rusk County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01534- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Russell County, Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./3:19-cv-00646- ALB-SMD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	9/6/2019	2019
Russell County, Virginia v. AmerisourceBergen Drug Corp., et al.	W.D. Va./1:18-cv-00032- EKD-PMS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; North Carolina Mutual Wholesale Drug; Rite Aid; Walmart; Par; SpecGx; West-Ward; Rhodes	7/10/2018; 3/14/2019	2018
Rutherford County v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./1:18-cv-00047	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/26/2018	2018

Rutherford County, TN v. Purdue Pharma L.P., et al.	M.D. Tenn./3:18-cv- 00238	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; Par; SpexGx; Walgreens; Walmart; CVS; West-Ward; Mylan; Murfreesboro; Kroger; Morris Dickson; Rhodes	2/26/2018; 3/18/2019	2018
Sagadahoc County v. Purdue Pharma L.P., et al.	D. Me./2:19-cv-00020- NT (removed from Super. Ct. Sagadahoc Cnty. (Me.)/BATSC-CV- 2018-47)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal- Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	11/21/2018	2018
Saint Elizabeth Medical Center, Inc. d/b/a St. Elizabeth Healthcare; St. Claire Medical Center, Inc. d/b/a St. Claire Regional Medical Center; Highlands Hospital Corporation d/b/a Highlands Regional Medical Center v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./2:18-cv-00146- GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Walgreens Boots Alliance; CVS; Wal-Mart; Miami-Luken	8/17/2018	2018

Saint Regis Mohawk Tribe v. Purdue Pharma L.P., et al.	N.D.N.Y./8:18-cv-01478- BKS-CFH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; SpecGx; John and Jane Does 1 through 100, inclusive	12/21/2018	2018
Sally Peterson, individually and as next friend and guardian of Baby E.A.P., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45472-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/14/2019	2019
Samantha DeMaro, individually and as next friend and guardian of Baby J.W.L.B., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45465-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/14/2019	2019
Samantha McAnany, individually and as next friend and guardian of Baby A.L.M. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45526-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/18/2019	2019

Sampson County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./7:19-cv-00107-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/12/2019	2019
San Juan County v. Purdue Pharma L.P., et al.	D.N.M./1:18-cv-00507-JHR-KBM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; RiteAid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	5/31/2018	2018
San Juan County v. Purdue Pharma L.P., et al.	W.D. Wa./2:18-cv-01638	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; SpecGx; Par; SpecGx; Rhodes; West-Ward; Hikma; Amneal; Impax	11/12/2018; 3/15/2019	2018
Sandoval County, NM v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45421-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019

Sandra Atkinson, individually and as next friend and guardian of Baby L.C. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45531-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Sandusky County Board of Commissioners v. Actavis Inc., et al.	N.D. Ohio/3:18-cv-00593 (removed from C.P. Sandusky County (OH)/18CV126)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Perry Fine; Scott Fishman; Insys; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Miami-Luken; Russell Portenoy; TEVA; Watson; Lynn Webster	2/9/2018	2018
Santa Rosa County v. AmerisourceBergen Drug Corp., et al.	N.D. Fla./3:18-cv-01439- MCR-EMT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	6/20/2018	2018
Sarasota County Public Hospital District d/b/a Memorial Healthcare System, Inc.	M.D. Fla./8:18-cv-02236- JSM-TGW	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	9/10/2018	2018
Sarasota County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./8:19-cv-01083- VMC-AAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Cardinal; Mallinckrodt; SpecGx; McKesson; AmerisourceBergen; Walgreens	5/6/2019	2019

Sargeant County v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00112-DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
Sarpy County, Nebraska, a municipal corporation v. AmerisourceBergen Drug Corp., et al	D. Ne./8:18-cv-00387	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Insys; Allergan; Watson; Actavis; Mallinckrodt; Noramco	8/15/2018	2018
Sauk County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01537-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Sawyer County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01664-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017

Schley County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45580-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	5/15/2018	2018
Schuyler County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45408-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Par; SpecGx; Insys; CVS; Walmart; Wagreens; H.D. Smith; Kroger	6/7/2019	2019
Scioto County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00682- EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/9/2017	2017
Scotland County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:19-cv-00385	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	4/8/2019	2019
Scott Anslum in his capacity as sheriff on behalf of the St. Mary Parish Sheriff's Office v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00955	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018

Scott County Board of Supervisors v. AmerisourceBergen Drug Corp., et al.	W.D. Va./2:18-cv-00020-EKD-PMS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Rite Aid; Thrift; Walgreens; Wal-Mart; JM Smith; Harvard Drug Group; Par; SpecGx; KVK	7/9/2018; 3/9/2019	2018
Scott County Indiana, a Political Subdivision of The State of Indiana, by and through its board of Commissioners v. Purdue Pharma L.P., et al.	S.D. Ind./4:17-cv-00193-RLY-DML (removed from Sup. Ct. Scott Cnty. (IN)/ Cause No. 72D01-1709-PL-70)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Samantha Beaver; Kevin L. Foster; Brittany Berkshire; Joe Gay, Jr.; Jesse Bobb; Michael White; Elsa Marie Neace; Glenn M. Fields; Claude Holt, Jr.; James Coomer; Lloyd E. McNear; Christopher C. Smith; Joel E. Barrett, Jr.; Does 1 through 100	9/11/2017	2017
Scott County, TN v. Purdue Pharma L.P., et al.	E.D. Tenn./3:18-cv-00083	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; Par; SpexGx; Walgreens; Walmart; Amneal; Mylan; H.D. Smith; Morris Dickson; Rhodes	3/2/2018; 3/18/2019	2018
Scott R. Berry, in his Official Capacity as the Sheriff of Oconee County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45165-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	3/22/2019	2019

Scotts Valley Band of Pomo Indians v. McKesson Corp., et al.	N.D. Cal./3:18-cv-02529 (removed from San Francisco County Super Ct. (CA)/CGC-18-564490)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Does 1 Through 100, Inclusive	2/21/2018	2018
Screven County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45198-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/27/2019	2019
Seattle Indian Health Board v. McKesson Corp., et al.	N.D. Ohio/1:18-op-45745-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Endo; Allergan; Watson; Actavis; Mallinckrodt	7/9/2018	2018
Sedgwick County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	D. Kan./6:17-cv-01313-EFM-KGG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	12/21/2017	2017
Seminole County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./6:19-cv-01064-RBD-LRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Publix; Walgreen	6/10/2019	2019
Seminole County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45181-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/27/2019	2019

Seminole Tribe of Florida v. AmerisourceBergen Drug Corp., et al.	S.D. Fla./0:19-cv-62286- RAR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Insys; Mallinckrodt; Walgreen; CVS	9/13/2019	2019
Seneca County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:18-cv-00168- EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/27/2018	2018
Seneca Nation of Indians v. AmerisourceBergen Drug Corp., et al.	W.D.N.Y./1:18-cv-00620- EAW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	5/31/2018	2018
Shakopee Mdewakanton Sioux Community v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45977-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Actavis; Allergan; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	8/16/2018	2018
Shannon County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45401-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Par; SpecGx; Insys; CVS; Walmart; Wagreens; H.D. Smith; Kroger	6/7/2019	2019
Shannon Hunt v. Purdue Pharma L.P., et al.	D. Md./1:18-cv-01349	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis	5/10/2018	2018

Sharkey-Issaquena Community Hospital v. McKesson Corp., et al.	N.D. Ohio/1:18-op- 45765-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS; Walgreens; Walmart	6/29/2018	2018
Shawano County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01540- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Sheboygan County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01560- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Sheet Metal Workers Local No. 25 Health and Welfare Fund v. Purdue Pharma L.P., et al.	E.D. Pa./2:17-cv-05079- TJS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Abbott; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	11/9/2017	2017

Shelby County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/3:18-cv-00164-TMR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/11/2018	2018
Shelby County v. Purdue Pharma L.P., et al.	W.D. Tenn./2:18-cv-02528-JTF-cgc	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mallinckrodt; Endo; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; AmerisourceBergen; Cardinal; McKesson	8/1/2018	2018
Shelby County, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./2:18-cv-00469-SGC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/26/2018	2018
Shelby County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46264-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-Mart; McQuery	11/20/2018; 3/15/2019	2018
Shelby L. Brant, individually and as next friend and guardian of Baby L.A.Z., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45494-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/17/2019	2019

Shelley Whittaker, individually and as next friend and guardian of Babies E.W., G.L.O., and N.S.G., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45475-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/14/2019	2019
Shenandoah County, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./5:19-cv-00056- EKD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
Sheriff Jeffrey F. Wiley, <i>as Officer Ex Officio of the Ascension Parish Sheriff's Office and Ascension Parish Law Enforcement District</i> v. Purdue Pharma L.P., et al.	W.D. La./3:18-cv-00658- JWD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal- Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys; Actavis; Watson; Allergan; Noramco	6/27/2018	2018

Sheriff Michael Tubbs, <i>as Officer Ex Officio of the Morehouse Parish Sheriff's Office and Morehouse Parish Law Enforcement District v.</i> Purdue Pharma L.P., et al.	W.D. La./3:18-cv-00846- TAD-KLH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal- Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	6/26/2018	2018
Shilo Shewmake, individually and as next friends and guardians of Babies L.G., A.S., and J.S., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45482-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/15/2019	2019
Shinnecock Indian Nation v. McKesson Corp., et al.	N.D. Ohio/1:18-op- 46142-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS; Walgreens; Walmart	10/9/2018	2018
Shoshone-Bannock Tribes v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45373-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Kroger	6/6/2019	2019
Sibley County v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01194	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; McKesson; AmerisourceBergen; Walgreens	5/3/2019	2019

Sid J. Gautreaux III, Parish of East Baton Rouge v. Purdue Pharma L.P., et al.	M.D. La./3:18-cv-00286- JWD-RLB (removed from 19th Judicial District Court, Parish of East Baton Rouge (LA)/666277)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal- Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	2/9/2018	2018
Skagit County, City of Sedro Woolley, City of Burlington, City of Mount Vernon v. Purdue Pharma L.P., et al.	W.D. Wa./2:18-cv-00120- JLR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Seattle Pain CenterAmerisourceBerg en; Cardinal; Cephalon; Hikma; Mylan; Par; TEVA; Walgreens; West- Ward	1/25/2018; 5/25/2018; 3/15/2019	2018
Smith County, TN v. Purdue Pharma L.P., et al.	M.D. Tenn./2:17-cv- 00078	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; AmerisourceBergen; McKesson; Cardinal; Par; SpecGx; Rhodes; Mylan; H.D. Smith; JM Smith; Morris Dickson; Walmart; KeySource	12/18/2017; 3/18/2019	2017
Smyth County, Virginia v. AmerisourceBergen Drug Corp., et al.	W.D. Va./1:18-cv-00028- EKD-PMS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS; North Carolina Wholesale Drug Co; JM Smith; Walgreens; Walmart; Amneal; Mylan; Par; SpecGx; West-Ward; Rhodes	6/28/2018; 3/14/2019	2018

Snohomish County, a Washington municipal corporation v. Purdue Pharma L.P., et al.	W.D. Wa./2:19-cv-00368-TSZ (removed from Super. Ct. Snohomish Cty. (WA)/19-2-00908-31)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Doctors Osteopathic Care; Delbert Whetstone; Seattle Pain Center; Frank D. Li; Statcare; Donald Dillinger; Thrifty Payless; Rite Aid; NW Green; Sevan Pharmacy; Hieu Tue Le	1/28/2019	2019
Sokaogon Chippewa Community v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45410-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger; H.D. Smith	6/7/2019	2019
Somerset County v. Purdue Pharma L.P., et al.	D. Me./1:19-cv-00025-NT (removed from Super. Ct. Somerset Cnty. (Me.)/SC-CV-18-34)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Andia; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	11/21/2018	2018
South Central Regional Medical Center v. McKesson Corp., et al.	N.D. Ohio/1:18-op-45763-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS; Walgreens; Walmart	6/29/2018	2018
South Central UFCW Unions and Employers Health & Welfare Trust v. McKesson Corp., et al.	N.D. Ohio/1:18-op-45998-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	8/23/2018	2018

South Fork Band of the Te-Moak Tribe of Western Shoshone Indians v. McKesson Corp., et al.	N.D. Ohio/1:18-op-46016-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	8/31/2018	2018
SouthEast Alaska Regional Health Consortium v. Purdue Pharma L.P., et al.	D. Alaska/3:18-cv-00217-TMB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Cephalon; TEVA; Janssen; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Abbott; Amneal; KVK; Cardinal; AmerisourceBergen; Anda; McKesson; Henry Shein	9/20/2018	2018
Southern Illinois Healthcare Foundation v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-cv-01376-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Actavis; Allergan; AmerisourceBergen; Cephalon; Cardinal; Depomed; Endo; Anda; H.D. Smith; Henry Schein; Insys; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; Miami-Luken; SpecGx; TEVA; Watson	6/13/2019	2019
Southwest Mississippi Regional Medical Center et al v. AmerisourceBergen Drug Corporation et al	S.D. Miss./5:17-cv-00145-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	11/30/2017	2017
Spalding County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45208-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/28/2019	2019
Spirit Lake Tribe v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45520-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/3/2018	2018

Spokane County v. Purdue Pharma L.P., et al.	E.D. Wa./2:18-cv-00209	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; Cephalon; Hikma; Mylan; Par; TEVA; Walgreens; West-Ward; KVK: Thrifty; Walmart; Rite Aid; Omnicare	6/21/2018; 3/13/2019	2018
Squaxin Island Tribe v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45531-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/4/2018	2018
St. Bernard Parish Government v. Wilkinson Family Pharmacy LLC, et al.	E.D. La./2:18-cv-02717 (removed from Parish of St. Bernard/17-1532)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Wilkinson Family Pharmacy LLC; Lynn Webster; Randall Brewer; Scott Fishman; Perry Fine; Watson; Actavis; Allergan; Endo; Janssen; Johnson & Johnson; Cephalon; TEVA	12/4/2017	2017
St. Charles County, Missouri v. Purdue Pharma L.P., et al.	E.D. Mo./4:18-cv-01376	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	8/20/2018	2018
St. Clair County, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./4:18-cv-00708-VEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	5/8/2018	2018

St. Croix Chippewa Indians of Wisconsin v. McKesson Corp., et al.	W.D. Wi./3:17-cv-00914	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; CVS; Kroger; Rite Aid; H.D. Smith; Miami-Luken; Amneal; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; TopRx; Rhodes	12/7/2017; 5/25/2018; 3/15/2019	2017
St. Croix County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01665- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017
St. Francois County v. Dannie E. Williams, M.D., et al.	E.D. Mo./4:19-cv-01722 (removed from 22nd Jud. Cir. Ct. (Mo.)/1922CC06445)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; CVS; Depomed; Express; Johnson & Johnson; Mallinckrodt; Mylan; Noramco; Optum; Target; TEVA; Walgreens; Walmart; Caremark; Delmar Primary Care Assoc.; Endo; Insys; SpecGx; UnitedHealth	6/6/2019	2019
St. James Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00818- SDD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Mallinckrodt	9/4/2018	2018

St. John the Baptist Parish v. AmerisourceBergen Drug Corp., et al.	E.D. La./2:18-cv-07070-NJB-JVM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Noramco; Endo; Allergan; Wason; Actavis; Mallinckrodt; Insys; CVS; Morris & Dickson; Endo; Wal-Mart; Walgreens; Louisiana Wholesale Drug Co.	7/27/2018	2018
St. Johns County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./3:19-cv-00699-TJC-PDB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Publix; Walgreen	6/10/2019	2019
St. Joseph County v. Purdue Pharma L.P., et al.	N.D. Ind./3:18-cv-00243	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	4/6/2018	2018
St. Landry Parish, Louisiana by and through its duly elected President William K. "Bull" Fontenot, Jr. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46042-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Anda; CVS; Rite Aid; Walgreens; Walmart; Amneal; Indivior; Mylan; Hikma; Louisiana Wholesale Drug Co; Albertsons; Morris & Dickson; Rhodes	9/5/2018	2018
St. Louis County v. Purdue Pharma L.P., et al.	E.D. Mo./4:17-cv-02703-CDP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Abbott; Endo; Perry Fine; Scott Fishman; Lynn Webster	11/10/2017	2017

St. Louis County, MN v. Purdue Pharma L.P., et al.	D. Minn./0:18-cv-00875-DWF-LIB (removed from 6th Jud. Ct. (MN))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; John Does 1-50	3/14/2018	2018
St. Lucie County, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./2:19-cv-14204	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen; Walmart	6/13/2019	2019
St. Martin Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00569-JWD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/21/2018	2018
St. Mary Parish School Board v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00957	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
St. Mary Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00938-JWD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/23/2018	2018
St. Tammany Fire Protection District No. 1 v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00968-SDD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
St. Tammany Fire Protection District No. 12 v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00965-BAJ-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018

St. Tammany Fire Protection District No. 13 v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00964- BAJ-ELD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
St. Tammany Fire Protection District No. 2 v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00962- BAJ-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
St. Tammany Fire Protection District No. 3 v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00966- SDD-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
St. Tammany Fire Protection District No. 4 v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00969- SDD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
St. Tammany Fire Protection District No. 5 v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00963- BAJ-ELD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
St. Tammany Parish Coroner's Office and Dr. Charles Preston v. Purdue Pharma L.P., et al.	E.D. La./2:18-cv-03457	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Watson; Actavis; Mallinckrodt; Cardinal; AmerisourceBergen; Allergan	3/31/2018	2018

St. Tammany Parish Government v. Purdue Pharma L.P., et al.	E.D. La./2:18-cv-08687-SSV-DEK (removed from 22nd Judicial District Court, Parish of St. Tammany (LA)/2018-13660)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Morris & Dickson	7/27/2018	2018
Standing Rock Sioux Tribe v. Purdue Pharma L.P., et al.	D.N.D./1:18-cv-00027-CSM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon, Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	2/12/2018	2018
Stark County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00174-DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS	8/13/2019	2019
Stark County, Ohio Board of County Commissioners v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46340-DAP (removed from C.P. Stark County (OH)/2018CV02230)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Allergan; Watson; Actavis; Rhodes; SpecGx; Insys; Warner Chilcott	11/14/2018; 12/19/2019 (Am.); 3/15/2019	2018
Starke County, Indiana v. AmerisourceBergen Drug Corp., et al.	N.D. Ind./3:18-cv-00970-PPS-MGG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	11/30/2018	2018
State of Alabama v. Purdue Pharma L.P., et al.	M.D. Ala./2:18-cv-00089-MHT-WC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes Pharmaceuticals L.P.	2/6/2018	2018
State of Illinois and St. Clair County, Illinois v. Purdue Pharma L.P., et al.	S.D. Ill/3:17-cv-00616-MJR-RJD (Removed from St. Clair Cnty. (IL)/17-L-204)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott	6/9/2017	2017
Steele County, Minnesota, Waseca County, Minnesota, and Minnesota Prairie Alliance v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-02389	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	8/29/2019	2019

Stephens County v. Purdue Pharma L.P., et al.	N.D. Texas/1:18-cv-00078-C	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Does 1-100 Inclusive	5/29/2018; 3/16/2019	2018
Stephens County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45195-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/27/2019	2019
Stockbridge-Munsee Community v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45032-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Insys; CVS; Walgreens; H.D. Smith; Walmart; Health Mart	1/25/2019	2019
Stokes County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:18-cv-00070	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
Stone County, Mississippi v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./1:18-cv-00175-LG-RHW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	5/23/2018	2018
Strafford County v. Purdue Pharma L.P., et al.	D.N.H./1:19-cv-00325 (removed from Strafford Super. Ct. (NH)/219-2018-CV-00364)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Rite-Aid; Walgreens; Walmart; Dr. Michael Dipre; Dr. Mark Weinreb; Christopher Clough; Dr. Greg Thompson	9/18/2018	2018

Sullivan County v. Purdue Pharma L.P., et al.	D.N.H./1:19-cv-00334 (Sullivan Super. Ct. (NH)/220-2018-CV- 00128)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Rite-Aid; Walgreens; Walmart; Dr. Michael Dipre; Dr. Mark Weinreb; Christopher Clough; Dr. Erik L. Knight	9/18/2018	2018
Sumner County, TN v. Purdue Pharma L.P., et al.	M.D. Tenn./2:18-cv- 00241	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/27/2018	2018
Sumter County, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./7:18-cv-00166- TMP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
Sumter County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./1:18-cv-00043- LJA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	2/22/2018	2018
Sunflower County, Miss v. Purdue Pharma L.P., et al.	N.D. Miss./4:17-cv- 00189-DMB-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/19/2017	2017
Surry County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:17-cv-01159	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	12/29/2017	2017

Sussex County, Delaware v. Purdue Pharma L.P., et al.	D. De./1:19-cv-01274-UNA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Abbott; Knoll; Allergan; Watson; McKesson; Actavis; Cardinal; Mallinckrodt; Covidien; Abbvie; CVS; Walmart; Rite Aid; Walgreens; AmerisourceBergen	7/9/2019	2019
Sussex County, New Jersey v. Purdue Pharma L.P., et al.	D.N.J./2:19-cv-13747-JMV-MF	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; CVS; Walgreens; Costco; Rite Aid	6/14/2019	2019
Suwannee County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./3:19-cv-00711-TJC-PDB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/13/2019	2019
Sweetwater County v. Purdue Pharma L.P., et al.	D. Wyo./1:19-cv-00007	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; AmerisourceBergen; Insys; Amneal; West-Ward; Mylan; Walgreens; Walmart	1/11/2019; 3/15/2019	2019
Swinomish Tribe v. Purdue Pharma L.P., et al.	W.D. Wa./2:18-cv-00980-JCC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; SpecGx; Mallinckrodt; Cardinal; McKesson; Health Mart; AmerisourceBergen	7/2/2018	2018
Sycuan Band of Kumeyaay Nation v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45582-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; TEVA; Watson	7/3/2019	2019

TAKOMA REGIONAL HOSPITAL, INC. F/K/A TAKOMA HOSPITAL, INC., AMISUB (SFH), INC., BAPTIST WOMENS HEALTH CENTER, LLC, CAMPBELL COUNTY HMA, LLC, CLARKSVILLE HEALTH SYSTEM, G.P., CLEVELAND TENNESSEE HOSPITAL COMPANY, LLC, COCKE COUNTY HMA, LLC, DICKENSON COMMUNITY HOSPITAL, HAWKINS COUNTY MEMORIAL. : HOSPITAL F/K/A HAWKINS COUNTY MEMORIAL HOSPITAL, JEFFERSON COUNTY HMA, LLC, JOHNSTON MEMORIAL HOSPITAL,	E.D. Tenn./2:19-cv- 00157 (removed from Cir. Ct. Greene Cnty. (Tenn.)/CC19CV295BB)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Amneal; TEVA; Cephalon; Johnson & Johnson; Janssen; Abbott; Assertio; Endo; Mallinckrodt; SpecGx; Allergan; Watson; Anda; H.D. Smith; Henry Schein; AmerisourceBergen; Miami-Luken; Cardinal; Rite Aid; CVS; Kroger; Walmart; Noramco; Walgreens; P&S Pharmacy; Lowell B. Grizzle; Henry Babenco; Sharon Naylor; Alicia Naylor; Gregory Madron	7/11/2019	2019
Taliaferro County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45562-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/11/2018	2018
Talladega County, Alabama and City of Talledega, Alabama v. Cardinal Health Inc., et al.	N.D. Ala./1:18-cv-00152- JEO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cardinal; AmerisourceBergen; McKesson; Actavis; Allergan; Cephalon; Endo; Insys; Janssen; Johnson & Johnson; Mallinckrodt; Noramco; TEVA; Watson; John and Jane Does 1-100	1/31/2018	2018
Tallahatchie County, Miss. v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:18-cv- 00077-NBB-RP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/26/2018	2018

Tallapoosa County, AL v. AmerisourceBergen Drug Corp., et al.	M.D. Ala./3:17-cv-00763-WC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	11/8/2017	2017
Tanana Chiefs Conference; Chugachmiut, Inc.; Copper River Native Association; Yukon-Kuskowkwim Health Corporation; Southcentral Foundation v. AmerisourceBergen Drug Corp., et al.	D. Alaska/3:18-cv-00260-SLG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; Walgreen; Kroger; Albertsons; Walmart; CVS	10/30/2018	2018
Tate County, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./3:19-cv-00044-DMB-RP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	3/1/2019	2019
Tattnall County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45574-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/15/2018	2018
Taylor Brooke Underwood, individually and as next friend and guardian of Baby C.U. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45537-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019

Taylor County, Florida v. Purdue Pharma L.P., et al.	N.D. Fla./4:19-cv-00270-MW-CAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/14/2019	2019
Taylor Regional Hospital v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./5:18-cv-00451-TES	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Noramco; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson	12/7/2018	2018
Tazewell County, Virginia v. AmerisourceBergen Drug Corp., et al.	W.D. Va./1:18-cv-00036-EKD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; North Carolina Mutual Wholesale Drug; Rite Aid; Walmart; Par; SpecGx; West-Ward; Rhodes; CVS; Walgreens; JM Smith	8/27/2018; 3/14/2019	2018
Teamsters Health Service and Insurance Plan Local 404 v. Purdue Pharma L.P., et al.	D. Mass./3:17-cv-12342	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	11/28/2017	2017
Teamsters Local 237 Retirees' Benefit Fund and Teamsters Local 237 Welfare Fund v. Purdue Pharma L.P., et al.	S.D.N.Y./1:18-cv-00336	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; Insys; AmerisourceBergen; Cardinal; McKesson	1/12/2018	2018
Teamsters Local 493 Health Service & Insurance Fund v. Purdue Pharma L.P., et al.	CT/3:17-cv-02092-AWT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Qualitest; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Abbott; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/18/2017	2017

Teamsters Local 671 Health Service & Insurance Fund v. Purdue Pharma L.P., et al.	CT/3:17-cv-02093-VAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Qualitest; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Abbott; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/18/2017	2017
Teamsters Local 677 Health Service & Insurance Fund v. Purdue Pharma L.P., et al.	CT/3:17-cv-02094-SRU	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Qualitest; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Abbott; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/18/2017	2017
Terry Deese in his official capacity as the Sheriff of Peach County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45314-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	5/9/2019	2019
The Arizona School Alliance for Workers' Compensation, Inc. v. Purdue Pharma L.P., et al.	D. Ariz./2:18-cv-01201-ESW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; John and Jane Does 1 through 100, inclusive	4/18/2018	2018
The Bear River Band of Rohnerville Rancheria v. Purdue Pharma L.P., et al.	N.D. Cal./1:18-cv-07431-RMI	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Noramco; Insys; Par; Mallinckrodt; SpecGx; Health Mart	12/10/2018	2018

The Blackfeet Tribe of the Blackfeet Indian Reservation v. AmerisourceBergen Drug Corp., et al.	D. Mt./4:18-cv-00089-BMM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	6/22/2018	2018
The Board of Commissioners of Okfuskee County, State of Oklahoma v. Purdue Pharma L.P., et al.	E.D. Okla./6:19-cv-00300 (removed from D. Ct. Okfuskee Cnty. (OK)/CJ-19-21)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Tamerlane Rozsa; Roger Kinney; Joshua Livingston; Joseph Knight; Christopher Moses; Jeremy Thomas	6/14/2019	2019
The Board of Commissioners of Oklahoma County v. Purdue Pharma L.P., et al.	W.D. Okla./5:19-cv-00926-PRW (removed from D. Ct. Oklahoma Cnty. (OK)/CJ-2019-4562)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Par; SpecGx; Mylan; Pd-Rx	8/16/2019	2019
The Board of Commissioners of the County of Allen v. Purdue Pharma L.P., et al.	N.D. Ind./1:18-cv-00003	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman and Lynn Webster	1/5/2018	2018
The Board of Commissioners of the County of Franklin v. Purdue Pharma L.P., et al.	S.D. Ind./1:18-cv-01647-TWP-DLP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; RiteAid; Walgreens; Wal-Mart; H.D. Smith; Miami-Luken	5/30/2018	2018
The Board of County Commissioners for Greenwood County, Kansas and Joe Lee, Greenwood County Attorney v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45384-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019

The Board of County Commissioners for Meade County, Kansas and Laura Lewis, Meade County Attorney v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45390-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
The Board of County Commissioners for Stanton County, Kansas and David Black, Stanton County Attorney v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45388-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
The Board of County Commissioners of Delaware County, State of Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla./4:18-cv-00460-CVE-JFJ (removed from D. Ct. Delaware Cnty. (OK)/CJ-2018-61)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Perry Fine; Scott Fishman; Lynn Webster; Dr. Tamerlane Rozsa, MD; Roger Kinner, MD; Joshua Livingston, DO; Joseph Knight, MD; Christopher Moses, DO; SpecGx; Par; West-Ward; Hikma; Mylan; Rhodes; John N. Kapoor; Miami-Luken; Noramco; Rite Aid; Sandoz; Eckerd; Burlington; Amneal; Anda	6/13/2018	2018

The Board of County Commissioners of Garvin County, State of Oklahoma v. Purdue Pharma L.P., et al.	W.D. Okla./5:18-cv-00820-HE (removed from Dist. Ct. Garvin Cnty./CJ-2018-79)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Perry Fine; Scott Fishman; Lynn Webster; Dr. Tamerlane Rozsa, MD; Roger Kinner, MD; Joshua Livingston, DO; Joseph Knight, MD; Christopher Moses, DO; SpecGx; Par; West-Ward; Hikma; Mylan; Rhodes; John N. Kapoor; Miami-Luken; Noramco; Rite Aid	7/20/2018	2018
The Board of County Commissioners of McClain County, State of Oklahoma v. Purdue Pharma L.P., et al.	W.D. Okla./5:18-cv-00857-R (removed from D. Ct. McClain Cnty. (OK)/CJ-18-128)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Perry Fine; Scott Fishman; Lynn Webster; Dr. Tamerlane Rozsa, MD; Roger Kinner, MD; Joshua Livingston, DO; Joseph Knight, MD; Christopher Moses, DO; SpecGx; Par; West-Ward; Hikma; Rhodes; Mylan; Morris & Dickson; John N. Kapoor; Miami-Luken; Noramco; Anda; Rite Aid	6/13/2018	2018

The Board of County Commissioners of Osage County, State of Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla./4:18-cv-00461-GKF-JFJ (removed from D. Ct. Osage Cnty. (OK)/CJ-2018-54)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Perry Fine; Scott Fishman; Lynn Webster; Dr. Tamerlane Rozsa, MD; Roger Kinner, MD; Joshua Livingston, DO; Joseph Knight, MD; Christopher Moses, DO; SpecGx; Par; West-Ward; Hikma; Sandoz; Rhodes; John N. Kapoor; Noramco; Miami-Luken; Anda; Rite Aid	6/13/2018; 3/18/2019	2018
--	--	---	---	-------------------------	------

The Board of County Commissioners of Ottawa County, State of Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla./4:18-cv-00466-TCK-JFJ (removed from D. Ct. Ottawa Cnty. (OK)/CJ-2018-53)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Perry Fine; Scott Fishman; Lynn Webster; Dr. Tamerlane Rozsa, MD; Roger Kinner, MD; Joshua Livingston, DO; Joseph Knight, MD; Christopher Moses, DO; SpecGx; Par; West-Ward; Hikma; Mylan; SAJ; Rhodes; John N. Kapoor; CVS; Miami-Luken; Noramco; Anda; Rite Aid	6/13/2018; 3/18/2019	2018
---	---	---	--	-------------------------	------

The Board of County Commissioners of Pawnee County, State of Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla./4:18-cv-00459-GKF-FHM (removed from D. Ct. Pawnee Cnty. (OK)/CJ-2018-59)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Perry Fine; Scott Fishman; Lynn Webster; Dr. Tamerlane Rozsa, MD; Roger Kinner, MD; Joshua Livingston, DO; Joseph Knight, MD; Christopher Moses, DO; SpecGx; Par; West-Ward; Hikma; Sandoz; Rhodes; John N. Kapoor; Noramco; Anda; Rite Aid	6/13/2018	2018
The Board of County Commissioners of Seminole County, State of Oklahoma v. Purdue Pharma L.P., et al.	E.D. Okla./6:18-cv-00372-SPS (removed from D. Ct. Seminole Cnty. (OK)/CJ-2018-114)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Tamerlane Rozsa; Roger Kinney; Joshua Livingston; Joseph Knight; Christopher Moses	10/9/2018	2018
The Board of County Commissioners of the County of Jefferson v. Purdue Pharma L.P., et al.	D. Colo./1:19-cv-00113	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	1/11/2019	2019
The Board of County Counsellors for Wabaunsee County, Kansas and Tim Leismann, Wabaunsee County Attorney v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45377-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/5/2019	2019

The Board of County Counselors for Dickenson County, Kansas and Andrea Purvis, Dickinson County Attorney v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45379-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
The Board of County Counselors for Elk County, Kansas and Joe Lee, Elk County Attorney v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45382-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
The Board of County Counselors for Grant County, Kansas and Jessica Akers, Grant County Attorney v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45394-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
The Borough of Ridgefield v. Purdue Pharma L.P., et al.	D.N.J./2:18-cv-10842 (removed from NJ state court, BER L-007640-17)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Endo; Insys; McKesson; Cardinal; AmerisourceBergen; Perry Fine; Scott Fishman; Lynn Webster	11/8/2017	2017
The Candler County Hospital Authority v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./6:18-cv-00012-JRH-GRS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	1/29/2018	2018
The Cherokee Nation v. Purdue Pharma L.P., et al.	E.D. Okla./6:18-cv-00236-KEW (removed from Dist. Ct. Sequoyah Cnty. (Okla.)/CJ-2018-86)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharma Manufacturing Inc.	N/A	6/19/2018	2018

The City of Amsterdam v. Purdue Pharma L.P., et al.	N.D.N.Y./1:19-cv-00896- MAD-CFH (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Bellco; Blenheim; Eveready; Kinray; PSS World; Rochester Drug; Darby; Rhodes; Par; Mallinckrodt; SpecGx; Mylan; Sandoz; West- Ward; Amneal; Noramco; John N. Kapoor; Anda; Discount Drug; HBC; Morris & Dickson; Publix; SAI; Value Drug; CVS; Smith Drug Co; Rite Aid; Walgreens; Wal-Mart; Miami-Luken; Kroger; Henry Schein; Express; Caremark; UnitedHealth; OptumRx; Prime; Navitus	6/25/2019	2019
The City of Auburn v. Purdue Pharma L.P., et al.	E.D.N.Y./2:18-cv-03800 (removed from Sup. Ct. Suffolk Cnty. (N.Y.)/400017-2019)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Bellco; Blenheim; Eveready; Kinray; PSS World; Rochester Drug; Darby; Rhodes; Par; Mallinckrodt; SpecGx; Mylan; Sandoz; West- Ward; Amneal; Noramco; John N. Kapoor; Anda; Discount Drug; HBC; Morris & Dickson; Publix; SAI; Value Drug; CVS; Smith Drug Co; Rite Aid; Walgreens; Wal-Mart; Miami-Luken; Kroger; Henry Schein; Express; Caremark; UnitedHealth; OptumRx; Prime; Navitus	6/7/2019	2019

THE CITY OF BARBERTON; THE VILLAGE OF BOSTON HEIGHTS; BOSTON TOWNSHIP; THE VILLAGE OF CLINTON; COPLEY TOWNSHIP; COVENTRY TOWNSHIP; THE CITY OF CUYAHOGA FALLS; THE CITY OF FAIRLAWN; THE CITY OF GREEN; THE VILLAGE OF LAKEMORE; THE VILLAGE OF MOGADORE; THE CITY OF MUNROE FALLS; THE CITY OF NEW FRANKLIN; THE CITY OF NORTON; THE VILLAGE OF PENINSULA; THE VILLAGE OF RICHFIELD; THE VILLAGE OF SILVER LAKE; SPRINGFIELD	N.D. Ohio/1:18-op- 45767-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Johnson & Johnson; Noramco; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Anda; Cardinal; CVS; Discount; HBC; Henry Schein; McKesson; Miami-Luken; Rite Aid; Walgreens; Wal-Mart	6/30/2018	2018
The City of Broadview Heights v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00721 (removed from C.P. Cuyahoag County (OH)/CV 18 893586)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Miami-Luken; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Walgreens; CVS; Rhodes; Mallinckrodt; John N. Kapoor; Anda; Rite Aid; Wal-Mart; Rhodes	2/26/2018	2018
The City of Brunswick v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00423	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	2/21/2018	2018

The City of Buckhannon, West Virginia v. McKesson Corporation, et al.	S.D. WV/2:18-cv-01263	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Mallinckrodt; SpecGx; Wal-Mart; CVS; Kroger; Rite Aid; Walmart; Rhodes; SpecGx; Watson; Actavis; Allergan; Warner Chilcott	8/28/2018; 3/15/2019	2018
The City of Clarksville, Tennessee v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-01008	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/1/2018	2018
The City of Coconut Creek, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./0:19-cv-60364- RNS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Health Mart; H.D. Smith; CVS; Walgreen; Wal- Mart	2/11/2019	2019
The City of Columbus v. Purdue Pharma L.P., et al.	S.D. Ohio/2:17-cv-01102- EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; AmerisourceBergen; McKesson; Cardinal; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/15/2017	2017
The City of Coral Gables v. Purdue Pharma L.P., et al.	S.D. Fla./1:18-cv-22580- UU	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; TEVA; Cephalon; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Walgreens	6/26/2018	2018

The City of Dayton v. Purdue Pharma L.P., et al.	S.D. Ohio/3:17-cv-00229 (removed from 2017-cv-02647/C.P. Montgomery Cnty., (OH))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Walgreens; Walmart; CVS; Miami-Luken; Rite Aid; Kroger; H.D. Smith; Rhodes; John N. Kapoor; Insys; Mallinckrodt; Noramco; Anda	6/5/2017; 7/10/2017	2017
The City of Eagle Pass, Texas v. Purdue Pharma L.P., et al.	W.D. Texas/2:18-cv-00051	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Endo; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; SpecGx; Par; Rhodes; John N. Kapoor; Miami-Luken; Noramco; Anda	8/9/2018; 3/15/2019	2018
The City of Elkhardt, Morton County, Kansas v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45380-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
The City of Elyria v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-cv-00017 (removed from C.P. Lorain Cnty., 17CV193904)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt	11/28/2017	2017

The City of Euclid v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46013 (removed from C.P. Cuyahoga Cnty. (OH)/CV18901359)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; RiteAid; Miami-Luken; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Rhodes; John N. Kapoor; Noramco; Anda	7/27/2018	2018
The City of Fall River v. Purdue Pharma L.P., et al.	D. Mass./1:18-cv-12363 (removed from Super. Ct. Britol Cnty. (Mass.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens	8/14/2018	2018
The City of Fargo v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00139-DLH-ARS	Purdue Pharma L.P.; The Purdue Frederick Company, Inc.; Purdue Pharmaceutical Products L.P.; Purdue Products L.P.;	Rhodes; Endo; Par; Janssen; TEVA; Cephalon; Allergan; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	7/9/2019	2019
The City of Findlay v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46339-DAP (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; PSS World; CVS; Walgreens; Walmart; Rite Aid; Miami-Luken; Mylan; Amneal; Kroger; Rhodes; John N. Kapoor; Noramco; Anda	3/18/2019	2019

The City of Fitchburg v. Purdue Pharma L.P., et al.	D. Mass./1:18-cv-12580-LTS (removed from Super. Ct. Middlesex Cnty. (Mass.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Rite Aid; Walgreens; Walmart; Dr. Fathalla Mashali; SpecGx; Par; West-Ward; Mylan; Walgreens; Rhodes; John N. Kapoor; Mallinckrodt; Miami-Luken; Noramco; Anda	8/17/2018	2018
The City of Florence, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./5:19-cv-00191-HNJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; TEVA; Watson	1/31/2019	2019
The City of Gainesville, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./2:18-cv-00039-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/29/2018	2018
The City of Gulfport, Mississippi v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45291-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Insys; CVS; Walgreens; Walmart	4/24/2019	2019
The City of Hallandale Beach, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./0:19-cv-60431-BB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Health Mart; H.D. Smith; CVS; Walgreen; Wal-Mart	2/18/2019	2019

The City of Inez, a Political Subdivision of the Commonwealth of Kentucky v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op-45499-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Insys; Noramco	6/17/2019	2019
The City of Kenova, West Virginia, a West Virginia municipal corporation v. AmerisourceBergen Drug Corp., et al.	S.D. WV/2:18-cv-01472	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Mallinckrodt; SpecGx; Wal-Mart; RiteAid; CVS; Kroger; Top Rx; Rhodes; Actavis; Watson; Allergan; Warner Chilcott	11/28/2018; 3/15/2019	2018
The City of Lakewood and The City of Wheat Ridge v. Purdue Pharma L.P., et al.	D. Colo./1:18-cv-01434-WYD-STV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt	6/8/2018	2018
The City of Laredo, Texas v. Purdue Pharma L.P., et al.	S.D. Texas/5:18-cv-00118	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Endo; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; SpecGx; Par; West-Ward; Amneal; Mylan; HEB; Morris & Dickson; Rhodes; John N. Kapoor; Noramco; Anda; Miami-Luken	8/9/2018; 3/18/2019	2018
The City of Lauderdale, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./0:19-cv-60472-JEM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Health Mart; H.D. Smith; CVS; Walgreen; Wal-Mart	2/22/2019	2019

The City of Lebanon, Ohio v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:18-cv-00078-EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	1/30/2018	2018
The City of Long Beach, Mississippi v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45517-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Insys; CVS; Walgreens; Walmart	6/18/2019	2019
The City of Lorain v. Purdue Pharma L.P., et al.	N.D. Ohio/1:17-cv-01639 (removed from 17CV192705/C.P. Lorain Cnty., (OH))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Walgreens; Walmart; CVS; Miami-Luken; Rite Aid; Kroger; H.D. Smith; Rhodes; John N. Kapoor; Insys; Mallinckrodt; Noramco; Anda	6/29/2017	2017
The City of Manter, Stanton County, Kansas v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45389-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
The City of Medford v. Purdue Pharma L.P., et al.	D. Mass./1:19-cv-10262-MLW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; Mallinckrodt; McKesson; AmerisourceBergen; CVS; Rite Aid; Walgreens; Walmart; Dr. Fathalla Mashali; Rhodes	2/11/2019	2019

The City of Miami v. Purdue Pharma L.P., et al.	S.D. Fla./1:18-cv-21920 (removed from Cir. Ct. Miami-Dade Cnty. (Fla.)/18012165CA23)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; Insys; Mallinckrodt; McKesson; AmerisourceBergen; Walgreens	4/18/2018	2018
The City of Milledgeville, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga/5:18-cv-00115-MTT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	4/6/2018	2018
The City of Miramar, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./0:19-cv-60313-XXXX	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Health Mart; H.D. Smith; CVS; Walgreen; Wal-Mart	2/5/2019	2019
The City of Montgomery, West Virginia v. AmerisourceBergen Drug Corp, et al.	S.D. WV/2:18-cv-01285	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Mallinckrodt; SpecGx; Wal-Mart; Walgreens; H.D. Smith; Kroger; CVS; RiteAid; Actavis; Watson; Rhodes; Allergan; Warner Chilcott	9/10/2018; 3/15/2019	2018
The City of Nashua v. Purdue Pharma L.P., et al.	D.N.H./1:17-cv-00730	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Insys; Mallinckrodt; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/20/2017	2017

The City of Nauvoo, Alabama; The City of Cardova, Alabama; The City of Carbon Hill, Alabama; The City of Sipse, Alabama; The City of Parrish, Alabama; The City of Oakman, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./6:18-cv-00799-LSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrdot; Insys; McKesson; AmerisourceBergen	5/24/2018	2018
The City of New Castle, City of Aliquippa and Union Township, on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	E.D. Pa./2:18-cv-01472 (removed from C.P. Philadelphia (PA)/180301961)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Noramco; Value Drug; SpecGx; Par; Amneal; KVK; CVS; Rite Aid; Walmart	3/16/2018; 3/6/2019	2018
The City of Newark, NJ v. Purdue Pharma L.P., et al.	D.N.J./2:18-cv-10310 (removed from Super. Ct. NJ. Essex Cty.)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo	10/1/2017	2017
The City of North Olmstead v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46012 (removed from C.P. Cuyahoga Cnty. (OH)/CV18901368)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; RiteAid; Miami-Luken; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Rhodes; John N. Kapoor; Noramco; Anda	7/26/2018	2018
The City of North Ridgeville v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46015	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; RiteAid; Miami-Luken; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Rhodes; John N. Kapoor; Noramco; Anda	8/30/2018	2018

The City of Ogdensburg v. Purdue Pharma L.P., et al.	N.D.N.Y./8:19-cv-00782- DNH-DJS (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Bellco; Blenheim; Eveready; Kinray; PSS World; Rochester Drug; Darby; Rhodes; Par; Mallinckrodt; SpecGx; Mylan; Sandoz; West- Ward; Amneal; Noramco; John N. Kapoor; Anda; Discount Drug; HBC; Morris & Dickson; Publix; SAI; Value Drug; CVS; Smith Drug Co; Rite Aid; Walgreens; Wal-Mart; Miami-Luken; Kroger; Henry Schein; Express; Caremark; UnitedHealth; OptumRx; Prime; Navitus	6/7/2019	2019
The City of Olmsted Falls v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46014 (removed from C.P. Cuyahoga Cnty. (OH)/CV18901368)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; RiteAid; Miami- Luken; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West- Ward; Mylan; Rhodes; John N. Kapoor; Noramco; Anda	7/11/2018	2018
The City of Paintsville, a Political Subdivision of the Commonwealth of Kentucky v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:19-op- 45559-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Insys; Noramco	6/24/2019	2019

The City of Parma Heights v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45733 (removed from C.P. Cuyahoga County (OH)/CV18-898654)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; Rite Aid; Miami-Luken; Perry Fine; Scott Fishman; Lynn Webster	5/31/2018	2018
The City of Parma v. Purdue Pharma L.P., et al.	N.D. Ohio/1:17-cv-01872 (CV-17-884281/C.P. Cuyahoga Cnty., (OH))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Walgreens; Walmart; CVS; Miami-Luken; Rite Aid; Kroger; H.D. Smith; Rhodes; John N. Kapoor; Insys; Mallinckrodt; Noramco; Anda	8/8/2017	2017
The City of Paterson, NJ v. Purdue Pharma L.P., et al.	D.N.J./2:17-cv-13433 (removed from Super. Ct. NJ. Passaic Cty.)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBergen	10/23/2017	2017
The City of Pompano Beach, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./0:19-cv-60305-WPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Health Mart; H.D. Smith; CVS; Walgreen; Wal-Mart	2/4/2019	2019

The City of Poughkeepsie, individually, and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	S.D.N.Y./7:19-cv-06800 (removed from Sup. Ct. Dutchess Cnty. (N.Y.)/2019-51786)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergenBerg en; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; John N. Kapoor; West-Ward; Value Drug	3/28/2019	2019
The City of Prestonburg, a Political Subdivision of the Commonwealth of Kentucky v. AmersouceBergen Drug Corp., et al.	N.D. Ohio/1:19-op-45294-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Insys	4/30/2019	2019
The City of Princeton, West Virginia, a West Virginia municipal corporation v. AmerisourceBergen Drug Corp., et al.	S.D. WV/1:18-cv-01242	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Mallinckrodt; SpecGx; Wal-Mart; Rhodes; Walmart; Kroger; CVS; Allergan; Watson; Allergan; Actavis; Warner Chilcott	8/20/2018; 3/15/2019	2018
The City of Quincy v. Purdue Pharma L.P., et al.	D. Mass./1:18-cv-12627 (removed from Super. Ct. Norfolk Cnty. (Mass.)/1882CV01079)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Cardinal; Mallinckrodt; SpecGx	8/23/2018	2018

The City of Rochester v. Purdue Pharma L.P., et al.	W.D.N.Y./6:19-cv-06490	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Bellco; Blenheim; Eveready; Kinray; PSS World; Rochester Drug; Darby; Rhodes; Par; Mallinckrodt; SpecGx; Mylan; Sandoz; West- Ward; Amneal; Noramco; John N. Kapoor; Anda; Discount Drug; HBC; Morris & Dickson; Publix; SAI; Value Drug; CVS; Smith Drug Co; Rite Aid; Walgreens; Wal-Mart; Miami-Luken; Kroger; Henry Schein; Express; Caremark; UnitedHealth; OptumRx; Prime; Navitus	6/5/2019	2019
The City of San Diego and the People of the State of California, by and through Mara W. Elliott, City Attorney of San Diego v. Purdue Pharma L.P., et al.	S.D. Cal./3:19-cv-00420-L-BGS	Purdue Pharma L.P.	Rhodes; Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	3/4/2019	2019
The City of Sandy Springs, Georgia, a municipal corporation v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-cv-01006	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys	5/1/2018	2018

The City of Saratoga Springs v. Purdue Pharma L.P., et al.	N.D.N.Y./1:19-cv-00789-DNH-DJS (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Bellco; Blenheim; Eveready; Kinray; PSS World; Rochester Drug; Darby; Rhodes; Par; Mallinckrodt; SpecGx; Mylan; Sandoz; West-Ward; Amneal; Noramco; John N. Kapoor; Anda; Discount Drug; HBC; Morris & Dickson; Publix; SAI; Value Drug; CVS; Smith Drug Co; Rite Aid; Walgreens; Wal-Mart; Miami-Luken; Kroger; Henry Schein; Express; Caremark; UnitedHealth; OptumRx; Prime; Navitus	6/7/2019	2019
The City of Seat Pleasant, Maryland v. Purdue Pharma L.P., et al.	D. Md./8:19-cv-00802 (removed from Cir. Ct. Prince George's Cnty. (MD)/CAL-18-41565)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Rite Aid; Walmart; CVS	11/2/2018	2018
The City of Springfield, Missouri v. Purdue Pharma L.P., et al.	W.D. Mo./6:18-cv-03167-SRB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Harvard Drug Group; Rugby; H.D. Smith; Walmart; Express; CVS; Caremark; Optum; RiteAid; Envision; Medtrak; UnitedHealth	5/30/2018	2018

The City of Strongsville v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46111-DAP (removed from C.P. Cuyahoga County (OH)/CV-18-902898)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Endo; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; RiteAid; Miami-Luken; Perry Fine; Scott Fishman; Lynn Webster	8/28/2018	2018
The City of Tampa v. Purdue Pharma L.P., et al.	M.D. Fla./8:18-cv-02792-SDM-CPT (removed from Cir. Ct. Hillsborough Cnty. (Fla.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; H.D. Smith; Anda; CVS; Walgreens	10/2/2018	2018
The City of Tifton, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./7:18-cv-00052-WLS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	4/5/2018	2018
The City of Toledo v. Purdue Pharma L.P., et al.	N.D. Ohio/3:17-cv-02516-JZ (removed from C.P. Lucas Cnty./G-4801-CI-0201704628-000)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Walgreens; Walmart; CVS; Miami-Luken; Rite Aid; Kroger; H.D. Smith; Rhodes; John N. Kapoor; Insys; Mallinckrodt; Noramco; Anda	10/30/2017	2017

The City of Ulysses, Grant County, Kansas v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45392-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
The City of Vienna, West Virginia, a West Virginia municipal corporation v. AmerisourceBergen Drug Corp., et al.	S.D. WV/2:19-cv-00052	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Mallinckrodt; SpecGx; Wal-Mart; RiteAid; CVS; Kroger; Top Rx	1/17/2019	2019
The City of Waynesboro, Virginia v. Purdue Pharma L.P., et al.	W.D. Va./5:19-cv-00058- EKD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1- 101	N/A	2019
The City of West Liberty, a Political Subdivision of the Commonwealth of Kentucky v. AmersouceBergen Drug Corp., et al.	N.D. Ohio/1:19-op- 45329-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Insys	5/15/2019	2019
The City of Wichita, Kansas v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45781	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; CVS; Cardinal; Cephalon; Endo; H.D. Smith; Health Mart; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; TEVA; Walgreens; Walmart	9/6/2019	2019

The City of Winfield, Alabama v. Purdue Pharma L.P., et al.	N.D. Ala./6:18-cv-00800- LSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrdot; Insys; McKesson; AmerisourceBergen	5/24/2018	2018
The Comanche Nation v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45442-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; CVS; Cardinal; Cephalon; Endo; H.D. Smith; Health Mart; Insys; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Rite Aid; TEVA; Kroger; Walgreens; Walmart; Watson	6/13/2019	2019
The County Commission of Craig County, Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv- 00317-JED-JFJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Johnson & Johnson; Par; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; Harvard Drug Co.; AmerisourceBergen; H.D. Smith	6/14/2019	2019
The County Commission of Creek County, Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv- 00134-CVE-FHM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Johnson & Johnson; Par; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; Harvard Drug Co.; AmerisourceBergen	3/11/2019	2019
The County Commission of Mayes County, Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv- 00136-CVE-JFJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Johnson & Johnson; Par; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; Harvard Drug Co.; AmerisourceBergen; H.D. Smith	3/12/2019	2019

The County Commission of Mingo County v. Purdue Pharma, L.P. et al	S.D. WV/2:18-cv-00476 (removed from Cit. Ct. Mingo Cnty. (WV)/18-C-2)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Johnson & Johnson; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Miami-Luken; RiteAid; WV Board of Pharmacy; Rhodes; Walmart	1/18/2018; 3/15/2019	2018
The County Commission of Monroe County, Florida v. Purdue Pharma L.P., et al.	S.D. Fla./4:19-cv-10049-XXXX	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Health Mart; H.D. Smith; CVS; Walgreen; Wal-Mart	4/3/2019	2019
The County Commission of Nowata County, Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv-00133-JED-FHM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Johnson & Johnson; Par; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; Harvard Drug Co.; AmerisourceBergen; H.D. Smith	3/12/2019	2019
The County Commission of Okmulgee County, Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla/4:19-cv-00131-CVE-JFJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Johnson & Johnson; Par; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; Harvard Drug Co.; AmerisourceBergen; H.D. Smith	3/11/2019	2019
The County Commission of Payne County, Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv-00320-CVE-JFJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Johnson & Johnson; Par; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; Harvard Drug Co.; AmerisourceBergen; H.D. Smith	6/14/2019	2019

The County Commission of Putnam County v. AmerisourceBergen Drug Corp., et al	S.D. WV/3:18-cv-00350	Purdue Pharma L.P.; Purdue Pharma Inc.; Purdue Pharmaceuticals L.P.; The P.F. Laboratories Inc.; Purdue Pharma Manufacturing L.P.	AmerisourceBergen; Cardinal; McKesson; P.F. Laboratories; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Mallinckrodt	2/23/2018	2018
The County Commission of Rogers County, Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv-00132-TCK-JFJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Johnson & Johnson; Par; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; Harvard Drug Co.; AmerisourceBergen; H.D. Smith	3/12/2019	2019
The County Commission of Washington County, Oklahoma v. Purdue Pharma L.P., et al.	N.D. Okla./4:19-cv-00130-CVE-FHM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Noramco; Mallinckrodt; Johnson & Johnson; Par; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; Harvard Drug Co.; AmerisourceBergen	3/12/2019	2019
The County of Albany, NY v. Purdue Pharma L.P., et al.	N.D.N.Y./1:18-cv-00024-GTS-CFH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo	1/5/2018	2018
The County of Ballard, Kentucky v. Purdue Pharma, L.P. et al.	N.D. Ohio/1:18-op-45593-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	5/16/2018	2018

The County of Cuyahoga v. Purdue Pharma L.P., et al.	N.D. Ohio/1:17-cv-02482-CAB (removed from C.P. Cuyahoga Cty)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; SpecGx; Par; West-Ward; Mylan; Walgreens; Walmart; CVS; Miami-Luken; Rite Aid; Kroger; H.D. Smith; Rhodes; John N. Kapoor; Insys; Mallinckrodt; Noramco; Anda	10/27/2017	2017
The County of Fayette, Ohio; The State of Ohio ex rel. Prosecuting Attorney of Fayette County, Jess Weade v. Purdue Pharma L.P., et al.	S.D. Ohio/2:19-cv-04347 (removed from C.P. Fayette County (OH)/CVH20190261)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; SpecGx; McKesson; AmerisourceBergen; Walgreens; CVS	8/29/2019	2019
The County of Floyd v. Purdue Pharma L.P., et al.	E.D. Ky./7:17-cv-00186-GFVT (removed from Cir. Ct. Floyd Cnty. (TN)/17-CI-797)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; Magna Pharmaceuticals; Xanodyne Pharmaceuticals; Richie Enterprises	10/23/2017	2017

The County of Fulton v. Purdue Pharma L.P., et al.	N.D. Ga./1:17-cv-04757-ELR (removed from State Court of Fulton County (GA)/17EV005007)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman and Lynn Webster; Medicine Center Pharmacy; Amarc Medical Clinic; J.M. Smith Corporation; Vaxserve, Inc.; PSS World Medical, Inc.; Attain Med., Inc.; and Bloodworth Wholesale Drugs, Inc.; Mylan; Par; West-Ward; CVS; Kroger; Walgreens; Rhodes; Rite Aid; Walmart; Miami-Luken; Anda	10/23/2017	2017
The County of Knott v. Purdue Pharma L.P., et al.	E.D. Ky./7:18-cv-00006-GFVT (removed from Cir. Ct. Knott Cnty. (KY)/17CI257)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; Magna; Xanodyne; Richie	12/13/2017	2017
The County of Medina, Ohio; The State of Ohio ex rel. Prosecuting Attorney of Medina County, S. Forrest Thompson v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45839-DAP (removed from C.P. Medina County (OH)/19CIV0838)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; SpecGx; McKesson; AmerisourceBergen; Walgreens; CVS; Allergan; Watson; Warner; Actavis	8/28/2019	2019

The County of Oneida, NY v. Purdue Pharma L.P., et al.	N.D.N.Y./6:18-cv-00314- DNH-TWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Johnson & Johnson; Janssen ; Endo; Mallinckrodt; Allergan; Watson; Actavis; Insys; AmerisourceBergen; Cardinal; McKesson; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; John Does; John Doe Corporation; Cephalon	3/14/2018	2018
The County of Onondaga, NY v. Purdue Pharma L.P., et al.	N.D.N.Y./5:18-cv-00100- TJM-TWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Johnson & Johnson; Janssen ; Endo; Mallinckrodt; Allergan; Watson; Actavis; Insys; AmerisourceBergen; Cardinal; McKesson; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; John Does; John Doe Corporation; Cephalon	1/23/2018	2018
The County of Osceola v. Purdue Pharma L.P., et al.	M.D. Fla./6:18-cv-00164- GKS-TBS (removed from 9th Cir. Ct. Osceola County (FL)/2017-CA- 2928)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Endo; McKesson; Cardinal; AmerisourceBergen; Anda; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/27/2017	2017
The County of Pike v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45368	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Endo; McKesson; Cardinal; AmerisourceBergen; Magna; Xanodyne; Richie; SpecGx; Par; Noramco; John N. Kapoor; Mallinckrodt; Miami-Luken; Walmart; Walgreens; Rite Aid; CVS	3/18/2019	2019

The County of Portage, Ohio; City of Ravenna, Ohio; City of Kent, Ohio; City of Aurora, Ohio v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45993 (removed from C.P. Portage Cnty. (OH)/2018CV00605)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; SpecGx; Jane Does 1-50	7/24/2018	2018
The County of Rio Arriba v. Purdue Pharma L.P., et al.	D.N.M./1:18-cv-01213-SCY-KBM (removed from state court)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endl; Allergan; Actavis; Watson; Mallinckrodt; Insys; CVS; Walgreens; Walmart; Pawankumar K. Jain; William P. Gaspar; Paula Enyeart; Michael Miller; and Leann Martinez	11/16/2018	2018
The County of Roosevelt v. Purdue Pharma L.P., et al.	D.N.M./1:18-cv-00795-KK-SMV (removed from Roosevelt Dist. Ct. (NM)/D-911-CV-2018-00307)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster; Pawankumar K. Jain; William P. Gaspar; Rhodes; Par; SpecGx; CVS; Mallinckrodt; John N. Kapoor; Miami-Luken; Insys; Noramco; Anda; Walmart; Rite Aid; Walgreens	7/13/2018	2018
The County of Tuscarawas, Ohio v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45098 (removed from C.P. Tuscarawas County (OH)/2019-CT-01-0064)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; SpecGx; Insys; Cardinal; McKesson; AmerisourceBergen; Walgreens; CVS	1/25/2019	2019

The County of Zavala, Texas v. Purdue Pharma L.P., et al.	W.D. Texas/2:18-cv- 00052	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Endo; Insys; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; SpecGx; Rhodes; John N. Kapoor; Par; MiamiOLuken; Noramco; Anda	8/9/2018; 3/15/2019	2018
The DCH Health Care Authority; The Healthcare Authority for Baptist Health, an Affiliate of UAB Health System; Medical West Hospital Authority, an Affiliate of UAB Health System; Evergreen Medical Center, LLC; Gilliard Health Services, Inc.; Crestwood Healthcare, L.P.; Triad of Alabama, LLC; QHG of Enterprise, Inc.; Affinity Hospital, LLC; Gadsden Regional Hospital Center, LLC; Foley Hospital Corporation; The Health Care Authority of Clarke County, Alabama; BBH PBMC, LLC; BBH WBMC, LLC; BBH SBMC, LLC; BBH CBMC, LLC; BBH BMC, LLC v. Purdue Pharma L.P., et al.	S.D. Ala./1:19-cv-00756 (removed from Cir. Ct. Conecuh Cnty. (AL)/CV- 19-07)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Amneal; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Abbott; Assertio; Endo; Par; Mallinckrodt; SpecGx; Allergan; Watson; Actavis; Anda; H.D. Smith; Henry Schein; AmerisourceBergen; Cardinal; Rite Aid; Kroger; CVS; Walmart; Walgreens	9/3/2019	2019
The Fiscal Court of Bracken County, on behalf of Bracken County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./2:18-cv-00041- GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis, Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	3/22/2018	2018

The Fiscal Court of Carter County, on behalf of Carter County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./0:18-cv-00035-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	3/22/2018	2018
The Fiscal Court of Elliott County, on behalf of Elliott County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./0:18-cv-00036-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	3/22/2018	2018
The Fiscal Court of Estill County, on behalf of Estill County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:18-cv-00536-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/18/2018	2018
The Fiscal Court of Martin County, on behalf of Martin County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./7:18-cv-00036-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	3/22/2018	2018
The Fiscal Court of Wayne County, on behalf of Wayne County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./6:18-cv-00089-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	3/22/2018	2018
The Fiscal Court of Whitley, on behalf of Whitley County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./6:17-cv-00250-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/13/2017; 10/4/2017 (Am.)	2017

The Fiscal Court of Woodford, on behalf of Woodford County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:17-cv-00475-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	12/2/2017	2017
The Fiscal Court of Bourbon County v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45533-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco; Depomed; Collegium	5/4/2018	2018
The Fiscal Court of Breckinridge County, on behalf of Breckinridge County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./3:18-cv-00714-RGJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	10/30/2018	2018
The Fiscal Court of Campbell County, on behalf of Campbell County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./2:17-cv-00167-GFVT-CJS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	9/20/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Carlisle County, on behalf of Carlisle County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./5:17-cv-00136-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	9/12/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Christian County, on behalf of Christian County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./5:17-cv-00146-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	9/25/2017; 10/3/2017 (Am.)	2017

The Fiscal Court of Clark County, on behalf of Clark County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:17-cv-00473-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/1/2017	2017
The Fiscal Court of Clay County, on behalf of Clay County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./6:17-cv-00255-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis, Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/20/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Cumberland County, on behalf of Cumberland County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./1:17-cv-00163-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis, Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/20/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Fleming County, on behalf of Fleming County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:17-cv-00368-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis, Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/12/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Franklin County, on behalf of Franklin County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./3:17-cv-00071-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis, Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/12/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Garrard County, on behalf of Garrard County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:17-cv-00369-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis, Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/12/2017; 10/3/2017 (Am.)	2017

The Fiscal Court of Green County, on behalf of Green County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./1:18-cv-00158-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	10/30/2018	2018
The Fiscal Court of Greenup County, on behalf of Greenup County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./0:17-cv-00105-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/25/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Hardin County, on behalf of Hardin County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./3:18-cv-00715-CHB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	10/30/2018	2018
The Fiscal Court of Harlan County, on behalf of Harlan County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./6:17-cv-00247-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/12/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Henderson County, on behalf of Henderson County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./4:17-cv-00130-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/29/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Henry County, on behalf of Henry County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./3:17-cv-00073-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/13/2017; 10/4/2017 (Am.)	2017

The Fiscal Court of Hopkins County, on behalf of Hopkins County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./4:17-cv-00157-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	12/1/2017	2017
The Fiscal Court of Jessamine County, on behalf of Jessamine County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:17-cv-00438-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	11/7/2017	2017
The Fiscal Court of Kenton County, on behalf of Kenton County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./2:17-cv-00182-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/29/2017; 10/30/2017 (Am.)	2017
The Fiscal Court of Knox County, on behalf of Knox County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./6:17-cv-00248-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/12/2017; 10/4/2017 (Am.)	2017
The Fiscal Court of Laurel County, on behalf of Laurel County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./6:17-cv-00269-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/29/2017; 10/4/2017 (Am.)	2017
The Fiscal Court of Lee County, Kentucky v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46100-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco; Collegium	9/26/2018	2018

The Fiscal Court of Leslie County, on behalf of Leslie County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./6:17-cv-00249-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/12/2017; 10/4/2017 (Am.)	2017
The Fiscal Court of Letcher County, on behalf of Letcher County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./7:18-cv-00107-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/18/2018	2018
The Fiscal Court of Lincoln County, on behalf of Lincoln County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:17-cv-00370-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/12/2017; 10/4/2017 (Am.)	2017
The Fiscal Court of Madison County, on behalf of Madison County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:17-cv-00371-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/12/2017; 10/4/2017 (Am.)	2017
The Fiscal Court of Marshall County, on behalf of Marshall County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./5:17-cv-00147-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/25/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Meade County, on behalf of Meade County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./3:18-cv-00716-RGJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	10/30/2018	2018

The Fiscal Court of Montgomery County, on behalf of Montgomery County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:18-cv-00541-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/21/2018	2018
The Fiscal Court of Morgan County, on behalf of Morgan County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./0:19-cv-00056-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	6/10/2019	2019
The Fiscal Court of Nicholas County, on behalf of Nicholas County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:17-cv-00373-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/13/2017; 10/4/2017 (Am.)	2017
The Fiscal Court of Oldham County, on behalf of Oldham County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./3:17-cv-00590-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/25/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Owen County v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45534-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco; Depomed; Collegium	5/4/2018	2018
The Fiscal Court of Owsley County, on behalf of Owsley County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./6:18-cv-00275-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	10/26/2018	2018

The Fiscal Court of Pendleton County, on behalf of Pendleton County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./2:17-cv-00161-GFVT-CJS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/13/2017; 10/4/2017 (Am.)	2017
The Fiscal Court of Perry County, on behalf of Perry County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./6:17-cv-00265-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/25/2017; 10/4/2017 (Am.)	2017
The Fiscal Court of Powell County, on behalf of Powell County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:18-cv-00538-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/20/2018	2018
The Fiscal Court of Pulaski County, on behalf of Pulaski County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./6:17-cv-00264-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/25/2017; 10/4/2017 (Am.)	2017
The Fiscal Court of Rowan County, on behalf of Rowan County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./0:17-cv-00130-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	12/2/2017	2017
The Fiscal Court of Scott County, on behalf of Scott County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./5:17-cv-00474-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	12/2/2017	2017

The Fiscal Court of Shelby County, on behalf of Shelby County v. AmerisourceBergen Drug Corp., et al.	E.D. Ky./3:17-cv-00072-GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/13/2017; 10/4/2017 (Am.)	2017
The Fiscal Court of Spencer County, on behalf of Spencer County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./3:17-cv-00557-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/13/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Union County, on behalf of Union County v. AmerisourceBergen Drug Corp., et al.	W.D. Ky./4:17-cv-00120-TBR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco	9/13/2017; 10/3/2017 (Am.)	2017
The Fiscal Court of Wolfe County, Kentucky v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46099-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco; Collegium	9/26/2018	2018
The Gilmer County Commission v. Cardinal Health Inc., et al.	S.D. WV/2:18-cv-01290	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Mallinckrodt; SpecGx; Wal-Mart; Walgreens; RiteAid; Rhodes; Actavis; Watson; Allergan; Warner Chilcott	9/10/2018; 3/15/2019	2018
The Hoopah Valley Tribe v. Purdue Pharma L.P., et al.	N.D. Cal./1:18-cv-07430-RMI	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; TEVA; Cephalon; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Noramco; Insys; Par; Mallinckrodt; SpecGx; Health Mart	12/10/2018	2018

The Hospital Authority of Wayne County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45278-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; McKesson; Cardinal; AmerisourceBergen	4/16/2019	2019
The Jicarilla Apache Nation v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45385-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; H.D. Smith	6/6/2019	2019
The Leech Lake Band of Ojibwe	D. Minn./0:17-cv-05491-JRT-LIB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/19/2017	2017
The Lummi Tribe of the Lummi Reservation v. Purdue Pharma L.P., et al.	W.D. Wa./2:18-cv-01065	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	7/19/2018	2018
The Makah Indian Tribe, a federally recognized Indian Tribe v. Purdue Pharma L.P., et al.	W.D. Wa./3:18-cv-05662	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	8/14/2018	2018
The Marshall County Health Care Authority v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45538-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco; Insys	5/7/2018	2018
The Mayor and Alderman of the City of Savannah v. AmerisourceBergen Drug Corp., et al.	S.D. Ga./4:18-cv-00087-WTM-GRS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/17/2018	2018

The Menominee Indian Tribe of Wisconsin v. Purdue Pharma L.P., et al.	E.D. Wi./1:18-cv-00414	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/15/2018	2018
The Modoc Nation, f/k/a The Modoc Tribe of Oklahoma v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45439-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; CVS; Cardinal; Cephalon; Endo; H.D. Smith; Health Mart; Insys; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Rite Aid; TEVA; Kroger; Walgreens; Walmart; Watson	6/13/2019	2019
The Montgomery County Board of County Commissioners v. Purdue Pharma L.P., et al.	S.D. Ohio/3:18-cv-00293-TMR (removed from C.P. Montgomery Cnty. (OH)/2018CV03413)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Endo; Mallinckrodt; SpecGx; Jane Does 1-50	7/25/2018	2018
The Muscogee (Creek) Nation v. Purdue Pharma L.P., et al.	N.D. Okla./4:18-cv-00180-JHP-JFJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; Actavis; Allergan; Amneal; Anda; Carefirst; City Drug Co.; Cityplex Pharm; Couch Pharm; CVS; Economy Pharm; Ernie's Pharm; Freeland-Brown Pharm; Gaddy Discount Drug; GCP; Gertman-Apothecary; H.D. Smith; KVK; Langsam; M&D Star Drug; Med-Con; Med-X; Morris & Dickson; Olympia Pharm; Omnicare; Pharmacy Buying Assoc; Pippenger; Reasor's; Rogers; SAJ; Smith Drug; Spoon Drug; TEVA; Drug Warehouse; Harvard Drug	4/3/2018; 7/9/2019	2018
The Navajo Nation v. Purdue Pharma L.P., et al.	D.N.M./1:18-cv-00338	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart	4/11/2018	2018

The Nisqually Indian Tribe v. Purdue Pharma L.P., et al.	W.D. Wa./3:18-cv-05247	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/28/2018	2018
The Parish of Jefferson; Jefferson Parish Hospital Service No. 1; and Jefferson Parish Hospital Service No. 2 v. AmerisourceBergen Drug Corp., et al.	E.D. La./2:18-cv-06343-NJB-KWR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	6/29/2018	2018
The People of the State of California acting by and through San Francisco City Attorney Dennis J. Herrera and the City and County of San Francisco v. Purdue Pharma L.P., et al.	N.D. Cal./3:18-cv-07591-LB	Purdue Pharma L.P.	Rhodes; Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	12/18/2018	2018
The People of the State of Illinois and Williamson County v. Purdue Pharma L.P., et al.	S.D. Ill./3:19-cv-00682 (removed from Cir. Ct. 1st Jud. Williamson Cnty. (Ill.)/2019L73)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	5/21/2019	2019
The People of the State of Illinois, the people of Alexander County and County of Alexander v. AmerisourceBergen Drug Corp., et al.	S.D. Ill/3:17-cv-00876-SMY-DGW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	8/17/2017; 11/9/2017 (Am.)	2017
The People of the State of Illinois, the people of Bond County and County of Bond v. AmerisourceBergen Drug Corp., et al.	S.D. Ill/3:17-cv-01170-SMY-DGW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	10/26/2017	2017

The People of the State of Illinois, the people of Christian County and County of Christian v. AmerisourceBergen Drug Corp., et al.	C.D. III/3:17-cv-03262-SEM-TSH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	11/14/2017	2017
The People of the State of Illinois, the people of Coles County and County of Coles v. AmerisourceBergen Drug Corp., et al.	C.D. III/1:18-cv-01022-JBM-JEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	1/17/2018	2018
The People of the State of Illinois, the people of Edwards County and County of Edwards v. AmerisourceBergen Drug Corp., et al.	S.D. III/3:17-cv-01340-DRH-DGW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/12/2017	2017
The People of the State of Illinois, the people of Gallatin County and County of Gallatin v. AmerisourceBergen Drug Corp., et al.	S.D. III/3:17-cv-01171-SMY-DGW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Associated Pharmacies; SpexGx LLC; Par; Amneal	10/26/2017; 3/5/2019 (Am.)	2017
The People of the State of Illinois, the people of Hamilton County and County of Hamilton v. AmerisourceBergen Drug Corp., et al.	S.D. III/3:17-cv-01185-SMY-DGW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	10/27/2017	2017
The People of the State of Illinois, the people of Hardin County and County of Hardin v. AmerisourceBergen Drug Corp., et al.	S.D. III/3:17-cv-01172-SMY-DGW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	10/26/2017	2017

The People of the State of Illinois, the people of Jasper County and County of Jasper v. AmerisourceBergen Drug Corp., et al.	S.D. Ill/3:17-cv-01342	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/12/2017	2017
The People of the State of Illinois, The People of Johnson County, and County of Johnson v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46148-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS; Walgreens; Walmart; Par; SpecGx; Insys; H.D. Smith; Kroger; J.M. Smith; Amneal	10/12/2018; 3/6/2019	2018
The People of the State of Illinois, the people of Pulaski County and County of Pulaski v. AmerisourceBergen Drug Corp., et al.	S.D. Ill/3:17-cv-01255	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt ; SpecGx; Par	11/17/2017; 3/6/2019 (Am.)	2017
The People of the State of Illinois, The People of Schuyler County, and County of Schuyler v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46147-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS; Walgreens; Walmart; Par; SpecGx; Insys; H.D. Smith; Kroger; Pharmacy Buying Assoc.; Amenal; Sun Pharm.	10/12/2018; 3/6/2019	2018
The People of the State of Illinois, the people of Shelby County and County of Shelby v. AmerisourceBergen Drug Corp., et al.	C.D. Ill/3:17-cv-03293-SEM-TSH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/12/2017	2017

The People of the State of Illinois, the people of Union County and Union County v. Purdue Pharma L.P., et al.	N.D. Ill./1:19-cv-02169 (Removed from Sangamon Cnty./2017-L-11 (transferred from Union Cnty. (Ill.)/2017-L-11))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Cephalon; Johnson & Johnson; Janssen; Noramco; Par; Allergan; Watson; Insys; Mallinckrodt; SpeGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Korger; Walmart	6/26/2017	2017
The People of the State of Illinois, the people of Wabash County and County of Wabash v. AmerisourceBergen Drug Corp., et al.	S.D. Ill/3:17-cv-01173-SMY-DGW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	10/26/2017	2017
The People of the State of Illinois, the people of Washington County and County of Washington v. AmerisourceBergen Drug Corp., et al.	S.D. Ill/3:17-cv-01174-SMY-DGW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; H.D. Smith; Par; SpecGx; Amneal	10/26/2017; 3/6/2019 (Am.)	2017
The People of the State of Illinois, the people of White County and County of White v. AmerisourceBergen Drug Corp., et al.	S.D. Ill/3:17-cv-01338-NJR-DGW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/12/2017	2017
The Town of Cherokee, Alabama, et al. v. Purdue Pharma L.P., et al.	N.D. Ala./3:17-cv-02086-UJH-MHH (removed from Cit. Ct. Franklin Ct. (AL)/33-CV-2017-900247)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Actavis; McKesson; Cardinal; AmerisourceBergen; Insys	11/9/2017	2017

The Town of Clendenin, West Virginia v. AmerisourceBergen Drug Corp, et al.	S.D. WV/2:18-cv-01284	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Mallinckrodt; SpecGx; Wal-Mart; Walgreens; H.D. Smith; Kroger; CVS; RiteAid; Anda; Omnicare; Miami- Luken ; Harvard Drug; Keysource; Masters; Actavis; Rhodes; Watson; Allergan; Warner Chilcott	9/10/2018; 3/15/2019	2018
The Town of Gauley Bridge, West Virginia, a West Virginia municipal corporation v. AmerisourceBergen Drug Corp., et al.	S.D. WV/2:18-cv-01392	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Mallinckrodt; SpecGx; Wal-Mart; RiteAid; CVS; Kroger; Top Rx; Watson; Actavis; Watson; Allergan; Warner Chilcott	10/30/2018; 3/15/2019	2018
The Town of Sophia, West Virginia v. AmerisourceBergen Drug Corp, et al.	S.D. WV/2:18-cv-01286	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Mallinckrodt; SpecGx; Wal-Mart; Walgreens; H.D. Smith; Kroger; CVS; RiteAid; Warner Chilcott; Allergan; Watson; Actavis; Rhodes	9/10/2018; 3/15/2019	2018
The Town of Whitesville, West Virginia v. AmerisourceBergen Drug Corp, et al.	S.D. WV/2:18-cv-01287	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Mallinckrodt; SpecGx; Wal-Mart; Walgreens; H.D. Smith; Kroger; CVS; RiteAid; Anda; Bellco; Qualitst; Generics; Actavis; Watson; Allergan; Warner Chilcott	9/10/2018; 3/15/2019	2018

The Unified Government of Macon Bibb County Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./5:18-cv-00106-LJA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/27/2018	2018
The University System of Louisiana v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:19-cv-00388-SDD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Mallinckrodt; CVS; Rite Aid; Walmart; Walgreens	6/14/2019	2019
Thomas Hickey v. Purdue Pharma L.P., et al.	D. Mass./1:19-cv-11806-MPK	Purdue Pharma L.P.; Purdue Pharma Inc.	N/A	8/22/2019	2019
Three Affiliated Tribes v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45376-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger	6/6/2019	2019
Thurston County v. Purdue Pharma L.P., et al.	W.D. Wa./3:18-cv-05238	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; Cephalon; Hikma; Mylan; Par; TEVA; Walgreens; West-Ward	3/26/2018	2018
Tippah County, Miss. v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./3:18-cv-00006-MPM-RP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	1/8/2018	2018
Tippecanoe County, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./4:18-cv-00040-JTM-JEM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	6/19/2018	2018

Tohono O'Odham Nation v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45411-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger; H.D. Smith	6/7/2019	2019
Tonto Apache Tribe v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45398-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Health Mart; Rite Aid; Kroger; H.D. Smith	6/7/2019	2019
Tony Mancuso, Sheriff of Calcasieu Parish v. Purdue Pharma L.P., et al.	W.D. LA/2:17-cv-01585 (removed from 14th Judicial District Court, Parish of Calcasieu/2017-4126H)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal-Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	10/5/2017	2017
Toombs County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45576-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/15/2018	2018
Torres Martinez Desert Cahuilla Indians v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46152-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	10/16/2018	2018

Touchette Regional Hospital v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45457-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Actavis; Allergan; AmerisourceBergen; Cephalon; Cardinal; Depomed; Endo; Anda; H.D. Smith; Henry Schein; Insys; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; Miami-Luken; SpecGx; TEVA; Watson	6/13/2019	2019
Town of Acquinnah v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11878-LTS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	8/31/2018	2018
Town of Acushnet, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-10982	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/16/2018	2018
Town of Agawam v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30088-MGM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/8/2018	2018
Town of Amesbury v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-10985-NMG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/16/2018	2018

Town of Arcola, Mississippi v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45419-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami- Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
Town of Arlington, Tennessee v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45471-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami- Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/14/2019	2019
Town of Athol, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:19-cv-40019	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	1/22/2019	2019
Town of Auburn v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40072	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/16/2018	2018

Town of Ayer, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-11277- RGS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/7/2019	2019
Town of Baldwin v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00939- SDD-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/23/2018	2018
Town of Barnstable v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11415	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	7/6/2018	2018
Town of Barrington v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00144- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Belchertown v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30105	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	7/6/2018	2018

Town of Berwick v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00927- JWD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/19/2018	2018
Town of Billerica v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-10667- FDS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	4/5/2018	2018
Town of Braintree v. Purdue Pharma L.P., et al.	D. Mass./1:19-cv-11464- WGY	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; Mallinckrodt; Walgreens	7/3/2019	2019
Town of Brewster v. AmerisourceBergen Drug Corp., et al	D. Mass./1:18-cv-10666- DJC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	4/5/2018	2018
Town of Bridgewater v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11183- NMG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/6/2018	2018
Town of Bristol v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00145- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018

Town of Brookline, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-10146-DJC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	1/22/2019	2019
Town of Brownstown, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./4:18-cv-00081-SEB-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	5/11/2018	2018
Town of Burrillville v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00146-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Butler, AL v. Purdue Pharma L.P., et al.	S.D. Ala./1:18-cv-0060-WS-N (removed from Cir. Ct. Choctaw Cnty. (Ala.)/15-cv-2018-900009)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Wal-Mart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	1/24/2018	2018
Town of Caledonia, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./1:19-cv-00022-SA-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	1/23/2019	2019
Town of Carver v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-10992-LTS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018

Town of Chandler, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./3:18-cv-00064-RLY	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	3/30/2018	2018
Town of Charlestown, RI v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00143-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Charlton v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40075	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018
Town of Chelmsford v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11421-NMG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	7/6/2018	2018
Town of Clarksburg v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30099	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/27/2018	2018

Town of Coventry, RI v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00147-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Cumberland, RI v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00141-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Danvers v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11172-WGY	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/5/2018	2018
Town of Danville, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:19-cv-00957-JPH-MJD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	3/7/2019	2019
Town of Dedham, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-12614-NMG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	12/20/2018	2018

Town of Dennis, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-10302- DPW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	2/15/2019	2019
Town of Derry, New Hampshire v. AmerisourceBergen Drug Corp., et al.	D.N.H./1:18-cv-00348	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/27/2018	2018
Town of Double Springs, Alabama, a municipal corporation v. Purdue Pharma L.P., et al.	N.D. Ala./5:18-cv-00802	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	5/25/2018	2018
Town of Douglas v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40076	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018
Town of Dudley v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40077	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018
Town of East Bridgewater v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11002- MLW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018

Town of East Greenwich v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00204-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Eastham v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11345-JCB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/27/2018	2018
Town of Easton v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-11933-PBS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par; PJC	9/11/2019	2019
Town of Enfield v. Purdue Pharma L.P., et al.	D. Conn./3:19-cv-00789-JBA (removed from Hartford State Super. Ct. (CT))	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	John Kapoor; McKesson; Cardinal; AmerisourceBergen; CVS; Rite Aid; Walgreens; Walmart; Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Insys	4/9/2019	2019

Town of Fairhaven, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-10154- RGS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	1/23/2019	2019
Town of Falmouth v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11855	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	8/28/2018	2018
Town of Ferriday, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46166-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Anda; CVS; Cardinal; Cephalon; Endo; H.D. Smith; Health Mart; Insys; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; Par; Rite Aid; SpecGx; TEVA; Walgreens; Wal- Mart; Watson; Amneal; Indivior; Sandoz; Louisiana Wholesale Drug Co.; Morris & Dickson; Rhodes	10/19/2018; 3/14/2019; 3/16/2019	2018
Town of Fort Deposit, Alabama v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45427-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami- Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019

Town of Foster v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00150- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Freetown v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11003- DPW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018
Town of Georgetown v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11338- GAO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/27/2018	2018
Town of Gloucester v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00152- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Grafton v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40094	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/6/2018	2018

Town of Hanson v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11004-WGY	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018
Town of Holliston v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11416	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	7/6/2018	2018
Town of Hopedale v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40078	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018
Town of Hopkinton, RI v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00153-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Jamestown, a municipal corporation v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00154-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018

Town of Johnston, RI v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00138-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Lake Providence, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46002-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Andia; CVS; Rite Aid; Walgreens; Walmart; Mylan; Sandoz; Hikma; West-Ward; Morris & Dickson; Harco; Rhodes	8/27/2018	2018
Town of Lakeville v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11005-LTS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018
Town of Leicester v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40079-TSH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/17/2018	2018
Town of Leverett v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30083	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/5/2018	2018

Town of Londonderry, New Hampshire v. AmerisourceBergen Drug Corp., et al.	D.N.H./1:18-cv-00411	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/21/2018	2018
Town of Longmeadow v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30144- MGM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	8/31/2018	2018
Town of Ludlow v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30107	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	7/9/2018	2018
Town of Lunenburg v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40160	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	9/25/2018	2018
Town of Madisonville v. Purdue Pharma L.P., et al.	E.D. La./2:18-cv-07974- CJB-DEK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Endo; TEVA; Cephalon; Janssen; Johnson & Johnson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen	8/21/2018	2018
Town of Marblehead v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11208- DJC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/8/2018	2018

Town of Marshfield v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11174-DPW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/5/2018	2018
Town of Mashpee v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11183-RGS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/6/2018	2018
Town of Mattapoisett v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11351-LTS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/27/2018	2018
Town of McKenzie, AL v. Purdue Pharma L.P., et al.	M.D. Ala./2:18-cv-00342-WC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/19/2018	2018
Town of Middleborough v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-12140-NMG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	10/12/2018	2018

Town of Middletown, Rhode Island, a municipal corporation v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00317	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Milford v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40098-TSH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/11/2018	2018
Town of Monroe, Connecticut v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45441-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Endo; Par; Janssen; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Mylan; West-Ward; Hikma; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; Smith's Food & Drug; H.D. Smith; CVS; Anda	6/13/2019	2019
Town of Mooresville, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-04058-JRS-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	12/27/2018	2018
Town of Munford, Alabama, a municipal corporation v. Cardinal Health, Inc., et al.	N.D. Ala./1:18-cv-00820-VEH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson	5/29/2018	2018
Town of Nantucket v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11015	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/18/2018	2018

Town of Narragansett v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00155-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of New Delhi, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45973-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Anda; CVS; Rite Aid; Walgreens; Walmart; Mylan; Sandoz; Hikma; West-Ward; Morris & Dickson; Harco; Rhodes	8/13/2018	2018
Town of North Andover v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-12015-LTS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	9/26/2018	2018
Town of North Attleborough v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11013	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/18/2018	2018

Town of North Kingstown v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00157- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of North Providence v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00137- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of North Reading v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11353- DPW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/28/2018	2018
Town of Norton v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11207- PBS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/8/2018	2018
Town of Norwell v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11138- ADB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018

Town of Norwood, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-10147- PBS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	1/22/2019	2019
Town of Orange, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30199- MGM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	12/20/2018	2018
Town of Oxford, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:19-cv-40077- DHH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/11/2019	2019
Town of Palmer v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30079	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018

Town of Pearl River v. Purdue Pharma L.P., et al.	E.D. La./2:19-cv-11775-LMA-MBN (removed from 22nd Judicial District Court, Parish of St. Tammany (LA)/201913023)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Actavis; Watson; Warner Chilcott; TEVA; Cephalon; Janssen; Johnson & Johnson; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Indivior; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Morris & Dickson; Amneal; West-Ward; Hikma; Novartis; Sandoz; Andia; H.D. Smith; Smith Drug; JM Smith; CVS; Rite Aid; Louisiana Wholesale Drug; Impax; Miley Meds Pharmacy; Family Drug Mart	6/12/2019	2019
Town of Pembroke v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11139-LTS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018
Town of Plainfield, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-04062-JMS-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	12/27/2018	2018
Town of Plainville v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11141-DPW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018
Town of Plymouth v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-10972-MPK	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/14/2018	2018

Town of Portsmouth, Rhode Island, a municipal corporation v. AmerisourceBergen Drug Corp., et al	D.R.I./1:19-cv-00315- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	6/6/2019	2019
Town of Provincetown, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-10292	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	2/15/2019	2019
Town of Rehoboth, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-10151- ADB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	1/23/2019	2019
Town of Richmond v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00158- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018

Town of Richwood, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 45772-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Endo; Par; Janssen; Noranco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; Health Mart; AmerisourceBergen; H.D. Smith; Anda; CVS; Rite Aid; Walgreens; Walmart; Mylan; Sandoz; Hikma; West- Ward; Morris & Dickson; Harco; Rhodes	7/2/2018	2018
Town of Rockland v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11142- FDS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018
Town of Salisbury v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-10643	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	4/3/2018	2018
Town of Sandwich v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11145- IT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018
Town of Scituate, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-10152- DJC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	1/23/2019	2019

Town of Scituate, Rhode Island, a municipal corporation v. AmerisourceBergen Drug Corp., et al	D.R.I./1:19-cv-00167-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	4/2/2019	2019
Town of Seekonk v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11354-DPW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/28/2018	2018
Town of Sheffield v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11357-KAR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/28/2018	2018
Town of Sheridan v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:17-cv-04651-TWP-TAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	12/16/2017	2017
Town of Shirley v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11367-ADB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/29/2018	2018

Town of Smithfield v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00159- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Somerset v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11177- DLC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/5/2018	2018
Town of South Hadley v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30108	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	7/9/2018	2018
Town of South Kingstown Municipal Corporation v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00160- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Southbridge v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40070- TSH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/14/2018	2018

Town of Spencer v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40090	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018
Town of Stoneham v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-12016- PBS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	9/26/2018	2018
Town of Stoughton, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-12615- NMG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	12/20/2018	2018
Town of Sturbridge v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40126- TSH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	7/26/2018	2018
Town of Sudbury v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11368- WGY	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/29/2018	2018

Town of Summit, Mississippi v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45418-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami- Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
Town of Sutton v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40091	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018
Town of Swampscott v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11422- LTS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	7/6/2018	2018
Town of Templeton v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11223	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/12/2018	2018
Town of Templeton v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40100	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/12/2018	2018

Town of Tewksbury, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-10153-FDS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	1/23/2019	2019
Town of Truro v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11148-WGY	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018
Town of Tyngsborough v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11178-DLC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	6/5/2018	2018
Town of Upland, Indiana v. AmerisourceBergen Drug Corp., et al.	N.D. Ind./1:18-cv-00395-TLS-SLC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Actavis; Watson; AmerisourceBergen; Cardinal; McKesson	11/30/2018	2018
Town of Upton v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40162	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	9/26/2018	2018

Town of Ware v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30109	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	7/9/2018	2018
Town of Warren v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40092	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018
Town of Warren, Rhode Island, a municipal corporation v. AmerisourceBergen Drug Corp., et al	D.R.I./1:19-cv-00163- WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	4/2/2019	2019
Town of Watertown v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-10971- DPW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/14/2018	2018
Town of Wellfleet, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:19-cv-11206- PBS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	5/30/2019	2019

Town of West Boylston v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40109-TSH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/29/2018	2018
Town of West Bridgewater v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11880-FDS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	8/31/2018	2018
Town of West Greenwich v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00161-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of West Springfield v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30080	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018
Town of West Warwick, RI v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00162-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018

Town of Westborough v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40110-TSH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/29/2018	2018
Town of Westerly v. AmerisourceBergen Drug Corp., et al	D.R.I./1:18-cv-00163-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Omnicare; Eckerd; SpecGx; Par; KVK; CVS; Rite Aid; Walmart; Walgreens	3/26/2018; 3/7/2019	2018
Town of Westford v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-11379-FDS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	6/29/2018	2018
Town of Wethersfield v. Purdue Pharma L.P., et al.	D. Conn./3:19-cv-01041 (removed from Hartford State Super. Ct. (CT))	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	John Kapoor; McKesson; Cardinal; AmerisourceBergen; CVS; Rite Aid; Walgreens; Walmart; Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Insys	5/22/2019	2019
Town of Weymouth v. Purdue Pharma L.P., et al.	D. Mass./1:19-cv-11443-WGY	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; Mallinckrodt; Walgreens	7/1/2019	2019

Town of Wilmington v. AmerisourceBergen Drug Corp., et al.	D. Mass./1:18-cv-12017-WGY	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco; SpecGX; Insys; CVS; H.D. Smith; Rite Aid; Walmart; Walgreens; Par	9/26/2018	2018
Town of Winchendon, Massachusetts v. AmerisourceBergen Drug Corp., et al.	D. Mass./4:18-cv-40071-TSH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/14/2018	2018
Town of Winthrop v. AmerisourceBergen Drug Corp., et al.	D. Mass./3:18-cv-30081	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Noramco	5/31/2018	2018
Town of Woonsocket, Rhode Island, a municipal corporation v. AmerisourceBergen Drug Corp., et al	D.R.I./1:19-cv-00203-WES-LDA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	4/22/2019	2019
Town of Yellow Bluff, Alabama v. Purdue Pharma L.P., et al.	S.D. Ala./1:18-cv-00124-CG-N	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	3/15/2018	2018
Town of Zionsville, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./1:18-cv-01927-JMS-DML	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	6/22/2018	2018

Towner County v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00109- DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS: Rite Aid; Kroger	6/14/2019	2019
Towns County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45172-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/25/2019	2019
Township of Bloomfield v. Purdue Pharma L.P., et al.	D.N.J./3:17-cv-13462- PGS-TJB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; McKesson: Cardinal; John Does 1-100	12/21/2017	2017
Township of Brick, New Jersey v. Purdue Pharma L.P., et al.	D.N.J./3:19-cv-17998- MAS-DEA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; Cardinal; AmerisourceBergen; Allergan; Watson; Actavis	9/13/2019	2019
Township of Irvington v. Purdue Pharma L.P., et al.	D.N.J./2:17-cv-12155- MCA-LDW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; McKesson: Cardinal; John Does 1-100	11/28/2017	2017

Township of Saddle Brook, New Jersey v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45431-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
Township of Teaneck, NJ v. Purdue Pharma L.P., et al.	D.N.J./2:18-cv-03394	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Cephalon; TEVA; Mallinckrodt; Insys; McKesson; Cardinal	3/9/2018	2018
Towntown of Centerville, Tennessee v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45425-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
Trempealeau County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01666-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017

Triad Health Systems, Inc. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45780	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; Cardinal; Cephalon; Endo; Janssen; Johnson & Johnson; Mallinckrodt; McKesson; Noramco; TEVA; Watson; Sandoz; Par; H.D. Smith; Depomed; Collegium; Amneal	9/6/2019	2019
Troup County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45715-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	6/13/2018	2018
Tulalip Tribes v. Purdue Pharma L.P., et al.	W.D. Wa./2:18-cv-00617	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; Cephalon; Hikma; Mylan; Par; TEVA; Walgreens; West-Ward	4/27/2018; 3/13/2019	2018
Tule River Indian Tribe of California v. AmerisourceBergen Drug Corp., et al.	N.D. Cal./3:19-cv-03222	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Mallinckrodt; SpecGx; Insys; Walmart; Walgreen	6/7/2019	2019
Tunica-Biloxi Tribe of Louisiana v. Purdue Pharma L.P., et al.	W.D. La./1:18-cv-01008	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Allergan; Watson; Actavis; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Kroger; RiteAid; Walgreens; H.D. Smith; Miami-Luken	8/6/2018	2018
Turtle Mountain Band of Chippewa Indians v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45521-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/3/2018	2018

Tuscaloosa County, Alabama v. AmerisourceBergen Drug Corp., et al.	N.D. Ala./7:18-cv-00164-LSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
Twiggs County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./5:18-cv-00101-CAR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/22/2018	2018
Twin Falls County v. Purdue Pharma L.P., et al.	D. Ida./1:19-cv-00348-CWD	Purdue Pharma L.P.	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters	9/10/2019	2019
Tyler M. Roach, natural Tutor on behalf of his minor child, Baby K.E.R., and as class representative for all Neonatal Abstinence Syndrome afflicted babies born in Louisiana v. McKesson Corp., et al.	E.D. La./2:18-cv-04165 (removed from 22nd Judicial District Court, Parish of St. Tammy (LA)/2018-10930)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Family Drug Mart	2/26/2018	2018
Tyrrell County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./2:18-cv-00022-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/23/2018	2018
U.S. ex rel., Robert E. Manchester, et al. v. Purdue Pharma L.P., et al.	D. Mass./1:16-cv-10947-MLW	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Products L.P.	McKesson; Cardinal; AmerisourceBergen	5/25/2016; 5/23/2018 (1st Am.) 6/19/2018 (2nd Am.); 8/3/2018 (3rd Am.)	2016
Unified Government of Wyandotte County/Kansas City, Kansas v. AmerisourceBergen Drug Corp., et al.	D. Kan./2:18-cv-02696-JWL-GEB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/18/2018	2018

Union County v. Purdue Pharma L.P., et al.	D.N.J./2:19-cv-05419 (removed from Super. Ct. NJ, Union Cnty./UNN-L-004319)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Rhodes; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; Abbvie; Abbott; AmerisourceBergen; Cardinal; McKesson	12/20/2018	2018
Union County, Florida v. Purdue Pharma L.P., et al.	M.D. Fla./3:19-cv-00716-TJC-MCR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Walgreen	6/14/2019	2019
Union County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ga./2:18-cv-00203-RWS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Insys; CVS; Kroger; Rite Aid; Walgreens; JM Smith	10/25/2018	2018
Union County, Miss. v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./3:18-cv-00008-SA-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	1/8/2018	2018
Union Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00890-JWD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/8/2018	2018
United Food and Commercial Workers Health and Welfare Fund of Northeastern Pennsylvania v. Purdue Pharma L.P., et al.	E.D. Pa./2:17-cv-05078-TJS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Abbott; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	11/9/2017	2017

United Food and Commercial Workers Local 1000 Oklahoma Health and Welfare Fund v. McKesson Corp., et al.	N.D. Ohio/1:18-op-45733-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	6/15/2018	2018
United Food and Commercial Workers Union UFCW Local 1529 and Employers Health and Welfare Plan and Trust v. McKesson Corporation, et al.	N.D. Ohio/1:18-op-45700-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	6/8/2018	2018
United Food and Commercial Workers Unions and Employers Health and Welfare Fund - Atlanta v. McKesson Corporation	N.D. Ohio/1:19-op-45005-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	1/11/2019	2019
United Food and Commercial Workers Local 1995 Employers Health and Welfare Fund v. McKesson Corp., et al.	N.D. Ohio/1:18-op-46109-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	9/27/2018	2018
United Government of Athens-Clarke County Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./3:18-cv-00015-CDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/7/2018	2018
United Keetoowah Band of Cherokee Indians v. AmerisourceBergen Drug Corp., et al.	D. Kan./2:19-cv-02300-CM-KGG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	6/13/2019	2019
Upper Sioux Community v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-45974-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Actavis; Allergan; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	8/16/2018	2018

Utah County, Utah v. Purdue Pharma Inc., et al.	D. Ut./2:18-cv-00784-EJF	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Smiths Food; Drug Centers; Par; Albertsons; Walmart; Walgreens; Rite Aid; CVS	10/9/2018; 3/14/2019	2018
Valley Hope Association, on behalf of itself and all other entities similarly situated v. AmerisourceBergen Drug Corp., et al.	D. Kan./2:18-cv-02276-KHV-KGG	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	5/25/2018	2018
Van Wert County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45571-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco; Insys	5/14/2018	2018
Vance County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./5:18-cv-00277-D	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/13/2018	2018
Vanderburgh County v. Purdue Pharma L.P., et al.	S.D. Ind./3:18-cv-00072-RLY-MPB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	4/6/2018	2018
Vermilion Parish Police Jury v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00958	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018

Vernon County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01667- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Vigo County, Indiana v. AmerisourceBergen Drug Corp., et al.	S.D. Ind./2:18-cv-00010- JMS-MJD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson	1/7/2018	2018
Village of Brooklyn Heights v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45450	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; Miami-Luken; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; CVS; Walgreens; Wal-Mart; Perry Fine; Scott Fishman; Lynn Webster	4/17/2018	2018
Village of Herkimer, New York v. Purdue Pharma L.P., et al.	N.D.N.Y./6:18-cv-00797- GLS-TWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Insys; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Andia; Rite Aid; Walmart	7/5/2018	2018

Village of Melrose Park, Village of Belwood, Village of Berkeley, City of Berwyn, City of Chicago Heights, Village of Hillside, City of Northlake, Village of Oak Lawn, City of Pekin, Village of River Forest, and Village of Tinley Park v. Purdue Pharma L.P., et al.	N.D. Ill./1:18-cv-05288 (removed from Cir. Ct. Cook Cnty (Ill.)/2018-CH- 06601)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Rhodes; Endo; Janssen; Johnson & Johnson; Insys; Noramco; Allergan; Actavis; Watson; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Paul Madison; William McMahon; Joseph Giacchino	5/23/2018	2018
Village of Newburgh Heights v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45449	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; Miami-Luken; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; CVS; Walgreens; Wal-Mart; Perry Fine; Scott Fishman; Lynn Webster	4/17/2018	2018
Vinton County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	S.D. Ohio/2:17-cv-00665- EAS-EPD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	10/11/2017	2017
W. Andrew Fox, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	E.D. Tenn./1:18-cv- 00194	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	8/21/2018	2018
W.E., on behalf of herself and all others similarly situated, by and through her Next Friend Pamela Osborne v. Purdue Pharma L.P., et al.	E.D. Ky./5:18-cv-00629- GFVT	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; AmerisourceBergen; Mallinckrodt; Cardinal; McKesson; Noramco; Par	11/28/2018	2018

Waikeisha Richardson, individually and as next friend and guardian of Babies E.M.1. and E.M.2. v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45538-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/20/2019	2019
Waldo County v. Purdue Pharma L.P., et al.	D. Me./1:19-cv-00144-NT (removed from Super. Ct. Waldo Cnty. (Me.))	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	2/1/2019	2019
Walker River Paiute Tribe of The Walker River Reservation v. McKesson Corporation, et al.	N.D. Ohio/1:18-op-45698-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Watson; Actavis; Allergan; Mallinckrodt	6/8/2018	2018
Walla Walla County v. Purdue Pharma L.P., et al.	E.D. Wa./4:18-cv-05131-SAB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Amnea; Hikma; Impax; Mylan; Par; Rite Aid; Walmart; West-Ward; Thrifty; KVK; Anda	8/7/2018; 3/13/2019	2018

Walsh County v. Purdue Pharma L.P., et al.	D.N.D./3:19-cv-00108-DLH-ARS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
Walter and Virginia Salmons, individually and as the next friend or guardian of Minor W.D. and on behalf of all other similarly situated v. Purdue Pharma L.P., et al.	S.D. WV/2:18-cv-00385	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Noramco; CVS; Rite Aid; SpecGx; Insys; Par; Walgreens; Walmart; Costco; Linden; Kroger; H.D. Smith; Anda; Rhodes	3/2/2018; 5/25/2018; 3/16/2019	2018
Walthall County, Miss. v. AmerisourceBergen Drug Corp., et al.	S.D. Miss./2:18-cv-00045-KS-MTP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/26/2018	2018
Walton County, Florida v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45423-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Actavis; Watson; John N. Kapoor; Insys; Miami-Luken; Mallinckrodt; West-Ward; Hikma; Mylan; SpecGx; Anda; McKesson; PSS World; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Rite Aid; Rhodes	6/10/2019	2019
Walton County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./3:18-cv-00032-CDL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt ; Noramco	3/9/2018	2018

Walworth County, Wisconsin v. AmerisourceBergen Drug Corp., et al.	E.D. Wi./2:18-cv-01181-JPS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; AmerisourceBergen; Noramco; Insys; CVS; Walgreens; Wal-Mart; SpecGx; Par; Amneal; KVK	8/1/2018; 3/13/2019	2018
Ward County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00173-DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS	8/13/2019	2019
Warren County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45425-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/13/2018	2018
Warren County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46196-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-Mart; McQuery; Amneal	10/29/2018; 3/8/2019	2018
Warren County, NC v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./5:18-cv-00163-FL	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/17/2018	2018

Warrensville Heights, Ohio v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op- 46299-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; PSS World; CVS; Walgreens; Walmart; Rite Aid; Miami-Luken; SpecGx; Par; West-Ward; Hikma; Mylan; John N. Kapoor; Noramco; Anda	12/6/2018; 3/15/2019	2018
Washburn County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01548- LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Washington County v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./2:18-cv-00062- BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	12/10/2018	2018

Washington County v. Purdue Pharma L.P., et al.	D. Me./1:19-cv-00024-NT (removed from Super. Ct. Washington Cnty. (Me.)/CV-18-27)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	11/21/2018	2018
Washington County v. Purdue Pharma L.P., et al.	W.D. Va./1:18-cv-00046-EKD (removed from Cir. Ct. Washington Cnty. (VA)/CL18-1769)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	8/6/2018	2018
Washington County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01532-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	11/28/2017; 5/25/2018; 3/15/2019	2017

Washington County, Alabama v. AmerisourceBergen Drug Corp., et al.	S.D. Ala./1:18-cv-00047- WS-B	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
Washington County, Florida v. AmerisourceBergen Drug Corp., et al.	N.D. Fla./5:18-cv-0093- RH-GRJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/11/2018	2018
Washington County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 45563-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/11/2018	2018
Washington County, Miss. v. Purdue Pharma L.P., et al.	N.D. Miss./4:17-cv- 00191-SA-JMV	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	12/21/2017	2017
Washington County, MN v. Purdue Pharma L.P., et al.	D. Minn./0:17-cv-05287- PAM-HB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	11/30/2017	2017
Washington County, Ohio and City of Marietta, Ohio v. Cardinal Health Inc., et al.	S.D. Ohio/2:18-cv-01706- EAS-EPD (removed from C.P. Washington County (OH)/18PT241)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cardinal; Kroger; Miami- Luken; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mylan; Rite Aid; Walgreen; McKesson; AmerisourceBergen; CVS; Wal-Mart	11/7/2018	2018

Washington County, TN v. AmerisourceBergen Drug Corp., et al.	E.D. Tenn./2:18-cv- 00205	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; JM Smith; Harvard Drug; SpecGx; Par; Amneal; Kroger; Rite Aid; CVS; Walgreens; Walmart	11/19/2018; 3/11/2019	2018
Washington Parish Government v. Purdue Pharma L.P., et al.	E.D. La./2:19-cv-11626 (removed from 22nd Judicial District Court, Parish of Washington (LA)/113499)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Actavis; Watson; Warner Chilcott; TEVA; Cephalon; Janssen; Johnson & Johnson; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Indivior; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart; Morris & Dickson; Amneal; West- Ward; Hikma; Norvatis; Sandoz; Anda; H.D. Smith; Smith Drug; JM Smith; CVS; Rite Aid; Louisiana Wholesale Drug; Impax	5/19/2019	2019
Watauga County, NC v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./5:18-cv-00064- MOC-DSC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/17/2018	2018
Waukesha County, Wisconsin v. AmerisourceBergen Drug Corp., et al.	E.D. Wi./2:18-cv-01087- PP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Mallinckrodt; Cardinal; McKesson; AmerisourceBergen; CVS; Walgreens; Wal- Mart; SpecGx; Par	7/16/2018; 3/13/2019	2018

Waupaca County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01553-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; Sandoz; West-Ward; Dakota Drug; Omnicare; Top Rx; Rhodes	11/7/2017; 3/15/2019	2017
Waushara County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01668-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	1/5/2018; 5/25/2018; 3/15/2019	2018
Wayne County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/5:18-cv-00275	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal; Noramco; Insys	2/2/2018	2018
Wayne County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45204-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/28/2019	2019

Wayne County, North Carolina v. AmerisourceBergen Drug Corp., et al.	E.D.N.C./5:18-cv-00189-BO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	4/27/2018	2018
Webster County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:18-op-46350-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; CVS; Walgreens; Kroger; Wal-Mart; McQuery; Pharmacy Buying Assoc.; J.M. Smith; SAJ; Amneal	12/21/2018; 3/15/2019	2018
Webster Parish v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00720-BAJ-EWD	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen	7/27/2018	2018
Wells County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00136-DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	7/9/2019	2019
Wendy Stewart, individually and as next friend and guardian of Baby K.J.C., on behalf of themselves and all others similarly situated v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45481-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	McKesson; Cardinal; AmerisourceBergen; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Depomed; Mallinckrodt; SpecGx; Insys; Par; Noramco; CVS; Rite Aid; Walgreens; Walmart; Miami-Luken; Costco; Anda; Kroger; H.D. Smith; Indivior; Rhodes	6/15/2019	2019

West Baton Rouge Fire Protection District No. 1 v. AmerisourceBergen Drug Corp., et al.	M.D. La./3:18-cv-00967-SDD-RLB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Noramco; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBergen; Par	10/26/2018	2018
West Bend Mutual Insurance Company v. AmerisourceBergen Drug Corp., et al.	N.D. Ill./1:19-cv-01461	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/28/2019	2019
West Boca Medical Center, Inc. v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45530-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Actavis; Allergan; AmerisourceBergen; CVS; Cardinal; Cephalon; Endo; Kroger; Mallinckrodt; McKesson; Rite Aid; TEVA; Wal-Mart; Walgreens; Watson	5/4/2018	2018
West Volusia Hospital Authority v. Purdue Pharma L.P., et al.	M.D. Fla./6:19-cv-01765-WWB-DCI	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; Par; Insys; SpecGx; Publix; Walgreen	9/10/2019	2019
WestCare Foundation, Inc. v. Purdue Pharma L.P., et al.	D. Nev./2:18-cv-00926-KJD-VCF	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Walmart	5/21/2018	2018
Westchester Heavy Construction Laborers Local 60 Health & Welfare Fund v. Purdue Pharma L.P., et al.	E.D.N.Y./1:19-cv-04944	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Allergan; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Par; Insys; Mallinckrodt; SpecGx; Cardinal; Anda; McKesson; AmerisourceBergen; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Cephalon; Miami-Luken	8/29/2019	2019

Westwego City v. Purdue Pharma L.P., et al.	E.D. La./2:19-cv-00366- SM-KWR	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Noramco; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen	1/17/2019	2019
Whatcom County v. Purdue Pharma L.P., et al.	W.D. Wa./2:18-cv-00950	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; SpecGx; Par; Mylan; Thrifty; Rite Aid; West- Ward; Hikma; Walgreens	6/27/2018; 3/14/2019	2018
White Earth Nation v. AmerisourceBergen Drug Corp., et al.	D. Minn./0:19-cv-01251- JNE-LIB	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	5/10/2019	2019
Whitman County v. Purdue Pharma L.P., et al.	E.D. Wa./2:18-cv-00252	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Anda; Hikma; Mylan; Walmart; West-Ward	8/9/2018; 3/13/2019	2018
Wilcox County, Alabama v. AmerisourceBergen Drug Corp., et al.	S.D. Ala./2:18-cv-00045	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/1/2018	2018
Wilkes County v. AmerisourceBergen Drug Corp., et al.	W.D.N.C./5:18-cv-00030	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	2/16/2018	2018

Wilkes County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45171-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Allergan; Watson; Actavis; Rhodes; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; JM Smith	3/25/2019	2019
Wilkes-Barre Township, Pennsylvania v. Purdue Pharma L.P., et al.	M.D. Pa./3:19-cv-00698- RDM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; Cephalon; TEVA; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Insys; Hikma; West-Ward; Indivior; Mylan; Amneal; Sandoz; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; Walgreen; CVS; Associated; Masters; Keysource; Qualitest	4/25/2019	2019
Wilkinson County, Georgia v. AmerisourceBergen Drug Corp., et al.	M.D. Ga./5:18-cv-00169- TES	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	5/16/2018	2018
William C. Masse, Jr., in his official capacity as the Sherriff of Baldwin County, Georgia v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op- 45361-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen	6/4/2019	2019
William Hilton, Sheriff of Rapides Parish v. Purdue Pharma L.P., et al.	W.D. LA/1:17-cv-01586 (removed from 9th Judicial District Court, Parish of Rapides)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal- Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys' Actavis; Watson; Allergan; Noramco	12/6/2017	2017

Williams County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/3:18-cv-00602	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/15/2018	2018
Williams County v. Purdue Pharma L.P., et al.	D.N.D./1:19-cv-00120-DLH-CRH	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Qualitest; Abbvie; Knoll; Allergan; Actavis; Mallinckrodt; Covidien; SpecGx; Cardinal; McKesson; AmerisourceBergen; Walgreens; Walmart; CVS; Rite Aid; Kroger	6/14/2019	2019
Williamson County, TN v. AmerisourceBergen Drug Corp., et al.	M.D. Tenn./3:18-cv-00008	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; JM Smith; SpecGx; Par; Amneal; Rite Aid; Kroger; Publix; Walmart; CVS; Walgreens	1/3/2018; 3/13/2019	2018
Winn Parish, Louisiana v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45295-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	Rhodes; Endo; Par; Janssen; Noramco; Johnson & Johnson; TEVA; Cephalon; Allergan; Watson; Actavis; Insys; Mallinckrodt; SpecGx; Cardinal; McKesson; AmerisourceBergen; Health Mart; H.D. Smith; CVS; Walgreen; Wal-Mart; Amneal; West-Ward; Hikma; Sandoz; Mylan; Louisiana Wholesale Drug Cop.; Morris & Dickson	5/3/2019; 5/30/2019	2019
Winnebago County v. AmerisourceBergen Drug Corp., et al.	N.D. Ill./3:18-cv-50093	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	3/13/2018	2018

Winnebago Tribe of Nebraska v. McKesson Corporation, et al.	D. Ne./8:18-cv-00203-LSC-MDN	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	McKesson; Cardinal; AmerisourceBergen; CVS; Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Insys; Allergan; Watson; Actavis; Mallinckrodt	5/8/2018	2018
Winona County v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-00875	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Mallinckrodt; McKesson; AmerisourceBergen; Walgreens	3/28/2019	2019
Winston Medical Center v. Purdue Pharma, L.P. et al	N.D. Miss./1:18-cv-00017-SA-DAS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Mallinckrodt; Noramco; CVS; Wagreen; Wal-Mart	2/1/2018	2018
Wise County Board of Supervisors v. AmerisourceBergen Drug Corp. et al.	W.D. Va./2:19-cv-00039	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBergen; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-	N/A	2019

Wood County v. Purdue Pharma L.P., et al.	E.D. Wi./2:17-cv-01558-LA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Allergan; Noramco; Actavis; Watson; Insys; Mallinckrodt; Cardinal; AmerisourceBergen; McKesson; CVS; Kroger; Rite Aid; Walgreens; Walmart; H.D. Smith; Miami-Luken; KVK; Mylan; Par; SpecGx; West-Ward; Dakota Drug; Omnicare; Rhodes	3/7/2018; 5/25/2018; 3/15/2019	2018
Worth County, Georgia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-45602-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Mallinckrodt; Noramco	5/18/2018	2018
Worth County, Missouri v. AmerisourceBergen Drug Corp., et al.	W.D. Mo./5:18-cv-06084-GAF	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	6/12/2018	2018
Wright County, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01813	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen	7/10/2019	2019
Wright County, Missouri v. Purdue Pharma L.P., et al.	N.D. Ohio/1:19-op-45383-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Noramco; Par; SpecGx; Insys; CVS; Walmart; Wagreens; H.D. Smith; Kroger	6/6/2019	2019

Wright Township, Pennsylvania v. Purdue Pharma L.P., et al.	M.D. Pa./3:19-cv-00963- RDM	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.; PLP Associates Holdings; PLP Associates Holdings Inc.; Purdue Holdings; BR Holdings Associates Inc.; BR Holdings Associates L.P.	Rhodes; Cephalon; TEVA; Johnson & Johnson; Janssen; Depomed; Endo; Par; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Insys; Hikma; West-Ward; Indivior; Mylan; Amneal; Sandoz; AmerisourceBergen; Cardinal; McKesson; H.D. Smith; Anda; Rite Aid; Walgreen; CVS; Associated; Masters; Keysource; Qualitest	6/5/2019	2019
Wyandot County Board of County Commissioners v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op- 46078-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt	9/18/2018	2018
Wyandotte Nation v. AmerisourceBergen Drug Corp., et al.	D. Kan./2:19-cv-02309- CM-JPO	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen; McKesson; Cardinal	6/14/2019	2019
Wydetta Williams, sherriff of East Carroll Parish v. Purdue Pharma L.P., et al.	W.D. La./1:18-cv-00262 (removed from 6th Judicial Court for the Parish of East Carroll/22848)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Randall Brewer; Lynn Webster; Rhodes; Smith Drug; Par; SpecGx; Mylan; H.D. Smith; Wal- Mart; Walgreens; Rite Aid; Kroger; CVS; AmerisourceBergen; McKesson; Cardinal; Mallinckrodt; Insys; Actavis; Watson; Allergan; Noramco	1/25/2018	2018

Wyoming County, PA v. Purdue Pharma L.P., et al.	M.D. Pa./3:18-cv-00755-UN4	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Mallinckrodt; Watson; McKesson; Cardinal; AmerisourceBergen; Noramco; Rochester Drug; Eckerd; Value Drug; Par; Amneal; CVS; Walmart; Rite Aid	4/5/2018; 3/15/2019	2018
Wythe County, Virginia v. AmerisourceBergen Drug Corp., et al.	W.D. Va./7:18-cv-00347-EKD-PMS	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; CVS' Rote Aid; Walmart; Amneal; Mylan; Par; Sandoz; SpecGx; West-Ward; Rhodes	7/19/2018; 3/14/2019	2018
Yadkin County v. AmerisourceBergen Drug Corp., et al.	M.D.N.C./1:17-cv-01085-WO-LPA	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt	12/1/2017	2017
Yalobusha County, Mississippi v. AmerisourceBergen Drug Corp., et al.	N.D. Miss./3:19-cv-00042-SA-RP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	3/1/2019	2019
Yancey County v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio/1:18-op-46071-DAP	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; AmerisourceBergen	8/23/2018	2018
Yellow Medicine County, Minnesota v. Purdue Pharma L.P., et al.	D. Minn./0:19-cv-01274-MJD-DTS	Purdue Pharma L.P.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Omnicare; Masters	5/14/2019	2019

Yerington Paiute Tribe v. Purdue Pharma L.P., et al.	D. Nev./3:18-cv-00572-LRH-WGC	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen, TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; McKesson; Noramco; Allergan; Watson; Actavis; Mallinckrodt; Insys	12/3/2018	2018
York County v. Purdue Pharma L.P., et al.	D. Me./2:19-cv-00022-NT (removed from Super. Ct. York Cnty. (Me.)/CV-18-222)	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Watson; Actavis; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Douglas J. Jordensen, DO; Perry Fine; Scott Fishman; Lynn Webster; CVS; Walgreens; Wal-Mart; Rite Aid; Mark E. Cieniawski, M.D.; Michael B. Bruehl, M.D.; John Kapoor; Anda; Miami-Luken; Mylan; West-Ward; Par; Hikma; Amneal; H.D. Smith; SpecGx	11/21/2018	2018
Yurok Tribe v. Purdue Pharma L.P., et al.	E.D. Cal./3:18-cv-01566	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Noramco; Endo; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Insys	3/12/2018	2018
Zachary R. Schneider, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	E.D. Wi./2:19-cv-00611-DEJ	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo Actavis; Watson; McKesson; Cardinal; AmerisourceBergen	4/26/2019	2019
Zenith Insurance Company and Znat Insurance Company v. AmerisourceBergen Drug Corp., et al.	C.D. Cal./2:18-cv-08479	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Watson; Allergan; Actavis; Mallinckrodt	10/2/2018	2018

Braxton County Commission, West Virginia v. Cardinal Health, Inc., et al.	N.D. Ohio 1:18-op-45313	Cardinal; McKesson; Rhodes; SpecGX; Actavis; Allergan; Watson; TEVA; Cephalon; Endo; CVS; Rite Aid; Janssen; Johnson & Johnson; Mallinckrodt; Warner Chilcott	2018
Calhoun County Commission, West Virginia v. AmerisourceBergen Drug Corp., et al.	N.D. Ohio 1:18-op-45312	AmerisourceBergen; Cardinal; McKesson; Walmart; Rite Aid; SpecGX; Endo; Rhodes; TEVA; Cephalon; Janssen; Watson; Actavis; Mallinckrodt; Johnson & Johnson; Allergan	2018
County of Tulare, California v. Purdue Pharma L.P., et al.	N.D. Ohio 1:18-op-45997	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Allergan; Actavis; Watson; Warner Chilcott; Johnson & Johnson; Noramco; Par; SpecGx; CVS; Rite Aid; Walgreen; Walmart; Rhodes; Hikma; West- Ward; Mylan	2018
County of Tuscola, Michigan v. Purdue Pharma et al.	N.D. Ohio 1:18-op-45870	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; AmerisourceBergen; Cardinal; McKesson; Allergan; Actavis; Watson; Omnicare; Masters; CVS; Rite Aid; Walgreen; Costco; Walmart; Rhodes; Anda; Johnson & Johnson; Mylan; Par; Noramco; SpexGX; Sandoz	2018

County of Washtenaw, N.D. Ohio 1:18-op-45886
Michigan v. Purdue
Pharma et al.

TEVA; Cephalon; Endo;
Janssen; Insys;
Mallinckrodt; Allergan;
Watson; Actavis;
Cardinal; McKesson,
Amerisource Bergen;
CVS; Omnicare; Masters;
Walgreen; Rite Aid;
Costco; Rhodes;
Walmart; Anda; Johnson
& Johnson; Mylan; Par;
Noramco; SpexGX;
Sandoz

2018

Deborah Dixon, as next N.D. Ohio 1:19-op-45511
friend and guardian of
baby S.E.T. v. Purdue
Pharma L.P., et al.

TEVA; Cephalon;
Johnson & Johnson;
Janssen; Allergan; Endo;
Actavis; Watson; Insys;
Mallinckrodt; McKesson;
Cardinal; Amerisource
Bergen; Perry Fine; Scott
Fishman; Lynn Webster;
KVK

2019

The City of Charleston, N.D. Ohio 1:18-op-45224
West Virginia v. Rite Aid
of Maryland, Inc., et al.

Rite Aid; Cardinal;
Amerisource Bergen;
Kroger; CVS; Omnicare;
McKesson; Walmart;
Miami-Luken; Harvard
Drug Group; Walgreen;
Anda; Masters;
Keysource; SpecGX;
Endo; TEVA; Cephalon;
Watson; Actavis;
Allergan; Rhodes;
Janssen; Warner
Chilcott; Mallinckrodt

2018

The City of Dunbar, West N.D. Ohio 1:18-op-45546
Virginia v.
AmerisourceBergen
Drug Corporation, et al.

AmeriSource Bergen;
Anda; Rite Aid; Cardinal;
Kroger; CVS; Omnicare;
McKesson; Walmart;
Miami-Luken; Kroger;
Harvard Drug Group;
Walgreen; Masters;
Keysource; SpecGX;
Endo; TEVA; Cephalon;
Watson; Actavis;
Allergan; Rhodes;
Janssen; Warner
Chilcott; Johnson &
Johnson; Mallinckrodt

2018

The City of Saint Albans, N.D. Ohio 1:18-op-45269
West Virginia v.
AmerisourceBergen
Drug Corporation, et al.

AmeriSource Bergen;
Anda; Rite Aid; Cardinal;
Kroger; CVS; Omnicare;
McKesson; Walmart;
Miami-Luken; Kroger;
Harvard Drug Group;
Walgreen; Masters;
Keysource; SpecGX;
Endo; TEVA; Cephalon;
Watson; Actavis;
Allergan; Rhodes;
Janssen; Warner
Chilcott; Johnson &
Johnson; Mallinckrodt

2018

The City of Smithers, N.D. Ohio 1:18-op-45319
West Virginia v.
AmerisourceBergen
Drug Corporation, et al.

AmeriSource Bergen;
Anda; Rite Aid; Cardinal;
Kroger; CVS; Omnicare;
McKesson; Walmart;
Miami-Luken; Kroger;
Harvard Drug Group;
Walgreen; Masters;
Keysource; SpecGX;
Endo; TEVA; Cephalon;
Watson; Actavis;
Allergan; Rhodes;
Janssen; Warner
Chilcott; Johnson &
Johnson; Mallinckrodt

2018

The City of Summersville, West N.D. Ohio 1:18-op-45316
Virginia v.
AmerisourceBergen
Drug Corporation, et al.

AmeriSource Bergen;
Cardinal; McKesson;
Walgreen; Walmart;
Endo; SpecGX; TEVA;
Cephalon; Actavis;
Allergan; Watson;
Janssen; Rhodes; CVS;
Mallinckrodt; Johnson &
Johnson; Warner
Chilcott

2018

The Nicholas County Commission, West N.D. Ohio 1:18-op-45314
Virginia v.
AmerisourceBergen
Drug Corporation, et al.

AmeriSource Bergen;
Cardinal; McKesson;
Walgreen; Walmart;
Endo; SpecGX; TEVA;
Cephalon; Actavis;
Allergan; Watson;
Janssen; Rhodes; CVS;
Mallinckrodt; Johnson &
Johnson; Warner
Chilcott; Rite Aid

2018

<p>The Town of Eleanor, West Virginia v. AmerisourceBergen Drug Corporation, et al.</p>	<p>N.D. Ohio 1:18-op-45387</p>	<p>AmeriSource Bergen; Cardinal; McKesson; Walgreen; Walmart; Endo; SpecGX; TEVA; Cephalon; Janssen; Actavis; Allergan; Watson; Janssen; Rhodes; Mallinckrodt; Johnson & Johnson; Warner Chilcott; Rite Aid</p>	<p>2018</p>
<p>The Town of Glenville, West Virginia v. AmerisourceBergen Drug Corporation, et al.</p>	<p>N.D. Ohio 1:18-op-45384</p>	<p>AmeriSource Bergen; Cardinal; McKesson; Walmart; Endo; SpecGX; TEVA; Cephalon; Actavis; Allergan; Watson; Janssen; Rhodes; Mallinckrodt; Johnson & Johnson; Warner Chilcott; Rite Aid</p>	<p>2018</p>
<p>The Town of Granville, West Virginia v. AmerisourceBergen Drug Corporation, et al.</p>	<p>N.D. Ohio 1:18-op-45320</p>	<p>AmeriSource Bergen; Anda; Cardinal; Omnicare; McKesson; Walmart; Miami-Luken; Endo; SpecGX; TEVA; Walgreen; Cephalon; Actavis; Allergan; Watson; Janssen; Rhodes; Mallinckrodt; Johnson & Johnson; Warner Chilcott; CVS</p>	<p>2018</p>
<p>The Town of Man, West Virginia v. AmerisourceBergen Drug Corporation, et al.</p>	<p>N.D. Ohio 1:18-op-45385</p>	<p>AmeriSource Bergen; Anda; Cardinal; McKesson; Walmart; Kroger; H.D. Smith; Harvard Drug Greoup; Miami-Luken; Cedardale; Bellco; SAJ; Masters; Endo; SpecGX; TEVA; Cephalon; Actavis; Allergan; Watson; Janssen; Rhodes; Mallinckrodt; Johnson & Johnson; Rite Aid</p>	<p>2018</p>
<p>The Town of Rainelle, West Virginia v. AmerisourceBergen Drug Company, et al.</p>	<p>N.D. Ohio 1:18-op-45322</p>	<p>AmeriSource Bergen; Cardinal; McKesson; Walmart; Kroger; Endo; SpecGX; TEVA; Cephalon; Actavis; Allergan; Watson; Janssen; Rhodes; Mallinckrodt; Johnson & Johnson; Rite Aid; Warner Chilcott</p>	<p>2018</p>

The Town of Rupert, West Virginia v. AmerisourceBergen Drug Corporation, et al.	N.D. Ohio 1:18-op-45323	AmeriSource Bergen; Cardinal; McKesson; Walmart; Kroger; Endo; SpecGX; TEVA; Cephalon; Actavis; Allergan; Watson; Janssen; Rhodes; Mallinckrodt; Johnson & Johnson; Warner Chilcott; KeySource; Associated	2018
The Town of Sutton, West Virginia v. Cardinal Health, Inc., et al.	N.D. Ohio 1:18-op-45318	Cardinal; McKesson; Endo; SpecGX; TEVA; Cephalon; Actavis; Allergan; Watson; Janssen; Rhodes; Mallinckrodt; Johnson & Johnson; Warner Chilcott; Rite Aid	2018
Town of Fort Gay, West Virginia v. Rite Aid of Maryland, Inc. et al.	N.D. Ohio 1:18-op-45225	Rite Aid; CVS; McKesson; Cardinal; SAJ (terminated); Walmart; Amerisource Bergen; Top Rx; Rhodes; TEVA; Janssen; Endo; Specgx; Watson; Actavis; Allergan; Cephalon; Johnson & Johnson; Mallinckrodt; Warner Chilcott	2018
Town of Quinwood, West Virginia v. AmerisourceBergen Drug Corporation, et al.	N.D. Ohio 1:18-op-45324	Amerisource Bergen; Cardinal; Kroger; McKesson; Walmart; Rhodes; Endo; SpecGX; Janssen; TEVA; Cephalon; Actavis; Allergan; Watson; Associated; Rite Aid; Mallinckrodt; Warner Chilcott; Johnson & Johnson	2018

County of Alpena, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio, 1:18-op- 45871	Cephalon; TEVA; Insys; Endo; Janssen; Mallinckrodt; Allergan; Actavis; Watson; Cardinal; Amerisource Bergen; Cardinal; McKesson; Omnicare; Masters; CVS (terminated); Walgreen; Rite Aid; Costco; Rhodes; Walmart; Anda; Johnson & Johnson; Mylan Par; Noramco; SpecGx; Sandoz	2018
County of Cass, Michigan v. Purdue Pharma L.P. et al	N.D. Ohio, 1:18-op- 45868	Cephalon; TEVA; Endo; Janssen; Insys; Allergan; Actavis; Mallinckrodt; Watson; Amerisource Bergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreen; Rite Aid; Rhodes; Anda; Walmart; Costco; Johnson & Johnson; Mylan; Par; Noramco; SpecGX	2018
County of Houghton, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio, 1:18-op- 45866	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson, Actavis, Amerisource Bergen; Cardinal; McKesson; Omnicare; Masters; CVS; Wagreen; Rite Aid; Costco; Rhodes; Anda; Johnson & Johnson; Mylan; Par; Noramco, SpecGx; Sandoz; Walmart	2018
County of Ingham, Michigan v. Purdue Pharma L.P. et al.	N.D. Ohio, 1:18-op- 46178	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson, Actavis, Amerisource Bergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreen; Rite Aid; Costco; Rhodes; Anda; Johnson & Johnson; Mylan; Par; Noramco, SpecGx; Sandoz; Walmart	2018

County of Ionia, Michigan v. Purdue Pharma L.P., et al.	N.D. Ohio, 1:19-op- 45261	AmerisourceBergen; Cardinal; McKesson; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Watson; Actavis; Mallinckrodt; NC Mutual Wholesale Drug Co.; SpecGx; Par; Amneal; KVK; CVS; Rite Aid; Walgreen; Walmart	2019
County of Iron, Michigan v. Purdue Pharma L.P. et al.	N.D. Ohio, 1:18-op- 45888	Cephalon; TEVA; Endo; Janssen; Insys; Mallinckrodt; Allergan; Watson; Actavis; AmerisourceBergen; Cardinal; McKesson; Omnicare; Masters; CVS; Walgreen; Rite Aid (terminated); Costco; Walmart; Rhodes; Anda; Johnson & Johnson; Mylan; Par; Noramco; SpecGx; Sandoz	2018
County of Kent, Michigan v. Purdue Pharma L.P. et al.	N.D. Ohio, 1:19-op- 45000	Cardinal; McKesson; AmerisourceBergen; Rite Aid; Walmart; H.D. Smith; Harcard Drug Group; Kroger; Miami- Luken; Anda; Cedardale; Bellco; SAJ; Masters; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Par; Allergan; Watson; Actavis; Mallinckrodt; SpecGx; Insys	2019
County of Montcalm, Michigan v. Purdue Pharma L.P. et al.	N.D. Ohio, 1:18-op- 45865	AmerisourceBergen; Cardinal; McKesson; Rite Aid; Walmart; Kroger; H.D. Smith; Harvard Drug Group; Miami- Luken; Anda; Cedardale; Bellco; SAJ (terminated); Masters; Rhodes; SpecGx; Endo; TEVA; Cephlaon; Watson; Actavis; Allergan; Janssen; Warner Chilcott; Johnson & Johnson; Mallinckrodt	2018

City of Logan, W. Va. V. AmerisourceBergen Drug Corp. et al.	N.D. Ohio, 1:18-op- 45317	AmerisourceBergen; Cardinal; McKesson; Rite Aid; Walmart; Kroger; H.D. Smith; Harvard Drug Group; Miami- Luken; Anda; Cedardale; Bellco; SAJ (terminated); Masters; Rhodes; SpecGx; Endo; TEVA; Cephlaon; Watson; Actavis; Allergan; Janssen; Warner Chilcott; Johnson & Johnson; Mallinckrodt	2018
City of Milton, W. Va. V. AmerisourceBergen Drug Corp. et al.	N.D. Ohio, 1:18-op- 45321	AmerisourceBergen; CVS; Cardinal; Rite Aid; Walmart; McKesson; Walgreen; Kroger; H.D. Smith; SpecGx; Endo; TEVA; Cephalon; Watson; Actavis; Allergan; Rhodes; Janssen; Warner Chilcott; Johnson & Johnson; Mallinckrodt	2018
City of Bluefield, W. Va. V. AmerisourceBergen Drug Corp. et al.	N.D. Ohio, 1:18-op- 45659	AmerisourceBergen; McKesson; Cardinal; CVS; Kroger; Rite Aid; Rhodes; TEVA; Cephalon; Janssen; Endo; SpecGx; Watson; Actavis; Allergan; Mallinckrodt; Warner Chilcott; Johnson & Johnson	2018
City of Hurricane, W. Va. V. AmerisourceBergen Drug Corp. et al.	N.D. Ohio, 1:18-op- 45293	AmerisourceBergen; McKesson; Cardinal; Walmart; Walgreen; Rite Aid; Rhodes; SpecGx; Endo; TEVA; Cephalon; Watson; Actavis; Allergan; Janssen; Warner Chilcott; Johnson & Johnson	2018

The Estate Of Justine Marie Aliotta, Joanne Aliotta individually and as administratrix of the Estate of JUSTINE MARIE ALIOTTA, deceased, Julissa Cecelia Torres an infant by her guardian JOANNE ALIOTTA, Plaintiff Class consisting of all other persons in New York so situated v. Purdue Pharma, Inc. et. al

Richmond County Supreme Court, No. 152057/2019

Purdue Pharma, Inc.; Purdue Pharma L.P.; The Purdue Frederick Company, Inc.

., Endo Health Solutions, Inc., Endo Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceuticals, Inc. f/k/a ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals, Usa, Inc., Cephalon, Inc.;, Allergan Plc f/k/a ACTAVIS PLC f/k/a WATSON PHARMACEUTICALS, INC., Allergan Finance, Llc, Watson Laboratories, Inc., Abbvie Inc., Amerisourcebergen Drug Corporation, Mckesson Corporation, Cardinal Health, Inc., Staten Island University

8/28/2019

2019

Case Name	Court/Docket No.	Purdue Entities Named as Defendants	Non-Purdue Co- Defendants	Filing Year
State of Arizona, ex rel. Mark Brnovich, Attorney General v. Purdue Pharma L.P., et al.	U.S. Supreme Court No. 22O151		N/A	2019

Case Name	Court and Docket No.	State	Purdue Entity Defendants	Non-Purdue Co-Defendants	Filed	Filing Year
Estate of Bruce Brockel v. John Patrick Couch, et al.	Cir. Ct. Mobile Cnty. (AL)/02-cv-2017-902787 (remanded from S.D. Ala./1:17-cv-00521)	Alabama	Purdue Pharma L.P.	John Patrick Couch; Rasan M. Tarabein; Physicians Pain Specialists of Alabama, P.C.; C&R Pharmacy, LLC; Eastern Shore Neurology Clinic,	10/25/2017	2017
The State of Alabama v. Purdue Pharma L.P., et al.	Cir. Ct. Montgomery Cnty. (AL)/03-CV-2019-901174	Alabama	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Endo; McKesson	6/20/2019	2019
State of Alaska v. Purdue Pharma L.P., et al.	Super. Ct. AK, 3rd Jud. Dist. /3AN-17-09966	Alaska	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Jane Does 1 - 10	10/30/2017	2017
Tucson Medical Center, a corporation v. Purdue Pharma L.P., et al.	Super. Ct. Pima Cnty. (Ariz.)/C20184991 (remanded from D. Ariz./4:19-cv-00358-LCK)	Arizona	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Amneal; TEVA; Cephalon; Johnson & Johnson; Janssen; Abbott; Endo; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Anda; H.D. Smith; Henry Schein; McKesson; AmerisourceBergen; Cardinal	10/9/2018	2018

City of Prescott v. Allergan PLC, et al.	Super. Ct. Yavapai Cnty./P1300CV201900393 (remanded from D. Ariz./3:19-cv-08165-CDB)	Arizona	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Actavis; Watson; Mallinckrodt; TEVA; Cephalon; Endo; Janssen; Insys; McKesson; Cardinal; AmerisourceBergen; Dr. Douglas J. Campbell; Dr. Randy Joe Spicer	4/23/2019	2019
Kingman Hospital, Inc.; Arizona Spine and Joint Hospital LLC; Bullhead City Hospital Corporation; Carondelet St. Joseph's Hospital; Holy Cross Hospital, Inc.; Hospital Development of West Phoenix, Inc.; Northwest Hospital, LLC; Oro Valley Hospital, LLC; Oasis Hospital; Orthopedic and Medical Specialty Company, LLC; St. Mary's Hospital of Tucson; VHS Acquisition Subsidiary Number 1, Inc.; and VHS of	Super. Ct. Mohave Cnty. (Ariz.)/S8015CV201900563 (remanded from D. Ariz./3:19-cv-08240-JJT)	Arizona	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Amneal; TEVA; Cephalon; Johnson & Johnson; Janssen; Abbott; Endo; Mallinckrodt; Insys; SpecGx; Allergan; Actavis; Watson; Anda; H.D. Smith; Henry Schein; McKesson; AmerisourceBergen; Cardinal; Miami-Luken; Kroger; Rite Aid; Wal-Mart; Noramco; Walgreens	6/18/2019	2019

Bullhead City v. Allergan PLC, et al.	Super. Ct. Mohave Cnty. (Ariz.)/S8015CV20 1900591	Arizona	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Actavis; Watson; Mallinckrodt; TEVA; Cephalon; Endo; Janssen; Johnson & Johnson; Cardinal; AmerisourceBerge n; John Kapoor; Michael Babich	6/25/2019	2019
City of Surprise v. Allergan PLC, et al.	Super. Ct. Maricopa Cnty. (Ariz.)/CV2019- 003439	Arizona	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Actavis; Watson; Mallinckrodt; TEVA; Cephalon; Endo; Janssen; Johnson & Johnson; Cardinal; AmerisourceBerge n; John Kapoor	7/2/2019	2019
County of La Paz v. Allergan PLC, et al.	Super. Ct. La Paz Cnty. (Ariz.)/S1500CV20 1900053	Arizona	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Actavis; Watson; Mallinckrodt; TEVA; Cephalon; Endo; Janssen; Johnson & Johnson; Cardinal; AmerisourceBerge n; John Kapoor	7/3/2019	2019
City of Glendale v. Allergan PLC, et al.	Super. Ct. Maricopa Cnty. (Ariz.)/CV2019- 010792	Arizona	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Actavis; Watson; Mallinckrodt; TEVA; Cephalon; Endo; Janssen; Johnson & Johnson; Cardinal; AmerisourceBerge n; John Kapoor; Patricia Sullivan; Nicole Hanna; John Eldridge; Haridner Takyar	7/17/2019	2019

State of Arizona, ex rel. Mark Brnovich, Attorney General v. Purdue Pharma L.P., et al.	Super. Ct. Pima Cnty. (Ariz.)/C20072471	Arizona	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	9/10/2018 (Order to Show Cause for violation of consent judgment)	2018
State of Arkansas, ex rel. Scott Ellington v. Purdue Pharma L.P., et al.	Cit. Ct., Crittenden Cnty. (Ark.)/CV- 2018-268	Arkansas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Watson; Actavis; Endo; Vintage; Mallinckrodt; Mylan; Sun; Aurobindo; Aurolife; Lupin; Collegium; Biodelivery; Shion; Abbvie; Abbott; Pernix; Daichi; Forest; Mayne; Apotex; West-Ward; Gemini; Poly; Akorn; Valeant; North America; ECR; Depomed; Validus; Egalet; Vernalis; UCB; Xanodyne; Vertical; Senty; Rhodes; Sandoz; AmerisourceBerge n; Cardinal;	3/15/2018	2018
State of Arkansas, ex rel. Leslie Rutledge v. Purdue Pharma L.P., et al.	Cir. Ct. Pulaski Cnty. (Ark.)/60CV- 18-2018	Arkansas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	3/29/2018	2018

County of Kern, and The People of the State of California, by and through Kern County Counsel Margo Raison v. Purdue Pharma L.P., et al.	Super. Ct. (Cal.)/BCV-19- 100861 (remanded from E.D. Cal./1:19-cv- 00557)	California	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Actavis; Watson; Allergan; Insys; Mallinckrodt; Cardinal; AmerisourceBerge n; McKesson	3/27/2019	2019
City of El Monte, and The People of the State of California, by and through El Monte City Attorney Rick Olivarez v. Purdue Pharma L.P., et al.	El Monte County Super. Ct. (Cal.)/19STCV1053 2 (remanded from C.D. Cal./2:19-cv- 03588)	California	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Actavis; Watson; Allergan; Insys; Mallinckrodt; Cardinal; AmerisourceBerge n; McKesson	3/28/2019	2019
The People of the State of California v. Purdue Pharma L.P., et al.	Los Angeles Cnty. Super. Ct. (Cal.)/19STCV1904 5	California	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	6/3/2019	2019
People of California v. Purdue Pharma L.P., et al.	Orange County Super. Ct. (Cal.)/30-2014- 00725287-CU-BT- CXC	California	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Actavis; Allergan; Watson; Does 1-100	5/21/2014; 7/6/2017 (4th Amend.); 6/8/2018 (6th Amen.)	2014
The State of Colorado ex rel. Cynthia H. Coffman, Attorney General v. Purdue Pharma L.P., et al.	Dist. Ct. Denver (Colo.)/2018CV33 300	Colorado	Purdue Pharma L.P.; Purdue Pharma Inc.	N/A	9/6/2018	2018

City of Waterbury v. Purdue Pharma L.P., et al.	Hartford State Super. Ct. (Conn.)/HHD-CV- 17-6088121-S	Connecticut	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	8/31/2017	2017
City of New Haven v. Purdue Pharma L.P., et al.	Hartford State Super. Ct. (Conn.)/HHD-CV- 17-6086134-S	Connecticut	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n	10/25/2017	2017
City of New Britain v. Purdue Pharma L.P., et al.	Hartford State Super. Ct. (Conn.)/HHD-CV- 18-6087132-S	Connecticut	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n	11/15/2017	2017
The City of Bridgeport, et al. v. Purdue Pharma L.P., et al.	Hartford State Super. Ct. (Conn.)/HHD-CV- 18-6088462-S	Connecticut	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	1/9/2018	2018

The City of New London v. Purdue Pharma L.P., et al.	Hartford State Super. Ct. (Conn.)/HHD-CV-18-6094421-S	Connecticut	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBergen; McKesson; Cardinal; AmerisourceBergen; John Kapoor	4/3/2018	2018
Town of Wallingford v. Purdue Pharma L.P., et al.	Hartford State Super. Ct. (Conn.)/HHD-CV-18-6094422-S	Connecticut	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBergen; McKesson; Cardinal; AmerisourceBergen; John Kapoor	4/10/2018	2018
The City of Ansonia, The City of Danubury, The City of Derby, and The City of Norwalk v. Purdue Pharma L.P., et al.	Hartford State Super. Ct. (Conn.)/HHD-CV-18-6098036-S (removed from J.D. of Ansonia-Milford at Milford (CT)/AAN-CV-18-6028560-S)	Connecticut	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBergen; McKesson; Cardinal; AmerisourceBergen; John Kapoor	5/24/2018	2018

The Town of Stratford; The Town of Berlin; The Town of Middlebury; The Town of Seymour; The Town of Prospect; The Town of Wolcott; The Town of Bethlehem; The Town of New Milford; The Town of Roxbury; and The Town of Coventry v. Purdue Pharma L.P., et al.	Hartford State Super. Ct. (Conn.)/HHD-CV-18-6099290-S	Connecticut	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerg	8/13/2018	2018
State of Connecticut v. Purdue Pharma L.P., et al.	Hartford State Super. Ct. (CT)	Connecticut	Purdue Pharma L.P.; Purdue Pharma Inc.; Purdue Holdings L.P.; PLP Associates Holdings L.P.; BR Holdings L.P.; Rosebay Medical Company L.P.; Beacon Company	N/A	12/20/2018	2018
Andrea Harley, individually and on behalf of all others similarly situated v. Purdue Pharma L.P., et al.	Norwalk/Stamford State Super. Ct.	Connecticut	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	6/5/2019	2019
District of Columbia v. Purdue Pharma L.P., et al.	Super. Ct. District of Columbia (DC)/2019 CA 003680 B	DC	Purdue Pharma L.P.; Purdue Pharma Inc.	N/A	6/3/2019	2019

State of Delaware, ex rel. Matthew P. Denn v. Purdue Pharma L.P., et al.	Super. Ct. of Delaware (remanded from DE/1:18-cv-00383- UNA)	Delaware	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; McKesson; Cardinal; AmerisourceBerge n; Anda; H.D. Smith; CVS; Walgreens	1/19/2018	2018
State of Florida, Office of the Attorney General, Department of Legal Affairs v. Purdue Pharma L.P., et al.	Cir. Ct. Pasco Cnty. (Fla.)	Florida	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Janssen; Johnson & Johnson; Cephalon; TEVA; Allergan; Actavis; AmerisourceBerge n; Cardinal; McKesson; Mallinckrodt	5/15/2018; 11/16/18 (Am.)	2018
State of Georgia v. Purdue Pharma L.P., et al.	Super. Ct. Gwinnett Cnty. (Ga.)/19-A-00060- 8	Georgia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Endo; Par; Qualitest; Allergan; Actavis; Watson; Mallinckrodt; SPecGx; McKesson; Cardinal; AmerisourceBerge n; J.M. Smith	1/3/2019	2019
Territory of Guam v. Purdue Pharma L.P., et al.	Super. Ct. Guam/CV-1020-19	Guam	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Transdermal Technologies L.P.	N/A	8/20/2019	2019
State of Hawaii, ex rel. Clare E. Connors, Attorney General v. Purdue Pharma L.P., et al.	1st Cir. Ct. of Hawaii/09-1-0862- 06 JHA	Hawaii	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	6/3/2019	2019

County of Hawai'i v. Purdue Pharma L.P., et al.	3rd Cir. Ct. of Hawaii/19-1-156	Hawaii	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Rhodes; Par; Mallinckrodt; SpecGx; Mylan; Sandoz; West- Ward; Amneal; Noramco; John N. Kapoor; Rudolph B. Puana, M.D.; Big Island Pain Center LLC; Puana Pain LLC	6/10/2019	2019
State of Idaho, Through Attorney General Lawrence G. Wasden vs. Purdue Pharma L.P., et al.	Ada County District Court, ID/CV01-19-10061	Idaho	Purdue Pharma L.P.; Purdue Pharma Inc.	N/A	6/3/2019	2019
The People of the State of Illinois, the people of Jersey County and Jersey County v. Purdue Pharma L.P., et al.	Cir. Ct. Cook Cnty. (Ill.)/2018-L-3908 (removed from 2018-L-3908 Sangamon Cnty. (Ill.)/2017-L-11 (transferred from Jersey Cnty. (Ill.)/2017-L-11))	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson	6/26/2017	2017
The People of the State of Illinois, the people of Kankakee Cnty v. Purdue Pharma L.P., et al.	Kankakee Cnty. (Ill.)/2017L104	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	9/25/2017	2017

The People of the State of Illinois and Kane County, Illinois v. Purdue Pharma L.P., et al.	Cir. Ct. Cook Cnty. (Ill.)/2018-L-002943 (removed from Cir. Ct. Kane County (Ill.))	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	12/21/2017	2017
The People of the State of Illinois and Will County, Illinois v. Purdue Pharma L.P., et al.	Cit. Ct. Cook Cnty./2018-L-004546 (Cir. Ct. Will County (Ill.)/2017MR003400)	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	12/21/2017	2017
The People of the State of Illinois and McHenry County, Illinois v. Purdue Pharma L.P., et al.	Cir. Ct. Cook Cnty. (Ill.)/2018-L-002948 (removed from Cir. Ct. McHenry County (Ill.)/17LA000399)	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	12/21/2017	2017
The People of the State of Illinois and DuPage County, Illinois v. Purdue Pharma L.P., et al.	Cit. Ct. Cook Cnty./2018-L-004542 (removed from Cir. Ct. DuPage County (Ill.))	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	12/21/2017	2017
County of Lake, et al. v. Purdue Pharma L.P., et al.	Cir. Ct. Cook Cnty. (Ill.)/2018-L-003728 (removed from Cir. Ct. Lake County (Ill.)/17CH1680)	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; American Academy of Pain Medicine; The American Geriatrics Society and American Pain Society	12/21/2017	2017

The People of the State of Illinois and Cook County, Illinois v. Purdue Pharma L.P., et al.	Cir. Ct. Cook County (Ill.)/2017-L-013180	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	12/27/2017	2017
The People of the State of Illinois and Champaign County, Illinois v. Purdue Pharma L.P., et al.	Cir. Ct. Champaign Cnty. (Ill.)/2018L6	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	1/11/2018	2018
The People of the State of Illinois and Bureau County, Illinois v. Purdue Pharma L.P., et al.	Cit. Ct. Cook Cnty./2018-L-004542 (removed from Cir. Ct. Bureau Cnty. (Ill.)/2018L1)	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	1/12/2018	2018
The People of the State of Illinois and Macon County, Illinois v. Purdue Pharma L.P., et al.	Cit. Ct. Cook Cnty. (Ill.)/2018-L-002916 (removed from Cir. Ct. Macon Cnty. (Ill.)/2018L7)	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	1/12/2018	2018
The People of the State of Illinois and Boone County, Illinois v. Purdue Pharma L.P., et al.	Cir. Ct. Boone Cnty. (Ill.)/2018L7	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	2/5/2018	2018

City of Granite City, Illinois v. AmerisourceBerge n Drug Corp., et al.	Cir. Ct. Madison Cnty. (Ill.)/18-L- 587 (remanded from S.D. Ill/3:18- cv-01367)	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	AmerisourceBerge n; Cardnial; McKesson; Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; H.D. Smith	5/2/2018	2018
The People of the State of Illinois, and Piatt County, Illinois v. Purdue Pharma L.P., et al.	Cir. Ct. Piatt Cnty. (Ill.)/2018L7	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBerge n; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	7/23/2018	2018
The Village of Lyons v. Purdue Pharma L.P., et al.	Cit. Ct. Lyons Cnty. (Ill.)/2018L008746	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBerge n; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	8/14/2018	2018

The Village of Summit v. Purdue Pharma L.P., et al.	Cit. Ct. Cook Cnty. (Ill.)/2018L008803	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBerge n; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	8/15/2018	2018
The Village of Bedford Park v. Purdue Pharma L.P., et al.	Cit. Ct. Cook Cnty. (Ill.)/2018L008819	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBerge n; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	8/15/2018	2018
The People of the State of Illinois, and DeKalb County, Illinois v. Purdue Pharma L.P., et al.	Cir. Ct. DeKalb Cnty. (Ill.)/2018L000072	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBerge n; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	8/20/2018	2018

The People of the State of Illinois, and Kendall County, Illinois v. Purdue Pharma L.P., et al.	Cir. Ct. Kendall Cnty. (Ill.)/2018L000078	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	8/21/2018	2018
The People of the State of Illinois, and Macoupin County, Illinois v. Purdue Pharma L.P., et al.	Cir. Ct. Macoupin Cnty. (Ill.)/2018L30	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	8/23/2018	2018
Village of Bridgeview v. Purdue Pharma L.P., et al.	Cit. Ct. Cook Cnty. (Ill.)/2018L009526	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	9/4/2018	2018

The People of the State of Illinois, and Henry County, Illinois v. Purdue Pharma L.P., et al.	Cir. Ct. Henry Cnty. (Ill.)/18L16	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	9/5/2018	2018
Village of Hodgkins v. Purdue Pharma L.P., et al.	Cir. Ct. Cook Cnty. (Ill.)/2018:009848	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	9/7/2018	2018
The City of Countryside v. Purdue Pharma L.P., et al.	Cir. Ct. Cook Cnty. (Ill.)/2018L012640	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	11/21/2018	2018

The City of Burbank v. Purdue Pharma L.P., et al.	Cir. Ct. Cook Cnty. (Ill.)/2018L012659	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBerge n; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	11/21/2018	2018
The Village of Evergreen Park v. Purdue Pharma L.P., et al.	Cir. Ct. Cook Cnty. (Ill.)/2018L012652	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBerge n; American Academy of Pain Medicine; American Geriatric Society; American Pain Society	11/21/2018	2018
The People of the State of Illinois v. Purdue Pharma L.P., et al.	Cir. Ct. Cook Cnty. Chancery Div./2019CH0440 6	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.	N/A	4/5/2019	2019

The People of the State of Illinois and LaSalle County v. Purdue Pharma L.P., et al.	Cir. Ct. 13th Jud. Cir., LaSalle Cnty. (Ill.)/2019L000052	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; McKesson; Cardinal; AmerisourceBergen; Rhodes; Allergan; Watson; Actavis; Par; Mallinckrodt; SpecGx; Andax; Insys; H.D. Smith; Miami-Luken; Constantino Perales, M.D.	4/22/2019	2019
The City of Sesser v. Purdue Pharma L.P., et al.	Cir. Ct. Cook Cnty. (Ill.)/2019L008147	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; McKesson; Cardinal; AmerisourceBergen; Perry Fine; Scott Fishman; Lynn Webster; AAPM; AGS; APS	7/24/2019	2019
The People of the State of Illinois and McLean County v. Purdue Pharma L.P., et al.	Cir. Ct. McLean Cnty. (Ill.)/2019L108	Illinois	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; McKesson; Cardinal; AmerisourceBergen; Rhodes; Allergan; Watson; Actavis; Par; Mallinckrodt; SpecGx; Andax; Insys; H.D. Smith; Miami-Luken; Constantino Perales, M.D.	8/9/2019	2019

State of Indiana v. Purdue Pharma L.P., et al.	Cir. Ct. Marion Cnty. (Ind.)	Indiana	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	11/14/2018	2018
State of Iowa, Thomas J. Miller, Attorney General of Iowa v. Purdue Pharma L.P., et al.	Polk Cnty. Dist. Ct. (IA)	Iowa	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharma Company; The P.F. Laboratories Inc.	N/A	5/16/2019	2019
State of Kansas, ex rel. Derek Schmidt, Attorney General v. Purdue Pharma L.P., et al.	Shawnee Cnty. Dist. Ct. (Kan.)/2019-cv-000369	Kansas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	5/16/2019	2019

Bowling Green- Warren County Community Hospital Corporation; The Medical Center at Clinton County, Inc.; The Medical Center at Clinton County, Inc.; The Medical Center at Franklin, Inc.; Arh Tug Valley Health Services, Inc. f/k/a Highlands Hospital Corporation; Baptist Health Madisonville, Inc.; Grayson County Hopsital Foundation, Inc.; The Harrison Memorial Hospital, Inc.; Pikeville Medical Center, Inc.; Saint Elizabeth Medical	Warren Cnty. Cir. Ct. (KY)/19-CI- 01146	Kentucky	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Amneal; TEVA; Cephalon; Johnson & Johnson; Janssen; Abbott; Depomed; Endo; Mallinckrodt; SpecGx; Allergan; Actavis; Watson; Anda; H.D. Smith; Henry Schein; AmerisourceBerge n; Miami-Luken; Richie Pharmacal; Cardinal; CVS; Rite Aid; Walgreens; Walmart	9/5/2019	2019
State of LA f/k/a Louisiana Dept. of Health v. Purdue Pharma L.P., et al.	19th Judicial District Court, Parish of East Baton Rouge (LA)/661638	Louisiana	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson	9/20/2017; 3/20/2018 (Am.)	2017
State of Maine v. Purdue Pharma L.P.	Super. Ct. Kennebec Cnty. (Me.)	Maine	Purdue Pharma L.P.; Purdue Pharma Inc.	N/A	6/3/2019	2019

Anne Arundel County, Maryland v. Purdue Pharma L.P., et al.	Cir. Ct. Anne Arundel Cnty. (MD)/C-02-CV-18- 000021 (remanded from D. Md./1:18-cv- 00519-GLR)	Maryland	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal McKesson; AmerisourceBerge n; William Tham, M.D.; Physical Medicine and Pain Management Associates, PC; Kofi Shaw-Taylor; Happiness Aguzie; Tomarco Harris; Minnie Ndem; Starlife Wellness Center LLC; Lawrence Vidaver, M.D.; Maryland Healing Waters, LLC; Jackie Syme, M.D.; Arundel Neurology	1/3/2018	2018
Mayor & City Council of Baltimore v. Purdue Pharma L.P., et al.	Baltimore Cnty. (MD)/25C1800515 (remanded from D. Md./1:18-cv- 00800)	Maryland	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Allergan; Actavis; Watson; Endo; McKesson; Cardinal; AmerisourceBerge n; Rosen-Hoffberg Rehab. & Pain Mgmt. Assoc.; Norman B. Rosen; Howard J. Hoffberg; Rhodes	1/31/2018	2018

Consumer Protection Division Office of the Attorney General v. Purdue Pharma L.P., et al.	CPD Case No.: 311366	Maryland	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals Products L.P.; Avrio Health Limited Partnership (f/k/a Purdue Products L.P.)	Rhodes	5/29/2019	2019
Commonwealth of Massachusetts v. Purdue Pharma L.P., et al.	Super. Ct. Suffolk Cnty. (Mass.)	Massachusetts	Purdue Pharma L.P.; Purdue Pharma Inc.	N/A	6/13/2018	2018
City of Worcester v. Purdue Pharma L.P., et al.	Super. Ct. Worcester Cnty. (Mass.)	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; John Kapoor	7/30/2018	2018
City of Boston, The Boston Public Health Commission, The Boston Housing Authority v. Purdue Pharma L.P., et al.	Super. Ct. Suffolk Cnty. (Mass.)/1884CV02 860B	Massachusetts	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Cardinal; Mallinckrodt; SpecGx; McKesson; AmerisourceBergen; Walgreens; Dr. Fathallah Mashali	9/13/2018	2018

City of Gloucester v. Purdue Pharma L.P., et al.	Super. Ct. Essex Cnty. (Mass.)/1877CV01 773	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; John Kapoor	12/3/2018	2018
City of Haverhill v. Purdue Pharma L.P., et al.	Super. Ct. Essex Cnty. (Mass.)/1899CV01 762A	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; John Kapoor	12/3/2018	2018
Town of Wakefield v. Purdue Pharma L.P., et al.	Super. Ct. Middlesex Cnty. (Mass.)/18-3458	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; John Kapoor	12/3/2018	2018

City of Salem v. Purdue Pharma L.P., et al.	Super. Ct. Essex Cnty. (Mass.)/1899CV01 767A	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; John Kapoor	12/3/2018	2018
Town of Lynnfield v. Purdue Pharma L.P., et al.	Super. Ct. Essex Cnty. (Mass.)/1899CV01 769D	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; John Kapoor	12/3/2018	2018
City of Framingham v. Purdue Pharma L.P., et al.	Super. Ct. Middlesex Cnty. (Mass.)/18-3483	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; John Kapoor	12/5/2018	2018

Town of Canton v. Purdue Pharma L.P., et al.	Super. Ct. Norfolk Cnty. (Mass.)/18- 1582	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; John Kapoor	12/11/2018	2018
Town of Springfield v. Purdue Pharma L.P., et al.	Super. Ct. Hampden Cnty. (Mass.)/18-938	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; John Kapoor	12/18/2018	2018
City of Chicopee v. Purdue Pharma L.P., et al.	Super. Ct. Hampden Cnty. (Mass.)/1979CV00 074	Massachusetts	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; John Kapoor	2/4/2019	2019

Town of Natick v. Purdue Pharma L.P., et al.	Super. Ct. Middlesex Cnty. (Mass.)/19-646	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; John Kapoor	3/7/2019	2019
Town of Randolph v. Purdue Pharma L.P., et al.	Super. Ct. Norfolk Cnty. (Mass.)/1982CV00 400	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n; John Kapoor; CVS; Rite Aid; Walgreens; Walmart	3/27/2019	2019
City of Cambridge v. Purdue Pharma L.P., et al.	Super. Ct. Middlesex Cnty. (Mass.)/19-1044	Massachusetts	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Collegium; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n; John Kapoor; CVS; Rite Aid; Walgreens; Walmart	4/12/2019	2019

State of Minnesota by its Attorney General, Lori Swanson v. Purdue Pharma L.P., et al.	4th Jud. Dist. Ct., Hennepin Cnty. (Minn.)	Minnesota	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	7/2/2018; 7/8/2019	2018
State of Mississippi v. Purdue Pharma L.P., et al.	Hinds Cnty. (Miss.)/25CH1:15-cv-001814	Mississippi	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson	12/15/2015	2015
Gary Carr, individually as next friend and on behalf of all wrongful death beneficiaries of Luther Greer, deceased v. Charles Elliott, M.D., et al.	Cir. Ct. Tippah Cnty. (Miss.)/CV2019-075-JKL	Mississippi	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Charles Elliott, M.D.; Primary Care Clinic of Ripley, P.A.; Marshall Hollis; Hollis Discount Pharmacy; Par; Endo; Hi-Tech; Akorn; Mallinckrodt; Actavis; TEVA	6/14/2019	2019
State of Missouri, ex rel. Joshua D. Hawley, in his official capacity as Missouri Attorney General v. Purdue Pharma L.P.	Cir. Ct. St. Louis City (MO)/1722-CC10626	Missouri	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Johnson & Johnson; Janssen	6/21/2017	2017

Jefferson County and Franklin County v. Dannie E. Williams, M.D., et al.	Cir. Ct. St. Louis City (MO)/1922- CC00203 (remanded and severed from E.D. Mo./4:19-cv- 00157-RLW)	Missouri	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Dannie E. William, M.D.; Delmar Primary Care; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Allergan; Actavis; Watson; Mallinckrodt; Cardinal; AmerisourceBerge n; Express; Wal- Mart; Target; Walgreens; CVS; Caremark; Mylan; Depomed; Insys; United Health; Optum	1/29/2019	2019
Cynthia Drake v. Westport Plaza Medical Group, Inc., et al.	Cir. Ct. Jackson Cnty. (MO)/1916- CV03720	Missouri	Purdue Pharma L.P.; Purdue Pharma Inc.	Westport Plaza; KC Wellness; Anita L. Klamet-Roult, NP; The Estate of Dr. George Kuruvilla	2/11/2019	2019
State of Montana v. Purdue Pharma L.P., et al.	Lewis & Clark Cty. (MT)/ADV-2017- 949 (remanded from D. Mt./6:18- cv-00033-SHE)	Montana	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Jane Does 1-10	11/30/2017	2017

City of Reno v. Purdue Pharma L.P., et al.	Dist Ct. Washoe County (Nev.)/CV18-01895 (removed from D. Nev./3:18-cv-00454-MMD-WCG)	Nevada	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc. d/b/a The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	TEVA; McKesson; AmerisourceBergen; Cardinal; AbbVie; Depomed; Daiichi; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; Robert Gene Rand, M.D.; Rand Family Care, LLC	9/20/2018	2018
State of Nevada v. McKesson Corp, et al.	Dist. Ct. Clark County (Nev.)/A-19-796755-B	Nevada	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; P.F. Laboratories, Inc.; Purdue Holdings L.P.; PLP Associates Holdings L.P.; Rosebay Medical Company L.P.; Beacon Company	McKesson; Cardinal; AmerisourceBergen; Walgreens; Walmart; CVS; TEVA; Actavis; Mallinckrodt; Insys; John Kapoor; Richard M. Simon; Sunrise Lee; Joseph A. Rowan; Michael J. Gurry; Michael Babich; Alec Burlakoff; TEVA; Cephalon; SpecGx	6/17/2019	2019
State of New Hampshire v. Purdue Pharma L.P., et al.	Merrimack Super. Ct. (NH)/217-2017-CV-00402 (remanded from USDC NH/1:17-cv-00427-PB)	New Hampshire	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	8/8/2017; 9/15/2017	2017

Gurbir S. Grewal, et al. v. Purdue Pharma L.P., et al.	Super. Ct. NJ Chancery. Div., Essex Cty.	New Jersey	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	XYZ Corporations 1-20	10/31/2017	2017
Francisco Perez, individually, as administrator and administrator ad prosequendum for the Estate of Tanny Robles- Perez, Fransheka Robles Gomez, Sarai Perez Robles, a minor, by Francisco Perez, his guardian ad litem v. Fred S. Revordero, M.D., et al.	Super. Ct. NJ Passaic Cnty./PAS- L-003289-18	New Jersey	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Fred S. Revordero, M.D.; Mort Jacobs Pharmacy; Nour Pharmacy; CVS; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo	10/5/2018	2018
Cumberland County v. Purdue Pharma L.P., et al.	Super. Ct. Cumberland Cnty. (NJ)/CUM-L- 000567-19	New Jersey	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Rhodes; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; Abbvie; Abbott; AmerisourceBerge n; Cardinal; McKesson	9/13/2019	2019
State of New Mexico, ex rel., Hector Balderas, Attorney General v. Purdue Pharma L.P., et al.	Santa Fe Dist. (NM)/D-101-CV- 201702541 (removed from D.N.M./1:18-cv- 00386)	New Mexico	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Russell Portenoy	9/7/2017; 3/6/2019 (Am. Cplt.)	2017

County of Schoharie v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.) - 400010/2017 (removed from Schoharie Cnty. (N.Y.)/2017-395)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	9/27/2017	2017
--	---	----------	--	--	-----------	------

County of Rensselaer v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. - 400011/Rensselaer Cnty. (N.Y.) (removed from Rensselaer Cnty. 2017-0025743)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	9/27/2017	2017
County of Seneca v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.) - 400006/2017 (removed from Seneca Cnty. (N.Y.) - 51181/2017)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Rhodes; Mallinckrodt; Par; CVS; Anda; Rite Aid; Walgreens; Wal-Mart	10/10/2017	2017

County of Niagara v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. - 400012/2017 (removed from Niagara Cnty. (N.Y.)/E162958/20 17)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	10/20/2017	2017
County of Oswego v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400007/2018 (removed from Sup. Ct. Oswego Cnty. (N.Y.)/EFC- 2017-0022)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester; Rhodes; Mallinckrodt; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens	1/4/2018	2018

The County of Madison v. Purdue Pharma L.P., et al.	Sup. Ct. Madison Cnty. (N.Y.)/2018- 1046	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	1/5/2018	2018
--	--	----------	---	--	----------	------

The County of Chautauqua v. Purdue Pharma L.P., et al.	Sup. Ct. Chautauqua Cnty. (N.Y.)/KI-2018-57	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	1/12/2018	2018
---	---	----------	---	--	-----------	------

The County of Clinton v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400003/2018 (removed from Clinton Cnty./2018-52)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	1/12/2018	2018
---	---	----------	--	---	-----------	------

The County of Greene v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400008/2018 (removed from Sup. Ct. Greene Cnty. (N.Y.)/2017- 45)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester; Rhodes; Mallinckrodt; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens	1/12/2018	2018
--	--	----------	---	--	-----------	------

County of St. Lawrence v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400002- 2019 (removed from Sup. Ct. St. Lawrence Cnty. (N.Y.)/CV-2018- 0151909)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	1/12/2018	2018
---	--	----------	--	---	-----------	------

County of Saratoga v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400009/2018 - Sup. Ct. Saratoga Cnty. (N.Y.)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	1/23/2018	2018
---	--	----------	--	---	-----------	------

City of Ithaca v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400002/2018 (removed from Tompkins Cnty. (N.Y.)/EF2018- 0032)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	1/24/2018	2018
The County of Monroe v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400017- 2018 (removed from Sup. Ct. Monroe Cnty. (N.Y.))	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester; Rhodes; Mallinckrodt; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens	1/24/2018	2018

The County of Warren v. Purdue Pharma L.P., et al.	Sup. Ct. Warren Cnty. (N.Y.)/2018- 64959	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	1/31/2018	2018
--	--	----------	---	--	-----------	------

County of Columbia v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. - 400015/2018 (removed from Sup. Ct. Columbia Cnty. (N.Y.)/12476- 18)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester; Rhodes; Mallinckrodt; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens	2/2/2018	2018
---	--	----------	---	--	----------	------

County of Westchester v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400010/2018 (removed from Sup. Ct. Westchester Cnty. (N.Y.)/51606- 2018)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	2/6/2018	2018
--	---	----------	--	---	----------	------

The County of Steuben v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400004/2018 (Removed from Steuben Cnty. (N.Y.)/E2018- 209CV)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	2/21/2018	2018
---	--	----------	--	---	-----------	------

The County of Genesee v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400011/2018 (removed from Sup. Ct. Genesee Cnty. (N.Y.)/66388- 2018)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	2/21/2018	2018
---	--	----------	--	---	-----------	------

The County of Hamilton v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400005/2018 (removed from Hamilton Cnty. (N.Y.)/2018-7399)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	2/26/2018	2018
---	---	----------	--	--	-----------	------

The County of Franklin v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400012/2018 (removed from Sup. Ct. Franklin Cnty. (N.Y.)/2018- 317)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	3/2/2018	2018
--	---	----------	--	---	----------	------

The Town of Amherst v. Purdue Pharma L.P., et al.	Sup. Ct. Erie Cnty. (N.Y.)/803887- 2018	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	3/6/2018	2018
The County of Ulster v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400011- 2019 (removed from Sup. Ct. Ulster Cnty. (N.Y.)/18-903)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Watson; Actavis; Allergan; McKesson; Cardinal; AmerisouceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rocherster Drug; Mallinckrodt; Rhodes; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart	3/15/2018	2018

The County of Livingston v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400013-2018 (removed from Sup. Ct. Livingston Cnty. (N.Y.)/000240-2018)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	3/15/2018	2018
The County of Fulton v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400018-2018 (removed from Sup. Ct. Fulton Cnty. (N.Y.)/06213)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Watson; Actavis; Allergan; McKesson; Cardinal; AmerisourceBergen; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Mallinckrodt; Rhodes; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart	3/26/2018	2018

The County of Herkimer v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400008- 2019 (removed Sup. Ct. Herkimer Cnty. (N.Y.)/2018- 104118)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester; Rhodes; Mallinckrodt; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens	4/4/2018	2018
---	--	----------	---	--	----------	------

The County of Ontario v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400001- 2019 (removed from Sup. Ct. Ontario Cnty. (N.Y.)/117724- 2018)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester; Rhodes; Mallinckrodt; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens	4/13/2018	2018
---	---	----------	---	--	-----------	------

The County of Lewis v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400007- 2019 (removed Sup. Ct. Lewis Cnty. (N.Y.)/EFCA2018- 000148)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Rhodes; Par; Mallinckrodt; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart	4/13/2018	2018
The Town of Cheektowaga v. Purdue Pharma L.P., et al.	Sup. Ct. Erie Cnty. (N.Y.)/806151- 2018	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	4/18/2018	2018

The County of Schuyler v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. - 400014/2018 (removed from Sup. Ct. Schuyler Cnty. (N.Y.)/18-91)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	5/11/2018	2018
--	---	----------	--	---	-----------	------

The County of Putnam v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400014-2019 (removed from Sup. Ct. Putnam Cnty. (N.Y.)/500511-2018)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	5/29/2018	2018
The County of Wyoming v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400013/2018	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBergen; Bellco; Darby; Eveready; Kinray; PSS World; Rochester; Rhodes; Mallinckrodt; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens	6/6/2018	2018

The County of Cayuga v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400013- 2019 (removed from Sup. Ct. Cayuga Cnty. (N.Y.)/2018-603)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	6/8/2018	2018
--	---	----------	---	---	----------	------

The Town of Lancaster v. Purdue Pharma L.P., et al.	Sup. Ct. Erie Cnty. (N.Y.)/809160- 2018	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	6/13/2018	2018
--	---	----------	---	--	-----------	------

The County of Yates v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400026/201 9 (removed from Yates Sup. Ct.)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Scott Fishman; Lynn Webster	6/18/2018	2018
---	--	----------	---	--	-----------	------

The County of Chenango v. Purdue Pharma L.P., et al.	Sup. Ct. Chenango Cnty. (N.Y.)/2018- 5072	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	6/19/2018	2018
---	---	----------	---	--	-----------	------

The County of Essex v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400019- 2019 (removed from Sup. Ct. Essex Cnty. (N.Y.)/CV18-0296)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	6/19/2018	2018
---	---	----------	---	--	-----------	------

The County of Chenago v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400021/201 9 (removed from Sup. Ct. Chenago Cnty. (N.Y.)/2018- 5072)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	6/19/2018	2018
The County of Tioga v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400022/201 9 (removed from Sup. Ct. Tioga Cnty. (N.Y.)/2018- 60025)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	6/19/2018	2018

The Town of Tonawanda v. Purdue Pharma L.P., et al.	Sup. Ct. Erie Cnty. (N.Y.)/810783- 2018	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	7/11/2018	2018
--	---	----------	---	--	-----------	------

The City of Mount Vernon v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400016- 2019 (removed from Sup. Ct. Westchester Cnty. (N.Y.)/60636- 2018)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	7/11/2018	2018
--	--	----------	---	---	-----------	------

The County of Ostego v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400023/201 9 (removed from Sup. Ct. Ostego Cnty - EF2018- 621)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Scott Fishman; Lynn Webster	8/1/2018	2018
The County of Cortland v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400019- 2018 (removed from Sup. Ct. Cortland Cnty. (N.Y.)/EF18-864)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Watson; Actavis; Allergan; McKesson; Cardinal; AmerisouceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rocherster Drug; Mallinckrodt; Rhodes; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart	8/6/2018	2018

The County of Cattaraugus v. Purdue Pharma L.P., et al.	Sup. Ct. Cattaraugus Cnty. (N.Y.)/87139-2018	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Russell Portenoy; Scott Fishman; Lynn Webster	8/9/2018	2018
--	--	----------	---	--	----------	------

City of Plattsburgh v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400003- 2019 (removed from Sup. Ct. Clinton (N.Y.))	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Rhodes; Par; Mallinckrodt; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart	1/7/2019	2019
---	--	----------	---	---	----------	------

City of Albany v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400004- 2019 (removed from Sup. Ct. Albany (N.Y.))	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Rhodes; Par; Mallinckrodt; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart	1/7/2019	2019
City of Schenectady v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400005- 2019 (removed Sup. Ct. Schenectady (N.Y.))	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Rhodes; Par; Mallinckrodt; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart	1/7/2019	2019
City of Troy v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400006- 2019 (removed Sup. Ct. Rennselaer (N.Y.))	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Rhodes; Par; Mallinckrodt; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart	1/7/2019	2019

City of Yonkers v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400020/2019 (removed from Sup. Ct. Westchester Cnty. (N.Y.)/58368-2019)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	5/29/2019	2019
The City of Buffalo v. Purdue Pharma L.P., et al.	Sup. Ct. Erie Cnty. (N.Y.)/811359-2019	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; Watson; Actavis; Allergan; McKesson; Cardinal; AmerisourceBergen; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Mallinckrodt; Rhodes; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart	9/5/2019	2019

City of New York v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400006/2018 (removed from Sup. Ct. New York Cnty. (N.Y.)/450133- 2018)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester; Rhodes; Mallinckrodt; Par; SpecGx; Anda; CVS; Rite Aid; Walgreens	1/23/2018; 2/21/2018	2018
County of Tompkins v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty - 400001/2018 (removed from Tompkins Cnty. (N.Y.)/EF2018- 0008)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerge nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	1/5/2018; 10/23/2018 (Am.)	2018

County of Broome v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.) - 400002/2017 (removed from Broome Cnty. (N.Y.)/ EFCA2017000252)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Rhodes; Mallinckrodt; Par; CVS; Anda; Rite Aid; Walgreens; Wal-Mart	2/1/2017; 10/10/2017	2017
County of Erie v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.) - 400003/2017 (removed from Erie Cnty. (N.Y.) - 801671/2017)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Rhodes; Mallinckrodt; Par; CVS; Anda; Rite Aid; Walgreens; Wal-Mart	2/1/2017; 10/10/2017	2017

County of Orange v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.) - 400004/2017 (removed from Orange Cnty. (N.Y.)/EF003572- 2017)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerger; n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Rhodes; Mallinckrodt; Par; CVS; Anda; Rite Aid; Walgreens; Wal-Mart	5/11/2017; 10/10/2017	2017
--	---	----------	--	---	--------------------------	------

County of Nassau v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk County (N.Y.) - 400008/2017 (removed from Suffolk Cnty. (N.Y.) - 613760/2016; Nassau Cnty. (N.Y.) - 605477/2017)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories; PRA Holdings, Inc.; Pharmaceutical Research Associates, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBerger; nBergen; American Medical Distributors; Bellco; Blenheim; Darby; Eveready; Kinray; PSS World; Rochester Drug Cooperative; Perry Fine; Scott Fishman; Lynn Webster; Rhodes; Par ; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Coventry	6/12/2017; 10/10/2017	2017
--	---	----------	--	---	--------------------------	------

County of Schenectady v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.) - 400009/2017 (has not yet been officially removed from Schenectady Cnty. (N.Y.)/2017- 1209)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerger; n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Rhodes; Mallinckrodt; Par; CVS; Anda; Rite Aid; Walgreens; Wal-Mart	6/15/2017; 10/10/2017	2017
The County of Washington v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400010- 2019 (removed from Sup. Ct. Washington Cnty. (N.Y.)/100037- 2018)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerger; n; American Medical Disrtibutors; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Rhodes; Par; Mallinckrodt; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart	6/15/2018; 4/1/2019	2018

County of Dutchess v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.) - 400005/2017 (removed from Dutchess Cnty. (N.Y.)/2017- 51340)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Rhodes; Mallinckrodt; Par; CVS; Anda; Rite Aid; Walgreens; Wal-Mart	6/6/2017; 10/10/2017	2017
---	--	----------	--	---	-------------------------	------

County of Sullivan v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.) - 400007/2017 (removed from Sullivan Cnty. (N.Y.) - 2017/961)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Rhodes; Mallinckrodt; Par; CVS; Anda; Rite Aid; Walgreens; Wal-Mart	6/7/2017; 10/10/2017	2017
--	--	----------	--	---	-------------------------	------

County of Suffolk v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk County (N.Y.) - 400001/2017 (Suffolk Cnty. (N.Y.) - 613760/2016)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Distributors; Bellco; Darby; Kinray; PSS; Rochester; Rhodes; Par; Mallinckrodt; Anda; CVS; Rite Aid; Walgreens; Wal-Mart; Anda	8/31/2016; 10/10/2017	2016
The County of Montgomery v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400009- 2019 (removed Sup. Ct. Montgomery Cnty. (N.Y.)/2018- 681)	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Insys; McKesson; Cardinal; AmerisourceBerge n; American Medical Disrtibutors; Bellco; Darby; Eveready; Kinray; PSS World; Rochester Drug; Rhodes; Par; Mallinckrodt; SpecGx; Anda; CVS; Rite Aid; Walgreens; Walmart	9/4/2018; 3/26/2019	2018

The People of the State of New York, by Letitia James, Attorney General of the State of New York v. Purdue Pharma L.P., et al.	Sup. Ct. Suffolk Cnty. (N.Y.)/400016-2018	New York	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.; Purdue Holdings LP; Rosebay Medical Company LP; The Beacon Company; PLP Associates Holdings LP	Johnson & Johnson; Janssen; Mallinckrodt; SpecGx; Endo; Par; TEVA; Cephalon; Allergan; Actavis; Watson; McKesson; AmerisourceBergerson; Rochester Drug	8/14/2018	2018
Fredrick Hill v. Purdue Pharma L.P., et al.	Super Ct. NJ Camden Cnty. L-003693-19	NJ	Purdue Pharma L.P., The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.; Purdue Holdings L.P.; Rosebay Medical Company L.P. ; The Beacon Company; PLP Associates Holdings L.P.			2019

State of North Carolina, ex rel. Joshua H. Stern, Attorney General v. Purdue Pharma L.P., et al.	Super. Ct. Wake Cnty. (N.C.)	North Carolina	Purdue Pharmaceuticals L.P.; Purdue Pharma Inc.; Purdue Pharma of North Carolina L.P.; Purdue Pharma Technologies Inc.; Purdue Pharma Manufacturing L.P.; Purdue Pharma Manufacturing (New York) Inc.; The Purdue Frederick Company Inc.	N/A	5/15/2018	2018
State of North Dakota, ex rel. Wayne Stenehjem, Attorney General v. Purdue Pharma L.P., et al.	Dist. Ct. Burleigh Cnty. (N.D.)/08-2018-CV-01300	North Dakota	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	5/15/2018	2018
State of Ohio, ex rel. Mike DeWine, Ohio Attorney General v. Purdue Pharma L.P., et al.	C.P. Ross Cnty., (OH)17CI000261	Ohio	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Does 1 through 100	5/31/2017	2017
State of Oklahoma, ex rel. Mike Hunter Ohio Attorney General v. Purdue Pharma L.P., et al.	D. Ct. Cleveland Cnty. (OK)/CJ-2017-816 (remanded from W.D. Okla./5:18-cv-00574-M)	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Allergan; Watson; Actavis	6/20/2017	2017

Board of County Commissioners of Grady County v. Purdue Pharma L.P., et al.	D. Ct. Grady Cnty. (OK)/CJ-2019-12	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	1/14/2019	2019
The Board of Commissioners of Logan County v. Purdue Pharma L.P., et al.	D. Ct. Logan Cnty. (OK)/CJ-2019-4563	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; William Valuck; Walgreens	2/25/2019	2019

The Board of Commissioners of Texas County v. Purdue Pharma L.P., et al.	D. Ct. Texas Cnty. (OK)/CJ-2019-11	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Walgreens	2/25/2019	2019
The Board of Commissioners of LeFlore County v. Purdue Pharma L.P., et al.	D. Ct. LeFlore Cnty. (OK)/CJ- 2019-34	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; Anda; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; Walgreens	2/25/2019	2019

Board of County Commissioners of Noble County v. Purdue Pharma L.P., et al.	D. Ct. Noble Cnty. (OK)/CJ-2019-05	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBergen; Andia; GCP; KeySource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster	3/11/2019	2019
---	------------------------------------	----------	---	--	-----------	------

Citizen Potawatomi Nation v. Purdue Pharma L.P., et al.	D. Ct. Pottawatomie Cnty. (OK)/CJ-2019-00270	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBergen; CVS; Walgreens; Morris & Dickson; Walmart	7/15/2019	2019
---	--	----------	---	---	-----------	------

City of Burns Flat v. Purdue Pharma L.P., et al.	D. Ct. Washita Cnty. (OK)/CJ- 2019-29	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; Insys; McKesson; Cardinal; AmerisourceBerge n; And; GCP; Keysource; Morris & Dickson; Quest; Harvard Drug Group; Physicians Total Care; Perry Fine; Lynn Webster; William Valuck; Harvey Jenkins; Russell Portenoy	7/19/2019	2019
Apache Tribe of Oklahoma v. Purdue Pharma L.P., et al.	D. Ct. Caddo Cnty. (OK)/CJ-2019-69	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Mylan; Sandoz; McKesson; Cardinal; AmerisourceBerge n; Walgreens; Morris & Dickson; Walmart; SAJ; H.D. Smith	7/26/2019	2019

Delaware Nation v. Purdue Pharma L.P., et al.	D. Ct. Caddo Cnty. (OK)/CJ-2019-70	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Mylan; Sandoz; McKesson; Cardinal; AmerisourceBerge n; Walgreens; Morris & Dickson; Walmart; SAJ; H.D. Smith	7/26/2019	2019
Sac and Fox Nation v. Purdue Pharma L.P., et al.	D. Ct. Lincoln Cnty. (OK)/CJ-2019-104	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Mylan; Sandoz; McKesson; Cardinal; AmerisourceBerge n; Walgreens; Morris & Dickson; Walmart; SAJ; H.D. Smith	7/26/2019	2019
The Thlopthlocco Tribal Town v. Purdue Pharma L.P., et al.	D. Ct. Creek (Bristow) Cnty. (OK)/CJ-2019-21	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Mylan; Sandoz; McKesson; Cardinal; AmerisourceBerge n; Walgreens; Morris & Dickson; Walmart; SAJ	7/30/2019	2019

Pawnee Nation of Oklahoma v. Purdue Pharma L.P., et al.	D. Ct. Pawnee Cnty. (OK)/CJ-2019-63	Oklahoma	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Mylan; Sandoz; McKesson; Cardinal; AmerisourceBergen; Walgreens; Morris & Dickson; Walmart; SAJ; H.D. Smith	7/30/2019	2019
State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon v. Purdue Pharma L.P., et al.	Cir. Ct. Multnomah Cnty. (OR)/18CV40526	Oregon	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	9/13/2018	2018
State of Oregon, ex rel. Ellen F. Rosenblum, Attorney General for the State of Oregon v. Purdue Pharma L.P., et al.	Cir. Ct. Multnomah Cnty. (OR)/19CV22185	Oregon	Purdue Pharma L.P.; Purdue Pharma Inc.	N/A	5/16/2019	2019
Lackawanna County, Pennsylvania v. Purdue Pharma L.P., et al.	C.P. Lackawanna Cnty (Pa.)/17-cv-5156	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; AmerisourceBergen; McKesson; Cardinal; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	9/25/2017	2017

Beaver County, Pennsylvania v. Purdue Pharma L.P., et al.	C.P. Beaver Cnty (Pa.)/11326-2017	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Russell Portenoy; Scott Fishman; Perry Fine; Lynn Webster; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n	10/13/2017	2017
Cambria County, Pennsylvania v. Purdue Pharma L.P., et al.	C.P. Cambria Cnty (Pa.)/2017-4131	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	10/24/2017	2017
Greene County, Pennsylvania v. Purdue Pharma L.P., et al.	C.P. Greene Cnty (Pa.)/791-2017	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	11/2/2017	2017

Armstrong County, PA v. Purdue Pharma L.P., et al.	C.P. Armstrong Cty., (Pa.)/2017- 1570-CV	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; AmerisourceBerge n; McKesson; Cardinal; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	11/9/2017	2017
Lawrence County, Pennsylvania v. Purdue Pharma L.P., et al.	C.P. Beaver Cnty (Pa.)/11180-2017	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; AmerisourceBerge n; McKesson; Cardinal; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	11/10/2017	2017
County of York v. Purdue Pharma L.P., et al.	C.P. York Cnty (Pa.)/2017-SU- 003372	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; AmerisourceBerge n; McKesson; Cardinal; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/8/2017	2017

County of Washington v. Purdue Pharma L.P., et al.	C.P. Washington Cnty (Pa.)/2017-6268	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; AmerisourceBergen; McKesson; Cardinal; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/11/2017	2017
County of Westmoreland v. Purdue Pharma L.P., et al.	C.P. Westmoreland Cnty (Pa.)/2017-5975	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; AmerisourceBergen; McKesson; Cardinal; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/15/2017	2017
County of Fayette v. Purdue Pharma L.P., et al.	C.P. Fayette County (Pa.)/2017-2676	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	12/20/2017	2017
People of Northampton County and Northampton County, PA v. Purdue Pharma L.P., et al.	C.P. Northampton County (Pa.)/C48-cv-2017-11557	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; Mylan	12/28/2017	2017

City of Philadelphia v. Allergan PLC, et al.	C.P. Philadelphia (Pa.)/002718	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Cehpalon; TEVA; Endo; Janssen; Johnson & Johnson	1/17/2018	2018
Dauphin County, PA v. Purdue Pharma L.P., et al.	C.P. Dauphin Cnty. (Pa.)/2018-CV-716-CV	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Perry Fine; Scott Fishman; Lynn Webster	1/29/2018	2018
Common Wealth of PA v. Purdue Pharma L.P., et al.	C.P. Philadelphia (Pa.)/995594	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Unknown	2/2/2018	2018
County of Cumberland v. Purdue Pharma L.P., et al.	C.P. Cumberland (Pa.)/2018-02147	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Perry Fine; Scott Fishman; Lynn Webster	2/13/2018	2018
County of Clarion v. Purdue Pharma L.P., et al.	C.P. Clarion Cnty. (Pa.)/285-CD-2018	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; AmerisourceBergen	3/16/2018	2018

Carpenters Health & Welfare of Philadelphia & Vicinity v. Purdue Pharma L.P., et al.	C.P. Philadelphia (Pa.)/180302264	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerg n; Par; Mallinckrodt; SpecGx; And a; CVS; Rite Aid; Walgreens; Walmart; Kroger; Insys; H.D. Smith; Miami-Luken; Rhodes	3/19/2018	2018
AFSCME District Council 47 Health & Welfare Fund v. Purdue Pharma L.P., et al.	C.P. Philadelphia (Pa.)/180302255	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerg n	3/19/2018	2018
Bricklayers and Allied Craftworkers Local Union No. 1 of PA/DE Health and Welfare Fund v. Purdue Pharma L.P., et al.	C.P. Philadelphia (Pa.)/180302256	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerg n	3/19/2018	2018
AFSCME District Council 33 Health & Welfare Fund v. Purdue Pharma L.P., et al.	C.P. Philadelphia (Pa.)/180302269	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerg n	3/22/2018	2018

The Commonwealth of PA by James Martin; People of Lehigh County and Lehigh County, PA v. Purdue Pharma L.P., et al.	C.P. Lehigh Cnty. (Pa.)/2018-C-0716	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBerg	3/23/2018	2018
Southeastern Pennsylvania Transportation Authority v. Endo Pharmaceuticals, Inc., et al.	C.P. Philadelphia Cnty. (Pa.)/002932	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Abbott; Janssen; Johnson & Johnson; Cephalon; TEVA; Allergan; Watson; Actavis	3/26/2018	2018
County of Bradford v. Purdue Pharma L.P., et al.	C.P. Bradford Cnty. (Pa.)/2018-CV-0059	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBerg	4/2/2018	2018
The Trustees of the Unite Here Local 634 Health & Welfare Fund v. Purdue Pharma L.P., et al.	C.P. Philadelphia Cnty. (Pa.)/180401123	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBerg	4/9/2018	2018

UFCW Local 23 and Employers Health Fund v. Endo Pharmaceuticals, Inc.	C.P. Philadelphia Cnty. (Pa.)/180403485	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Abbott; Janssen; Johnson & Johnson; Cephalon; TEVA; Allergan; Watson; Actavis; Mallinckrodt; AbbVie; Zogenix; Pernix; West- Ward; Shionogi; Validus	4/24/2018	2018
Philadelphia Federation of Teachers Health and Welfare Fund v. Endo Pharmaceuticals, Inc., et al.	C.P. Philadelphia Cnty. (Pa.)/180403891	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Abbott; Janssen; Johnson & Johnson; Cephalon; TEVA; Allergan; Watson; Actavis; Depomed	4/26/2018	2018
County of Allegheny v. Purdue Pharma L.P., et al.	C.P. Allegheny Cnty. (Pa.)/18- 006155	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Johnson & Johnson; Janssen; TEVA; Mallinckrodt; Cardinal; McKesson; AmerisourceBerge n	5/15/2018	2018
City of Pittsburgh v. Purdue Pharma L.P., et al.	C.P. Allegheny Cnty. (Pa.)/18- 006153	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Johnson & Johnson; Janssen; TEVA; Mallinckrodt; Cardinal; McKesson; AmerisourceBerge n	5/15/2018	2018
Iron Workers District Council of Philadelphia and Vicinity, Benefit Fund v. Abbott Laboratories, Inc.	C.P. Philadelphia Cnty. (Pa.)/180502442	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Abbvie; Depomed; Endo; Janssen; Johnson & Johnson; Pernix; Shiongi; West- Ward; Zogenix	5/23/2018	2018

Bucks County v. Purdue Pharma L.P., et al.	C.P. Bucks Cnty. (Pa.)	Pennsylvania	Purdue Pharma L.P., d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Mallinckrodt; Insys; Collegium; John Kapoor	5/29/2018	2018
County of Monroe v. Purdue Pharma L.P., et al.	C.P. Monroe Cnty. (Pa.)/3972CV18	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n	6/4/2018	2018
Mercer County v. Purdue Pharma L.P., et al.	C.P. Mercer Cnty. (Pa.)/2018-1596	Pennsylvania	Purdue Pharma L.P., d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Mallinckrodt; Insys; Collegium; John Kapoor	6/6/2018	2018

Clinton County v. Purdue Pharma L.P., et al.	C.P. Clinton Cnty. (Pa.)/752-18	Pennsylvania	Purdue Pharma L.P., d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Mallinckrodt; Insys; Collegium; John Kapoor	6/14/2018	2018
County of Erie v. Purdue Pharma L.P., et al.	C.P. Erie Cnty. (Pa.)/11577-18	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n	6/18/2018	2018
Mahoning Township v. Purdue Pharma L.P., et al.	C.P. Philadelphia Cnty. (Pa.)/180603466	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n	6/28/2018	2018
Schuylkill County, Pa. v. Purdue Pharma L.P., et al.	C.P. Schuylkill Cnty. (Pa.)/S-1241-18	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n	7/16/2018	2018

Wampum Borough v. Purdue Pharma L.P., et al.	C.P. Wampum Cnty. (Pa.)/001963	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n	7/18/2018	2018
County of Tioga v. Purdue Pharma L.P., et al.	C.P. Tioga Cnty. (Pa.)/563CV2018	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n	7/30/2018	2018
City of Lock Haven v. Purdue Pharma L.P., et al.	C.P. Clinton Cnty. (Pa.)/1126-2018	Pennsylvania	Purdue Pharma L.P. d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Collegium; Insys; Mallinckrodt; John Kapoor	9/4/2018	2018
Clearfield County, Pennsylvania v. Purdue Pharma L.P., et al.	C.P. Clearfield Cnty. (Pa.)/2018- 1484-CD	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	9/14/2018	2018

Western Pennsylvania Electrical Employees Insurance Trust Fund v. Endo Pharmaceuticals Inc., et al.	C.P. Philadelphia Cnty. (Pa.)/002038	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Depomed	12/3/2018	2018
International Brotherhood of Electrical Workers Local 98 Health & Welfare Fund and International Brotherhood of Electrical Workers Local 89 Sound and Communication Health & Welfare Fund v. Endo Pharmaceuticals Inc., et al.	C.P. Philadelphia Cnty. (Pa.)/002063	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Endo; Par; Janssen; Johnson & Johnson; Assertio; TEVA; Cephalon; Allergan; Actavis; Watson; SpecGx; Sentyln; Amneal; Impax; Rhodes; Mylan; Akrimax; Apotex; Zydus; Aurolife; Sandoz	3/15/2019	2019
IBEW Local 728 Family Healthcare Plan v. Allergan PLC, et al.	C.P. Philadelphia Cnty. (Pa.)/003872	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Actavis; Watson; Breckenridge; Collegium; Assertio; Egalet; Endo; Indivior; Johnson & Johnson; Janssen; KVK; Mylan; Rhodes; TEVA; Cephalon	3/29/2019	2019

International Union of Painters and Allied Trades, District Council No. 21 Welfare Fund v. Allergan PLC, et al.	C.P. Philadelphia Cnty. (Pa.)/001983	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Watson; Actavis; Morris Corp. Ctr.; Alvogen; Amneal; Impax; Collegium; Assertio; Endo; Janssen; Johnson & Johnson; KVK; Mallinckrodt; SpecGx; Mylan; Par; Rhodes; Sandoz; TEVA; Cephalon; West-Ward; Zydus	4/12/2019	2019
Newtown Township v. Purdue Pharma L.P., et al.	C.P. Bucks Cnty. (Pa.)/2019-03043	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Allergan; Watson; McKesson; Cardinal; AmerisourceBerg n	4/24/2019	2019
Commonwealth of Pennsylvania by Attorney General Josh Shapiro v. Purdue Pharma L.P., et al.	Commonwealth Ct. of PA/257-md-19	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	5/2/2019	2019
The Municipality of Norristown and The Township of West Norriton v. Purdue Pharma L.P., et al.	C.P. Montgomery Cnty. (Pa.)/2019-12178	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerg n	5/9/2019	2019

Franklin County v. Purdue Pharma L.P., et al.	C.P. Franklin Cnty. (Pa.)/2019-2445	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergeson	6/14/2019	2019
Warrington Township v. Purdue Pharma L.P., et al.	C.P. Bucks Cnty. (Pa.)/2019-04956	Pennsylvania	Purdue Pharma L.P., d/b/a Purdue Pharma (Delaware) Limited Partnership; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergeson; John Kapoor	7/9/2019	2019
Steamfitters Local 449 Medical & Benefit Fund v. Allergan PLC, et al.	C.P. Philadelphia Cnty. (Pa.)/19091412	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Allergan; Actavis; Watson; Amneal; Endo; Impax; Janssen; Johnson & Johnson; SpecGx; Mylan; Par; Mallinckrodt; Sandoz; TEVA	9/11/2019	2019
Commonwealth of PA v. Purdue Pharma L.P., et al.	C.P. Delaware Cnty (Pa.)/CV-2017-008095	Pennsylvania	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergeson	2/2/2018 11/14/2018	2018
The Commonwealth of Puerto Rico v. Purdue Pharma L.P., et al.	Super. Ct. San Juan (P.R.)/SJ2018CV01659	Puerto Rico	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharma De Puerto Rico	Jane Does 1-10	3/27/2018	2018

State of Rhode Island, by and through Peter F. Kilmartin, Attorney General v. Purdue Pharma L.P., et al.	Super. Ct. (RI)/PC-18-4555	Rhode Island	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Cardinal; McKesson; AmerisourceBergen; Rhodes; John N. Kapoor; TEVA; Cephalon; Mallinckrodt; SpecGx	6/25/2018; 11/19/2018 (Am.)	2018
State of South Carolina, <i>ex rel.</i> Alan Wilson Attorney General v. Purdue Pharma L.P., et al.	C.P. Richland Cnty. (S.C.)/2017CP4004 872	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	8/15/2017	2017
Spartanburg County v. Purdue Pharma L.P., et al.	C.P. Spartanburg Cnty. (S.C.)/2018CP4200 760 (removed from D.S.C./7:18-cv-01799)	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBergen; Rite Aid; Miami-Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	3/5/2018	2018

County of Anderson v. Rite Aid of South Carolina Inc., et al.	C.P. Anderson Cnty. (S.C.)/18CP040110 8 (removed from D.S.C./8:18-cv- 01947-MDL)	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	6/6/2018	2018
--	---	----------------	--	--	----------	------

County of Pickens v. Purdue Pharma L.P., et al.	C.P. Pikens Cnty. (S.C.)/18CP390067 5	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	6/13/2018	2018
County of Colleton v. Purdue Pharma L.P., et al.	C.P. Colleton Cnty. (S.C.)/18CP150043 6	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	6/19/2018	2018

County of Dorchester v. Purdue Pharma L.P., et al.	C.P. Dorchester Cnty. (S.C.)/18CP180112 2	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	6/19/2018	2018
County of Beaufort v. Purdue Pharma L.P., et al.	C.P. Beaufort Cnty. (S.C.)/18CP070124 5	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	6/19/2018	2018
County of Allendale v. Purdue Pharma L.P., et al.	C.P. Allendale Cnty. (S.C.)/18CP030012 5	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	6/25/2018	2018

County of Jasper v. Purdue Pharma L.P., et al.	C.P. Jasper Cnty. (S.C.)/18CP270033 2	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	6/25/2018	2018
County of Kershaw and The Kershaw County Hospital Board a/k/a Kershaw Health d/b/Health Service District of Kershaw County v. Purdue Pharma L.P., et al.	C.P. Kershaw Cnty. (S.C.)/18CP280055 3	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	6/25/2018	2018
County of Hampton v. Purdue Pharma L.P., et al.	C.P. Hampton Cnty. (S.C.)/18CP250025 8	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	6/25/2018	2018

County of Williamsburg v. Purdue Pharma L.P., et al.	C.P. Williamsburg Cnty. (S.C.)/18CP450027 6	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	6/27/2018	2018
County of Lexington v. Purdue Pharma L.P., et al.	C.P. Lexington Cnty. (S.C.)/2018CP3220 7 (remanded from D.S.C./3:18-cv- 02357)	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; CVS; Jeffrey Ward; Insys; Smith; Aathirayen Thiagarajah; Spine & Pain LLC	6/27/2018	2018
County of Lee v. Rite Aid of South Carolina, Inc., et al.	C.P. Lee Cnty. (S.C.)/2018CP3100 207	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	7/2/2018	2018

County of Orangeburg v. Rite Aid of South Carolina, Inc., et al.	C.P. Orangeburg Cnty. (S.C.)/2018-CP-38-00841	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	7/3/2018	2018
County of Fairfield v. Rite Aid of South Carolina, Inc., et al.	C.P. Fairfield Cnty. (S.C.)/2018CP2000 272	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	7/3/2018	2018
County of Chesterfield v. Rite Aid of South Carolina, Inc., et al.	C.P. Chesterfield Cnty. (S.C.)/2018-CP-13410	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	7/3/2018	2018

County of Oconee v. Rite Aid of South Carolina, Inc., et al.	C.P. Oconee Cnty. (S.C.)/2018370045 8	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	7/26/2018	2018
---	---	----------------	--	--	-----------	------

County of Cherokee v. Rite Aid of South Carolina, Inc., et al.	C.P. Cherokee Cnty. (S.C.)/2018CP1100 503	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	8/2/2018	2018
--	--	----------------	--	--	----------	------

County of Union v.	C.P. Union Cnty.	South Carolina	Purdue Pharma	Rhodes; TEVA;	8/2/2018	2018
Rite Aid of South	(S.C.)/2018CP4400		L.P.;	Cephalon;		
Carolina, Inc., et	288		Purdue Pharma	Johnson &		
al.			Inc.;	Johnson; Janssen;		
			The Purdue	Noramco;		
			Frederick	Depomed; Endo;		
			Company Inc.;	Allergan; Actavis;		
			The P.F.	Watson; Insys;		
			Laboratories, Inc.	Mallinckrodt;		
				SpecGx; Mylan;		
				McKesson;		
				Cardinal;		
				AmerisourceBerge		
				n; Rite Aid; Miami-		
				Luken; Walgreens;		
				Smith Drug;		
				Walmart; CVS;		
				Mark Waldrop;		
				Michael Maden;		
				Wendy Kay;		
				Jeffrey Ward;		
				Aathirayen		
				Thiyagarajah;		
				Spine and Pain		

County of Laurens v. Rite Aid of South Carolina, Inc., et al.	C.P. Laurens Cnty. (S.C.)/2018CP3000 606	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	8/14/2018	2018
--	--	----------------	--	--	-----------	------

County of York v. Rite Aid of South Carolina, Inc., et al.	C.P. York Cnty. (S.C.)/2018CP4602 446	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	8/15/2018	2018
---	---	----------------	--	--	-----------	------

County of Greenwood v. Rite Aid of South Carolina, Inc., et al.	C.P. Cherokee Cnty. (S.C.)/2018CP2400 775	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	8/23/2018	2018
---	--	----------------	--	--	-----------	------

County of Bamberg v. Purdue Pharma L.P., et al.	C.P. Bamberg Cnty. (S.C.)/2018CP5001 89	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	9/13/2018	2018
--	--	----------------	---	--	-----------	------

County of Barnwell v. Purdue Pharma L.P., et al.	C.P. Barnwell Cnty. (S.C.)/18CP600329	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rite Aid of SC; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Wal-Mart; CVS; Smith Drug; Aathirayed Thiyagaraj; Spine & Pain; Mackie Walker	9/13/2018	2018
County of Aiken v. Rite Aid of South Carolina Inc., et al.	C.P. Aiken Cnty. (S.C.)/2019CP0201 086	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	5/2/2019	2019

County of Edgefield v. Rite Aid of South Carolina Inc., et al.	C.P. Edgefield Cnty. (S.C.)/2019CP1900 120	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	5/2/2019	2019
---	---	----------------	--	--	----------	------

County of Florence v. Rite Aid of South Carolina Inc., et al.	C.P. Florence Cnty. (S.C.)/2019CP2101 213	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	5/2/2019	2019
--	---	----------------	--	--	----------	------

County of	C.P. McCormick	South Carolina	Purdue Pharma	Rhodes; TEVA;	5/2/2019	2019
McCormick v. Rite	Cnty.		L.P.;	Cephalon;		
Aid of South	(S.C.)/2019CP3500		Purdue Pharma	Johnson &		
Carolina Inc., et al.	031		Inc.;	Johnson; Janssen;		
			The Purdue	Noramco;		
			Frederick	Depomed; Endo;		
			Company Inc.;	Allergan; Actavis;		
			The P.F.	Watson; Insys;		
			Laboratories, Inc.	Mallinckrodt;		
				SpecGx; Mylan;		
				McKesson;		
				Cardinal;		
				AmerisourceBerge		
				n; Rite Aid; Miami-		
				Luken; Walgreens;		
				Smith Drug;		
				Walmart; CVS;		
				Mark Waldrop;		
				Michael Maden;		
				Wendy Kay;		
				Jeffrey Ward;		
				Aathirayen		
				Thiyagarajah;		
				Spine and Pain		

County of Sumter v. Rite Aid of South Carolina Inc., et al.	C.P. Sumter Cnty. (S.C.)/2019CP4300 891	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	5/2/2019	2019
--	---	----------------	--	--	----------	------

County of Calhoun v. Rite Aid of South Carolina Inc., et al.	C.P. Calhoun Cnty./2019CP0900 065	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	5/2/2019	2019
---	---	----------------	--	--	----------	------

County of Dillon v.	C.P. Dillon	South Carolina	Purdue Pharma	Rhodes; TEVA;	5/2/2019	2019
Rite Aid of South	Cnty./2019CP1700		L.P.;	Cephalon;		
Carolina Inc., et al.	213		Purdue Pharma	Johnson &		
			Inc.;	Johnson; Janssen;		
			The Purdue	Noramco;		
			Frederick	Depomed; Endo;		
			Company Inc.;	Allergan; Actavis;		
			The P.F.	Watson; Insys;		
			Laboratories, Inc.	Mallinckrodt;		
				SpecGx; Mylan;		
				McKesson;		
				Cardinal;		
				AmerisourceBerge		
				n; Rite Aid; Miami-		
				Luken; Walgreens;		
				Smith Drug;		
				Walmart; CVS;		
				Mark Waldrop;		
				Michael Maden;		
				Wendy Kay;		
				Jeffrey Ward;		
				Aathirayen		
				Thiyagarajah;		
				Spine and Pain		

County of Marion v. Rite Aid of South Carolina Inc., et al.	C.P. Marion Cnty./2019CP3300 299	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	5/2/2019	2019
--	--	----------------	--	--	----------	------

County of Lancaster v. Rite Aid of South Carolina Inc., et al.	C.P. Lancaster Cnty./2019CP2900 540	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	5/2/2019	2019
---	---	----------------	--	--	----------	------

County of Horry v. Rite Aid of South Carolina Inc., et al.	C.P. Horry Cnty./2019CP2602 684	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	5/6/2019	2019
--	---------------------------------------	----------------	--	--	----------	------

County of	C.P. Abbeville	South Carolina	Purdue Pharma	Rhodes; TEVA;	5/20/2019	2019
Abbeville v. Rite	Cnty./2019CP0100		L.P.;	Cephalon;		
Aid of South	154		Purdue Pharma	Johnson &		
Carolina Inc., et al.			Inc.;	Johnson; Janssen;		
			The Purdue	Noramco;		
			Frederick	Depomed; Endo;		
			Company Inc.;	Allergan; Actavis;		
			The P.F.	Watson; Insys;		
			Laboratories, Inc.	Mallinckrodt;		
				SpecGx; Mylan;		
				McKesson;		
				Cardinal;		
				AmerisourceBerge		
				n; Rite Aid; Miami-		
				Luken; Walgreens;		
				Smith Drug;		
				Walmart; CVS;		
				Mark Waldrop;		
				Michael Maden;		
				Wendy Kay;		
				Jeffrey Ward;		
				Aathirayen		
				Thiyagarajah;		
				Spine and Pain		

County of	C.P. Clarendon	South Carolina	Purdue Pharma	Rhodes; TEVA;	5/20/2019	2019
Clarendon v. Rite	Cnty./2019CP1400		L.P.;	Cephalon;		
Aid of South	236		Purdue Pharma	Johnson &		
Carolina Inc., et al.			Inc.;	Johnson; Janssen;		
			The Purdue	Noramco;		
			Frederick	Depomed; Endo;		
			Company Inc.;	Allergan; Actavis;		
			The P.F.	Watson; Insys;		
			Laboratories, Inc.	Mallinckrodt;		
				SpecGx; Mylan;		
				McKesson;		
				Cardinal;		
				AmerisourceBerge		
				n; Rite Aid; Miami-		
				Luken; Walgreens;		
				Smith Drug;		
				Walmart; CVS;		
				Mark Waldrop;		
				Michael Maden;		
				Wendy Kay;		
				Jeffrey Ward;		
				Aathirayen		
				Thiyagarajah;		
				Spine and Pain		

County of Saluda v. Rite Aid of South Carolina Inc., et al.	C.P. Clarendon Cnty./2019CP4100 111	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	5/20/2019	2019
--	---	----------------	--	--	-----------	------

City of North Charleston v. Purdue Pharma L.P., et al.	C.P. Charleston Cnty./2019CP1039 78	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	7/25/2019	2019
---	---	----------------	--	--	-----------	------

City of Charleston v. Purdue Pharma L.P., et al.	C.P. Charleston Cnty./2019CP1042 94	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	8/15/2019	2019
--	---	----------------	--	--	-----------	------

Town of Mount Pleasant v. Purdue Pharma L.P., et al.	C.P. Charleston Cnty./2019CP1043 02	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBergen; Rite Aid; Miami-Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	8/15/2019	2019
--	--	----------------	---	---	-----------	------

Greenville County v. Purdue Pharma L.P., et al.	C.P. Greenville Cnty. (S.C.)/2018CP2301 294 (remanded from D.S.C./6:18- cv-01085-MDL)	South Carolina	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories, Inc.	Rhodes; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Depomed; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Mylan; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Miami- Luken; Walgreens; Smith Drug; Walmart; CVS; Mark Waldrop; Michael Maden; Wendy Kay; Jeffrey Ward; Aathirayen Thiyagarajah; Spine and Pain	3/5/2018; 3/15/2018 (Am.)	2018
State of South Dakota, <i>ex rel.</i> Marty J. Jackley, South Dakota Attorney General v. Purdue Pharma L.P., et al.	Cir. Ct. Hughes Cnty. (SD)	South Dakota	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	3/14/2018	2018
Jared Effler, et al. v. Purdue Pharma, L.P., et al.	Cir. Ct. Campbell Cnty. (Tenn.)/16596	Tennessee	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Mallinckrodt; Endo; Tennessee Pain Institute; Timothy Gowder; Gary Arlan Moore; Joshua Hurst	9/29/2017	2017

Shelby County, by the Shelby Board of Commissioners v. Purdue Pharma L.P., et al.	Cir. Ct. Shelby Cnty. (Tenn.)/No. CT-004500-17	Tennessee	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Cardinal; AmerisourceBergen; Tennessee CVS Pharmacy; Rite Aid of Tennessee; Center Pointe Medical Clinic; Elizabeth Campbell; Pamela Moore; Russell Portenoy	11/2/2017	2017
State of Tennessee, ex rel Herbert H. Slatery III, Attorney General and Reporter v. Purdue Pharma L.P., a foreign limited partnership	Cit. Ct. Knox Cnty. (Tenn.)/1-173-18	Tennessee	Purdue Pharma L.P., a foreign limited partnership	N/A	5/15/2018	2018
Bryant C. Dunaway, et al. v. Purdue Pharma L.P., et al.	Cir. Ct. Cumberland Cnty. (Tenn.)/CCI-2018-CV-6347	Tennessee	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mallinckrodt; Endo; TEVA; David Florence; Mark Murphy; Nathan Paul Haskins; Montclair Health & Wellness LLC d/b/a Specialty Associates; and North Alabama Pain Services, LLC	1/10/2018; 8/7/2018 (Am.)	2018

Barry Staubus, et al. v. Purdue Pharma, L.P., et al.	Cir. Ct. Sullivan Cnty. (Tenn.)/No. C41816 (remanded from federal court)	Tennessee	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mallinckrodt; Endo; Center Pointe Medical Clinic, Inc.; Elizabeth Ann Bowers Campbell; Pamela Moore; and Abdelrahman Hassabu Mohamed	6/13/2017; 7/19/2017	2017
Maverick County, Texas v. Purdue Pharma L.P., et al.	Maverick Cnty. Dist. Ct. (Tex.)/17-10-34909-MCVAJA	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; McKesson; Walsh; Cardinal; AmerisourceBerg n; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	10/27/2017	2017
County of Hopkins v. Purdue Pharma L.P., et al.	Hopkins Cnty. Dist. Ct. (Tex.)/CV43486 (remanded from federal court)	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbott; Knoll; Allergan; Watson; Actavis; Insys; Pfizer; McKesson; Cardinal; AmerisourceBerg n; Don Martin O'Neil, MD; Howard Gregg Diamond, MD; Does 1-100, inclusive	10/31/2017	2017

County of Delta v. AmerisourceBerge n Drug Corp., et al.	Delta Cnty. Dist. Ct. (Tex.)/11125 (remanded from E.D. Texas/4:18-cv- 00095)	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBerge n; Don Martin O'Neal, M.D.; Does 1-100 Inclusive	12/19/2017	2017
County of Van Zandt v. AmerisourceBerge n Drug Corp., et al.	Van Zandt Cnty. Dist. Ct. (Tex.)/17- 00302 (remanded from E.D. Texas/6:18-cv- 00064)	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBerge n; Does 1-100 Inclusive	12/29/2017	2017
County of Falls v. Purdue Pharma L.P., et al.	Falls Cnty. Dist. Ct. (Tex.) (remanded from W.D. Texas/6:18-cv- 00047-RP-JCM)	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBerge n; Does 1-100 Inclusive	1/4/2018	2018

County of Dallas v. Purdue Pharma L.P., et al.	Dallas Cnty. Dist. Ct. (Tex.)/DC-18-00290 (remanded from N.D. Texas/3:18-cv-00426-M)	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; Insys; McKesson; Cardinal; AmerisourceBergen; Dr. Richard Andrews; Dr. Theodore Okechuku; Dr. Nicholas Padron; Does 1-100, inclusive	1/8/2018	2018
County of Travis v. Purdue Pharma L.P., et al.	Travis Cnty. Dist. Ct. (Tex.)/D-1-GN-18-000625 (remanded from W.D. Texas/1:18-cv-00254-RP)	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Abbvie; Knoll; Allergan; Watson; Actavis; McKesson; Cardinal; AmerisourceBergen; Does 1-100, inclusive	2/5/2018	2018
County of Coryell v. Purdue Pharma L.P., et al.	Coryell Cnty. Dist. Ct. (Tex.)/DC-18-47530	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	3/30/2018	2018
County of Parker v. Purdue Pharma L.P., et al.	Parker Cnty. Dist. Ct. (Tex.)/CV18-0363	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	4/2/2018	2018

County of Hidalgo v. Purdue Pharma L.P., et al.	Hidalgo Cnty. Dist. Ct. (Tex.)/C-1349- 18-C	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n	4/12/2018	2018
County of Cameron v. Purdue Pharma L.P., et al.	Cameron Cnty. Dist. Ct. (Tex.)/2018-DCL- 02237-G	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n	4/12/2018	2018
County of Liberty v. Purdue Pharma L.P., et al.	Liberty Cnty. Dist. Ct. (Tex.)/CV1813222	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n	4/12/2018	2018
County of Waller v. Purdue Pharma L.P., et al.	Waller Cnty. Dist. Ct. (Tex.)/18-04- 24828	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n	4/12/2018	2018
County of Harrison v. Purdue Pharma L.P., et al.	Harrison Cnty. Dist. Ct. (Tex.)/18- 0442	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n	4/13/2018	2018

County of Milam v. Purdue Pharma L.P., et al.	Milam Cnty. Dist. Ct. (Tex.)/CV38786	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	4/17/2018	2018
County of Burnet v. Purdue Pharma L.P., et al.	Burnet Cnty. Dist. Ct. (Tex.)/48005	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	4/20/2018	2018
County of Kerr v. Purdue Pharma L.P., et al.	Kerr Cnty. Dist. Ct. (Tex.)/18389B	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n	4/30/2018	2018
County of Bee v. Purdue Pharma L.P., et al.	Bee Cnty. Dist. Ct. (Tex.)/B-18-1204- CV-B	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/3/2018	2018
County of Bexar v. Purdue Pharma L.P., et al.	Bexar Cnty. Dist. Ct. (Tex.)/2018CI0872 8	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Janssen; Endo; Abbott; Knoll; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n; Johnson & Johnson; Noramco; Depomed; Abbvie; Mylan; Mission; Advanced Pharma d/b/a Avella of Houston	5/10/2018	2018

County of Cooke v. Purdue Pharma L.P., et al.	Cooke Cnty. Dist. Ct. (Tex.)/CV18- 00306	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/14/2018	2018
County of Ector v. Purdue Pharma L.P., et al.	Ector Cnty. Dist. Ct. (Tex.)/A-18-05- 0509-CV	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/14/2018	2018
County of Robertson v. Purdue Pharma L.P., et al.	Robertson Cnty. Dist. Ct. (Tex.)/18- 05-20551-CV	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/14/2018	2018
State of Texas v. Purdue Pharma L.P., et al.	Travis Cnty. Dist. Ct. (Tex.)/D-1-GN- 18-002403	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Transdermal Technologies L.P.	N/A	5/15/2018	2018
County of Houston v. Purdue Pharma L.P., et al.	Houston Cnty. Dist. Ct. (Tex.)/18- 0124	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/15/2018	2018
County of Marion v. Purdue Pharma L.P., et al.	Marion Cnty. Dist. Ct. (Tex.)/1800071	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/15/2018	2018

County of Nacogdoches v. Purdue Pharma L.P., et al.	Nacogdoches Cnty. Dist. Ct./C1833767	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/15/2018	2018
County of Potter v. Purdue Pharma L.P., et al.	Potter Cnty. Dist. Ct./107399-A-CV	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/15/2018	2018
County of Cass v. Purdue Pharma L.P., et al.	Cass Cnty. Dist. Ct. (Tex.)/18C246	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/15/2018	2018
County of Orange v. Purdue Pharma L.P., et al.	Orange Cnty. Dist. Ct. (Tex.)/B180185- C	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/15/2018	2018
County of Fannin v. Purdue Pharma L.P., et al.	Fannin Cnty. Dist. Ct./CV-18-43702	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/16/2018	2018
County of Limestone v. Purdue Pharma L.P., et al.	Limestone Cnty. Dist. Ct./31438-A	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/16/2018	2018
County of Wood v. Purdue Pharma L.P., et al.	Wood Cnty. Dist. Ct./2018-275	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/16/2018	2018

County of Trinity v. Purdue Pharma L.P., et al.	Trinity Cnty. Dist. Ct. (Tex.)	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/16/2018	2018
County of Panola v. Purdue Pharma L.P., et al.	Panola Cnty. Dist. Ct. (Tex.)/2018-66	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/16/2018	2018
County of Shelby v. Purdue Pharma L.P., et al.	Shelby Cnty. Dist. Ct. (Tex.)/18CV34421	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/16/2018	2018
County of Dimmit v. Purdue Pharma L.P., et al.	Dimmit Cnty. Dist. Ct. (Tex.)/18-05- 13434-DCV	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/16/2018	2018
County of McMullen v. Purdue Pharma L.P., et al.	McMullen Cnty. Dist. Ct. (Tex.)/M- 18-0007-CV-B	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/16/2018	2018
County of Kendall v. Purdue Pharma L.P., et al.	Kendall Cnty. Dist. Ct. (Tex.)/DC-18- 272	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	5/18/2018	2018

County of El Paso v. Purdue Pharma L.P., et al.	El Paso Cnty. Dist. Ct. (Tex.)/2018DCV19 28	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Janssen; Endo; Abbott; Abbvie; Knoll; Abbott; Allergan; Watson; Actavis; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n	5/23/2018	2018
County of Grayson v. Purdue Pharma L.P., et al.	Grayson Cnty. Dist. Ct. (Tex.)/CV- 18-1055	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Does 1 Through 100, Inclusive	6/19/2018	2018
County of San Patricio v. Purdue Pharma L.P., et al.	San Patricio Cnty. Dist. Ct. (Tex.)/S- 18-5625CV-A	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.; Purdue Pharma Manufacturing L.P.	TEVA; Cephalon; Janssen; Johnson & Johnson; Noramco; Depomed; Endo; Abbvie; Knoll; Allergan; Actavis; Watson ; Actavis; Mallinckrodt; Insys; Mylan; Mission; McKesson; Cardinal; AmerisourceBerge n; Advanced Pharma	6/28/2018	2018

County of Nueces and Nueces County Hospital District v. Purdue Pharma L.P., et al.	Nueces Cnty. Dist. Ct. (Tex.)/2018CCV- 61176-4	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.; Purdue Pharma Manufacturing L.P.	TEVA; Cephalon; Janssen; Johnson & Johnson; Noramco; Depomed; Endo; Abbvie; Knoll; Allergan; Actavis; Watson ; Actavis; Mallinckrodt; Insys; Mylan; Mission; McKesson; Cardinal; AmerisourceBerge n; Advanced Pharma	7/3/2018	2018
Nicholas A. Padron v. Purdue Pharma L.P., et al.	Dallas Cnty. Dist. Ct. (Tex.)/DC-18- 12305	Texas	Purdue Pharma L.P.	Janssen; Endo; AbbVie; Knoll; Actavis	7/9/2018	2018
Johnson County v. Purdue Pharma, L.P. et al.	Johnson Cnty. Dist. Ct. (Tex.)/DC- C201800848 (removed from S.D. Texas/4:19-cv- 01637)	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.	Abbott Laboratories; AbbVie, Inc.; Actavis, LLC; Allergan Sales, LLC; Allergan, PLC; Allergan, USA; AmerisourceBerge n Drug Corporation; Cardinal Health, Inc.; Cephalon, Inc.; CVS Health; Dang Medical Clinic, P.A.; Dang Occupational Consultants, Inc.; John Tai Dang, MD; Endo Health Solutions, Inc.; Endo Pharmaceuticals, Inc.; Insys Manufacturing, LLC; Insys Therapeutics, Inc.; Janssen	11/2/2018	2018

County of Walker v. Abbott Laboratories, Inc., et al.	Walker Cnty. Dist. Ct. (Tex.)/1929076	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; Purdue Pharmaceuticals, L.P.	Abbott; Abbvie; Actavis; Advanced Pharma; Allergan; Alpharma; AmerisourceBerge n; Watson; Apotex; Aveva; Cardinal; Caremark; Cephalon; CuraScript; CVS; Depomed; Endo; Express; Fresenius; H.D. Smith; ICU Med. Sales; Impax; Insys; Janssen; JM Smith; Johnson & Johnson; Knoll; Mallinckrodt; McKesson; Medco; Mission Pharmaceutical; Mylan; Navitus; Neos; Nesher; Noven; Optum; Paddock; Par; Perrigo;	1/11/2019	2019
Fire and Police Retirement Health Care Fund, San Antonio v. Richard D. Sackler, et al.	Bexar Cnty. Dist. Ct. (Tex.)/2019-CI- 06151 (remanded from S.D. Tex./4:19-cv- 02089)	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; Insys; TEVA; Cephalon; Johnson & Johnson; Janssen; Noramco; Endo; Qualitest; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n; Abbott; CVS; Walgreens	4/18/2019	2019

City of Houston, Texas v. Purdue Pharma L.P., et al.	Harris Cnty. Dist. Ct. (Tex.)/2019- 43219	Texas	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Noramco; Johnson & Johnson; Janssen; Endo; Par; Abbvie; Knoll; Allergan; Actavis; Watson; TEVA; Cephalon; Mallinckrodt; SpecGx; McKesson; Cardinal; AmerisourceBerge n	6/24/2019	2019
Summit County, Utah v. Purdue Pharma L.P., et al.	3rd Dist. Ct. Summit Cnty. (Ut.)/180500119	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n; Perry Fine; Lynn Webster; Rhodes; John N. Kapoor; Par; Qualitest; SpecGx; Amneal; UCB; KVK; Ethex; Xanodyne; Alvogen; Abbvie; Apotex; American Drug Stores; Albertsons; Auburn; Masters; River City Pharma; Harvard Drug; Top Tx; Henry Schein; PSS World; CVS; Rite Aid;	3/27/2018	2018
Salt Lake County v. Purdue Pharma L.P., et al.	3rd Dist. Ct. Salt Lake Cnty. (Ut.)/180902421 (removed from D. Ut./2:19-cv-00626- TC)	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Lynn Webster; Russell Portenoy	4/10/2018	2018

Weber County, Utah v. Purdue Pharma L.P., et al.	2nd Dist. Ct. Weber Cnty. (Ut.)/180903087 (remanded from D. Utah/1:18-cv- 00089-EJF)	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n; Perry Fine; Lynn Webster; Rhodes; John N. Kapoor; Par; Qualitest; SpecGx; Amneal; UCB; KVK; Ethex; Xanodyne; Alvogen; Abbvie; Apotex; American Drug Stores; Albertsons; Auburn; Masters; River City Pharma; Harvard Drug; Top Tx; Henry Schein; PSS World; CVS; Rite Aid;	5/25/2018	2018
--	---	------	---	---	-----------	------

Uintah County, Utah; Duscesne County, Utah; Daggett County, Utah; and Tri- County Health Department v. Purdue Pharma L.P., et al.	8th Dist. Ct. Uintah Cnty. (Ut.)/180800056 (remanded from D. Utah/2:18-cv- 00585-DBP)	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBerger; Perry Fine; Lynn Webster; Rhodes; John N. Kapoor; Par; Qualitest; SpecGx; Amneal; UCB; KVK; Ethex; Xanodyne; Alvogen; Abbvie; Apotex; American Drug Stores; Albertsons; Auburn; Masters; River City Pharma; Harvard Drug; Top Tx; Henry Schein; PSS World; CVS; Rite Aid;	6/4/2018	2018
---	--	------	---	--	----------	------

Wasatch County, Utah v. Purdue Pharma L.P., et al.	4th Dist. Ct. Wasatch Cnty. (Ut.)/180500079	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n; Perry Fine; Lynn Webster; Rhodes; John N. Kapoor; Par; Qualitest; SpecGx; Amneal; UCB; KVK; Ethex; Xanodyne; Alvogen; Abbvie; Apotex; American Drug Stores; Albertsons; Auburn; Masters; River City Pharma; Harvard Drug; Top Tx; Henry Schein; PSS World; CVS; Rite Aid;	6/28/2018	2018
Davis County v. Purdue Pharma L.P., et al.	2nd Dist. Ct. Davis Cnty. (Ut.)/180700870	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Anesta; Allergan; Watson; Actavis; Janssen; Johnson & Johnson; Noramco; Depomed; Endo; Abbvie; Knoll; Mallinckrodt; Mylan; Lipone; Spriaso; McKesson; Cardinal; AmerisourceBerge n; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	8/28/2018	2018

Iron County v. Purdue Pharma L.P., et al.	5th Jud. Dist. Ct. Iron Cnty. (Ut.)/180500149	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.; Purdue Pharma Manufacturing L.P.	TEVA; Cephalon; Anesta; Allergan; Watson; Actavis; Janssen; Johnson & Johnson; Noramco; Depomed; Endo; Abbvie; Knoll; Mallinckrodt; Mylan; Lipone; Spriaso; McKesson; Cardinal; AmerisourceBerge n; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	10/26/2018	2018
San Juan County v. Purdue Pharma L.P., et al.	7th Jud. Dist. Ct. Grand Cnty. (Ut.)/180700040	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.; Purdue Pharma Manufacturing L.P.	TEVA; Cephalon; Anesta; Allergan; Watson; Actavis; Janssen; Johnson & Johnson; Noramco; Depomed; Endo; Abbvie; Knoll; Mallinckrodt; Mylan; Lipone; Spriaso; McKesson; Cardinal; AmerisourceBerge n; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	11/8/2018	2018

Grand County v. Purdue Pharma L.P., et al.	7th Jud. Dist. Ct. Grand Cnty. (Ut.)	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.; Purdue Pharma Manufacturing L.P.	TEVA; Cephalon; Anesta; Allergan; Watson; Actavis; Janssen; Johnson & Johnson; Noramco; Depomed; Endo; Abbvie; Knoll; Mallinckrodt; Mylan; Lipone; Spriaso; McKesson; Cardinal; AmerisourceBerge n; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	11/8/2018	2018
Millard County v. Purdue Pharma L.P., et al.	4th Jud. Dist. Ct. Millard Cnty. (Ut.)/180700044	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.; Purdue Pharma Manufacturing L.P.	TEVA; Cephalon; Anesta; Allergan; Watson; Actavis; Janssen; Johnson & Johnson; Noramco; Depomed; Endo; Abbvie; Knoll; Mallinckrodt; Mylan; Lipone; Spriaso; McKesson; Cardinal; AmerisourceBerge n; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	11/9/2018	2018

Sanpete County v. Purdue Pharma L.P., et al.	6th Jud. Dist. Ct. Sanpete Cnty. (Ut.)/180600095	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; Purdue Pharmaceuticals L.P.; Purdue Pharma Manufacturing L.P.	TEVA; Cephalon; Anesta; Allergan; Watson; Actavis; Janssen; Johnson & Johnson; Noramco; Depomed; Endo; Abbvie; Knoll; Mallinckrodt; Mylan; Lipone; Spriaso; McKesson; Cardinal; AmerisourceBergen; Russell Portenoy; Perry Fine; Scott Fishman; Lynn Webster	11/13/2018	2018
Washington County, Utah; Kane County, Utah; Beaver County, Utah; Garfield County, Utah v. Purdue Pharma L.P., et al.	5th Dist. Ct. Washington Cnty. (Ut.)/190500179	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBergen; Perry Fine; Lynn Webster; Rhodes; John N. Kapoor; Par; Qualitest; SpecGx; Amneal; UCB; KVK; Ethex; Xanodyne; Alvogen; Abbvie; Apotex; American Drug Stores; Albertsons; Auburn; Masters; River City Pharma; Harvard Drug; Top Tx; Henry Schein; PSS World; CVS; Rite Aid;	4/3/2019	2019

Sevier County, Utah; Juab County, Utah; Emery County, Utah; Wayne County, Utah; Piute County, Utah v. Purdue Pharma L.P., et al.	3rd Dist. Ct. Weber Cnty. (Ut.)	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n; Perry Fine; Lynn Webster; Rhodes; John N. Kapoor; Par; Qualitest; SpecGx; Amneal; UCB; KVK; Ethex; Xanodyne; Alvogen; Abbvie; Apotex; American Drug Stores; Albertsons; Auburn; Masters; River City Pharma; Harvard Drug; Top Tx; Henry Schein; PSS World; CVS; Rite Aid;	7/26/2019	2019
--	------------------------------------	------	---	---	-----------	------

Tooele County, Utah v. Purdue Pharma L.P., et al.	3rd Dist. Ct. Tooele Cnty. (Ut.)	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n; Perry Fine; Lynn Webster; Rhodes; John N. Kapoor; Par; Qualitest; SpecGx; Amneal; UCB; KVK; Ethex; Xanodyne; Alvogen; Abbvie; Apotex; American Drug Stores; Albertsons; Auburn; Masters; River City Pharma; Harvard Drug; Top Tx; Henry Schein; PSS World; CVS; Rite Aid;	3/28/2018; 7/26/2019 (Am.)	2018
---	-------------------------------------	------	---	---	-------------------------------	------

Cache County, Utah; Rich County, Utah v. Purdue Pharma L.P., et al.	1st Dist. Ct. Cache Cnty. (Ut.)/190100112	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.; The P.F. Laboratories Inc.	TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n; Perry Fine; Lynn Webster; Rhodes; John N. Kapoor; Par; Qualitest; SpecGx; Amneal; UCB; KVK; Ethex; Xanodyne; Alvogen; Abbvie; Apotex; American Drug Stores; Albertsons; Auburn; Masters; River City Pharma; Harvard Drug; Top Tx; Henry Schein; PSS World; CVS; Rite Aid;	4/3/2019; 7/26/2019 (Am.)	2019
State of Utah v. Purdue Pharma L.P., et al.	7th Dist. Ct. Carbon Cnty. (Ut.)/180700055	Utah	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	5/31/2018	2018
State of Vermont v. Purdue Pharma L.P., et al.	Super. Ct. Chittenden Civ. Div./757-9-18- CRCV	Vermont	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	9/5/2018	2018
Commonwealth of Virginia, ex rel. Mark R. Herring, Attorney General v. Purdue Pharma L.P., et al.	Cir. Ct. Tazewell Cnty. (VA)	Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	6/27/2018	2018

City of Martinsville, Virginia v. Purdue Pharma L.P., et al.	Cir. Ct. Martinsville Cnty. (VA)/CL18000240- 00	Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBerge n; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	10/4/2018	2018
Dinwiddie County, Virginia v. Purdue Pharma L.P., et al.	Cir. Ct. Dinwiddie Cnty. (VA)/CL19- 317	Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBerge n; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	4/4/2019	2019

The County Board of Arlington County, Virginia v. Purdue Pharma L.P., et al.	Cir. Ct. Arlington Cnty. (VA)/CL19- 1081	Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBerge n; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
--	--	----------	---	--	-----	------

Mecklenburg County, Virginia v. Purdue Pharma L.P., et al.	Cir. Ct. Mecklenburg Cnty. (VA)/CL18000240- 00	Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Abbott; Mallinckrodt; Endo; TEVA; Cephalon; Carr; Janssen; Watson; Allergan; Actavis; Insys; McKesson; Cardinal; Barr; Henry Schein; General Injectables & Vaccines; Insource; AmerisourceBerge n; Express; CVS; Caremark; UnitedHealth; Optum; Par; Amneal; KVK; Impax; Mylan; Does 1-101	N/A	2019
---	--	----------	---	--	-----	------

State of Washington v. Purdue Pharma L.P., et al.	Super. Ct. King Cty. (WA)/17-2-25505-0 SEA	Washington	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Does 1 through 99; Doe Corporations 1 through 99	9/28/2017	2017
Brooke County Commission v. Purdue Pharma L.P., et al.	Cir. Ct. Marshall Cnty. (W.V.)/17-C-248H (remanded from N.D. WV/5:18-cv-00009)	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mark Radcliffe; Mark Ross; Patty Carnes; TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; Rite Aid; Kroger; CVS; Wal-Mart; Goodwin; West VA Board of Pharmacy; David Potters; Edita P. Milan; Tressie Montene Duffy, M.D.; Eugenio Aldea Menez, M.D.; Scott James Feathers, D.P.M.; Amy Lynn Beaver, P.A.-C	12/13/2017	2017

Hancock County Commission v. Purdue Pharma L.P., et al.	Cir. Ct. Marshall Cnty. (W.V.)/17-C- 249H (remanded from N.D. WV/5:18-cv- 00010)	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mark Radcliffe; Mark Ross; Patty Carnes; TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Kroger; CVS; Wal- Mart; Goodwin; West VA Board of Pharmacy; David Potters; Edita P. Milan; Tressie Montene Duffy, M.D.; Eugenio Aldea Menez, M.D.; Scott James Feathers, D.P.M.; Amy Lynn Beaver, P.A.-C	12/13/2017	2017
--	--	---------------	---	--	------------	------

Harrison County Commission v. Purdue Pharma L.P., et al.	Cir. Ct. Marshall Cnty. (W.V.)/17-C- 250H (remanded from N.D. WV/5:18-cv- 00011)	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mark Radcliffe; Mark Ross; Patty Carnes; TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Kroger; CVS; Wal- Mart; Goodwin; West VA Board of Pharmacy; David Potters; Edita P. Milan; Tressie Montene Duffy, M.D.; Eugenio Aldea Menez, M.D.; Scott James Feathers, D.P.M.; Amy Lynn Beaver, P.A.-C	12/13/2017	2017
---	---	---------------	---	--	------------	------

Lewis County Commission v. Purdue Pharma L.P., et al.	Cir. Ct. Marshall Cnty. (W.V.)/17-C- 251H (remanded from N.D. WV/5:18-cv- 00012)	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mark Radcliffe; Mark Ross; Patty Carnes; TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Kroger; CVS; Wal- Mart; Goodwin; West VA Board of Pharmacy; David Potters; Edita P. Milan; Tressie Montene Duffy, M.D.; Eugenio Aldea Menez, M.D.; Scott James Feathers, D.P.M.; Amy Lynn Beaver, P.A.-C	12/13/2017	2017
--	---	---------------	---	--	------------	------

Marshall County Commission v. Purdue Pharma L.P., et al.	Cir. Ct. Marshall Cnty. (W.V.)/17-C- 252H (remanded from N.D. WV/5:18-cv- 00013)	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mark Radcliffe; Mark Ross; Patty Carnes; TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Kroger; CVS; Wal- Mart; Goodwin; West VA Board of Pharmacy; David Potters; Edita P. Milan; Tressie Montene Duffy, M.D.; Eugenio Aldea Menez, M.D.; Scott James Feathers, D.P.M.; Amy Lynn Beaver, P.A.-C	12/13/2017	2017
---	---	---------------	---	--	------------	------

Ohio County Commission v. Purdue Pharma L.P., et al.	Cir. Ct. Marshall Cnty. (W.V.)/17-C- 253H (remanded from N.D. WV/5:18-cv- 00014)	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mark Radcliffe; Mark Ross; Patty Carnes; TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Kroger; CVS; Wal- Mart; Goodwin; West VA Board of Pharmacy; David Potters; Edita P. Milan; Tressie Montene Duffy, M.D.; Eugenio Aldea Menez, M.D.; Scott James Feathers, D.P.M.; Amy Lynn Beaver, P.A.-C	12/13/2017	2017
---	---	---------------	---	--	------------	------

Tyler County Commission v. Purdue Pharma L.P., et al.	Cir. Ct. Marshall Cnty. (W.V.)/17-C- 254H (remanded from N.D. WV/5:18-cv- 00015)	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mark Radcliffe; Mark Ross; Patty Carnes; TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Kroger; CVS; Wal- Mart; Goodwin; West VA Board of Pharmacy; David Potters; Edita P. Milan; Tressie Montene Duffy, M.D.; Eugenio Aldea Menez, M.D.; Scott James Feathers, D.P.M.; Amy Lynn Beaver, P.A.-C	12/13/2017	2017
--	---	---------------	---	--	------------	------

Wetzel County Commission v. Purdue Pharma L.P., et al.	Cir. Ct. Marshall Cnty. (W.V.)/17-C- 255H (remanded from N.D. WV/5:18-cv- 00016)	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mark Radcliffe; Mark Ross; Patty Carnes; TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Kroger; CVS; Wal- Mart; Goodwin; West VA Board of Pharmacy; David Potters; Edita P. Milan; Tressie Montene Duffy, M.D.; Eugenio Aldea Menez, M.D.; Scott James Feathers, D.P.M.; Amy Lynn Beaver, P.A.-C	12/13/2017	2017
Monongalia County Commission; Marion County Commission; Doddridge County Commission; Randolph County Commission; and Upshur County Commission v. Purdue Pharma L.P., et al.	Cir. Ct. Marshall Cnty. (W.V.)/18-C- 222H	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Endo; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Kroger; CVS; Wal- Mart; Goodwin; Miami-Luken; David Potters; Tressie Montene Duffy; Eugenio Aldea Menez; Scott James Feathers; Amy Lynn Beaver; Carl N. Hooker	9/28/2018	2018

The County Commission of Mason County; The County Commission of Barbour County; Mayor Chris Tatum on behalf of The Village of Barboursville; The County Commission of Taylor County; The County Commission of Webster County; and Mayor Don E. McCourt, on behalf of the Town of Addison a/k/a The Town of Webster Springs v. Purdue Pharma L.P., et al.	Cir. Ct. Marshall County (W.V.)/19- c-4	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	TEVA; Cephalon; Janssen; Johnson & Johnson; Mallinckrodt; Noramco; Endo; Insys; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBerge n; Rite Aid; Wal- Mart; Carl Hooker	12/18/2018	2018
---	---	---------------	---	--	------------	------

West Virginia University Hospitals Inc.; Appalachian Regional Healthcare, Inc.; Bluefield Hospital Company, LLC; Charleston Area Medical Center, Inc.; Davis Memorial Hospital; Broadus Hospital Association; Webster County Memorial Hospital, Inc.; Grafton City Hospital, Inc.; Greenbrier VMC, LLC; Monongalia County General Hospital Company; Preston Memorial Hospital Corporation;	Cir. Ct. Marshall Cnty. (WV)	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Amneal; TEVA; Cephalon; Johnson & Johnson; Janssen; Abbott; Assertio; Endo; Mallinckrodt; Insys; SpecGx; Allergan; Watson; Actavis; Anda; H.D. Smith; Henry Schein; AmerisourceBerge n; Miami-Luken; Cardinal; Rite Aid; Kroger; CVS; Wal- Mart; Noramco; Carl N. Hooker	4/29/2019	2019
--	---------------------------------	---------------	---	---	-----------	------

Roane County Commission; The City of Spencer; Jackson County Commission; The City of Ripley; The Town of Ravenswood; Wood County Commission; The City of Williamstown; Wirt County Commission; The Town of Elizabeth; Pleasants County Commission; City of St. Mary's; Ritchie County Commission; Town of Harrisville v. Mylan Pharmaceuticals Inc., et al.	Cir. Ct. Marshall Cnty. (WV)/19-C- 96-108H	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Mylan; TEVA; Cephalon; Johnson & Johnson; Janssen; Endo; Allergan; Actavis; Watson; Insys; Mallinckrodt; SpecGx; Fruth; Rite Aid; Walgreen; McKesson; Cardinal; AmerisourceBerge n; CVS; Kroger; Wal-Mart; Miami- Luken	5/3/2019	2019
State of West Virginia, ex rel. Patrick Morrissey, Attorney General v. Purdue Pharma L.P., et al.	Cir. Ct. Boone Cnty. (WV)	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.	N/A	5/15/2019	2019

Mayor Peggy Knotts Barney, on behalf of the City of Grafton, and Mayor Philip Bowers, on behalf of the City of Philippi v. Purdue Pharma L.P., et al.	Cir. Ct. Marshall Cnty. (WV)/19-C-151, 152	West Virginia	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	Rhodes; TEVA; Cephalon; Janssen; Johnson & Johnson; Noramco; Mallinckrodt; Johnson & Johnson; Endo; Allergan; Actavis; Watson; McKesson; Cardinal; AmerisourceBergen; H.D. Smith; Rite Aid; Walmart; WV Board of Pharmacy	6/26/2019	2019
State of Wisconsin v. Purdue Pharma L.P., et al.	Cir. Ct. Dane Cnty. (Wis.)/2019CX000009	Wisconsin	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	5/16/2019	2019
State of Wyoming, ex rel. Peter K. Michael, Attorney General v. Purdue Pharma L.P., et al.	1st Jud. Ct. Laramie Cnty. (Wy.)/190-576	Wyoming	Purdue Pharma L.P.; Purdue Pharma Inc.; The Purdue Frederick Company Inc.	N/A	10/18/2018	2018
County of Apache v. Apache Cnty. Super. Ct., Case No. S0100cv201900101				Actavis; Allergan; AmerisourceBergen; Babich; Brownsberger; Cardinal; Cephalon; Endo; Hall; Harper; Janssen; Johnson & Johnson; Mallinckrodt; TEVA; Trujillo; Watson; Western Drug		2019
Terri Daley as Index	Cir. Ct. Dupage Cnty. 2019-L-000312					2019

City of Henderson v. Eighth Jud. Dist. Ct. Clark Cnty. A-19-800695-B Dept. 11	TEVA; Cephalon; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Johnson & Johnson; Janssen; Noramco; AmerisourceBerge n; Cardinal; McKesson; Walgreen; Walmart; CVS; Masters; C&R; Maxsam; Holper	2019
City of Las Vegas v. Eighth Jud. Dist. Ct. Clark Cnty. A-19-800697-B Dept. 27	TEVA; Cephalon; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Johnson & Johnson; Janssen; Noramco; AmerisourceBerge n; Cardinal; McKesson; Walgreen; Walmart; CVS; Masters; C&R; Maxsam; Holper	2019
City of North Las Vegas v. Eighth Jud. Dist. Ct. Clark Cnty. A-19-800699-B Dept. 11	TEVA; Cephalon; Endo; Par; Allergan; Actavis; Watson; Mallinckrodt; SpecGx; Johnson & Johnson; Janssen; Noramco; AmerisourceBerge n; Cardinal; McKesson; Walgreen; Walmart; CVS; Masters; C&R; Maxsam; Holper	2019

Board of County Cc D. Ct. Cleveland Cnty. CJ-2019-592

TEVA; Cephalon;
Johnson &
Johnson; Janssen;
Endo; Allergan;
Actavis; Watson;
Insys;
Mallinckrodt;
Watson;
McKesson;
Cardinal;
AmerisourceBerge
n; Par; SpecGx;
Mylan; Sandoz;
Morris & Dickson;
CVS; Walgreen;
Walmart

2019

Board of County Cc D. Ct. Coal Cnty. CJ-2019-11

Cephalon; TEVA;
Janssen; Johnson
& Johnson; Endo;
Allergan; Actavis;
Watson;
Mallinckrodt;
McKesson;
Cardinal;
AmerisourceBerge
n; Anda; GCP;
Morris & Dickson;
Keysource; Quest;
Harvard Drug
Group; Physicians
Total Care; CVS;
Walgreen; SAJ;
H.D. Smith

2019

Board of County Cc D. Ct. Greer Cnty. CJ-2019-12

Cephalon; TEVA;
Janssen; Johnson
& Johnson; Endo;
Allergan; Actavis;
Watson;
Mallinckrodt;
McKesson;
Cardinal;
AmerisourceBerge
n; Anda; GCP;
Morris & Dickson;
Keysource; Quest;
Harvard Drug
Group; Physicians
Total Care; CVS;
Walgreen; SAJ;
H.D. Smith

2019

Board of County Cc D. Ct. Hughes Cnty. CJ-2019-36

Cephalon; TEVA;
Janssen; Johnson
& Johnson; Endo;
Allergan; Actavis;
Watson;
Mallinckrodt;
McKesson;
Cardinal;
AmerisourceBerge
n; Anda; GCP;
Morris & Dickson;
Keysource; Quest;
Harvard Drug
Group; Physicians
Total Care; CVS;
Walgreen; SAJ;
H.D. Smith

2019

Board of County Cc D. Ct. Jackson Cnty. CJ-2019-70

Cephalon; TEVA;
Janssen; Johnson
& Johnson; Endo;
Allergan; Actavis;
Watson;
Mallinckrodt;
McKesson;
Cardinal;
AmerisourceBerge
n; Anda; GCP;
Morris & Dickson;
Keysource; Quest;
Harvard Drug
Group; Physicians
Total Care; CVS;
Walgreen; SAJ;
H.D. Smith

2019

Board of County Cc D. Ct. Lincoln Cnty. CJ-2019-89

Cephalon; TEVA;
Janssen; Johnson
& Johnson; Endo;
Allergan; Actavis;
Watson;
Mallinckrodt;
McKesson;
Cardinal;
AmerisourceBerge
n; Anda; GCP;
Morris & Dickson;
Keysource; Quest;
Harvard Drug
Group; Physicians
Total Care; CVS;
Walgreen; SAJ;
H.D. Smith

2019

Board of County Cc D. Ct. McCurtain Cnty. CJ-2019-54	Cephalon; TEVA; Janssen; Johnson & Johnson; Endo; Allergan; Actavis; Watson; Mallinckrodt; McKesson; Cardinal; AmerisourceBerge n; Anda; GCP; Morris & Dickson; Keysource; Quest; Harvard Drug Group; Physicians Total Care; CVS; Walgreen; SAJ; H.D. Smith, Riddles	2019
Pike County, Pa. v. C.P. Pike Cnty. No. 602-2018		2018
County of Nacogdo Harris Cnty. Dist. Ct. 2018-77027	Endo; Johnson & Johnson; Janssen; Ortho-Mcneil- Janssen Pharmaceuticals	2018
In the Matter of Pu DCP Case No. 107102.	N/A	2019

Appendix H

Produced in Native Format - Appendix H.xlsx

Purdue Cash Distributions

Posting Date	Amount	Category	Total Cumulative	U.S. Cumulative	Tax Cumulative	Ex-U.S. Cumulative	U.S. + Tax Cumulative	U.S. + Ex-U.S. Cumulative	Ex-U.S. + Tax Cumulative
12/21/17	35,000,000	Tax	35,000,000	0	35,000,000	0	35,000,000	0	35,000,000
09/07/17	7,637,723	Tax	42,637,723	0	42,637,723	0	42,637,723	0	42,637,723
09/07/17	7,637,723	Tax	50,275,447	0	50,275,447	0	50,275,447	0	50,275,447
09/06/17	150,745	Tax	50,426,191	0	50,426,191	0	50,426,191	0	50,426,191
09/06/17	251,241	Tax	50,677,432	0	50,677,432	0	50,677,432	0	50,677,432
07/31/17	120,596	Tax	50,798,028	0	50,798,028	0	50,798,028	0	50,798,028
06/30/17	198,544	U.S. Partner	50,996,572	198,544	50,798,028	0	50,996,572	198,544	50,798,028
06/07/17	7,537,227	Tax	58,533,799	198,544	58,335,255	0	58,533,799	198,544	58,335,255
06/07/17	7,537,227	Tax	66,071,026	198,544	65,872,482	0	66,071,026	198,544	65,872,482
06/06/17	15,074	Tax	66,086,100	198,544	65,887,556	0	66,086,100	198,544	65,887,556
06/06/17	200,993	Tax	66,287,093	198,544	66,088,549	0	66,287,093	198,544	66,088,549
06/05/17	5,025	Tax	66,292,118	198,544	66,093,574	0	66,292,118	198,544	66,093,574
06/05/17	5,025	Tax	66,297,143	198,544	66,098,599	0	66,297,143	198,544	66,098,599
05/08/17	20,099,272	Tax	86,396,415	198,544	86,197,871	0	86,396,415	198,544	86,197,871
05/08/17	20,099,272	Tax	106,495,687	198,544	106,297,143	0	106,495,687	198,544	106,297,143
03/14/17	1,457,197	Tax	107,952,884	198,544	107,754,340	0	107,952,884	198,544	107,754,340
03/14/17	1,607,942	Tax	109,560,826	198,544	109,362,282	0	109,560,826	198,544	109,362,282
03/14/17	4,522,336	Tax	114,083,162	198,544	113,884,618	0	114,083,162	198,544	113,884,618
03/13/17	10,000	Tax	114,093,162	198,544	113,894,618	0	114,093,162	198,544	113,894,618
03/13/17	75,372	Tax	114,168,535	198,544	113,969,991	0	114,168,535	198,544	113,969,991
03/13/17	100,496	Tax	114,269,031	198,544	114,070,487	0	114,269,031	198,544	114,070,487
03/13/17	125,620	Tax	114,394,652	198,544	114,196,108	0	114,394,652	198,544	114,196,108
03/13/17	1,607,942	Tax	116,002,593	198,544	115,804,049	0	116,002,593	198,544	115,804,049
03/13/17	7,537,227	Tax	123,539,820	198,544	123,341,276	0	123,539,820	198,544	123,341,276
03/13/17	27,134,017	Tax	150,673,838	198,544	150,475,294	0	150,673,838	198,544	150,475,294
03/13/17	27,134,017	Tax	177,807,855	198,544	177,609,311	0	177,807,855	198,544	177,609,311
03/10/17	5,025	Tax	177,812,880	198,544	177,614,336	0	177,812,880	198,544	177,614,336
03/10/17	5,025	Tax	177,817,905	198,544	177,619,361	0	177,817,905	198,544	177,619,361
03/10/17	10,050	Tax	177,827,954	198,544	177,629,410	0	177,827,954	198,544	177,629,410
03/10/17	452,234	Tax	178,280,188	198,544	178,081,644	0	178,280,188	198,544	178,081,644
03/10/17	452,234	Tax	178,732,421	198,544	178,533,877	0	178,732,421	198,544	178,533,877
03/10/17	7,537,227	Tax	186,269,648	198,544	186,071,104	0	186,269,648	198,544	186,071,104
03/09/17	8,040	Tax	186,277,688	198,544	186,079,144	0	186,277,688	198,544	186,079,144
03/09/17	10,000	Tax	186,287,689	198,544	186,089,145	0	186,287,689	198,544	186,089,145
03/09/17	10,050	Tax	186,297,738	198,544	186,099,194	0	186,297,738	198,544	186,099,194
03/09/17	15,074	Tax	186,312,813	198,544	186,114,269	0	186,312,813	198,544	186,114,269
03/09/17	100,496	Tax	186,413,309	198,544	186,214,765	0	186,413,309	198,544	186,214,765
03/09/17	125,620	Tax	186,538,929	198,544	186,340,385	0	186,538,929	198,544	186,340,385
03/09/17	200,993	Tax	186,739,922	198,544	186,541,378	0	186,739,922	198,544	186,541,378
12/31/16	-23,170,000	U.S. Partner	163,569,922	-22,971,456	186,541,378	0	163,569,922	-22,971,456	186,541,378
12/31/16	282,925	U.S. Partner	163,852,847	-22,688,531	186,541,378	0	163,852,847	-22,688,531	186,541,378
12/22/16	60,323	Ex U.S.	163,913,170	-22,688,531	186,541,378	60,323	163,852,847	-22,628,208	186,601,701
12/22/16	60,323	Ex U.S.	163,973,493	-22,688,531	186,541,378	120,646	163,852,847	-22,567,885	186,662,024

12/22/16	508,512	U.S. Partner	164,482,005	-22,180,019	186,541,378	120,646	164,361,359	-22,059,374	186,662,024
12/22/16	992,085	Ex U.S.	165,474,090	-22,180,019	186,541,378	1,112,731	164,361,359	-21,067,289	187,654,109
12/22/16	1,080,450	Ex U.S.	166,554,540	-22,180,019	186,541,378	2,193,181	164,361,359	-19,986,839	188,734,559
12/22/16	2,700,000	Ex U.S.	169,254,540	-22,180,019	186,541,378	4,893,181	164,361,359	-17,286,839	191,434,559
12/22/16	2,800,000	Ex U.S.	172,054,540	-22,180,019	186,541,378	7,693,181	164,361,359	-14,486,839	194,234,559
12/22/16	8,542,191	U.S. Partner	180,596,730	-13,637,829	186,541,378	7,693,181	172,903,549	-5,944,648	194,234,559
12/22/16	8,542,191	U.S. Partner	189,138,921	-5,095,638	186,541,378	7,693,181	181,445,740	2,597,543	194,234,559
12/21/16	2,660,750	Ex U.S.	191,799,671	-5,095,638	186,541,378	10,353,931	181,445,740	5,258,293	196,895,309
12/16/16	4,990,930	Ex U.S.	196,790,601	-5,095,638	186,541,378	15,344,861	181,445,740	10,249,223	201,886,239
12/09/16	7,537,227	Tax	204,327,828	-5,095,638	194,078,605	15,344,861	188,982,967	10,249,223	209,423,466
12/08/16	7,537,227	Tax	211,865,055	-5,095,638	201,615,832	15,344,861	196,520,194	10,249,223	216,960,693
11/29/16	1,150,000	Ex U.S.	213,015,055	-5,095,638	201,615,832	16,494,861	196,520,194	11,399,223	218,110,693
11/29/16	1,150,000	Ex U.S.	214,165,055	-5,095,638	201,615,832	17,644,861	196,520,194	12,549,223	219,260,693
11/20/16	796,434	Ex U.S.	214,961,489	-5,095,638	201,615,832	18,441,295	196,520,194	13,345,656	220,057,127
11/20/16	796,434	Ex U.S.	215,757,922	-5,095,638	201,615,832	19,237,728	196,520,194	14,142,090	220,853,560
11/19/16	31,800	Ex U.S.	215,789,722	-5,095,638	201,615,832	19,269,528	196,520,194	14,173,890	220,885,360
11/19/16	1,060,000	Ex U.S.	216,849,722	-5,095,638	201,615,832	20,329,528	196,520,194	15,233,890	221,945,360
11/19/16	2,915,000	Ex U.S.	219,764,722	-5,095,638	201,615,832	23,244,528	196,520,194	18,148,890	224,860,360
11/18/16	393,946	Ex U.S.	220,158,668	-5,095,638	201,615,832	23,638,474	196,520,194	18,542,836	225,254,306
11/18/16	393,946	Ex U.S.	220,552,614	-5,095,638	201,615,832	24,032,420	196,520,194	18,936,782	225,648,252
11/18/16	2,100,000	Ex U.S.	222,652,614	-5,095,638	201,615,832	26,132,420	196,520,194	21,036,782	227,748,252
11/18/16	2,100,000	Ex U.S.	224,752,614	-5,095,638	201,615,832	28,232,420	196,520,194	23,136,782	229,848,252
11/18/16	2,200,000	Ex U.S.	226,952,614	-5,095,638	201,615,832	30,432,420	196,520,194	25,336,782	232,048,252
11/18/16	2,650,000	Ex U.S.	229,602,614	-5,095,638	201,615,832	33,082,420	196,520,194	27,986,782	234,698,252
11/18/16	7,056,000	Ex U.S.	236,658,614	-5,095,638	201,615,832	40,138,420	196,520,194	35,042,782	241,754,252
11/17/16	2,000,000	Ex U.S.	238,658,614	-5,095,638	201,615,832	42,138,420	196,520,194	37,042,782	243,754,252
11/16/16	930,000	Ex U.S.	239,588,614	-5,095,638	201,615,832	43,068,420	196,520,194	37,972,782	244,684,252
10/31/16	243,754	Ex U.S.	239,832,368	-5,095,638	201,615,832	43,312,174	196,520,194	38,216,535	244,928,006
10/31/16	243,754	Ex U.S.	240,076,122	-5,095,638	201,615,832	43,555,928	196,520,194	38,460,289	245,171,760
10/31/16	3,000,000	Ex U.S.	243,076,122	-5,095,638	201,615,832	46,555,928	196,520,194	41,460,289	248,171,760
10/31/16	4,365,900	Ex U.S.	247,442,022	-5,095,638	201,615,832	50,921,828	196,520,194	45,826,189	252,537,660
10/21/16	897,188	Ex U.S.	248,339,209	-5,095,638	201,615,832	51,819,015	196,520,194	46,723,377	253,434,847
10/12/16	1,102,200	Ex U.S.	249,441,409	-5,095,638	201,615,832	52,921,215	196,520,194	47,825,577	254,537,047
10/06/16	2,305,000	Ex U.S.	251,746,409	-5,095,638	201,615,832	55,226,215	196,520,194	50,130,577	256,842,047
10/03/16	8,542,191	U.S. Partner	260,288,600	3,446,552	201,615,832	55,226,215	205,062,385	58,672,767	256,842,047
10/03/16	8,542,191	U.S. Partner	268,830,790	11,988,743	201,615,832	55,226,215	213,604,575	67,214,958	256,842,047
09/15/16	90,447	Tax	268,921,237	11,988,743	201,706,279	55,226,215	213,695,022	67,214,958	256,932,494
09/15/16	401,985	Tax	269,323,222	11,988,743	202,108,264	55,226,215	214,097,007	67,214,958	257,334,479
09/15/16	1,205,956	Tax	270,529,179	11,988,743	203,314,221	55,226,215	215,302,964	67,214,958	258,540,436
09/15/16	29,143,945	Tax	299,673,123	11,988,743	232,458,165	55,226,215	244,446,908	67,214,958	287,684,380
09/13/16	95,472	Tax	299,768,595	11,988,743	232,553,637	55,226,215	244,542,380	67,214,958	287,779,852
09/13/16	150,745	Tax	299,919,339	11,988,743	232,704,381	55,226,215	244,693,124	67,214,958	287,930,596
09/13/16	2,813,898	Tax	302,733,237	11,988,743	235,518,279	55,226,215	247,507,022	67,214,958	290,744,494
09/13/16	2,813,898	Tax	305,547,136	11,988,743	238,332,177	55,226,215	250,320,921	67,214,958	293,558,392
09/13/16	29,143,945	Tax	334,691,080	11,988,743	267,476,122	55,226,215	279,464,865	67,214,958	322,702,337
09/12/16	675,000	Ex U.S.	335,366,080	11,988,743	267,476,122	55,901,215	279,464,865	67,889,958	323,377,337
09/08/16	60,298	Tax	335,426,378	11,988,743	267,536,420	55,901,215	279,525,163	67,889,958	323,437,635
09/08/16	95,472	Tax	335,521,849	11,988,743	267,631,891	55,901,215	279,620,634	67,889,958	323,533,106
08/31/16	295,459	Ex U.S.	335,817,309	11,988,743	267,631,891	56,196,674	279,620,634	68,185,417	323,828,566

08/31/16	295,459	Ex U.S.	336,112,768	11,988,743	267,631,891	56,492,134	279,620,634	68,480,877	324,124,025
08/31/16	5,292,000	Ex U.S.	341,404,768	11,988,743	267,631,891	61,784,134	279,620,634	73,772,877	329,416,025
08/24/16	2,000,000	Ex U.S.	343,404,768	11,988,743	267,631,891	63,784,134	279,620,634	75,772,877	331,416,025
08/18/16	4,290,580	Ex U.S.	347,695,348	11,988,743	267,631,891	68,074,714	279,620,634	80,063,457	335,706,605
08/17/16	1,000,000	Ex U.S.	348,695,348	11,988,743	267,631,891	69,074,714	279,620,634	81,063,457	336,706,605
08/09/16	1,256,205	Tax	349,951,553	11,988,743	268,888,096	69,074,714	280,876,839	81,063,457	337,962,809
08/08/16	3,337,500	Ex U.S.	353,289,053	11,988,743	268,888,096	72,412,214	280,876,839	84,400,957	341,300,309
08/08/16	3,337,500	Ex U.S.	356,626,553	11,988,743	268,888,096	75,749,714	280,876,839	87,738,457	344,637,809
07/31/16	23,984	U.S. Partner	356,650,537	12,012,727	268,888,096	75,749,714	280,900,823	87,762,441	344,637,809
07/31/16	49,080	U.S. Partner	356,699,617	12,061,808	268,888,096	75,749,714	280,949,904	87,811,521	344,637,809
07/31/16	160,794	Tax	356,860,411	12,061,808	269,048,890	75,749,714	281,110,698	87,811,521	344,798,604
07/31/16	1,041,890	U.S. Partner	357,902,301	13,103,698	269,048,890	75,749,714	282,152,588	88,853,411	344,798,604
07/25/16	246,216	Ex U.S.	358,148,517	13,103,698	269,048,890	75,995,930	282,152,588	89,099,627	345,044,820
07/25/16	246,216	Ex U.S.	358,394,733	13,103,698	269,048,890	76,242,146	282,152,588	89,345,843	345,291,036
07/25/16	300,000	Ex U.S.	358,694,733	13,103,698	269,048,890	76,542,146	282,152,588	89,645,843	345,591,036
07/25/16	300,000	Ex U.S.	358,994,733	13,103,698	269,048,890	76,842,146	282,152,588	89,945,843	345,891,036
07/25/16	4,410,000	Ex U.S.	363,404,733	13,103,698	269,048,890	81,252,146	282,152,588	94,355,843	350,301,036
07/12/16	3,000,000	Ex U.S.	366,404,733	13,103,698	269,048,890	84,252,146	282,152,588	97,355,843	353,301,036
07/12/16	3,000,000	Ex U.S.	369,404,733	13,103,698	269,048,890	87,252,146	282,152,588	100,355,843	356,301,036
06/30/16	15,074	Tax	369,419,808	13,103,698	269,063,964	87,252,146	282,167,662	100,355,843	356,316,110
06/30/16	20,099	Tax	369,439,907	13,103,698	269,084,064	87,252,146	282,187,761	100,355,843	356,336,210
06/30/16	25,124	Tax	369,465,031	13,103,698	269,109,188	87,252,146	282,212,886	100,355,843	356,361,334
06/30/16	50,248	Tax	369,515,279	13,103,698	269,159,436	87,252,146	282,263,134	100,355,843	356,411,582
06/30/16	50,248	Tax	369,565,528	13,103,698	269,209,684	87,252,146	282,313,382	100,355,843	356,461,830
06/30/16	60,298	Tax	369,625,825	13,103,698	269,269,982	87,252,146	282,373,680	100,355,843	356,522,128
06/30/16	90,447	Tax	369,716,272	13,103,698	269,360,429	87,252,146	282,464,126	100,355,843	356,612,575
06/30/16	90,447	Tax	369,806,719	13,103,698	269,450,875	87,252,146	282,554,573	100,355,843	356,703,021
06/30/16	140,695	Tax	369,947,414	13,103,698	269,591,570	87,252,146	282,695,268	100,355,843	356,843,716
06/30/16	160,794	Tax	370,108,208	13,103,698	269,752,365	87,252,146	282,856,062	100,355,843	357,004,510
06/30/16	170,844	Tax	370,279,052	13,103,698	269,923,208	87,252,146	283,026,906	100,355,843	357,175,354
06/30/16	7,034,745	U.S. Partner	377,313,797	20,138,443	269,923,208	87,252,146	290,061,651	107,390,589	357,175,354
06/30/16	7,034,745	U.S. Partner	384,348,542	27,173,188	269,923,208	87,252,146	297,096,396	114,425,334	357,175,354
06/30/16	18,835,028	Tax	403,183,570	27,173,188	288,758,236	87,252,146	315,931,424	114,425,334	376,010,382
06/30/16	18,835,028	Tax	422,018,598	27,173,188	307,593,264	87,252,146	334,766,452	114,425,334	394,845,410
06/28/16	2,750,000	Ex U.S.	424,768,598	27,173,188	307,593,264	90,002,146	334,766,452	117,175,334	397,595,410
06/27/16	1,000,000	Ex U.S.	425,768,598	27,173,188	307,593,264	91,002,146	334,766,452	118,175,334	398,595,410
06/21/16	1,269,113	Ex U.S.	427,037,710	27,173,188	307,593,264	92,271,258	334,766,452	119,444,446	399,864,522
06/21/16	1,500,000	Ex U.S.	428,537,710	27,173,188	307,593,264	93,771,258	334,766,452	120,944,446	401,364,522
06/21/16	2,617,192	Ex U.S.	431,154,902	27,173,188	307,593,264	96,388,450	334,766,452	123,561,638	403,981,714
06/21/16	2,763,845	Ex U.S.	433,918,747	27,173,188	307,593,264	99,152,295	334,766,452	126,325,483	406,745,559
06/21/16	3,000,000	Ex U.S.	436,918,747	27,173,188	307,593,264	102,152,295	334,766,452	129,325,483	409,745,559
06/21/16	4,117,565	Ex U.S.	441,036,312	27,173,188	307,593,264	106,269,860	334,766,452	133,443,048	413,863,124
06/17/16	168,765	Ex U.S.	441,205,077	27,173,188	307,593,264	106,438,625	334,766,452	133,611,813	414,031,889
06/15/16	25,124	Tax	441,230,202	27,173,188	307,618,388	106,438,625	334,791,576	133,611,813	414,057,013
06/15/16	200,993	Tax	441,431,194	27,173,188	307,819,381	106,438,625	334,992,569	133,611,813	414,258,006
06/15/16	502,482	Tax	441,933,676	27,173,188	308,321,863	106,438,625	335,495,051	133,611,813	414,760,488
06/10/16	854,219	Tax	442,787,895	27,173,188	309,176,082	106,438,625	336,349,270	133,611,813	415,614,707
06/10/16	854,219	Tax	443,642,114	27,173,188	310,030,301	106,438,625	337,203,489	133,611,813	416,468,926
06/07/16	35,174	Tax	443,677,288	27,173,188	310,065,475	106,438,625	337,238,663	133,611,813	416,504,100

06/07/16	100,496	Tax	443,777,784	27,173,188	310,165,971	106,438,625	337,339,159	133,611,813	416,604,596
05/31/16	854,219	Ex U.S.	444,632,003	27,173,188	310,165,971	107,292,844	337,339,159	134,466,032	417,458,815
05/31/16	854,219	Ex U.S.	445,486,222	27,173,188	310,165,971	108,147,063	337,339,159	135,320,252	418,313,034
05/25/16	1,350,000	Ex U.S.	446,836,222	27,173,188	310,165,971	109,497,063	337,339,159	136,670,252	419,663,034
05/24/16	93,562	Ex U.S.	446,929,785	27,173,188	310,165,971	109,590,626	337,339,159	136,763,814	419,756,596
05/24/16	93,562	Ex U.S.	447,023,347	27,173,188	310,165,971	109,684,188	337,339,159	136,857,376	419,850,159
05/24/16	1,100,000	Ex U.S.	448,123,347	27,173,188	310,165,971	110,784,188	337,339,159	137,957,376	420,950,159
05/24/16	1,675,800	Ex U.S.	449,799,147	27,173,188	310,165,971	112,459,988	337,339,159	139,633,176	422,625,959
05/24/16	1,952,125	Ex U.S.	451,751,272	27,173,188	310,165,971	114,412,113	337,339,159	141,585,301	424,578,084
05/23/16	1,000,000	Ex U.S.	452,751,272	27,173,188	310,165,971	115,412,113	337,339,159	142,585,301	425,578,084
05/23/16	1,000,000	Ex U.S.	453,751,272	27,173,188	310,165,971	116,412,113	337,339,159	143,585,301	426,578,084
04/30/16	-270,838	Tax	453,480,434	27,173,188	309,895,133	116,412,113	337,068,321	143,585,301	426,307,246
04/30/16	-270,838	Tax	453,209,596	27,173,188	309,624,296	116,412,113	336,797,484	143,585,301	426,036,408
04/28/16	4,175,000	Ex U.S.	457,384,596	27,173,188	309,624,296	120,587,113	336,797,484	147,760,301	430,211,408
04/25/16	221,594	Ex U.S.	457,606,191	27,173,188	309,624,296	120,808,707	336,797,484	147,981,895	430,433,003
04/25/16	221,594	Ex U.S.	457,827,785	27,173,188	309,624,296	121,030,302	336,797,484	148,203,490	430,654,597
04/25/16	396,620	Ex U.S.	458,224,405	27,173,188	309,624,296	121,426,922	336,797,484	148,600,110	431,051,217
04/25/16	3,969,000	Ex U.S.	462,193,405	27,173,188	309,624,296	125,395,922	336,797,484	152,569,110	435,020,217
04/25/16	4,000,000	Ex U.S.	466,193,405	27,173,188	309,624,296	129,395,922	336,797,484	156,569,110	439,020,217
04/25/16	4,000,000	Ex U.S.	470,193,405	27,173,188	309,624,296	133,395,922	336,797,484	160,569,110	443,020,217
04/22/16	562,450	Ex U.S.	470,755,855	27,173,188	309,624,296	133,958,372	336,797,484	161,131,560	443,582,667
04/12/16	1,500,000	Ex U.S.	472,255,855	27,173,188	309,624,296	135,458,372	336,797,484	162,631,560	445,082,667
04/08/16	10,049,636	U.S. Partner	482,305,491	37,222,824	309,624,296	135,458,372	346,847,120	172,681,196	445,082,667
04/08/16	10,049,636	U.S. Partner	492,355,127	47,272,460	309,624,296	135,458,372	356,896,756	182,730,832	445,082,667
04/06/16	5,025	Tax	492,360,152	47,272,460	309,629,320	135,458,372	356,901,781	182,730,832	445,087,692
04/06/16	1,000,000	Ex U.S.	493,360,152	47,272,460	309,629,320	136,458,372	356,901,781	183,730,832	446,087,692
04/06/16	1,000,000	Ex U.S.	494,360,152	47,272,460	309,629,320	137,458,372	356,901,781	184,730,832	447,087,692
04/06/16	1,000,000	Ex U.S.	495,360,152	47,272,460	309,629,320	138,458,372	356,901,781	185,730,832	448,087,692
04/06/16	1,500,000	Ex U.S.	496,860,152	47,272,460	309,629,320	139,958,372	356,901,781	187,230,832	449,587,692
04/06/16	2,800,000	Ex U.S.	499,660,152	47,272,460	309,629,320	142,758,372	356,901,781	190,030,832	452,387,692
03/31/16	100,496	Tax	499,760,648	47,272,460	309,729,817	142,758,372	357,002,277	190,030,832	452,488,188
03/31/16	150,745	Tax	499,911,393	47,272,460	309,880,561	142,758,372	357,153,021	190,030,832	452,638,933
03/31/16	331,638	Tax	500,243,031	47,272,460	310,212,199	142,758,372	357,484,659	190,030,832	452,970,571
03/31/16	351,737	Tax	500,594,768	47,272,460	310,563,936	142,758,372	357,836,397	190,030,832	453,322,308
03/31/16	427,110	Tax	501,021,878	47,272,460	310,991,046	142,758,372	358,263,506	190,030,832	453,749,418
03/30/16	75,372	Tax	501,097,250	47,272,460	311,066,418	142,758,372	358,338,878	190,030,832	453,824,790
03/30/16	100,496	Tax	501,197,746	47,272,460	311,166,915	142,758,372	358,439,375	190,030,832	453,925,286
03/30/16	301,489	Tax	501,499,235	47,272,460	311,468,404	142,758,372	358,740,864	190,030,832	454,226,775
03/30/16	803,971	Tax	502,303,206	47,272,460	312,272,375	142,758,372	359,544,835	190,030,832	455,030,746
03/30/16	3,517,373	Tax	505,820,579	47,272,460	315,789,747	142,758,372	363,062,207	190,030,832	458,548,119
03/30/16	3,517,373	Tax	509,337,952	47,272,460	319,307,120	142,758,372	366,579,580	190,030,832	462,065,491
03/29/16	5,025	Tax	509,342,976	47,272,460	319,312,145	142,758,372	366,584,605	190,030,832	462,070,516
03/29/16	5,025	Tax	509,348,001	47,272,460	319,317,169	142,758,372	366,589,630	190,030,832	462,075,541
03/29/16	7,500	Tax	509,355,501	47,272,460	319,324,670	142,758,372	366,597,130	190,030,832	462,083,041
03/29/16	25,124	Tax	509,380,625	47,272,460	319,349,794	142,758,372	366,622,254	190,030,832	462,108,165
03/29/16	30,149	Tax	509,410,774	47,272,460	319,379,943	142,758,372	366,652,403	190,030,832	462,138,314
03/29/16	30,149	Tax	509,440,923	47,272,460	319,410,091	142,758,372	366,682,552	190,030,832	462,168,463
03/29/16	35,174	Tax	509,476,097	47,272,460	319,445,265	142,758,372	366,717,725	190,030,832	462,203,637
03/29/16	50,248	Tax	509,526,345	47,272,460	319,495,513	142,758,372	366,767,974	190,030,832	462,253,885

03/29/16	50,248	Tax	509,576,593	47,272,460	319,545,762	142,758,372	366,818,222	190,030,832	462,304,133
03/29/16	50,248	Tax	509,626,841	47,272,460	319,596,010	142,758,372	366,868,470	190,030,832	462,354,381
03/29/16	50,248	Tax	509,677,090	47,272,460	319,646,258	142,758,372	366,918,718	190,030,832	462,404,629
03/29/16	60,298	Tax	509,737,387	47,272,460	319,706,556	142,758,372	366,979,016	190,030,832	462,464,927
03/29/16	75,372	Tax	509,812,760	47,272,460	319,781,928	142,758,372	367,054,388	190,030,832	462,540,300
03/29/16	90,447	Tax	509,903,206	47,272,460	319,872,375	142,758,372	367,144,835	190,030,832	462,630,746
03/29/16	125,620	Tax	510,028,827	47,272,460	319,997,995	142,758,372	367,270,455	190,030,832	462,756,367
03/29/16	135,670	Tax	510,164,497	47,272,460	320,133,665	142,758,372	367,406,125	190,030,832	462,892,037
03/29/16	236,166	Tax	510,400,663	47,272,460	320,369,832	142,758,372	367,642,292	190,030,832	463,128,203
03/29/16	238,642	Tax	510,639,305	47,272,460	320,608,473	142,758,372	367,880,934	190,030,832	463,366,845
03/29/16	268,804	Tax	510,908,109	47,272,460	320,877,277	142,758,372	368,149,737	190,030,832	463,635,649
03/29/16	401,985	Tax	511,310,094	47,272,460	321,279,262	142,758,372	368,551,723	190,030,832	464,037,634
03/29/16	434,412	Tax	511,744,506	47,272,460	321,713,674	142,758,372	368,986,134	190,030,832	464,472,046
03/29/16	439,509	Tax	512,184,015	47,272,460	322,153,183	142,758,372	369,425,643	190,030,832	464,911,554
03/29/16	552,730	Tax	512,736,745	47,272,460	322,705,913	142,758,372	369,978,373	190,030,832	465,464,284
03/29/16	552,730	Tax	513,289,475	47,272,460	323,258,643	142,758,372	370,531,103	190,030,832	466,017,014
03/29/16	2,336,540	Tax	515,626,015	47,272,460	325,595,183	142,758,372	372,867,643	190,030,832	468,353,555
03/29/16	2,336,540	Tax	517,962,555	47,272,460	327,931,724	142,758,372	375,204,184	190,030,832	470,690,095
03/29/16	6,783,504	Tax	524,746,060	47,272,460	334,715,228	142,758,372	381,987,688	190,030,832	477,473,599
03/29/16	10,351,125	Tax	535,097,185	47,272,460	345,066,353	142,758,372	392,338,813	190,030,832	487,824,725
03/29/16	10,351,125	Tax	545,448,310	47,272,460	355,417,478	142,758,372	402,689,938	190,030,832	498,175,850
03/25/16	172,351	Ex U.S.	545,620,661	47,272,460	355,417,478	142,930,723	402,689,938	190,203,183	498,348,201
03/25/16	172,351	Ex U.S.	545,793,012	47,272,460	355,417,478	143,103,074	402,689,938	190,375,534	498,520,552
03/25/16	3,087,000	Ex U.S.	548,880,012	47,272,460	355,417,478	146,190,074	402,689,938	193,462,534	501,607,552
03/22/16	3,030,210	Ex U.S.	551,910,222	47,272,460	355,417,478	149,220,284	402,689,938	196,492,744	504,637,762
02/22/16	1,544,760	Ex U.S.	553,454,982	47,272,460	355,417,478	150,765,044	402,689,938	198,037,504	506,182,522
02/22/16	5,848,020	Ex U.S.	559,303,002	47,272,460	355,417,478	156,613,064	402,689,938	203,885,524	512,030,542
02/22/16	17,654,400	Ex U.S.	576,957,402	47,272,460	355,417,478	174,267,464	402,689,938	221,539,924	529,684,942
02/17/16	40,198,544	Tax	617,155,946	47,272,460	395,616,022	174,267,464	442,888,482	221,539,924	569,883,486
02/17/16	40,198,544	Tax	657,354,491	47,272,460	435,814,566	174,267,464	483,087,027	221,539,924	610,082,030
02/11/16	1,134,600	Ex U.S.	658,489,091	47,272,460	435,814,566	175,402,064	483,087,027	222,674,524	611,216,630
02/01/16	1,000,000	Ex U.S.	659,489,091	47,272,460	435,814,566	176,402,064	483,087,027	223,674,524	612,216,630
02/01/16	1,350,000	Ex U.S.	660,839,091	47,272,460	435,814,566	177,752,064	483,087,027	225,024,524	613,566,630
01/29/16	596,255	Ex U.S.	661,435,346	47,272,460	435,814,566	178,348,319	483,087,027	225,620,779	614,162,885
01/28/16	13,582,960	Ex U.S.	675,018,306	47,272,460	435,814,566	191,931,279	483,087,027	239,203,739	627,745,845
01/21/16	7,000,000	Ex U.S.	682,018,306	47,272,460	435,814,566	198,931,279	483,087,027	246,203,739	634,745,845
01/19/16	1,965,600	Ex U.S.	683,983,906	47,272,460	435,814,566	200,896,879	483,087,027	248,169,339	636,711,445
01/15/16	283,148	Ex U.S.	684,267,054	47,272,460	435,814,566	201,180,028	483,087,027	248,452,488	636,994,594
01/15/16	283,148	Ex U.S.	684,550,203	47,272,460	435,814,566	201,463,176	483,087,027	248,735,636	637,277,742
01/15/16	5,071,500	Ex U.S.	689,621,703	47,272,460	435,814,566	206,534,676	483,087,027	253,807,136	642,349,242
01/15/16	18,635,580	Ex U.S.	708,257,283	47,272,460	435,814,566	225,170,256	483,087,027	272,442,716	660,984,822
01/13/16	543,200	Ex U.S.	708,800,483	47,272,460	435,814,566	225,713,456	483,087,027	272,985,916	661,528,022
01/07/16	218,080	Ex U.S.	709,018,563	47,272,460	435,814,566	225,931,536	483,087,027	273,203,996	661,746,102
01/07/16	327,120	Ex U.S.	709,345,683	47,272,460	435,814,566	226,258,656	483,087,027	273,531,116	662,073,222
01/07/16	1,363,000	Ex U.S.	710,708,683	47,272,460	435,814,566	227,621,656	483,087,027	274,894,116	663,436,222
01/07/16	1,908,200	Ex U.S.	712,616,883	47,272,460	435,814,566	229,529,856	483,087,027	276,802,316	665,344,422
01/07/16	4,034,480	Ex U.S.	716,651,363	47,272,460	435,814,566	233,564,336	483,087,027	280,836,796	669,378,902
01/07/16	6,324,320	Ex U.S.	722,975,683	47,272,460	435,814,566	239,888,656	483,087,027	287,161,116	675,703,222
01/07/16	7,469,240	Ex U.S.	730,444,923	47,272,460	435,814,566	247,357,896	483,087,027	294,630,356	683,172,462

12/31/15	-7,412,907	U.S. Partner	723,032,016	39,859,553	435,814,566	247,357,896	475,674,120	287,217,449	683,172,462
12/31/15	98,486	Ex U.S.	723,130,502	39,859,553	435,814,566	247,456,383	475,674,120	287,315,936	683,270,949
12/31/15	98,486	Ex U.S.	723,228,989	39,859,553	435,814,566	247,554,869	475,674,120	287,414,422	683,369,435
12/31/15	1,764,000	Ex U.S.	724,992,989	39,859,553	435,814,566	249,318,869	475,674,120	289,178,422	685,133,435
12/31/15	53,765,553	U.S. Partner	778,758,541	93,625,106	435,814,566	249,318,869	529,439,672	342,943,975	685,133,435
12/31/15	53,765,553	U.S. Partner	832,524,094	147,390,659	435,814,566	249,318,869	583,205,225	396,709,528	685,133,435
12/23/15	2,181,400	Ex U.S.	834,705,494	147,390,659	435,814,566	251,500,269	583,205,225	398,890,928	687,314,835
12/22/15	925,000	Ex U.S.	835,630,494	147,390,659	435,814,566	252,425,269	583,205,225	399,815,928	688,239,835
12/22/15	925,000	Ex U.S.	836,555,494	147,390,659	435,814,566	253,350,269	583,205,225	400,740,928	689,164,835
12/22/15	2,500,000	Ex U.S.	839,055,494	147,390,659	435,814,566	255,850,269	583,205,225	403,240,928	691,664,835
12/15/15	100,496	Tax	839,155,991	147,390,659	435,915,063	255,850,269	583,305,722	403,240,928	691,765,332
12/13/15	700,000	Ex U.S.	839,855,991	147,390,659	435,915,063	256,550,269	583,305,722	403,940,928	692,465,332
12/13/15	24,924,360	Ex U.S.	864,780,351	147,390,659	435,915,063	281,474,629	583,305,722	428,865,288	717,389,692
12/13/15	30,148,908	Ex U.S.	894,929,259	147,390,659	435,915,063	311,623,537	583,305,722	459,014,196	747,538,600
12/13/15	30,148,908	Ex U.S.	925,078,167	147,390,659	435,915,063	341,772,445	583,305,722	489,163,104	777,687,508
12/13/15	39,291,240	Ex U.S.	964,369,407	147,390,659	435,915,063	381,063,685	583,305,722	528,454,344	816,978,748
12/13/15	89,939,218	Tax	1,054,308,624	147,390,659	525,854,280	381,063,685	673,244,939	528,454,344	906,917,966
12/10/15	150,745	Tax	1,054,459,369	147,390,659	526,005,025	381,063,685	673,395,684	528,454,344	907,068,710
12/10/15	803,971	Tax	1,055,263,340	147,390,659	526,808,996	381,063,685	674,199,655	528,454,344	907,872,681
12/10/15	803,971	Tax	1,056,067,311	147,390,659	527,612,967	381,063,685	675,003,626	528,454,344	908,676,652
12/08/15	544,200	Ex U.S.	1,056,611,511	147,390,659	527,612,967	381,607,885	675,003,626	528,998,544	909,220,852
12/04/15	2,100,000	Ex U.S.	1,058,711,511	147,390,659	527,612,967	383,707,885	675,003,626	531,098,544	911,320,852
11/23/15	403,788	Ex U.S.	1,059,115,299	147,390,659	527,612,967	384,111,673	675,003,626	531,502,332	911,724,640
11/20/15	4,988,880	Ex U.S.	1,064,104,179	147,390,659	527,612,967	389,100,553	675,003,626	536,491,212	916,713,520
11/18/15	186,386	Ex U.S.	1,064,290,564	147,390,659	527,612,967	389,286,939	675,003,626	536,677,598	916,899,905
11/18/15	186,386	Ex U.S.	1,064,476,950	147,390,659	527,612,967	389,473,324	675,003,626	536,863,983	917,086,291
11/18/15	992,402	Ex U.S.	1,065,469,351	147,390,659	527,612,967	390,465,726	675,003,626	537,856,385	918,078,693
11/18/15	992,402	Ex U.S.	1,066,461,753	147,390,659	527,612,967	391,458,127	675,003,626	538,848,786	919,071,094
11/18/15	3,338,370	Ex U.S.	1,069,800,123	147,390,659	527,612,967	394,796,497	675,003,626	542,187,156	922,409,464
11/18/15	4,500,000	Ex U.S.	1,074,300,123	147,390,659	527,612,967	399,296,497	675,003,626	546,687,156	926,909,464
11/16/15	1,500,000	Ex U.S.	1,075,800,123	147,390,659	527,612,967	400,796,497	675,003,626	548,187,156	928,409,464
11/16/15	1,500,000	Ex U.S.	1,077,300,123	147,390,659	527,612,967	402,296,497	675,003,626	549,687,156	929,909,464
11/10/15	3,228,000	Ex U.S.	1,080,528,123	147,390,659	527,612,967	405,524,497	675,003,626	552,915,156	933,137,464
11/04/15	173,904	Ex U.S.	1,080,702,027	147,390,659	527,612,967	405,698,401	675,003,626	553,089,060	933,311,368
10/31/15	3,406,500	Ex U.S.	1,084,108,527	147,390,659	527,612,967	409,104,901	675,003,626	556,495,560	936,717,868
10/22/15	1,200,000	Ex U.S.	1,085,308,527	147,390,659	527,612,967	410,304,901	675,003,626	557,695,560	937,917,868
10/19/15	383,200	Ex U.S.	1,085,691,727	147,390,659	527,612,967	410,688,101	675,003,626	558,078,760	938,301,068
10/16/15	335,281	Ex U.S.	1,086,027,008	147,390,659	527,612,967	411,023,383	675,003,626	558,414,042	938,636,349
10/16/15	1,000,000	Ex U.S.	1,087,027,008	147,390,659	527,612,967	412,023,383	675,003,626	559,414,042	939,636,349
10/16/15	1,000,000	Ex U.S.	1,088,027,008	147,390,659	527,612,967	413,023,383	675,003,626	560,414,042	940,636,349
10/16/15	7,100,000	Ex U.S.	1,095,127,008	147,390,659	527,612,967	420,123,383	675,003,626	567,514,042	947,736,349
09/23/15	1,300,000	Ex U.S.	1,096,427,008	147,390,659	527,612,967	421,423,383	675,003,626	568,814,042	949,036,349
09/23/15	2,000,000	Ex U.S.	1,098,427,008	147,390,659	527,612,967	423,423,383	675,003,626	570,814,042	951,036,349
09/23/15	2,000,000	Ex U.S.	1,100,427,008	147,390,659	527,612,967	425,423,383	675,003,626	572,814,042	953,036,349
09/18/15	2,500,000	Ex U.S.	1,102,927,008	147,390,659	527,612,967	427,923,383	675,003,626	575,314,042	955,536,349
09/18/15	4,968,040	Ex U.S.	1,107,895,048	147,390,659	527,612,967	432,891,423	675,003,626	580,282,082	960,504,389
09/15/15	67,835,043	U.S. Partner	1,175,730,091	215,225,702	527,612,967	432,891,423	742,838,669	648,117,125	960,504,389
09/15/15	67,835,043	U.S. Partner	1,243,565,135	283,060,745	527,612,967	432,891,423	810,673,712	715,952,168	960,504,389
09/14/15	3,015	Tax	1,243,568,150	283,060,745	527,615,982	432,891,423	810,676,727	715,952,168	960,507,404

09/14/15	75,372	Tax	1,243,643,522	283,060,745	527,691,354	432,891,423	810,752,099	715,952,168	960,582,777
09/14/15	270,838	Ex U.S.	1,243,914,360	283,060,745	527,691,354	433,162,260	810,752,099	716,223,006	960,853,614
09/14/15	270,838	Ex U.S.	1,244,185,197	283,060,745	527,691,354	433,433,098	810,752,099	716,493,843	961,124,452
09/14/15	502,482	Tax	1,244,687,679	283,060,745	528,193,836	433,433,098	811,254,581	716,493,843	961,626,934
09/14/15	1,607,942	Tax	1,246,295,621	283,060,745	529,801,777	433,433,098	812,862,523	716,493,843	963,234,875
09/14/15	4,851,000	Ex U.S.	1,251,146,621	283,060,745	529,801,777	438,284,098	812,862,523	721,344,843	968,085,875
09/14/15	5,326,307	Tax	1,256,472,928	283,060,745	535,128,085	438,284,098	818,188,830	721,344,843	973,412,183
09/14/15	57,728,124	Tax	1,314,201,052	283,060,745	592,856,209	438,284,098	875,916,954	721,344,843	1,031,140,307
09/11/15	270,838	Tax	1,314,471,890	283,060,745	593,127,047	438,284,098	876,187,792	721,344,843	1,031,411,145
09/11/15	270,838	Tax	1,314,742,728	283,060,745	593,397,884	438,284,098	876,458,630	721,344,843	1,031,681,982
09/11/15	3,968,650	Ex U.S.	1,318,711,378	283,060,745	593,397,884	442,252,748	876,458,630	725,313,493	1,035,650,632
09/10/15	8,040	Tax	1,318,719,417	283,060,745	593,405,924	442,252,748	876,466,669	725,313,493	1,035,658,672
09/10/15	10,050	Tax	1,318,729,467	283,060,745	593,415,974	442,252,748	876,476,719	725,313,493	1,035,668,722
09/10/15	18,089	Tax	1,318,747,556	283,060,745	593,434,063	442,252,748	876,494,808	725,313,493	1,035,686,811
09/10/15	75,372	Tax	1,318,822,929	283,060,745	593,509,435	442,252,748	876,570,180	725,313,493	1,035,762,183
09/10/15	110,546	Tax	1,318,933,475	283,060,745	593,619,981	442,252,748	876,680,726	725,313,493	1,035,872,729
09/10/15	115,571	Tax	1,319,049,045	283,060,745	593,735,552	442,252,748	876,796,297	725,313,493	1,035,988,300
09/10/15	130,645	Tax	1,319,179,691	283,060,745	593,866,197	442,252,748	876,926,943	725,313,493	1,036,118,945
09/10/15	200,993	Tax	1,319,380,683	283,060,745	594,067,190	442,252,748	877,127,935	725,313,493	1,036,319,938
09/10/15	462,283	Tax	1,319,842,967	283,060,745	594,529,473	442,252,748	877,590,219	725,313,493	1,036,782,221
09/10/15	502,482	Tax	1,320,345,448	283,060,745	595,031,955	442,252,748	878,092,700	725,313,493	1,037,284,703
09/10/15	703,475	Tax	1,321,048,923	283,060,745	595,735,430	442,252,748	878,796,175	725,313,493	1,037,988,178
09/10/15	791,911	Tax	1,321,840,834	283,060,745	596,527,341	442,252,748	879,588,086	725,313,493	1,038,780,089
09/10/15	979,840	Tax	1,322,820,674	283,060,745	597,507,180	442,252,748	880,567,926	725,313,493	1,039,759,928
09/10/15	6,808,628	Tax	1,329,629,302	283,060,745	604,315,809	442,252,748	887,376,554	725,313,493	1,046,568,557
09/10/15	6,808,628	Tax	1,336,437,931	283,060,745	611,124,437	442,252,748	894,185,183	725,313,493	1,053,377,185
09/10/15	57,728,124	Tax	1,394,166,055	283,060,745	668,852,561	442,252,748	951,913,307	725,313,493	1,111,105,310
09/09/15	500,000	Ex U.S.	1,394,666,055	283,060,745	668,852,561	442,752,748	951,913,307	725,813,493	1,111,605,310
09/09/15	550,000	Ex U.S.	1,395,216,055	283,060,745	668,852,561	443,302,748	951,913,307	726,363,493	1,112,155,310
09/09/15	550,000	Ex U.S.	1,395,766,055	283,060,745	668,852,561	443,852,748	951,913,307	726,913,493	1,112,705,310
09/04/15	639,996	Ex U.S.	1,396,406,051	283,060,745	668,852,561	444,492,744	951,913,307	727,553,489	1,113,345,306
09/01/15	3,500,000	Ex U.S.	1,399,906,051	283,060,745	668,852,561	447,992,744	951,913,307	731,053,489	1,116,845,306
08/28/15	817,148	Ex U.S.	1,400,723,198	283,060,745	668,852,561	448,809,892	951,913,307	731,870,637	1,117,662,453
08/28/15	1,600,000	Ex U.S.	1,402,323,198	283,060,745	668,852,561	450,409,892	951,913,307	733,470,637	1,119,262,453
08/28/15	1,900,000	Ex U.S.	1,404,223,198	283,060,745	668,852,561	452,309,892	951,913,307	735,370,637	1,121,162,453
08/28/15	2,077,500	Ex U.S.	1,406,300,698	283,060,745	668,852,561	454,387,392	951,913,307	737,448,137	1,123,239,953
08/28/15	2,077,500	Ex U.S.	1,408,378,198	283,060,745	668,852,561	456,464,892	951,913,307	739,525,637	1,125,317,453
08/13/15	502	Tax	1,408,378,701	283,060,745	668,853,064	456,464,892	951,913,809	739,525,637	1,125,317,955
08/13/15	7,234	Tax	1,408,385,935	283,060,745	668,860,298	456,464,892	951,921,043	739,525,637	1,125,325,189
08/12/15	4,391	Tax	1,408,390,325	283,060,745	668,864,688	456,464,892	951,925,434	739,525,637	1,125,329,580
08/11/15	208,462	Tax	1,408,598,787	283,060,745	669,073,150	456,464,892	952,133,895	739,525,637	1,125,538,042
06/29/15	1,150,000	Ex U.S.	1,409,748,787	283,060,745	669,073,150	457,614,892	952,133,895	740,675,637	1,126,688,042
06/29/15	1,150,000	Ex U.S.	1,410,898,787	283,060,745	669,073,150	458,764,892	952,133,895	741,825,637	1,127,838,042
06/24/15	307,770	Ex U.S.	1,411,206,557	283,060,745	669,073,150	459,072,662	952,133,895	742,133,407	1,128,145,812
06/24/15	307,770	Ex U.S.	1,411,514,327	283,060,745	669,073,150	459,380,432	952,133,895	742,441,177	1,128,453,582
06/24/15	5,512,500	Ex U.S.	1,417,026,827	283,060,745	669,073,150	464,892,932	952,133,895	747,953,677	1,133,966,082
06/12/15	26,827,915	Tax	1,443,854,742	283,060,745	695,901,065	464,892,932	978,961,811	747,953,677	1,160,793,997
06/10/15	2,617,518	Tax	1,446,472,261	283,060,745	698,518,584	464,892,932	981,579,329	747,953,677	1,163,411,515
06/10/15	29,445,434	Tax	1,475,917,694	283,060,745	727,964,017	464,892,932	1,011,024,762	747,953,677	1,192,856,949

05/20/15	8,918,400	Ex U.S.	1,484,836,094	283,060,745	727,964,017	473,811,332	1,011,024,762	756,872,077	1,201,775,349
05/06/15	1,670,000	Ex U.S.	1,486,506,094	283,060,745	727,964,017	475,481,332	1,011,024,762	758,542,077	1,203,445,349
05/06/15	2,100,000	Ex U.S.	1,488,606,094	283,060,745	727,964,017	477,581,332	1,011,024,762	760,642,077	1,205,545,349
04/27/15	2,011,505	Ex U.S.	1,490,617,599	283,060,745	727,964,017	479,592,837	1,011,024,762	762,653,582	1,207,556,854
04/27/15	2,200,000	Ex U.S.	1,492,817,599	283,060,745	727,964,017	481,792,837	1,011,024,762	764,853,582	1,209,756,854
04/14/15	2,600,000	Ex U.S.	1,495,417,599	283,060,745	727,964,017	484,392,837	1,011,024,762	767,453,582	1,212,356,854
04/14/15	3,500,000	Ex U.S.	1,498,917,599	283,060,745	727,964,017	487,892,837	1,011,024,762	770,953,582	1,215,856,854
04/14/15	3,500,000	Ex U.S.	1,502,417,599	283,060,745	727,964,017	491,392,837	1,011,024,762	774,453,582	1,219,356,854
04/14/15	9,000,000	Ex U.S.	1,511,417,599	283,060,745	727,964,017	500,392,837	1,011,024,762	783,453,582	1,228,356,854
03/31/15	201	Tax	1,511,417,800	283,060,745	727,964,218	500,392,837	1,011,024,963	783,453,582	1,228,357,055
03/31/15	1,005	Tax	1,511,418,805	283,060,745	727,965,223	500,392,837	1,011,025,968	783,453,582	1,228,358,060
03/31/15	9,045	Tax	1,511,427,850	283,060,745	727,974,268	500,392,837	1,011,035,013	783,453,582	1,228,367,105
03/31/15	12,060	Tax	1,511,439,909	283,060,745	727,986,327	500,392,837	1,011,047,073	783,453,582	1,228,379,164
03/31/15	20,099	Tax	1,511,460,009	283,060,745	728,006,427	500,392,837	1,011,067,172	783,453,582	1,228,399,263
03/31/15	31,154	Tax	1,511,491,163	283,060,745	728,037,580	500,392,837	1,011,098,326	783,453,582	1,228,430,417
03/31/15	125,620	Tax	1,511,616,783	283,060,745	728,163,201	500,392,837	1,011,223,946	783,453,582	1,228,556,038
03/31/15	127,182	Tax	1,511,743,965	283,060,745	728,290,383	500,392,837	1,011,351,128	783,453,582	1,228,683,220
03/31/15	165,819	Tax	1,511,909,784	283,060,745	728,456,202	500,392,837	1,011,516,947	783,453,582	1,228,849,039
03/31/15	351,737	Tax	1,512,261,521	283,060,745	728,807,939	500,392,837	1,011,868,685	783,453,582	1,229,200,776
03/31/15	381,255	Ex U.S.	1,512,642,776	283,060,745	728,807,939	500,774,092	1,011,868,685	783,834,837	1,229,582,031
03/31/15	417,060	Tax	1,513,059,836	283,060,745	729,224,999	500,774,092	1,012,285,745	783,834,837	1,229,999,091
03/31/15	507,507	Tax	1,513,567,343	283,060,745	729,732,506	500,774,092	1,012,793,251	783,834,837	1,230,506,598
03/31/15	1,085,361	Ex U.S.	1,514,652,704	283,060,745	729,732,506	501,859,452	1,012,793,251	784,920,198	1,231,591,958
03/31/15	1,085,361	Ex U.S.	1,515,738,064	283,060,745	729,732,506	502,944,813	1,012,793,251	786,005,558	1,232,677,319
03/31/15	1,286,353	Tax	1,517,024,418	283,060,745	731,018,859	502,944,813	1,014,079,605	786,005,558	1,233,963,672
03/31/15	1,325,372	Tax	1,518,349,790	283,060,745	732,344,231	502,944,813	1,015,404,977	786,005,558	1,235,289,045
03/31/15	1,452,554	Tax	1,519,802,344	283,060,745	733,796,786	502,944,813	1,016,857,531	786,005,558	1,236,741,599
03/31/15	1,620,537	Tax	1,521,422,881	283,060,745	735,417,323	502,944,813	1,018,478,068	786,005,558	1,238,362,136
03/31/15	25,158,487	Tax	1,546,581,368	283,060,745	760,575,810	502,944,813	1,043,636,555	786,005,558	1,263,520,623
03/30/15	151	Tax	1,546,581,519	283,060,745	760,575,960	502,944,813	1,043,636,706	786,005,558	1,263,520,774
03/30/15	502	Tax	1,546,582,021	283,060,745	760,576,463	502,944,813	1,043,637,208	786,005,558	1,263,521,276
03/30/15	1,005	Tax	1,546,583,026	283,060,745	760,577,468	502,944,813	1,043,638,213	786,005,558	1,263,522,281
03/30/15	1,005	Tax	1,546,584,031	283,060,745	760,578,473	502,944,813	1,043,639,218	786,005,558	1,263,523,286
03/30/15	1,507	Tax	1,546,585,539	283,060,745	760,579,980	502,944,813	1,043,640,726	786,005,558	1,263,524,793
03/30/15	1,507	Tax	1,546,587,046	283,060,745	760,581,488	502,944,813	1,043,642,233	786,005,558	1,263,526,301
03/30/15	2,010	Tax	1,546,589,056	283,060,745	760,583,498	502,944,813	1,043,644,243	786,005,558	1,263,528,311
03/30/15	3,015	Tax	1,546,592,071	283,060,745	760,586,513	502,944,813	1,043,647,258	786,005,558	1,263,531,326
03/30/15	4,020	Tax	1,546,596,091	283,060,745	760,590,532	502,944,813	1,043,651,278	786,005,558	1,263,535,345
03/30/15	4,020	Tax	1,546,600,111	283,060,745	760,594,552	502,944,813	1,043,655,298	786,005,558	1,263,539,365
03/30/15	5,025	Tax	1,546,605,135	283,060,745	760,599,577	502,944,813	1,043,660,322	786,005,558	1,263,544,390
03/30/15	5,025	Tax	1,546,610,160	283,060,745	760,604,602	502,944,813	1,043,665,347	786,005,558	1,263,549,415
03/30/15	11,055	Tax	1,546,621,215	283,060,745	760,615,656	502,944,813	1,043,676,402	786,005,558	1,263,560,470
03/30/15	11,708	Tax	1,546,632,923	283,060,745	760,627,364	502,944,813	1,043,688,110	786,005,558	1,263,572,177
03/30/15	12,060	Tax	1,546,644,982	283,060,745	760,639,424	502,944,813	1,043,700,169	786,005,558	1,263,584,237
03/30/15	15,074	Tax	1,546,660,057	283,060,745	760,654,498	502,944,813	1,043,715,244	786,005,558	1,263,599,311
03/30/15	20,099	Tax	1,546,680,156	283,060,745	760,674,598	502,944,813	1,043,735,343	786,005,558	1,263,619,411
03/30/15	30,149	Tax	1,546,710,305	283,060,745	760,704,746	502,944,813	1,043,765,492	786,005,558	1,263,649,560
03/30/15	36,179	Tax	1,546,746,484	283,060,745	760,740,925	502,944,813	1,043,801,671	786,005,558	1,263,685,738
03/30/15	55,273	Tax	1,546,801,757	283,060,745	760,796,198	502,944,813	1,043,856,944	786,005,558	1,263,741,011

03/30/15	110,546	Tax	1,546,912,303	283,060,745	760,906,744	502,944,813	1,043,967,489	786,005,558	1,263,851,557
03/30/15	175,869	Tax	1,547,088,171	283,060,745	761,082,613	502,944,813	1,044,143,358	786,005,558	1,264,027,426
03/30/15	229,132	Tax	1,547,317,303	283,060,745	761,311,745	502,944,813	1,044,372,490	786,005,558	1,264,256,558
03/30/15	326,613	Tax	1,547,643,916	283,060,745	761,638,358	502,944,813	1,044,699,103	786,005,558	1,264,583,171
03/30/15	339,277	Tax	1,547,983,193	283,060,745	761,977,634	502,944,813	1,045,038,380	786,005,558	1,264,922,448
03/30/15	401,985	Tax	1,548,385,178	283,060,745	762,379,620	502,944,813	1,045,440,365	786,005,558	1,265,324,433
03/30/15	401,985	Tax	1,548,787,164	283,060,745	762,781,605	502,944,813	1,045,842,351	786,005,558	1,265,726,418
03/30/15	532,553	Tax	1,549,319,717	283,060,745	763,314,159	502,944,813	1,046,374,904	786,005,558	1,266,258,972
03/30/15	538,553	Tax	1,549,858,270	283,060,745	763,852,712	502,944,813	1,046,913,457	786,005,558	1,266,797,525
03/30/15	1,620,537	Tax	1,551,478,807	283,060,745	765,473,249	502,944,813	1,048,533,994	786,005,558	1,268,418,062
03/30/15	2,598,700	Tax	1,554,077,507	283,060,745	768,071,949	502,944,813	1,051,132,694	786,005,558	1,271,016,762
03/30/15	6,096,109	Tax	1,560,173,616	283,060,745	774,168,058	502,944,813	1,057,228,803	786,005,558	1,277,112,871
03/30/15	27,757,187	Tax	1,587,930,804	283,060,745	801,925,245	502,944,813	1,084,985,990	786,005,558	1,304,870,058
03/23/15	372,680	Ex U.S.	1,588,303,484	283,060,745	801,925,245	503,317,493	1,084,985,990	786,378,238	1,305,242,738
03/23/15	1,597,200	Ex U.S.	1,589,900,684	283,060,745	801,925,245	504,914,693	1,084,985,990	787,975,438	1,306,839,938
03/23/15	4,259,200	Ex U.S.	1,594,159,884	283,060,745	801,925,245	509,173,893	1,084,985,990	792,234,638	1,311,099,138
03/23/15	6,016,120	Ex U.S.	1,600,176,004	283,060,745	801,925,245	515,190,013	1,084,985,990	798,250,758	1,317,115,258
02/17/15	8,717,175	Ex U.S.	1,608,893,179	283,060,745	801,925,245	523,907,188	1,084,985,990	806,967,933	1,325,832,433
02/04/15	860,700	Ex U.S.	1,609,753,879	283,060,745	801,925,245	524,767,888	1,084,985,990	807,828,633	1,326,693,133
02/03/15	1,250,000	Ex U.S.	1,611,003,879	283,060,745	801,925,245	526,017,888	1,084,985,990	809,078,633	1,327,943,133
02/03/15	1,250,000	Ex U.S.	1,612,253,879	283,060,745	801,925,245	527,267,888	1,084,985,990	810,328,633	1,329,193,133
02/03/15	2,000,000	Ex U.S.	1,614,253,879	283,060,745	801,925,245	529,267,888	1,084,985,990	812,328,633	1,331,193,133
01/18/15	357,013	Ex U.S.	1,614,610,892	283,060,745	801,925,245	529,624,901	1,084,985,990	812,685,647	1,331,550,147
01/18/15	357,013	Ex U.S.	1,614,967,905	283,060,745	801,925,245	529,981,915	1,084,985,990	813,042,660	1,331,907,160
01/18/15	6,394,500	Ex U.S.	1,621,362,405	283,060,745	801,925,245	536,376,415	1,084,985,990	819,437,160	1,338,301,660
01/13/15	4,000,000	Ex U.S.	1,625,362,405	283,060,745	801,925,245	540,376,415	1,084,985,990	823,437,160	1,342,301,660
01/13/15	4,000,000	Ex U.S.	1,629,362,405	283,060,745	801,925,245	544,376,415	1,084,985,990	827,437,160	1,346,301,660
12/31/14	-27,330,000	U.S. Partner	1,602,032,405	255,730,745	801,925,245	544,376,415	1,057,655,990	800,107,160	1,346,301,660
12/31/14	-3,999,471	U.S. Partner	1,598,032,934	251,731,274	801,925,245	544,376,415	1,053,656,519	796,107,689	1,346,301,660
12/31/14	-3,656,940	U.S. Partner	1,594,375,994	248,074,334	801,925,245	544,376,415	1,049,999,579	792,450,749	1,346,301,660
12/31/14	-250,000	U.S. Partner	1,594,125,994	247,824,334	801,925,245	544,376,415	1,049,749,579	792,200,749	1,346,301,660
12/31/14	-250,000	U.S. Partner	1,593,875,994	247,574,334	801,925,245	544,376,415	1,049,499,579	791,950,749	1,346,301,660
12/31/14	4,307,734	U.S. Partner	1,598,183,727	251,882,068	801,925,245	544,376,415	1,053,807,313	796,258,482	1,346,301,660
12/23/14	1,800,000	Ex U.S.	1,599,983,727	251,882,068	801,925,245	546,176,415	1,053,807,313	798,058,482	1,348,101,660
12/23/14	2,900,709	Ex U.S.	1,602,884,436	251,882,068	801,925,245	549,077,124	1,053,807,313	800,959,191	1,351,002,369
12/23/14	2,900,710	Ex U.S.	1,605,785,146	251,882,068	801,925,245	551,977,834	1,053,807,313	803,859,901	1,353,903,079
12/19/14	7,838,716	Ex U.S.	1,613,623,863	251,882,068	801,925,245	559,816,550	1,053,807,313	811,698,617	1,361,741,795
12/19/14	7,838,716	Ex U.S.	1,621,462,579	251,882,068	801,925,245	567,655,266	1,053,807,313	819,537,334	1,369,580,511
12/16/14	602,978	Tax	1,622,065,557	251,882,068	802,528,223	567,655,266	1,054,410,291	819,537,334	1,370,183,489
12/16/14	1,507,445	Tax	1,623,573,002	251,882,068	804,035,669	567,655,266	1,055,917,736	819,537,334	1,371,690,935
12/16/14	3,718,365	Tax	1,627,291,368	251,882,068	807,754,034	567,655,266	1,059,636,102	819,537,334	1,375,409,300
12/16/14	89,114,573	Tax	1,716,405,940	251,882,068	896,868,607	567,655,266	1,148,750,674	819,537,334	1,464,523,873
12/12/14	282,897	Tax	1,716,688,838	251,882,068	897,151,504	567,655,266	1,149,033,572	819,537,334	1,464,806,770
12/12/14	758,748	Tax	1,717,447,585	251,882,068	897,910,252	567,655,266	1,149,792,319	819,537,334	1,465,565,517
12/12/14	4,522,336	Tax	1,721,969,921	251,882,068	902,432,588	567,655,266	1,154,314,655	819,537,334	1,470,087,854
12/12/14	4,522,336	Tax	1,726,492,257	251,882,068	906,954,924	567,655,266	1,158,836,992	819,537,334	1,474,610,190
12/12/14	8,366,897	Tax	1,734,859,154	251,882,068	915,321,821	567,655,266	1,167,203,888	819,537,334	1,482,977,087
12/12/14	22,169,150	Ex U.S.	1,757,028,304	251,882,068	915,321,821	589,824,416	1,167,203,888	841,706,484	1,505,146,237
12/12/14	97,481,470	Tax	1,854,509,774	251,882,068	1,012,803,290	589,824,416	1,264,685,358	841,706,484	1,602,627,706

12/11/14	4,120	Tax	1,854,513,894	251,882,068	1,012,807,411	589,824,416	1,264,689,478	841,706,484	1,602,631,827
12/11/14	5,527	Tax	1,854,519,422	251,882,068	1,012,812,938	589,824,416	1,264,695,006	841,706,484	1,602,637,354
12/11/14	26,129	Tax	1,854,545,551	251,882,068	1,012,839,067	589,824,416	1,264,721,135	841,706,484	1,602,663,483
12/11/14	35,174	Tax	1,854,580,724	251,882,068	1,012,874,241	589,824,416	1,264,756,308	841,706,484	1,602,698,657
12/11/14	60,298	Tax	1,854,641,022	251,882,068	1,012,934,539	589,824,416	1,264,816,606	841,706,484	1,602,758,955
12/11/14	75,372	Tax	1,854,716,394	251,882,068	1,013,009,911	589,824,416	1,264,891,978	841,706,484	1,602,834,327
12/11/14	80,397	Tax	1,854,796,791	251,882,068	1,013,090,308	589,824,416	1,264,972,375	841,706,484	1,602,914,724
12/11/14	216,067	Tax	1,855,012,859	251,882,068	1,013,306,375	589,824,416	1,265,188,443	841,706,484	1,603,130,791
12/11/14	502,482	Tax	1,855,515,340	251,882,068	1,013,808,857	589,824,416	1,265,690,924	841,706,484	1,603,633,273
12/04/14	28,842,455	U.S. Partner	1,884,357,796	280,724,523	1,013,808,857	589,824,416	1,294,533,380	870,548,939	1,603,633,273
12/04/14	28,842,455	U.S. Partner	1,913,200,251	309,566,978	1,013,808,857	589,824,416	1,323,375,835	899,391,394	1,603,633,273
11/30/14	205,013	Ex U.S.	1,913,405,264	309,566,978	1,013,808,857	590,029,429	1,323,375,835	899,596,407	1,603,838,285
11/30/14	1,250,000	Ex U.S.	1,914,655,264	309,566,978	1,013,808,857	591,279,429	1,323,375,835	900,846,407	1,605,088,285
11/30/14	1,250,000	Ex U.S.	1,915,905,264	309,566,978	1,013,808,857	592,529,429	1,323,375,835	902,096,407	1,606,338,285
11/30/14	1,250,000	Ex U.S.	1,917,155,264	309,566,978	1,013,808,857	593,779,429	1,323,375,835	903,346,407	1,607,588,285
11/30/14	2,000,000	Ex U.S.	1,919,155,264	309,566,978	1,013,808,857	595,779,429	1,323,375,835	905,346,407	1,609,588,285
11/30/14	3,740,000	Ex U.S.	1,922,895,264	309,566,978	1,013,808,857	599,519,429	1,323,375,835	909,086,407	1,613,328,285
11/17/14	472,333	Ex U.S.	1,923,367,597	309,566,978	1,013,808,857	599,991,761	1,323,375,835	909,558,740	1,613,800,618
11/17/14	472,333	Ex U.S.	1,923,839,930	309,566,978	1,013,808,857	600,464,094	1,323,375,835	910,031,073	1,614,272,951
10/30/14	190,125	Ex U.S.	1,924,030,055	309,566,978	1,013,808,857	600,654,219	1,323,375,835	910,221,198	1,614,463,076
10/30/14	253,500	Ex U.S.	1,924,283,555	309,566,978	1,013,808,857	600,907,719	1,323,375,835	910,474,698	1,614,716,576
10/30/14	316,875	Ex U.S.	1,924,600,430	309,566,978	1,013,808,857	601,224,594	1,323,375,835	910,791,573	1,615,033,451
10/30/14	3,422,250	Ex U.S.	1,928,022,680	309,566,978	1,013,808,857	604,646,844	1,323,375,835	914,213,823	1,618,455,701
10/30/14	4,309,500	Ex U.S.	1,932,332,180	309,566,978	1,013,808,857	608,956,344	1,323,375,835	918,523,323	1,622,765,201
10/30/14	5,386,875	Ex U.S.	1,937,719,055	309,566,978	1,013,808,857	614,343,219	1,323,375,835	923,910,198	1,628,152,076
10/30/14	6,210,750	Ex U.S.	1,943,929,805	309,566,978	1,013,808,857	620,553,969	1,323,375,835	930,120,948	1,634,362,826
10/30/14	7,288,125	Ex U.S.	1,951,217,930	309,566,978	1,013,808,857	627,842,094	1,323,375,835	937,409,073	1,641,650,951
10/20/14	183,529	Ex U.S.	1,951,401,459	309,566,978	1,013,808,857	628,025,624	1,323,375,835	937,592,602	1,641,834,481
10/20/14	183,529	Ex U.S.	1,951,584,989	309,566,978	1,013,808,857	628,209,153	1,323,375,835	937,776,132	1,642,018,010
10/20/14	3,287,214	Ex U.S.	1,954,872,203	309,566,978	1,013,808,857	631,496,367	1,323,375,835	941,063,346	1,645,305,224
10/17/14	5,000,000	Ex U.S.	1,959,872,203	309,566,978	1,013,808,857	636,496,367	1,323,375,835	946,063,346	1,650,305,224
09/28/14	100,496	Ex U.S.	1,959,972,699	309,566,978	1,013,808,857	636,596,864	1,323,375,835	946,163,842	1,650,405,721
09/23/14	7,709,219	Ex U.S.	1,967,681,918	309,566,978	1,013,808,857	644,306,083	1,323,375,835	953,873,061	1,658,114,940
09/21/14	1,769,892	Ex U.S.	1,969,451,810	309,566,978	1,013,808,857	646,075,974	1,323,375,835	955,642,953	1,659,884,831
09/20/14	1,450,000	Ex U.S.	1,970,901,810	309,566,978	1,013,808,857	647,525,974	1,323,375,835	957,092,953	1,661,334,831
09/19/14	25,124	Tax	1,970,926,934	309,566,978	1,013,833,981	647,525,974	1,323,400,959	957,092,953	1,661,359,955
09/19/14	150,745	Tax	1,971,077,678	309,566,978	1,013,984,726	647,525,974	1,323,551,704	957,092,953	1,661,510,700
09/19/14	376,861	Tax	1,971,454,540	309,566,978	1,014,361,587	647,525,974	1,323,928,565	957,092,953	1,661,887,561
09/19/14	2,411,913	Tax	1,973,866,452	309,566,978	1,016,773,500	647,525,974	1,326,340,478	957,092,953	1,664,299,474
09/19/14	50,433,426	Tax	2,024,299,878	309,566,978	1,067,206,926	647,525,974	1,376,773,904	957,092,953	1,714,732,900
09/11/14	7,537	Tax	2,024,307,416	309,566,978	1,067,214,463	647,525,974	1,376,781,441	957,092,953	1,714,740,437
09/10/14	3,015	Tax	2,024,310,430	309,566,978	1,067,217,478	647,525,974	1,376,784,456	957,092,953	1,714,743,452
09/10/14	271,340	Tax	2,024,581,771	309,566,978	1,067,488,818	647,525,974	1,377,055,796	957,092,953	1,715,014,792
09/10/14	283,902	Tax	2,024,865,673	309,566,978	1,067,772,720	647,525,974	1,377,339,699	957,092,953	1,715,298,694
09/10/14	2,914,394	Tax	2,027,780,067	309,566,978	1,070,687,115	647,525,974	1,380,254,093	957,092,953	1,718,213,089
09/10/14	2,914,394	Tax	2,030,694,462	309,566,978	1,073,601,509	647,525,974	1,383,168,487	957,092,953	1,721,127,483
09/10/14	4,839,572	Tax	2,035,534,034	309,566,978	1,078,441,081	647,525,974	1,388,008,060	957,092,953	1,725,967,055
09/10/14	55,272,998	Tax	2,090,807,032	309,566,978	1,133,714,079	647,525,974	1,443,281,058	957,092,953	1,781,240,054
09/09/14	40,199	Tax	2,090,847,231	309,566,978	1,133,754,278	647,525,974	1,443,321,256	957,092,953	1,781,280,252

09/09/14	50,248	Tax	2,090,897,479	309,566,978	1,133,804,526	647,525,974	1,443,371,504	957,092,953	1,781,330,500
09/09/14	50,248	Tax	2,090,947,727	309,566,978	1,133,854,774	647,525,974	1,443,421,753	957,092,953	1,781,380,749
09/09/14	50,248	Tax	2,090,997,975	309,566,978	1,133,905,022	647,525,974	1,443,472,001	957,092,953	1,781,430,997
09/09/14	80,397	Tax	2,091,078,372	309,566,978	1,133,985,420	647,525,974	1,443,552,398	957,092,953	1,781,511,394
09/09/14	175,869	Tax	2,091,254,241	309,566,978	1,134,161,288	647,525,974	1,443,728,267	957,092,953	1,781,687,262
09/09/14	326,613	Tax	2,091,580,854	309,566,978	1,134,487,901	647,525,974	1,444,054,880	957,092,953	1,782,013,876
09/09/14	427,110	Tax	2,092,007,964	309,566,978	1,134,915,011	647,525,974	1,444,481,989	957,092,953	1,782,440,985
09/03/14	4,500,000	Ex U.S.	2,096,507,964	309,566,978	1,134,915,011	652,025,974	1,444,481,989	961,592,953	1,786,940,985
09/03/14	4,500,000	Ex U.S.	2,101,007,964	309,566,978	1,134,915,011	656,525,974	1,444,481,989	966,092,953	1,791,440,985
08/20/14	5,000,000	Ex U.S.	2,106,007,964	309,566,978	1,134,915,011	661,525,974	1,444,481,989	971,092,953	1,796,440,985
08/06/14	3,250,000	Ex U.S.	2,109,257,964	309,566,978	1,134,915,011	664,775,974	1,444,481,989	974,342,953	1,799,690,985
08/06/14	3,250,000	Ex U.S.	2,112,507,964	309,566,978	1,134,915,011	668,025,974	1,444,481,989	977,592,953	1,802,940,985
07/31/14	123,108	Ex U.S.	2,112,631,072	309,566,978	1,134,915,011	668,149,082	1,444,481,989	977,716,061	1,803,064,093
07/31/14	123,108	Ex U.S.	2,112,754,180	309,566,978	1,134,915,011	668,272,190	1,444,481,989	977,839,169	1,803,187,201
07/31/14	2,205,000	Ex U.S.	2,114,959,180	309,566,978	1,134,915,011	670,477,190	1,444,481,989	980,044,169	1,805,392,201
07/23/14	1,500,000	Ex U.S.	2,116,459,180	309,566,978	1,134,915,011	671,977,190	1,444,481,989	981,544,169	1,806,892,201
07/10/14	1,909,180	Ex U.S.	2,118,368,360	309,566,978	1,134,915,011	673,886,370	1,444,481,989	983,453,349	1,808,801,381
07/10/14	10,500,490	Ex U.S.	2,128,868,850	309,566,978	1,134,915,011	684,386,860	1,444,481,989	993,953,839	1,819,301,871
07/10/14	11,414,169	Ex U.S.	2,140,283,019	309,566,978	1,134,915,011	695,801,029	1,444,481,989	1,005,368,008	1,830,716,040
06/30/14	6,000,000	Ex U.S.	2,146,283,019	309,566,978	1,134,915,011	701,801,029	1,444,481,989	1,011,368,008	1,836,716,040
06/30/14	6,799,500	Ex U.S.	2,153,082,519	309,566,978	1,134,915,011	708,600,529	1,444,481,989	1,018,167,508	1,843,515,540
06/16/14	100,496	Tax	2,153,183,015	309,566,978	1,135,015,507	708,600,529	1,444,582,486	1,018,167,508	1,843,616,037
06/16/14	653,226	Tax	2,153,836,241	309,566,978	1,135,668,734	708,600,529	1,445,235,712	1,018,167,508	1,844,269,263
06/16/14	11,462,143	Tax	2,165,298,384	309,566,978	1,147,130,876	708,600,529	1,456,697,854	1,018,167,508	1,855,731,405
06/11/14	954,715	Tax	2,166,253,099	309,566,978	1,148,085,591	708,600,529	1,457,652,570	1,018,167,508	1,856,686,121
06/11/14	954,715	Tax	2,167,207,815	309,566,978	1,149,040,307	708,600,529	1,458,607,285	1,018,167,508	1,857,640,836
06/11/14	1,099,903	Tax	2,168,307,717	309,566,978	1,150,140,209	708,600,529	1,459,707,188	1,018,167,508	1,858,740,739
06/11/14	12,562,045	Tax	2,180,869,762	309,566,978	1,162,702,254	708,600,529	1,472,269,233	1,018,167,508	1,871,302,784
06/06/14	1,081,385	Ex U.S.	2,181,951,147	309,566,978	1,162,702,254	709,681,914	1,472,269,233	1,019,248,893	1,872,384,169
06/06/14	1,081,385	Ex U.S.	2,183,032,532	309,566,978	1,162,702,254	710,763,299	1,472,269,233	1,020,330,278	1,873,465,554
06/06/14	2,500,000	Ex U.S.	2,185,532,532	309,566,978	1,162,702,254	713,263,299	1,472,269,233	1,022,830,278	1,875,965,554
06/06/14	2,500,000	Ex U.S.	2,188,032,532	309,566,978	1,162,702,254	715,763,299	1,472,269,233	1,025,330,278	1,878,465,554
05/29/14	1,600,000	Ex U.S.	2,189,632,532	309,566,978	1,162,702,254	717,363,299	1,472,269,233	1,026,930,278	1,880,065,554
04/18/14	2,000,000	Ex U.S.	2,191,632,532	309,566,978	1,162,702,254	719,363,299	1,472,269,233	1,028,930,278	1,882,065,554
04/15/14	40,199	Tax	2,191,672,731	309,566,978	1,162,742,453	719,363,299	1,472,309,431	1,028,930,278	1,882,105,752
04/15/14	50,248	Tax	2,191,722,979	309,566,978	1,162,792,701	719,363,299	1,472,359,680	1,028,930,278	1,882,156,001
04/15/14	100,496	Tax	2,191,823,475	309,566,978	1,162,893,198	719,363,299	1,472,460,176	1,028,930,278	1,882,256,497
04/15/14	200,993	Tax	2,192,024,468	309,566,978	1,163,094,190	719,363,299	1,472,661,169	1,028,930,278	1,882,457,490
04/15/14	326,613	Tax	2,192,351,081	309,566,978	1,163,420,803	719,363,299	1,472,987,782	1,028,930,278	1,882,784,103
04/15/14	477,358	Tax	2,192,828,439	309,566,978	1,163,898,161	719,363,299	1,473,465,140	1,028,930,278	1,883,261,461
04/15/14	552,730	Tax	2,193,381,169	309,566,978	1,164,450,891	719,363,299	1,474,017,870	1,028,930,278	1,883,814,191
04/15/14	653,226	Tax	2,194,034,395	309,566,978	1,165,104,117	719,363,299	1,474,671,096	1,028,930,278	1,884,467,417
04/15/14	803,971	Tax	2,194,838,366	309,566,978	1,165,908,088	719,363,299	1,475,475,067	1,028,930,278	1,885,271,388
04/14/14	11,004,820	Tax	2,205,843,186	309,566,978	1,176,912,908	719,363,299	1,486,479,887	1,028,930,278	1,896,276,208
04/14/14	11,462,143	Tax	2,217,305,328	309,566,978	1,188,375,051	719,363,299	1,497,942,029	1,028,930,278	1,907,738,350
04/11/14	16,079	Tax	2,217,321,408	309,566,978	1,188,391,130	719,363,299	1,497,958,108	1,028,930,278	1,907,754,429
04/11/14	125,620	Tax	2,217,447,028	309,566,978	1,188,516,751	719,363,299	1,498,083,729	1,028,930,278	1,907,880,050
04/11/14	7,386,482	Tax	2,224,833,511	309,566,978	1,195,903,233	719,363,299	1,505,470,211	1,028,930,278	1,915,266,532
04/10/14	4,020	Tax	2,224,837,531	309,566,978	1,195,907,253	719,363,299	1,505,474,231	1,028,930,278	1,915,270,552

04/10/14	5,025	Tax	2,224,842,555	309,566,978	1,195,912,278	719,363,299	1,505,479,256	1,028,930,278	1,915,275,577
04/10/14	10,050	Tax	2,224,852,605	309,566,978	1,195,922,327	719,363,299	1,505,489,306	1,028,930,278	1,915,285,627
04/10/14	16,079	Tax	2,224,868,685	309,566,978	1,195,938,407	719,363,299	1,505,505,385	1,028,930,278	1,915,301,706
04/10/14	25,124	Tax	2,224,893,809	309,566,978	1,195,963,531	719,363,299	1,505,530,509	1,028,930,278	1,915,326,830
04/10/14	25,124	Tax	2,224,918,933	309,566,978	1,195,988,655	719,363,299	1,505,555,633	1,028,930,278	1,915,351,954
04/10/14	40,199	Tax	2,224,959,131	309,566,978	1,196,028,853	719,363,299	1,505,595,832	1,028,930,278	1,915,392,153
04/10/14	50,248	Tax	2,225,009,379	309,566,978	1,196,079,102	719,363,299	1,505,646,080	1,028,930,278	1,915,442,401
04/10/14	55,273	Tax	2,225,064,652	309,566,978	1,196,134,375	719,363,299	1,505,701,353	1,028,930,278	1,915,497,674
04/10/14	80,397	Tax	2,225,145,050	309,566,978	1,196,214,772	719,363,299	1,505,781,750	1,028,930,278	1,915,578,071
04/10/14	80,397	Tax	2,225,225,447	309,566,978	1,196,295,169	719,363,299	1,505,862,147	1,028,930,278	1,915,658,468
04/10/14	80,397	Tax	2,225,305,844	309,566,978	1,196,375,566	719,363,299	1,505,942,544	1,028,930,278	1,915,738,865
04/10/14	160,794	Tax	2,225,466,638	309,566,978	1,196,536,360	719,363,299	1,506,103,338	1,028,930,278	1,915,899,659
04/10/14	160,794	Tax	2,225,627,432	309,566,978	1,196,697,154	719,363,299	1,506,264,133	1,028,930,278	1,916,060,454
04/10/14	175,869	Tax	2,225,803,301	309,566,978	1,196,873,023	719,363,299	1,506,440,001	1,028,930,278	1,916,236,322
04/10/14	200,993	Tax	2,226,004,293	309,566,978	1,197,074,016	719,363,299	1,506,640,994	1,028,930,278	1,916,437,315
04/10/14	200,993	Tax	2,226,205,286	309,566,978	1,197,275,008	719,363,299	1,506,841,987	1,028,930,278	1,916,638,308
04/10/14	276,930	Tax	2,226,482,216	309,566,978	1,197,551,938	719,363,299	1,507,118,917	1,028,930,278	1,916,915,237
04/10/14	286,415	Tax	2,226,768,631	309,566,978	1,197,838,353	719,363,299	1,507,405,331	1,028,930,278	1,917,201,652
04/10/14	401,985	Tax	2,227,170,616	309,566,978	1,198,240,338	719,363,299	1,507,807,317	1,028,930,278	1,917,603,638
04/10/14	443,086	Tax	2,227,613,702	309,566,978	1,198,683,425	719,363,299	1,508,250,403	1,028,930,278	1,918,046,724
04/10/14	552,730	Tax	2,228,166,432	309,566,978	1,199,236,155	719,363,299	1,508,803,133	1,028,930,278	1,918,599,454
04/10/14	954,715	Tax	2,229,121,148	309,566,978	1,200,190,870	719,363,299	1,509,757,848	1,028,930,278	1,919,554,169
04/10/14	954,715	Tax	2,230,075,863	309,566,978	1,201,145,585	719,363,299	1,510,712,564	1,028,930,278	1,920,508,885
04/10/14	1,054,743	Tax	2,231,130,607	309,566,978	1,202,200,329	719,363,299	1,511,767,307	1,028,930,278	1,921,563,628
04/10/14	1,099,903	Tax	2,232,230,509	309,566,978	1,203,300,231	719,363,299	1,512,867,210	1,028,930,278	1,922,663,531
04/10/14	12,059,563	Tax	2,244,290,072	309,566,978	1,215,359,795	719,363,299	1,524,926,773	1,028,930,278	1,934,723,094
04/10/14	12,562,045	Tax	2,256,852,117	309,566,978	1,227,921,840	719,363,299	1,537,488,818	1,028,930,278	1,947,285,139
04/09/14	5,025	Tax	2,256,857,142	309,566,978	1,227,926,865	719,363,299	1,537,493,843	1,028,930,278	1,947,290,164
04/09/14	40,199	Tax	2,256,897,341	309,566,978	1,227,967,063	719,363,299	1,537,534,041	1,028,930,278	1,947,330,362
04/09/14	80,397	Tax	2,256,977,738	309,566,978	1,228,047,460	719,363,299	1,537,614,439	1,028,930,278	1,947,410,760
04/08/14	7,500,000	Ex U.S.	2,264,477,738	309,566,978	1,228,047,460	726,863,299	1,537,614,439	1,036,430,278	1,954,910,760
04/02/14	45,474,603	U.S. Partner	2,309,952,341	355,041,581	1,228,047,460	726,863,299	1,583,089,042	1,081,904,881	1,954,910,760
04/02/14	45,474,603	U.S. Partner	2,355,426,944	400,516,185	1,228,047,460	726,863,299	1,628,563,645	1,127,379,484	1,954,910,760
03/27/14	551,100	Ex U.S.	2,355,978,044	400,516,185	1,228,047,460	727,414,399	1,628,563,645	1,127,930,584	1,955,461,860
03/27/14	757,763	Ex U.S.	2,356,735,807	400,516,185	1,228,047,460	728,172,162	1,628,563,645	1,128,688,346	1,956,219,622
03/25/14	275,550	Ex U.S.	2,357,011,357	400,516,185	1,228,047,460	728,447,712	1,628,563,645	1,128,963,896	1,956,495,172
03/25/14	413,325	Ex U.S.	2,357,424,682	400,516,185	1,228,047,460	728,861,037	1,628,563,645	1,129,377,221	1,956,908,497
03/25/14	413,325	Ex U.S.	2,357,838,007	400,516,185	1,228,047,460	729,274,362	1,628,563,645	1,129,790,546	1,957,321,822
03/25/14	1,377,750	Ex U.S.	2,359,215,757	400,516,185	1,228,047,460	730,652,112	1,628,563,645	1,131,168,296	1,958,699,572
03/25/14	2,548,838	Ex U.S.	2,361,764,594	400,516,185	1,228,047,460	733,200,949	1,628,563,645	1,133,717,134	1,961,248,410
03/25/14	5,511,000	Ex U.S.	2,367,275,594	400,516,185	1,228,047,460	738,711,949	1,628,563,645	1,139,228,134	1,966,759,410
03/25/14	6,199,875	Ex U.S.	2,373,475,469	400,516,185	1,228,047,460	744,911,824	1,628,563,645	1,145,428,009	1,972,959,285
03/21/14	1,300,000	Ex U.S.	2,374,775,469	400,516,185	1,228,047,460	746,211,824	1,628,563,645	1,146,728,009	1,974,259,285
03/21/14	2,700,000	Ex U.S.	2,377,475,469	400,516,185	1,228,047,460	748,911,824	1,628,563,645	1,149,428,009	1,976,959,285
03/21/14	2,700,000	Ex U.S.	2,380,175,469	400,516,185	1,228,047,460	751,611,824	1,628,563,645	1,152,128,009	1,979,659,285
03/17/14	2,100,000	Ex U.S.	2,382,275,469	400,516,185	1,228,047,460	753,711,824	1,628,563,645	1,154,228,009	1,981,759,285
03/10/14	1,155,708	Ex U.S.	2,383,431,177	400,516,185	1,228,047,460	754,867,533	1,628,563,645	1,155,383,717	1,982,914,993
03/10/14	1,155,708	Ex U.S.	2,384,586,885	400,516,185	1,228,047,460	756,023,241	1,628,563,645	1,156,539,425	1,984,070,701
03/05/14	3,870,000	Ex U.S.	2,388,456,885	400,516,185	1,228,047,460	759,893,241	1,628,563,645	1,160,409,425	1,987,940,701

03/05/14	6,500,000	Ex U.S.	2,394,956,885	400,516,185	1,228,047,460	766,393,241	1,628,563,645	1,166,909,425	1,994,440,701
02/19/14	305,865	Ex U.S.	2,395,262,750	400,516,185	1,228,047,460	766,699,106	1,628,563,645	1,167,215,290	1,994,746,566
01/30/14	1,200,000	Ex U.S.	2,396,462,750	400,516,185	1,228,047,460	767,899,106	1,628,563,645	1,168,415,290	1,995,946,566
01/23/14	1,250,000	Ex U.S.	2,397,712,750	400,516,185	1,228,047,460	769,149,106	1,628,563,645	1,169,665,290	1,997,196,566
01/23/14	1,250,000	Ex U.S.	2,398,962,750	400,516,185	1,228,047,460	770,399,106	1,628,563,645	1,170,915,290	1,998,446,566
01/23/14	3,000,000	Ex U.S.	2,401,962,750	400,516,185	1,228,047,460	773,399,106	1,628,563,645	1,173,915,290	2,001,446,566
01/23/14	3,000,000	Ex U.S.	2,404,962,750	400,516,185	1,228,047,460	776,399,106	1,628,563,645	1,176,915,290	2,004,446,566
01/08/14	4,336,418	Tax	2,409,299,168	400,516,185	1,232,383,878	776,399,106	1,632,900,063	1,176,915,290	2,008,782,984
01/08/14	5,024,818	U.S. Partner	2,414,323,986	405,541,003	1,232,383,878	776,399,106	1,637,924,881	1,181,940,108	2,008,782,984
01/08/14	5,024,818	U.S. Partner	2,419,348,804	410,565,821	1,232,383,878	776,399,106	1,642,949,699	1,186,964,926	2,008,782,984
01/02/14	386,911	Tax	2,419,735,715	410,565,821	1,232,770,789	776,399,106	1,643,336,610	1,186,964,926	2,009,169,895
01/02/14	4,723,329	Tax	2,424,459,044	410,565,821	1,237,494,118	776,399,106	1,648,059,939	1,186,964,926	2,013,893,224
12/31/13	-20,235,500	U.S. Partner	2,404,223,544	390,330,321	1,237,494,118	776,399,106	1,627,824,439	1,166,729,426	2,013,893,224
12/24/13	226,117	Tax	2,404,449,661	390,330,321	1,237,720,235	776,399,106	1,628,050,555	1,166,729,426	2,014,119,341
12/24/13	226,117	Tax	2,404,675,778	390,330,321	1,237,946,352	776,399,106	1,628,276,672	1,166,729,426	2,014,345,457
12/23/13	200,993	Tax	2,404,876,771	390,330,321	1,238,147,344	776,399,106	1,628,477,665	1,166,729,426	2,014,546,450
12/20/13	887,900	Ex U.S.	2,405,764,671	390,330,321	1,238,147,344	777,287,006	1,628,477,665	1,167,617,326	2,015,434,350
12/20/13	6,830,000	Ex U.S.	2,412,594,671	390,330,321	1,238,147,344	784,117,006	1,628,477,665	1,174,447,326	2,022,264,350
12/20/13	9,562,000	Ex U.S.	2,422,156,671	390,330,321	1,238,147,344	793,679,006	1,628,477,665	1,184,009,326	2,031,826,350
12/20/13	12,977,000	Ex U.S.	2,435,133,671	390,330,321	1,238,147,344	806,656,006	1,628,477,665	1,196,986,326	2,044,803,350
12/17/13	653,226	Tax	2,435,786,897	390,330,321	1,238,800,571	806,656,006	1,629,130,891	1,196,986,326	2,045,456,576
12/17/13	27,385,258	Tax	2,463,172,155	390,330,321	1,266,185,829	806,656,006	1,656,516,149	1,196,986,326	2,072,841,835
12/11/13	10,050	Tax	2,463,182,205	390,330,321	1,266,195,879	806,656,006	1,656,526,199	1,196,986,326	2,072,851,884
12/11/13	50,248	Tax	2,463,232,453	390,330,321	1,266,246,127	806,656,006	1,656,576,447	1,196,986,326	2,072,902,132
12/11/13	55,273	Tax	2,463,287,726	390,330,321	1,266,301,400	806,656,006	1,656,631,720	1,196,986,326	2,072,957,405
12/11/13	75,372	Tax	2,463,363,098	390,330,321	1,266,376,772	806,656,006	1,656,707,093	1,196,986,326	2,073,032,778
12/11/13	301,489	Tax	2,463,664,587	390,330,321	1,266,678,261	806,656,006	1,657,008,582	1,196,986,326	2,073,334,267
12/11/13	6,987,510	Ex U.S.	2,470,652,097	390,330,321	1,266,678,261	813,643,516	1,657,008,582	1,203,973,836	2,080,321,777
12/11/13	15,074,454	Tax	2,485,726,551	390,330,321	1,281,752,715	813,643,516	1,672,083,036	1,203,973,836	2,095,396,231
12/11/13	15,074,454	Tax	2,500,801,005	390,330,321	1,296,827,169	813,643,516	1,687,157,490	1,203,973,836	2,110,470,685
12/11/13	27,385,258	Tax	2,528,186,264	390,330,321	1,324,212,427	813,643,516	1,714,542,748	1,203,973,836	2,137,855,943
12/10/13	55,273	Tax	2,528,241,537	390,330,321	1,324,267,700	813,643,516	1,714,598,021	1,203,973,836	2,137,911,216
12/10/13	55,273	Tax	2,528,296,810	390,330,321	1,324,322,973	813,643,516	1,714,653,294	1,203,973,836	2,137,966,489
12/10/13	73,865	Ex U.S.	2,528,370,674	390,330,321	1,324,322,973	813,717,380	1,714,653,294	1,204,047,701	2,138,040,354
12/10/13	73,865	Ex U.S.	2,528,444,539	390,330,321	1,324,322,973	813,791,245	1,714,653,294	1,204,121,566	2,138,114,219
12/10/13	85,422	Tax	2,528,529,961	390,330,321	1,324,408,395	813,791,245	1,714,738,716	1,204,121,566	2,138,199,641
12/10/13	85,422	Tax	2,528,615,383	390,330,321	1,324,493,817	813,791,245	1,714,824,138	1,204,121,566	2,138,285,063
12/10/13	135,670	Tax	2,528,751,053	390,330,321	1,324,629,487	813,791,245	1,714,959,808	1,204,121,566	2,138,420,733
12/10/13	1,323,000	Ex U.S.	2,530,074,053	390,330,321	1,324,629,487	815,114,245	1,714,959,808	1,205,444,566	2,139,743,733
12/10/13	2,210,920	Tax	2,532,284,973	390,330,321	1,326,840,407	815,114,245	1,717,170,728	1,205,444,566	2,141,954,653
12/10/13	2,210,920	Tax	2,534,495,893	390,330,321	1,329,051,327	815,114,245	1,719,381,648	1,205,444,566	2,144,165,572
12/05/13	55,273	Tax	2,534,551,166	390,330,321	1,329,106,600	815,114,245	1,719,436,921	1,205,444,566	2,144,220,845
12/05/13	100,496	Tax	2,534,651,662	390,330,321	1,329,207,097	815,114,245	1,719,537,417	1,205,444,566	2,144,321,342
12/05/13	2,800,000	Ex U.S.	2,537,451,662	390,330,321	1,329,207,097	817,914,245	1,719,537,417	1,208,244,566	2,147,121,342
11/20/13	3,000,000	Ex U.S.	2,540,451,662	390,330,321	1,329,207,097	820,914,245	1,719,537,417	1,211,244,566	2,150,121,342
11/20/13	3,000,000	Ex U.S.	2,543,451,662	390,330,321	1,329,207,097	823,914,245	1,719,537,417	1,214,244,566	2,153,121,342
11/19/13	550,000	Ex U.S.	2,544,001,662	390,330,321	1,329,207,097	824,464,245	1,719,537,417	1,214,794,566	2,153,671,342
11/19/13	700,000	Ex U.S.	2,544,701,662	390,330,321	1,329,207,097	825,164,245	1,719,537,417	1,215,494,566	2,154,371,342
10/28/13	759,605	Ex U.S.	2,545,461,267	390,330,321	1,329,207,097	825,923,850	1,719,537,417	1,216,254,171	2,155,130,947

10/28/13	5,179,125	Ex U.S.	2,550,640,392	390,330,321	1,329,207,097	831,102,975	1,719,537,417	1,221,433,296	2,160,310,072
10/28/13	10,634,470	Ex U.S.	2,561,274,862	390,330,321	1,329,207,097	841,737,445	1,719,537,417	1,232,067,766	2,170,944,542
10/28/13	14,708,715	Ex U.S.	2,575,983,577	390,330,321	1,329,207,097	856,446,160	1,719,537,417	1,246,776,481	2,185,653,257
10/28/13	20,852,995	Tax	2,596,836,572	390,330,321	1,350,060,091	856,446,160	1,740,390,412	1,246,776,481	2,206,506,252
10/23/13	890,000	Ex U.S.	2,597,726,572	390,330,321	1,350,060,091	857,336,160	1,740,390,412	1,247,666,481	2,207,396,252
10/23/13	1,007,728	Ex U.S.	2,598,734,300	390,330,321	1,350,060,091	858,343,888	1,740,390,412	1,248,674,209	2,208,403,980
10/18/13	678,350	Tax	2,599,412,651	390,330,321	1,350,738,442	858,343,888	1,741,068,762	1,248,674,209	2,209,082,330
10/18/13	678,350	Tax	2,600,091,001	390,330,321	1,351,416,792	858,343,888	1,741,747,113	1,248,674,209	2,209,760,680
10/18/13	20,852,995	Tax	2,620,943,996	390,330,321	1,372,269,787	858,343,888	1,762,600,107	1,248,674,209	2,230,613,675
10/18/13	65,573,875	U.S. Partner	2,686,517,871	455,904,196	1,372,269,787	858,343,888	1,828,173,983	1,314,248,084	2,230,613,675
10/18/13	65,573,875	U.S. Partner	2,752,091,746	521,478,071	1,372,269,787	858,343,888	1,893,747,858	1,379,821,959	2,230,613,675
10/16/13	5,024,818	U.S. Partner	2,757,116,564	526,502,889	1,372,269,787	858,343,888	1,898,772,676	1,384,846,777	2,230,613,675
10/16/13	5,024,818	U.S. Partner	2,762,141,382	531,527,707	1,372,269,787	858,343,888	1,903,797,494	1,389,871,595	2,230,613,675
09/27/13	700,000	Ex U.S.	2,762,841,382	531,527,707	1,372,269,787	859,043,888	1,903,797,494	1,390,571,595	2,231,313,675
09/27/13	700,000	Ex U.S.	2,763,541,382	531,527,707	1,372,269,787	859,743,888	1,903,797,494	1,391,271,595	2,232,013,675
09/27/13	2,500,000	Ex U.S.	2,766,041,382	531,527,707	1,372,269,787	862,343,888	1,903,797,494	1,393,771,595	2,234,513,675
09/27/13	2,500,000	Ex U.S.	2,768,541,382	531,527,707	1,372,269,787	864,743,888	1,903,797,494	1,396,271,595	2,237,013,675
09/17/13	1,460,000	Ex U.S.	2,770,001,382	531,527,707	1,372,269,787	866,203,888	1,903,797,494	1,397,731,595	2,238,473,675
09/17/13	1,650,000	Ex U.S.	2,771,651,382	531,527,707	1,372,269,787	867,853,888	1,903,797,494	1,399,381,595	2,240,123,675
09/17/13	1,758,686	Tax	2,773,410,068	531,527,707	1,374,028,473	867,853,888	1,905,556,180	1,399,381,595	2,241,882,362
09/13/13	46,228,326	Tax	2,819,638,394	531,527,707	1,420,256,799	867,853,888	1,951,784,506	1,399,381,595	2,288,110,687
09/11/13	50,248	Tax	2,819,688,642	531,527,707	1,420,307,047	867,853,888	1,951,834,754	1,399,381,595	2,288,160,935
09/11/13	50,248	Tax	2,819,738,891	531,527,707	1,420,357,295	867,853,888	1,951,885,002	1,399,381,595	2,288,211,184
09/11/13	147,730	Ex U.S.	2,819,886,620	531,527,707	1,420,357,295	868,001,618	1,951,885,002	1,399,529,325	2,288,358,913
09/11/13	147,730	Ex U.S.	2,820,034,350	531,527,707	1,420,357,295	868,149,348	1,951,885,002	1,399,677,054	2,288,506,643
09/11/13	1,507,445	Tax	2,821,541,795	531,527,707	1,421,864,741	868,149,348	1,953,392,448	1,399,677,054	2,290,014,088
09/11/13	1,507,445	Tax	2,823,049,241	531,527,707	1,423,372,186	868,149,348	1,954,899,893	1,399,677,054	2,291,521,534
09/11/13	2,646,000	Ex U.S.	2,825,695,241	531,527,707	1,423,372,186	870,795,348	1,954,899,893	1,402,323,054	2,294,167,534
09/11/13	46,228,326	Tax	2,871,923,566	531,527,707	1,469,600,512	870,795,348	2,001,128,219	1,402,323,054	2,340,395,860
09/10/13	200,993	Tax	2,872,124,559	531,527,707	1,469,801,505	870,795,348	2,001,329,211	1,402,323,054	2,340,596,852
08/26/13	837,500	Ex U.S.	2,872,962,059	531,527,707	1,469,801,505	871,632,848	2,001,329,211	1,403,160,554	2,341,434,352
08/26/13	837,500	Ex U.S.	2,873,799,559	531,527,707	1,469,801,505	872,470,348	2,001,329,211	1,403,998,054	2,342,271,852
08/26/13	2,500,000	Ex U.S.	2,876,299,559	531,527,707	1,469,801,505	874,970,348	2,001,329,211	1,406,498,054	2,344,771,852
08/20/13	9,700,000	Ex U.S.	2,885,999,559	531,527,707	1,469,801,505	884,670,348	2,001,329,211	1,416,198,054	2,354,471,852
08/07/13	1,333,900	Ex U.S.	2,887,333,459	531,527,707	1,469,801,505	886,004,248	2,001,329,211	1,417,531,954	2,355,805,752
08/07/13	12,138,490	Ex U.S.	2,899,471,949	531,527,707	1,469,801,505	898,142,738	2,001,329,211	1,429,670,444	2,367,944,242
07/25/13	800,000	Ex U.S.	2,900,271,949	531,527,707	1,469,801,505	898,942,738	2,001,329,211	1,430,470,444	2,368,744,242
07/17/13	2,000,000	Ex U.S.	2,902,271,949	531,527,707	1,469,801,505	900,942,738	2,001,329,211	1,432,470,444	2,370,744,242
07/10/13	1,283,800	Ex U.S.	2,903,555,749	531,527,707	1,469,801,505	902,226,538	2,001,329,211	1,433,754,244	2,372,028,042
07/10/13	4,500,000	Ex U.S.	2,908,055,749	531,527,707	1,469,801,505	906,726,538	2,001,329,211	1,438,254,244	2,376,528,042
07/10/13	4,500,000	Ex U.S.	2,912,555,749	531,527,707	1,469,801,505	911,226,538	2,001,329,211	1,442,754,244	2,381,028,042
07/10/13	14,121,800	Ex U.S.	2,926,677,549	531,527,707	1,469,801,505	925,348,338	2,001,329,211	1,456,876,044	2,395,149,842
07/09/13	700,000	Ex U.S.	2,927,377,549	531,527,707	1,469,801,505	926,048,338	2,001,329,211	1,457,576,044	2,395,849,842
07/09/13	21,104,236	U.S. Partner	2,948,481,785	552,631,943	1,469,801,505	926,048,338	2,022,433,447	1,478,680,280	2,395,849,842
07/09/13	21,104,236	U.S. Partner	2,969,586,020	573,736,178	1,469,801,505	926,048,338	2,043,537,683	1,499,784,516	2,395,849,842
06/25/13	39,136	Tax	2,969,625,157	573,736,178	1,469,840,641	926,048,338	2,043,576,819	1,499,784,516	2,395,888,979
06/25/13	884,384	Tax	2,970,509,541	573,736,178	1,470,725,025	926,048,338	2,044,461,203	1,499,784,516	2,396,773,363
06/21/13	573,608	Tax	2,971,083,149	573,736,178	1,471,298,633	926,048,338	2,045,034,811	1,499,784,516	2,397,346,971
06/21/13	884,384	Tax	2,971,967,533	573,736,178	1,472,183,017	926,048,338	2,045,919,195	1,499,784,516	2,398,231,355

06/21/13	904,467	Tax	2,972,872,000	573,736,178	1,473,087,484	926,048,338	2,046,823,663	1,499,784,516	2,399,135,822
06/19/13	147,730	Ex U.S.	2,973,019,730	573,736,178	1,473,087,484	926,196,067	2,046,823,663	1,499,932,245	2,399,283,552
06/19/13	147,730	Ex U.S.	2,973,167,459	573,736,178	1,473,087,484	926,343,797	2,046,823,663	1,500,079,975	2,399,431,281
06/19/13	2,512,409	Tax	2,975,679,868	573,736,178	1,475,599,893	926,343,797	2,049,336,072	1,500,079,975	2,401,943,690
06/18/13	2,646,000	Ex U.S.	2,978,325,868	573,736,178	1,475,599,893	928,989,797	2,049,336,072	1,502,725,975	2,404,589,690
06/17/13	31,153,872	Tax	3,009,479,740	573,736,178	1,506,753,765	928,989,797	2,080,489,943	1,502,725,975	2,435,743,562
06/17/13	31,153,872	Tax	3,040,633,612	573,736,178	1,537,907,637	928,989,797	2,111,643,815	1,502,725,975	2,466,897,434
06/12/13	100,496	Tax	3,040,734,108	573,736,178	1,538,008,133	928,989,797	2,111,744,311	1,502,725,975	2,466,997,930
06/12/13	100,496	Tax	3,040,834,605	573,736,178	1,538,108,630	928,989,797	2,111,844,808	1,502,725,975	2,467,098,426
06/12/13	200,993	Tax	3,041,035,597	573,736,178	1,538,309,622	928,989,797	2,112,045,800	1,502,725,975	2,467,299,419
06/12/13	200,993	Tax	3,041,236,590	573,736,178	1,538,510,615	928,989,797	2,112,246,793	1,502,725,975	2,467,500,412
06/12/13	226,117	Tax	3,041,462,707	573,736,178	1,538,736,732	928,989,797	2,112,472,910	1,502,725,975	2,467,726,529
06/12/13	251,241	Tax	3,041,713,948	573,736,178	1,538,987,973	928,989,797	2,112,724,151	1,502,725,975	2,467,977,770
06/12/13	251,241	Tax	3,041,965,189	573,736,178	1,539,239,214	928,989,797	2,112,975,392	1,502,725,975	2,468,229,010
06/12/13	326,613	Tax	3,042,291,802	573,736,178	1,539,565,827	928,989,797	2,113,302,005	1,502,725,975	2,468,555,624
06/12/13	2,512,409	Tax	3,044,804,211	573,736,178	1,542,078,236	928,989,797	2,115,814,414	1,502,725,975	2,471,068,033
06/12/13	2,512,409	Tax	3,047,316,620	573,736,178	1,544,590,645	928,989,797	2,118,326,823	1,502,725,975	2,473,580,442
06/11/13	317,038	Tax	3,047,633,658	573,736,178	1,544,907,683	928,989,797	2,118,643,861	1,502,725,975	2,473,897,480
06/06/13	317,038	Tax	3,047,950,696	573,736,178	1,545,224,721	928,989,797	2,118,960,899	1,502,725,975	2,474,214,517
05/30/13	750,000	Ex U.S.	3,048,700,696	573,736,178	1,545,224,721	929,739,797	2,118,960,899	1,503,475,975	2,474,964,517
05/30/13	750,000	Ex U.S.	3,049,450,696	573,736,178	1,545,224,721	930,489,797	2,118,960,899	1,504,225,975	2,475,714,517
05/29/13	5,024,818	U.S. Partner	3,054,475,514	578,760,996	1,545,224,721	930,489,797	2,123,985,717	1,509,250,793	2,475,714,517
05/29/13	5,024,818	U.S. Partner	3,059,500,332	583,785,814	1,545,224,721	930,489,797	2,129,010,535	1,514,275,611	2,475,714,517
05/21/13	600,000	Ex U.S.	3,060,100,332	583,785,814	1,545,224,721	931,089,797	2,129,010,535	1,514,875,611	2,476,314,517
04/30/13	3,027,416	U.S. Partner	3,063,127,747	586,813,230	1,545,224,721	931,089,797	2,132,037,950	1,517,903,027	2,476,314,517
04/22/13	1,720,752	Ex U.S.	3,064,848,499	586,813,230	1,545,224,721	932,810,549	2,132,037,950	1,519,623,779	2,478,035,269
04/18/13	20,099	Tax	3,064,868,599	586,813,230	1,545,244,820	932,810,549	2,132,058,050	1,519,623,779	2,478,055,369
04/16/13	351,737	Tax	3,065,220,336	586,813,230	1,545,596,557	932,810,549	2,132,409,787	1,519,623,779	2,478,407,106
04/16/13	904,467	Tax	3,066,124,803	586,813,230	1,546,501,024	932,810,549	2,133,314,254	1,519,623,779	2,479,311,573
04/15/13	80,397	Tax	3,066,205,200	586,813,230	1,546,581,421	932,810,549	2,133,394,651	1,519,623,779	2,479,391,970
04/15/13	341,688	Tax	3,066,546,888	586,813,230	1,546,923,109	932,810,549	2,133,736,339	1,519,623,779	2,479,733,658
04/15/13	341,688	Tax	3,066,888,575	586,813,230	1,547,264,797	932,810,549	2,134,078,026	1,519,623,779	2,480,075,346
04/12/13	150,745	Tax	3,067,039,320	586,813,230	1,547,415,541	932,810,549	2,134,228,771	1,519,623,779	2,480,226,090
04/12/13	31,153,872	Tax	3,098,193,192	586,813,230	1,578,569,413	932,810,549	2,165,382,643	1,519,623,779	2,511,379,962
04/11/13	2,512,409	Tax	3,100,705,601	586,813,230	1,581,081,822	932,810,549	2,167,895,052	1,519,623,779	2,513,892,371
04/11/13	2,512,409	Tax	3,103,218,010	586,813,230	1,583,594,231	932,810,549	2,170,407,461	1,519,623,779	2,516,404,780
04/11/13	31,153,872	Tax	3,134,371,881	586,813,230	1,614,748,103	932,810,549	2,201,561,332	1,519,623,779	2,547,558,652
04/10/13	1,507	Tax	3,134,373,389	586,813,230	1,614,749,610	932,810,549	2,201,562,840	1,519,623,779	2,547,560,159
04/10/13	1,507	Tax	3,134,374,896	586,813,230	1,614,751,118	932,810,549	2,201,564,347	1,519,623,779	2,547,561,666
04/10/13	18,089	Tax	3,134,392,986	586,813,230	1,614,769,207	932,810,549	2,201,582,437	1,519,623,779	2,547,579,756
04/10/13	40,134	Tax	3,134,433,120	586,813,230	1,614,809,341	932,810,549	2,201,622,571	1,519,623,779	2,547,619,890
04/10/13	65,134	Tax	3,134,498,253	586,813,230	1,614,874,475	932,810,549	2,201,687,705	1,519,623,779	2,547,685,024
04/10/13	150,745	Tax	3,134,648,998	586,813,230	1,615,025,219	932,810,549	2,201,838,449	1,519,623,779	2,547,835,768
04/10/13	8,341,198	Tax	3,142,990,196	586,813,230	1,623,366,417	932,810,549	2,210,179,647	1,519,623,779	2,556,176,966
04/09/13	15,074	Tax	3,143,005,270	586,813,230	1,623,381,492	932,810,549	2,210,194,721	1,519,623,779	2,556,192,041
04/09/13	25,124	Tax	3,143,030,394	586,813,230	1,623,406,616	932,810,549	2,210,219,846	1,519,623,779	2,556,217,165
04/09/13	25,124	Tax	3,143,055,519	586,813,230	1,623,431,740	932,810,549	2,210,244,970	1,519,623,779	2,556,242,289
04/09/13	50,248	Tax	3,143,105,767	586,813,230	1,623,481,988	932,810,549	2,210,295,218	1,519,623,779	2,556,292,537
04/09/13	50,248	Tax	3,143,156,015	586,813,230	1,623,532,236	932,810,549	2,210,345,466	1,519,623,779	2,556,342,785

04/09/13	125,620	Tax	3,143,281,635	586,813,230	1,623,657,857	932,810,549	2,210,471,086	1,519,623,779	2,556,468,406
04/09/13	125,620	Tax	3,143,407,256	586,813,230	1,623,783,477	932,810,549	2,210,596,707	1,519,623,779	2,556,594,026
04/09/13	200,993	Tax	3,143,608,249	586,813,230	1,623,984,470	932,810,549	2,210,797,700	1,519,623,779	2,556,795,019
04/09/13	251,241	Tax	3,143,859,489	586,813,230	1,624,235,711	932,810,549	2,211,048,941	1,519,623,779	2,557,046,260
04/09/13	251,241	Tax	3,144,110,730	586,813,230	1,624,486,952	932,810,549	2,211,300,181	1,519,623,779	2,557,297,501
04/09/13	301,489	Tax	3,144,412,219	586,813,230	1,624,788,441	932,810,549	2,211,601,671	1,519,623,779	2,557,598,990
04/09/13	301,489	Tax	3,144,713,709	586,813,230	1,625,089,930	932,810,549	2,211,903,160	1,519,623,779	2,557,900,479
04/09/13	301,489	Tax	3,145,015,198	586,813,230	1,625,391,419	932,810,549	2,212,204,649	1,519,623,779	2,558,201,968
04/09/13	326,613	Tax	3,145,341,811	586,813,230	1,625,718,032	932,810,549	2,212,531,262	1,519,623,779	2,558,528,581
04/09/13	457,258	Tax	3,145,799,069	586,813,230	1,626,175,291	932,810,549	2,212,988,520	1,519,623,779	2,558,985,839
04/09/13	457,258	Tax	3,146,256,328	586,813,230	1,626,632,549	932,810,549	2,213,445,779	1,519,623,779	2,559,443,098
04/09/13	2,512,409	Tax	3,148,768,737	586,813,230	1,629,144,958	932,810,549	2,215,958,188	1,519,623,779	2,561,955,507
04/05/13	61,035,339	U.S. Partner	3,209,804,076	647,848,569	1,629,144,958	932,810,549	2,276,993,527	1,580,659,118	2,561,955,507
04/05/13	61,035,339	U.S. Partner	3,270,839,414	708,883,908	1,629,144,958	932,810,549	2,338,028,866	1,641,694,456	2,561,955,507
03/28/13	2,000,000	Ex U.S.	3,272,839,414	708,883,908	1,629,144,958	934,810,549	2,338,028,866	1,643,694,456	2,563,955,507
03/28/13	4,600,000	Ex U.S.	3,277,439,414	708,883,908	1,629,144,958	939,410,549	2,338,028,866	1,648,294,456	2,568,555,507
03/28/13	8,400,000	Ex U.S.	3,285,839,414	708,883,908	1,629,144,958	947,810,549	2,338,028,866	1,656,694,456	2,576,955,507
03/25/13	452,234	Tax	3,286,291,648	708,883,908	1,629,597,192	947,810,549	2,338,481,099	1,656,694,456	2,577,407,740
03/25/13	4,120,351	Tax	3,290,411,999	708,883,908	1,633,717,542	947,810,549	2,342,601,450	1,656,694,456	2,581,528,091
03/21/13	40,199	Tax	3,290,452,197	708,883,908	1,633,757,741	947,810,549	2,342,641,648	1,656,694,456	2,581,568,290
03/21/13	4,160,549	Tax	3,294,612,747	708,883,908	1,637,918,290	947,810,549	2,346,802,198	1,656,694,456	2,585,728,839
02/28/13	65,315	Ex U.S.	3,294,678,062	708,883,908	1,637,918,290	947,875,864	2,346,802,198	1,656,759,771	2,585,794,154
02/28/13	84,910	Ex U.S.	3,294,762,971	708,883,908	1,637,918,290	947,960,773	2,346,802,198	1,656,844,681	2,585,879,064
02/28/13	195,945	Ex U.S.	3,294,958,916	708,883,908	1,637,918,290	948,156,718	2,346,802,198	1,657,040,626	2,586,075,009
02/28/13	522,520	Ex U.S.	3,295,481,436	708,883,908	1,637,918,290	948,679,238	2,346,802,198	1,657,563,146	2,586,597,529
02/28/13	1,045,040	Ex U.S.	3,296,526,476	708,883,908	1,637,918,290	949,724,278	2,346,802,198	1,658,608,186	2,587,642,569
02/28/13	1,306,300	Ex U.S.	3,297,832,776	708,883,908	1,637,918,290	951,030,578	2,346,802,198	1,659,914,486	2,588,948,869
02/28/13	1,567,560	Ex U.S.	3,299,400,336	708,883,908	1,637,918,290	952,598,138	2,346,802,198	1,661,482,046	2,590,516,429
02/28/13	4,963,940	Ex U.S.	3,304,364,276	708,883,908	1,637,918,290	957,562,078	2,346,802,198	1,666,445,986	2,595,480,369
02/28/13	9,274,730	Ex U.S.	3,313,639,006	708,883,908	1,637,918,290	966,836,808	2,346,802,198	1,675,720,716	2,604,755,099
02/28/13	11,885,524	Ex U.S.	3,325,524,530	708,883,908	1,637,918,290	978,722,332	2,346,802,198	1,687,606,240	2,616,640,622
02/27/13	98,486	Ex U.S.	3,325,623,016	708,883,908	1,637,918,290	978,820,818	2,346,802,198	1,687,704,726	2,616,739,109
02/27/13	98,486	Ex U.S.	3,325,721,503	708,883,908	1,637,918,290	978,919,305	2,346,802,198	1,687,803,212	2,616,837,595
02/27/13	1,764,000	Ex U.S.	3,327,485,503	708,883,908	1,637,918,290	980,683,305	2,346,802,198	1,689,567,212	2,618,601,595
02/21/13	1,472,272	Ex U.S.	3,328,957,774	708,883,908	1,637,918,290	982,155,577	2,346,802,198	1,691,039,484	2,620,073,867
02/21/13	1,472,272	Ex U.S.	3,330,430,046	708,883,908	1,637,918,290	983,627,848	2,346,802,198	1,692,511,756	2,621,546,138
02/21/13	1,600,000	Ex U.S.	3,332,030,046	708,883,908	1,637,918,290	985,227,848	2,346,802,198	1,694,111,756	2,623,146,138
02/21/13	20,088,000	Ex U.S.	3,352,118,046	708,883,908	1,637,918,290	1,005,315,848	2,346,802,198	1,714,199,756	2,643,234,138
01/31/13	9,099	Tax	3,352,127,145	708,883,908	1,637,927,389	1,005,315,848	2,346,811,297	1,714,199,756	2,643,243,237
01/31/13	9,329	Tax	3,352,136,474	708,883,908	1,637,936,718	1,005,315,848	2,346,820,626	1,714,199,756	2,643,252,566
01/31/13	12,811	Tax	3,352,149,285	708,883,908	1,637,949,530	1,005,315,848	2,346,833,437	1,714,199,756	2,643,265,378
01/31/13	24,824	Tax	3,352,174,109	708,883,908	1,637,974,353	1,005,315,848	2,346,858,261	1,714,199,756	2,643,290,201
01/31/13	25,631	Tax	3,352,199,739	708,883,908	1,637,999,984	1,005,315,848	2,346,883,891	1,714,199,756	2,643,315,832
01/31/13	32,855	Tax	3,352,232,595	708,883,908	1,638,032,839	1,005,315,848	2,346,916,747	1,714,199,756	2,643,348,687
01/31/13	98,058	Tax	3,352,330,653	708,883,908	1,638,130,897	1,005,315,848	2,347,014,805	1,714,199,756	2,643,446,745
01/30/13	212,607	Tax	3,352,543,260	708,883,908	1,638,343,504	1,005,315,848	2,347,227,412	1,714,199,756	2,643,659,353
01/30/13	836,750	Ex U.S.	3,353,380,010	708,883,908	1,638,343,504	1,006,152,598	2,347,227,412	1,715,036,506	2,644,496,103
01/28/13	400,000	Ex U.S.	3,353,780,010	708,883,908	1,638,343,504	1,006,552,598	2,347,227,412	1,715,436,506	2,644,896,103
01/28/13	1,163,250	Ex U.S.	3,354,943,260	708,883,908	1,638,343,504	1,007,715,848	2,347,227,412	1,716,599,756	2,646,059,353

01/24/13	130,536	Ex U.S.	3,355,073,796	708,883,908	1,638,343,504	1,007,846,384	2,347,227,412	1,716,730,292	2,646,189,889
01/17/13	3,000,000	Ex U.S.	3,358,073,796	708,883,908	1,638,343,504	1,010,846,384	2,347,227,412	1,719,730,292	2,649,189,889
12/31/12	-35,846,302	U.S. Partner	3,322,227,494	673,037,606	1,638,343,504	1,010,846,384	2,311,381,110	1,683,883,990	2,649,189,889
12/31/12	6,000,000	U.S. Partner	3,328,227,494	679,037,606	1,638,343,504	1,010,846,384	2,317,381,110	1,689,883,990	2,649,189,889
12/31/12	6,000,000	U.S. Partner	3,334,227,494	685,037,606	1,638,343,504	1,010,846,384	2,323,381,110	1,695,883,990	2,649,189,889
12/21/12	628,102	Tax	3,334,855,596	685,037,606	1,638,971,607	1,010,846,384	2,324,009,212	1,695,883,990	2,649,817,991
12/21/12	18,591,825	Tax	3,353,447,421	685,037,606	1,657,563,432	1,010,846,384	2,342,601,037	1,695,883,990	2,668,409,816
12/21/12	30,148,905	U.S. Partner	3,383,596,327	715,186,511	1,657,563,432	1,010,846,384	2,372,749,943	1,726,032,895	2,668,409,816
12/21/12	30,148,905	U.S. Partner	3,413,745,232	745,335,416	1,657,563,432	1,010,846,384	2,402,898,848	1,756,181,801	2,668,409,816
12/20/12	10,050	Tax	3,413,755,282	745,335,416	1,657,573,481	1,010,846,384	2,402,908,898	1,756,181,801	2,668,419,865
12/20/12	40,199	Tax	3,413,795,480	745,335,416	1,657,613,680	1,010,846,384	2,402,949,096	1,756,181,801	2,668,460,064
12/20/12	713,524	Tax	3,414,509,005	745,335,416	1,658,327,204	1,010,846,384	2,403,662,620	1,756,181,801	2,669,173,588
12/20/12	713,524	Tax	3,415,222,529	745,335,416	1,659,040,728	1,010,846,384	2,404,376,144	1,756,181,801	2,669,887,112
12/20/12	18,632,024	Tax	3,433,854,552	745,335,416	1,677,672,752	1,010,846,384	2,423,008,168	1,756,181,801	2,688,519,136
12/17/12	2,261,168	Tax	3,436,115,720	745,335,416	1,679,933,919	1,010,846,384	2,425,269,336	1,756,181,801	2,690,780,304
12/17/12	48,238,249	Tax	3,484,353,969	745,335,416	1,728,172,168	1,010,846,384	2,473,507,585	1,756,181,801	2,739,018,552
12/13/12	30,149	Tax	3,484,384,118	745,335,416	1,728,202,317	1,010,846,384	2,473,537,734	1,756,181,801	2,739,048,701
12/13/12	60,298	Tax	3,484,444,416	745,335,416	1,728,262,615	1,010,846,384	2,473,598,031	1,756,181,801	2,739,108,999
12/13/12	351,737	Tax	3,484,796,153	745,335,416	1,728,614,352	1,010,846,384	2,473,949,769	1,756,181,801	2,739,460,736
12/13/12	3,366,628	Tax	3,488,162,781	745,335,416	1,731,980,980	1,010,846,384	2,477,316,396	1,756,181,801	2,742,827,364
12/13/12	3,366,628	Tax	3,491,529,408	745,335,416	1,735,347,608	1,010,846,384	2,480,683,024	1,756,181,801	2,746,193,992
12/13/12	48,238,249	Tax	3,539,767,657	745,335,416	1,783,585,856	1,010,846,384	2,528,921,273	1,756,181,801	2,794,432,241
12/12/12	30,149	Tax	3,539,797,806	745,335,416	1,783,616,005	1,010,846,384	2,528,951,422	1,756,181,801	2,794,462,389
12/11/12	60,298	Tax	3,539,858,104	745,335,416	1,783,676,303	1,010,846,384	2,529,011,720	1,756,181,801	2,794,522,687
10/25/12	91,231	Ex U.S.	3,539,949,335	745,335,416	1,783,676,303	1,010,937,615	2,529,011,720	1,756,273,032	2,794,613,918
10/25/12	1,019,439	Ex U.S.	3,540,968,774	745,335,416	1,783,676,303	1,011,957,054	2,529,011,720	1,757,292,471	2,795,633,357
10/18/12	79,844,351	U.S. Partner	3,620,813,125	825,179,768	1,783,676,303	1,011,957,054	2,608,856,071	1,837,136,822	2,795,633,357
10/18/12	79,844,351	U.S. Partner	3,700,657,476	905,024,119	1,783,676,303	1,011,957,054	2,688,700,422	1,916,981,173	2,795,633,357
10/17/12	3,740,910	Ex U.S.	3,704,398,386	905,024,119	1,783,676,303	1,015,697,964	2,688,700,422	1,920,722,083	2,799,374,267
10/17/12	4,462,840	Ex U.S.	3,708,861,226	905,024,119	1,783,676,303	1,020,160,804	2,688,700,422	1,925,184,923	2,803,837,107
10/17/12	10,500,800	Ex U.S.	3,719,362,026	905,024,119	1,783,676,303	1,030,661,604	2,688,700,422	1,935,685,723	2,814,337,907
09/17/12	901,500	Ex U.S.	3,720,263,526	905,024,119	1,783,676,303	1,031,563,104	2,688,700,422	1,936,587,223	2,815,239,407
09/17/12	2,713,401	Tax	3,722,976,928	905,024,119	1,786,389,705	1,031,563,104	2,691,413,824	1,936,587,223	2,817,952,809
09/17/12	49,243,212	Tax	3,772,220,140	905,024,119	1,835,632,917	1,031,563,104	2,740,657,036	1,936,587,223	2,867,196,021
09/17/12	49,243,212	Tax	3,821,463,352	905,024,119	1,884,876,129	1,031,563,104	2,789,900,248	1,936,587,223	2,916,439,233
09/14/12	346,712	Tax	3,821,810,065	905,024,119	1,885,222,841	1,031,563,104	2,790,246,960	1,936,587,223	2,916,785,946
09/13/12	58,886	Tax	3,821,868,950	905,024,119	1,885,281,727	1,031,563,104	2,790,305,846	1,936,587,223	2,916,844,831
09/13/12	58,887	Tax	3,821,927,837	905,024,119	1,885,340,614	1,031,563,104	2,790,364,733	1,936,587,223	2,916,903,718
09/13/12	477,358	Tax	3,822,405,195	905,024,119	1,885,817,972	1,031,563,104	2,790,842,091	1,936,587,223	2,917,381,076
09/13/12	2,411,912	Tax	3,824,817,107	905,024,119	1,888,229,884	1,031,563,104	2,793,254,003	1,936,587,223	2,919,792,988
09/13/12	2,411,912	Tax	3,827,229,020	905,024,119	1,890,641,797	1,031,563,104	2,795,665,916	1,936,587,223	2,922,204,901
09/12/12	5,025	Tax	3,827,234,045	905,024,119	1,890,646,821	1,031,563,104	2,795,670,940	1,936,587,223	2,922,209,926
09/12/12	150,745	Tax	3,827,384,789	905,024,119	1,890,797,566	1,031,563,104	2,795,821,685	1,936,587,223	2,922,360,670
09/12/12	150,745	Tax	3,827,535,534	905,024,119	1,890,948,311	1,031,563,104	2,795,972,430	1,936,587,223	2,922,511,415
08/06/12	6,218,211	Ex U.S.	3,833,753,745	905,024,119	1,890,948,311	1,037,781,316	2,795,972,430	1,942,805,435	2,928,729,626
07/13/12	153,028	Ex U.S.	3,833,906,773	905,024,119	1,890,948,311	1,037,934,343	2,795,972,430	1,942,958,462	2,928,882,654
07/13/12	226,481	Ex U.S.	3,834,133,253	905,024,119	1,890,948,311	1,038,160,824	2,795,972,430	1,943,184,943	2,929,109,134
07/13/12	279,122	Ex U.S.	3,834,412,375	905,024,119	1,890,948,311	1,038,439,946	2,795,972,430	1,943,464,065	2,929,388,256
07/13/12	299,934	Ex U.S.	3,834,712,309	905,024,119	1,890,948,311	1,038,739,880	2,795,972,430	1,943,763,999	2,929,688,190

07/13/12	326,700	Ex U.S.	3,835,039,009	905,024,119	1,890,948,311	1,039,066,580	2,795,972,430	1,944,090,699	2,930,014,890
07/13/12	759,016	Ex U.S.	3,835,798,026	905,024,119	1,890,948,311	1,039,825,596	2,795,972,430	1,944,849,715	2,930,773,907
07/13/12	1,065,071	Ex U.S.	3,836,863,097	905,024,119	1,890,948,311	1,040,890,668	2,795,972,430	1,945,914,787	2,931,838,978
07/13/12	2,799,791	Ex U.S.	3,839,662,888	905,024,119	1,890,948,311	1,043,690,459	2,795,972,430	1,948,714,578	2,934,638,769
07/13/12	4,345,981	Ex U.S.	3,844,008,869	905,024,119	1,890,948,311	1,048,036,440	2,795,972,430	1,953,060,559	2,938,984,750
07/13/12	10,482,996	Ex U.S.	3,854,491,865	905,024,119	1,890,948,311	1,058,519,436	2,795,972,430	1,963,543,555	2,949,467,746
07/11/12	56,780,439	U.S. Partner	3,911,272,304	961,804,558	1,890,948,311	1,058,519,436	2,852,752,868	2,020,323,993	2,949,467,746
07/11/12	56,780,439	U.S. Partner	3,968,052,742	1,018,584,996	1,890,948,311	1,058,519,436	2,909,533,307	2,077,104,432	2,949,467,746
06/25/12	508,360	Ex U.S.	3,968,561,102	1,018,584,996	1,890,948,311	1,059,027,796	2,909,533,307	2,077,612,792	2,949,976,106
06/25/12	9,277,570	Ex U.S.	3,977,838,672	1,018,584,996	1,890,948,311	1,068,305,366	2,909,533,307	2,086,890,362	2,959,253,676
06/25/12	12,709,000	Ex U.S.	3,990,547,672	1,018,584,996	1,890,948,311	1,081,014,366	2,909,533,307	2,099,599,362	2,971,962,676
06/18/12	251,241	Tax	3,990,798,913	1,018,584,996	1,891,199,551	1,081,014,366	2,909,784,548	2,099,599,362	2,972,213,917
06/18/12	3,065,139	Tax	3,993,864,052	1,018,584,996	1,894,264,690	1,081,014,366	2,912,849,686	2,099,599,362	2,975,279,056
06/13/12	10,050	Tax	3,993,874,102	1,018,584,996	1,894,274,740	1,081,014,366	2,912,859,736	2,099,599,362	2,975,289,105
06/13/12	628,102	Tax	3,994,502,204	1,018,584,996	1,894,902,842	1,081,014,366	2,913,487,838	2,099,599,362	2,975,917,208
06/13/12	3,014,891	Tax	3,997,517,094	1,018,584,996	1,897,917,733	1,081,014,366	2,916,502,729	2,099,599,362	2,978,932,098
06/13/12	3,014,891	Tax	4,000,531,985	1,018,584,996	1,900,932,623	1,081,014,366	2,919,517,619	2,099,599,362	2,981,946,989
06/13/12	42,962,190	Tax	4,043,494,175	1,018,584,996	1,943,894,813	1,081,014,366	2,962,479,809	2,099,599,362	3,024,909,179
06/13/12	42,962,190	Tax	4,086,456,365	1,018,584,996	1,986,857,004	1,081,014,366	3,005,442,000	2,099,599,362	3,067,871,369
06/12/12	7,034,745	U.S. Partner	4,093,491,110	1,025,619,741	1,986,857,004	1,081,014,366	3,012,476,744	2,106,634,106	3,067,871,369
06/12/12	7,034,745	U.S. Partner	4,100,525,855	1,032,654,485	1,986,857,004	1,081,014,366	3,019,511,489	2,113,668,851	3,067,871,369
06/07/12	286,415	Tax	4,100,812,269	1,032,654,485	1,987,143,418	1,081,014,366	3,019,797,904	2,113,668,851	3,068,157,784
06/07/12	286,415	Tax	4,101,098,684	1,032,654,485	1,987,429,833	1,081,014,366	3,020,084,318	2,113,668,851	3,068,444,198
05/31/12	653,226	Tax	4,101,751,910	1,032,654,485	1,988,083,059	1,081,014,366	3,020,737,544	2,113,668,851	3,069,097,425
05/31/12	894,534	Tax	4,102,646,444	1,032,654,485	1,988,977,593	1,081,014,366	3,021,632,078	2,113,668,851	3,069,991,959
05/31/12	3,892,105	Ex U.S.	4,106,538,549	1,032,654,485	1,988,977,593	1,084,906,471	3,021,632,078	2,117,560,956	3,073,884,064
05/31/12	12,950,000	Ex U.S.	4,119,488,549	1,032,654,485	1,988,977,593	1,097,856,471	3,021,632,078	2,130,510,956	3,086,834,064
04/30/12	86,723	Ex U.S.	4,119,575,272	1,032,654,485	1,988,977,593	1,097,943,194	3,021,632,078	2,130,597,679	3,086,920,787
04/30/12	113,407	Ex U.S.	4,119,688,679	1,032,654,485	1,988,977,593	1,098,056,601	3,021,632,078	2,130,711,086	3,087,034,194
04/30/12	133,420	Ex U.S.	4,119,822,099	1,032,654,485	1,988,977,593	1,098,190,021	3,021,632,078	2,130,844,506	3,087,167,614
04/30/12	173,446	Ex U.S.	4,119,995,545	1,032,654,485	1,988,977,593	1,098,363,467	3,021,632,078	2,131,017,952	3,087,341,060
04/30/12	306,866	Ex U.S.	4,120,302,411	1,032,654,485	1,988,977,593	1,098,670,333	3,021,632,078	2,131,324,818	3,087,647,926
04/30/12	533,680	Ex U.S.	4,120,836,091	1,032,654,485	1,988,977,593	1,099,204,013	3,021,632,078	2,131,858,498	3,088,181,606
04/30/12	4,442,886	Ex U.S.	4,125,278,977	1,032,654,485	1,988,977,593	1,103,646,899	3,021,632,078	2,136,301,384	3,092,624,492
04/30/12	7,071,260	Ex U.S.	4,132,350,237	1,032,654,485	1,988,977,593	1,110,718,159	3,021,632,078	2,143,372,644	3,099,695,752
04/30/12	7,171,325	Ex U.S.	4,139,521,562	1,032,654,485	1,988,977,593	1,117,889,484	3,021,632,078	2,150,543,969	3,106,867,077
04/30/12	14,342,650	Ex U.S.	4,153,864,212	1,032,654,485	1,988,977,593	1,132,232,134	3,021,632,078	2,164,886,619	3,121,209,727
04/20/12	15,074	Tax	4,153,879,286	1,032,654,485	1,988,992,668	1,132,232,134	3,021,647,153	2,164,886,619	3,121,224,801
04/18/12	401,985	Tax	4,154,281,272	1,032,654,485	1,989,394,653	1,132,232,134	3,022,049,138	2,164,886,619	3,121,626,787
04/17/12	12,562,044	U.S. Partner	4,166,843,316	1,045,216,529	1,989,394,653	1,132,232,134	3,034,611,182	2,177,448,663	3,121,626,787
04/17/12	12,562,044	U.S. Partner	4,179,405,360	1,057,778,573	1,989,394,653	1,132,232,134	3,047,173,226	2,190,010,707	3,121,626,787
04/16/12	50,248	Tax	4,179,455,608	1,057,778,573	1,989,444,901	1,132,232,134	3,047,223,474	2,190,010,707	3,121,677,035
04/16/12	251,241	Tax	4,179,706,849	1,057,778,573	1,989,696,142	1,132,232,134	3,047,474,715	2,190,010,707	3,121,928,276
04/16/12	2,663,153	Tax	4,182,370,002	1,057,778,573	1,992,359,295	1,132,232,134	3,050,137,869	2,190,010,707	3,124,591,429
04/16/12	42,962,190	Tax	4,225,332,192	1,057,778,573	2,035,321,486	1,132,232,134	3,093,100,059	2,190,010,707	3,167,553,619
04/14/12	276,365	Tax	4,225,608,557	1,057,778,573	2,035,597,851	1,132,232,134	3,093,376,424	2,190,010,707	3,167,829,984
04/10/12	552,730	Tax	4,226,161,287	1,057,778,573	2,036,150,580	1,132,232,134	3,093,929,154	2,190,010,707	3,168,382,714
04/10/12	587,904	Tax	4,226,749,191	1,057,778,573	2,036,738,484	1,132,232,134	3,094,517,057	2,190,010,707	3,168,970,618
04/10/12	638,152	Tax	4,227,387,343	1,057,778,573	2,037,376,636	1,132,232,134	3,095,155,209	2,190,010,707	3,169,608,770

04/10/12	2,713,401	Tax	4,230,100,744	1,057,778,573	2,040,090,037	1,132,232,134	3,097,868,611	2,190,010,707	3,172,322,171
04/10/12	2,713,401	Tax	4,232,814,146	1,057,778,573	2,042,803,439	1,132,232,134	3,100,582,012	2,190,010,707	3,175,035,573
04/10/12	9,547,153	Tax	4,242,361,299	1,057,778,573	2,052,350,592	1,132,232,134	3,110,129,166	2,190,010,707	3,184,582,726
04/10/12	42,962,190	Tax	4,285,323,489	1,057,778,573	2,095,312,783	1,132,232,134	3,153,091,356	2,190,010,707	3,227,544,916
04/09/12	45,223,358	U.S. Partner	4,330,546,848	1,103,001,931	2,095,312,783	1,132,232,134	3,198,314,714	2,235,234,065	3,227,544,916
04/09/12	45,223,358	U.S. Partner	4,375,770,206	1,148,225,290	2,095,312,783	1,132,232,134	3,243,538,072	2,280,457,423	3,227,544,916
04/06/12	5,025	Tax	4,375,775,231	1,148,225,290	2,095,317,807	1,132,232,134	3,243,543,097	2,280,457,423	3,227,549,941
04/06/12	206,018	Tax	4,375,981,248	1,148,225,290	2,095,523,825	1,132,232,134	3,243,749,114	2,280,457,423	3,227,755,958
04/06/12	667,499	Tax	4,376,648,747	1,148,225,290	2,096,191,324	1,132,232,134	3,244,416,613	2,280,457,423	3,228,423,457
03/23/12	1,008,194	Ex U.S.	4,377,656,940	1,148,225,290	2,096,191,324	1,133,240,327	3,244,416,613	2,281,465,617	3,229,431,651
02/28/12	90	Tax	4,377,657,031	1,148,225,290	2,096,191,414	1,133,240,327	3,244,416,704	2,281,465,617	3,229,431,741
02/23/12	1,005	Tax	4,377,658,036	1,148,225,290	2,096,192,419	1,133,240,327	3,244,417,709	2,281,465,617	3,229,432,746
02/13/12	472,333	Tax	4,378,130,369	1,148,225,290	2,096,664,752	1,133,240,327	3,244,890,041	2,281,465,617	3,229,905,079
02/11/12	512,531	Tax	4,378,642,900	1,148,225,290	2,097,177,283	1,133,240,327	3,245,402,573	2,281,465,617	3,230,417,610
02/09/12	175,869	Tax	4,378,818,769	1,148,225,290	2,097,353,152	1,133,240,327	3,245,578,442	2,281,465,617	3,230,593,479
02/09/12	512,531	Tax	4,379,331,300	1,148,225,290	2,097,865,683	1,133,240,327	3,246,090,973	2,281,465,617	3,231,106,010
12/31/11	-32,049,000	U.S. Partner	4,347,282,300	1,116,176,290	2,097,865,683	1,133,240,327	3,214,041,973	2,249,416,617	3,231,106,010
12/31/11	-1,296,049	Tax	4,345,986,251	1,116,176,290	2,096,569,634	1,133,240,327	3,212,745,924	2,249,416,617	3,229,809,961
12/31/11	389,496	Tax	4,346,375,747	1,116,176,290	2,096,959,130	1,133,240,327	3,213,135,419	2,249,416,617	3,230,199,457
12/31/11	1,680,000	U.S. Partner	4,348,055,747	1,117,856,290	2,096,959,130	1,133,240,327	3,214,815,419	2,251,096,617	3,230,199,457
12/31/11	2,892,230	Ex U.S.	4,350,947,976	1,117,856,290	2,096,959,130	1,136,132,557	3,214,815,419	2,253,988,847	3,233,091,687
12/31/11	3,818,861	Tax	4,354,766,838	1,117,856,290	2,100,777,991	1,136,132,557	3,218,634,281	2,253,988,847	3,236,910,548
12/31/11	6,670,000	U.S. Partner	4,361,436,838	1,124,526,290	2,100,777,991	1,136,132,557	3,225,304,281	2,260,658,847	3,236,910,548
12/31/11	17,586,862	Tax	4,379,023,699	1,124,526,290	2,118,364,853	1,136,132,557	3,242,891,142	2,260,658,847	3,254,497,410
12/15/11	175,869	Tax	4,379,199,568	1,124,526,290	2,118,540,721	1,136,132,557	3,243,067,011	2,260,658,847	3,254,673,278
12/15/11	2,813,898	Tax	4,382,013,466	1,124,526,290	2,121,354,619	1,136,132,557	3,245,880,909	2,260,658,847	3,257,487,176
12/15/11	49,243,212	Tax	4,431,256,678	1,124,526,290	2,170,597,831	1,136,132,557	3,295,124,121	2,260,658,847	3,306,730,388
12/14/11	1,507,445	Tax	4,432,764,123	1,124,526,290	2,172,105,277	1,136,132,557	3,296,631,566	2,260,658,847	3,308,237,834
12/13/11	3,818,861	Tax	4,436,582,985	1,124,526,290	2,175,924,138	1,136,132,557	3,300,450,428	2,260,658,847	3,312,056,695
12/13/11	49,243,212	Tax	4,485,826,197	1,124,526,290	2,225,167,350	1,136,132,557	3,349,693,640	2,260,658,847	3,361,299,907
12/12/11	12,009,314	U.S. Partner	4,497,835,511	1,136,535,604	2,225,167,350	1,136,132,557	3,361,702,954	2,272,668,161	3,361,299,907
12/12/11	12,009,314	U.S. Partner	4,509,844,825	1,148,544,918	2,225,167,350	1,136,132,557	3,373,712,268	2,284,677,475	3,361,299,907
11/30/11	9,359,000	Ex U.S.	4,519,203,825	1,148,544,918	2,225,167,350	1,145,491,557	3,373,712,268	2,294,036,475	3,370,658,907
10/31/11	24,688,885	Ex U.S.	4,543,892,710	1,148,544,918	2,225,167,350	1,170,180,442	3,373,712,268	2,318,725,360	3,395,347,792
09/16/11	301,489	Tax	4,544,194,199	1,148,544,918	2,225,468,839	1,170,180,442	3,374,013,757	2,318,725,360	3,395,649,282
09/15/11	115,571	Tax	4,544,309,770	1,148,544,918	2,225,584,410	1,170,180,442	3,374,129,328	2,318,725,360	3,395,764,852
09/15/11	3,517,372	Tax	4,547,827,142	1,148,544,918	2,229,101,782	1,170,180,442	3,377,646,700	2,318,725,360	3,399,282,225
09/15/11	59,292,847	Tax	4,607,119,990	1,148,544,918	2,288,394,630	1,170,180,442	3,436,939,547	2,318,725,360	3,458,575,072
09/14/11	452,234	Tax	4,607,572,223	1,148,544,918	2,288,846,863	1,170,180,442	3,437,391,781	2,318,725,360	3,459,027,306
09/14/11	3,341,504	Tax	4,610,913,727	1,148,544,918	2,292,188,367	1,170,180,442	3,440,733,285	2,318,725,360	3,462,368,809
09/13/11	1,028,345	Tax	4,611,942,072	1,148,544,918	2,293,216,712	1,170,180,442	3,441,761,630	2,318,725,360	3,463,397,154
09/13/11	1,028,345	Tax	4,612,970,417	1,148,544,918	2,294,245,057	1,170,180,442	3,442,789,975	2,318,725,360	3,464,425,499
09/13/11	59,292,847	Tax	4,672,263,264	1,148,544,918	2,353,537,904	1,170,180,442	3,502,082,822	2,318,725,360	3,523,718,347
09/12/11	376,861	Tax	4,672,640,126	1,148,544,918	2,353,914,766	1,170,180,442	3,502,459,683	2,318,725,360	3,524,095,208
09/12/11	492,432	Tax	4,673,132,558	1,148,544,918	2,354,407,198	1,170,180,442	3,502,952,115	2,318,725,360	3,524,587,640
09/08/11	100,496	Tax	4,673,233,054	1,148,544,918	2,354,507,694	1,170,180,442	3,503,052,612	2,318,725,360	3,524,688,136
09/06/11	70,749,431	U.S. Partner	4,743,982,485	1,219,294,349	2,354,507,694	1,170,180,442	3,573,802,043	2,389,474,791	3,524,688,136
09/06/11	70,749,431	U.S. Partner	4,814,731,917	1,290,043,780	2,354,507,694	1,170,180,442	3,644,551,475	2,460,224,223	3,524,688,136
08/31/11	5,693,200	Ex U.S.	4,820,425,117	1,290,043,780	2,354,507,694	1,175,873,642	3,644,551,475	2,465,917,423	3,530,381,336

07/08/11	452,234	Tax	4,820,877,350	1,290,043,780	2,354,959,928	1,175,873,642	3,645,003,708	2,465,917,423	3,530,833,570
07/08/11	452,234	Tax	4,821,329,584	1,290,043,780	2,355,412,161	1,175,873,642	3,645,455,942	2,465,917,423	3,531,285,804
07/08/11	3,215,883	Tax	4,824,545,467	1,290,043,780	2,358,628,045	1,175,873,642	3,648,671,825	2,465,917,423	3,534,501,687
07/08/11	100,496,351	U.S. Partner	4,925,041,819	1,390,540,132	2,358,628,045	1,175,873,642	3,749,168,177	2,566,413,774	3,534,501,687
07/08/11	100,496,351	U.S. Partner	5,025,538,170	1,491,036,483	2,358,628,045	1,175,873,642	3,849,664,528	2,666,910,126	3,534,501,687
06/16/11	301,489	Tax	5,025,839,659	1,491,036,483	2,358,929,534	1,175,873,642	3,849,966,017	2,666,910,126	3,534,803,176
06/15/11	401,985	Tax	5,026,241,645	1,491,036,483	2,359,331,519	1,175,873,642	3,850,368,003	2,666,910,126	3,535,205,161
06/15/11	3,517,372	Tax	5,029,759,017	1,491,036,483	2,362,848,891	1,175,873,642	3,853,885,375	2,666,910,126	3,538,722,534
06/15/11	5,024,818	U.S. Partner	5,034,783,835	1,496,061,301	2,362,848,891	1,175,873,642	3,858,910,192	2,671,934,943	3,538,722,534
06/15/11	5,024,818	U.S. Partner	5,039,808,652	1,501,086,119	2,362,848,891	1,175,873,642	3,863,935,010	2,676,959,761	3,538,722,534
06/15/11	57,785,402	Tax	5,097,594,054	1,501,086,119	2,420,634,293	1,175,873,642	3,921,720,412	2,676,959,761	3,596,507,936
06/15/11	57,785,402	Tax	5,155,379,456	1,501,086,119	2,478,419,696	1,175,873,642	3,979,505,814	2,676,959,761	3,654,293,338
06/13/11	698,450	Tax	5,156,077,906	1,501,086,119	2,479,118,145	1,175,873,642	3,980,204,264	2,676,959,761	3,654,991,787
06/13/11	698,450	Tax	5,156,776,356	1,501,086,119	2,479,816,595	1,175,873,642	3,980,902,713	2,676,959,761	3,655,690,237
06/13/11	4,453,788	Tax	5,161,230,144	1,501,086,119	2,484,270,383	1,175,873,642	3,985,356,502	2,676,959,761	3,660,144,025
06/13/11	4,453,788	Tax	5,165,683,932	1,501,086,119	2,488,724,171	1,175,873,642	3,989,810,290	2,676,959,761	3,664,597,814
06/09/11	125,620	Tax	5,165,809,553	1,501,086,119	2,488,849,792	1,175,873,642	3,989,935,910	2,676,959,761	3,664,723,434
05/31/11	10,519,356	Tax	5,176,328,909	1,501,086,119	2,499,369,148	1,175,873,642	4,000,455,267	2,676,959,761	3,675,242,790
04/30/11	50,593,415	Ex U.S.	5,226,922,323	1,501,086,119	2,499,369,148	1,226,467,057	4,000,455,267	2,727,553,175	3,725,836,205
04/19/11	301,489	Tax	5,227,223,812	1,501,086,119	2,499,670,637	1,226,467,057	4,000,756,756	2,727,553,175	3,726,137,694
04/18/11	3,517,372	Tax	5,230,741,185	1,501,086,119	2,503,188,009	1,226,467,057	4,004,274,128	2,727,553,175	3,729,655,066
04/18/11	57,785,402	Tax	5,288,526,587	1,501,086,119	2,560,973,411	1,226,467,057	4,062,059,530	2,727,553,175	3,787,440,468
04/15/11	20,099	Tax	5,288,546,686	1,501,086,119	2,560,993,511	1,226,467,057	4,062,079,629	2,727,553,175	3,787,460,567
04/15/11	125,620	Tax	5,288,672,306	1,501,086,119	2,561,119,131	1,226,467,057	4,062,205,250	2,727,553,175	3,787,586,188
04/13/11	155,054	Tax	5,288,827,360	1,501,086,119	2,561,274,185	1,226,467,057	4,062,360,303	2,727,553,175	3,787,741,242
04/13/11	390,492	Tax	5,289,217,852	1,501,086,119	2,561,664,677	1,226,467,057	4,062,750,795	2,727,553,175	3,788,131,733
04/13/11	753,723	Tax	5,289,971,574	1,501,086,119	2,562,418,399	1,226,467,057	4,063,504,518	2,727,553,175	3,788,885,456
04/13/11	753,723	Tax	5,290,725,297	1,501,086,119	2,563,172,122	1,226,467,057	4,064,258,240	2,727,553,175	3,789,639,179
04/13/11	4,322,573	Tax	5,295,047,870	1,501,086,119	2,567,494,695	1,226,467,057	4,068,580,814	2,727,553,175	3,793,961,752
04/13/11	57,785,402	Tax	5,352,833,272	1,501,086,119	2,625,280,097	1,226,467,057	4,126,366,216	2,727,553,175	3,851,747,154
04/12/11	153,614	Tax	5,352,986,886	1,501,086,119	2,625,433,711	1,226,467,057	4,126,519,829	2,727,553,175	3,851,900,768
04/12/11	894,758	Tax	5,353,881,644	1,501,086,119	2,626,328,469	1,226,467,057	4,127,414,588	2,727,553,175	3,852,795,526
04/11/11	10,288,348	Tax	5,364,169,992	1,501,086,119	2,636,616,817	1,226,467,057	4,137,702,936	2,727,553,175	3,863,083,874
04/08/11	40,199	Tax	5,364,210,191	1,501,086,119	2,636,657,016	1,226,467,057	4,137,743,134	2,727,553,175	3,863,124,072
04/08/11	125,620	Tax	5,364,335,811	1,501,086,119	2,636,782,636	1,226,467,057	4,137,868,755	2,727,553,175	3,863,249,693
04/08/11	154,333	Tax	5,364,490,145	1,501,086,119	2,636,936,969	1,226,467,057	4,138,023,088	2,727,553,175	3,863,404,026
04/08/11	4,322,573	Tax	5,368,812,718	1,501,086,119	2,641,259,543	1,226,467,057	4,142,345,661	2,727,553,175	3,867,726,599
04/08/11	95,320,789	U.S. Partner	5,464,133,507	1,596,406,908	2,641,259,543	1,226,467,057	4,237,666,451	2,822,873,965	3,867,726,599
04/08/11	95,320,789	U.S. Partner	5,559,454,297	1,691,727,697	2,641,259,543	1,226,467,057	4,332,987,240	2,918,194,754	3,867,726,599
04/05/11	40,199	Tax	5,559,494,495	1,691,727,697	2,641,299,741	1,226,467,057	4,333,027,438	2,918,194,754	3,867,766,798
03/29/11	-415,705	Tax	5,559,078,790	1,691,727,697	2,640,884,036	1,226,467,057	4,332,611,733	2,918,194,754	3,867,351,093
03/02/11	5,024,818	U.S. Partner	5,564,103,608	1,696,752,515	2,640,884,036	1,226,467,057	4,337,636,551	2,923,219,572	3,867,351,093
03/02/11	5,024,818	U.S. Partner	5,569,128,425	1,701,777,332	2,640,884,036	1,226,467,057	4,342,661,368	2,928,244,389	3,867,351,093
02/11/11	6,632,759	Tax	5,575,761,184	1,701,777,332	2,647,516,795	1,226,467,057	4,349,294,128	2,928,244,389	3,873,983,852
02/09/11	93,070	Ex U.S.	5,575,854,254	1,701,777,332	2,647,516,795	1,226,560,126	4,349,294,128	2,928,337,459	3,874,076,922
02/09/11	93,070	Ex U.S.	5,575,947,324	1,701,777,332	2,647,516,795	1,226,653,196	4,349,294,128	2,928,430,529	3,874,169,991
02/09/11	1,666,980	Ex U.S.	5,577,614,304	1,701,777,332	2,647,516,795	1,228,320,176	4,349,294,128	2,930,097,509	3,875,836,971
02/09/11	6,632,759	Tax	5,584,247,063	1,701,777,332	2,654,149,554	1,228,320,176	4,355,926,887	2,930,097,509	3,882,469,730
02/08/11	545,600	Ex U.S.	5,584,792,663	1,701,777,332	2,654,149,554	1,228,865,776	4,355,926,887	2,930,643,109	3,883,015,330

02/08/11	2,728,000	Ex U.S.	5,587,520,663	1,701,777,332	2,654,149,554	1,231,593,776	4,355,926,887	2,933,371,109	3,885,743,330
02/08/11	6,547,200	Ex U.S.	5,594,067,863	1,701,777,332	2,654,149,554	1,238,140,976	4,355,926,887	2,939,918,309	3,892,290,530
02/08/11	7,229,200	Ex U.S.	5,601,297,063	1,701,777,332	2,654,149,554	1,245,370,176	4,355,926,887	2,947,147,509	3,899,519,730
01/26/11	-334,697	Tax	5,600,962,366	1,701,777,332	2,653,814,857	1,245,370,176	4,355,592,190	2,947,147,509	3,899,185,033
01/14/11	59,092	Ex U.S.	5,601,021,458	1,701,777,332	2,653,814,857	1,245,429,268	4,355,592,190	2,947,206,600	3,899,244,125
01/14/11	59,092	Ex U.S.	5,601,080,550	1,701,777,332	2,653,814,857	1,245,488,360	4,355,592,190	2,947,265,692	3,899,303,217
01/14/11	1,058,400	Ex U.S.	5,602,138,950	1,701,777,332	2,653,814,857	1,246,546,760	4,355,592,190	2,948,324,092	3,900,361,617
12/31/10	-490,000	Ex U.S.	5,601,648,950	1,701,777,332	2,653,814,857	1,246,056,760	4,355,592,190	2,947,834,092	3,899,871,617
12/31/10	48,759,674	Ex U.S.	5,650,408,624	1,701,777,332	2,653,814,857	1,294,816,434	4,355,592,190	2,996,593,766	3,948,631,291
12/22/10	3,482,199	Tax	5,653,890,822	1,701,777,332	2,657,297,056	1,294,816,434	4,359,074,388	2,996,593,766	3,952,113,490
12/22/10	4,019,854	Tax	5,657,910,676	1,701,777,332	2,661,316,910	1,294,816,434	4,363,094,242	2,996,593,766	3,956,133,344
12/22/10	4,019,854	Tax	5,661,930,530	1,701,777,332	2,665,336,764	1,294,816,434	4,367,114,096	2,996,593,766	3,960,153,198
12/16/10	50,248,176	U.S. Partner	5,712,178,706	1,752,025,508	2,665,336,764	1,294,816,434	4,417,362,272	3,046,841,942	3,960,153,198
12/16/10	50,248,176	U.S. Partner	5,762,426,882	1,802,273,684	2,665,336,764	1,294,816,434	4,467,610,448	3,097,090,118	3,960,153,198
12/15/10	95,472	Tax	5,762,522,353	1,802,273,684	2,665,432,236	1,294,816,434	4,467,705,919	3,097,090,118	3,960,248,669
12/15/10	111,094	Tax	5,762,633,447	1,802,273,684	2,665,543,329	1,294,816,434	4,467,817,013	3,097,090,118	3,960,359,763
12/15/10	302,986	Tax	5,762,936,433	1,802,273,684	2,665,846,316	1,294,816,434	4,468,120,000	3,097,090,118	3,960,662,749
12/15/10	351,737	Tax	5,763,288,171	1,802,273,684	2,666,198,053	1,294,816,434	4,468,471,737	3,097,090,118	3,961,014,487
12/15/10	2,009,927	Tax	5,765,298,098	1,802,273,684	2,668,207,980	1,294,816,434	4,470,481,664	3,097,090,118	3,963,024,414
12/15/10	4,170,599	Tax	5,769,468,696	1,802,273,684	2,672,378,579	1,294,816,434	4,474,652,262	3,097,090,118	3,967,195,012
12/15/10	71,352,410	Tax	5,840,821,106	1,802,273,684	2,743,730,988	1,294,816,434	4,546,004,672	3,097,090,118	4,038,547,422
12/15/10	75,618,480	Tax	5,916,439,585	1,802,273,684	2,819,349,468	1,294,816,434	4,621,623,152	3,097,090,118	4,114,165,902
12/07/10	80,397,081	U.S. Partner	5,996,836,667	1,882,670,765	2,819,349,468	1,294,816,434	4,702,020,233	3,177,487,199	4,114,165,902
12/07/10	80,397,081	U.S. Partner	6,077,233,748	1,963,067,846	2,819,349,468	1,294,816,434	4,782,417,314	3,257,884,280	4,114,165,902
12/01/10	123,108	Ex U.S.	6,077,356,856	1,963,067,846	2,819,349,468	1,294,939,542	4,782,417,314	3,258,007,388	4,114,289,010
12/01/10	123,108	Ex U.S.	6,077,479,964	1,963,067,846	2,819,349,468	1,295,062,650	4,782,417,314	3,258,130,496	4,114,412,118
12/01/10	2,205,000	Ex U.S.	6,079,684,964	1,963,067,846	2,819,349,468	1,297,267,650	4,782,417,314	3,260,335,496	4,116,617,118
10/25/10	283,888	Tax	6,079,968,852	1,963,067,846	2,819,633,356	1,297,267,650	4,782,701,202	3,260,335,496	4,116,901,006
10/12/10	-2,249	Tax	6,079,966,603	1,963,067,846	2,819,631,107	1,297,267,650	4,782,698,953	3,260,335,496	4,116,898,757
09/20/10	105,521,169	U.S. Partner	6,185,487,772	2,068,589,015	2,819,631,107	1,297,267,650	4,888,220,122	3,365,856,665	4,116,898,757
09/20/10	105,521,169	U.S. Partner	6,291,008,941	2,174,110,184	2,819,631,107	1,297,267,650	4,993,741,291	3,471,377,834	4,116,898,757
09/15/10	11,055	Tax	6,291,019,996	2,174,110,184	2,819,642,162	1,297,267,650	4,993,752,346	3,471,377,834	4,116,909,811
09/15/10	15,074	Tax	6,291,035,070	2,174,110,184	2,819,657,236	1,297,267,650	4,993,767,420	3,471,377,834	4,116,924,886
09/15/10	60,298	Tax	6,291,095,368	2,174,110,184	2,819,717,534	1,297,267,650	4,993,827,718	3,471,377,834	4,116,985,184
09/15/10	387,927	Tax	6,291,483,295	2,174,110,184	2,820,105,461	1,297,267,650	4,994,215,645	3,471,377,834	4,117,373,111
09/15/10	387,927	Tax	6,291,871,222	2,174,110,184	2,820,493,388	1,297,267,650	4,994,603,572	3,471,377,834	4,117,761,038
09/15/10	427,109	Tax	6,292,298,332	2,174,110,184	2,820,920,497	1,297,267,650	4,995,030,682	3,471,377,834	4,118,188,147
09/15/10	477,358	Tax	6,292,775,689	2,174,110,184	2,821,397,855	1,297,267,650	4,995,508,039	3,471,377,834	4,118,665,505
09/15/10	2,512,409	Tax	6,295,288,098	2,174,110,184	2,823,910,264	1,297,267,650	4,998,020,448	3,471,377,834	4,121,177,914
09/15/10	7,034,745	Tax	6,302,322,843	2,174,110,184	2,830,945,008	1,297,267,650	5,005,055,193	3,471,377,834	4,128,212,658
09/15/10	76,377,227	Tax	6,378,700,070	2,174,110,184	2,907,322,235	1,297,267,650	5,081,432,420	3,471,377,834	4,204,589,885
09/15/10	76,463,654	Tax	6,455,163,724	2,174,110,184	2,983,785,889	1,297,267,650	5,157,896,074	3,471,377,834	4,281,053,539
09/13/10	11,474	Tax	6,455,175,197	2,174,110,184	2,983,797,363	1,297,267,650	5,157,907,548	3,471,377,834	4,281,065,013
08/17/10	196,973	Ex U.S.	6,455,372,170	2,174,110,184	2,983,797,363	1,297,464,623	5,157,907,548	3,471,574,807	4,281,261,986
08/17/10	196,973	Ex U.S.	6,455,569,143	2,174,110,184	2,983,797,363	1,297,661,596	5,157,907,548	3,471,771,780	4,281,458,959
08/17/10	3,528,000	Ex U.S.	6,459,097,143	2,174,110,184	2,983,797,363	1,301,189,596	5,157,907,548	3,475,299,780	4,284,986,959
07/29/10	6,532,263	Tax	6,465,629,406	2,174,110,184	2,990,329,626	1,301,189,596	5,164,439,810	3,475,299,780	4,291,519,221
07/29/10	6,532,263	Tax	6,472,161,669	2,174,110,184	2,996,861,889	1,301,189,596	5,170,972,073	3,475,299,780	4,298,051,484
06/30/10	26,959,188	Ex U.S.	6,499,120,857	2,174,110,184	2,996,861,889	1,328,148,784	5,170,972,073	3,502,258,968	4,325,010,672

06/30/10	27,135,612	Ex U.S.	6,526,256,469	2,174,110,184	2,996,861,889	1,355,284,396	5,170,972,073	3,529,394,580	4,352,146,284
06/15/10	257,538	Tax	6,526,514,007	2,174,110,184	2,997,119,427	1,355,284,396	5,171,229,611	3,529,394,580	4,352,403,822
06/14/10	116,545	Tax	6,526,630,551	2,174,110,184	2,997,235,971	1,355,284,396	5,171,346,156	3,529,394,580	4,352,520,367
06/14/10	317,085	Tax	6,526,947,636	2,174,110,184	2,997,553,056	1,355,284,396	5,171,663,241	3,529,394,580	4,352,837,452
06/14/10	57,785,402	Tax	6,584,733,039	2,174,110,184	3,055,338,459	1,355,284,396	5,229,448,643	3,529,394,580	4,410,622,854
06/11/10	1,515,017	Ex U.S.	6,586,248,055	2,174,110,184	3,055,338,459	1,356,799,412	5,229,448,643	3,530,909,597	4,412,137,871
06/11/10	1,515,017	Ex U.S.	6,587,763,072	2,174,110,184	3,055,338,459	1,358,314,429	5,229,448,643	3,532,424,613	4,413,652,887
06/11/10	4,111,040	Tax	6,591,874,112	2,174,110,184	3,059,449,499	1,358,314,429	5,233,559,683	3,532,424,613	4,417,763,928
06/10/10	121,090	Ex U.S.	6,591,995,202	2,174,110,184	3,059,449,499	1,358,435,519	5,233,559,683	3,532,545,703	4,417,885,018
06/07/10	59,250,105	Tax	6,651,245,308	2,174,110,184	3,118,699,604	1,358,435,519	5,292,809,789	3,532,545,703	4,477,135,123
05/31/10	2,490	Tax	6,651,247,797	2,174,110,184	3,118,702,094	1,358,435,519	5,292,812,279	3,532,545,703	4,477,137,613
05/31/10	2,501	Tax	6,651,250,298	2,174,110,184	3,118,704,595	1,358,435,519	5,292,814,779	3,532,545,703	4,477,140,114
05/31/10	1,005,480	Tax	6,652,255,778	2,174,110,184	3,119,710,075	1,358,435,519	5,293,820,259	3,532,545,703	4,478,145,594
05/28/10	45,022	Tax	6,652,300,801	2,174,110,184	3,119,755,097	1,358,435,519	5,293,865,282	3,532,545,703	4,478,190,616
05/28/10	67,963	Tax	6,652,368,763	2,174,110,184	3,119,823,060	1,358,435,519	5,293,933,244	3,532,545,703	4,478,258,579
05/28/10	78,611	Tax	6,652,447,375	2,174,110,184	3,119,901,671	1,358,435,519	5,294,011,856	3,532,545,703	4,478,337,190
05/28/10	108,221	Tax	6,652,555,595	2,174,110,184	3,120,009,892	1,358,435,519	5,294,120,076	3,532,545,703	4,478,445,411
05/28/10	179,450	Tax	6,652,735,045	2,174,110,184	3,120,189,342	1,358,435,519	5,294,299,527	3,532,545,703	4,478,624,861
05/28/10	1,164,886	Tax	6,653,899,932	2,174,110,184	3,121,354,228	1,358,435,519	5,295,464,413	3,532,545,703	4,479,789,747
05/27/10	4,924,035	Tax	6,658,823,967	2,174,110,184	3,126,278,263	1,358,435,519	5,300,388,448	3,532,545,703	4,484,713,782
05/26/10	4,924,035	Tax	6,663,748,001	2,174,110,184	3,131,202,298	1,358,435,519	5,305,312,483	3,532,545,703	4,489,637,817
05/21/10	-334,980	Tax	6,663,413,021	2,174,110,184	3,130,867,318	1,358,435,519	5,304,977,502	3,532,545,703	4,489,302,836
05/21/10	-334,681	Tax	6,663,078,340	2,174,110,184	3,130,532,637	1,358,435,519	5,304,642,821	3,532,545,703	4,488,968,155
05/20/10	2,813,898	Tax	6,665,892,238	2,174,110,184	3,133,346,534	1,358,435,519	5,307,456,719	3,532,545,703	4,491,782,053
05/12/10	146,200	Tax	6,666,038,438	2,174,110,184	3,133,492,735	1,358,435,519	5,307,602,919	3,532,545,703	4,491,928,253
05/07/10	-190	Tax	6,666,038,248	2,174,110,184	3,133,492,545	1,358,435,519	5,307,602,729	3,532,545,703	4,491,928,063
04/22/10	607	Ex U.S.	6,666,038,855	2,174,110,184	3,133,492,545	1,358,436,126	5,307,602,729	3,532,546,310	4,491,928,670
04/22/10	607	Ex U.S.	6,666,039,461	2,174,110,184	3,133,492,545	1,358,436,732	5,307,602,729	3,532,546,917	4,491,929,277
04/22/10	609	Ex U.S.	6,666,040,071	2,174,110,184	3,133,492,545	1,358,437,342	5,307,602,729	3,532,547,526	4,491,929,886
04/22/10	609	Ex U.S.	6,666,040,680	2,174,110,184	3,133,492,545	1,358,437,951	5,307,602,729	3,532,548,135	4,491,930,496
04/22/10	245,000	Ex U.S.	6,666,285,680	2,174,110,184	3,133,492,545	1,358,682,951	5,307,602,729	3,532,793,135	4,492,175,496
04/22/10	245,000	Ex U.S.	6,666,530,680	2,174,110,184	3,133,492,545	1,358,927,951	5,307,602,729	3,533,038,135	4,492,420,496
04/21/10	1,300	Tax	6,666,531,980	2,174,110,184	3,133,493,845	1,358,927,951	5,307,604,029	3,533,038,135	4,492,421,796
04/21/10	1,306	Tax	6,666,533,286	2,174,110,184	3,133,495,150	1,358,927,951	5,307,605,335	3,533,038,135	4,492,423,101
04/21/10	174,574	U.S. Partner	6,666,707,860	2,174,284,759	3,133,495,150	1,358,927,951	5,307,779,909	3,533,212,710	4,492,423,101
04/21/10	174,574	U.S. Partner	6,666,882,434	2,174,459,333	3,133,495,150	1,358,927,951	5,307,954,483	3,533,387,284	4,492,423,101
04/21/10	175,354	U.S. Partner	6,667,057,788	2,174,634,686	3,133,495,150	1,358,927,951	5,308,129,837	3,533,562,637	4,492,423,101
04/21/10	175,354	U.S. Partner	6,667,233,141	2,174,810,040	3,133,495,150	1,358,927,951	5,308,305,190	3,533,737,991	4,492,423,101
04/21/10	525,000	Tax	6,667,758,141	2,174,810,040	3,134,020,150	1,358,927,951	5,308,830,190	3,533,737,991	4,492,948,101
04/21/10	70,500,000	U.S. Partner	6,738,258,141	2,245,310,040	3,134,020,150	1,358,927,951	5,379,330,190	3,604,237,991	4,492,948,101
04/21/10	70,500,000	U.S. Partner	6,808,758,141	2,315,810,040	3,134,020,150	1,358,927,951	5,449,830,190	3,674,737,991	4,492,948,101
04/16/10	-724	Tax	6,808,757,417	2,315,810,040	3,134,019,426	1,358,927,951	5,449,829,466	3,674,737,991	4,492,947,377
04/16/10	-2	Tax	6,808,757,416	2,315,810,040	3,134,019,425	1,358,927,951	5,449,829,465	3,674,737,991	4,492,947,376
04/16/10	-2	Tax	6,808,757,414	2,315,810,040	3,134,019,423	1,358,927,951	5,449,829,463	3,674,737,991	4,492,947,374
04/15/10	489	Tax	6,808,757,903	2,315,810,040	3,134,019,912	1,358,927,951	5,449,829,952	3,674,737,991	4,492,947,863
04/15/10	491	Tax	6,808,758,394	2,315,810,040	3,134,020,403	1,358,927,951	5,449,830,443	3,674,737,991	4,492,948,354
04/15/10	817	Tax	6,808,759,211	2,315,810,040	3,134,021,220	1,358,927,951	5,449,831,260	3,674,737,991	4,492,949,171
04/15/10	821	Tax	6,808,760,032	2,315,810,040	3,134,022,041	1,358,927,951	5,449,832,081	3,674,737,991	4,492,949,992
04/15/10	1,609	Tax	6,808,761,641	2,315,810,040	3,134,023,650	1,358,927,951	5,449,833,690	3,674,737,991	4,492,951,601

04/15/10	1,616	Tax	6,808,763,257	2,315,810,040	3,134,025,266	1,358,927,951	5,449,835,306	3,674,737,991	4,492,953,217
04/15/10	1,733	Tax	6,808,764,990	2,315,810,040	3,134,026,999	1,358,927,951	5,449,837,039	3,674,737,991	4,492,954,950
04/15/10	1,741	Tax	6,808,766,731	2,315,810,040	3,134,028,740	1,358,927,951	5,449,838,780	3,674,737,991	4,492,956,691
04/15/10	197,394	Tax	6,808,964,125	2,315,810,040	3,134,226,134	1,358,927,951	5,450,036,174	3,674,737,991	4,493,154,085
04/15/10	330,000	Tax	6,809,294,125	2,315,810,040	3,134,556,134	1,358,927,951	5,450,366,174	3,674,737,991	4,493,484,085
04/15/10	649,782	Tax	6,809,943,907	2,315,810,040	3,135,205,916	1,358,927,951	5,451,015,956	3,674,737,991	4,494,133,867
04/15/10	700,000	Tax	6,810,643,907	2,315,810,040	3,135,905,916	1,358,927,951	5,451,715,956	3,674,737,991	4,494,833,867
04/14/10	7	Tax	6,810,643,915	2,315,810,040	3,135,905,924	1,358,927,951	5,451,715,964	3,674,737,991	4,494,833,875
04/14/10	7	Tax	6,810,643,922	2,315,810,040	3,135,905,931	1,358,927,951	5,451,715,971	3,674,737,991	4,494,833,882
04/14/10	442	Tax	6,810,644,364	2,315,810,040	3,135,906,373	1,358,927,951	5,451,716,413	3,674,737,991	4,494,834,324
04/14/10	444	Tax	6,810,644,808	2,315,810,040	3,135,906,817	1,358,927,951	5,451,716,857	3,674,737,991	4,494,834,768
04/14/10	2,972	Tax	6,810,647,780	2,315,810,040	3,135,909,789	1,358,927,951	5,451,719,829	3,674,737,991	4,494,837,740
04/14/10	178,564	Tax	6,810,826,344	2,315,810,040	3,136,088,353	1,358,927,951	5,451,898,393	3,674,737,991	4,495,016,304
04/13/10	96	Tax	6,810,826,440	2,315,810,040	3,136,088,449	1,358,927,951	5,451,898,489	3,674,737,991	4,495,016,400
04/13/10	96	Tax	6,810,826,536	2,315,810,040	3,136,088,545	1,358,927,951	5,451,898,585	3,674,737,991	4,495,016,496
04/13/10	38,656	Tax	6,810,865,192	2,315,810,040	3,136,127,201	1,358,927,951	5,451,937,241	3,674,737,991	4,495,055,152
04/12/10	10,130	Tax	6,810,875,322	2,315,810,040	3,136,137,331	1,358,927,951	5,451,947,371	3,674,737,991	4,495,065,282
04/12/10	10,175	Tax	6,810,885,497	2,315,810,040	3,136,147,506	1,358,927,951	5,451,957,546	3,674,737,991	4,495,075,457
04/12/10	4,090,736	Tax	6,814,976,233	2,315,810,040	3,140,238,242	1,358,927,951	5,456,048,282	3,674,737,991	4,499,166,193
04/09/10	386	Tax	6,814,976,618	2,315,810,040	3,140,238,628	1,358,927,951	5,456,048,668	3,674,737,991	4,499,166,578
04/09/10	388	Tax	6,814,977,006	2,315,810,040	3,140,239,015	1,358,927,951	5,456,049,055	3,674,737,991	4,499,166,966
04/09/10	25,617	Tax	6,815,002,623	2,315,810,040	3,140,264,632	1,358,927,951	5,456,074,672	3,674,737,991	4,499,192,583
04/09/10	25,731	Tax	6,815,028,354	2,315,810,040	3,140,290,363	1,358,927,951	5,456,100,403	3,674,737,991	4,499,218,314
04/09/10	155,838	Tax	6,815,184,192	2,315,810,040	3,140,446,201	1,358,927,951	5,456,256,241	3,674,737,991	4,499,374,152
04/09/10	10,344,971	Tax	6,825,529,163	2,315,810,040	3,150,791,172	1,358,927,951	5,466,601,212	3,674,737,991	4,509,719,123
04/08/10	202	Tax	6,825,529,364	2,315,810,040	3,150,791,373	1,358,927,951	5,466,601,413	3,674,737,991	4,509,719,324
04/08/10	203	Tax	6,825,529,567	2,315,810,040	3,150,791,576	1,358,927,951	5,466,601,616	3,674,737,991	4,509,719,527
04/08/10	619	Tax	6,825,530,186	2,315,810,040	3,150,792,195	1,358,927,951	5,466,602,235	3,674,737,991	4,509,720,146
04/08/10	622	Tax	6,825,530,808	2,315,810,040	3,150,792,817	1,358,927,951	5,466,602,857	3,674,737,991	4,509,720,768
04/08/10	81,540	Tax	6,825,612,348	2,315,810,040	3,150,874,357	1,358,927,951	5,466,684,397	3,674,737,991	4,509,802,308
04/08/10	250,000	Tax	6,825,862,348	2,315,810,040	3,151,124,357	1,358,927,951	5,466,934,397	3,674,737,991	4,510,052,308
04/07/10	1,239	Tax	6,825,863,587	2,315,810,040	3,151,125,596	1,358,927,951	5,466,935,636	3,674,737,991	4,510,053,547
04/07/10	1,244	Tax	6,825,864,832	2,315,810,040	3,151,126,841	1,358,927,951	5,466,936,881	3,674,737,991	4,510,054,792
04/07/10	12,133	Tax	6,825,876,964	2,315,810,040	3,151,138,973	1,358,927,951	5,466,949,013	3,674,737,991	4,510,066,924
04/07/10	12,187	Tax	6,825,889,151	2,315,810,040	3,151,151,160	1,358,927,951	5,466,961,200	3,674,737,991	4,510,079,111
04/07/10	178,104	Tax	6,826,067,255	2,315,810,040	3,151,329,264	1,358,927,951	5,467,139,304	3,674,737,991	4,510,257,215
04/07/10	178,899	Tax	6,826,246,155	2,315,810,040	3,151,508,164	1,358,927,951	5,467,318,204	3,674,737,991	4,510,436,115
04/07/10	500,337	Tax	6,826,746,492	2,315,810,040	3,152,008,501	1,358,927,951	5,467,818,541	3,674,737,991	4,510,936,452
04/07/10	4,899,714	Tax	6,831,646,206	2,315,810,040	3,156,908,215	1,358,927,951	5,472,718,255	3,674,737,991	4,515,836,166
04/07/10	71,925,483	Tax	6,903,571,689	2,315,810,040	3,228,833,698	1,358,927,951	5,544,643,738	3,674,737,991	4,587,761,649
04/06/10	32	Tax	6,903,571,720	2,315,810,040	3,228,833,729	1,358,927,951	5,544,643,769	3,674,737,991	4,587,761,680
04/06/10	32	Tax	6,903,571,752	2,315,810,040	3,228,833,761	1,358,927,951	5,544,643,801	3,674,737,991	4,587,761,712
04/06/10	167	Tax	6,903,571,920	2,315,810,040	3,228,833,929	1,358,927,951	5,544,643,969	3,674,737,991	4,587,761,880
04/06/10	168	Tax	6,903,572,088	2,315,810,040	3,228,834,097	1,358,927,951	5,544,644,137	3,674,737,991	4,587,762,048
04/06/10	194	Tax	6,903,572,282	2,315,810,040	3,228,834,291	1,358,927,951	5,544,644,331	3,674,737,991	4,587,762,242
04/06/10	195	Tax	6,903,572,476	2,315,810,040	3,228,834,485	1,358,927,951	5,544,644,525	3,674,737,991	4,587,762,436
04/06/10	267	Tax	6,903,572,743	2,315,810,040	3,228,834,752	1,358,927,951	5,544,644,792	3,674,737,991	4,587,762,703
04/06/10	268	Tax	6,903,573,011	2,315,810,040	3,228,835,020	1,358,927,951	5,544,645,060	3,674,737,991	4,587,762,971
04/06/10	2,870	Tax	6,903,575,881	2,315,810,040	3,228,837,890	1,358,927,951	5,544,647,930	3,674,737,991	4,587,765,841

04/06/10	2,883	Tax	6,903,578,764	2,315,810,040	3,228,840,773	1,358,927,951	5,544,650,813	3,674,737,991	4,587,768,724
04/06/10	12,133	Tax	6,903,590,897	2,315,810,040	3,228,852,906	1,358,927,951	5,544,662,946	3,674,737,991	4,587,780,857
04/06/10	12,187	Tax	6,903,603,084	2,315,810,040	3,228,865,093	1,358,927,951	5,544,675,133	3,674,737,991	4,587,793,044
04/06/10	12,815	Tax	6,903,615,899	2,315,810,040	3,228,877,908	1,358,927,951	5,544,687,948	3,674,737,991	4,587,805,859
04/06/10	67,627	Tax	6,903,683,526	2,315,810,040	3,228,945,535	1,358,927,951	5,544,755,575	3,674,737,991	4,587,873,486
04/06/10	78,223	Tax	6,903,761,749	2,315,810,040	3,229,023,758	1,358,927,951	5,544,833,798	3,674,737,991	4,587,951,709
04/06/10	107,686	Tax	6,903,869,435	2,315,810,040	3,229,131,444	1,358,927,951	5,544,941,484	3,674,737,991	4,588,059,395
04/06/10	1,159,132	Tax	6,905,028,567	2,315,810,040	3,230,290,576	1,358,927,951	5,546,100,616	3,674,737,991	4,589,218,527
04/06/10	4,899,714	Tax	6,909,928,281	2,315,810,040	3,235,190,290	1,358,927,951	5,551,000,330	3,674,737,991	4,594,118,241
04/05/10	174,574	Tax	6,910,102,855	2,315,810,040	3,235,364,864	1,358,927,951	5,551,174,904	3,674,737,991	4,594,292,815
04/05/10	175,354	Tax	6,910,278,209	2,315,810,040	3,235,540,218	1,358,927,951	5,551,350,258	3,674,737,991	4,594,468,169
04/05/10	70,500,000	Tax	6,980,778,209	2,315,810,040	3,306,040,218	1,358,927,951	5,621,850,258	3,674,737,991	4,664,968,169
03/30/10	6	Tax	6,980,778,215	2,315,810,040	3,306,040,224	1,358,927,951	5,621,850,264	3,674,737,991	4,664,968,175
03/30/10	6	Tax	6,980,778,221	2,315,810,040	3,306,040,230	1,358,927,951	5,621,850,270	3,674,737,991	4,664,968,181
03/30/10	202	Tax	6,980,778,423	2,315,810,040	3,306,040,432	1,358,927,951	5,621,850,472	3,674,737,991	4,664,968,383
03/30/10	203	Tax	6,980,778,626	2,315,810,040	3,306,040,635	1,358,927,951	5,621,850,675	3,674,737,991	4,664,968,586
03/30/10	565	Tax	6,980,779,192	2,315,810,040	3,306,041,201	1,358,927,951	5,621,851,241	3,674,737,991	4,664,969,152
03/30/10	568	Tax	6,980,779,759	2,315,810,040	3,306,041,768	1,358,927,951	5,621,851,808	3,674,737,991	4,664,969,719
03/30/10	580	Tax	6,980,780,339	2,315,810,040	3,306,042,348	1,358,927,951	5,621,852,388	3,674,737,991	4,664,970,299
03/30/10	583	Tax	6,980,780,922	2,315,810,040	3,306,042,931	1,358,927,951	5,621,852,971	3,674,737,991	4,664,970,882
03/30/10	2,593	Tax	6,980,783,515	2,315,810,040	3,306,045,524	1,358,927,951	5,621,855,564	3,674,737,991	4,664,973,475
03/30/10	81,540	Tax	6,980,865,055	2,315,810,040	3,306,127,064	1,358,927,951	5,621,937,104	3,674,737,991	4,665,055,015
03/30/10	228,321	Tax	6,981,093,376	2,315,810,040	3,306,355,385	1,358,927,951	5,622,165,425	3,674,737,991	4,665,283,336
03/30/10	234,199	Tax	6,981,327,575	2,315,810,040	3,306,589,584	1,358,927,951	5,622,399,624	3,674,737,991	4,665,517,535
03/29/10	3	Tax	6,981,327,578	2,315,810,040	3,306,589,587	1,358,927,951	5,622,399,627	3,674,737,991	4,665,517,538
03/29/10	3	Tax	6,981,327,580	2,315,810,040	3,306,589,589	1,358,927,951	5,622,399,629	3,674,737,991	4,665,517,540
03/29/10	3	Tax	6,981,327,584	2,315,810,040	3,306,589,593	1,358,927,951	5,622,399,633	3,674,737,991	4,665,517,544
03/29/10	3	Tax	6,981,327,587	2,315,810,040	3,306,589,596	1,358,927,951	5,622,399,636	3,674,737,991	4,665,517,547
03/29/10	13	Tax	6,981,327,600	2,315,810,040	3,306,589,609	1,358,927,951	5,622,399,649	3,674,737,991	4,665,517,560
03/29/10	48	Tax	6,981,327,648	2,315,810,040	3,306,589,657	1,358,927,951	5,622,399,697	3,674,737,991	4,665,517,608
03/29/10	48	Tax	6,981,327,696	2,315,810,040	3,306,589,705	1,358,927,951	5,622,399,745	3,674,737,991	4,665,517,656
03/29/10	110	Tax	6,981,327,806	2,315,810,040	3,306,589,815	1,358,927,951	5,622,399,855	3,674,737,991	4,665,517,766
03/29/10	1,125	Tax	6,981,328,931	2,315,810,040	3,306,590,940	1,358,927,951	5,622,400,980	3,674,737,991	4,665,518,891
03/29/10	1,302	Tax	6,981,330,233	2,315,810,040	3,306,592,242	1,358,927,951	5,622,402,282	3,674,737,991	4,665,520,193
03/29/10	19,290	Tax	6,981,349,523	2,315,810,040	3,306,611,532	1,358,927,951	5,622,421,572	3,674,737,991	4,665,539,483
03/26/10	-1,667,750	Tax	6,979,681,773	2,315,810,040	3,304,943,782	1,358,927,951	5,620,753,822	3,674,737,991	4,663,871,733
03/26/10	-4,148	Tax	6,979,677,625	2,315,810,040	3,304,939,634	1,358,927,951	5,620,749,674	3,674,737,991	4,663,867,585
03/26/10	-4,130	Tax	6,979,673,495	2,315,810,040	3,304,935,504	1,358,927,951	5,620,745,544	3,674,737,991	4,663,863,455
03/11/10	6,706	Tax	6,979,680,201	2,315,810,040	3,304,942,210	1,358,927,951	5,620,752,250	3,674,737,991	4,663,870,161
03/11/10	6,736	Tax	6,979,686,937	2,315,810,040	3,304,948,946	1,358,927,951	5,620,758,986	3,674,737,991	4,663,876,897
03/11/10	2,708,129	Tax	6,982,395,066	2,315,810,040	3,307,657,075	1,358,927,951	5,623,467,115	3,674,737,991	4,666,585,026
03/01/10	293,000	U.S. Partner	6,982,688,066	2,316,103,040	3,307,657,075	1,358,927,951	5,623,760,115	3,675,030,991	4,666,585,026
03/01/10	293,000	U.S. Partner	6,982,981,065	2,316,396,040	3,307,657,075	1,358,927,951	5,624,053,114	3,675,323,991	4,666,585,026
03/01/10	294,308	U.S. Partner	6,983,275,373	2,316,690,348	3,307,657,075	1,358,927,951	5,624,347,422	3,675,618,299	4,666,585,026
03/01/10	294,308	U.S. Partner	6,983,569,681	2,316,984,656	3,307,657,075	1,358,927,951	5,624,641,730	3,675,912,607	4,666,585,026
03/01/10	118,325,000	U.S. Partner	7,101,894,681	2,435,309,656	3,307,657,075	1,358,927,951	5,742,966,730	3,794,237,607	4,666,585,026
03/01/10	118,325,000	U.S. Partner	7,220,219,681	2,553,634,656	3,307,657,075	1,358,927,951	5,861,291,730	3,912,562,607	4,666,585,026
02/09/10	9,533	U.S. Partner	7,220,229,215	2,553,644,189	3,307,657,075	1,358,927,951	5,861,301,264	3,912,572,140	4,666,585,026
02/09/10	9,533	U.S. Partner	7,220,238,748	2,553,653,723	3,307,657,075	1,358,927,951	5,861,310,797	3,912,581,674	4,666,585,026

02/09/10	9,576	U.S. Partner	7,220,248,324	2,553,663,299	3,307,657,075	1,358,927,951	5,861,320,373	3,912,591,250	4,666,585,026
02/09/10	9,576	U.S. Partner	7,220,257,900	2,553,672,875	3,307,657,075	1,358,927,951	5,861,329,949	3,912,600,826	4,666,585,026
02/09/10	3,850,000	U.S. Partner	7,224,107,900	2,557,522,875	3,307,657,075	1,358,927,951	5,865,179,949	3,916,450,826	4,666,585,026
02/09/10	3,850,000	U.S. Partner	7,227,957,900	2,561,372,875	3,307,657,075	1,358,927,951	5,869,029,949	3,920,300,826	4,666,585,026
01/07/10	437	U.S. Partner	7,227,958,337	2,561,373,312	3,307,657,075	1,358,927,951	5,869,030,386	3,920,301,263	4,666,585,026
01/07/10	437	U.S. Partner	7,227,958,774	2,561,373,748	3,307,657,075	1,358,927,951	5,869,030,823	3,920,301,699	4,666,585,026
01/07/10	439	U.S. Partner	7,227,959,213	2,561,374,187	3,307,657,075	1,358,927,951	5,869,031,262	3,920,302,138	4,666,585,026
01/07/10	439	U.S. Partner	7,227,959,652	2,561,374,626	3,307,657,075	1,358,927,951	5,869,031,701	3,920,302,577	4,666,585,026
01/07/10	176,400	U.S. Partner	7,228,136,052	2,561,551,026	3,307,657,075	1,358,927,951	5,869,208,101	3,920,478,977	4,666,585,026
01/07/10	176,400	U.S. Partner	7,228,312,452	2,561,727,426	3,307,657,075	1,358,927,951	5,869,384,501	3,920,655,377	4,666,585,026
12/31/2009	-10,078	Tax	7,228,302,374	2,561,727,426	3,307,646,997	1,358,927,951	5,869,374,423	3,920,655,377	4,666,574,948
12/31/2009	-25	Tax	7,228,302,349	2,561,727,426	3,307,646,972	1,358,927,951	5,869,374,398	3,920,655,377	4,666,574,923
12/31/2009	-25	Tax	7,228,302,324	2,561,727,426	3,307,646,947	1,358,927,951	5,869,374,373	3,920,655,377	4,666,574,898
12/31/2009	111,576,000	Ex U.S.	7,339,878,324	2,561,727,426	3,307,646,947	1,470,503,951	5,869,374,373	4,032,231,377	4,778,150,898
12/11/2009	15,678	Tax	7,339,894,002	2,561,727,426	3,307,662,625	1,470,503,951	5,869,390,051	4,032,231,377	4,778,166,576
12/11/2009	15,748	Tax	7,339,909,750	2,561,727,426	3,307,678,373	1,470,503,951	5,869,405,799	4,032,231,377	4,778,182,324
12/11/2009	308,599	Tax	7,340,218,349	2,561,727,426	3,307,986,972	1,470,503,951	5,869,714,398	4,032,231,377	4,778,490,923
12/11/2009	309,966	Tax	7,340,528,315	2,561,727,426	3,308,296,938	1,470,503,951	5,870,024,364	4,032,231,377	4,778,800,889
12/11/2009	6,331,322	Tax	7,346,859,637	2,561,727,426	3,314,628,260	1,470,503,951	5,876,355,686	4,032,231,377	4,785,132,211
12/11/2009	124,620,105	Tax	7,471,479,742	2,561,727,426	3,439,248,365	1,470,503,951	6,000,975,791	4,032,231,377	4,909,752,316
12/10/2009	8	Tax	7,471,479,750	2,561,727,426	3,439,248,373	1,470,503,951	6,000,975,799	4,032,231,377	4,909,752,324
12/10/2009	8	Tax	7,471,479,758	2,561,727,426	3,439,248,381	1,470,503,951	6,000,975,807	4,032,231,377	4,909,752,332
12/10/2009	52	Tax	7,471,479,809	2,561,727,426	3,439,248,432	1,470,503,951	6,000,975,858	4,032,231,377	4,909,752,383
12/10/2009	52	Tax	7,471,479,861	2,561,727,426	3,439,248,484	1,470,503,951	6,000,975,910	4,032,231,377	4,909,752,435
12/10/2009	314	Tax	7,471,480,175	2,561,727,426	3,439,248,798	1,470,503,951	6,000,976,224	4,032,231,377	4,909,752,749
12/10/2009	316	Tax	7,471,480,491	2,561,727,426	3,439,249,114	1,470,503,951	6,000,976,540	4,032,231,377	4,909,753,065
12/10/2009	406	Tax	7,471,480,897	2,561,727,426	3,439,249,520	1,470,503,951	6,000,976,946	4,032,231,377	4,909,753,471
12/10/2009	408	Tax	7,471,481,305	2,561,727,426	3,439,249,928	1,470,503,951	6,000,977,354	4,032,231,377	4,909,753,879
12/10/2009	433	Tax	7,471,481,738	2,561,727,426	3,439,250,361	1,470,503,951	6,000,977,787	4,032,231,377	4,909,754,312
12/10/2009	435	Tax	7,471,482,173	2,561,727,426	3,439,250,796	1,470,503,951	6,000,978,222	4,032,231,377	4,909,754,747
12/10/2009	718	Tax	7,471,482,891	2,561,727,426	3,439,251,514	1,470,503,951	6,000,978,940	4,032,231,377	4,909,755,465
12/10/2009	721	Tax	7,471,483,611	2,561,727,426	3,439,252,234	1,470,503,951	6,000,979,660	4,032,231,377	4,909,756,185
12/10/2009	936	Tax	7,471,484,548	2,561,727,426	3,439,253,171	1,470,503,951	6,000,980,597	4,032,231,377	4,909,757,122
12/10/2009	941	Tax	7,471,485,488	2,561,727,426	3,439,254,111	1,470,503,951	6,000,981,537	4,032,231,377	4,909,758,062
12/10/2009	3,217	Tax	7,471,488,705	2,561,727,426	3,439,257,328	1,470,503,951	6,000,984,754	4,032,231,377	4,909,761,279
12/10/2009	4,659	Tax	7,471,493,364	2,561,727,426	3,439,261,987	1,470,503,951	6,000,989,413	4,032,231,377	4,909,765,938
12/10/2009	4,679	Tax	7,471,498,043	2,561,727,426	3,439,266,666	1,470,503,951	6,000,994,092	4,032,231,377	4,909,770,617
12/10/2009	19,692	Tax	7,471,517,735	2,561,727,426	3,439,286,358	1,470,503,951	6,001,013,784	4,032,231,377	4,909,790,309
12/10/2009	19,692	Tax	7,471,537,427	2,561,727,426	3,439,306,050	1,470,503,951	6,001,033,476	4,032,231,377	4,909,810,001
12/10/2009	19,779	Tax	7,471,557,206	2,561,727,426	3,439,325,829	1,470,503,951	6,001,053,255	4,032,231,377	4,909,829,780
12/10/2009	19,779	Tax	7,471,576,985	2,561,727,426	3,439,345,608	1,470,503,951	6,001,073,034	4,032,231,377	4,909,849,559
12/10/2009	20,798	Tax	7,471,597,783	2,561,727,426	3,439,366,406	1,470,503,951	6,001,093,832	4,032,231,377	4,909,870,357
12/10/2009	126,953	Tax	7,471,724,736	2,561,727,426	3,439,493,359	1,470,503,951	6,001,220,785	4,032,231,377	4,909,997,310
12/10/2009	164,099	Tax	7,471,888,835	2,561,727,426	3,439,657,458	1,470,503,951	6,001,384,884	4,032,231,377	4,910,161,409
12/10/2009	174,770	Tax	7,472,063,605	2,561,727,426	3,439,832,228	1,470,503,951	6,001,559,654	4,032,231,377	4,910,336,179
12/10/2009	289,802	Tax	7,472,353,407	2,561,727,426	3,440,122,030	1,470,503,951	6,001,849,456	4,032,231,377	4,910,625,981
12/10/2009	314,463	Tax	7,472,667,870	2,561,727,426	3,440,436,493	1,470,503,951	6,002,163,919	4,032,231,377	4,910,940,444
12/10/2009	315,855	Tax	7,472,983,725	2,561,727,426	3,440,752,348	1,470,503,951	6,002,479,774	4,032,231,377	4,911,256,299
12/10/2009	378,144	Tax	7,473,361,869	2,561,727,426	3,441,130,492	1,470,503,951	6,002,857,918	4,032,231,377	4,911,634,443

12/10/2009	1,881,227	Tax	7,475,243,096	2,561,727,426	3,443,011,719	1,470,503,951	6,004,739,145	4,032,231,377	4,913,515,670
12/10/2009	7,952,070	Tax	7,483,195,166	2,561,727,426	3,450,963,789	1,470,503,951	6,012,691,215	4,032,231,377	4,921,467,740
12/10/2009	7,952,070	Tax	7,491,147,236	2,561,727,426	3,458,915,859	1,470,503,951	6,020,643,285	4,032,231,377	4,929,419,810
12/10/2009	126,987,953	Tax	7,618,135,189	2,561,727,426	3,585,903,812	1,470,503,951	6,147,631,238	4,032,231,377	5,056,407,763
12/3/2009	401,164	U.S. Partner	7,618,536,352	2,562,128,590	3,585,903,812	1,470,503,951	6,148,032,401	4,032,632,541	5,056,407,763
12/3/2009	402,940	U.S. Partner	7,618,939,293	2,562,531,530	3,585,903,812	1,470,503,951	6,148,435,342	4,033,035,481	5,056,407,763
12/3/2009	162,000,000	U.S. Partner	7,780,939,293	2,724,531,530	3,585,903,812	1,470,503,951	6,310,435,342	4,195,035,481	5,056,407,763
12/2/2009	401,164	U.S. Partner	7,781,340,456	2,724,932,693	3,585,903,812	1,470,503,951	6,310,836,505	4,195,436,644	5,056,407,763
12/2/2009	402,940	U.S. Partner	7,781,743,396	2,725,335,634	3,585,903,812	1,470,503,951	6,311,239,445	4,195,839,585	5,056,407,763
12/2/2009	162,000,000	U.S. Partner	7,943,743,396	2,887,335,634	3,585,903,812	1,470,503,951	6,473,239,445	4,357,839,585	5,056,407,763
11/30/2009	23,872	U.S. Partner	7,943,767,268	2,887,359,506	3,585,903,812	1,470,503,951	6,473,263,317	4,357,863,457	5,056,407,763
11/30/2009	23,978	U.S. Partner	7,943,791,246	2,887,383,483	3,585,903,812	1,470,503,951	6,473,287,295	4,357,887,434	5,056,407,763
11/19/2009	-9,496	Tax	7,943,781,750	2,887,383,483	3,585,894,316	1,470,503,951	6,473,277,799	4,357,887,434	5,056,398,267
11/19/2009	-24	Tax	7,943,781,726	2,887,383,483	3,585,894,292	1,470,503,951	6,473,277,775	4,357,887,434	5,056,398,243
11/19/2009	-24	Tax	7,943,781,703	2,887,383,483	3,585,894,269	1,470,503,951	6,473,277,752	4,357,887,434	5,056,398,220
11/19/2009	1	Tax	7,943,781,704	2,887,383,483	3,585,894,270	1,470,503,951	6,473,277,753	4,357,887,434	5,056,398,221
11/19/2009	1	Tax	7,943,781,705	2,887,383,483	3,585,894,271	1,470,503,951	6,473,277,754	4,357,887,434	5,056,398,222
11/19/2009	392	Tax	7,943,782,097	2,887,383,483	3,585,894,663	1,470,503,951	6,473,278,146	4,357,887,434	5,056,398,614
10/30/2009	-32,337	Tax	7,943,749,760	2,887,383,483	3,585,862,326	1,470,503,951	6,473,245,809	4,357,887,434	5,056,366,277
10/30/2009	-80	Tax	7,943,749,680	2,887,383,483	3,585,862,245	1,470,503,951	6,473,245,729	4,357,887,434	5,056,366,196
10/30/2009	-80	Tax	7,943,749,599	2,887,383,483	3,585,862,165	1,470,503,951	6,473,245,649	4,357,887,434	5,056,366,116
10/1/2009	485	U.S. Partner	7,943,750,085	2,887,383,969	3,585,862,165	1,470,503,951	6,473,246,134	4,357,887,920	5,056,366,116
10/1/2009	485	U.S. Partner	7,943,750,570	2,887,384,454	3,585,862,165	1,470,503,951	6,473,246,619	4,357,888,405	5,056,366,116
10/1/2009	488	U.S. Partner	7,943,751,058	2,887,384,942	3,585,862,165	1,470,503,951	6,473,247,107	4,357,888,892	5,056,366,116
10/1/2009	488	U.S. Partner	7,943,751,545	2,887,385,429	3,585,862,165	1,470,503,951	6,473,247,594	4,357,889,380	5,056,366,116
10/1/2009	196,000	U.S. Partner	7,943,947,545	2,887,581,429	3,585,862,165	1,470,503,951	6,473,443,594	4,358,085,380	5,056,366,116
10/1/2009	196,000	U.S. Partner	7,944,143,545	2,887,777,429	3,585,862,165	1,470,503,951	6,473,639,594	4,358,281,380	5,056,366,116
9/30/2009	-1,293,742	Tax	7,942,849,803	2,887,777,429	3,584,568,423	1,470,503,951	6,472,345,852	4,358,281,380	5,055,072,374
9/30/2009	-58,862	Tax	7,942,790,941	2,887,777,429	3,584,509,561	1,470,503,951	6,472,286,990	4,358,281,380	5,055,013,512
9/30/2009	-24,265	Tax	7,942,766,676	2,887,777,429	3,584,485,296	1,470,503,951	6,472,262,725	4,358,281,380	5,054,989,247
9/30/2009	-24,163	Tax	7,942,742,513	2,887,777,429	3,584,461,133	1,470,503,951	6,472,238,562	4,358,281,380	5,054,965,084
9/30/2009	-17,839	Tax	7,942,724,674	2,887,777,429	3,584,443,294	1,470,503,951	6,472,220,723	4,358,281,380	5,054,947,245
9/30/2009	-17,756	Tax	7,942,706,918	2,887,777,429	3,584,425,538	1,470,503,951	6,472,202,967	4,358,281,380	5,054,929,489
9/30/2009	-12,687	Tax	7,942,694,231	2,887,777,429	3,584,412,851	1,470,503,951	6,472,190,280	4,358,281,380	5,054,916,802
9/30/2009	-12,655	Tax	7,942,681,576	2,887,777,429	3,584,400,196	1,470,503,951	6,472,177,625	4,358,281,380	5,054,904,147
9/30/2009	-8,383	Tax	7,942,673,193	2,887,777,429	3,584,391,813	1,470,503,951	6,472,169,242	4,358,281,380	5,054,895,764
9/30/2009	-6,435	Tax	7,942,666,758	2,887,777,429	3,584,385,378	1,470,503,951	6,472,162,807	4,358,281,380	5,054,889,329
9/30/2009	-3,572	Tax	7,942,663,186	2,887,777,429	3,584,381,806	1,470,503,951	6,472,159,235	4,358,281,380	5,054,885,757
9/30/2009	-3,218	Tax	7,942,659,968	2,887,777,429	3,584,378,588	1,470,503,951	6,472,156,017	4,358,281,380	5,054,882,539
9/30/2009	-3,204	Tax	7,942,656,765	2,887,777,429	3,584,375,385	1,470,503,951	6,472,152,814	4,358,281,380	5,054,879,336
9/30/2009	-1,926	Tax	7,942,654,839	2,887,777,429	3,584,373,459	1,470,503,951	6,472,150,888	4,358,281,380	5,054,877,410
9/30/2009	-1,925	Tax	7,942,652,914	2,887,777,429	3,584,371,534	1,470,503,951	6,472,148,963	4,358,281,380	5,054,875,485
9/30/2009	-1,896	Tax	7,942,651,018	2,887,777,429	3,584,369,638	1,470,503,951	6,472,147,067	4,358,281,380	5,054,873,589
9/30/2009	-1,887	Tax	7,942,649,131	2,887,777,429	3,584,367,751	1,470,503,951	6,472,145,180	4,358,281,380	5,054,871,702
9/30/2009	-1,544	Tax	7,942,647,587	2,887,777,429	3,584,366,207	1,470,503,951	6,472,143,636	4,358,281,380	5,054,870,158
9/30/2009	-1,538	Tax	7,942,646,049	2,887,777,429	3,584,364,669	1,470,503,951	6,472,142,098	4,358,281,380	5,054,868,620
9/30/2009	-1,380	Tax	7,942,644,669	2,887,777,429	3,584,363,289	1,470,503,951	6,472,140,718	4,358,281,380	5,054,867,240
9/30/2009	-1,377	Tax	7,942,643,292	2,887,777,429	3,584,361,912	1,470,503,951	6,472,139,341	4,358,281,380	5,054,865,863
9/30/2009	-505	Tax	7,942,642,787	2,887,777,429	3,584,361,407	1,470,503,951	6,472,138,836	4,358,281,380	5,054,865,358

9/30/2009	-504	Tax	7,942,642,283	2,887,777,429	3,584,360,903	1,470,503,951	6,472,138,332	4,358,281,380	5,054,864,854
9/30/2009	-146	Tax	7,942,642,137	2,887,777,429	3,584,360,757	1,470,503,951	6,472,138,186	4,358,281,380	5,054,864,708
9/30/2009	-146	Tax	7,942,641,991	2,887,777,429	3,584,360,611	1,470,503,951	6,472,138,040	4,358,281,380	5,054,864,562
9/30/2009	-60	Tax	7,942,641,931	2,887,777,429	3,584,360,551	1,470,503,951	6,472,137,980	4,358,281,380	5,054,864,502
9/30/2009	-60	Tax	7,942,641,870	2,887,777,429	3,584,360,490	1,470,503,951	6,472,137,920	4,358,281,380	5,054,864,441
9/30/2009	-60	Tax	7,942,641,810	2,887,777,429	3,584,360,430	1,470,503,951	6,472,137,859	4,358,281,380	5,054,864,381
9/30/2009	-60	Tax	7,942,641,751	2,887,777,429	3,584,360,371	1,470,503,951	6,472,137,800	4,358,281,380	5,054,864,322
9/30/2009	-44	Tax	7,942,641,706	2,887,777,429	3,584,360,326	1,470,503,951	6,472,137,755	4,358,281,380	5,054,864,277
9/30/2009	-44	Tax	7,942,641,662	2,887,777,429	3,584,360,282	1,470,503,951	6,472,137,711	4,358,281,380	5,054,864,233
9/30/2009	-44	Tax	7,942,641,618	2,887,777,429	3,584,360,238	1,470,503,951	6,472,137,667	4,358,281,380	5,054,864,189
9/30/2009	-44	Tax	7,942,641,574	2,887,777,429	3,584,360,194	1,470,503,951	6,472,137,623	4,358,281,380	5,054,864,145
9/30/2009	-32	Tax	7,942,641,542	2,887,777,429	3,584,360,162	1,470,503,951	6,472,137,591	4,358,281,380	5,054,864,113
9/30/2009	-31	Tax	7,942,641,511	2,887,777,429	3,584,360,131	1,470,503,951	6,472,137,560	4,358,281,380	5,054,864,082
9/30/2009	-31	Tax	7,942,641,479	2,887,777,429	3,584,360,099	1,470,503,951	6,472,137,528	4,358,281,380	5,054,864,050
9/30/2009	-31	Tax	7,942,641,448	2,887,777,429	3,584,360,068	1,470,503,951	6,472,137,497	4,358,281,380	5,054,864,019
9/30/2009	-21	Tax	7,942,641,427	2,887,777,429	3,584,360,047	1,470,503,951	6,472,137,476	4,358,281,380	5,054,863,998
9/30/2009	-21	Tax	7,942,641,406	2,887,777,429	3,584,360,026	1,470,503,951	6,472,137,456	4,358,281,380	5,054,863,977
9/30/2009	-19	Tax	7,942,641,387	2,887,777,429	3,584,360,007	1,470,503,951	6,472,137,437	4,358,281,380	5,054,863,958
9/30/2009	-16	Tax	7,942,641,371	2,887,777,429	3,584,359,991	1,470,503,951	6,472,137,421	4,358,281,380	5,054,863,942
9/30/2009	-16	Tax	7,942,641,356	2,887,777,429	3,584,359,976	1,470,503,951	6,472,137,405	4,358,281,380	5,054,863,927
9/30/2009	-9	Tax	7,942,641,347	2,887,777,429	3,584,359,967	1,470,503,951	6,472,137,396	4,358,281,380	5,054,863,918
9/30/2009	-9	Tax	7,942,641,338	2,887,777,429	3,584,359,958	1,470,503,951	6,472,137,387	4,358,281,380	5,054,863,909
9/30/2009	-5	Tax	7,942,641,333	2,887,777,429	3,584,359,953	1,470,503,951	6,472,137,382	4,358,281,380	5,054,863,904
9/30/2009	-5	Tax	7,942,641,328	2,887,777,429	3,584,359,948	1,470,503,951	6,472,137,377	4,358,281,380	5,054,863,899
9/30/2009	-5	Tax	7,942,641,323	2,887,777,429	3,584,359,943	1,470,503,951	6,472,137,372	4,358,281,380	5,054,863,894
9/30/2009	-5	Tax	7,942,641,319	2,887,777,429	3,584,359,939	1,470,503,951	6,472,137,368	4,358,281,380	5,054,863,890
9/30/2009	-5	Tax	7,942,641,314	2,887,777,429	3,584,359,934	1,470,503,951	6,472,137,363	4,358,281,380	5,054,863,885
9/30/2009	-5	Tax	7,942,641,309	2,887,777,429	3,584,359,929	1,470,503,951	6,472,137,358	4,358,281,380	5,054,863,880
9/30/2009	-5	Tax	7,942,641,305	2,887,777,429	3,584,359,925	1,470,503,951	6,472,137,354	4,358,281,380	5,054,863,876
9/30/2009	-5	Tax	7,942,641,300	2,887,777,429	3,584,359,920	1,470,503,951	6,472,137,349	4,358,281,380	5,054,863,871
9/30/2009	-4	Tax	7,942,641,296	2,887,777,429	3,584,359,916	1,470,503,951	6,472,137,345	4,358,281,380	5,054,863,867
9/30/2009	-4	Tax	7,942,641,292	2,887,777,429	3,584,359,912	1,470,503,951	6,472,137,341	4,358,281,380	5,054,863,863
9/30/2009	-4	Tax	7,942,641,288	2,887,777,429	3,584,359,908	1,470,503,951	6,472,137,337	4,358,281,380	5,054,863,859
9/30/2009	-4	Tax	7,942,641,285	2,887,777,429	3,584,359,905	1,470,503,951	6,472,137,334	4,358,281,380	5,054,863,856
9/30/2009	-3	Tax	7,942,641,281	2,887,777,429	3,584,359,901	1,470,503,951	6,472,137,330	4,358,281,380	5,054,863,852
9/30/2009	-3	Tax	7,942,641,278	2,887,777,429	3,584,359,898	1,470,503,951	6,472,137,327	4,358,281,380	5,054,863,849
9/30/2009	-3	Tax	7,942,641,274	2,887,777,429	3,584,359,894	1,470,503,951	6,472,137,323	4,358,281,380	5,054,863,845
9/30/2009	-3	Tax	7,942,641,271	2,887,777,429	3,584,359,891	1,470,503,951	6,472,137,320	4,358,281,380	5,054,863,842
9/30/2009	-1	Tax	7,942,641,270	2,887,777,429	3,584,359,890	1,470,503,951	6,472,137,319	4,358,281,380	5,054,863,841
9/30/2009	-1	Tax	7,942,641,268	2,887,777,429	3,584,359,888	1,470,503,951	6,472,137,317	4,358,281,380	5,054,863,839
9/30/2009	-1	Tax	7,942,641,267	2,887,777,429	3,584,359,887	1,470,503,951	6,472,137,316	4,358,281,380	5,054,863,838
9/30/2009	-1	Tax	7,942,641,266	2,887,777,429	3,584,359,886	1,470,503,951	6,472,137,315	4,358,281,380	5,054,863,837
9/30/2009	19	Tax	7,942,641,285	2,887,777,429	3,584,359,905	1,470,503,951	6,472,137,334	4,358,281,380	5,054,863,856
9/30/2009	19	Tax	7,942,641,304	2,887,777,429	3,584,359,924	1,470,503,951	6,472,137,353	4,358,281,380	5,054,863,875
9/30/2009	54	Tax	7,942,641,358	2,887,777,429	3,584,359,978	1,470,503,951	6,472,137,407	4,358,281,380	5,054,863,929
9/30/2009	54	Tax	7,942,641,412	2,887,777,429	3,584,360,032	1,470,503,951	6,472,137,462	4,358,281,380	5,054,863,983
9/30/2009	385	Tax	7,942,641,798	2,887,777,429	3,584,360,418	1,470,503,951	6,472,137,847	4,358,281,380	5,054,864,369
9/30/2009	387	Tax	7,942,642,185	2,887,777,429	3,584,360,805	1,470,503,951	6,472,138,234	4,358,281,380	5,054,864,756
9/30/2009	396	Tax	7,942,642,581	2,887,777,429	3,584,361,201	1,470,503,951	6,472,138,630	4,358,281,380	5,054,865,152

9/30/2009	397	Tax	7,942,642,978	2,887,777,429	3,584,361,598	1,470,503,951	6,472,139,027	4,358,281,380	5,054,865,549
9/30/2009	495	Tax	7,942,643,473	2,887,777,429	3,584,362,093	1,470,503,951	6,472,139,522	4,358,281,380	5,054,866,044
9/30/2009	497	Tax	7,942,643,971	2,887,777,429	3,584,362,591	1,470,503,951	6,472,140,020	4,358,281,380	5,054,866,542
9/30/2009	7,625	Tax	7,942,651,596	2,887,777,429	3,584,370,216	1,470,503,951	6,472,147,645	4,358,281,380	5,054,874,167
9/30/2009	21,899	Tax	7,942,673,495	2,887,777,429	3,584,392,115	1,470,503,951	6,472,169,544	4,358,281,380	5,054,896,066
9/30/2009	32,068	U.S. Partner	7,942,705,563	2,887,809,497	3,584,392,115	1,470,503,951	6,472,201,612	4,358,313,448	5,054,896,066
9/30/2009	32,210	U.S. Partner	7,942,737,773	2,887,841,708	3,584,392,115	1,470,503,951	6,472,233,822	4,358,345,659	5,054,896,066
9/30/2009	155,650	Tax	7,942,893,423	2,887,841,708	3,584,547,765	1,470,503,951	6,472,389,472	4,358,345,659	5,055,051,716
9/30/2009	159,752	Tax	7,943,053,175	2,887,841,708	3,584,707,517	1,470,503,951	6,472,549,224	4,358,345,659	5,055,211,468
9/30/2009	200,000	Tax	7,943,253,175	2,887,841,708	3,584,907,517	1,470,503,951	6,472,749,224	4,358,345,659	5,055,411,468
9/17/2009	214,202	U.S. Partner	7,943,467,377	2,888,055,909	3,584,907,517	1,470,503,951	6,472,963,426	4,358,559,860	5,055,411,468
9/17/2009	214,202	U.S. Partner	7,943,681,579	2,888,270,111	3,584,907,517	1,470,503,951	6,473,177,628	4,358,774,062	5,055,411,468
9/17/2009	215,150	U.S. Partner	7,943,896,729	2,888,485,261	3,584,907,517	1,470,503,951	6,473,392,778	4,358,989,212	5,055,411,468
9/17/2009	215,150	U.S. Partner	7,944,111,879	2,888,700,411	3,584,907,517	1,470,503,951	6,473,607,928	4,359,204,362	5,055,411,468
9/17/2009	86,500,000	U.S. Partner	8,030,611,879	2,975,200,411	3,584,907,517	1,470,503,951	6,560,107,928	4,445,704,362	5,055,411,468
9/17/2009	86,500,000	U.S. Partner	8,117,111,879	3,061,700,411	3,584,907,517	1,470,503,951	6,646,607,928	4,532,204,362	5,055,411,468
9/10/2009	165	Tax	8,117,112,044	3,061,700,411	3,584,907,681	1,470,503,951	6,646,608,093	4,532,204,362	5,055,411,632
9/10/2009	165	Tax	8,117,112,208	3,061,700,411	3,584,907,846	1,470,503,951	6,646,608,257	4,532,204,362	5,055,411,797
9/10/2009	165	Tax	8,117,112,374	3,061,700,411	3,584,908,011	1,470,503,951	6,646,608,423	4,532,204,362	5,055,411,962
9/10/2009	165	Tax	8,117,112,539	3,061,700,411	3,584,908,177	1,470,503,951	6,646,608,588	4,532,204,362	5,055,412,128
9/10/2009	66,502	Tax	8,117,179,041	3,061,700,411	3,584,974,679	1,470,503,951	6,646,675,090	4,532,204,362	5,055,478,630
9/10/2009	66,502	Tax	8,117,245,543	3,061,700,411	3,585,041,181	1,470,503,951	6,646,741,592	4,532,204,362	5,055,545,132
9/10/2009	147,341	Tax	8,117,392,884	3,061,700,411	3,585,188,522	1,470,503,951	6,646,888,933	4,532,204,362	5,055,692,473
9/10/2009	147,993	Tax	8,117,540,878	3,061,700,411	3,585,336,515	1,470,503,951	6,647,036,927	4,532,204,362	5,055,840,466
9/10/2009	59,500,000	Tax	8,177,040,878	3,061,700,411	3,644,836,515	1,470,503,951	6,706,536,927	4,532,204,362	5,115,340,466
9/3/2009	6,843	Tax	8,177,047,721	3,061,700,411	3,644,843,359	1,470,503,951	6,706,543,770	4,532,204,362	5,115,347,310
9/3/2009	6,874	Tax	8,177,054,595	3,061,700,411	3,644,850,232	1,470,503,951	6,706,550,644	4,532,204,362	5,115,354,183
9/3/2009	2,763,522	Tax	8,179,818,117	3,061,700,411	3,647,613,754	1,470,503,951	6,709,314,166	4,532,204,362	5,118,117,705
8/31/2009	8,667	U.S. Partner	8,179,826,784	3,061,709,078	3,647,613,754	1,470,503,951	6,709,322,833	4,532,213,029	5,118,117,705
8/31/2009	8,706	U.S. Partner	8,179,835,489	3,061,717,784	3,647,613,754	1,470,503,951	6,709,331,538	4,532,221,735	5,118,117,705
8/21/2009	-92	Tax	8,179,835,397	3,061,717,784	3,647,613,662	1,470,503,951	6,709,331,446	4,532,221,735	5,118,117,613
8/19/2009	26	Tax	8,179,835,423	3,061,717,784	3,647,613,688	1,470,503,951	6,709,331,472	4,532,221,735	5,118,117,639
8/19/2009	26	Tax	8,179,835,448	3,061,717,784	3,647,613,713	1,470,503,951	6,709,331,497	4,532,221,735	5,118,117,664
8/19/2009	156	Tax	8,179,835,604	3,061,717,784	3,647,613,869	1,470,503,951	6,709,331,653	4,532,221,735	5,118,117,820
8/19/2009	156	Tax	8,179,835,760	3,061,717,784	3,647,614,025	1,470,503,951	6,709,331,809	4,532,221,735	5,118,117,976
8/19/2009	214	Tax	8,179,835,975	3,061,717,784	3,647,614,240	1,470,503,951	6,709,332,024	4,532,221,735	5,118,118,191
8/19/2009	215	Tax	8,179,836,190	3,061,717,784	3,647,614,455	1,470,503,951	6,709,332,239	4,532,221,735	5,118,118,406
8/19/2009	355	Tax	8,179,836,545	3,061,717,784	3,647,614,810	1,470,503,951	6,709,332,594	4,532,221,735	5,118,118,761
8/19/2009	357	Tax	8,179,836,902	3,061,717,784	3,647,615,167	1,470,503,951	6,709,332,951	4,532,221,735	5,118,119,118
8/19/2009	2,307	Tax	8,179,839,209	3,061,717,784	3,647,617,474	1,470,503,951	6,709,335,258	4,532,221,735	5,118,121,425
8/19/2009	2,317	Tax	8,179,841,525	3,061,717,784	3,647,619,790	1,470,503,951	6,709,337,574	4,532,221,735	5,118,123,741
8/19/2009	6,843	Tax	8,179,848,369	3,061,717,784	3,647,626,634	1,470,503,951	6,709,344,418	4,532,221,735	5,118,130,585
8/19/2009	6,874	Tax	8,179,855,242	3,061,717,784	3,647,633,508	1,470,503,951	6,709,351,291	4,532,221,735	5,118,137,458
8/19/2009	7,500	Tax	8,179,862,742	3,061,717,784	3,647,641,007	1,470,503,951	6,709,358,791	4,532,221,735	5,118,144,958
8/19/2009	7,533	Tax	8,179,870,275	3,061,717,784	3,647,648,541	1,470,503,951	6,709,366,324	4,532,221,735	5,118,152,491
8/19/2009	10,298	Tax	8,179,880,573	3,061,717,784	3,647,658,839	1,470,503,951	6,709,376,622	4,532,221,735	5,118,162,789
8/19/2009	62,857	Tax	8,179,943,430	3,061,717,784	3,647,721,696	1,470,503,951	6,709,439,479	4,532,221,735	5,118,225,646
8/19/2009	86,533	Tax	8,180,029,963	3,061,717,784	3,647,808,229	1,470,503,951	6,709,526,012	4,532,221,735	5,118,312,179
8/19/2009	143,487	Tax	8,180,173,450	3,061,717,784	3,647,951,716	1,470,503,951	6,709,669,499	4,532,221,735	5,118,455,666

8/19/2009	157,543	Tax	8,180,330,993	3,061,717,784	3,648,109,258	1,470,503,951	6,709,827,042	4,532,221,735	5,118,613,209
8/19/2009	158,241	Tax	8,180,489,234	3,061,717,784	3,648,267,499	1,470,503,951	6,709,985,283	4,532,221,735	5,118,771,450
8/19/2009	931,440	Tax	8,181,420,674	3,061,717,784	3,649,198,939	1,470,503,951	6,710,916,723	4,532,221,735	5,119,702,890
8/19/2009	2,763,522	Tax	8,184,184,196	3,061,717,784	3,651,962,461	1,470,503,951	6,713,680,245	4,532,221,735	5,122,466,412
8/19/2009	3,028,648	Tax	8,187,212,844	3,061,717,784	3,654,991,109	1,470,503,951	6,716,708,893	4,532,221,735	5,125,495,060
8/19/2009	63,619,776	Tax	8,250,832,620	3,061,717,784	3,718,610,885	1,470,503,951	6,780,328,669	4,532,221,735	5,189,114,836
7/31/2009	-29,800	Tax	8,250,802,820	3,061,717,784	3,718,581,085	1,470,503,951	6,780,298,869	4,532,221,735	5,189,085,036
7/31/2009	-74	Tax	8,250,802,746	3,061,717,784	3,718,581,011	1,470,503,951	6,780,298,795	4,532,221,735	5,189,084,962
7/31/2009	-74	Tax	8,250,802,672	3,061,717,784	3,718,580,937	1,470,503,951	6,780,298,721	4,532,221,735	5,189,084,888
7/27/2009	1,176	Tax	8,250,803,848	3,061,717,784	3,718,582,113	1,470,503,951	6,780,299,897	4,532,221,735	5,189,086,064
7/27/2009	1,181	Tax	8,250,805,029	3,061,717,784	3,718,583,295	1,470,503,951	6,780,301,079	4,532,221,735	5,189,087,246
7/27/2009	475,000	Tax	8,251,280,029	3,061,717,784	3,719,058,295	1,470,503,951	6,780,776,079	4,532,221,735	5,189,562,246
7/16/2009	546	U.S. Partner	8,251,280,576	3,061,718,330	3,719,058,295	1,470,503,951	6,780,776,625	4,532,222,281	5,189,562,246
7/16/2009	546	U.S. Partner	8,251,281,122	3,061,718,876	3,719,058,295	1,470,503,951	6,780,777,171	4,532,222,827	5,189,562,246
7/16/2009	548	U.S. Partner	8,251,281,670	3,061,719,424	3,719,058,295	1,470,503,951	6,780,777,719	4,532,223,375	5,189,562,246
7/16/2009	548	U.S. Partner	8,251,282,218	3,061,719,973	3,719,058,295	1,470,503,951	6,780,778,267	4,532,223,924	5,189,562,246
7/16/2009	220,500	U.S. Partner	8,251,502,718	3,061,940,473	3,719,058,295	1,470,503,951	6,780,998,767	4,532,444,424	5,189,562,246
7/16/2009	220,500	U.S. Partner	8,251,723,218	3,062,160,973	3,719,058,295	1,470,503,951	6,781,219,267	4,532,664,924	5,189,562,246
6/26/2009	-808,212	Tax	8,250,915,006	3,062,160,973	3,718,250,083	1,470,503,951	6,780,411,055	4,532,664,924	5,188,754,034
6/26/2009	-2,010	Tax	8,250,912,996	3,062,160,973	3,718,248,072	1,470,503,951	6,780,409,045	4,532,664,924	5,188,752,023
6/26/2009	-2,001	Tax	8,250,910,995	3,062,160,973	3,718,246,071	1,470,503,951	6,780,407,044	4,532,664,924	5,188,750,022
6/24/2009	200,582	U.S. Partner	8,251,111,577	3,062,361,555	3,718,246,071	1,470,503,951	6,780,607,626	4,532,865,506	5,188,750,022
6/24/2009	200,582	U.S. Partner	8,251,312,158	3,062,562,136	3,718,246,071	1,470,503,951	6,780,808,208	4,533,066,087	5,188,750,022
6/24/2009	201,470	U.S. Partner	8,251,513,629	3,062,763,607	3,718,246,071	1,470,503,951	6,781,009,678	4,533,267,558	5,188,750,022
6/24/2009	201,470	U.S. Partner	8,251,715,099	3,062,965,077	3,718,246,071	1,470,503,951	6,781,211,148	4,533,469,028	5,188,750,022
6/24/2009	81,000,000	U.S. Partner	8,332,715,099	3,143,965,077	3,718,246,071	1,470,503,951	6,862,211,148	4,614,469,028	5,188,750,022
6/24/2009	81,000,000	U.S. Partner	8,413,715,099	3,224,965,077	3,718,246,071	1,470,503,951	6,943,211,148	4,695,469,028	5,188,750,022
6/15/2009	6,465	Tax	8,413,721,564	3,224,965,077	3,718,252,536	1,470,503,951	6,943,217,613	4,695,469,028	5,188,756,487
6/15/2009	6,494	Tax	8,413,728,058	3,224,965,077	3,718,259,030	1,470,503,951	6,943,224,107	4,695,469,028	5,188,762,981
6/15/2009	147,341	Tax	8,413,875,399	3,224,965,077	3,718,406,371	1,470,503,951	6,943,371,448	4,695,469,028	5,188,910,322
6/15/2009	147,993	Tax	8,414,023,392	3,224,965,077	3,718,554,365	1,470,503,951	6,943,519,441	4,695,469,028	5,189,058,316
6/15/2009	2,610,885	Tax	8,416,634,277	3,224,965,077	3,721,165,250	1,470,503,951	6,946,130,326	4,695,469,028	5,191,669,201
6/15/2009	59,500,000	Tax	8,476,134,277	3,224,965,077	3,780,665,250	1,470,503,951	7,005,630,326	4,695,469,028	5,251,169,201
5/26/2009	6,030	Tax	8,476,140,308	3,224,965,077	3,780,671,280	1,470,503,951	7,005,636,357	4,695,469,028	5,251,175,231
5/26/2009	6,057	Tax	8,476,146,364	3,224,965,077	3,780,677,337	1,470,503,951	7,005,642,413	4,695,469,028	5,251,181,288
5/26/2009	155,522	Tax	8,476,301,886	3,224,965,077	3,780,832,858	1,470,503,951	7,005,797,935	4,695,469,028	5,251,336,809
5/26/2009	156,210	Tax	8,476,458,097	3,224,965,077	3,780,989,069	1,470,503,951	7,005,954,146	4,695,469,028	5,251,493,020
5/26/2009	2,435,089	Tax	8,478,893,186	3,224,965,077	3,783,424,158	1,470,503,951	7,008,389,235	4,695,469,028	5,253,928,109
5/26/2009	62,803,611	Tax	8,541,696,797	3,224,965,077	3,846,227,769	1,470,503,951	7,071,192,846	4,695,469,028	5,316,731,720
5/18/2009	21	Tax	8,541,696,817	3,224,965,077	3,846,227,789	1,470,503,951	7,071,192,866	4,695,469,028	5,316,731,740
5/18/2009	21	Tax	8,541,696,838	3,224,965,077	3,846,227,810	1,470,503,951	7,071,192,887	4,695,469,028	5,316,731,761
5/18/2009	108	Tax	8,541,696,946	3,224,965,077	3,846,227,918	1,470,503,951	7,071,192,995	4,695,469,028	5,316,731,869
5/18/2009	109	Tax	8,541,697,054	3,224,965,077	3,846,228,027	1,470,503,951	7,071,193,104	4,695,469,028	5,316,731,978
5/18/2009	120	Tax	8,541,697,174	3,224,965,077	3,846,228,147	1,470,503,951	7,071,193,223	4,695,469,028	5,316,732,098
5/18/2009	120	Tax	8,541,697,294	3,224,965,077	3,846,228,267	1,470,503,951	7,071,193,343	4,695,469,028	5,316,732,218
5/18/2009	165	Tax	8,541,697,459	3,224,965,077	3,846,228,432	1,470,503,951	7,071,193,508	4,695,469,028	5,316,732,383
5/18/2009	166	Tax	8,541,697,625	3,224,965,077	3,846,228,598	1,470,503,951	7,071,193,674	4,695,469,028	5,316,732,549
5/18/2009	249	Tax	8,541,697,874	3,224,965,077	3,846,228,847	1,470,503,951	7,071,193,924	4,695,469,028	5,316,732,798
5/18/2009	250	Tax	8,541,698,125	3,224,965,077	3,846,229,097	1,470,503,951	7,071,194,174	4,695,469,028	5,316,733,048

5/18/2009	292	Tax	8,541,698,417	3,224,965,077	3,846,229,389	1,470,503,951	7,071,194,466	4,695,469,028	5,316,733,340
5/18/2009	293	Tax	8,541,698,710	3,224,965,077	3,846,229,683	1,470,503,951	7,071,194,759	4,695,469,028	5,316,733,634
5/18/2009	1,737	Tax	8,541,700,448	3,224,965,077	3,846,231,420	1,470,503,951	7,071,196,497	4,695,469,028	5,316,735,371
5/18/2009	1,745	Tax	8,541,702,193	3,224,965,077	3,846,233,165	1,470,503,951	7,071,198,242	4,695,469,028	5,316,737,116
5/18/2009	8,279	Tax	8,541,710,472	3,224,965,077	3,846,241,444	1,470,503,951	7,071,206,521	4,695,469,028	5,316,745,395
5/18/2009	43,692	Tax	8,541,754,164	3,224,965,077	3,846,285,136	1,470,503,951	7,071,250,213	4,695,469,028	5,316,789,087
5/18/2009	48,326	Tax	8,541,802,490	3,224,965,077	3,846,333,462	1,470,503,951	7,071,298,539	4,695,469,028	5,316,837,413
5/18/2009	66,660	Tax	8,541,869,150	3,224,965,077	3,846,400,122	1,470,503,951	7,071,365,199	4,695,469,028	5,316,904,073
5/18/2009	100,653	Tax	8,541,969,803	3,224,965,077	3,846,500,775	1,470,503,951	7,071,465,852	4,695,469,028	5,317,004,726
5/18/2009	117,936	Tax	8,542,087,739	3,224,965,077	3,846,618,711	1,470,503,951	7,071,583,788	4,695,469,028	5,317,122,662
5/18/2009	701,566	Tax	8,542,789,305	3,224,965,077	3,847,320,277	1,470,503,951	7,072,285,354	4,695,469,028	5,317,824,228
4/29/2009	23,896	U.S. Partner	8,542,813,201	3,224,988,973	3,847,320,277	1,470,503,951	7,072,309,250	4,695,492,924	5,317,824,228
4/29/2009	24,002	U.S. Partner	8,542,837,203	3,225,012,975	3,847,320,277	1,470,503,951	7,072,333,252	4,695,516,926	5,317,824,228
4/29/2009	9,650,000	U.S. Partner	8,552,487,203	3,234,662,975	3,847,320,277	1,470,503,951	7,081,983,252	4,705,166,926	5,317,824,228
4/24/2009	23,896	U.S. Partner	8,552,511,100	3,234,686,872	3,847,320,277	1,470,503,951	7,082,007,149	4,705,190,823	5,317,824,228
4/24/2009	24,002	U.S. Partner	8,552,535,102	3,234,710,874	3,847,320,277	1,470,503,951	7,082,031,151	4,705,214,825	5,317,824,228
4/24/2009	9,650,000	U.S. Partner	8,562,185,102	3,244,360,874	3,847,320,277	1,470,503,951	7,091,681,151	4,714,864,825	5,317,824,228
4/17/2009	-51,495	Tax	8,562,133,607	3,244,360,874	3,847,268,782	1,470,503,951	7,091,629,656	4,714,864,825	5,317,772,733
4/17/2009	-128	Tax	8,562,133,479	3,244,360,874	3,847,268,654	1,470,503,951	7,091,629,528	4,714,864,825	5,317,772,605
4/17/2009	-128	Tax	8,562,133,351	3,244,360,874	3,847,268,526	1,470,503,951	7,091,629,401	4,714,864,825	5,317,772,477
4/15/2009	32	Tax	8,562,133,383	3,244,360,874	3,847,268,558	1,470,503,951	7,091,629,432	4,714,864,825	5,317,772,509
4/15/2009	32	Tax	8,562,133,415	3,244,360,874	3,847,268,590	1,470,503,951	7,091,629,464	4,714,864,825	5,317,772,541
4/15/2009	9,281	Tax	8,562,142,696	3,244,360,874	3,847,277,871	1,470,503,951	7,091,638,745	4,714,864,825	5,317,781,822
4/15/2009	9,322	Tax	8,562,152,018	3,244,360,874	3,847,287,193	1,470,503,951	7,091,648,067	4,714,864,825	5,317,791,144
4/15/2009	10,153	Tax	8,562,162,171	3,244,360,874	3,847,297,346	1,470,503,951	7,091,658,220	4,714,864,825	5,317,801,297
4/15/2009	10,198	Tax	8,562,172,369	3,244,360,874	3,847,307,544	1,470,503,951	7,091,668,418	4,714,864,825	5,317,811,495
4/15/2009	12,743	Tax	8,562,185,112	3,244,360,874	3,847,320,287	1,470,503,951	7,091,681,161	4,714,864,825	5,317,824,238
4/15/2009	32,192	Tax	8,562,217,304	3,244,360,874	3,847,352,479	1,470,503,951	7,091,713,353	4,714,864,825	5,317,856,430
4/15/2009	32,192	Tax	8,562,249,496	3,244,360,874	3,847,384,671	1,470,503,951	7,091,745,545	4,714,864,825	5,317,888,622
4/15/2009	32,335	Tax	8,562,281,831	3,244,360,874	3,847,417,006	1,470,503,951	7,091,777,880	4,714,864,825	5,317,920,957
4/15/2009	32,335	Tax	8,562,314,166	3,244,360,874	3,847,449,341	1,470,503,951	7,091,810,215	4,714,864,825	5,317,953,292
4/15/2009	148,579	Tax	8,562,462,745	3,244,360,874	3,847,597,920	1,470,503,951	7,091,958,794	4,714,864,825	5,318,101,871
4/15/2009	149,237	Tax	8,562,611,982	3,244,360,874	3,847,747,157	1,470,503,951	7,092,108,031	4,714,864,825	5,318,251,108
4/15/2009	161,501	Tax	8,562,773,483	3,244,360,874	3,847,908,657	1,470,503,951	7,092,269,532	4,714,864,825	5,318,412,608
4/15/2009	162,216	Tax	8,562,935,698	3,244,360,874	3,848,070,873	1,470,503,951	7,092,431,747	4,714,864,825	5,318,574,824
4/15/2009	3,748,003	Tax	8,566,683,701	3,244,360,874	3,851,818,876	1,470,503,951	7,096,179,750	4,714,864,825	5,322,322,827
4/15/2009	4,100,000	Tax	8,570,783,701	3,244,360,874	3,855,918,876	1,470,503,951	7,100,279,750	4,714,864,825	5,326,422,827
4/15/2009	13,000,000	Tax	8,583,783,701	3,244,360,874	3,868,918,876	1,470,503,951	7,113,279,750	4,714,864,825	5,339,422,827
4/15/2009	13,000,000	Tax	8,596,783,701	3,244,360,874	3,881,918,876	1,470,503,951	7,126,279,750	4,714,864,825	5,352,422,827
4/15/2009	60,000,000	Tax	8,656,783,701	3,244,360,874	3,941,918,876	1,470,503,951	7,186,279,750	4,714,864,825	5,412,422,827
4/15/2009	65,217,996	Tax	8,722,001,697	3,244,360,874	4,007,136,872	1,470,503,951	7,251,497,746	4,714,864,825	5,477,640,823
4/7/2009	2	Tax	8,722,001,700	3,244,360,874	4,007,136,875	1,470,503,951	7,251,497,749	4,714,864,825	5,477,640,826
4/7/2009	2	Tax	8,722,001,702	3,244,360,874	4,007,136,877	1,470,503,951	7,251,497,751	4,714,864,825	5,477,640,828
4/7/2009	272	Tax	8,722,001,975	3,244,360,874	4,007,137,150	1,470,503,951	7,251,498,024	4,714,864,825	5,477,641,101
4/7/2009	274	Tax	8,722,002,248	3,244,360,874	4,007,137,423	1,470,503,951	7,251,498,297	4,714,864,825	5,477,641,374
4/7/2009	508	Tax	8,722,002,756	3,244,360,874	4,007,137,931	1,470,503,951	7,251,498,805	4,714,864,825	5,477,641,882
4/7/2009	510	Tax	8,722,003,266	3,244,360,874	4,007,138,441	1,470,503,951	7,251,499,315	4,714,864,825	5,477,642,392
4/7/2009	805	Tax	8,722,004,071	3,244,360,874	4,007,139,246	1,470,503,951	7,251,500,120	4,714,864,825	5,477,643,196
4/7/2009	808	Tax	8,722,004,879	3,244,360,874	4,007,140,054	1,470,503,951	7,251,500,928	4,714,864,825	5,477,644,005

4/7/2009	1,000	Tax	8,722,005,879	3,244,360,874	4,007,141,054	1,470,503,951	7,251,501,928	4,714,864,825	5,477,645,005
4/7/2009	110,000	Tax	8,722,115,879	3,244,360,874	4,007,251,054	1,470,503,951	7,251,611,928	4,714,864,825	5,477,755,005
4/7/2009	205,000	Tax	8,722,320,879	3,244,360,874	4,007,456,054	1,470,503,951	7,251,816,928	4,714,864,825	5,477,960,005
4/7/2009	325,000	Tax	8,722,645,879	3,244,360,874	4,007,781,054	1,470,503,951	7,252,141,928	4,714,864,825	5,478,285,005
4/6/2009	167	Tax	8,722,646,046	3,244,360,874	4,007,781,220	1,470,503,951	7,252,142,095	4,714,864,825	5,478,285,171
4/6/2009	167	Tax	8,722,646,213	3,244,360,874	4,007,781,388	1,470,503,951	7,252,142,262	4,714,864,825	5,478,285,339
4/6/2009	186	Tax	8,722,646,399	3,244,360,874	4,007,781,573	1,470,503,951	7,252,142,448	4,714,864,825	5,478,285,524
4/6/2009	187	Tax	8,722,646,585	3,244,360,874	4,007,781,760	1,470,503,951	7,252,142,634	4,714,864,825	5,478,285,711
4/6/2009	198	Tax	8,722,646,783	3,244,360,874	4,007,781,958	1,470,503,951	7,252,142,832	4,714,864,825	5,478,285,909
4/6/2009	199	Tax	8,722,646,982	3,244,360,874	4,007,782,157	1,470,503,951	7,252,143,031	4,714,864,825	5,478,286,108
4/6/2009	381	Tax	8,722,647,364	3,244,360,874	4,007,782,538	1,470,503,951	7,252,143,413	4,714,864,825	5,478,286,489
4/6/2009	383	Tax	8,722,647,747	3,244,360,874	4,007,782,921	1,470,503,951	7,252,143,796	4,714,864,825	5,478,286,872
4/6/2009	384	Tax	8,722,648,130	3,244,360,874	4,007,783,305	1,470,503,951	7,252,144,179	4,714,864,825	5,478,287,256
4/6/2009	386	Tax	8,722,648,516	3,244,360,874	4,007,783,691	1,470,503,951	7,252,144,565	4,714,864,825	5,478,287,642
4/6/2009	433	Tax	8,722,648,949	3,244,360,874	4,007,784,124	1,470,503,951	7,252,144,998	4,714,864,825	5,478,288,075
4/6/2009	435	Tax	8,722,649,385	3,244,360,874	4,007,784,559	1,470,503,951	7,252,145,434	4,714,864,825	5,478,288,510
4/6/2009	2,031	Tax	8,722,651,415	3,244,360,874	4,007,786,590	1,470,503,951	7,252,147,464	4,714,864,825	5,478,290,541
4/6/2009	2,040	Tax	8,722,653,455	3,244,360,874	4,007,788,630	1,470,503,951	7,252,149,504	4,714,864,825	5,478,292,581
4/6/2009	2,972	Tax	8,722,656,426	3,244,360,874	4,007,791,601	1,470,503,951	7,252,152,475	4,714,864,825	5,478,295,552
4/6/2009	2,985	Tax	8,722,659,411	3,244,360,874	4,007,794,586	1,470,503,951	7,252,155,460	4,714,864,825	5,478,298,537
4/6/2009	22,287	Tax	8,722,681,698	3,244,360,874	4,007,816,873	1,470,503,951	7,252,177,747	4,714,864,825	5,478,320,824
4/6/2009	22,386	Tax	8,722,704,083	3,244,360,874	4,007,839,258	1,470,503,951	7,252,200,133	4,714,864,825	5,478,343,209
4/6/2009	67,250	Tax	8,722,771,333	3,244,360,874	4,007,906,508	1,470,503,951	7,252,267,383	4,714,864,825	5,478,410,459
4/6/2009	75,000	Tax	8,722,846,333	3,244,360,874	4,007,981,508	1,470,503,951	7,252,342,383	4,714,864,825	5,478,485,459
4/6/2009	80,000	Tax	8,722,926,333	3,244,360,874	4,008,061,508	1,470,503,951	7,252,422,383	4,714,864,825	5,478,565,459
4/6/2009	154,000	Tax	8,723,080,333	3,244,360,874	4,008,215,508	1,470,503,951	7,252,576,383	4,714,864,825	5,478,719,459
4/6/2009	155,000	Tax	8,723,235,333	3,244,360,874	4,008,370,508	1,470,503,951	7,252,731,383	4,714,864,825	5,478,874,459
4/6/2009	175,000	Tax	8,723,410,333	3,244,360,874	4,008,545,508	1,470,503,951	7,252,906,383	4,714,864,825	5,479,049,459
4/6/2009	820,000	Tax	8,724,230,333	3,244,360,874	4,009,365,508	1,470,503,951	7,253,726,383	4,714,864,825	5,479,869,459
4/6/2009	1,200,000	Tax	8,725,430,333	3,244,360,874	4,010,565,508	1,470,503,951	7,254,926,383	4,714,864,825	5,481,069,459
4/6/2009	9,000,000	Tax	8,734,430,333	3,244,360,874	4,019,565,508	1,470,503,951	7,263,926,383	4,714,864,825	5,490,069,459
3/12/2009	12,382	U.S. Partner	8,734,442,715	3,244,373,256	4,019,565,508	1,470,503,951	7,263,938,764	4,714,877,207	5,490,069,459
3/12/2009	12,436	U.S. Partner	8,734,455,152	3,244,385,692	4,019,565,508	1,470,503,951	7,263,951,201	4,714,889,643	5,490,069,459
3/12/2009	235,250	U.S. Partner	8,734,690,402	3,244,620,943	4,019,565,508	1,470,503,951	7,264,186,451	4,715,124,893	5,490,069,459
3/12/2009	236,292	U.S. Partner	8,734,926,694	3,244,857,235	4,019,565,508	1,470,503,951	7,264,422,743	4,715,361,186	5,490,069,459
3/12/2009	247,632	U.S. Partner	8,735,174,326	3,245,104,866	4,019,565,508	1,470,503,951	7,264,670,375	4,715,608,817	5,490,069,459
3/12/2009	248,728	U.S. Partner	8,735,423,054	3,245,353,595	4,019,565,508	1,470,503,951	7,264,919,103	4,715,857,546	5,490,069,459
3/12/2009	5,000,000	U.S. Partner	8,740,423,054	3,250,353,595	4,019,565,508	1,470,503,951	7,269,919,103	4,720,857,546	5,490,069,459
3/12/2009	95,000,000	U.S. Partner	8,835,423,054	3,345,353,595	4,019,565,508	1,470,503,951	7,364,919,103	4,815,857,546	5,490,069,459
3/12/2009	100,000,000	U.S. Partner	8,935,423,054	3,445,353,595	4,019,565,508	1,470,503,951	7,464,919,103	4,915,857,546	5,490,069,459
2/28/2009	24,763	U.S. Partner	8,935,447,817	3,445,378,358	4,019,565,508	1,470,503,951	7,464,943,866	4,915,882,309	5,490,069,459
2/28/2009	24,873	U.S. Partner	8,935,472,690	3,445,403,231	4,019,565,508	1,470,503,951	7,464,968,739	4,915,907,182	5,490,069,459
2/28/2009	29,295	U.S. Partner	8,935,501,985	3,445,432,526	4,019,565,508	1,470,503,951	7,464,998,034	4,915,936,477	5,490,069,459
2/28/2009	29,425	U.S. Partner	8,935,531,410	3,445,461,950	4,019,565,508	1,470,503,951	7,465,027,459	4,915,965,901	5,490,069,459
2/12/2009	-961,732	Tax	8,934,569,678	3,445,461,950	4,018,603,777	1,470,503,951	7,464,065,727	4,915,965,901	5,489,107,728
2/12/2009	-25,268	Tax	8,934,544,410	3,445,461,950	4,018,578,508	1,470,503,951	7,464,040,459	4,915,965,901	5,489,082,459
2/12/2009	-2,392	Tax	8,934,542,018	3,445,461,950	4,018,576,116	1,470,503,951	7,464,038,067	4,915,965,901	5,489,080,067
2/12/2009	-2,382	Tax	8,934,539,636	3,445,461,950	4,018,573,735	1,470,503,951	7,464,035,685	4,915,965,901	5,489,077,686
2/12/2009	-801	Tax	8,934,538,835	3,445,461,950	4,018,572,933	1,470,503,951	7,464,034,884	4,915,965,901	5,489,076,884

2/12/2009	-63	Tax	8,934,538,772	3,445,461,950	4,018,572,871	1,470,503,951	7,464,034,821	4,915,965,901	5,489,076,822
2/12/2009	-63	Tax	8,934,538,709	3,445,461,950	4,018,572,808	1,470,503,951	7,464,034,758	4,915,965,901	5,489,076,759
2/12/2009	-2	Tax	8,934,538,707	3,445,461,950	4,018,572,806	1,470,503,951	7,464,034,756	4,915,965,901	5,489,076,757
2/12/2009	-2	Tax	8,934,538,705	3,445,461,950	4,018,572,804	1,470,503,951	7,464,034,755	4,915,965,901	5,489,076,755
1/1/2009	55,750	U.S. Partner	8,934,594,455	3,445,517,700	4,018,572,804	1,470,503,951	7,464,090,504	4,916,021,651	5,489,076,755
1/1/2009	55,997	U.S. Partner	8,934,650,452	3,445,573,697	4,018,572,804	1,470,503,951	7,464,146,501	4,916,077,648	5,489,076,755
1/1/2009	7,551,499	U.S. Partner	8,942,201,950	3,453,125,195	4,018,572,804	1,470,503,951	7,471,697,999	4,923,629,146	5,489,076,755
1/1/2009	7,551,499	U.S. Partner	8,949,753,449	3,460,676,694	4,018,572,804	1,470,503,951	7,479,249,498	4,931,180,645	5,489,076,755
12/31/2008	-216,688	Tax	8,949,536,761	3,460,676,694	4,018,356,116	1,470,503,951	7,479,032,810	4,931,180,645	5,488,860,067
12/31/2008	50,124	Tax	8,949,586,885	3,460,676,694	4,018,406,240	1,470,503,951	7,479,082,934	4,931,180,645	5,488,910,191
12/31/2008	52,399	U.S. Partner	8,949,639,284	3,460,729,093	4,018,406,240	1,470,503,951	7,479,135,333	4,931,233,044	5,488,910,191
12/31/2008	105,260	Tax	8,949,744,544	3,460,729,093	4,018,511,500	1,470,503,951	7,479,240,593	4,931,233,044	5,489,015,451
12/31/2008	110,272	Tax	8,949,854,816	3,460,729,093	4,018,621,773	1,470,503,951	7,479,350,865	4,931,233,044	5,489,125,724
12/31/2008	135,242	U.S. Partner	8,949,990,059	3,460,864,335	4,018,621,773	1,470,503,951	7,479,486,108	4,931,368,286	5,489,125,724
12/31/2008	501,238	Tax	8,950,491,297	3,460,864,335	4,019,123,011	1,470,503,951	7,479,987,346	4,931,368,286	5,489,626,962
12/31/2008	12,703,999	Ex U.S.	8,963,195,296	3,460,864,335	4,019,123,011	1,483,207,950	7,479,987,346	4,944,072,285	5,502,330,961
12/31/2008	63,403,447	Ex U.S.	9,026,598,743	3,460,864,335	4,019,123,011	1,546,611,397	7,479,987,346	5,007,475,732	5,565,734,408
12/22/2008	1,002	Tax	9,026,599,745	3,460,864,335	4,019,124,013	1,546,611,397	7,479,988,348	5,007,475,732	5,565,735,410
12/22/2008	1,007	Tax	9,026,600,753	3,460,864,335	4,019,125,021	1,546,611,397	7,479,989,356	5,007,475,732	5,565,736,418
12/22/2008	1,754	Tax	9,026,602,507	3,460,864,335	4,019,126,775	1,546,611,397	7,479,991,110	5,007,475,732	5,565,738,172
12/22/2008	3,002	Tax	9,026,605,509	3,460,864,335	4,019,129,777	1,546,611,397	7,479,994,112	5,007,475,732	5,565,741,174
12/22/2008	5,764	Tax	9,026,611,274	3,460,864,335	4,019,135,542	1,546,611,397	7,479,999,877	5,007,475,732	5,565,746,939
12/22/2008	250,619	Tax	9,026,861,893	3,460,864,335	4,019,386,161	1,546,611,397	7,480,250,496	5,007,475,732	5,565,997,558
12/22/2008	10,689,373	Tax	9,037,551,266	3,460,864,335	4,030,075,534	1,546,611,397	7,490,939,869	5,007,475,732	5,576,686,931
12/18/2008	3,408,419	Tax	9,040,959,685	3,460,864,335	4,033,483,953	1,546,611,397	7,494,348,288	5,007,475,732	5,580,095,350
12/16/2008	15,037	Tax	9,040,974,722	3,460,864,335	4,033,498,990	1,546,611,397	7,494,363,325	5,007,475,732	5,580,110,387
12/16/2008	62,655	Tax	9,041,037,377	3,460,864,335	4,033,561,645	1,546,611,397	7,494,425,980	5,007,475,732	5,580,173,042
12/16/2008	200,495	Tax	9,041,237,872	3,460,864,335	4,033,762,140	1,546,611,397	7,494,626,475	5,007,475,732	5,580,373,537
12/16/2008	200,495	Tax	9,041,438,368	3,460,864,335	4,033,962,636	1,546,611,397	7,494,826,971	5,007,475,732	5,580,574,033
12/15/2008	7,519	Tax	9,041,445,886	3,460,864,335	4,033,970,154	1,546,611,397	7,494,834,489	5,007,475,732	5,580,581,551
12/15/2008	55,136	Tax	9,041,501,022	3,460,864,335	4,034,025,290	1,546,611,397	7,494,889,625	5,007,475,732	5,580,636,687
12/15/2008	100,248	Tax	9,041,601,270	3,460,864,335	4,034,125,538	1,546,611,397	7,494,989,873	5,007,475,732	5,580,736,935
12/15/2008	225,557	Tax	9,041,826,827	3,460,864,335	4,034,351,095	1,546,611,397	7,495,215,430	5,007,475,732	5,580,962,492
12/15/2008	158,074,925	Tax	9,199,901,752	3,460,864,335	4,192,426,020	1,546,611,397	7,653,290,355	5,007,475,732	5,739,037,417
11/30/2008	-6,457,529	Tax	9,193,444,223	3,460,864,335	4,185,968,491	1,546,611,397	7,646,832,826	5,007,475,732	5,732,579,888
11/30/2008	2,798,226	U.S. Partner	9,196,242,449	3,463,662,561	4,185,968,491	1,546,611,397	7,649,631,052	5,010,273,958	5,732,579,888
11/30/2008	200,495,264	U.S. Partner	9,396,737,713	3,664,157,825	4,185,968,491	1,546,611,397	7,850,126,316	5,210,769,222	5,732,579,888
11/3/2008	-533	Tax	9,396,737,180	3,664,157,825	4,185,967,958	1,546,611,397	7,850,125,783	5,210,769,222	5,732,579,355
10/31/2008	25,000	U.S. Partner	9,396,762,180	3,664,182,825	4,185,967,958	1,546,611,397	7,850,150,783	5,210,794,222	5,732,579,355
10/31/2008	50,000	U.S. Partner	9,396,812,180	3,664,232,825	4,185,967,958	1,546,611,397	7,850,200,783	5,210,844,222	5,732,579,355
10/31/2008	1,743,412	Tax	9,398,555,592	3,664,232,825	4,187,711,370	1,546,611,397	7,851,944,195	5,210,844,222	5,734,322,767
10/10/2008	99,752,501	U.S. Partner	9,498,308,092	3,763,985,325	4,187,711,370	1,546,611,397	7,951,696,695	5,310,596,722	5,734,322,767
10/2/2008	99,752,501	U.S. Partner	9,598,060,593	3,863,737,826	4,187,711,370	1,546,611,397	8,051,449,196	5,410,349,223	5,734,322,767
9/15/2008	132,500	Tax	9,598,193,093	3,863,737,826	4,187,843,870	1,546,611,397	8,051,581,696	5,410,349,223	5,734,455,267
9/15/2008	2,170,000	Tax	9,600,363,093	3,863,737,826	4,190,013,870	1,546,611,397	8,053,751,696	5,410,349,223	5,736,625,267
9/15/2008	6,000,000	Tax	9,606,363,093	3,863,737,826	4,196,013,870	1,546,611,397	8,059,751,696	5,410,349,223	5,742,625,267
9/15/2008	93,500,000	Tax	9,699,863,093	3,863,737,826	4,289,513,870	1,546,611,397	8,153,251,696	5,410,349,223	5,836,125,267
9/9/2008	15,000	Tax	9,699,878,093	3,863,737,826	4,289,528,870	1,546,611,397	8,153,266,696	5,410,349,223	5,836,140,267
9/9/2008	30,000	Tax	9,699,908,093	3,863,737,826	4,289,558,870	1,546,611,397	8,153,296,696	5,410,349,223	5,836,170,267

9/9/2008	37,500	Tax	9,699,945,593	3,863,737,826	4,289,596,370	1,546,611,397	8,153,334,196	5,410,349,223	5,836,207,767
9/9/2008	50,000	Tax	9,699,995,593	3,863,737,826	4,289,646,370	1,546,611,397	8,153,384,196	5,410,349,223	5,836,257,767
8/31/2008	862,246	U.S. Partner	9,700,857,839	3,864,600,072	4,289,646,370	1,546,611,397	8,154,246,442	5,411,211,469	5,836,257,767
8/12/2008	-945,698	Tax	9,699,912,141	3,864,600,072	4,288,700,672	1,546,611,397	8,153,300,744	5,411,211,469	5,835,312,069
7/23/2008	-172,186	Tax	9,699,739,955	3,864,600,072	4,288,528,486	1,546,611,397	8,153,128,558	5,411,211,469	5,835,139,883
7/1/2008	124,382,614	U.S. Partner	9,824,122,569	3,988,982,686	4,288,528,486	1,546,611,397	8,277,511,172	5,535,594,083	5,835,139,883
7/1/2008	124,382,614	U.S. Partner	9,948,505,183	4,113,365,300	4,288,528,486	1,546,611,397	8,401,893,786	5,659,976,697	5,835,139,883
6/24/2008	29,000	Tax	9,948,534,183	4,113,365,300	4,288,557,486	1,546,611,397	8,401,922,786	5,659,976,697	5,835,168,883
6/24/2008	116,000	Tax	9,948,650,183	4,113,365,300	4,288,673,486	1,546,611,397	8,402,038,786	5,659,976,697	5,835,284,883
6/24/2008	2,350,000	Tax	9,951,000,183	4,113,365,300	4,291,023,486	1,546,611,397	8,404,388,786	5,659,976,697	5,837,634,883
6/24/2008	2,750,000	Tax	9,953,750,183	4,113,365,300	4,293,773,486	1,546,611,397	8,407,138,786	5,659,976,697	5,840,384,883
6/17/2008	4	Tax	9,953,750,187	4,113,365,300	4,293,773,490	1,546,611,397	8,407,138,790	5,659,976,697	5,840,384,887
6/17/2008	1,240	Tax	9,953,751,427	4,113,365,300	4,293,774,730	1,546,611,397	8,407,140,030	5,659,976,697	5,840,386,127
6/13/2008	3,590,000	Tax	9,957,341,427	4,113,365,300	4,297,364,730	1,546,611,397	8,410,730,030	5,659,976,697	5,843,976,127
6/13/2008	119,000,000	Tax	10,076,341,427	4,113,365,300	4,416,364,730	1,546,611,397	8,529,730,030	5,659,976,697	5,962,976,127
6/12/2008	2,000	Tax	10,076,343,427	4,113,365,300	4,416,366,730	1,546,611,397	8,529,732,030	5,659,976,697	5,962,978,127
6/12/2008	2,938	Tax	10,076,346,365	4,113,365,300	4,416,369,668	1,546,611,397	8,529,734,968	5,659,976,697	5,962,981,065
6/12/2008	44,721	Tax	10,076,391,086	4,113,365,300	4,416,414,389	1,546,611,397	8,529,779,689	5,659,976,697	5,963,025,786
6/3/2008	63,000	Tax	10,076,454,086	4,113,365,300	4,416,477,389	1,546,611,397	8,529,842,689	5,659,976,697	5,963,088,786
6/3/2008	67,000	Tax	10,076,521,086	4,113,365,300	4,416,544,389	1,546,611,397	8,529,909,689	5,659,976,697	5,963,155,786
6/3/2008	150,000	Tax	10,076,671,086	4,113,365,300	4,416,694,389	1,546,611,397	8,530,059,689	5,659,976,697	5,963,305,786
6/3/2008	155,000	Tax	10,076,826,086	4,113,365,300	4,416,849,389	1,546,611,397	8,530,214,689	5,659,976,697	5,963,460,786
6/3/2008	280,000	Tax	10,077,106,086	4,113,365,300	4,417,129,389	1,546,611,397	8,530,494,689	5,659,976,697	5,963,740,786
5/31/2008	-781,247	Tax	10,076,324,839	4,113,365,300	4,416,348,142	1,546,611,397	8,529,713,442	5,659,976,697	5,962,959,539
5/15/2008	8,900	Tax	10,076,333,739	4,113,365,300	4,416,357,042	1,546,611,397	8,529,722,342	5,659,976,697	5,962,968,439
5/15/2008	8,900	Tax	10,076,342,639	4,113,365,300	4,416,365,942	1,546,611,397	8,529,731,242	5,659,976,697	5,962,977,339
5/12/2008	24,865,294	U.S. Partner	10,101,207,933	4,138,230,593	4,416,365,942	1,546,611,397	8,554,596,536	5,684,841,990	5,962,977,339
5/12/2008	24,865,294	U.S. Partner	10,126,073,226	4,163,095,887	4,416,365,942	1,546,611,397	8,579,461,829	5,709,707,284	5,962,977,339
4/23/2008	94,345	Tax	10,126,167,571	4,163,095,887	4,416,460,287	1,546,611,397	8,579,556,174	5,709,707,284	5,963,071,684
4/17/2008	19,783	Tax	10,126,187,354	4,163,095,887	4,416,480,070	1,546,611,397	8,579,575,957	5,709,707,284	5,963,091,467
4/17/2008	74,562	Tax	10,126,261,916	4,163,095,887	4,416,554,632	1,546,611,397	8,579,650,519	5,709,707,284	5,963,166,029
4/15/2008	3,850,000	Tax	10,130,111,916	4,163,095,887	4,420,404,632	1,546,611,397	8,583,500,519	5,709,707,284	5,967,016,029
4/14/2008	15,000	Tax	10,130,126,916	4,163,095,887	4,420,419,632	1,546,611,397	8,583,515,519	5,709,707,284	5,967,031,029
4/14/2008	15,000	Tax	10,130,141,916	4,163,095,887	4,420,434,632	1,546,611,397	8,583,530,519	5,709,707,284	5,967,046,029
4/14/2008	129,000,000	Tax	10,259,141,916	4,163,095,887	4,549,434,632	1,546,611,397	8,712,530,519	5,709,707,284	6,096,046,029
4/9/2008	125,000	Tax	10,259,266,916	4,163,095,887	4,549,559,632	1,546,611,397	8,712,655,519	5,709,707,284	6,096,171,029
4/9/2008	125,000	Tax	10,259,391,916	4,163,095,887	4,549,684,632	1,546,611,397	8,712,780,519	5,709,707,284	6,096,296,029
4/2/2008	19,310	Tax	10,259,411,226	4,163,095,887	4,549,703,942	1,546,611,397	8,712,799,829	5,709,707,284	6,096,315,339
4/2/2008	19,310	Tax	10,259,430,536	4,163,095,887	4,549,723,252	1,546,611,397	8,712,819,139	5,709,707,284	6,096,334,649
4/1/2008	500	Tax	10,259,431,036	4,163,095,887	4,549,723,752	1,546,611,397	8,712,819,639	5,709,707,284	6,096,335,149
4/1/2008	2,000	Tax	10,259,433,036	4,163,095,887	4,549,725,752	1,546,611,397	8,712,821,639	5,709,707,284	6,096,337,149
4/1/2008	2,000	Tax	10,259,435,036	4,163,095,887	4,549,727,752	1,546,611,397	8,712,823,639	5,709,707,284	6,096,339,149
4/1/2008	5,000	Tax	10,259,440,036	4,163,095,887	4,549,732,752	1,546,611,397	8,712,828,639	5,709,707,284	6,096,344,149
4/1/2008	5,000	Tax	10,259,445,036	4,163,095,887	4,549,737,752	1,546,611,397	8,712,833,639	5,709,707,284	6,096,349,149
4/1/2008	5,000	Tax	10,259,450,036	4,163,095,887	4,549,742,752	1,546,611,397	8,712,838,639	5,709,707,284	6,096,354,149
4/1/2008	5,000	Tax	10,259,455,036	4,163,095,887	4,549,747,752	1,546,611,397	8,712,843,639	5,709,707,284	6,096,359,149
4/1/2008	5,000	Tax	10,259,460,036	4,163,095,887	4,549,752,752	1,546,611,397	8,712,848,639	5,709,707,284	6,096,364,149
4/1/2008	10,000	Tax	10,259,470,036	4,163,095,887	4,549,762,752	1,546,611,397	8,712,858,639	5,709,707,284	6,096,374,149
4/1/2008	29,500	Tax	10,259,499,536	4,163,095,887	4,549,792,252	1,546,611,397	8,712,888,139	5,709,707,284	6,096,403,649

4/1/2008	77,000	Tax	10,259,576,536	4,163,095,887	4,549,869,252	1,546,611,397	8,712,965,139	5,709,707,284	6,096,480,649
4/1/2008	100,000	Tax	10,259,676,536	4,163,095,887	4,549,969,252	1,546,611,397	8,713,065,139	5,709,707,284	6,096,580,649
4/1/2008	102,500	Tax	10,259,779,036	4,163,095,887	4,550,071,752	1,546,611,397	8,713,167,639	5,709,707,284	6,096,683,149
4/1/2008	126,000	Tax	10,259,905,036	4,163,095,887	4,550,197,752	1,546,611,397	8,713,293,639	5,709,707,284	6,096,809,149
4/1/2008	150,000	Tax	10,260,055,036	4,163,095,887	4,550,347,752	1,546,611,397	8,713,443,639	5,709,707,284	6,096,959,149
4/1/2008	214,000	Tax	10,260,269,036	4,163,095,887	4,550,561,752	1,546,611,397	8,713,657,639	5,709,707,284	6,097,173,149
4/1/2008	2,500,000	Tax	10,262,769,036	4,163,095,887	4,553,061,752	1,546,611,397	8,716,157,639	5,709,707,284	6,099,673,149
3/27/2008	2,520,000	Tax	10,265,289,036	4,163,095,887	4,555,581,752	1,546,611,397	8,718,677,639	5,709,707,284	6,102,193,149
3/27/2008	2,935,000	Tax	10,268,224,036	4,163,095,887	4,558,516,752	1,546,611,397	8,721,612,639	5,709,707,284	6,105,128,149
3/24/2008	30,000	Tax	10,268,254,036	4,163,095,887	4,558,546,752	1,546,611,397	8,721,642,639	5,709,707,284	6,105,158,149
3/24/2008	60,000	Tax	10,268,314,036	4,163,095,887	4,558,606,752	1,546,611,397	8,721,702,639	5,709,707,284	6,105,218,149
3/24/2008	67,500	Tax	10,268,381,536	4,163,095,887	4,558,674,252	1,546,611,397	8,721,770,139	5,709,707,284	6,105,285,649
3/24/2008	150,000	Tax	10,268,531,536	4,163,095,887	4,558,824,252	1,546,611,397	8,721,920,139	5,709,707,284	6,105,435,649
3/24/2008	185,000	Tax	10,268,716,536	4,163,095,887	4,559,009,252	1,546,611,397	8,722,105,139	5,709,707,284	6,105,620,649
2/26/2008	-1,000	Tax	10,268,715,536	4,163,095,887	4,559,008,252	1,546,611,397	8,722,104,139	5,709,707,284	6,105,619,649
2/21/2008	36,000	Tax	10,268,751,536	4,163,095,887	4,559,044,252	1,546,611,397	8,722,140,139	5,709,707,284	6,105,655,649
2/21/2008	36,000	Tax	10,268,787,536	4,163,095,887	4,559,080,252	1,546,611,397	8,722,176,139	5,709,707,284	6,105,691,649
1/28/2008	118	Tax	10,268,787,654	4,163,095,887	4,559,080,370	1,546,611,397	8,722,176,257	5,709,707,284	6,105,691,767
1/23/2008	24,850,345	U.S. Partner	10,293,637,999	4,187,946,231	4,559,080,370	1,546,611,397	8,747,026,602	5,734,557,628	6,105,691,767
1/23/2008	24,850,345	U.S. Partner	10,318,488,343	4,212,796,576	4,559,080,370	1,546,611,397	8,771,876,946	5,759,407,973	6,105,691,767
1/11/2008	-303,489	Tax	10,318,184,854	4,212,796,576	4,558,776,881	1,546,611,397	8,771,573,457	5,759,407,973	6,105,388,278
1/11/2008	-959	Tax	10,318,183,895	4,212,796,576	4,558,775,922	1,546,611,397	8,771,572,498	5,759,407,973	6,105,387,319

Sources:

[A] Summary of PPLP Distributions, PPLPUCC9011830859.

[B] In re Purdue Pharma L.P. et al., Case No. 19-23649-rdd (U.S. Bankruptcy Court Southern District of New York) (ECF No. 2907), Notice of Filing of Report of the Special Committee, p. 25.

PPLP Distributions (\$ millions)
PPLPUCC9011830859 versus Alix Partners
2008-2017

PPLPUCC9011830859^[1]					Alix Partners			Difference	
	Tax	Non-Tax	Total Cash	Total Non-Cash	Tax	Non-Tax	Total Cash	Tax	Non-Tax
	Distributions	Distributions	Distributions	Distributions^[2]	Distributions	Distributions	Distributions	Distributions	Distributions^[3]
2008	\$540	\$828	\$1,368	\$73	\$540	\$828	\$1,368	\$0	\$0
2009	\$711	\$1,011	\$1,721	\$55	\$711	\$1,011	\$1,721	\$0	\$0
2010	\$654	\$972	\$1,626	\$32	\$654	\$972	\$1,626	\$0	\$0
2011	\$556	\$667	\$1,223	\$0	\$556	\$667	\$1,223	\$0	\$0
2012	\$460	\$562	\$1,021	\$0	\$460	\$562	\$1,021	\$0	\$0
2013	\$401	\$533	\$934	\$230	\$401	\$533	\$934	\$0	\$0
2014	\$436	\$360	\$795	\$2	\$436	\$360	\$795	\$0	\$0
2015	\$366	\$533	\$899	\$0	\$366	\$426	\$792	\$0	\$107
2016	\$249	\$294	\$544	\$0	\$249	\$401	\$651	\$0	-\$107
2017	\$187	\$0	\$187	\$264	\$187	\$0	\$187	\$0	\$0
Total	\$4,559	\$5,759	\$10,318	\$657	\$4,559	\$5,759	\$10,318	\$0	\$0

Notes:

- [1] PPLPUCC9011830859 reports distributions made from PPLP whereas Alix Partners separately reports distributions made from either PPLP or Rhodes. The above table compares distributions made from PPLP as reported in both sources.
- [2] PPLPUCC9011830859 reports \$657 million of non-cash distributions comprising "Outstanding Loans by PPLP to PRA" and "Non-Cash / Stock Distributions" that Alix Partners did not consider in its analysis of cash distributions.
- [3] PPLPUCC9011830859 and Alix Partners report the same \$10.318 billion amount of cash distributions from 2008 through 2017. The remaining difference is one of timing, as PPLPUCC9011830859 reports 2015 non-tax distributions that are \$107 million higher than those reported by Alix Partners, but 2016 non-tax distributions that are \$107 million lower than those reported by Alix Partners. Specifically, Alix Partners noted the following: "Purdue recorded an accrued distribution of \$107.0 million as of December 31, 2015, which was not paid until 2016. The October 19, 2018 MDL presentation reflected distributions in the year accrued. This is a timing difference only and has no net effect on Total Net Cash Distributions for the ten-year period from January 2008 through December 31, 2017."

Sources:

- [A] Summary of PPLP Distributions, PPLPUCC9011830859.
- [B] *In re Purdue Pharma L.P. et al.*, Case No. 19-23649-rdd (U.S. Bankruptcy Court Southern District of New York) (ECF No. 2907), Notice of Filing of Report of the Special Committee, p. 25.

PPLP Distributions (\$ millions)
Appendix H versus PPLPUCC9011830859
2008-2017

Appendix H Summary					Reconciliation								
					Appendix H			PPLPUCC9011830859			Difference		
	Ex U.S.	Tax	U.S. Partner	Total	Tax	Non Tax	Total	Tax	Non Tax	Total	Tax	Non Tax	Total
2008	76,107,446	540,203,118	752,119,882	1,368,430,446	540	828	1,368	540	828	1,368	0	0	0
2009	111,576,000	710,915,729	898,949,268	1,721,440,997	711	1,011	1,721	711	1,011	1,721	0	0	0
2010	112,381,191	653,842,217	859,950,094	1,626,173,502	654	972	1,626	654	972	1,626	0	0	0
2011	113,306,433	555,949,174	553,552,043	1,222,807,650	556	667	1,223	556	667	1,223	0	0	0
2012	122,393,943	459,522,179	439,341,382	1,021,257,504	460	562	1,021	460	562	1,021	0	0	0
2013	234,447,279	400,849,386	298,318,087	933,614,752	401	533	934	401	533	934	0	0	0
2014	232,022,691	435,568,873	127,505,075	795,096,639	436	360	795	436	360	795	0	0	0
2015	297,018,519	366,110,679	235,788,285	898,917,483	366	533	899	366	533	899	0	0	0
2016	247,357,896	249,273,188	47,073,916	543,705,000	249	294	544	249	294	544	0	0	0
2017		186,541,378	198,544	186,739,922	187	0	187	187	0	187	0	0	0
Total	1,546,611,397	4,558,775,922	4,212,796,576	10,318,183,895	4,559	5,759	10,318	4,559	5,759	10,318	0	0	0

Sources:

[A] Summary of PPLP Distributions, PPLPUCC9011830859.

[B] Appendix H.

Alix - Tax Distributions		PPLPUCC9011830859 - Tax Distributions	
2008	540.2		540.2
2009	710.9		710.9
2010	653.8		653.8
2011	555.9		555.9
2012	459.5		459.5
2013	400.8		400.8
2014	435.6		435.6
2015	366.1		366.1
2016	249.3		249.3
2017	186.5		186.5

Alix - Non-Tax Distributions		PPLPUCC9011830859 - Non-Tax Distributions	
2008	828.2		828.2
2009	1010.5		1,010.5
2010	972.3		972.3
2011	666.9		666.9
2012	561.7		561.7
2013	532.8		532.8
2014	359.5		359.5
2015	425.8		532.8
2016	401.4		294.4
2017	0.2		0.0

PPLPUCC9011830859 - Non-Cash Distributions	
2008	73.5
2009	55.3
2010	32.2
2011	0.0
2012	0.0
2013	230.1
2014	2.2
2015	0.0
2016	0.0
2017	263.8

PPLP Cash Transfers to PRA LP

Year	Non-Tax Distributions	Outstanding Loans by PPLP to PRA ¹	Tax Distributions	Non-Cash / Stock Distributions	Total	
1995	-	-	-	-	-	1,000,000
1996	-	-	2	-	2	
1997	1	-	9	-	10	
1998	6	-	36	-	42	
1999	17	-	77	-	94	
2000	-	-	154	-	154	
2001	36	-	183	-	219	
2002	45	-	151	-	196	
2003	18	-	79	-	97	
2004	-	-	61	-	61	
2005	2	-	58	-	60	
2006	1	-	123	-	124	
2007	3	-	259	-	263	
2008	828	-	540	73	1,442	
2009	1,011	-	711	55	1,777	
2010	972	-	654	32	1,658	
2011	667	-	556	-	1,223	
2012	562	-	460	-	1,021	
2013	533	-	401	230	1,164	
2014	360	-	436	2	797	
2015	533	-	366	-	899	
2016	294	-	249	-	544	
2017	-	247	187	17	450	
2018	-	-	-	-	-	
	<u>5,889</u>	<u>247</u>	<u>5,751</u>	<u>410</u>	<u>12,297</u>	

Note 1 - \$313M was originally lent in 2017, of which \$66M has been repaid

Check (66)

Source: In re Purdue Pharma L.P. et al., Case No. 19-23649-rdd (U.S. Bankruptcy Court Southern District of New York) (ECF No. 2907), Notice of Filing of Report of the Special Committee, p. 25.

Alix - Tax Distributions

2008	540.2
2009	710.9
2010	653.8
2011	555.9
2012	459.5
2013	400.8
2014	435.6
2015	366.1
2016	249.3
2017	186.5

Alix - Non-Tax Distributions

2008	828.2
2009	1010.5
2010	972.3
2011	666.9
2012	561.7
2013	532.8
2014	359.5
2015	425.8
2016	401.4
2017	0.2